<SEC-DOCUMENT>0001104659-15-078291.txt : 20151112
<SEC-HEADER>0001104659-15-078291.hdr.sgml : 20151112
<ACCEPTANCE-DATETIME>20151112160322
ACCESSION NUMBER:		0001104659-15-078291
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151112
DATE AS OF CHANGE:		20151112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		151224219

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a15-18093_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, DC 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark One)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160; </font><b><font size="3" style="font-size:12.0pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended September&nbsp;30, 2015</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font></b><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="3" style="font-size:12.0pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number: 001-37467</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Catabasis Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in Its Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">26-3687168</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other   Jurisdiction of<br>   Incorporation or Organization)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer<br>   Identification No.)</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">One   Kendall Square</font></b><br>    <b>Bldg. 1400E, Suite&nbsp;B14202</b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cambridge,   Massachusetts</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">02139</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal   Executive Offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(617) 349-1971</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s Telephone Number,&nbsp;Including Area Code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes &nbsp;</font><font face="Wingdings">x</font>&nbsp;&nbsp;No&nbsp;<font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;</font><font face="Wingdings">x</font>&nbsp;&nbsp;No&nbsp;<font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer&#148;, &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. (Check one):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large&nbsp;accelerated&nbsp;filer </font><font face="Wingdings">o</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated&nbsp;filer </font><font face="Wingdings">o</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated filer </font><font face="Wingdings">x</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller&nbsp;reporting&nbsp;company   </font><font face="Wingdings">o</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Do not check if a   smaller reporting company)</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;</font><font face="Wingdings">o</font>&nbsp;&nbsp;No&nbsp;<font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of November&nbsp;1, 2015, there were 15,297,794 shares of the registrant&#146;s Common Stock, par value $0.001 per share, outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667381\18093-1-ba.htm',USER='105733',CD='Nov 12 03:32 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="TableOfContents"></a><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="80%" valign="bottom" style="padding:0in 0in 0in 0in;width:80.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PARTIFINANCIALINFORMATION_054310" title="Click to goto "><b>PART&nbsp;I. FINANCIAL   INFORMATION</b></a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_054311">Item&nbsp;1.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_054311">Condensed   Financial Statements (unaudited)</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedBalanceSheets_054317" title="Click to goto ">Condensed Balance Sheets as of September&nbsp;30, 2015   and December&nbsp;31, 2014</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedStatementsofOperationsa_054409" title="Click to goto ">Condensed Statements of Operations and Comprehensive   Loss for the three and nine months ended September&nbsp;30, 2015 and 2014</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedStatementsofCashFlows_054444" title="Click to goto ">Condensed Statements of Cash Flows for the nine months   ended September&nbsp;30, 2015 and 2014</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NotestoCondensedFinancialStateme_054929" title="Click to goto ">Notes to Condensed Financial Statements</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionandAn_055659">Item&nbsp;2.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionandAn_055659">Management&#146;s   Discussion and Analysis of Financial Condition and Results of Operations</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QualitativeandQuantitative_060859">Item&nbsp;3.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QualitativeandQuantitative_060859">Quantitative   and Qualitative Disclosures About Market Risk</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsandProcedures_060901">Item&nbsp;4.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsandProcedures_060901">Controls   and Procedures</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PARTIIOTHERINFORMATION_060937" title="Click to goto "><b>PART&nbsp;II. OTHER   INFORMATION</b></a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1A_RiskFactors_060939">Item&nbsp;1A.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1A_RiskFactors_060939">Risk   Factors</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesofEquityS_061649">Item&nbsp;2.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesofEquityS_061649">Unregistered   Sales of Equity Securities and Use of Proceeds</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_061655">Item&nbsp;6.</a></font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_061655">Exhibits</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SIGNATURES_061743" title="Click to goto "><b>SIGNATURES</b></a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></u></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667196\18093-1-bg.htm',USER='105733',CD='Nov 12 01:21 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Quarterly Report on Form&nbsp;10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form&nbsp;10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These forward-looking statements include, among other things, statements about:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our plans to identify, develop and commercialize novel small molecule drugs based on our SMART linker technology platform;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>ongoing and planned clinical trials for our product candidates, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the anticipated results;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our plans to enter into collaborations for the development and commercialization of product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the potential benefits of any future collaboration;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to receive research and development funding and achieve anticipated milestones under our collaborations;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our commercialization, marketing and manufacturing capabilities and strategy;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our intellectual property position and strategy;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to identify additional products or product candidates with significant commercial potential;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>developments relating to our competitors and our industry; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the impact of government laws and regulations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_174125_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-bi.htm',USER='105933',CD='Nov 11 18:25 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Quarterly Report on Form&nbsp;10-Q, particularly in the &#147;Risk Factors&#148; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_174126_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-bi.htm',USER='105933',CD='Nov 11 18:25 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;I&#151;FINANCIAL INFORMATION</font></b><a name="PARTIFINANCIALINFORMATION_054310"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1. Financial Statements</font></b><a name="Item1_FinancialStatements_054311"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Catabasis Pharmaceuticals,&nbsp;Inc</font></b>.</p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Balance Sheets</font></b><a name="CondensedBalanceSheets_054317"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(in thousands, except share and per share data)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Unaudited)</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Assets</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,709</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,668</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses   and other current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">591</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">354</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current   assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73,300</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,022</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Property and   equipment, net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">216</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">288</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted cash</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">113</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other   non-current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">541</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73,657</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,964</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liabilities   and stockholders&#146; equity (deficit)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current   liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,783</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,132</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,437</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,793</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion   of notes payable, net of discount</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,191</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">309</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current   liabilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,411</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,234</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent,   net of current portion</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notes payable,   net of current portion and discount</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,549</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,439</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other liability</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">114</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant   liability</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,113</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,871</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments   (Note 7)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;A   convertible preferred stock, $0.001 par value per share; 0 and 68,837,703   shares authorized, issued and outstanding at September&nbsp;30, 2015 and   December&nbsp;31, 2014, respectively</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47,898</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Series&nbsp;B   convertible preferred stock, $0.001 par value per share; 0 and 37,830,473   shares authorized, and 0 and 34,129,571 shares issued and outstanding at   September&nbsp;30, 2015 and December&nbsp;31, 2014, respectively</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32,248</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders&#146;   equity (deficit):</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock,   $0.001 par value per share, 5,000,000 and 0 shares authorized at September&nbsp;30,   2015 and December&nbsp;31, 2014, respectively, 0 shares issued and   outstanding</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock,   $0.001 par value, 150,000,000 shares authorized at September&nbsp;30, 2015   and 132,000,000 shares authorized at December&nbsp;31, 2014; 15,297,794 and 493,200   shares issued and outstanding at September&nbsp;30, 2015 and   December&nbsp;31, 2014, respectively</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional   paid-in capital</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">157,933</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,326</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated   deficit</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(98,404</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(75,380</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   stockholders&#146; equity (deficit)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59,544</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(73,053</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities,   convertible preferred stock and stockholders&#146; equity (deficit)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">73,657</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,964</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The accompanying notes are an integral part of these condensed financial statements.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_174343_4191"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fa.htm',USER='105933',CD='Nov 11 18:28 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Catabasis Pharmaceuticals,&nbsp;Inc</font></b>.</p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Statements of Operations and Comprehensive Loss</font></b><a name="CondensedStatementsofOperationsa_054409"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(in thousands, except share and per share data)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Unaudited)</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating   expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,813</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,543</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,360</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,361</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,388</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,427</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,966</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,443</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating   expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,201</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,970</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22,326</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,804</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from   operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,201</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,970</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(22,326</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,804</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other (expense)   income:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other (expense)   income, net</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(282</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(57</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(709</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(57</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(284</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(55</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(698</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(54</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss and   comprehensive loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,485</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,025</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23,024</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,858</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per   share - basic and diluted</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.55</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13.55</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4.11</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(38.34</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted-average   common shares outstanding used in net loss per share - basic and diluted</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,297,794</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">444,787</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,596,412</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">413,622</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The accompanying notes are an integral part of these condensed financial statements.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_174442_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fa.htm',USER='105933',CD='Nov 11 18:28 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Catabasis Pharmaceuticals,&nbsp;Inc</font></b>.</p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Statements of Cash Flows</font></b><a name="CondensedStatementsofCashFlows_054444"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(in thousands)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Unaudited)</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operating   activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23,024</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,858</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reconciliation   of net loss to net cash used in operating &nbsp;activities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation and   amortization</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">130</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">190</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based   compensation expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,143</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">605</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-cash   interest expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">209</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in   assets and liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses   and other current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(237</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(126</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">619</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">544</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">112</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">151</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(19</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   operating activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(21,050</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,492</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchases of   available-for-sale securities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,976</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchases of   property and equipment</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(60</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(159</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   investing activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(60</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,135</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from   initial public offering, net of issuance costs</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">61,776</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from   issuance of preferred stock, net of issuance costs</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,331</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from   exercise of common stock options</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from   borrowings</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debt issuance   costs</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(282</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash   provided by financing activities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79,151</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,828</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net increase   (decrease) in cash and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58,041</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,799</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents, beginning of period</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,668</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30,474</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents, end of period</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,709</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,675</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Supplemental   disclosure of cash flow information</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash paid for   interest</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">500</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Non-cash   financing activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants for the   purchase of series B preferred stock issued in conjunction with credit   facility</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">107</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Initial public   offering costs in accounts payable and accrued liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reclassification   of deferred IPO costs from non-current assets to additional paid-in capital</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,787</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reclassification   of warrant liability to additional paid-in capital</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">206</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The accompanying notes are an integral part of these condensed financial statements.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="PB_5_174519_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fa.htm',USER='105933',CD='Nov 11 18:28 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Catabasis Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Condensed Financial Statements</font></b><a name="NotestoCondensedFinancialStateme_054929"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">(Unaudited)</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Organization and Operations</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The Company</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on the Company&#146;s proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company&#146;s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of the Company&#146;s proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company seeks to develop therapies that modulate multiple targets in the disease pathway. The Company targets therapeutic areas and specific diseases with significant unmet medical needs where it believes it will have a competitive advantage. The Company&#146;s focus is on treatments for rare diseases, such as Duchenne Muscular Dystrophy (&#147;DMD&#148;).&#160; The Company is also developing other product candidates for the treatment of serious lipid disorders. The Company was incorporated in the State of Delaware on June&nbsp;26, 2008.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Initial Public Offering</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2015, the Company completed its Initial Public Offering (the &#147;IPO&#148;).&#160; All of the shares issued and sold in the IPO were registered pursuant to a registration statement on Form&nbsp;S-1, as amended.&#160; An aggregate of 5,750,000 shares of Common Stock registered pursuant to the registration statement were sold at a price to the public of $12.00 per share (including 750,000 shares of Common Stock sold pursuant to the exercise of an overallotment option granted to the Company&#146;s underwriters in connection with the IPO).&#160; Net proceeds of the IPO were $61.7 million, after deducting underwriting discounts, commissions and offering-related expenses payable by the Company of approximately $7.3 million. In connection with the IPO, all shares of the Company&#146;s convertible preferred stock (the &#147;Preferred Stock&#148;) were automatically converted into an aggregate of 9,029,549 shares of its Common Stock and its outstanding warrants to purchase 315,688 shares of Preferred Stock were automatically converted into warrants to purchase 24,566 shares of Common Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015, the Company had an accumulated deficit of $98.4 million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since inception. The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company&#146;s products. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Summary of Significant Accounting Policies</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Reverse stock split</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the IPO, the Company&#146;s board of directors and stockholders approved a 1-for-12.85 reverse stock split of the Company&#146;s Common Stock which was effected on June&nbsp;11, 2015. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="PB_6_174934_262"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">fractional shares. All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of Preferred Stock were convertible into shares of Common Stock have been adjusted to reflect the effects of the reverse stock split.&nbsp;&nbsp;Shares of Common Stock reserved for future issuance have been presented on an as converted basis and the financial statements disclose the adjusted conversion ratios.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (&#147;U.S.&nbsp;GAAP&#148;) and include all adjustments necessary for the fair presentation of the Company&#146;s financial position for the periods presented.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The unaudited interim condensed financial statements of the Company included herein have been prepared, pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#147;SEC&#148;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules&nbsp;and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements as of and for the year ended December&nbsp;31, 2014 and notes thereto, included in the Company&#146;s prospectus dated June&nbsp;24, 2015, filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;on June&nbsp;25, 2015 (the &#147;Prospectus&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#146;s management, the accompanying unaudited interim condensed financial statements contain all adjustments which are necessary to fairly present the Company&#146;s financial position as of September&nbsp;30, 2015, the results of its operations for the three and nine months ended September&nbsp;30, 2015 and 2014 and its cash flows for the nine months ended September&nbsp;30, 2015 and 2014. Such adjustments are of a normal and recurring nature. The results for the nine months ended September&nbsp;30, 2015 are not necessarily indicative of the results for the year ending December&nbsp;31, 2015, or for any future period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Use of Estimates</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preparation of the Company&#146;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company utilized significant estimates and assumptions in determining the fair value of its Common Stock prior to completion of the IPO. The board of directors determined the estimated fair value of the Common Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of convertible preferred stock, the achievement of research and development milestones, the superior rights and preferences of securities senior to the Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants (&#147;AICPA&#148;), Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation (&#147;AICPA Practice Aid&#148;), to estimate the fair value of its Common Stock. The methodologies included the Option Pricing Method utilizing the Backsolve Method (a form of the market approach defined in the AICPA Practice Aid) and the Probability-Weighted Expected Return Method based upon the probability of occurrence of certain future liquidity events such as an initial public offering or sale of the Company. Each valuation methodology includes estimates and assumptions</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="PB_7_174938_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">that required the Company&#146;s judgment. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract, are determined by the Company based on input from internal project management, as well as from third-party service providers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#146;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate their fair values at September&nbsp;30, 2015 and December&nbsp;31, 2014, due to their short-term nature. There have been no changes to the valuation methods during the year ended December&nbsp;31, 2014 or the nine months ended September&nbsp;30, 2015. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between levels during the year ended 2014 or the nine months ended September&nbsp;30, 2015. At September&nbsp;30, 2015, the carrying value of the Company&#146;s debt approximated fair value, which was determined using Level 3 inputs, including a quoted interest rate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#147;FASB&#148;) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In April&nbsp;2015, the FASB issued ASU No.&nbsp;2015-03, <i>Simplifying the Presentation of Debt Issuance Costs</i>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability rather than as a deferred charge. It is effective for annual reporting periods beginning after December&nbsp;15, 2015, but early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &#151; Going Concern (&#147;ASU 2014-15&#148;), which is effective for annual periods ending after December&nbsp;15, 2016.&#160; Early adoption is permitted.&#160; ASU 2014-15 provides new guidance on (1)&nbsp;management&#146;s responsibility in evaluating whether or not there is substantial doubt about a company&#146;s ability to continue as a going concern within one year from the date the financial statements are issued each reporting period and (2)&nbsp;related financial statement disclosures.&#160; The Company has not adopted the guidance prescribed by ASU 2014-15 and does not expect the new guidance to have a significant effect on its financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="PB_8_174942_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Instruments</b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following tables present information about the Company&#146;s financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. The Company determines the fair value of the preferred stock warrants (Note 6) using Level 3 inputs. Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="64%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:64.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;September&nbsp;30,&nbsp;2015</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices<br>   in&nbsp;Active<br>   Markets<br>   (Level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant&nbsp;<br>   Observable&nbsp;<br>   Inputs<br>   (Level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant&nbsp;<br>   Unobservable&nbsp;<br>   Inputs<br>   (Level&nbsp;3)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Money market   funds</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,005</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,005</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,005</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">72,005</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="196" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="77" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="64%" colspan="11" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:64.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices<br>   in&nbsp;Active<br>   Markets<br>   (Level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant&nbsp;<br>   Observable&nbsp;<br>   Inputs<br>   (Level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant&nbsp;<br>   Unobservable&nbsp;<br>   Inputs<br>   (Level&nbsp;3)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.9%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.9%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Money market   funds</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,506</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.9%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,506</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,506</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,506</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.9%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant   Liability</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.9%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.9%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015 and December&nbsp;31, 2014, the Company&#146;s cash equivalents consisted principally of money market funds, which approximate their fair value due to their short-term nature. In connection with the completion of the IPO, warrants exercisable for Preferred Stock were automatically converted into warrants exercisable for Common Stock, resulting in the reclassification of the related warrant liability to additional paid-in capital as the warrants to purchase shares of Common Stock are accounted for as equity instruments (Note 6).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Accrued Expenses</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses consisted of the following (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="PB_9_175036_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="67%" valign="bottom" style="padding:0in 0in 0in 0in;width:67.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,<br>   2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="67%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:67.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued   compensation</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,237</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">796</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="top" style="padding:0in 0in 0in 0in;width:67.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued   contracted research costs</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,109</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:67.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued   professional fees</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">159</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">791</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="top" style="padding:0in 0in 0in 0in;width:67.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued other</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">241</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">97</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:67.9%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,437</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,793</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notes Payable</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;27, 2014, the Company entered into a credit facility with MidCap Financial Trust, Flexpoint MCLS Holdings, LLC and Square 1 Bank, which was subsequently amended on March&nbsp;31, 2015 (as amended, the &#147;Credit Facility&#148;). The Credit Facility provides for initial borrowings of $5.0 million under a term loan (&#147;Term Loan A&#148;) and additional borrowings of up to $20.0 million under other term loans, for a maximum of $25.0 million. On August&nbsp;27, 2014, the Company received proceeds of $5.0 million from the issuance of promissory notes under Term Loan A. On March&nbsp;31, 2015, the Company received proceeds of $5.0 million from the issuance of promissory notes under another term loan (&#147;Term Loan B&#148;).&#160; The remaining amounts available for borrowing under this arrangement expired unused as of July&nbsp;31, 2015, leaving total borrowings under the Credit Facility at $10.0 million.&#160; All amounts outstanding under the Credit Facility are due on October&nbsp;1, 2018 and are collateralized by substantially all of the Company&#146;s personal property, other than its intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest-only payments were due monthly on amounts outstanding under the Credit Facility until September&nbsp;1, 2015 and, thereafter, interest and principal payments are due in 36 equal monthly installments from October&nbsp;1, 2015 through September&nbsp;1, 2018.&#160; Amounts due under the Credit Facility bear interest at an annual rate of 7.49%. In addition, a final payment equal to 3.48% of any amounts drawn under the Credit Facility is due upon the earlier of the maturity date, acceleration of the term loans or prepayment of all or part of the term loans. The final payment is being accrued as additional interest expense using the effective-interest method from the date of issuance through the maturity date, and is recorded within other long-term liabilities.&#160;&#160; In the event of prepayment, the Company is obligated to pay 1% to 3% of the amount of the outstanding principal depending upon the timing of the prepayment. The effective interest rate as of September&nbsp;30, 2015 was 11.2%.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In conjunction with Term Loan A, the Company issued warrants to purchase 157,844 shares of series B convertible preferred stock at an exercise price of $0.9503 per share (the &#147;2014 Warrants&#148;) to the lenders. In conjunction with Term Loan B, the Company issued warrants to purchase an additional 157,844 shares of series B convertible preferred stock at an exercise price of $0.9503 per share (the &#147;2015 Warrants&#148;) to the lenders (see Note 6). The 2014 Warrants and 2015 Warrants were exercisable immediately and have seven-year lives. The 2014 Warrants and 2015 Warrants were initially valued at $0.1 million and $0.1 million, respectively, using the Black-Scholes option-pricing model. The Company recorded debt discounts of $0.1 million and $0.1 million upon issuance of the 2014 Warrants and 2015 Warrants, respectively, which are being accreted as interest expense using the effective-interest method over the remaining term of the loan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are no financial covenants associated with the Credit Facility; however, there are negative covenants restricting the Company&#146;s activities, including limitations on asset dispositions, mergers or </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="PB_10_175100_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">acquisitions; encumbering or granting a security interest in its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and entering into certain other business transactions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon the occurrence and continuation of an event of default, the lenders have the right to exercise certain remedies against the Company and the collateral securing the loans under the Credit Facility, including cash.&#160; Events of default include, among other things, failure to pay amounts due under the Credit Facility, insolvency, the occurrence of a material adverse event, which includes a material adverse change in the business, operations or conditions (financial or otherwise) of the Company or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against the Company in an amount greater than $250,000. The occurrence of a material adverse change could result in acceleration of the payment of the debt. At September&nbsp;30, 2015 and December&nbsp;31, 2014, the Company concluded that the likelihood of the acceleration of the debt was remote, as a material adverse change had not occurred and was unlikely to occur and therefore the debt was classified in current and long-term liabilities based on scheduled principal payments. Following the occurrence and during the continuance of an event of default, borrowings under the Credit Facility shall bear interest at a rate per annum, which is five hundred basis points, or 5.0%, above the rate that is otherwise applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company assessed all terms and features of the Credit Facility in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, the Company assessed the economic characteristics and risks of the Credit Facility, including put and call features. The Company determined that all features of the Credit Facility were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company&#146;s financial statements. The Company will continue to reassess the features on a quarterly basis to determine if they require separate accounting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounted for the amendment to the Credit Facility, effective March&nbsp;31, 2015, as a debt modification pursuant to ASC Topic 470-50 <i>Modifications and Extinguishments.</i></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated future principal payments at September&nbsp;30, 2015 are as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;">
<tr>
<td width="80%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;Ending&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amount</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remainder 2015</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">834</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2016</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,333</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,333</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2018</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,500</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.6%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less: discount   for warrants and costs paid to lender</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(260</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less: current   portion</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,191</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Note payable,   net of current portion and discount</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,549</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated future principal payments at December&nbsp;31, 2014 are as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="PB_11_175123_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="78%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Year&nbsp;Ending&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amount</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">416</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2016</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,667</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,667</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2018</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,250</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less: discount   for warrants and costs paid to lender</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(252</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less: current   portion</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(309</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.86%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Note payable,   net of current portion and discount</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,439</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three and nine months ended September&nbsp;30, 2015, the Company recognized $0.3 million and $0.7 million, respectively, of interest expense related to the Credit Facility.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Warrants</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;27, 2014 and March&nbsp;31, 2015, the Company issued the 2014 Warrants and 2015 Warrants to purchase an aggregate 315,688 shares of series B convertible preferred stock at an exercise price of $0.9503 per share to the lenders in connection with the Credit Facility (Note 5). The 2014 Warrants and 2015 Warrants were exercisable immediately on issuance and have a seven-year life. The 2014 Warrants and 2015 Warrants were recorded as a liability and re-measured at each reporting date using the then-current assumptions. In connection with the completion of the IPO, the 2014 Warrants and the 2015 Warrants were automatically converted into warrants exercisable for Common Stock, resulting in the reclassification of the related warrant liability to additional paid-in capital as the warrants to purchase shares of Common Stock met the criteria to be accounted for as equity instruments. The warrant liability was re-measured to fair value prior to reclassification to additional paid-in capital. As of September&nbsp;30, 2015, the Company had no outstanding warrant liability.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides a roll-forward of the fair value of the 2014 Warrants and 2015 Warrants determined by Level 3 inputs (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   December&nbsp;31, 2014</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">108</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of   warrants at fair value</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">107</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair   value, recorded as a component of the other (expense) income, net</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reclassification   to additional paid-in capital</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(206</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   September&nbsp;30, 2015</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value of warrants exercisable for 315,688 shares of series B convertible preferred stock, which upon the IPO were automatically converted into warrants exercisable for 24,566 shares of Common Stock with an exercise price of $12.14, was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="PB_12_175237_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fn.htm',USER='105933',CD='Nov 11 18:30 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="64%" valign="bottom" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">June&nbsp;30,&nbsp;2015&nbsp;(1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,&nbsp;2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free   interest rate</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.97</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.95</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend   yield</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.00</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.00</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected term   (in years)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.7</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected   volatility</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75.79</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78.16</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;&#160; Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Commitments</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In November&nbsp;2010, the Company entered into a five-year, non-cancelable operating lease for office and laboratory space. In December&nbsp;2011, the Company signed a lease amendment (the &#147;2011 Lease Amendment&#148;) that expanded the leased premises beginning in the second quarter of 2012. The 2011 Lease Amendment also extended the term of the existing lease through June&nbsp;30, 2017. The 2011 Lease Amendment includes a free rent period for the expansion premises and escalating rent payments. In July, 2015, the Company signed another lease amendment (the &#147;2015 Lease Amendment&#148;) that expanded the leased premises beginning in the third quarter of 2015.&#160; The 2015 Lease Amendment includes escalating rent payments and is effective through June&nbsp;30, 2017. The Company is recognizing rent expense on a straight-line basis over the lease term. The lease agreement provides for a five-year extension upon the completion of the lease term.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Future minimum payments required under the non-cancelable operating lease as of September&nbsp;30, 2015 are summarized as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="78%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:78.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;Ending&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amount</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.88%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remainder 2015</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">235</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.88%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2016</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">937</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.88%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2017</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">467</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.88%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total minimum   lease payments</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.54%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:14.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,639</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rent expense for the three months ended September&nbsp;30, 2015 and 2014 was $0.2 million and $0.2 million, respectively. Rent expense for the nine months ended September&nbsp;30, 2015 and 2014 was $0.6 million and $0.5 million, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Convertible Preferred Stock</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;13, 2015, the Company&#146;s board of directors authorized the Company to increase the authorized number of shares of Series&nbsp;B Preferred Stock to 56,026,590 in connection with an anticipated Series&nbsp;B Preferred Stock financing. The Company subsequently issued 13,062,965 shares of Series&nbsp;B Preferred Stock at $0.9503 per share, and received net proceeds of $12.3 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon closing the Company&#146;s IPO on June&nbsp;30, 2015, all outstanding shares of the Company&#146;s preferred stock were automatically converted into 9,029,549 shares of Common Stock.&#160; As of September&nbsp;30, 2015, the Company has 5,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share, with none issued or outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the board of </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="PB_13_175449_8382"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fp.htm',USER='105933',CD='Nov 11 17:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">directors of the Company. Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Common Stock Reserved for Future Issuance</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has reserved for future issuance the following number of shares of Common Stock:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,<br>   2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conversion of   Series&nbsp;A Preferred Stock</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,356,996</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conversion of   Series&nbsp;B Preferred Stock</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,655,992</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants for the   purchase of Preferred Stock</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,283</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants for the   purchase of Common Stock</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59,405</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34,839</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options to   purchase Common Stock</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,572,959</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,385,341</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employee Stock   Purchase Plan</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">182,352</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,814,716</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,445,451</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Stock-based compensation</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to the Company&#146;s IPO, the Company granted awards to eligible participants under the 2008 equity incentive plan (&#147;2008 Plan&#148;). In June&nbsp;2015, the Company&#146;s board of directors adopted and the Company&#146;s stockholders approved the 2015 Stock Incentive Plan (&#147;2015 Plan&#148;), which became effective immediately prior to the effectiveness of the Company&#146;s IPO. Subsequent to the Company&#146;s IPO, option grants are awarded to eligible participants only under the 2015 Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The 2015 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The Company&#146;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2015 Plan. The maximum number of shares of Common Stock that may be delivered in satisfaction of awards under the 2015 Plan is 1,068,287 shares, plus (1)&nbsp;25,942 shares that were available for grant under the 2008 Plan immediately prior to the closing of the IPO, (2)&nbsp;the number of shares of Common Stock subject to outstanding awards under the 2008 Plan upon closing of the IPO that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right and (3)&nbsp;an annual increase, to be added the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2016 and continuing until, and including, the fiscal year ending December&nbsp;31, 2025, equal to the lowest of 1,297,334 shares of Common Stock, 4% of the number of shares of Common Stock outstanding on the first day of the fiscal year and an amount determined by the Company&#146;s board of directors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015, the Company had reserved 1,466,274 shares of Common Stock under the 2008 Plan, of which none remained available for future issuance.&#160; As of September&nbsp;30, 2015, the Company had reserved 1,106,685 shares of Common Stock under the 2015 Plan, of which 860,948 shares remained available for future issuance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="PB_14_175504_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fp.htm',USER='105933',CD='Nov 11 17:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Stock Options</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A summary of the Company&#146;s stock option activity and related information follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted-<br>   Average&nbsp;<br>   Exercise&nbsp;Price</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted-<br>   Average&nbsp;<br>   Remaining&nbsp;<br>   Contractual&nbsp;<br>   Term&nbsp;(years)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Agregate&nbsp;<br>   Intrinsic&nbsp;Value&nbsp;<br>   (in&nbsp;thousands)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outstanding at   December&nbsp;31, 2014</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,226,140</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.15</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,579</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">550,797</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.69</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercised</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(25,045</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.05</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cancelled or   forfeited</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(39,881</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.46</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outstanding at   September&nbsp;30, 2015</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,712,011</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.57</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.11</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,560</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercisable at   September&nbsp;30, 2015</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">755,860</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.27</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.89</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,659</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested or   expected to vest at September&nbsp;30, 2015</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,586,233</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.30</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.02</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,489</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The total intrinsic value of options exercised for the three months ended September&nbsp;30, 2015 and 2014 was $0, and $0.2 million, respectively. The total intrinsic value of options exercised for the nine months ended September&nbsp;30, 2015 and 2014 was $0.2 million and $0.3 million, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At September&nbsp;30, 2015, the total unrecognized compensation expense related to unvested stock option awards, including estimated forfeitures, was $5.2 million. The Company expects to recognize that cost over a weighted-average period of approximately 3.1 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Stock-based compensation expense</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#146;s statements of operations as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">173</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">505</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">289</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">315</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">132</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">638</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">316</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">488</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">232</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,143</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">605</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Employee Stock Purchase Plan</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2015, the Company&#146;s board of directors adopted and the Company&#146;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#147;2015 ESPP&#148;) which became effective upon closing of the Company&#146;s IPO. The 2015 ESPP authorizes the initial issuance of up to a total of 182,352 shares of Common Stock to participating eligible employees. The number of shares increases each January&nbsp;1, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2026, by an amount equal to the lesser of one percent of the Company&#146;s outstanding shares as of the end of the immediately preceding fiscal year, 364,705 shares and any lower amount determined by the Company&#146;s board of directors. As of September&nbsp;30, 2015 there has been no activity under the 2015 ESPP.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="PB_15_175540_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fp.htm',USER='105933',CD='Nov 11 17:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Net Loss Per Share</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options, warrants to purchase Common Stock and warrants to purchase preferred stock are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,012,987</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,012,987</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock options</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,712,011</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,214,700</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,712,011</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,214,700</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock   warrants</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59,405</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34,839</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59,405</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34,839</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock   warrants</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,283</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,283</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,771,416</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,274,809</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,771,416</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,274,809</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="PB_16_175555_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-fp.htm',USER='105933',CD='Nov 11 17:56 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</font></b><a name="Item2_ManagementsDiscussionandAn_055659"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed financial statements and the related notes appearing elsewhere in this Quarterly Report on Form&nbsp;10-Q.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on our proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. Our SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological targets in one or more related disease pathways. We engineer bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of our proprietary SMART linkers. Our SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability, and we seek to develop therapies that modulate multiple targets in the disease pathway. We target therapeutic areas and specific diseases with significant unmet medical need where we believe we will have a competitive advantage. Our focus is on treatments for rare diseases, such as Duchenne muscular dystrophy, or DMD. We are also developing other product candidates for the treatment of serious lipid disorders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have applied our SMART linker technology platform to build a development pipeline that includes three clinical-stage product candidates and multiple programs in preclinical development. Our current drug candidates are small molecules. CAT-1004 is an oral small molecule that we believe has the potential to be a disease-modifying therapy for the treatment of DMD, which may be able to regenerate muscle in boys regardless of the underlying dystrophin mutation. DMD is an ultimately fatal genetic disorder involving progressive muscle degeneration. In June&nbsp;2015, we initiated enrollment in a Phase 1 / 2 clinical trial of CAT-1004 in boys affected by DMD, which we refer to as the MoveDMD</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&#160;trial. Our two other clinical-stage product candidates, CAT-2054 and CAT-2003, are members of our CAT-2000 series of molecules. We are initially developing CAT-2054 for the treatment of patients with hypercholesterolemia, or elevated low density lipoprotein cholesterol, or LDL-C, levels, for whom existing treatments are insufficient. Hypercholesterolemia is a disease that increases the risk of cardiovascular events. In January&nbsp;2015, we initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. In August&nbsp;2015, we reported top-line data for the full range of doses tested in the single and multiple ascending dose portions of the trial. We have completed three Phase 2a trials of CAT-2003 in patient populations with elevated triglycerides or hypertriglyceridemia. CAT-4001 is in preclinical studies and is being developed for the treatment of severe, rare neurodegenerative diseases, such as Friedreich&#146;s ataxia and amyotrophic lateral sclerosis, two diseases of the central nervous system in which the Nrf2 and NF-<font face="Symbol">k</font>B pathways have been implicated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since our inception in June&nbsp;2008, we have devoted substantially all of our resources to developing our proprietary platform technology, identifying potential product candidates, undertaking preclinical studies and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="PB_17_175703_2977"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">conducting clinical trials for our three clinical-stage compounds, building our intellectual property portfolio, organizing and staffing our company, business planning, raising capital, and providing general and administrative support for these operations. To date, we have primarily financed our operations through private placements of our preferred stock, a secured debt financing, and our initial public offering, or IPO.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2015, we completed our IPO, in which we sold an aggregate of 5,750,000 shares of our common stock, including 750,000 shares of common stock sold pursuant to the underwriters&#146; exercise of their option to purchase additional shares of common stock, at a price to the public of $12.00 per share.&#160;&#160; Net proceeds from the IPO were $61.7 million, after deducting underwriting discounts, commissions and offering-related expenses of approximately $7.3 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with our IPO, all shares of our preferred stock were automatically converted into an aggregate of 9,029,549 shares of our common stock and our outstanding warrants to purchase 315,688 shares of preferred stock were automatically converted into warrants to purchase 24,566 shares of common stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the IPO, we also effected a one-for-12.85 reverse split of our common stock.&#160; All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of preferred stock are convertible into shares of common stock have been adjusted to reflect the effects of the reverse stock split.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have not generated any revenue to date. We have incurred significant annual net operating losses in every year since our inception and expect to incur a net operating loss in 2015 and continue to incur net operating losses for the foreseeable future. As of September&nbsp;30, 2015, we had an accumulated deficit of $98.4 million. We expect to continue to incur significant expenses and increasing operating losses for the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase significantly if and as we continue to develop and conduct clinical trials with respect to our CAT-1004 and CAT-2054 product candidates; initiate and continue research, preclinical and clinical development efforts for our other product candidates and potential product candidates; maintain, expand and protect our intellectual property portfolio; establish a commercial infrastructure to support the marketing and sale of certain of our product candidates; hire additional personnel, such as clinical, regulatory, quality control and scientific personnel; and operate as a public company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From our inception through September&nbsp;30, 2015, we had raised an aggregate of $172.1 million, composed of $92.9 million from private placements of preferred stock, $69.0 million in gross proceeds from our IPO, $10 million from a secured debt financing and $0.2 million from common stock option exercises.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financial Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated any revenue from product sales or any other source and do not expect to generate any revenue from the sale of products in the near future. In the future, we will seek to generate revenue primarily from a combination of product sales and collaborations with strategic partners.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>employee-related expenses including salaries, benefits and stock-based compensation expense;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="PB_18_175739_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical trials and research and development and preclinical activities on our behalf;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the cost of consultants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the cost of lab supplies and acquiring, developing and manufacturing preclinical study materials; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following summarizes our most advanced current research and development programs:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>CAT-1004 is an orally administered SMART linker conjugate of salicylate and the omega-3 fatty acid docosahexaenoic acid, or DHA, that we designed to enhance the activity of salicylate and DHA in modulating the NF-<font face="Symbol">k</font>B pathway at multiple points. NF-<font face="Symbol">k</font>B, or nuclear factor kappa- light-chain-enhancer of activated B cells, is a protein that coordinates cellular response to damage, stress and inflammation and plays an important role in muscle health. We initiated patient enrollment in a Phase 1/2 clinical trial of CAT-1004 for the treatment of DMD in June&nbsp;2015. There are three cohorts in the dose-ranging Part&nbsp;A of the trial and we have completed dosing for cohorts 1 and 2 and are currently scheduling cohort 3.&#160; We expect to release results for safety, tolerability, and pharmacokinetics from Part&nbsp;A of this trial early in the first quarter of 2016.&#160; Assuming adequate safety, tolerability, and pharmacokinetics in Part&nbsp;A of the trial, we intend to initiate the 12-week, double-blind, placebo-controlled efficacy Part&nbsp;B portion of this trial in the first half of 2016 and expect to report efficacy data from Part&nbsp;B in late 2016. If the results from our Phase 1/2 clinical trial and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month Phase 3 pivotal clinical trial of CAT-1004 in 2017 and to seek marketing approval based on this Phase 3 trial. The U.S. Food and Drug Administration has granted CAT-1004 orphan drug, fast track and rare pediatric disease designations for the treatment of DMD. The European Commission has granted CAT-1004 orphan medicinal product designation for DMD.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>CAT-2054 is an orally administered SMART linker conjugate of the omega-3 fatty acid eicosapentaenoic acid, or EPA, and nicotinic acid, designed to modulate the SREBP pathway primarily in the liver. SREBP is a master regulator of lipid metabolism. We are initially developing CAT-2054 to treat patients with hypercholesterolemia for whom existing treatments are insufficient. In January&nbsp;2015, we initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. In August&nbsp;2015, we reported top-line data for the full range of doses tested in the single and multiple ascending dose portions of the trial. We are actively recruiting and expect to begin dosing for a four-week Phase 2a randomized, double-blind, placebo-controlled trial of CAT-2054 in hypercholesterolemia in the fourth quarter of 2015. We plan to enroll approximately 150 patients. The primary efficacy endpoint for this trial will be percent reduction in LDL cholesterol on top of atorvastatin 40 mg.&#160; We also will explore the activity of CAT-2054 on other metabolic parameters such as triglycerides and glucose. We expect to report data from the CAT-2054 Phase 2a trial in the third quarter of 2016.&#160; Depending on the results of the planned Phase 2a clinical trial, we may initiate a</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="PB_19_175759_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phase 2b clinical trial of CAT-2054 in hypercholesterolemia or another SREBP-mediated disease such as non-alcoholic steatohepatitis.</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>CAT-2003 is an orally administered SMART linker conjugate of EPA and nicotinic acid that we designed to modulate the SREBP pathway. We have completed three Phase 2a trials of CAT-2003 in patient populations with elevated triglycerides or hypertriglyceridemia.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other research and development programs include our CAT-4001 development program and activities related to exploratory efforts, target validation and lead optimization for our early stage programs and our proprietary platform technology.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs. We record our research and development expenses net of any research and development tax incentives we are entitled to receive from government authorities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes our research and development expenses by program (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CAT-1004</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,200</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">340</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CAT-2054</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,354</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,566</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CAT-2003</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">927</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,656</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other research   and platform programs</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,654</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">976</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Costs not   directly allocated to programs:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employee   expenses including cash compensation, benefits and stock-based compensation</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,651</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,385</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">611</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">552</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consultants and   professional expenses, including stock-based compensation</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">609</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">527</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">354</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">359</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total costs not   directly allocated to programs</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,225</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,823</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research   and development expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,360</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,361</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The successful development of our product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of these product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from CAT-1004, CAT-2054 or any of our other current or potential product candidates. This is due to the numerous risks and uncertainties associated with developing medicines, including the uncertainties of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establishing an appropriate safety profile with investigational new drug application, or IND, enabling toxicology studies;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>successful enrollment in, and completion of clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="PB_20_175846_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>receipt of marketing approvals from applicable regulatory authorities;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a continued acceptable safety profile of the products following approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as our product candidate development programs progress. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities, potential commercialization of our product candidates and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company including expenses related to services associated with maintaining compliance with exchange listing and Securities and Exchange Commission requirements, insurance costs and investor relations costs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Other (Expense) Income, Net</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other (expense) income, net consists of interest expense incurred on debt instruments, amortized deferred financing costs and amortized debt discount, and changes in the fair value of the warrant liability, as offset by any interest income earned on our cash and cash equivalents. Upon completion of our IPO in June&nbsp;2015, </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="PB_21_175858_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">warrants to purchase preferred stock were converted to warrants to purchase common stock and as a result, the Company no longer records fair value adjustment for its warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates&#151;which also would have been reasonable&#151;could have been used. The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, we evaluate estimates, which include, but are not limited to, estimates related to clinical trial accruals, stock-based compensation expense, warrants to purchase redeemable securities, and reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from those estimates or assumptions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There have been no material changes to our accounting policies from those described in our prospectus filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;on June&nbsp;25, 2015, or the Prospectus. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies disclosed in our Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended September&nbsp;30, 2015 and 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 22.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes our results of operations for the three months ended </font>September&nbsp;30, 2015 and 2014 (in thousands):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="95%" style="border-collapse:collapse;margin-left:22.3pt;">
<tr>
<td width="53%" valign="bottom" style="padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;to&nbsp;Period&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="53%" valign="bottom" style="padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Change</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating   expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,813</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,543</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,270</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,388</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,427</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">961</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating   expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,201</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,970</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,231</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from   operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,201</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,970</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,231</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense,   net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(284</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(55</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(229</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.22%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,485</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,025</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.62%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,460</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Research and Development Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses increased by $1.3 million to $5.8 million for the three months ended September&nbsp;30, 2015 from $4.5 million for the three months ended September&nbsp;30, 2014, an increase of 29%. The increase in research and development expenses was primarily attributable to a net increase of $0.7 million in employee compensation, of which, $0.4 million was attributable to obligations under a letter agreement with a former employee, pursuant to which we agreed to make severance payments.&#160; The remaining $0.3 million of the </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="PB_22_180004_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">employee compensation increase was driven by a 21% increase in headcount, primarily in the area of development and manufacturing.&#160; Direct program costs also increased by $0.5 million, reflecting an increase of $1.3 million for CAT-1004 driven by the start of a Phase 1/2 clinical trial, and an increase of $0.2 million in our general research and platform programs. These increases were partially offset by a decrease of $0.9 million in CAT-2003 costs due to the completion of two Phase 2 clinical trials that were active in the three months ended September&nbsp;30, 2014 and a decrease of $0.1 million for CAT-2054 attributable to the completion of pre-clinical manufacturing efforts that were active in the three months ended September&nbsp;30, 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">General and Administrative Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses increased by $1.0 million to $2.4 million for the three months ended September&nbsp;30, 2015 from $1.4 million for the three months ended September&nbsp;30, 2014, an increase of 71%. The increase in general and administrative expenses was primarily attributable to increased employee costs of $0.4 million associated with salaries, benefits, and stock-based compensation expenses from hiring additional senior personnel; increased consulting and professional fees of $0.4 million, including fees for market assessments for our lead drug programs, public company directors&#146; fees and compensation consultant fees; and increased fees and insurance expense of $0.2 million due to our public company directors and officers insurance policy and various expenses associated with public company filings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Other (Expense) Income, Net</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other (expense) income, net consists of interest expense, which increased by $0.2 million for the three months ended September&nbsp;30, 2015 due to the interest expense on our credit facility, which we entered into in August&nbsp;2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Nine Months Ended September&nbsp;30, 2015 and 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes our results of operations for the nine months ended September&nbsp;30, 2015 and 2014, together with the dollar change in those items (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="95%" style="border-collapse:collapse;margin-left:22.3pt;">
<tr>
<td width="53%" valign="bottom" style="padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;to&nbsp;Period&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="53%" valign="bottom" style="padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Change</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating   expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,360</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,361</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,999</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,966</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,443</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,523</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating   expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22,326</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,804</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,522</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from   operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(22,326</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,804</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,522</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense,   net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(698</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(54</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(644</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:53.6%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23,024</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,858</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,166</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:1.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Research and Development Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses increased by $5.0 million to $16.4 million for the nine months ended September&nbsp;30, 2015 from $11.4 million for the nine months ended September&nbsp;30, 2014, an increase of 44%. The increase in research and development expenses was primarily attributable to a net increase of $3.6 million in </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="PB_23_180052_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">direct program costs, reflecting an increase of $3.9 million in costs related to CAT-1004 primarily related to the initiation of a Phase 1/2 clinical trial, partially offset by a net decrease of $0.3 million in costs related to our other programs. In addition, the costs related to internal research and development increased by $1.3 million, $0.9 million of which was attributable to compensation increases for new hires and $0.4 million of which was attributable to obligations under a letter agreement with a former employee, pursuant to which we agreed to make severance payments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">General and Administrative Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses increased by $1.5 million to $6.0 million for the nine months ended September&nbsp;30, 2015 from $4.4 million for the nine months ended September&nbsp;30, 2014, an increase of 34%. The increase in general and administrative expenses was primarily attributable to increased employee costs of $0.8 million associated with hiring additional senior personnel, and an increase of $0.5 million in consulting and professional expense, including recruiting costs related to the hiring of a chief business officer and senior vice president of corporate development, fees for compensation consultants and public company directors&#146; fees; and increased insurance expense of $0.2 million due to our public company directors and officers insurance policy and various expenses associated with public company filings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Other Expense, Net</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense, net consists of interest expense, which increased by $0.7 million for the nine months ended September&nbsp;30, 2015 due to the interest expense on our credit facility which we entered into in August&nbsp;2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and Capital Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Overview</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From our inception through September&nbsp;30, 2015, we had raised an aggregate of $172.1 million, of which $92.9 million consisted of gross proceeds from private placements of preferred stock, $10.0 million consisted of gross proceeds from a secured debt financing, $69.0 million consisted of gross proceeds from our IPO, and $0.2 million resulted from common stock option exercises. As of September&nbsp;30, 2015, we had $72.7 million in cash and cash equivalents.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Initial Public Offering</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2015, we completed the sale of an aggregate of 5,750,000 shares of our common stock, including 750,000 shares of common stock sold pursuant to the underwriters&#146; exercise of their option to purchase additional shares of common stock, in our IPO, at a price to the public of $12.00 per share.&#160;&#160; Net proceeds from the IPO were $61.7 million, after deducting underwriting discounts, commissions and offering-related expenses of approximately $7.3 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Credit Facility</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;27, 2014, we entered into a loan and security agreement with MidCap Financial Trust, Flexpoint MCLS Holdings, LLC and Square 1 Bank. On March&nbsp;31, 2015, we entered into an amendment to the credit facility, as amended, the Credit Facility. The Credit Facility provides for initial borrowings of $5.0 million and additional borrowings of up to $20.0 million. Concurrently with entering into the Credit Facility in August&nbsp;2014, we borrowed $5.0 million under a term loan under the Credit Facility and we issued to the lenders warrants to purchase an aggregate of 157,844 shares of our series B preferred stock (24,566 shares of common stock on an as-converted basis) at an exercise price of $0.9503 per share. Concurrently with the amendment to </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="PB_24_180108_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Credit Facility, we drew down an additional $5.0 million under our term loan under the Credit Facility and we issued to the lenders warrants to purchase an aggregate of 157,844 shares of our series B preferred stock (24,566 shares of common stock on an as-converted basis) at an exercise price of $0.9503 per share. The remaining amounts available for borrowing under this arrangement expired unused as of July&nbsp;31, 2015. All borrowings under the Credit Facility are due on October&nbsp;1, 2018 and are collateralized by substantially all of our personal property, other than our intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are no financial covenants associated with the Credit Facility; however, there are negative covenants that prohibit us from transferring any of our material assets, exclusively licensing our intellectual property (subject to certain exceptions), merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties or redeeming stock or paying dividends.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Credit Facility also includes events of default, the occurrence and continuation of any of which provides the lenders the right to exercise remedies against us and the collateral securing the loans under the Credit Facility, including cash. These events of default include, among other things, failure to pay amounts due under the Credit Facility, insolvency, the occurrence of a material adverse event, which includes a material adverse change in our business, operations or conditions (financial or otherwise) or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against us in an amount greater than $250,000. The occurrence of a material adverse change could result in acceleration of payment of the debt. At September&nbsp;30, 2015 and December&nbsp;31, 2014, we concluded that the likelihood of the acceleration of the debt was remote, as a material adverse change had not occurred and was unlikely to occur and therefore the debt was classified in current and long-term liabilities based on scheduled principal payments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We were obligated to make monthly interest-only payments on any term loans borrowed under the Credit Facility until September&nbsp;1, 2015 and we are obligated to pay 36 consecutive, equal monthly installments of principal and interest from October&nbsp;1, 2015 through September&nbsp;1, 2018. Term loans under the Credit Facility bear interest at an annual rate of 7.49%. Following the occurrence and during the continuance of an event of default, borrowings under the Credit Facility will bear interest at an annual rate that is 5.00% above the rate that is otherwise applicable. In addition, a final payment equal to 3.48% of any amounts drawn under the Credit Facility is due upon the earlier of the maturity date, acceleration of the term loans or prepayment of all or part of the term loans.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Preferred Stock Financing</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In March&nbsp;2015, we raised $12.4 million in gross proceeds from the sale of 13,062,965 shares of our series B preferred stock at a price per share of $0.9503.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Cash Flows</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides information regarding our cash flows for the nine months ended September&nbsp;30, 2015 and 2014 (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="PB_25_180118_7672"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\107905\15-18093-1\task7668863\18093-1-fr.htm',USER='107905',CD='Nov 12 21:16 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   operating activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(21,050</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,492</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   investing activities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(60</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,135</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash   provided by financing activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79,151</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,828</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net increase   (decrease) in cash and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58,041</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14,799</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Nine Months Ended September&nbsp;30, 2015 and 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Net Cash Used in Operating Activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities was $21.1 million for the nine months ended September&nbsp;30, 2015 and consisted primarily of a net loss of $23.0 million adjusted for non-cash items (including stock-based compensation expense of $1.1 million, non-cash interest expense of $0.2 million and depreciation and amortization expense of $0.1 million), along with an increase in accounts payable of $0.6 million and an increase in accrued expenses of $0.1 million, partially offset by an increase in prepaid expenses and other current assets of $0.2 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities was $14.5 million for the nine months ended September&nbsp;30, 2014 and consisted primarily of a net loss of $15.9 million adjusted for non-cash items (including stock-based compensation expense of $0.6 million and depreciation and amortization expense of $0.2 million), and a net increase in operating assets of $0.6 million, which resulted primarily from a net increase in accounts payable and accrued expenses of $0.7 million, partially offset by an increase in prepaid expenses and other current assets of $0.1 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Net Cash Used in Investing Activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities was $0.1 million during the nine months ended September&nbsp;30, 2015 compared to $5.1 million during the nine months ended September&nbsp;30, 2014, a decrease of $5.0 million, which resulted from our acquisition of $5.0 million in available-for-sale securities in September&nbsp;of 2014.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Net Cash Provided by Financing Activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by financing activities was $79.2 million during the nine months ended September&nbsp;30, 2015 compared to $4.8 million during the nine months ended September&nbsp;30, 2014. The cash provided by financing activities for the nine months ended September&nbsp;30, 2015 primarily consisted of net proceeds received from the IPO of $61.8 million, net proceeds of $12.3 million from the issuance of 13,062,965 shares of our series B preferred stock in March&nbsp;2015, and $5.0 million from our borrowings under the Credit Facility in March&nbsp;2015.&#160; The cash provided by financing activities for the nine months ended September&nbsp;30, 2014 primarily consisted of $5.0 million in proceeds from borrowings under the Credit Facility, together with $0.1 million in proceeds from the exercise of common stock options, partially offset by issuance costs of $0.3 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Funding Requirements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, and conduct clinical trials and seek marketing approval for, our product </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="PB_26_180809_5695"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ft.htm',USER='108647',CD='Nov 12 02:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect that our cash and cash equivalents, including the proceeds from our recent IPO, will enable us to fund our operating expenses and capital expenditure requirements through the first quarter of 2017. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of CAT-1004, CAT-2054 and our other current and potential product candidates, and because the extent to which we may enter into collaborations with third parties for the development of these product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the success of any future collaborations;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the extent to which we acquire or in-license other medicines and technologies;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the costs, timing and outcome of regulatory review of our product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to establish and maintain collaborations on favorable terms, if at all.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#146; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#146; rights. Additional debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">27<a name="PB_27_180851_536"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ft.htm',USER='108647',CD='Nov 12 02:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission, or SEC, rules.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contractual Obligations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In July&nbsp;2015, we entered into an amendment to our lease in order to expand the rentable square footage of our leased premises from approximately 14,817 square feet to approximately 18,876 square feet. Pursuant to the amendment we became responsible for paying rent with respect to such additional square footage on September&nbsp;1, 2015. As a result, the future minimum payments under the lease increased from approximately $1.5 million to approximately $1.8 million, of which approximately $1.6 million remained outstanding as of September&nbsp;30, 2015. Our obligation to make these payments runs through June&nbsp;30, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no other material changes to our contractual obligations and commitments described under Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">28<a name="PB_28_180855_5926"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ft.htm',USER='108647',CD='Nov 12 02:17 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3. Qualitative and Quantitative Disclosures about Market Risk</font></b><a name="Item3_QualitativeandQuantitative_060859"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of September&nbsp;30, 2015, we had cash and cash equivalents of $72.7 million and, as of December&nbsp;31, 2014, we had cash and cash equivalents of $14.7 million, consisting primarily of money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our marketable securities until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015 and December&nbsp;31, 2014, we had no liabilities denominated in foreign currencies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4. Controls and Procedures</font></b><a name="Item4_ControlsandProcedures_060901"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Management&#146;s Evaluation of our Disclosure Controls and Procedures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We maintain disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)&nbsp;or 15d-15(e)&nbsp;under the Exchange Act) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1)&nbsp;recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules&nbsp;and forms and (2)&nbsp;accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of September&nbsp;30, 2015, our disclosure controls and procedures were effective at the reasonable assurance level.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We continue to review and document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the nine months ended September&nbsp;30, 2015, there have been no changes in our internal control over financial reporting, as such term is defined in Rules&nbsp;13a-15 (f)&nbsp;and 15(d)-15(f)&nbsp;promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">29<a name="PB_29_180903_4688"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ft.htm',USER='108647',CD='Nov 12 02:17 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II &#151; OTHER INFORMATION</font></b><a name="PARTIIOTHERINFORMATION_060937"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1A. Risk Factors</font></b><a name="Item1A_RiskFactors_060939"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We operate in a dynamic and rapidly changing business environment that involves multiple risks and substantial uncertainty. The following discussion addresses risks and uncertainties that could cause, or contribute to causing, actual results to differ from expectations in material ways. In evaluating our business, investors should pay particular attention to the risks and uncertainties described below and in other sections of this Quarterly Report on Form&nbsp;10-Q and in our subsequent filings with the Securities and Exchange Commission, or SEC. These risks and uncertainties, or other events that we do not currently anticipate or that we currently deem immaterial also may affect our results of operations, cash flows and financial condition. The trading price of our common stock could also decline due to any of these risks, and you could lose all or part of your investment.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have incurred significant losses since inception and expect to incur significant and increasing losses for at least the next several years. We may never achieve or maintain profitability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred significant annual net operating losses in every year since our inception. We expect to continue to incur significant and increasing operating losses for at least the next several years. Our net losses were $18.1 million and $21.9 million for the years ended December&nbsp;31, 2013 and 2014, respectively, and $23.0 million for the nine months ended September&nbsp;30, 2015. As of September&nbsp;30, 2015, we had an accumulated deficit of $98.4 million. We have not generated any revenues from product sales, have not completed the development of any product candidate and may never have a product candidate approved for commercialization. We have financed our operations to date primarily through our initial public offering of common stock, private placements of our preferred stock and debt financing, and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical development programs. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146; equity (deficit) and working capital.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that our expenses will increase substantially if and as we:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>continue to develop and conduct clinical trials with respect to our product candidates CAT-1004 and CAT-2054, including an ongoing Phase&nbsp;1/2 clinical trial of CAT-1004 for which we initiated patient enrollment in June&nbsp;2015, and a Phase 2a clinical trial of CAT-2054 for which we intend to begin dosing in the fourth quarter of 2015;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>initiate and continue research and preclinical and clinical development efforts for our other product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>seek to identify and develop additional product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain marketing approval, if any;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">30<a name="PB_30_181019_6609"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>maintain, expand and protect our intellectual property portfolio;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>hire and retain additional personnel, such as clinical, quality control and scientific personnel;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>add operational, financial and management information systems and personnel, including personnel to support our product development and help us comply with our obligations as a public company; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>add equipment and physical infrastructure to support our research and development programs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or any future collaborator is, able to obtain marketing approval for, and successfully commercialize, one or more of our product candidates. This will require our, or any of our future collaborators&#146;, success in a range of challenging activities, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of increased expenses, and if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators does, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We began operations in 2008. Our operations to date have been limited to financing and staffing our company and developing our technology and conducting preclinical research and early-stage clinical trials for our product candidates. We have not yet demonstrated an ability to successfully conduct pivotal clinical trials, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development, especially clinical-stage biopharmaceutical companies such as ours. Predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">31<a name="PB_31_181027_2983"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">increase in connection with our ongoing activities, particularly as we initiate new clinical trials of, initiate new research and preclinical development efforts for and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we may incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a future collaborator. Furthermore, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will be required to expend significant funds in order to advance the development of CAT-1004 and CAT-2054, as well as our other product candidates. In addition, while we may seek one or more collaborators for future development of our product candidates, and, in particular, expect that we would conduct any large Phase&nbsp;3 clinical trial of CAT-2054 for the treatment of hypercholesterolemia in collaboration with one or more partners that would pay most of the associated costs, we may not be able to enter into a collaboration for any of our product candidates on suitable terms or at all. In any event, our existing cash and cash equivalents, including the net proceeds from our initial public offering of common stock, will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of any of our product candidates. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources.&#160; We do not have any committed external source of funds.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adequate additional financing may not be available to us on acceptable terms, or at all. Further, our ability to obtain additional debt financing may be limited by covenants we have made under our loan and security agreement with MidCap, Flexpoint and Square 1, including our negative pledge with respect to intellectual property in favor of MidCap, Flexpoint and Square 1, as well as our pledge to MidCap, Flexpoint and Square 1 of substantially all of our assets, other than our intellectual property, as collateral. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our existing cash and cash equivalents as of September&nbsp;30, 2015, including the net proceeds from our recent initial public offering of common stock, will enable us to fund our operating expenses, debt service and capital expenditure requirements through the first quarter of 2017. Our estimate as to how long we expect our existing cash and cash equivalents to be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, our product candidates and potential product candidates, including current and future clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to identify a collaborator for CAT-2054 and the terms and timing of any collaboration agreement that we may establish for the development and commercialization of CAT-2054;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to enter into and the terms and timing of any additional collaborations, licensing or other arrangements that we may establish;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">32<a name="PB_32_181031_6228"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the number and characteristics of future product candidates that we pursue and their development requirements;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the outcome, timing and costs of seeking regulatory approvals;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>subject to receipt of marketing approval, revenue, if any, received from commercial sales of our product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the costs of operating as a public company.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The audit opinion on our financial statements contains a going concern explanatory paragraph.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on our cash balances, recurring losses, net capital deficiency and debt outstanding as of December&nbsp;31, 2014 and our projected spending in 2015, which raise substantial doubt about our ability to continue as a going concern, the audit opinion on our audited financial statements as of and for the year ended December&nbsp;31, 2014 contains a going concern explanatory paragraph. Given our planned expenditures for the next several years, including, without limitation, expenditures in connection with our clinical trials of CAT-1004 and CAT-2054, our independent registered public accounting firm may conclude, in connection with the audit of our financial statements for fiscal year 2015 or any other subsequent period, that there is substantial doubt regarding our ability to continue as a going concern. If we are unable to continue as a going concern, we might have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. Additionally, amounts due under our credit facility may become immediately due and payable upon the occurrence of a material adverse change, as defined under the loan agreement. In addition, the inclusion of a going concern explanatory paragraph by our auditors, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital or to enter into critical contractual relations with third parties.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, our existing stockholders&#146; ownership interest may be substantially diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. Additional debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. For example, our</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">33<a name="PB_33_181036_6479"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">credit facility with MidCap, Flexpoint and Square 1 contains restrictive covenants that, among other things and subject to certain exceptions, prohibit us from transferring any of our material assets, exclusively licensing our intellectual property (subject to certain exceptions), merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties or redeeming stock or paying dividends. Future debt securities or other financing arrangements could contain similar or more restrictive negative covenants. In addition, securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#146;s ability to oversee the development of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our existing and any future indebtedness could adversely affect our ability to operate our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015, we had $10.0&nbsp;million of outstanding borrowings under our credit facility with MidCap, Flexpoint and Square&nbsp;1. We are required to repay principal and interest on these borrowings in monthly installments through October&nbsp;2018. Subject to the restrictions in this existing credit facility, we could in the future incur additional indebtedness beyond our borrowings from MidCap, Flexpoint and Square&nbsp;1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our outstanding indebtedness, including any additional indebtedness beyond our borrowings from MidCap, Flexpoint and Square&nbsp;1, combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>increasing our vulnerability to adverse changes in general economic, industry and market conditions;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents. However, we may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under our existing debt instruments. Failure to make payments or comply with other covenants under our existing debt instruments could result in an event of default and acceleration of amounts due. Under our loan and security agreement with MidCap, Flexpoint and Square 1, the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, assets or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">34<a name="PB_34_181040_2639"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">condition is an event of default. If an event of default occurs and the lenders accelerate the amounts due, we may not be able to make accelerated payments, and the lenders could seek to enforce security interests in the collateral securing such indebtedness, which includes substantially all of our assets other than our intellectual property. In addition, the covenants under our credit facility, the pledge of our assets as collateral and the negative pledge with respect to our intellectual property could limit our ability to obtain additional debt financing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our approach to the discovery and development of product candidates based on our SMART linker technology platform is unproven, and we do not know whether we will be able to develop any products of commercial value.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are focused on discovering and developing novel bi-functional small molecule drugs by applying our SMART linker technology platform. While we believe that applying our SMART linker technology platform may potentially enable drug research and clinical development that is more efficient than conventional small molecule drug research and development, this approach is unproven. We have not yet succeeded and may never succeed in demonstrating efficacy and safety for any of our product candidates in later stage clinical trials or in obtaining marketing approval thereafter. For example, although we have discovered and evaluated numerous compounds using our SMART linker technology platform, we have not yet advanced a compound into Phase&nbsp;3 clinical development and no product created using the SMART linker technology platform has ever been approved for sale.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are dependent on the success of our product candidates CAT-1004 and CAT-2054. If we are unable to complete the clinical development of, obtain marketing approval for or successfully commercialize at least one of these product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently have no products approved for sale and are investing a significant portion of our efforts and financial resources in the development of CAT-1004 for the treatment of Duchenne muscular dystrophy, or DMD, and CAT-2054 for the treatment of hypercholesterolemia. Our prospects are substantially dependent on our ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize at least one of these product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The success of CAT-1004 and CAT-2054 will depend on several factors, including the following:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>successful completion of our ongoing clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>initiation and successful enrollment and completion of additional clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration, or FDA, or any comparable foreign regulatory authority for marketing approval;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>timely receipt of marketing approvals from applicable regulatory authorities;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the performance of our future collaborators, if any;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the extent of any required post-marketing approval commitments to applicable regulatory authorities;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">35<a name="PB_35_181043_2794"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establishment of supply arrangements with third-party raw materials suppliers and manufacturers;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establishment of arrangements with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>protection of our rights in our intellectual property portfolio;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>successful launch of commercial sales following any marketing approval;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a continued acceptable safety profile following any marketing approval;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>commercial acceptance by patients, the medical community and third-party payors following any marketing approval; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to compete with other therapies, including, in the case of CAT-1004, therapies targeting dystrophin, utrophin,&#160; myostatin and inflammatory mediators.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for and successfully commercialize at least one of CAT-1004 or CAT-2054, on our own or with any future collaborator, or experience delays as a result of any of these or other factors, our business could be substantially harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our SMART linker technology platform may fail to help us discover and develop additional potential product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A significant portion of the research that we are conducting involves the development of new compounds using our SMART linker technology platform. The drug discovery that we are conducting using our SMART linker technology platform may not be successful in creating compounds that have commercial value or therapeutic utility. Our SMART linker technology platform may initially show promise in identifying potential product candidates, yet fail to yield viable product candidates for clinical development or commercialization for a number of reasons, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>compounds created through our SMART linker technology platform may not demonstrate improved efficacy, safety or tolerability;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; or</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a potential product candidate may not be capable of being produced at an acceptable cost.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new product candidates. If we are</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">36<a name="PB_36_181047_8299"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any new drug applications, or NDAs, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our NDAs for either of our most advanced product candidates, it may require that we conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA or application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">37<a name="PB_37_181050_8247"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Because we are developing CAT-1004 for the treatment of DMD, a disease for which regulatory authorities have not issued definitive guidance as to how to measure and demonstrate efficacy, there is increased risk that the outcome of our clinical trials will not be satisfactory for marketing approval.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is currently no approved therapy for DMD in the United States. In addition, there has been limited historical clinical trial experience for the development of drugs to treat the underlying cause of DMD. As a result, the design and conduct of clinical trials for this disease, particularly for drugs to address the underlying cause of this disease, is subject to increased risk. In particular, regulatory authorities in the United States and European Union have not issued definitive guidance as to how to measure and demonstrate efficacy. We anticipate that the primary endpoint in our Phase&nbsp;1/2 clinical trial of CAT-1004 for the treatment of DMD will be change in muscle inflammation as measured by magnetic resonance imaging, or MRI, of leg muscles. MRI markers of leg muscle inflammation have been observed to increase with age but decrease with initiation of steroid therapy. We intend to include as exploratory endpoints the timed function tests best suited for this age group, specifically the 10 meter walk/run, time to stand and 4-stair climb tests. However, due to the age and development stage of the patients we intend to enroll in this clinical trial, these endpoints may not be sufficiently sensitive to demonstrate efficacy over the period of the trial.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific indications that we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. For example, our IND for CAT-2003 was placed on partial clinical hold by the FDA in November&nbsp;2012 because of the need for additional nonclinical work to support potential expansion of dosing and duration of our proposed Phase&nbsp;1 multiple ascending dose trial. Although the partial clinical hold was removed in July&nbsp;2013, it is possible that any of our development programs may be placed on full or partial clinical hold by regulatory authorities at any point, which would delay and possibly prevent further development of our product candidates. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">38<a name="PB_38_181055_5893"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the risk of failure inherent in drug development, certain of the compounds that we are developing and may develop in the future using our SMART linker technology platform may be particularly susceptible to failure to the extent they are based on compounds that others have previously studied or tested, but did not progress in development due to safety, tolerability or efficacy concerns or otherwise. Our failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other comparable foreign regulators, we, or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable foreign regulatory authorities, such as the European Medicines Agency, or the EMA, impose similar restrictions. We, and any future collaborators, may never receive such approvals. We, and any future collaborators, must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we, or they, will be able to obtain these approvals.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted an NDA to the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product candidates. Any inability to complete preclinical and clinical development successfully could result in additional costs to us, or any future collaborators, and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. Moreover, if (1)&nbsp;we, or any future collaborators, are required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing that we, or they contemplate, (2)&nbsp;we, or any future collaborators, are unable to successfully complete clinical trials of our product candidates or other testing, (3)&nbsp;the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4)&nbsp;there are unacceptable safety concerns associated with our product candidates, we, or any future collaborators, may:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>be delayed in obtaining marketing approval for our product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>not obtain marketing approval at all;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>obtain approval for indications or patient populations that are not as broad as intended or desired;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>be subject to additional post-marketing testing or other requirements; or</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>be required to remove the product from the market after obtaining marketing approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">39<a name="PB_39_181058_9862"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Adverse events or undesirable side effects caused by, or other unexpected properties of, any of our product candidates may be identified during development that could delay or prevent their marketing approval or limit their use.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us, any future collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. For example, in our clinical trials of CAT-2003 we observed gastrointestinal tolerability issues, including nausea, diarrhea and vomiting, and in some cases these adverse events led to dose reductions or discontinuations. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we, or any future collaborators, may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we, or any future collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates, potential marketing approval or commercialization of our product candidates could be delayed or prevented.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We, or any future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval or commercialization of our product candidates, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>clinical trials of our product candidates may produce unfavorable or inconclusive results;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we, or any future collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials or abandon product development programs;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the number of patients required for clinical trials of our product candidates may be larger than we, or any future collaborators, anticipate, patient enrollment in these clinical trials may be slower than we, or any future collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we, or any future collaborators, anticipate;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the cost of planned clinical trials of our product candidates may be greater than we anticipate;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our third-party contractors or those of any future collaborators, including those manufacturing our product candidates or components or ingredients thereof or conducting clinical trials on our behalf or on behalf of any future collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us or any future collaborators in a timely manner or at all;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>regulators or institutional review boards may not authorize us, any future collaborators or our or their investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we, or any future collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">40<a name="PB_40_181101_9111"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\108647\15-18093-1\task7667265\18093-1-ga.htm',USER='108647',CD='Nov 12 02:20 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial&#146;s duration;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we, or any future collaborators, may have to delay, suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, such as the delay we experienced in one of our Phase&nbsp;2 clinical trials of CAT-2003 while we reformulated CAT-2003 in a coated capsule and evaluated its tolerability;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>regulators or institutional review boards may require that we, or any future collaborators, or our or their investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the FDA or comparable foreign regulatory authorities may disagree with our, or any future collaborators&#146;, clinical trial designs or our or their interpretation of data from preclinical studies and clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we, or any future collaborators, enter into agreements for clinical and commercial supplies;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product development costs for us, or any future collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we, or any future collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any future collaborators, to bring products to market before we, or any future collaborators, do and impair our ability, or the ability of any future collaborators, to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">41<a name="PB_41_181213_3881"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we, or any future collaborators, experience delays or difficulties in the enrollment of patients in clinical trials, our or their receipt of necessary regulatory approvals could be delayed or prevented.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We, or any future collaborators, may not be able to initiate or continue clinical trials for any of our product candidates if we, or they, are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory authorities, such as the EMA. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the size and nature of the patient population;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the severity of the disease under investigation;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the proximity of patients to clinical sites;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the eligibility criteria for the trial;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the design of the clinical trial;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>efforts to facilitate timely enrollment;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>competing clinical trials; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In particular, the successful completion of our clinical development program for CAT-1004 for the treatment of DMD is dependent upon our ability to enroll a sufficient number of patients with DMD. DMD is a rare disease with a small patient population. Further, there are only a limited number of specialist physicians that regularly treat patients with DMD and major clinical centers that support DMD treatment are concentrated in a few geographic regions. In addition, other companies are conducting clinical trials and have announced plans for future clinical trials that are seeking, or are likely to seek, to enroll patients with DMD and patients are generally only able to enroll in a single trial at a time. The small population of patients, competition for these patients and the limited trial sites may make it difficult for us to enroll enough patients to complete our clinical trials for CAT-1004 in a timely and cost-effective manner.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The clinical trials that we conduct may also have inclusion criteria that further limit the population of patients that we are able to enroll. For example, for the Phase&nbsp;1/2 clinical trial of CAT-1004 for which we initiated patient enrollment in June&nbsp;2015, we are enrolling only ambulatory boys between ages four and seven who have not used steroids for at least six months prior to the trial. These inclusion criteria could present challenges to enrollment because steroid therapy for DMD is often initiated in this age range.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our inability, or the inability of any future collaborators, to enroll a sufficient number of patients for our, or their, clinical trials could result in significant delays or may require us or them to abandon one or more clinical trials altogether. Enrollment delays in our, or their, clinical trials may result in increased development costs for our product candidates, delay or halt the development of and approval processes for our product candidates and jeopardize our, or any future collaborators&#146;, ability to commence sales of and generate revenues from our product candidates, which could cause the value of our company to decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">42<a name="PB_42_181226_2270"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any future collaborators, to market the drug could be compromised.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>regulatory authorities may withdraw their approval of the drug or seize the drug;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148; warning or a contraindication;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>we, or any future collaborators, could be sued and held liable for harm caused to patients;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the drug may become less competitive; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our reputation may suffer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never commercialized a product. Even if one of our product candidates is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">43<a name="PB_43_181232_6952"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the efficacy and safety of the product;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the potential advantages of the product compared to alternative treatments;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the prevalence and severity of any side effects;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the clinical indications for which the product is approved;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>limitations or warnings, including distribution or use restrictions, contained in the product&#146;s approved labeling;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the product&#146;s convenience and ease of administration compared to alternative treatments;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the willingness of the target patient population to try, and of physicians to prescribe, the product;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the strength of sales, marketing and distribution support;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the approval of other new products for the same indications;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>changes in the standard of care for the targeted indications for the product;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the timing of market introduction of our approved products as well as competitive products;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>availability and amount of reimbursement from government payors, managed care plans and other third-party payors;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>adverse publicity about the product or favorable publicity about competitive products; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>potential product liability claims.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The potential market opportunities for our product candidates are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many assumptions, including industry knowledge and publications, third-party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution arrangements with third parties, we may not be successful in commercializing any product candidates that we develop if and when those product candidates are approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not have a sales, marketing or distribution infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">44<a name="PB_44_181238_9801"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">we must either develop a sales and marketing organization or outsource these functions to third parties. We plan to use a combination of focused in-house sales and marketing capabilities and third-party collaboration, licensing and distribution arrangements to sell any of our products that receive marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We generally plan to seek to retain full commercialization rights in the United States and Canada for products that we can commercialize with a specialized sales force and to retain co-promotion or similar rights in the United States and Canada when feasible in indications requiring a larger commercial infrastructure. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire or retain a sales force in the United States or Canada that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, our operating results may be adversely affected. If a potential partner has development or commercialization expertise that we believe is particularly relevant to one of our products, then we may seek to collaborate with that potential partner even if we believe we could otherwise develop and commercialize the product independently.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We plan to collaborate with third parties for commercialization in the United States and Canada of any products that require a large sales, marketing and product distribution infrastructure. We also plan to commercialize our product candidates outside the United States and Canada through collaboration, licensing and distribution arrangements with third parties. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues may be lower, perhaps substantially lower, than if we were to directly market and sell products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we may have little or no control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we do not establish sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our product candidates that receive marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The development and commercialization of new drug products is highly competitive. We expect that we, and any future collaborators, will face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to any of our product candidates that we, or they, may seek to develop or commercialize in the future. Specifically, there are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the key indications of our most advanced programs, including DMD and hypercholesterolemia.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are initially developing CAT-1004 for the treatment of DMD. While there are currently no therapies approved for the treatment of DMD in the United States, corticosteroid therapy is often prescribed to treat the inflammation underlying DMD and to delay loss of ambulation. In addition, a number of companies are developing therapies to treat DMD, one of which is already on the market in Europe and others are in the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">45<a name="PB_45_181242_2440"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">process of registration or late stage clinical development, including BioMarin Pharmaceuticals, Eli Lilly, Marathon Pharmaceuticals, PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are initially developing CAT-2054 for the treatment of hypercholesterolemia. There are many widely available products, including statins, cholesterol absorption inhibitors and PCSK9 monoclonal antibodies, approved for the treatment of patients with hypercholesterolemia. The market and development pipeline for cholesterol regulating therapies is especially large and competitive. If CAT-2054 is approved for the treatment of hypercholesterolemia, either as monotherapy or in combination therapies, it will face intense competition from current approved therapies as well as a number of therapeutic approaches in development, including cholesterol ester transfer protein inhibitors, including those being developed by Amgen and Merck; and other alternative therapies being developed by a range of competitors, including Esperion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we, or any future collaborators, may develop. Our competitors also may obtain FDA or other marketing approval for their products before we, or any future collaborators, are able to obtain approval for ours, which could result in our competitors establishing a strong market position before we, or any future collaborators, are able to enter the market.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of our existing and potential future competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Once an NDA is approved, the product covered thereby becomes a &#147;reference-listed drug&#148; in the FDA&#146;s publication, &#147;Approved Drug Products with Therapeutic Equivalence Evaluations.&#148; Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">46<a name="PB_46_181249_5340"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug may be typically lost to the generic product.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed drug. It is unclear whether the FDA will treat the active ingredients in our product candidates as NCEs and, therefore, afford them five years of NCE data exclusivity if they are approved. If any product we develop does not receive five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of approval. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Competition that our products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives that could harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not available, or reimbursement is available only to limited levels, we, or any future collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any future collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any future collaborators, to commercialize any of our product candidates will depend in part on the extent to which</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">47<a name="PB_47_181254_1065"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">coverage and reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any future collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we, or any future collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or any future collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We face an inherent risk of product liability claims as a result of the clinical testing of our product candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we or any future collaborators commercially sell any product that we may or they may develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>decreased demand for our product candidates or products that we may develop;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>injury to our reputation and significant negative media attention;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">48<a name="PB_48_181259_9995"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>withdrawal of clinical trial participants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>significant costs to defend resulting litigation;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>substantial monetary awards to trial participants or patients;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>loss of revenue;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>reduced resources of our management to pursue our business strategy; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the inability to commercialize any products that we may develop.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we maintain general liability insurance of $2.0&nbsp;million in the aggregate and clinical trial liability insurance of $3.0&nbsp;million in the aggregate, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Dependence on Third Parties</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We expect to seek one or more collaborators for the development and commercialization of one or more of our product candidates. For example, conducting pivotal Phase&nbsp;3 clinical trials of CAT-2054 in patients with hypercholesterolemia will likely involve significant cost and we expect that we would conduct any large Phase&nbsp;3 clinical trial of CAT-2054 in patients with hypercholesterolemia in collaboration with one or more partners. Likely collaborators may include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In addition, if we are able to obtain marketing approval for CAT-1004 and other product candidates from foreign regulatory authorities, we may enter into strategic relationships with international biotechnology or pharmaceutical companies for the commercialization of CAT-1004 and other product candidates outside of the United States and Canada.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">49<a name="PB_49_181306_6763"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. In addition, our loan and security agreement with MidCap, Flexpoint and Square 1 contains, and any collaboration agreements that we enter into in the future may contain, restrictions on our ability to enter into potential collaborations or to otherwise develop specified compounds.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we enter into collaborations with third parties for the development and commercialization of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to enter into collaborations for the development and commercialization of certain of our product candidates. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaborations involving our product candidates pose a number of risks, including the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborators may not perform their obligations as expected;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">50<a name="PB_50_181310_158"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-gc.htm',USER='105933',CD='Nov 11 18:13 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our business could be significantly harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct these clinical trials and expect to rely on these third parties to conduct clinical trials of any other product candidate that we develop. Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new contract research organization begins work. As a result, delays would likely occur, which could materially impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Further, our reliance on these third parties for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, notwithstanding the obligations of a contract research organization for a trial of one of our product candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as current Good Clinical Practices, or cGCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and institutional review boards. If we or our third-party contractors fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the marketing approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. We are also required to register clinical trials and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">51<a name="PB_51_181415_5226"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be impaired.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We contract with third parties for the manufacture and distribution of our product candidates for clinical trials and expect to continue to do so in connection with our future development and commercialization efforts. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently have no manufacturing facilities and limited personnel with manufacturing experience. We rely on contract manufacturers to produce both drug substance and drug product required for our clinical trials. We plan to continue to rely upon contract manufacturers, and, potentially collaboration partners, to manufacture commercial quantities of our products, if approved. Reliance on such third-party contractors entails risks, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>manufacturing delays if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the possible breach by the third-party contractors of our agreements with them;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the failure of third-party contractors to comply with applicable regulatory requirements;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">52<a name="PB_52_181420_5753"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the possible misappropriation of our proprietary information, including our trade secrets and know-how.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently rely, and expect to continue to rely, on a small number of third-party contract manufacturers to supply the majority of our active pharmaceutical ingredient and required finished product for our preclinical studies and clinical trials. We do not have long-term agreements with any of these third parties. If any of our existing manufacturers should become unavailable to us for any reason, we may incur some delay in identifying or qualifying replacements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations, delay our clinical trials and, if our products are approved for sale, result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our product candidates. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to future contract manufacture caused by problems at suppliers could delay shipment of our product candidates, increase our cost of goods sold and result in lost sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any of our product candidates are approved by any regulatory agency, we plan to enter into agreements with third-party contract manufacturers for the commercial production and distribution of those products. It may be difficult for us to reach agreement with a contract manufacturer on satisfactory terms or in a timely manner. In addition, we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under current good manufacturing practices, or cGMPs, that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization efforts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third-party manufacturers are required to comply with cGMPs and similar regulatory requirements outside the United States. Facilities used by our third-party manufacturers must be approved by the FDA after we submit an NDA and before potential approval of the product candidate. Similar regulations apply to manufacturers of our product candidates for use or sale in foreign countries. We do not control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our product candidates. If our manufacturers cannot successfully manufacture material that conforms to our specifications or the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable product candidate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, our manufacturers are subject to ongoing periodic inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements both prior to and following the receipt of marketing approval for any of our product candidates. Some of these inspections may be unannounced. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of which could adversely affect supplies of our product candidates and significantly harm our business, financial condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">53<a name="PB_53_181423_1002"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to commercialize our product candidates successfully may be adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary product candidates. If we do not adequately protect our intellectual property, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our novel product candidates that are important to our business. The patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file&nbsp;a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in post-grant review procedures, oppositions, derivations, reexaminations, inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">54<a name="PB_54_181427_1031"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our pending and future patent applications may not result in patents being issued which protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">While we have obtained composition of matter patents with respect to our most advanced product candidates, we also rely on trade secret protection for certain aspects of technology platform, including certain aspects of our SMART linker technology platform. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent contractors, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business and competitive position could be harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">55<a name="PB_55_181429_7990"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates and use our SMART linker technology platform without infringing the intellectual property and other proprietary rights of third parties. Third parties have U.S. and non-U.S. issued patents and pending patent applications relating to compounds and methods of use for the treatment of DMD and hypercholesterolemia, the key indications for our priority programs. If any third-party patents or patent applications are found to cover our product candidates or their methods of use, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates, including interference proceedings before the USPTO. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">56<a name="PB_56_181432_2846"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law in September&nbsp;2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#147;first to file&#148; system. The first-to-file provisions, however, only became effective in March&nbsp;2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our or our collaboration partners&#146; patent applications and the enforcement or defense of our or our collaboration partners&#146; issued patents, all of which could harm our business, results of operations and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">57<a name="PB_57_181435_457"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">58<a name="PB_58_181439_2959"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of our employees and our licensors&#146; employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical and clinical studies, the marketing approval process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drug products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">59<a name="PB_59_181443_3821"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which regulations differ from country to country. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other countries until we, or they, receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to market and sell our products in the European Union and many other jurisdictions, we, and any future collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. While we have obtained orphan drug designation from the FDA and orphan medicinal product designation from the European</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">60<a name="PB_60_181446_3011"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='60',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commission (EC) for CAT-1004 for the treatment of DMD, we, or any future collaborators, may seek orphan drug designations for other product candidates or in other jurisdictions and may be unable to obtain such designations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because FDA has taken the position that, under certain circumstances, another drug with the same active moiety can be approved for the same condition.&#160; Specifically, the FDA&#146;s regulations provide that it can approve another drug&#160; with the same active moiety&#160; for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we, or any future collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved labeling. Thus, we and any future collaborators will not be able to promote any products we develop for indications or uses for which they are not approved.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, manufacturers of approved products and those manufacturers&#146; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accordingly, assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the marketing approvals for our products withdrawn by regulatory</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">61<a name="PB_61_181449_9487"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='61',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ge.htm',USER='105933',CD='Nov 11 18:14 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">authorities and our, or any future collaborators&#146;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Any of our product candidates for which we, or any future collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any of our product candidates for which we, or any future collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding off-label use and if we, or any future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>restrictions on such products, manufacturers or manufacturing processes;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>restrictions on the labeling or marketing of a product;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>restrictions on product distribution or use;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>requirements to conduct post-marketing studies or clinical trials;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>warning letters or untitled letters;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>withdrawal of the products from the market;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>refusal to approve pending applications or supplements to approved applications that we submit;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">62<a name="PB_62_181610_9681"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='62',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>recall of products;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>restrictions on coverage by third-party payors;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>fines, restitution or disgorgement of profits or revenues;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>suspension or withdrawal of marketing approvals;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>refusal to permit the import or export of products;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>product seizure; or</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>injunctions or the imposition of civil or criminal penalties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that will be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, became law in 2010 and includes the following provisions of potential importance to our product candidates:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>expansion of federal healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>extension of manufacturers&#146; Medicaid rebate liability;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>expansion of eligibility criteria for Medicaid programs;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to report financial arrangements with physicians and teaching hospitals;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">63<a name="PB_63_181616_9799"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='63',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, other </font>legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August&nbsp;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April&nbsp;2013 and will remain in effect through 2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent product labeling and post-marketing testing and other requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our relationships with customers and third-party payors, among others, will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our arrangements with third-party payors and customers, if any, will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. These include the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Anti-Kickback Statute.</font></i>&#160; The federal healthcare Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">False Claims Laws.</font></i>&#160; The federal false claims laws impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">64<a name="PB_64_181620_4015"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='64',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">HIPAA.</font></i>&#160; The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;</p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Transparency Requirements.</font></i>&#160; Federal laws require applicable manufacturers of covered drugs, biologics, devices and supplies to report payments and other transfers of value to physicians and teaching hospitals and ownership and investment interests by physicians; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Analogous State and Foreign Laws.</font></i>&#160; Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope, can apply to our business activities, including sales or marketing arrangements, and claims involving healthcare items or services and are generally broad and are enforced by many different federal and state agencies as well as through private actions. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">65<a name="PB_65_181624_2784"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='65',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In some countries, such as the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">A fast track designation by the FDA may not actually lead to a faster development, regulatory review or approval process.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet needs for this condition, the treatment sponsor may apply for FDA fast track designation. In July&nbsp;2015, the FDA notified us that we obtained fast track designation for CAT-1004 for the treatment of DMD. Fast track designation does not ensure that we will experience a faster development, regulatory review or approval process compared to conventional FDA procedures. Additionally, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Employee Matters and Managing Growth</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our Chief Executive Officer and to attract, retain and motivate qualified personnel.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are highly dependent on the pharmaceutical research and development and business development expertise of Jill C. Milne, our President and Chief Executive Officer. Although we have entered into an employment agreement with Dr.&nbsp;Milne, this agreement does not prevent her from terminating her employment with us at any time. In the future, we may be dependent on other members of our management, scientific and development team.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. If we lose one or more of our executive officers or other key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">66<a name="PB_66_181627_1605"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='66',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to grow our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug manufacturing, regulatory affairs and sales, marketing and distribution. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a disproportionate amount of its attention to manag</font>ing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or identify, recruit and train additional qualified personnel. Our inability to manage the expansion of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our shares of common stock began trading on The NASDAQ Global Market on June&nbsp;25, 2015.&#160; Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The price of our common stock is likely to be highly volatile, which could result in substantial losses for our stockholders.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our stock price is likely to be highly volatile. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may lose some or all of your investment. The market price for our common stock may be influenced by many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the success of existing or new competitive products or technologies;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">67<a name="PB_67_181631_1629"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='67',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the timing and results of clinical trials of CAT-1004, CAT-2054 and any of our other product candidates;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>commencement or termination of collaborations for our development programs;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>failure or discontinuation of any of our development programs;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>results of clinical trials of product candidates of our competitors;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>regulatory or legal developments in the United States and other countries;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>developments or disputes concerning patent applications, issued patents or other proprietary rights;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the recruitment or departure of key personnel;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the level of expenses related to any of our product candidates or clinical development programs;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the results of our efforts to develop additional product candidates or products;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>announcement or expectation of additional financing efforts;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>sales of our common stock by us, our insiders or other stockholders;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>variations in our financial results or those of companies that are perceived to be similar to us;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>changes in estimates or recommendations by securities analysts, if any, that cover our stock;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>changes in the structure of healthcare payment systems;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>market conditions in the pharmaceutical and biotechnology sectors;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>general economic, industry and market conditions; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the other factors described in this &#147;Risk Factors&#148; section.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally, in the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because smaller pharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">68<a name="PB_68_181634_6467"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='68',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or SOX Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In our prospectus filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;on June&nbsp;25, 2015, we did not include all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ Global Market and other applicable securities rules&nbsp;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are currently evaluating these rules&nbsp;and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules&nbsp;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to SOX Section&nbsp;404 we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form&nbsp;10-K with the SEC. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">69<a name="PB_69_181637_4102"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='69',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. As of November&nbsp;1, 2015, we have outstanding 15,297,794 shares of common stock, of which 9,547,794 shares are subject to restrictions on transfer under 180-day lock up arrangements with the underwriters of our public offering.&#160; These restrictions are due to expire on December&nbsp;21, 2015, resulting in these shares becoming eligible for resale into the public market on December&nbsp;22, 2015 if they are registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including under Rules&nbsp;144 or 701.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;14, 2015, we filed a registration statement registering all shares of common stock that we may issue under our equity compensation plans. As of November&nbsp;1, 2015, we had outstanding options to purchase an aggregate of approximately 1,683,323 shares of our common stock, of which options to purchase approximately 974,831 shares were vested. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the applicable lock-up agreements entered into in connection with our public offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We do not anticipate paying any cash dividends on our capital stock in the foreseeable future, accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. Furthermore, the terms of our credit facility with MidCap, Flexpoint and Square 1 preclude us from paying dividends, and any future debt agreements may also preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control all matters submitted to stockholders for approval.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock and their affiliates, in the aggregate, beneficially owned shares representing approximately 79.6% of our capital stock as of November&nbsp;1, 2015. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>delay, defer or prevent a change in control;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>entrench our management or the board of directors; or</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">70<a name="PB_70_181641_4129"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='70',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establish a classified board of directors such that all members of the board are not elected at one time;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>allow the authorized number of our directors to be changed only by resolution of our board of directors;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>limit the manner in which stockholders can remove directors from the board;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>limit who may call a special meeting of stockholder meetings;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it is desired by, or beneficial to, our stockholders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors and officers.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">71<a name="PB_71_181646_7128"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='71',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any of our directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against us and our directors and officers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The trading market for our common stock will likely depend, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us, or provide favorable coverage. If one or more analysts downgrade our stock or change their opinion of our stock, our share price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></b><a name="Item2_UnregisteredSalesofEquityS_061649"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recent Sales of Unregistered Securities</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Set forth below is information regarding options granted by us during the three months ended September&nbsp;30, 2015 that were not registered under the Securities Act of 1933, as amended, or the Securities Act. Included is the consideration, if any, we received for such options and information relating to the section of the Securities Act, or rule&nbsp;of the Securities and Exchange Commission, or the SEC, under which exemption from registration was claimed. No underwriters were involved in any such issuances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three months ended September&nbsp;30, 2015, we granted options to purchase an aggregate of 161,867 shares of common stock, at an exercise price of $14.05 per share, to an executive officer and director and to a consultant pursuant to our 2015 Stock Incentive Plan.&#160; The stock options described above were issued in reliance on the exemption provided by Section&nbsp;4(a)(2)&nbsp;of the Securities Act.&#160; All recipients either received adequate information about us or had access, through employment or other relationships, to such information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Use of Proceeds from IPO</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2015, we completed our initial public offering, or our IPO, in which we issued and sold 5,750,000 shares of our common stock at a public offering price of $12.00 per share, including 750,000 shares of common stock sold pursuant to the underwriters&#146; exercise of their option to purchase additional shares of common stock, for aggregate gross proceeds of $69.0 million. All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144), which was declared effective by the SEC on June&nbsp;24, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The net offering proceeds to us, after deducting underwriting discounts of $4.8 million and offering expenses payable by us totaling $2.4 million, were approximately $61.7 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2015, we had used approximately $7.8 million of the net offering proceeds primarily to fund the costs of the clinical development of CAT-1004 and CAT-2054, to fund research and development to advance other product candidates and for working capital and general corporate purposes. None of the offering proceeds were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates, other than payments in the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">72<a name="PB_72_181653_3263"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='72',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;on June&nbsp;25, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 6. Exhibits</font></b><a name="Item6_Exhibits_061655"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The exhibits filed as part of this Quarterly Report on Form&nbsp;10-Q are set forth on the Exhibits Index, which Exhibit&nbsp;Index is incorporated herein by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">73<a name="PB_73_181657_6333"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='73',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>   Number</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Amendment of   Lease dated as of July 16, 2015, by and between the Registrant and DWF IV one   Kendall, LLC</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of   principal executive officer pursuant to Rules&nbsp;13a-14(a)&nbsp;or   15d-14(a)&nbsp;of the Securities Exchange Act of 1934, as adopted pursuant to   Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of   principal financial officer pursuant to Rules&nbsp;13a-14(a)&nbsp;or   15d-14(a)&nbsp;of the Securities Exchange Act of 1934, as adopted pursuant to   Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certifications pursuant   to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of   The Sarbanes-Oxley Act of 2002, by the Registrant&#146;s principal executive   officer and principal financial officer</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.INS*</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Instance Document</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.SCH*</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension   Schema Document</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.CAL*</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy   Calculation Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.DEF*</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension   Definition Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.LAB*</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Label   Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.PRE*</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy   Presentation Linkbase Document</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*Submitted electronically herewith</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">74<a name="PB_74_181706_2077"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='74',FILE='C:\jms\109191\15-18093-1\task7668639\18093-1-gg.htm',USER='109191',CD='Nov 12 18:21 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name="SIGNATURES_061743"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Catabasis   Pharmaceuticals,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;12, 2015</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:   </font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   IAN C. SANDERSON</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ian   C. Sanderson</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Chief   Financial Officer and Treasurer (Principal Financial Officer and Principal   Accounting Officer)</font></i></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">75<a name="PB_75_181750_854"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='75',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-jc.htm',USER='105933',CD='Nov 11 18:18 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a15-18093_1ex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECOND AMENDMENT OF LEASE,</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THIS SECOND AMENDMENT OF LEASE (this </font>&#147;Amendment&#148;) is effective as ofthe 16th day of July, 2015 (the &#147;<u>Effective Date&#148;</u>), by and between DWF IV ONE KENDALL, LLC, a Delaware limited liability company having an address c/o Divco West Real Estate Services,&nbsp;Inc., One Kendall Square, Cambridge, Massachusetts 02139, Attention:&#160; Property Manager (&#147;<u>Landlord&#148;</u>) and CATABASIS PHARMACEUTICALS,&nbsp;INC., a Delaware corporation having a mailing address at One Kendall Square, Building 1400, Suite&nbsp;B14202, Cambridge, Massachusetts 02139 (&#147;Tenant&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BACKGROUND:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Reference is made to a certain Lease Agreement dated December&nbsp;17, 2010, by and between RB Kendall Fee, LLC, as landlord, and Tenant, as tenant (the &#147;Original Lease&#148;), demising approximately 14,784 rentable square feet of space on the second (2&#148;a) floor of Building 1400 (the &#147;<u>Existing Premises&#148;</u>) in One Kendall Square, Cambridge, Massachusetts, as amended by (i)&nbsp;a First Amendment of Lease dated as of December&nbsp;21, 2011 (the &#147;First Amendment&#148;)&#160; and (ii)&nbsp;a Letter dated April&nbsp;18, 2012 (as so amended, the Original Lease shall be referred to herein as the &#147;Lease&#148;). Capitalized terms used, but not defmed herein, shall have the same meaning as in the Lease.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Landlord is the successor to RB Kendall Fee, LLC, and Landlord and Tenant are the current holders, respectively, of the landlord&#146;s and tenant&#146;s interests in the Lease.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">C.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The current term of the Lease is scheduled to expire on June&nbsp;30,2017.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">D.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Landlord and Tenant now desire to amend the Lease to add to the Existing Premises an additional approximately 4,059 rentable square feet of space for office use on the third (3rd) floor of Building 1400, all as more particularly set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AGREEMENTS:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree to amend the Lease as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Inclusion of Second Expansion Premises; Second Expansion Premises Term.</u> Effective as of the date that Landlord tenders delivery of the Second Expansion Premises to Tenant (the &#147;<u>Second Expansion Premises Commencement Date&#148;</u>), there shall be added to the Premises under the Lease the approximately 4,059 rentable square feet of space on the third (3rd) floor of Building No.&nbsp;1400 of the Complex, as more particularly shown on Exhibit&nbsp;2(Part&nbsp;II) attached hereto as the &#147;Second Expansion Premises&#148; (the &#147;<u>Second Expansion Premises&#148;</u>), which Exhibit&nbsp;2(Part&nbsp;<u>II</u>) shall be deemed, as of the Second Expansion Premises Commencement Date, to be attached to the Lease as part of Exhibit&nbsp;2.&#160; Exhibit&nbsp;2(Part&nbsp;I) hereto shall hereby be deemed to replace Exhibit&nbsp;2 to the Original Lease and <u>Exhibit&nbsp;I</u> of the First Amendment.&#160; As of the Second Expansion Premises Commencement Date, Exhibit&nbsp;2(Part&nbsp;I) and Exhibit&nbsp;2(Part&nbsp;II) shall together form Exhibit&nbsp;2 under the Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accordingly, as of the Second Expansion Premises Commencement Date: the term &#147;Premises&#148; in Exhibit&nbsp;1, Sheet 1 shall be amended to state:&#160; </font>&#147;An area on the second (2&#176;d) floor of Building No.&nbsp;1400 (the <b>&#147;<u>Existing Premises&#148;</u>), </b>substantially as shown on Exhibit&nbsp;2(Part&nbsp;I) attached hereto and an area on the third (3ra) of Building No.&nbsp;1400 (the <b>&#147;Second Expansion Premises&#148;), </b>as shown on Exhibit&nbsp;2(Part&nbsp;II) attached hereto.&#148;</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">The Term of the Lease for the Second Expansion Premises shall be the period beginning on the Second Expansion Premises Commencement Date and ending on June&nbsp;30, 2017 (the <b>&#147;<u>Second Expansion Premises Term&#148;</u>).&#160; </b>Landlord anticipates delivering possession of the Second Expansion Premises to Tenant on the Effective Date; provided, however, that if Landlord, for any reason whatsoever, cannot deliver possession of the Second Expansion Premises to Tenant on the Effective Date, this Amendment shall not be void or voidable, nor shall Landlord be liable for any loss or damage resulting therefrom, but in that event, there shall be no accrual of Yearly Rent (subject to the provisions hereof) with respect to the Second Expansion Premises until Landlord delivers possession of the Second Expansion Premises to Tenant.&#160; Tenant&#146;s inability or failure to take possession of the Second Expansion Premises when</font>  </font>delivery is tendered by Landlord shall not delay the Second Expansion Premises Commencement Date or Tenant&#146;s obligation to pay Yearly Rent with respect thereto.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Except for the below-described use of the Second Expansion Premises in Section&nbsp;3 of this Amendment and as otherwise provided herein and except to the extent inconsistent herewith, all terms and provisions ofthe Lease shall be applicable to Tenant&#146;s leasing of the Second</font>  </font>Expansion Premises.&#160; As of the Second Expansion Premises Commencement Date, the Premises under the Lease shall consist of the Existing Premises and the Second Expansion Premises.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;As-Is&#148; Condition of Second Expansion Premises.&#160; The Second Expansion Premises shall be leased to Tenant as of, and Landlord shall deliver possession thereof to Tenant on, the Second Expansion Premises Commencement Date in its &#147;as is&#148; condition as of the date of this Amendment (provided that the same shall be in broom clean condition and free of all tenants and/or occupants and their personal property), without any obligation on the part of Landlord to perform any construction therein or to prepare the same for Tenant&#146;s occupancy or otherwise or to pay any allowances therefor.&#160; Article&nbsp;4 of the Original Lease and Sections 6 and 7 of the First Amendment shall not apply to the Second Expansion Premises.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Permitted Use of Second Expansion Premises.&#160; Notwithstanding any terms or provisions of the Lease to the contrary, including <u>Exhibit&nbsp;1</u> of the Original Lease, Tenant shall only use the Second Expansion Premises for general office purposes and not for any other purposes.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font style="height:2px;left:0px;margin-left:345px;margin-top:34px;position:absolute;width:28px;z-index:-1895824384;"><img width="28" height="2" src="g180931ki01i001.gif"></font>4.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Payment of Yearly Rent Attributable to Second Expansion Premises</u>.&#160; Throughout the Second Expansion Premises Term (i.e., through June&nbsp;30, 2017), in addition to all other amounts due and payable by Tenant under the Lease, Tenant shall pay to Landlord monthly installments of Yearly Rent attributable to the Second Expansion Premises as follows and otherwise as set forth in the Yearly Rent payment provisions of the Lease:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_213158_6456"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="60%" style="border-collapse:collapse;margin-left:1.5in;">
<tr>
<td width="74%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:74.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Monthly<br>    <font style="position:relative;top:.5pt;">Rent</font></font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Amendment   Premises Commencement Date -August 31,2015</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.00</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">September&nbsp;1,   2015 &#150; May&nbsp;31,2016</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" style="padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,544.75</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;1,2016   - May31,2017</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,883.00</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;1,   2017 - June&nbsp;30, 2017</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" style="padding:0in 0in 0in 0in;width:18.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,221.25</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Operating Expense Sha:re and Tax Share for Expansion Premises</u>.&#160; Effective as of the Second Expansion Premises Commencement Date and continuing for the Second Expansion Premises Term <u>(i.e.</u>, through June&nbsp;30, 2017), Tenant shall make Tax Share and Operating Expense Share payments attributable to the Second Expansion Premises in accordance with the terms and conditions of Article&nbsp;9 of the Lease, as amended hereby; provided, however, that with respect to such payments for the Second Expansion Premises only, any reference in Article&nbsp;9, or in any definition used to calculate Tax Share or Operating Share, to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 60.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;&#147;Tenant&#146;s Proportionate Building Share&#148; shall be deemed to be a reference to 3.14%;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 60.65pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;</font>&#147;Tenant&#146;s Proportionate Common Share&#148; shall be deemed to be a reference to 0.63%; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 60.65pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;&#147;Premises&#148; shall be deemed to be a reference to the Second Expansion Premises.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Electricity Charges for Second Expansion Premises.&#160; During the Second Expansion Premises Term, (i)&nbsp;in the event that electricity consumption for the Second Expansion Premises is separately metered, Tenant shall pay directly to the appropriate utility provider any and all costs of electricity utilized in or for the Second Expansion Premises and in support of any of Tenant&#146;s equipment, wherever located, or (ii)&nbsp;in the event that electricity consumption for the Second Expansion Premises is measured by a checkmeter, sub-meter or other measuring device, Tenant shall pay to Landlord, as additional rent, for Tenant&#146;s electrical consumption in the manner set forth in Section&nbsp;8.l(b)&nbsp;ofthe Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Use of Hazardous Materials In Second Expansion Premises</u>.&#160; Notwithstanding any terms or provisions of the Lease to the contrary, Tenant shall not use, store or permit to exist any Hazardous Materials in the Second Expansion Premises, except only for Tenant&#146;s lawful use and storage of and normal and customary amounts of office cleaning and office machine products.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Use And Storage By Tenant of Hazardous Materials </u><u>In </u><u>Existing Premises</u>.&#160; Except as set forth below, Tenant shall not use, store or permit to exist in the Existing Premises any Hazardous Materials.&#160; Without in any way limiting or restricting Tenant&#146;s obligations under Section&nbsp;29.11 of the Lease, Tenant represents and warrants that the list attached hereto as Schedule 1 is a complete list of all Hazardous Materials and quantities used and stored by Tenant in the Existing Premises as of the Effective Date.&#160; In addition, Tenant shall not use, store or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_213635_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">permit to exist in the Existing Premises any Hazardous Materials other than those listed on <u>Schedule 1</u> (the &#147;Existing Premises Permitted Hazardous Materials and Quantities&#148;); provided, however, that, subject to the following provisions of this Section&nbsp;8, Tenant may make reasonable adjustments to the types of Hazardous Materials and quantities used or stored in the Existing Premises so long as:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such types and quantities of Hazardous Materials used or stored in the Existing Premises are materially consistent with the types and quantities of the Existing Premises Permitted Hazardous Materials and Quantities and are necessary to Tenant&#146;s business;</p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant has obtained and maintains all licenses, permits, registrations and consents required by applicable law (including, without limitation, Environmental Laws) (collectively, <b>&#147;<u>Required Permits&#148;</u>)&#160; </b>to use or store all such types and quantities of Hazardous Materials in the Existing Premises; provided, however, that to the extent that any of such types and/or quantities of Hazardous Materials are listed and/or identified on <u>Schedule 2</u> attached hereto, (i)&nbsp;Tenant shall provide Landlord with ten (10)&nbsp;days&#146; advanced written notice prior to Tenant filing any application for a Required Permit with any local, federal or state governmental agency, authority, commission, board or the like (each, a <b>&#147;Governmental Authority&#148;), </b>which notice shall include a copy of the proposed application, (ii)&nbsp;Tenant shall provide Landlord with at least five (5)&nbsp;days&#146; advanced written notice of any meetings with any such Governmental Authority or hearings initiated by any such Governmental Authority regarding or related to the use or storage of such Hazardous Materials in the Existing Premises, (iii)&nbsp;Landlord and its consultants shall have the right to participate in any such meeting or hearing, and (iv)&nbsp;Tenant shall otherwise keep Landlord reasonably apprised of (A)&nbsp;its discussions with any such Governmental Authority regarding the use or storage of such Hazardous Materials in the Existing Premises, and (B)&nbsp;the status of any application for any Required Permit filed with any Governmental Authority; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Within five (5)&nbsp;days of Landlord&#146;s written request from time to time, Tenant shall have provided Landlord with a revised, complete and updated <u>Schedule 1</u> reflecting the reasonable adjustments made by Tenant, and which shall constitute a complete list of all Hazardous Materials and quantities used and stored by Tenant in the Existing Premises as of the date of such revised <u>Schedule 1.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, under no circumstances shall Tenant use, store or permit to exist:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any ofthe Hazardous Materials or classes thereof listed and/or identified on <u>Schedule 3</u> attached hereto; or</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any Hazardous Materials subject to regulation under 780 CMR 307 that would cause the limitations on quantities of classes of such Hazardous Materials set forth on <u>Schedule 4</u> attached hereto to be exceeded.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_213823_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Tenant shall promptly provide Landlord with copies of any and all licenses, permits, registrations or consents relating to the use or storage of Hazardous Materials that are obtained or renewed during the Lease term.&#160; In addition, at Landlord&#146;s written request, Tenant shall complete a Hazardous Materials audit checklist, in a form reasonably acceptable to Landlord, at least annually or at sooner intervals upon Landlord&#146;s written request if Landlord has reason to believe that Tenant has violated the provisions of this <u>Section&nbsp;8</u> or other provisions of the Lease governing Hazardous Materials.&#160; In addition, Tenant shall not permit the imposition of any lien</font>  </font>by any Governmental Authority or other party to secure payment for damages caused by, or the recovery of any costs or expenses for, the cleanup, remediation, investigation, transport, disposal, release or threatened release of any Hazardous Material.&#160; Tenant also shall provide Landlord with prompt written notice in reasonable detail of (i)&nbsp;any release or threatened release at, on, under or from the Premises of which Tenant becomes aware which would reasonably be expected to exceed reportable quantities or give rise to a violation of any Environmental Laws or any provision of this Lease, or which could result in a legal obligation to investigate or remediate Hazardous Materials pursuant to, Environmental Laws; (ii)&nbsp;any notice received by Tenant, or of which Tenant has knowledge, from any Governmental Authority in connection with any such release or any violation ofEnvironmental Laws, or in connection with the presence or alleged presence of any Hazardous Materials at the Premises; or (iii)&nbsp;any incurrence of expense by any Governmental Authority or other party in connection with the assessment, containment, removal or disposal of any Hazardous Materials located at, on, in, or under, or emanating from the Premises.&#160; For purposes ofthe indemnity provisions set forth in Section&nbsp;29.11(e)&nbsp;ofthe Lease, a breach by Tenant of the provisions ofthis <u>Section&nbsp;8</u> shall be deemed to be a breach under Article&nbsp;<u>29.11</u> of the Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the provisions of Section&nbsp;29.11</font>(f)&nbsp;of the Lease, upon the expiration or earlier termination of the Lease, Tenant and anyone claiming by, through, or under Tenant, shall (A)&nbsp;provide Landlord with a completed and signed Laboratory Decommissioning Checklist in the form of <u>Schedule 5</u> attached hereto, which shall be subject to the review and approval of Landlord, on or before the date that Tenant, and anyone claiming by, through or under Tenant, vacates the Premises, and immediately prior to the time that Tenant delivers the Premises to Landlord, (B)&nbsp;decommission all laboratory space in and about the Premises, including without limitation, to the extent required to deliver a complete Laboratory Decommissioning Checklist, and otherwise in accordance with applicable laws and best practices for similarly used laboratory space, and to the satisfaction of Landlord and any Governmental Authority involved in the closure, (C)&nbsp;terminate all licenses, permits, registrations and consents obtained by Tenant and/or by anyone else by, through or on behalf of Tenant, for the use or storage of Hazardous Materials at the Premises, (D)&nbsp;dispose of all Hazardous Materials stored in and about the Premises in compliance with applicable laws (including, without limitation, all Environmental Laws), (E)&nbsp;decontaminate all surfaces and fixed equipment in the Premises, and (F)&nbsp;review and remediate and properly dispose of any specific Hazardous Materials that may be associated with any laboratory fixtures used by Tenant in the Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Amendments to EXHIBIT&nbsp;1, SHEET 1 of Lease.&#160; EXHIBIT&nbsp;1, SHEET 1 ofthe Lease is hereby amended as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The mailing address for Landlord under EXHIBIT&nbsp;1, SHEET 1 shall be deleted and the following shall be substituted therefor:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="PB_5_214144_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Landlord</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Mailing Address:</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>DWF IV One Kendall, LLC</p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Divco West Real Estate Services,&nbsp;Inc. </font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Kendall Square</font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cambridge, MA 02139</font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: &#160;Property Manager</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">With copies to:</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>DWF IV One Kendall, LLC</p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Divco West Real Estate Services,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">575 Market Street, 35th Floor</font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">San Francisco, CA 94105</font></p>
<p style="margin:0in 0in .0001pt 158.15pt;text-indent:-.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:&#160; Asset Manager</font></p>
<p style="margin:0in 0in .0001pt 158.15pt;text-indent:-.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 158.15pt;text-indent:-.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.2in;text-indent:-.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nutter, McClennen&nbsp;&amp; Fish LLP</font></p>
<p style="margin:0in 0in .0001pt 2.2in;text-indent:-.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Seaport West</font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">155 Seaport Boulevard</font></p>
<p style="margin:0in 0in .0001pt 2.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, MA 02210</font></p>
<p style="margin:0in 0in .0001pt 157.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:&#160; Timothy M. Smith,&nbsp;Esq.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The following shall be inserted as the Rent Payment Address under EXHIBIT&nbsp;1, SHEET 1:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;Rent Payment Address:&#160; </font></b>Tenant shall make rent and other payments under the Lease in accordance with the instructions and to the addresses as noted below, which payment instructions and addresses may be changed by written notice from Landlord to Tenant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant shall make all checks, in payment of rent and other sums due to Landlord under this Lease, payable to the order ofDWF IV ONE KENDALL, LLC, as mortgagor, for the benefit of GERMAN AMERICAN CAPITAL CORPORATION, as mortgagee, Account No. 432916030 and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Tenant shall deliver such checks or otherwise make such payment as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By Mail:</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City National Bank</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">P.O.&nbsp;Box 7129</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:.5pt;">San Francisco, CA 94120-7502</font></p>
<p style="margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By Wire:</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Account Name:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>DWF IV One Kendall, LLC</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Account Number:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>432916030</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bank Name:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>City National Bank- CBS/SF</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="PB_6_215156_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bank Address:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>150 California Street, 13th Floor</p>
<p style="margin:0in 0in .0001pt 3.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">San Francisco, CA 94111</font></p>
<p style="margin:0in 0in .0001pt 3.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:.5pt;">USA</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ABA Routing #:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>1220-1606-6</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Swift#:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>CINAUS6L</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contact:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="position:relative;top:.5pt;">Hoa Pham (415) 284-5700&quot;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Parking Passes.</u>&#160;&#160; Effective as ofthe Second Expansion Premises Commencement Date, Tenant shall be entitled to a total of eighteen (18) monthly parking passes at the One Kendall Square Parking Garage (the &#147;<u>Garage&#148;</u>)&#160; pursuant to and in accordance with Section&nbsp;29.14 of the Original Lease, at the then-current prevailing rate in the Garage, as such rate may vary from time to time.&#160; The current rate for such passes as of May&nbsp;1, 2015 is $260.00 per month.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Broker</u>.&#160; Landlord and Tenant each represents and warrants to the other party that it has not authorized, retained or employed, or acted by implication to authorize, retain or employ, any real estate broker or salesman to act for it or on its behalf in connection with this Amendment so as to cause the other party to be responsible for the payment of a brokerage commission, except for Cushman&nbsp;&amp; Wakefield of Massachusetts and CB Richard Ellis (collectively, the <b>&#147;<u>Broker&#148;</u>). </b>Any fees payable to the Broker are the responsibility of Landlord pursuant to separate written agreement with the Broker.&#160; Landlord and Tenant shall each indemnify, defend and hold the other party harmless from and against any and all claims by any real estate broker or salesman (other than the Broker) whom the indemnifying party authorized, retained or employed, or acted by implication to authorize, retain or employ, to act for the indemnifying party in connection with this Amendment.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterpart Execution</u>.&#160; This Amendment may be executed in counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one fully executed original Amendment, binding upon the parties hereto, notwithstanding that all of the parties hereto may not be signatories to the same counterpart.&#160; Additionally, telecopied ore&#173; mailed signatures may be used in place of original signatures on this Amendment.&#160; Landlord and Tenant intend to be bound by the signatures on the telecopied or e-mailed document, are aware that the other party will rely on the telecopied or e-mailed signatures, and hereby waive any defenses to the enforcement of the terms of this Amendment based on the form of signature.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous</u>. In all other respects, the Lease shall remain unmodified and shall continue in full force and effect, as amended hereby. The parties hereby ratify, confirm, and reaffirm all of the terms and conditions of the Lease, as amended hereby.&#160; Tenant represents and warrants to Landlord that, as of the date hereof, (a)&nbsp;Tenant is not in default under any of the terms and provisions of the Lease, (b)&nbsp;there are no uncured defaults or unfulfilled obligations on the part of Landlord under the Lease, and (c)&nbsp;no condition or circumstance exists which, with the giving of notice or the passage of time or both, would constitute a default by Landlord under the Lease.&#160; Tenant further acknowledges that Tenant has no defenses, offsets, liens, claims or counterclaims against Landlord under the Lease or against the obligations of Tenant under the Lease (including, without limitation, any rental payments or other charges due or to become due under the Lease).</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Authorization to Execute.&#160; Tenant represents and warrants to Landlord that the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="PB_7_215522_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">person signing this Amendment on behalf of Tenant is duly authorized to execute and deliver this Amendment on behalf of Tenant in accordance with a duly adopted resolution or other applicable authorization of Tenant, and that this Amendment is binding upon Tenant in accordance with its terms.&#160; Further, if requested by Landlord, Tenant shall, within thirty (30) days after such request, deliver to Landlord a certified copy of a resolution or other applicable authorization of said organization authorizing or ratifying the execution of this Amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Reservation</u>.&#160; Preparation of this Amendment by Landlord or Landlord&#146;s attorney and the submission of this Amendment to Tenant for examination or signature is without prejudice and does not constitute a reservation, option or offer to lease the Premises. This Amendment shall not be binding or effective until this Amendment shall have been executed and delivered by each of the parties hereto, and Landlord reserves the right to withdraw this Amendment upon written notice to Tenant from consideration or negotiation at any time prior to Landlord&#146;s execution and delivery of this Amendment, which withdrawal shall be without prejudice, recourse or liability.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signatures on Following Page]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="PB_8_215600_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\109206\15-18093-1\task7668638\18093-1-ki-01.htm',USER='109206',CD='Nov 12 18:21 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 2.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.2pt;text-indent:36.15pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF the parties hereto have executed this Second Amendment of Lease on the date first written above in multiple copies, each to be considered an original hereof, as a sealed instrument.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="53%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:53.74%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LANDLORD:</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="53%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:53.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="53%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:53.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DWF   IV ONE KENDALL, LLC, a Delaware limited liability company</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Divco   West Real Estate Services,&nbsp;Inc., <br>   a Delaware corporation, its Agent</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman"><img width="211" height="73" src="g180931ki03i001.gif"></font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TENANT:</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="53%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:53.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS   PHARMACEUTICALS,&nbsp;INC., a Delaware corporation</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="53%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:53.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="261" height="68" src="g180931ki03i002.gif"></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="PB_9_221051_3867"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT&nbsp;2(Part&nbsp;</font>I)&#150;OUTLINE OF EXISTING PREMISES</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 5.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This plan is intended only to show the general outline of the Existing Premises as of the date of this Amendment.&#160; Any depiction of interior windows, walls, cubicles, modules, furniture and equipment on this plan is for illustrative purposes only, but does not mean that such items exist. Landlord is not required to provide, install or construct any such items.&#160; </font>It does not in any way supersede any of Landlord&#146;s rights set forth in the Lease or this Amendment with respect to arrangements and/or locations of public parts of the Building.&#160; It is not necessarily to scale; any measurements or distances shown should be taken as approximate.&#160; The inclusion of elevators, stairways, electrical and mechanical closets, and other similar facilities for the benefit of occupants of the Building does not mean such items are part of the Existing Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="558" height="155" src="g180931ki03i003.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LEASE EXHIBIT: &nbsp;&nbsp;BUILDING 1400 FLOOR 2</font></p>    </td>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.16%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:-1.0pt;">DM:OWEST, ONE KENDAI.l SQUAAE, CMIBRIDGE.   liA</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:.5pt;">R.E.&#160; </font><font style="position:relative;top:.5pt;">DINNEI!N&#160; AltCI!IIECl&#146;S&nbsp;</font><font style="position:relative;top:.5pt;">&amp;&#160; Pi..ANNERs,JNc.</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">nJ,..,.r..uo.-a-..t&#160;&#160;&#160; </font></b><i>....... </i><i>CUIIUUJ&#160;&#160; IJII1D1m:t&#160; </i><b><i style="font-weight:bold;">Jai17U11110</i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="PB_10_222214_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT&nbsp;2(Part&nbsp;II)&#150; OUTLINE OF SECOND EXPANSION PREMISES</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This plan is intended only to show the general outline of the Second Expansion Premises as of the date of this Amendment.&#160; Any depiction of interior windows, walls, cubicles, modules, furniture and equipment on this plan is for illustrative purposes only, but does not mean that such items exist.&#160; Landlord is not required to provide, install or construct any such items.&#160; </font>It does not in any way supersede any of Landlord&#146;s rights set forth in the Lease or this Amendment with respect to arrangements and/or locations of public parts of the Building.&#160; It is not necessarily to scale; any measurements or distances shown should be taken as approximate.&#160; The inclusion of elevators, stairways, electrical and mechanical closets, and other similar facilities for the benefit of occupants of the Building does not mean such items are part of the Second Expansion Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="525" height="273" src="g180931ki03i004.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LEASE EXHIBIT:&nbsp;&nbsp; BUILDING 1400 - FLOOR 3</font></p>    </td>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.16%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:-1.0pt;">DIYCOWEST, ONE KENDAll SQUARE.   CN.IBRIDGE,&nbsp;&nbsp; ILl.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="197" height="15" src="g180931ki03i005.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt 1.0pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule&nbsp;1</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">List of Existing Premises Permitted Hazardous Materials and Quantities</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[See Attached]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt 1.0pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 2</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hazardous Materials Requiring Prior Notice to Landlord</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Selected biological agents and toxins (Select Agents) as defined by the Federal Select Agent Program (http://www.selectagents.gov/) which have the potential to pose a severe threat to public, animal or plant health or to animal or plant products <u>and</u> require registration to possess, use or transfer. Select Agents are regulated under 7CFR Part&nbsp;331, 9 CFR Part&nbsp;121 and 42 CFR Part&nbsp;73, and may also be regulated by the City of Cambridge.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Chemicals that present a high level of security risk under the April&nbsp;2007 Department of Homeland Security- Chemical Facilities Anti-Terrorism Standards (CFATS) regulation (http://www.dhs.gov/identifying-facilities-covered-chemical-security-regulation), that are at or above the applicable Screening Threshold Quantity.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The following chemicals: </p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Perchloric Acid</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Picric Acid</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pyrophoric Material: As defined in 780 CMR as a chemical with an auto ignition temperature in air, at or below a temperature of 130&#176;F (54.4&#176;C).</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Oxidizer Class&nbsp;3: As defined in 780 CMR as an oxidizer that will cause a severe increase in the burning rate of combustible materials with which the oxidizer comes in contact or that will undergo vigorous self-sustained decomposition due to contamination or exposure to heat.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Toxic Gas: As defined in 527 CMR as a gas that has a median lethal concentration (LC50) in air of more than 200 parts per million, but not more than 2,000 parts per million by volume of gas or vapor, or 2 milligrams per liter but no more than 20 milligrams per liter of mist, fume, or dust, when administered by continuous inhalation for 1 hour (or less if death occurs within 1 hour) to albino rats weighing between 0.44lb and 0.66lb (200 and 300 grams) each.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corrosive Gas: As defined in 527 CMR as a gas that causes visible destruction of or irreversible alterations in living tissue by chemical action at the site of contact.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Radioactive Materials and Devices: as regulated in 105 CMR 120 Radiation Control Program.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule3</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prohibited Hazardous Materials</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Explosive Materials:</u> as defined in 18 USC 841(c)&nbsp;ofthe Federal explosives statutes in United States Code, CHAPTER 40- IMPORTATION, MANUFACTURE, DISTRIBUTION AND STORAGE OF EXPLOSIVE MATERIALS.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Oxidizer Class&nbsp;4:</u> As defined in 780 CMR as an oxidizer that can undergo an explosive reaction due to contamination or exposure to thermal or physical shock. Additionally, the oxidizer will enhance the burning rate and is capable of causing spontaneous ignition of combustibles.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Organic Peroxides:</u> As defined in 780 CMR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unclassified detonable: Organic peroxides which are capable of detonation. These peroxides present an extremely high explosion hazard through rapid explosive decomposition.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Class&nbsp;1: Class&nbsp;I organic peroxides are capable of deflagration, but not detonation. These peroxides present a high explosion hazard through rapid decomposition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unstable (reactive) <u>ma</u>terials: As defined in 780 CMR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Class&nbsp;4: Materials that in themselves are readily capable of detonation or explosive decomposition or explosive reaction at normal temperatures and pressures. This class includes, among others, materials that are sensitive to localized thermal or mechanical shock at normal temperatures and pressures.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Class&nbsp;3: Materials that in themselves are capable of detonation or explosive decomposition or explosive reaction, but that require a strong initiating source or that must be heated under confmement before initiation. This class includes, among others, materials that are sensitive to thermal or mechanical shock at elevated temperatures and pressures.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Water-reactive materials:</u> As defined in 780 CMR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Class&nbsp;3: Materials which react explosively with water without requiring heat or confinement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Cryogenic liquids (flammable or oxidizing): As defined in 780 CMR as any liquid that has a boiling point below -200&#176;F (-129&#176;C).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Highly Toxic Gas: As defined in 527 CMR as a chemical that has a median lethal concentration (LC50) in air of200 parts per million by volume or less of gas or vapor, or 2 milligrams per liter or less of mist, fume, or dust, when administered by continuous inhalation</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">for I hour (or less if death occurs within I hour) to albino rats weighing between 0.44lb and</font>  </font>0.66 lb (200 and 300 grams) each.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unstable (reactive) gas: As defined in 527 CMR as a gas that, in the pure state or as commercially produced, will vigorously polymerize, decompose, or condense; become self&#173; reactive; or otherwise undergo a violent chemical reaction under condition of shock, pressure, or temperature.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pyrophoric gas: As defined in 527 CFR as a gas with an auto ignition temperature in air, at or below a temperature of 130&#176;F (54.4&#176;C).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\15-18093-1\task7666708\18093-1-ki-03.htm',USER='105537',CD='Nov 12 00:32 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Schedule 4   Total Allowable Quantities of Hazardous Materials in Existing Premises 780   CMR Table 307.8(1) 780 CMR Table 307.8(1) Note D 780 CMR Table 307.8(1) Note   E 780 CMR Table 417.2 780 CMR Table 417.2 Class Baseline permitted storage   Adjusted for 100% A.S. Adjusted for 100% cabinets Adjusted for both A.S.   &amp; cab. % Above or Below Grade Total Control Areas NET STORAGE PERMITTED   FOR TOTAL CONTROL TENANT STORAGE PERMITTED Flammable liquid 1A 30 gallons 60   60 120 0.75 3 270 158.32 gallons Flammable liquid 1B 60 gallons 120 120 240   0.75 3 540 316.64 gallons Flammable liquid 1C 90 gallons 180 180 360 0.75 3   810 474.95 gallons Flammable liquid Combined Class 1 120 gallons 240 240 480   0.75 3 1080 633.27 gallons Combustible liquid Class 2 120 gallons 240 240 480   0.75 3 1080 633.27 gallons Combustible Liquid Class 3A 330 gallons 660 660   1320 0.75 3 2970 1741.50 gallons Combustible liquid Class 3B 13200 gallons No   Limit if storage area has automatic sprinkler system(307.8(l) Note F) 26400   No Limit if storage area has automatic sprinkler system(307.8(l) Note F) 0.75   3 No Limit If storage area has automatic sprinkler system[307.8(l) Note F) No   Limit if storage area has automatic sprinkler system(307.8(l) Note F) gallons   Flammable Gas (Gaseous and Liquified) 30 gallons 1000 ft3 at STP 60 2000 60   2000 120 4000 0.75 0.75 33 270 9000 158.32 5277.28 gallons ft3 at STP   Flammable Solid 125 lbs 250 250 500 0.75 3 1125 659.65 lbs Organic Peroxide   UD 1 lbs Facility must have automatic sprinkler system (307.8(1) Note H) 2 2   0.75 3 4.5 2.64 lbs Organic Peroxide 5 lbs 10 10 20 0.75 3 45 2639 lbs   Organic Peroxide 50 lbs 100 100 200 0.75 3 450 263.86 lbs Organic Peroxide   III 125 lbs 250 250 500 0.75 3 1125 659.65 lbs Oxidizer 4 libs Facility must   have automatic sprinkler system (307.8(1) Note H) 2 2 0.75 3 4.5 2.64 lbs   Oxidizer 3 10 lbs 20 20 40 0.75 3 90 52.77 lbs Oxidizer 2 250 lbs 500 500   1000 0.75 3 2250 1319.32 lbs Oxidizer 1 1000 lbs 2000 2000 4000 0.75 3 9000   5277.28 lbs Oxidizer Gas (Gaseous or Liquified] 15 gallons 1500 ft3 at STP 30   3000 30 3000 60 6000 0.75 0.75 33 135 13500 79.16 7915.32 gallons ft3 at STP   Cryogenics Flammable or Oxidizing 45 gallons 90 gallons Not applicable (780   CMR 307.8(1)) 90 0.75 3 202.5 118.74 gallons Pyrophoric Material 4 lbs   Facility must have automatic sprinkler system (307.811) Note H) 8 8 0.75 3 18   10.55 lbs Unstable Class 4 1 lbs Facility must have automatic sprinkler   system (307.8(1) Note H) 2 2 0.75 3 4.5 2.64 lbs Unstable Class 3 5 lbs 10 10   20 0.75 3 45 26.39 lbs Unstable Class 2 50 lbs 100 100 200 0.75 3 450 263.86   lbs Unstable Class 1 125 lbs 250 250 500 0.75 3 1125 659.66 lbs Water   Reactive Class 3 5 lbs 10 10 20 0.75 3 45 26.39 lbs Water Reactive Class 2 50   lbs 100 100 200 0.75 3 450 263.86 lbs Water Reactive No limit No limit No   limit No limit 0.75 3 No limit No limit lbs SF DISTRIBUTION Suite Total   Allocation 14784 25213 0.59</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="942" src="g180931ki05i001.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667271\18093-1-ki-05.htm',USER='105733',CD='Nov 12 02:21 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt 1.0pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule 5</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Laboratory Decommissioning Checklist</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tenant Laboratory Decommissioning Checklist</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tenant Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tenant</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Location:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Waste Management</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">If</font></i><i>you used and/or stored the following materials, please put a </i>&#147; <i>v&#148; </i><i>in the &#147;used and/or stored&#148; box.&#160; Indicate the disposal vendor and date of final removal from the laboratory.</i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Item</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Used&nbsp;and/or&nbsp;Stored</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Disposal&nbsp;Vendor<br>   Name</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Removal&nbsp;Date</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hazardous (Chemical) Waste</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gas Cylinders</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biological Waste and Sharps</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Animal Carcasses and Waste</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Radioactive Waste</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Controlled Substances</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Select Agents</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Permits and Licenses</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">If</font></i><i>you possessed any of the following permits and/or licenses, please put a </i><i>&#147;v&#148; </i><i>in the &#147;Applicable&#148; box.&#160; Indicate the date you requested termination of the permit or license, </i><i>and </i><i>whether confirmation has been received from the regulatory agency.</i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667271\18093-1-ki-07.htm',USER='105733',CD='Nov 12 02:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="25%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Permit&nbsp;or<br>   License</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Regulatory&nbsp;Agency</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Applicable?</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Date&nbsp;of<br>   Termination<br>   Request</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Confirmation<br>   from<br>   Regulator<br>   Received?</font></b></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Recombinant DNA Permit</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City of Cambridge</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosafety Permit</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City of Cambridge</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Laboratory Animal Use Permit</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City of Cambridge</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Flammables Permit</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City of Cambridge</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Wastewater Discharge Permit</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Massachusetts Water Resources Authority</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hazardous Waste Generator ID#</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Massachusetts Department of Environmental Protection</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Radiation Control License</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Massachusetts Department of Public Health</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Controlled Substances Registration</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Massachusetts Department of Public Health&nbsp;&amp;   United States Drug Enforcement Agency</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Select Agent Registration</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">United States <i>I </i>Department   of Agriculture or Homeland Security</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Laboratory Decontamination Survey</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Were all fixed surfaces in the laboratory such as   benches, fume hoods, sinks, cold rooms and warm rooms decontaminated with a   disinfectant or other efficacious decontaminant?</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">lf&#147;YES&#148;, briefly describe the decontaminants used,   specific to the hazardous materials in use and storage in the laboratory.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Did you use any mercury-containing equipment such as   thermometers, or elemental mercury?</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667271\18093-1-ki-07.htm',USER='105733',CD='Nov 12 02:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If&#147;YES&#148;, briefly   describe:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If&#147;YES&#148;, have you had the sink traps tested for   mercury contamination? If &#147;YES&#148;, attach results.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the results of the mercury test indicated the   presence of mercury, did you have it removed and decontaminated? If&#147;YES&#148;,   attach documentation.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Did you use any perchlorates in the chemical fume   hoods?</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If&#147;YES&#148;, indicate the location of the fume hood(s):</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If&#147;YES&#148;, have you had the fume hood(s)&nbsp;tested   for perchlorate residues? If &#147;YES&#148;, attach results.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the results of the perchlorate test indicated the   presence of residues, did you have the fume hood and associated ductwork   decontaminated? If&#147;YES&#148;, attach documentation.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Is there any equipment remaining in the laboratory   that will not be removed, such as but not limited to biosafety cabinets,   incubators, or freezers?</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If&#147;YES&#148;, briefly describe the equipment and the   methods used to decontaminate the equipment:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the lease period, was there ever a chemical   spill in the laboratory?</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">YES</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:-1.0pt;">NO</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;position:relative;top:-1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If&#147;YES&#148;, please provide information on the material   and quantity involved in the spill, and approximate date of the spill:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print Name of Persqn mpleting This Form:</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">El\zaiOe__ =\h J-\O'Q/Yl</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="543" height="79" src="g180931ki07i001.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667271\18093-1-ki-07.htm',USER='105733',CD='Nov 12 02:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature   of Company Officer:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="207" height="57" src="g180931ki07i002.gif"></font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">=l--....:..._/!_+_/_..:_(5&nbsp; </font></i></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\15-18093-1\task7667271\18093-1-ki-07.htm',USER='105733',CD='Nov 12 02:26 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a15-18093_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Jill C. Milne, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have reviewed this Quarterly Report on Form&nbsp;10-Q of Catabasis Pharmaceuticals,&nbsp;Inc.;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize, and report financial information; and</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;12, 2015</font></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   JILL C. MILNE, PH.D.</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jill   C. Milne, Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-ma.htm',USER='105933',CD='Nov 11 18:40 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a15-18093_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.2</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I,&nbsp;Ian C. Sanderson, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have reviewed this Quarterly Report on Form&nbsp;10-Q of Catabasis Pharmaceuticals,&nbsp;Inc.;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize, and report financial information; and</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;12, 2015</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   IAN C. SANDERSON</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ian   C. Sanderson</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Treasurer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-mc.htm',USER='105933',CD='Nov 11 18:41 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a15-18093_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AS ADOPTED PURSUANT TO</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Quarterly Report on Form&nbsp;10-Q of Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;) for the period ended September&nbsp;30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; the Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp; the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;12, 2015</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   JILL C. MILNE, PH.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jill   C. Milne, Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;12, 2015</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   IAN C. SANDERSON</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ian   C. Sanderson</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Treasurer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105933\15-18093-1\task7666523\18093-1-me.htm',USER='105933',CD='Nov 11 18:20 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>catb-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.0.103.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2015 12:23:04 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:catb="http://www.catabasis.com/20150930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="catb-20150930.xsd" />
  <!--Context Section-->
  <context id="As_Of_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesAconvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesAconvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_6_30_2015_To_6_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2015-06-30</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_6_11_2015_To_6_11_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2015-06-11</startDate>
      <endDate>2015-06-11</endDate>
    </period>
  </context>
  <context id="As_Of_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">catb:AnnualIncreaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">catb:StockIncentivePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">catb:AnnualIncreaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">catb:StockIncentivePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2015_us-gaap_PlanNameAxis_catb_EmployeeStockPurchasePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">catb:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_EmployeeStockPurchasePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">catb:AnnualIncreaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">catb:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_3_13_2015_To_3_13_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleBpreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-13</startDate>
      <endDate>2015-03-13</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanB2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">catb:TermLoanB2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_8_27_2014_To_8_27_2014_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">catb:TermLoanA2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-08-27</startDate>
      <endDate>2014-08-27</endDate>
    </period>
  </context>
  <context id="As_Of_3_13_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleBpreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-13</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanOtherThanAndBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">catb:TermLoanOtherThanAndBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">catb:TermLoanA2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_11_1_2010_To_11_30_2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2010-11-01</startDate>
      <endDate>2010-11-30</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2011_To_12_31_2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2011-12-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_DerivativeByNatureAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_DerivativeByNatureAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:WarrantsPreferredStock2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:WarrantsPreferredStock2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_dei_LegalEntityAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleBpreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">catb:StockIncentivePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2008Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">catb:StockIncentivePlan2008Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_EmployeeStockPurchasePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleBpreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleApreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleApreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2015_us-gaap_StatementClassOfStockAxis_catb_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanB2015Member_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">catb:TermLoanB2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:WarrantsPreferredStock2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">catb:TermLoanA2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:WarrantsPreferredStock2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleBpreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_8_27_2014_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">catb:SeriesConvertibleBpreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-08-27</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">catb:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_PreferredStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">catb:PreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">catb:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_9_30_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_11_1_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <instant>2015-11-01</instant>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_9_30_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_9_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="Unit12">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit1">
    <measure>iso4217:USD</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <catb:AccruedContractedResearchCostsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1109000</catb:AccruedContractedResearchCostsCurrent>
  <catb:AccruedContractedResearchCostsCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">800000</catb:AccruedContractedResearchCostsCurrent>
  <catb:ClassOfWarrantOrRightExercisablePeriod contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">P7Y</catb:ClassOfWarrantOrRightExercisablePeriod>
  <catb:DebtCostsDiscounts contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">-252000</catb:DebtCostsDiscounts>
  <catb:DebtCostsDiscounts contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">-260000</catb:DebtCostsDiscounts>
  <catb:DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">32000</catb:DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities>
  <catb:FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">0</catb:FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount>
  <catb:FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">0</catb:FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount>
  <catb:IncreaseDecreaseInDeferredRent contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-19000</catb:IncreaseDecreaseInDeferredRent>
  <catb:IncreaseDecreaseInDeferredRent contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-4000</catb:IncreaseDecreaseInDeferredRent>
  <catb:LongTermDebtOutstandingAmountDuePercentage contextRef="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit12" decimals="4">0.0348</catb:LongTermDebtOutstandingAmountDuePercentage>
  <catb:LongTermDebtOutstandingAmountDuePercentage contextRef="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="4">0.0300</catb:LongTermDebtOutstandingAmountDuePercentage>
  <catb:LongTermDebtOutstandingAmountDuePercentage contextRef="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit12" decimals="4">0.0100</catb:LongTermDebtOutstandingAmountDuePercentage>
  <catb:LongTermNotesPayableNet contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4439000</catb:LongTermNotesPayableNet>
  <catb:LongTermNotesPayableNet contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">6549000</catb:LongTermNotesPayableNet>
  <catb:MinimumNumberOfDiseasePathwaysModulatedSimultaneously contextRef="As_Of_9_30_2015" unitRef="Unit12" decimals="INF">1</catb:MinimumNumberOfDiseasePathwaysModulatedSimultaneously>
  <catb:NumberOfLinkers contextRef="As_Of_9_30_2015" unitRef="Unit12" decimals="INF">1</catb:NumberOfLinkers>
  <catb:NumberOfMoleculesUsedToCreateProductCandidates contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit12" decimals="INF">2</catb:NumberOfMoleculesUsedToCreateProductCandidates>
  <catb:NumberOfPerferredStockSeries contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit12" decimals="INF">1</catb:NumberOfPerferredStockSeries>
  <catb:OtherIncomeLossFairValueAdjustmentToWarrants contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">-9000</catb:OtherIncomeLossFairValueAdjustmentToWarrants>
  <catb:ReclassificationNonCurrentAssetsToEquity contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">1787000</catb:ReclassificationNonCurrentAssetsToEquity>
  <catb:ReclassificationStockWarrantsToEquity contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">206000</catb:ReclassificationStockWarrantsToEquity>
  <catb:SaleOfStockProceedsRecognizedNet contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-5">61700000</catb:SaleOfStockProceedsRecognizedNet>
  <catb:ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Estimated future principal payments at September&amp;nbsp;30, 2015 are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Period&amp;nbsp;Ending&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Remainder 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;834
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,333
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,333
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: discount for warrants and costs paid to lender&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(260
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,191
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Note payable, net of current portion and discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.58%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,549
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Estimated future principal payments at December&amp;nbsp;31, 2014 are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year&amp;nbsp;Ending&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;416
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,667
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,667
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: discount for warrants and costs paid to lender&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(252
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(309
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Note payable, net of current portion and discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,439
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</catb:ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock>
  <catb:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Conversion of Series&amp;nbsp;A Preferred Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,356,996&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Conversion of Series&amp;nbsp;B Preferred Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,655,992&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants for the purchase of Preferred Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants for the purchase of Common Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,405&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,839&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options to purchase Common Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,572,959&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,385,341&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;182,352&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,814,716&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,445,451&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</catb:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock>
  <catb:ScheduleOfWarrantsFairValueActivityTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table provides a roll-forward of the fair value of the 2014 Warrants and 2015 Warrants determined by Level 3 inputs (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Fair&amp;nbsp;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Issuance of warrants at fair value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;107
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Change in fair value, recorded as a component of the other (expense) income, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Reclassification to additional paid-in capital&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(206
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</catb:ScheduleOfWarrantsFairValueActivityTableTextBlock>
  <catb:ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2015&amp;nbsp;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.97&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.95&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;75.79&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;78.16&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</catb:ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock>
  <catb:StockOfferingFees contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-5">7300000</catb:StockOfferingFees>
  <catb:StockSplitPolicyTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Reverse stock split&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In connection with the IPO, the Company&amp;#x2019;s board of directors and stockholders approved a 1-for-12.85 reverse stock split of the Company&amp;#x2019;s Common Stock which was effected on June&amp;nbsp;11, 2015. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of Preferred Stock were convertible into shares of Common Stock have been adjusted to reflect the effects of the reverse stock split.&amp;nbsp;&amp;nbsp;Shares of Common Stock reserved for future issuance have been presented on an as converted basis and the financial statements disclose the adjusted conversion ratios.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</catb:StockSplitPolicyTextBlock>
  <catb:WarrantsAndRightsIssued contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">107000</catb:WarrantsAndRightsIssued>
  <catb:WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">110000</catb:WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility>
  <catb:WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">107000</catb:WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility>
  <catb:WarrantsOrRightsReclassifiedToEquity contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">206000</catb:WarrantsOrRightsReclassifiedToEquity>
  <catb:WarrantsTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;6.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August&amp;nbsp;27, 2014 and March&amp;nbsp;31, 2015, the Company issued the 2014 Warrants and 2015 Warrants to purchase an aggregate 315,688 shares of series B convertible preferred stock at an exercise price of $0.9503 per share to the lenders in connection with the Credit Facility (Note 5). The 2014 Warrants and 2015 Warrants were exercisable immediately on issuance and have a seven-year life. The 2014 Warrants and 2015 Warrants were recorded as a liability and re-measured at each reporting date using the then-current assumptions. In connection with the completion of the IPO, the 2014 Warrants and the 2015 Warrants were automatically converted into warrants exercisable for Common Stock, resulting in the reclassification of the related warrant liability to additional paid-in capital as the warrants to purchase shares of Common Stock met the criteria to be accounted for as equity instruments. The warrant liability was re-measured to fair value prior to reclassification to additional paid-in capital. As of September&amp;nbsp;30, 2015, the Company had no outstanding warrant liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table provides a roll-forward of the fair value of the 2014 Warrants and 2015 Warrants determined by Level 3 inputs (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Fair&amp;nbsp;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Issuance of warrants at fair value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;107
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Change in fair value, recorded as a component of the other (expense) income, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Reclassification to additional paid-in capital&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(206
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of warrants exercisable for 315,688 shares of series B convertible preferred stock, which upon the IPO were automatically converted into warrants exercisable for 24,566 shares of Common Stock with an exercise price of $12.14, was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June&amp;nbsp;30,&amp;nbsp;2015&amp;nbsp;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.97&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.95&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:64.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;75.79&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;78.16&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</catb:WarrantsTextBlock>
  <dei:AmendmentFlag contextRef="Duration_1_1_2015_To_9_30_2015">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2015_To_9_30_2015">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2015_To_9_30_2015">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2015_To_9_30_2015">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2015_To_9_30_2015">2015-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2015_To_9_30_2015">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2015_To_9_30_2015">0001454789</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_11_1_2015" unitRef="Unit13" decimals="INF">15297794</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2015_To_9_30_2015">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2015_To_9_30_2015">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2015_To_9_30_2015">CATABASIS PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;4.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Accrued Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,237&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;796&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued contracted research costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;800&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,109&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued professional fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;159&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;241&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;97&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,437&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,793&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1132000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">1783000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">2793000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">2437000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">791000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">159000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">2326000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">157933000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">605000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">316000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">289000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">232000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">132000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">1143000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">638000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">505000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">488000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">315000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">173000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">21000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">209000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit13" decimals="INF">9274809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember" unitRef="Unit13" decimals="INF">34839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_PreferredStockWarrantsMember" unitRef="Unit13" decimals="INF">12283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">8012987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="INF">1214700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit13" decimals="INF">9274809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember" unitRef="Unit13" decimals="INF">34839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_PreferredStockWarrantsMember" unitRef="Unit13" decimals="INF">12283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">8012987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="INF">1214700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit13" decimals="INF">1771416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember" unitRef="Unit13" decimals="INF">59405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="INF">1712011</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit13" decimals="INF">1771416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_catb_CommonStockWarrantsMember" unitRef="Unit13" decimals="INF">59405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="INF">1712011</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">15964000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">73657000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">15022000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">73300000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">13506000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">13506000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_9_30_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">72005000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">72005000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (&amp;#x201C;U.S.&amp;nbsp;GAAP&amp;#x201D;) and include all adjustments necessary for the fair presentation of the Company&amp;#x2019;s financial position for the periods presented.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The unaudited interim condensed financial statements of the Company included herein have been prepared, pursuant to the rules&amp;nbsp;and regulations of the Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules&amp;nbsp;and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements as of and for the year ended December&amp;nbsp;31, 2014 and notes thereto, included in the Company&amp;#x2019;s prospectus dated June&amp;nbsp;24, 2015, filed with the SEC pursuant to Rule&amp;nbsp;424(b)(4)&amp;nbsp;on June&amp;nbsp;25, 2015 (the &amp;#x201C;Prospectus&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&amp;#x2019;s management, the accompanying unaudited interim condensed financial statements contain all adjustments which are necessary to fairly present the Company&amp;#x2019;s financial position as of September&amp;nbsp;30, 2015, the results of its operations for the three and nine months ended September&amp;nbsp;30, 2015 and 2014 and its cash flows for the nine months ended September&amp;nbsp;30, 2015 and 2014. Such adjustments are of a normal and recurring nature. The results for the nine months ended September&amp;nbsp;30, 2015 are not necessarily indicative of the results for the year ending December&amp;nbsp;31, 2015, or for any future period.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit1" decimals="-3">30474000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_9_30_2014" unitRef="Unit1" decimals="-3">15675000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">14668000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">72709000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-14799000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">58041000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_8_27_2014_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit14" decimals="4">0.9503</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit14" decimals="4">0.9503</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_9_30_2015" unitRef="Unit14" decimals="2">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_9_30_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2014Member" unitRef="Unit14" decimals="4">0.9503</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_9_30_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanB2015Member_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2015Member" unitRef="Unit14" decimals="4">0.9503</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_8_27_2014_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit13" decimals="INF">315688</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit13" decimals="INF">315688</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_6_30_2015_us-gaap_StatementClassOfStockAxis_catb_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="INF">24566</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">24566</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_9_30_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2014Member" unitRef="Unit13" decimals="INF">157844</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_9_30_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanB2015Member_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2015Member" unitRef="Unit13" decimals="INF">157844</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2014" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_9_30_2015" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;7.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Commitments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In November&amp;nbsp;2010, the Company entered into a five-year, non-cancelable operating lease for office and laboratory space. In December&amp;nbsp;2011, the Company signed a lease amendment (the &amp;#x201C;2011 Lease Amendment&amp;#x201D;) that expanded the leased premises beginning in the second quarter of 2012. The 2011 Lease Amendment also extended the term of the existing lease through June&amp;nbsp;30, 2017. The 2011 Lease Amendment includes a free rent period for the expansion premises and escalating rent payments. In July, 2015, the Company signed another lease amendment (the &amp;#x201C;2015 Lease Amendment&amp;#x201D;) that expanded the leased premises beginning in the third quarter of 2015.&amp;nbsp;&amp;nbsp;The 2015 Lease Amendment includes escalating rent payments and is effective through June&amp;nbsp;30, 2017. The Company is recognizing rent expense on a straight-line basis over the lease term. The lease agreement provides for a five-year extension upon the completion of the lease term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future minimum payments required under the non-cancelable operating lease as of September&amp;nbsp;30, 2015 are summarized as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Period&amp;nbsp;Ending&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Remainder 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;235&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;937&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;467&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,639&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Rent expense for the three months ended September&amp;nbsp;30, 2015 and 2014 was $0.2 million and $0.2 million, respectively. Rent expense for the nine months ended September&amp;nbsp;30, 2015 and 2014 was $0.6 million and $0.5 million, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">9445451</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_CommonStockWarrantsMember" unitRef="Unit13" decimals="INF">34839</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_PreferredStockWarrantsMember" unitRef="Unit13" decimals="INF">12283</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleApreferredStockMember" unitRef="Unit13" decimals="INF">5356996</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit13" decimals="INF">2655992</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="INF">1385341</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">2814716</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_CommonStockWarrantsMember" unitRef="Unit13" decimals="INF">59405</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_EmployeeStockPurchasePlan2015Member" unitRef="Unit13" decimals="INF">182352</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2008Member" unitRef="Unit13" decimals="INF">1466274</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member" unitRef="Unit13" decimals="INF">1106685</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="INF">2572959</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_9_30_2015" unitRef="Unit14" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">132000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">15297794</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">15297794</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">493200</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">15000</us-gaap:CommonStockValue>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit13" decimals="INF">315688</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Duration_6_1_2015_To_6_30_2015_dei_LegalEntityAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="INF">315688</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:DebtDisclosureTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;5.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Notes Payable&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August&amp;nbsp;27, 2014, the Company entered into a credit facility with MidCap Financial Trust, Flexpoint MCLS Holdings, LLC and Square 1 Bank, which was subsequently amended on March&amp;nbsp;31, 2015 (as amended, the &amp;#x201C;Credit Facility&amp;#x201D;). The Credit Facility provides for initial borrowings of $5.0 million under a term loan (&amp;#x201C;Term Loan A&amp;#x201D;) and additional borrowings of up to $20.0 million under other term loans, for a maximum of $25.0 million. On August&amp;nbsp;27, 2014, the Company received proceeds of $5.0 million from the issuance of promissory notes under Term Loan A. On March&amp;nbsp;31, 2015, the Company received proceeds of $5.0 million from the issuance of promissory notes under another term loan (&amp;#x201C;Term Loan B&amp;#x201D;).&amp;nbsp;&amp;nbsp;The remaining amounts available for borrowing under this arrangement expired unused as of July&amp;nbsp;31, 2015, leaving total borrowings under the Credit Facility at $10.0 million.&amp;nbsp;&amp;nbsp;All amounts outstanding under the Credit Facility are due on October&amp;nbsp;1, 2018 and are collateralized by substantially all of the Company&amp;#x2019;s personal property, other than its intellectual property.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Interest-only payments were due monthly on amounts outstanding under the Credit Facility until September&amp;nbsp;1, 2015 and, thereafter, interest and principal payments are due in 36 equal monthly installments from October&amp;nbsp;1, 2015 through September&amp;nbsp;1, 2018.&amp;nbsp;&amp;nbsp;Amounts due under the Credit Facility bear interest at an annual rate of 7.49%. In addition, a final payment equal to 3.48% of any amounts drawn under the Credit Facility is due upon the earlier of the maturity date, acceleration of the term loans or prepayment of all or part of the term loans. The final payment is being accrued as additional interest expense using the effective-interest method from the date of issuance through the maturity date, and is recorded within other long-term liabilities.&amp;nbsp;&amp;nbsp;&amp;nbsp;In the event of prepayment, the Company is obligated to pay 1% to 3% of the amount of the outstanding principal depending upon the timing of the prepayment. The effective interest rate as of September&amp;nbsp;30, 2015 was 11.2%.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In conjunction with Term Loan A, the Company issued warrants to purchase 157,844 shares of series B convertible preferred stock at an exercise price of $0.9503 per share (the &amp;#x201C;2014 Warrants&amp;#x201D;) to the lenders. In conjunction with Term Loan B, the Company issued warrants to purchase an additional 157,844 shares of series B convertible preferred stock at an exercise price of $0.9503 per share (the &amp;#x201C;2015 Warrants&amp;#x201D;) to the lenders (see Note 6). The 2014 Warrants and 2015 Warrants were exercisable immediately and have seven-year lives. The 2014 Warrants and 2015 Warrants were initially valued at $0.1 million and $0.1 million, respectively, using the Black-Scholes option-pricing model. The Company recorded debt discounts of $0.1 million and $0.1 million upon issuance of the 2014 Warrants and 2015 Warrants, respectively, which are being accreted as interest expense using the effective-interest method over the remaining term of the loan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;There are no financial covenants associated with the Credit Facility; however, there are negative covenants restricting the Company&amp;#x2019;s activities, including limitations on asset dispositions, mergers or acquisitions; encumbering or granting a security interest in its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and entering into certain other business transactions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Upon the occurrence and continuation of an event of default, the lenders have the right to exercise certain remedies against the Company and the collateral securing the loans under the Credit Facility, including cash.&amp;nbsp;&amp;nbsp;Events of default include, among other things, failure to pay amounts due under the Credit Facility, insolvency, the occurrence of a material adverse event, which includes a material adverse change in the business, operations or conditions (financial or otherwise) of the Company or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against the Company in an amount greater than $250,000. The occurrence of a material adverse change could result in acceleration of the payment of the debt. At September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014, the Company concluded that the likelihood of the acceleration of the debt was remote, as a material adverse change had not occurred and was unlikely to occur and therefore the debt was classified in current and long-term liabilities based on scheduled principal payments. Following the occurrence and during the continuance of an event of default, borrowings under the Credit Facility shall bear interest at a rate per annum, which is five hundred basis points, or 5.0%, above the rate that is otherwise applicable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company assessed all terms and features of the Credit Facility in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, the Company assessed the economic characteristics and risks of the Credit Facility, including put and call features. The Company determined that all features of the Credit Facility were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company&amp;#x2019;s financial statements. The Company will continue to reassess the features on a quarterly basis to determine if they require separate accounting.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounted for the amendment to the Credit Facility, effective March&amp;nbsp;31, 2015, as a debt modification pursuant to ASC Topic 470-50 &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Modifications and Extinguishments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Estimated future principal payments at September&amp;nbsp;30, 2015 are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Period&amp;nbsp;Ending&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Remainder 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;834
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,333
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,333
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: discount for warrants and costs paid to lender&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(260
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,191
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Note payable, net of current portion and discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.58%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,549
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:80.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Estimated future principal payments at December&amp;nbsp;31, 2014 are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year&amp;nbsp;Ending&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;416
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,667
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,667
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: discount for warrants and costs paid to lender&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(252
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less: current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(309
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Note payable, net of current portion and discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,439
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the three and nine months ended September&amp;nbsp;30, 2015, the Company recognized $0.3 million and $0.7 million, respectively, of interest expense related to the Credit Facility.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit12" decimals="3">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit12" decimals="3">0.050</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit12" decimals="4">0.0749</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentRestrictiveCovenants contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">0</us-gaap:DebtInstrumentRestrictiveCovenants>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2014Member" unitRef="Unit1" decimals="-5">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2015Member" unitRef="Unit1" decimals="-5">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">67000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">39000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">190000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">130000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="As_Of_12_31_2014_us-gaap_DerivativeByNatureAxis_us-gaap_WarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">108000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="As_Of_12_31_2014_us-gaap_DerivativeByNatureAxis_us-gaap_WarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">108000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">0</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">108000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;10.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Stock-based compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Prior to the Company&amp;#x2019;s IPO, the Company granted awards to eligible participants under the 2008 equity incentive plan (&amp;#x201C;2008 Plan&amp;#x201D;). In June&amp;nbsp;2015, the Company&amp;#x2019;s board of directors adopted and the Company&amp;#x2019;s stockholders approved the 2015 Stock Incentive Plan (&amp;#x201C;2015 Plan&amp;#x201D;), which became effective immediately prior to the effectiveness of the Company&amp;#x2019;s IPO. Subsequent to the Company&amp;#x2019;s IPO, option grants are awarded to eligible participants only under the 2015 Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The 2015 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The Company&amp;#x2019;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2015 Plan. The maximum number of shares of Common Stock that may be delivered in satisfaction of awards under the 2015 Plan is 1,068,287 shares, plus (1)&amp;nbsp;25,942 shares that were available for grant under the 2008 Plan immediately prior to the closing of the IPO, (2)&amp;nbsp;the number of shares of Common Stock subject to outstanding awards under the 2008 Plan upon closing of the IPO that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right and (3)&amp;nbsp;an annual increase, to be added the first day of each fiscal year, beginning with the fiscal year ending December&amp;nbsp;31, 2016 and continuing until, and including, the fiscal year ending December&amp;nbsp;31, 2025, equal to the lowest of 1,297,334 shares of Common Stock, 4% of the number of shares of Common Stock outstanding on the first day of the fiscal year and an amount determined by the Company&amp;#x2019;s board of directors.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of September&amp;nbsp;30, 2015, the Company had reserved 1,466,274 shares of Common Stock under the 2008 Plan, of which none remained available for future issuance.&amp;nbsp;&amp;nbsp;As of September&amp;nbsp;30, 2015, the Company had reserved 1,106,685 shares of Common Stock under the 2015 Plan, of which 860,948 shares remained available for future issuance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Stock Options&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the Company&amp;#x2019;s stock option activity and related information follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Exercise&amp;nbsp;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Remaining&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Contractual&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Term&amp;nbsp;(years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Agregate&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Intrinsic&amp;nbsp;Value&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in&amp;nbsp;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,226,140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.14
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,579
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;550,797
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.69
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(25,045
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.05
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Cancelled or forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39,881
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,712,011
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,560
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercisable at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;755,860
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.27
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.89
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,659
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested or expected to vest at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,586,233
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,489
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The total intrinsic value of options exercised for the three months ended September&amp;nbsp;30, 2015 and 2014 was $0, and $0.2 million, respectively. The total intrinsic value of options exercised for the nine months ended September&amp;nbsp;30, 2015 and 2014 was $0.2 million and $0.3 million, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;At September&amp;nbsp;30, 2015, the total unrecognized compensation expense related to unvested stock option awards, including estimated forfeitures, was $5.2 million. The Company expects to recognize that cost over a weighted-average period of approximately 3.1 years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Stock-based compensation expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&amp;#x2019;s statements of operations as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Nine&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;100&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;505&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;289&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;315&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;638&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;316&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;232&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,143&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;605&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June&amp;nbsp;2015, the Company&amp;#x2019;s board of directors adopted and the Company&amp;#x2019;s stockholders approved the 2015 Employee Stock Purchase Plan (the &amp;#x201C;2015 ESPP&amp;#x201D;) which became effective upon closing of the Company&amp;#x2019;s IPO. The 2015 ESPP authorizes the initial issuance of up to a total of 182,352 shares of Common Stock to participating eligible employees. The number of shares increases each January&amp;nbsp;1, commencing on January&amp;nbsp;1, 2016 and ending on December&amp;nbsp;31, 2026, by an amount equal to the lesser of one percent of the Company&amp;#x2019;s outstanding shares as of the end of the immediately preceding fiscal year, 364,705 shares and any lower amount determined by the Company&amp;#x2019;s board of directors. As of September&amp;nbsp;30, 2015 there has been no activity under the 2015 ESPP.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit14" decimals="2">-38.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit14" decimals="2">-13.55</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit14" decimals="2">-4.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit14" decimals="2">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;11.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options, warrants to purchase Common Stock and warrants to purchase preferred stock are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Nine&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,012,987&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,012,987&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,712,011&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,214,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,712,011&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,214,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,405&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,839&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,405&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,839&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,771,416&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,274,809&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,771,416&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,274,809&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">796000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">1237000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-5">5200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;September&amp;nbsp;30,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quoted&amp;nbsp;Prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;in&amp;nbsp;Active&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Markets&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Observable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Unobservable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quoted&amp;nbsp;Prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;in&amp;nbsp;Active&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Markets&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Observable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Unobservable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrant Liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="Item-0002" contextRef="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">P6Y8M12D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Item-0003" contextRef="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember">P6Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="4">0.7816</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Item-0004" contextRef="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="4">0.7579</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="4">0.0195</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Item-0001" contextRef="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="4">0.0197</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;3.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following tables present information about the Company&amp;#x2019;s financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. The Company determines the fair value of the preferred stock warrants (Note 6) using Level 3 inputs. Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;September&amp;nbsp;30,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quoted&amp;nbsp;Prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;in&amp;nbsp;Active&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Markets&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Observable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Unobservable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72,005&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quoted&amp;nbsp;Prices&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;in&amp;nbsp;Active&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Markets&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Observable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Significant&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Unobservable&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Inputs&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,506&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrant Liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:31.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014, the Company&amp;#x2019;s cash equivalents consisted principally of money market funds, which approximate their fair value due to their short-term nature. In connection with the completion of the IPO, warrants exercisable for Preferred Stock were automatically converted into warrants exercisable for Common Stock, resulting in the reclassification of the related warrant liability to additional paid-in capital as the warrants to purchase shares of Common Stock are accounted for as equity instruments (Note 6).&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&amp;#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate their fair values at September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014, due to their short-term nature. There have been no changes to the valuation methods during the year ended December&amp;nbsp;31, 2014 or the nine months ended September&amp;nbsp;30, 2015. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between levels during the year ended 2014 or the nine months ended September&amp;nbsp;30, 2015. At September&amp;nbsp;30, 2015, the carrying value of the Company&amp;#x2019;s debt approximated fair value, which was determined using Level 3 inputs, including a quoted interest rate.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">4443000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">1427000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">5966000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">2388000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">544000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">619000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">151000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">112000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">2000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">126000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">237000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">57000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">57000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">709000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">282000</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseDebt contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit1" decimals="-5">700000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit1" decimals="-5">300000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">1000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">500000</us-gaap:InterestPaid>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="Duration_12_1_2011_To_12_31_2011">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Duration_11_1_2010_To_11_30_2010">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">8871000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">14113000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">15964000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">73657000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4234000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">7411000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">108000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LineOfCredit contextRef="As_Of_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit1" decimals="-5">10000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityFrequencyOfPayments contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember">36</us-gaap:LineOfCreditFacilityFrequencyOfPayments>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member" unitRef="Unit1" decimals="-5">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanOtherThanAndBMember" unitRef="Unit1" decimals="-5">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_3_31_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit1" decimals="-5">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LitigationSettlementAmount contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember" unitRef="Unit1" decimals="-3">250000000</us-gaap:LitigationSettlementAmount>
  <us-gaap:LongTermDebt contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">5000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">10000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">2500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">3333000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">1667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">3333000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">416000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">834000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">4439000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">6549000</us-gaap:LongTermNotesPayable>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">13506000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">13506000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="As_Of_9_30_2015_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">72005000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="As_Of_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">72005000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:NatureOfOperations contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;1.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Organization and Operations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;The Company&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Catabasis Pharmaceuticals,&amp;nbsp;Inc. (the &amp;#x201C;Company&amp;#x201D;) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on the Company&amp;#x2019;s proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company&amp;#x2019;s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of the Company&amp;#x2019;s proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company seeks to develop therapies that modulate multiple targets in the disease pathway. The Company targets therapeutic areas and specific diseases with significant unmet medical needs where it believes it will have a competitive advantage. The Company&amp;#x2019;s focus is on treatments for rare diseases, such as Duchenne Muscular Dystrophy (&amp;#x201C;DMD&amp;#x201D;).&amp;nbsp;&amp;nbsp;The Company is also developing other product candidates for the treatment of serious lipid disorders. The Company was incorporated in the State of Delaware on June&amp;nbsp;26, 2008.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Initial Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June&amp;nbsp;2015, the Company completed its Initial Public Offering (the &amp;#x201C;IPO&amp;#x201D;).&amp;nbsp;&amp;nbsp;All of the shares issued and sold in the IPO were registered pursuant to a registration statement on Form&amp;nbsp;S-1, as amended.&amp;nbsp;&amp;nbsp;An aggregate of 5,750,000 shares of Common Stock registered pursuant to the registration statement were sold at a price to the public of $12.00 per share (including 750,000 shares of Common Stock sold pursuant to the exercise of an overallotment option granted to the Company&amp;#x2019;s underwriters in connection with the IPO).&amp;nbsp;&amp;nbsp;Net proceeds of the IPO were $61.7 million, after deducting underwriting discounts, commissions and offering-related expenses payable by the Company of approximately $7.3 million. In connection with the IPO, all shares of the Company&amp;#x2019;s convertible preferred stock (the &amp;#x201C;Preferred Stock&amp;#x201D;) were automatically converted into an aggregate of 9,029,549 shares of its Common Stock and its outstanding warrants to purchase 315,688 shares of Preferred Stock were automatically converted into warrants to purchase 24,566 shares of Common Stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of September&amp;nbsp;30, 2015, the Company had an accumulated deficit of $98.4 million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since inception. The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company&amp;#x2019;s products. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">4828000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">79151000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-5135000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-60000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-14492000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-21050000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-15858000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-6025000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-23024000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-8485000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April&amp;nbsp;2015, the FASB issued ASU No.&amp;nbsp;2015-03, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="display:inline;"&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability rather than as a deferred charge. It is effective for annual reporting periods beginning after December&amp;nbsp;15, 2015, but early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &amp;#x2014; Going Concern (&amp;#x201C;ASU 2014-15&amp;#x201D;), which is effective for annual periods ending after December&amp;nbsp;15, 2016.&amp;nbsp;&amp;nbsp;Early adoption is permitted.&amp;nbsp;&amp;nbsp;ASU 2014-15 provides new guidance on (1)&amp;nbsp;management&amp;#x2019;s responsibility in evaluating whether or not there is substantial doubt about a company&amp;#x2019;s ability to continue as a going concern within one year from the date the financial statements are issued each reporting period and (2)&amp;nbsp;related financial statement disclosures.&amp;nbsp;&amp;nbsp;The Company has not adopted the guidance prescribed by ASU 2014-15 and does not expect the new guidance to have a significant effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-54000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-55000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-698000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-284000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">309000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">3191000</us-gaap:NotesPayableCurrent>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">15804000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">5970000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">22326000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">8201000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-15804000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">-5970000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-22326000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-8201000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">1639000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">467000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">937000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">235000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-5">500000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-5">200000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-5">600000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-5">200000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">97000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">241000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">541000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">28000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">23000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">114000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">3000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">11000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">-2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">282000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">7000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">4976000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">159000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_9_30_2015" unitRef="Unit14" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_3_13_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit13" decimals="INF">56026590</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_3_13_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit13" decimals="INF">13062965</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;8.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March&amp;nbsp;13, 2015, the Company&amp;#x2019;s board of directors authorized the Company to increase the authorized number of shares of Series&amp;nbsp;B Preferred Stock to 56,026,590 in connection with an anticipated Series&amp;nbsp;B Preferred Stock financing. The Company subsequently issued 13,062,965 shares of Series&amp;nbsp;B Preferred Stock at $0.9503 per share, and received net proceeds of $12.3 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Upon closing the Company&amp;#x2019;s IPO on June&amp;nbsp;30, 2015, all outstanding shares of the Company&amp;#x2019;s preferred stock were automatically converted into 9,029,549 shares of Common Stock.&amp;nbsp;&amp;nbsp;As of September&amp;nbsp;30, 2015, the Company has 5,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share, with none issued or outstanding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preferred stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the board of directors of the Company. Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2014" unitRef="Unit1" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_9_30_2015" unitRef="Unit1" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">354000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">591000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">61776000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_8_27_2014_To_8_27_2014_us-gaap_LongtermDebtTypeAxis_catb_TermLoanA2014Member" unitRef="Unit1" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_LongtermDebtTypeAxis_catb_TermLoanB2015Member" unitRef="Unit1" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">12331000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Duration_3_13_2015_To_3_13_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit1" decimals="-5">12300000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">110000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">51000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">288000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">216000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">11361000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">4543000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">16360000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">5813000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">113000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">113000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">-75380000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">-98404000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,237&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;796&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued contracted research costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;800&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,109&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued professional fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;159&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;241&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;97&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,437&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,793&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Nine&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,012,987&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,012,987&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,712,011&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,214,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,712,011&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,214,700&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Common stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,405&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,839&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,405&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,839&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Preferred stock warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,771,416&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,274,809&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,771,416&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,274,809&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&amp;#x2019;s statements of operations as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Nine&amp;nbsp;Months&amp;nbsp;Ended&amp;nbsp;September&amp;nbsp;30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;173&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;100&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;505&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;289&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;315&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;638&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;316&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;232&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,143&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;605&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future minimum payments required under the non-cancelable operating lease as of September&amp;nbsp;30, 2015 are summarized as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Period&amp;nbsp;Ending&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Remainder 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;235&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;937&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;467&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.54%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,639&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:78.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Exercise&amp;nbsp;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Remaining&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Contractual&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Term&amp;nbsp;(years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Agregate&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Intrinsic&amp;nbsp;Value&amp;nbsp;&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in&amp;nbsp;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,226,140
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.14
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.15
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,579
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;550,797
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.69
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(25,045
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.05
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Cancelled or forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39,881
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,712,011
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,560
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercisable at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;755,860
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.27
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.89
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,659
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested or expected to vest at September&amp;nbsp;30, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,586,233
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,489
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit1" decimals="-3">605000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">1143000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_EmployeeStockPurchasePlan2015Member" unitRef="Unit13" decimals="INF">364705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_6_30_2015_us-gaap_PlanNameAxis_catb_EmployeeStockPurchasePlan2015Member" unitRef="Unit13" decimals="INF">182352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2008Member" unitRef="Unit13" decimals="INF">25942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member" unitRef="Unit13" decimals="INF">1068287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_9_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member" unitRef="Unit13" decimals="INF">1297334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2008Member" unitRef="Unit13" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_9_30_2015_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member" unitRef="Unit13" decimals="INF">860948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">3659000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">755860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_9_30_2015" unitRef="Unit14" decimals="2">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2015_To_9_30_2015">P6Y10M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2014_To_9_30_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-5">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_7_1_2014_To_9_30_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-5">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit13" decimals="INF">39881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit14" decimals="2">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit13" decimals="INF">550797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">6579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">4560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2014" unitRef="Unit13" decimals="INF">1226140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">1712011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="2">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_9_30_2015" unitRef="Unit14" decimals="2">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2014_To_12_31_2014">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_9_30_2015">P8Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_9_30_2015" unitRef="Unit13" decimals="INF">1586233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_9_30_2015" unitRef="Unit14" decimals="2">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2015_To_9_30_2015">P8Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit1" decimals="-3">4489000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="Duration_1_1_2015_To_9_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_StockIncentivePlan2015Member" unitRef="Unit12" decimals="2">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_AwardDateAxis_catb_AnnualIncreaseMember_us-gaap_PlanNameAxis_catb_EmployeeStockPurchasePlan2015Member" unitRef="Unit12" decimals="4">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit14" decimals="2">2.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit14" decimals="2">11.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_13_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit14" decimals="4">0.9503</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit14" decimals="2">12.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;2.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Reverse stock split&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In connection with the IPO, the Company&amp;#x2019;s board of directors and stockholders approved a 1-for-12.85 reverse stock split of the Company&amp;#x2019;s Common Stock which was effected on June&amp;nbsp;11, 2015. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of Preferred Stock were convertible into shares of Common Stock have been adjusted to reflect the effects of the reverse stock split.&amp;nbsp;&amp;nbsp;Shares of Common Stock reserved for future issuance have been presented on an as converted basis and the financial statements disclose the adjusted conversion ratios.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (&amp;#x201C;U.S.&amp;nbsp;GAAP&amp;#x201D;) and include all adjustments necessary for the fair presentation of the Company&amp;#x2019;s financial position for the periods presented.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The unaudited interim condensed financial statements of the Company included herein have been prepared, pursuant to the rules&amp;nbsp;and regulations of the Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules&amp;nbsp;and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements as of and for the year ended December&amp;nbsp;31, 2014 and notes thereto, included in the Company&amp;#x2019;s prospectus dated June&amp;nbsp;24, 2015, filed with the SEC pursuant to Rule&amp;nbsp;424(b)(4)&amp;nbsp;on June&amp;nbsp;25, 2015 (the &amp;#x201C;Prospectus&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&amp;#x2019;s management, the accompanying unaudited interim condensed financial statements contain all adjustments which are necessary to fairly present the Company&amp;#x2019;s financial position as of September&amp;nbsp;30, 2015, the results of its operations for the three and nine months ended September&amp;nbsp;30, 2015 and 2014 and its cash flows for the nine months ended September&amp;nbsp;30, 2015 and 2014. Such adjustments are of a normal and recurring nature. The results for the nine months ended September&amp;nbsp;30, 2015 are not necessarily indicative of the results for the year ending December&amp;nbsp;31, 2015, or for any future period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The preparation of the Company&amp;#x2019;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilized significant estimates and assumptions in determining the fair value of its Common Stock prior to completion of the IPO. The board of directors determined the estimated fair value of the Common Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of convertible preferred stock, the achievement of research and development milestones, the superior rights and preferences of securities senior to the Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants (&amp;#x201C;AICPA&amp;#x201D;), Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation (&amp;#x201C;AICPA Practice Aid&amp;#x201D;), to estimate the fair value of its Common Stock. The methodologies included the Option Pricing Method utilizing the Backsolve Method (a form of the market approach defined in the AICPA Practice Aid) and the Probability-Weighted Expected Return Method based upon the probability of occurrence of certain future liquidity events such as an initial public offering or sale of the Company. Each valuation methodology includes estimates and assumptions that required the Company&amp;#x2019;s judgment. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract, are determined by the Company based on input from internal project management, as well as from third-party service providers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&amp;#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate their fair values at September&amp;nbsp;30, 2015 and December&amp;nbsp;31, 2014, due to their short-term nature. There have been no changes to the valuation methods during the year ended December&amp;nbsp;31, 2014 or the nine months ended September&amp;nbsp;30, 2015. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between levels during the year ended 2014 or the nine months ended September&amp;nbsp;30, 2015. At September&amp;nbsp;30, 2015, the carrying value of the Company&amp;#x2019;s debt approximated fair value, which was determined using Level 3 inputs, including a quoted interest rate.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April&amp;nbsp;2015, the FASB issued ASU No.&amp;nbsp;2015-03, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="display:inline;"&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability rather than as a deferred charge. It is effective for annual reporting periods beginning after December&amp;nbsp;15, 2015, but early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &amp;#x2014; Going Concern (&amp;#x201C;ASU 2014-15&amp;#x201D;), which is effective for annual periods ending after December&amp;nbsp;15, 2016.&amp;nbsp;&amp;nbsp;Early adoption is permitted.&amp;nbsp;&amp;nbsp;ASU 2014-15 provides new guidance on (1)&amp;nbsp;management&amp;#x2019;s responsibility in evaluating whether or not there is substantial doubt about a company&amp;#x2019;s ability to continue as a going concern within one year from the date the financial statements are issued each reporting period and (2)&amp;nbsp;related financial statement disclosures.&amp;nbsp;&amp;nbsp;The Company has not adopted the guidance prescribed by ASU 2014-15 and does not expect the new guidance to have a significant effect on its financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">-73053000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2015" unitRef="Unit1" decimals="-3">59544000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;9.&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Common Stock Reserved for Future Issuance&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has reserved for future issuance the following number of shares of Common Stock:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Conversion of Series&amp;nbsp;A Preferred Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,356,996&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Conversion of Series&amp;nbsp;B Preferred Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,655,992&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants for the purchase of Preferred Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants for the purchase of Common Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;59,405&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,839&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options to purchase Common Stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,572,959&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,385,341&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;182,352&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,814,716&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,445,451&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Duration_6_11_2015_To_6_11_2015" unitRef="Unit12" decimals="6">0.077821</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="INF">9029549</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_6_30_2015_To_6_30_2015" unitRef="Unit13" decimals="INF">9029549</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="INF">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit13" decimals="INF">750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit13" decimals="INF">25045</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleApreferredStockMember" unitRef="Unit1" decimals="-3">47898000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesConvertibleBpreferredStockMember" unitRef="Unit1" decimals="-3">32248000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit14" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit14" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit14" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit14" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">68837703</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">37830473</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">68837703</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">34129571</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">68837703</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">34129571</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesAconvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_SeriesBConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2015_To_9_30_2015">&lt;div&gt; &lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The preparation of the Company&amp;#x2019;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilized significant estimates and assumptions in determining the fair value of its Common Stock prior to completion of the IPO. The board of directors determined the estimated fair value of the Common Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of convertible preferred stock, the achievement of research and development milestones, the superior rights and preferences of securities senior to the Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants (&amp;#x201C;AICPA&amp;#x201D;), Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation (&amp;#x201C;AICPA Practice Aid&amp;#x201D;), to estimate the fair value of its Common Stock. The methodologies included the Option Pricing Method utilizing the Backsolve Method (a form of the market approach defined in the AICPA Practice Aid) and the Probability-Weighted Expected Return Method based upon the probability of occurrence of certain future liquidity events such as an initial public offering or sale of the Company. Each valuation methodology includes estimates and assumptions that required the Company&amp;#x2019;s judgment. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract, are determined by the Company based on input from internal project management, as well as from third-party service providers.&lt;/font&gt;
		&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:0%;margin-right:0%;"&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">108000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2014Member" unitRef="Unit1" decimals="-5">100000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_9_30_2015_us-gaap_StatementClassOfStockAxis_catb_WarrantsPreferredStock2015Member" unitRef="Unit1" decimals="-5">100000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_9_30_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_StatementClassOfStockAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">0</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_9_30_2014" unitRef="Unit13" decimals="0">413622</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_7_1_2014_To_9_30_2014" unitRef="Unit13" decimals="0">444787</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_9_30_2015" unitRef="Unit13" decimals="0">5596412</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit13" decimals="0">15297794</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0002" xlink:label="Item-0002_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0003" xlink:label="Item-0003_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0004" xlink:label="Item-0004_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0001" xlink:label="Item-0001_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0001_lbl" xlink:to="Footnote-01" order="1" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">(1)   Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>catb-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.0.103.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2015 12:24:07 PM-->
<!--Modified on: 11/12/2015 12:24:07 PM-->
<xsd:schema targetNamespace="http://www.catabasis.com/20150930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:catb="http://www.catabasis.com/20150930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>00300 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" id="DisclosureFinancialInstrumentsDetails">
        <link:definition>40301 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40401 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" id="DisclosureNotesPayableDetails2">
        <link:definition>40502 - Disclosure - Notes Payable (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNotesPayableCalc2Details2" id="DisclosureNotesPayableCalc2Details2">
        <link:definition>40502 - Disclosure - Notes Payable Calc2 (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>40701 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureOrganizationAndOperations" id="DisclosureOrganizationAndOperations">
        <link:definition>10101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolices" id="DisclosureSummaryOfSignificantAccountingPolices">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Polices</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments">
        <link:definition>10301 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10401 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNotesPayable" id="DisclosureNotesPayable">
        <link:definition>10501 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>10601 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>10701 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>10801 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuance" id="DisclosureCommonStockReservedForFutureIssuance">
        <link:definition>10901 - Disclosure - Common Stock Reserved for Future Issuance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11001 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11101 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" id="DisclosureSummaryOfSignificantAccountingPolicesPolices">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Polices (Polices)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables">
        <link:definition>30303 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30403 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNotesPayableTables" id="DisclosureNotesPayableTables">
        <link:definition>30503 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>30603 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureCommitmentsTables" id="DisclosureCommitmentsTables">
        <link:definition>30703 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceTables" id="DisclosureCommonStockReservedForFutureIssuanceTables">
        <link:definition>30903 - Disclosure - Common Stock Reserved for Future Issuance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31003 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31103 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureOrganizationAndOperationsDetails" id="DisclosureOrganizationAndOperationsDetails">
        <link:definition>40101 - Disclosure - Organization and Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails" id="DisclosureSummaryOfSignificantAccountingPolicesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Polices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails" id="DisclosureNotesPayableDetails">
        <link:definition>40501 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureWarrantsDetails" id="DisclosureWarrantsDetails">
        <link:definition>40601 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockDetails">
        <link:definition>40801 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceDetails" id="DisclosureCommonStockReservedForFutureIssuanceDetails">
        <link:definition>40901 - Disclosure - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>41001 - Disclosure - Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails2" id="DisclosureStockBasedCompensationDetails2">
        <link:definition>41002 - Disclosure - Stock-based compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails3" id="DisclosureStockBasedCompensationDetails3">
        <link:definition>41003 - Disclosure - Stock-based compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41101 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="catb-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="catb-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="catb-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="catb-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="StockSplitPolicyTextBlock" id="catb_StockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="catb_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" id="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="catb_AccruedContractedResearchCostsCurrent" name="AccruedContractedResearchCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_SeriesAconvertiblePreferredStockMember" name="SeriesAconvertiblePreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility" name="WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities" name="DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_StockOfferingFees" name="StockOfferingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_StockIncentivePlan2015Member" name="StockIncentivePlan2015Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_StockIncentivePlan2008Member" name="StockIncentivePlan2008Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_EmployeeStockPurchasePlan2015Member" name="EmployeeStockPurchasePlan2015Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_AnnualIncreaseMember" name="AnnualIncreaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_SeriesConvertibleApreferredStockMember" name="SeriesConvertibleApreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_SeriesConvertibleBpreferredStockMember" name="SeriesConvertibleBpreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_NumberOfPerferredStockSeries" name="NumberOfPerferredStockSeries" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock" name="ScheduleOfWarrantsFairValueActivityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock" name="ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount" name="FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock" name="ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_LongTermDebtOutstandingAmountDuePercentage" name="LongTermDebtOutstandingAmountDuePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsPreferredStock2014Member" name="WarrantsPreferredStock2014Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsPreferredStock2015Member" name="WarrantsPreferredStock2015Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_TermLoanB2015Member" name="TermLoanB2015Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_TermLoanA2014Member" name="TermLoanA2014Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ClassOfWarrantOrRightExercisablePeriod" name="ClassOfWarrantOrRightExercisablePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_DebtCostsDiscounts" name="DebtCostsDiscounts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_LongTermNotesPayableNet" name="LongTermNotesPayableNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsDisclosuresAbstract" name="WarrantsDisclosuresAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsAndRightsIssued" name="WarrantsAndRightsIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_WarrantsOrRightsReclassifiedToEquity" name="WarrantsOrRightsReclassifiedToEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" name="MinimumNumberOfDiseasePathwaysModulatedSimultaneously" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_NumberOfMoleculesUsedToCreateProductCandidates" name="NumberOfMoleculesUsedToCreateProductCandidates" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_NumberOfLinkers" name="NumberOfLinkers" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ReclassificationNonCurrentAssetsToEquity" name="ReclassificationNonCurrentAssetsToEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_ReclassificationStockWarrantsToEquity" name="ReclassificationStockWarrantsToEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_OtherIncomeLossFairValueAdjustmentToWarrants" name="OtherIncomeLossFairValueAdjustmentToWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_TermLoanOtherThanAndBMember" name="TermLoanOtherThanAndBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" name="AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="catb_SaleOfStockProceedsRecognizedNet" name="SaleOfStockProceedsRecognizedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>catb-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.0.103.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2015 12:24:07 PM-->
<!--Modified on: 11/12/2015 12:24:07 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.catabasis.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.catabasis.com/role/StatementCondensedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.catabasis.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableDetails2" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableCalc2Details2" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableCalc2Details2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommitmentsDetails" roleURI="http://www.catabasis.com/role/DisclosureCommitmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.catabasis.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_635829278459286315" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635829278459286315" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635829278459286315" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635829278459286315" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635829278459286315" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635829278459286315" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_635829278459286315" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_635829278459286315" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_635829278459286315" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635829278459286315" xlink:to="us-gaap_LiabilitiesCurrent_635829278459286315" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635829278459286315" xlink:to="us-gaap_AccountsPayableCurrent_635829278459286315" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635829278459286315" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635829278459286315" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635829278459286315" xlink:to="us-gaap_NotesPayableCurrent_635829278459286315" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635829278459286315" xlink:to="us-gaap_DeferredRentCreditNoncurrent_635829278459286315" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_635829278459286315" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635829278459286315" xlink:to="us-gaap_LongTermNotesPayable_635829278459286315" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635829278459286315" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635829278459442304" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635829278459286315" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_635829278459442304" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635829278459286315" xlink:to="us-gaap_CommitmentsAndContingencies_635829278459442304" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_635829278459442304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635829278459442304" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635829278459442304" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635829278459442304" xlink:to="us-gaap_PreferredStockValue_635829278459442304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635829278459442304" xlink:to="us-gaap_CommonStockValue_635829278459442304" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635829278459442304" xlink:to="us-gaap_AdditionalPaidInCapital_635829278459442304" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635829278459442304" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635829278459442304" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_635829278459442304" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_635829278459442304" xlink:to="us-gaap_OperatingIncomeLoss_635829278459442304" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635829278459442304" xlink:to="us-gaap_OperatingExpenses_635829278459442304" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635829278459442304" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635829278459442304" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635829278459442304" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635829278459442304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_635829278459442304" xlink:to="us-gaap_NonoperatingIncomeExpense_635829278459442304" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_635829278459442304" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635829278459442304" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_635829278459442304" xlink:to="us-gaap_InterestExpense_635829278459442304" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Condensed Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_NetIncomeLoss_635829278459442304" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635829278459442304" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_ShareBasedCompensation_635829278459442304" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635829278459442304" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635829278459442304" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_635829278459442304" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_635829278459442304" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_635829278459442304" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_IncreaseDecreaseInDeferredRent" xlink:label="catb_IncreaseDecreaseInDeferredRent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278459442304" xlink:to="catb_IncreaseDecreaseInDeferredRent_635829278459442304" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635829278459442304" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_635829278459442304" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635829278459442304" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_635829278459442304" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635829278459442304" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635829278459442304" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_635829278459442304" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278459442304" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_635829278459442304" order="5" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_635829278459442304" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635829278459442304" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AccruedContractedResearchCostsCurrent" xlink:label="catb_AccruedContractedResearchCostsCurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="catb_AccruedContractedResearchCostsCurrent_635829278459442304" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635829278459442304" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635829278459442304" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" xlink:type="extended" xlink:title="40502 - Disclosure - Notes Payable (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_635748988717938522" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_635748988717938522" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635829278459442304" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_635748988717938522" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635829278459442304" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_635748988717938522" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635829278459442304" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_635748988717938522" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_635829278459442304" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableCalc2Details2" xlink:type="extended" xlink:title="40502 - Disclosure - Notes Payable Calc2 (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DebtCostsDiscounts" xlink:label="catb_DebtCostsDiscounts_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="catb_DebtCostsDiscounts_635829278459442304" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_NotesPayableCurrent_635829278459442304" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermNotesPayableNet" xlink:label="catb_LongTermNotesPayableNet_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="catb_LongTermNotesPayableNet_635829278459442304" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.catabasis.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635748990384007842" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635748990384007842" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_635829278459442304" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635748990384007842" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635829278459442304" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635829278459442304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635748990384007842" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635829278459442304" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>catb-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.0.103.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2015 12:24:07 PM-->
<!--Modified on: 11/12/2015 12:24:07 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DocumentAndEntityInformationAbstract" xlink:label="catb_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_DocumentAndEntityInformationAbstract" xlink:to="catb_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of notes payable, net of discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes payable, net of current portion and discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments (Note 7)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, $.0001 par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value per share, 5,000,000 and 0 shares authorized at September 30, 2015 and December 31, 2014, respectively, 0 shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 150,000,000 shares authorized at September 30, 2015 and 132,000,000 shares authorized at December 31, 2014; 15,297,794 and 493,200 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before benefit from income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - basic and diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding used in net loss per share - basic and diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Financing Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_IncreaseDecreaseInDeferredRent" xlink:label="catb_IncreaseDecreaseInDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_IncreaseDecreaseInDeferredRent" xlink:to="catb_IncreaseDecreaseInDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the value of rent made during the current reporting period for benefits that will be received over a period of years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease in Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="catb_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash financing activities</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility" xlink:label="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility" xlink:to="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of warrants issued for purchase of preferred stock that is issued in conjunction with credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued for Purchase of Preferred Stock in Conjunction with Credit Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for the purchase of series B preferred stock issued in conjunction with credit facility</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of deferred initial public offering cost is included in accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Initial Public Offering Cost Included in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial public offering costs in accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ReclassificationNonCurrentAssetsToEquity" xlink:label="catb_ReclassificationNonCurrentAssetsToEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ReclassificationNonCurrentAssetsToEquity" xlink:to="catb_ReclassificationNonCurrentAssetsToEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ReclassificationNonCurrentAssetsToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the noncash reclassification of noncurrent assets to additional paid-in capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ReclassificationNonCurrentAssetsToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Non Current Assets To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ReclassificationNonCurrentAssetsToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of deferred IPO costs from non-current assets to additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ReclassificationStockWarrantsToEquity" xlink:label="catb_ReclassificationStockWarrantsToEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ReclassificationStockWarrantsToEquity" xlink:to="catb_ReclassificationStockWarrantsToEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ReclassificationStockWarrantsToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the noncash reclassification of stock warrants to additional paid-in capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ReclassificationStockWarrantsToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Stock Warrants To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ReclassificationStockWarrantsToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of warrant liability to additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Polices</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Polices</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants.</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsTextBlock" xlink:label="catb_WarrantsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsTextBlock" xlink:to="catb_WarrantsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure on warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_WarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockSplitPolicyTextBlock" xlink:label="catb_StockSplitPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_StockSplitPolicyTextBlock" xlink:to="catb_StockSplitPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_StockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents disclosure of accounting policy for a stock split, which may include a description of the stock split arrangement and the retroactive effect given by a stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_StockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Split Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_StockSplitPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock" xlink:label="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock" xlink:to="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the estimated future principal payments of notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Future Principal Payments Notes Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated future principal payments</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfWarrantsFairValueActivityTableTextBlock" xlink:label="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock" xlink:to="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the activity related to warrants during the period. Including but not limited to beginning and ending balance, increase/decrease in the fair value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Warrants Fair Value Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roll-forward of the fair value of warrants determined by Level 3 inputs</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock" xlink:label="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock" xlink:to="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the weighted average assumptions used to determine the fair value of warrants. Estimations were based on the Black-Scholes option pricing model.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Weigthed Average Assumptions Fair Value Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted-average assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum annual lease commitments under noncancelable operating lease</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:to="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Shares Reserved For Future Issuance Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the Company's stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of anti-dilutive common stock equivalents excluded from calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" xlink:label="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" xlink:to="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the minimum number of disease pathways targeted in treatment by modulating multiple biological targets within these pathways.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Number Of Disease Pathways Modulated Simultaneously</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of disease pathways within which multiple biological targets are modulated during treatment</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfMoleculesUsedToCreateProductCandidates" xlink:label="catb_NumberOfMoleculesUsedToCreateProductCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_NumberOfMoleculesUsedToCreateProductCandidates" xlink:to="catb_NumberOfMoleculesUsedToCreateProductCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_NumberOfMoleculesUsedToCreateProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of molecules, aka bioactives, from which the company engineers bi-functional product candidates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_NumberOfMoleculesUsedToCreateProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Molecules Used To Create Product Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_NumberOfMoleculesUsedToCreateProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of bioactives used to engineer bi-functional product candidates</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfLinkers" xlink:label="catb_NumberOfLinkers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_NumberOfLinkers" xlink:to="catb_NumberOfLinkers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_NumberOfLinkers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of proprietary SMART (Safely Metabolized And Rationally Targeted) linkers used in treatment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_NumberOfLinkers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Linkers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_NumberOfLinkers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of SMART linkers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:label="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SaleOfStockProceedsRecognizedNet" xlink:label="catb_SaleOfStockProceedsRecognizedNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_SaleOfStockProceedsRecognizedNet" xlink:to="catb_SaleOfStockProceedsRecognizedNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_SaleOfStockProceedsRecognizedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the proceeds recognized by the company as consideration for the sale of stock during a public offering. The amount recognized included issuance costs paid and accrued and is net of offering-related expenses including but not limited to underwriting discounts and commissions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_SaleOfStockProceedsRecognizedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Proceeds Recognized Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_SaleOfStockProceedsRecognizedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockOfferingFees" xlink:label="catb_StockOfferingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_StockOfferingFees" xlink:to="catb_StockOfferingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_StockOfferingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the fees and liabilities incurred during a pubic offering of common stock. This amount reduces the amount of proceeds received from the public offering. Includes but is not limited to underwriting discounts, commissions, offering expenses payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_StockOfferingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Offering Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_StockOfferingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discounts, commissions and offering-related expenses payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock issued upon conversion of Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock warrants converted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares after conversion of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount" xlink:label="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount" xlink:to="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets and/or liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2 or out of Level 2 of the fair value hierarchy into Level 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Transfers Between Levels Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers of assets or liabilities between levels</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosure Item Amounts [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate Of Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measured at fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeByNatureAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeByNatureAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, by Nature [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_DerivativeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets at fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities at fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AccruedContractedResearchCostsCurrent" xlink:label="catb_AccruedContractedResearchCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_AccruedContractedResearchCostsCurrent" xlink:to="catb_AccruedContractedResearchCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_AccruedContractedResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date for contracted research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_AccruedContractedResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued contracted research costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Frequency of Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of monthly payments (in number of payments)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermDebtOutstandingAmountDuePercentage" xlink:label="catb_LongTermDebtOutstandingAmountDuePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_LongTermDebtOutstandingAmountDuePercentage" xlink:to="catb_LongTermDebtOutstandingAmountDuePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_LongTermDebtOutstandingAmountDuePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount due as payment for long-term debt expressed as percentage of long-term debt outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_LongTermDebtOutstandingAmountDuePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Outstanding Amount Due Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_LongTermDebtOutstandingAmountDuePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of amount outstanding due as a payment (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ClassOfWarrantOrRightExercisablePeriod" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ClassOfWarrantOrRightExercisablePeriod" xlink:to="catb_ClassOfWarrantOrRightExercisablePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time period the warrants or rights are exercisable, in PpYyMmDd format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercisable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRestrictiveCovenants" xlink:to="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Restrictive Covenants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial covenants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="us-gaap_LitigationSettlementAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmount" xlink:to="us-gaap_LitigationSettlementAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Settlement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final judgment amount that would trigger lender rights for remedy</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate increase in the event of a default (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of Long-term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder 2015</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DebtCostsDiscounts" xlink:label="catb_DebtCostsDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_DebtCostsDiscounts" xlink:to="catb_DebtCostsDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_DebtCostsDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the discounts on warrants issued and debt issuance costs paid to lenders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_DebtCostsDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Costs Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_DebtCostsDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: discount for warrants and costs paid to lender</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermNotesPayableNet" xlink:label="catb_LongTermNotesPayableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_LongTermNotesPayableNet" xlink:to="catb_LongTermNotesPayableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_LongTermNotesPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion, discounts and issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_LongTermNotesPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Notes Payable Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_LongTermNotesPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note payable, net of current portion and discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsDisclosuresAbstract" xlink:label="catb_WarrantsDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsDisclosuresAbstract" xlink:to="catb_WarrantsDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roll-forward of fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsAndRightsIssued" xlink:label="catb_WarrantsAndRightsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsAndRightsIssued" xlink:to="catb_WarrantsAndRightsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsAndRightsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of outstanding derivative securities issued during the period that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsAndRightsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants And Rights Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_WarrantsAndRightsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of warrants at fair value</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_OtherIncomeLossFairValueAdjustmentToWarrants" xlink:label="catb_OtherIncomeLossFairValueAdjustmentToWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_OtherIncomeLossFairValueAdjustmentToWarrants" xlink:to="catb_OtherIncomeLossFairValueAdjustmentToWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_OtherIncomeLossFairValueAdjustmentToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the increase (decrease) in the fair value of warrants recorded as a component of other income (loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_OtherIncomeLossFairValueAdjustmentToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income Loss Fair Value Adjustment To Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_OtherIncomeLossFairValueAdjustmentToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value, recorded as a component of other income, net</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsOrRightsReclassifiedToEquity" xlink:label="catb_WarrantsOrRightsReclassifiedToEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsOrRightsReclassifiedToEquity" xlink:to="catb_WarrantsOrRightsReclassifiedToEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsOrRightsReclassifiedToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of derivative securities reclassified to equity that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsOrRightsReclassifiedToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Or Rights Reclassified To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="catb_WarrantsOrRightsReclassifiedToEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Operating Leased Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leased Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Operating [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of the operating lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leasing Arrangements, Operating Leases, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension term upon the completion of the initial lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum annual lease commitments under the noncancelable operating lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases Future Minimum Payments Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder 2015</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OperatingLeases, Future Minimum Payments, Due In Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due In Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Shares, Par Value and Other Disclosures</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfPerferredStockSeries" xlink:label="catb_NumberOfPerferredStockSeries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_NumberOfPerferredStockSeries" xlink:to="catb_NumberOfPerferredStockSeries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_NumberOfPerferredStockSeries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of series that may be used to issue preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_NumberOfPerferredStockSeries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Perferred Stock Series</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_NumberOfPerferredStockSeries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of series used to issue preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleApreferredStockMember" xlink:label="catb_SeriesConvertibleApreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_SeriesConvertibleApreferredStockMember" xlink:to="catb_SeriesConvertibleApreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_SeriesConvertibleApreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Series A convertible preferred stock, which possess conversion and redemption features.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_SeriesConvertibleApreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Convertible Apreferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_SeriesConvertibleApreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_SeriesConvertibleBpreferredStockMember" xlink:to="catb_SeriesConvertibleBpreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_SeriesConvertibleBpreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Series B convertible preferred stock, which possess conversion and redemption features.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_SeriesConvertibleBpreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Convertible Bpreferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_SeriesConvertibleBpreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for future issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockIncentivePlan2015Member" xlink:label="catb_StockIncentivePlan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_StockIncentivePlan2015Member" xlink:to="catb_StockIncentivePlan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_StockIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2015 Stock Incentive Plan ("2015 Plan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_StockIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plan2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_StockIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockIncentivePlan2008Member" xlink:label="catb_StockIncentivePlan2008Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_StockIncentivePlan2008Member" xlink:to="catb_StockIncentivePlan2008Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_StockIncentivePlan2008Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2008 Stock Incentive Plan ("2008 Plan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_StockIncentivePlan2008Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plan2008 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_StockIncentivePlan2008Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2008 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding Common Stock available for issuance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled or forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled or forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at end of period</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested stock option awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average amortization period over which cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_EmployeeStockPurchasePlan2015Member" xlink:label="catb_EmployeeStockPurchasePlan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_EmployeeStockPurchasePlan2015Member" xlink:to="catb_EmployeeStockPurchasePlan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_EmployeeStockPurchasePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2015 Employee Stock Purchase Plan ("2015 ESPP").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_EmployeeStockPurchasePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_EmployeeStockPurchasePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential increase in shares available for issuance as determined by the Board of Directors (in shares)</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" xlink:label="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" xlink:to="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesAconvertiblePreferredStockMember" xlink:label="catb_SeriesAconvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_SeriesAconvertiblePreferredStockMember" xlink:to="catb_SeriesAconvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_SeriesAconvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Series A convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_SeriesAconvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Aconvertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_SeriesAconvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesBConvertiblePreferredStockMember" xlink:label="catb_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_SeriesBConvertiblePreferredStockMember" xlink:to="catb_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Series B Convertible Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentCompanyMember" xlink:to="us-gaap_ParentCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent Company [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment option for underwriters</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_CommonStockWarrantsMember" xlink:to="catb_CommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for the purchase of Common Stock</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2014Member" xlink:label="catb_WarrantsPreferredStock2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsPreferredStock2014Member" xlink:to="catb_WarrantsPreferredStock2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsPreferredStock2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining the the warrants issued to purchase Series B Convertible Preferred Stock ("2014 Warrants").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsPreferredStock2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Preferred Stock2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_WarrantsPreferredStock2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Warrants</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2015Member" xlink:label="catb_WarrantsPreferredStock2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_WarrantsPreferredStock2015Member" xlink:to="catb_WarrantsPreferredStock2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_WarrantsPreferredStock2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the warrants issued to purchase Series B Convertible Preferred Stock ("2015 Warrants").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_WarrantsPreferredStock2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Preferred Stock2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_WarrantsPreferredStock2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revolving Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanB2015Member" xlink:label="catb_TermLoanB2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_TermLoanB2015Member" xlink:to="catb_TermLoanB2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_TermLoanB2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Term Loan B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_TermLoanB2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan B2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_TermLoanB2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan B</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanA2014Member" xlink:label="catb_TermLoanA2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_TermLoanA2014Member" xlink:to="catb_TermLoanA2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_TermLoanA2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Term Loan A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_TermLoanA2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan A2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_TermLoanA2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan A</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanOtherThanAndBMember" xlink:label="catb_TermLoanOtherThanAndBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_TermLoanOtherThanAndBMember" xlink:to="catb_TermLoanOtherThanAndBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_TermLoanOtherThanAndBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents term loan other than A and B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_TermLoanOtherThanAndBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Other Than And B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_TermLoanOtherThanAndBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Term Loan</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_PreferredStockWarrantsMember" xlink:label="catb_PreferredStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_PreferredStockWarrantsMember" xlink:to="catb_PreferredStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_PreferredStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security that gives the holder the right to purchase shares of preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_PreferredStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_PreferredStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for the purchase of Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AnnualIncreaseMember" xlink:label="catb_AnnualIncreaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="catb_AnnualIncreaseMember" xlink:to="catb_AnnualIncreaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="catb_AnnualIncreaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the annual increase of shares available for issuance under the Company's stock-based compensation plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="catb_AnnualIncreaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Increase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="catb_AnnualIncreaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual minimum increase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>catb-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.0.103.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2015 12:24:07 PM-->
<!--Modified on: 11/12/2015 12:24:07 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.catabasis.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedBalanceSheetsParenthetical" roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.catabasis.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.catabasis.com/role/StatementCondensedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureOrganizationAndOperations" roleURI="http://www.catabasis.com/role/DisclosureOrganizationAndOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureSummaryOfSignificantAccountingPolices" roleURI="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolices" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureFinancialInstruments" roleURI="http://www.catabasis.com/role/DisclosureFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureAccruedExpenses" roleURI="http://www.catabasis.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayable" roleURI="http://www.catabasis.com/role/DisclosureNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureWarrants" roleURI="http://www.catabasis.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommitments" roleURI="http://www.catabasis.com/role/DisclosureCommitments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureConvertiblePreferredStock" roleURI="http://www.catabasis.com/role/DisclosureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommonStockReservedForFutureIssuance" roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNetLossPerShare" roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureSummaryOfSignificantAccountingPolicesPolices" roleURI="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://www.catabasis.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.catabasis.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableTables" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureWarrantsTables" roleURI="http://www.catabasis.com/role/DisclosureWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommitmentsTables" roleURI="http://www.catabasis.com/role/DisclosureCommitmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommonStockReservedForFutureIssuanceTables" roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureOrganizationAndOperationsDetails" roleURI="http://www.catabasis.com/role/DisclosureOrganizationAndOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureSummaryOfSignificantAccountingPolicesDetails" roleURI="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.catabasis.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableDetails" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableDetails2" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureWarrantsDetails" roleURI="http://www.catabasis.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommitmentsDetails" roleURI="http://www.catabasis.com/role/DisclosureCommitmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://www.catabasis.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationDetails2" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationDetails3" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.catabasis.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_635829278460066260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_635829278460066260" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_635829278460066260" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_635829278460066260" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_635829278460066260" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_635829278460066260" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_635829278460066260" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_635829278460066260" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_635829278460066260" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_635829278460066260" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_635829278460066260" order="11" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_635829278460066260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460066260" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460066260" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460066260" xlink:to="us-gaap_ClassOfStockDomain_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleApreferredStockMember" xlink:label="catb_SeriesConvertibleApreferredStockMember_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460066260" xlink:to="catb_SeriesConvertibleApreferredStockMember_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460066260" xlink:to="catb_SeriesConvertibleBpreferredStockMember_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460066260" xlink:to="us-gaap_StatementLineItems_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_AssetsAbstract_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635829278460066260" xlink:to="us-gaap_AssetsCurrentAbstract_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635829278460066260" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635829278460066260" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635829278460066260" xlink:to="us-gaap_AssetsCurrent_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635829278460066260" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635829278460066260" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635829278460066260" xlink:to="us-gaap_OtherAssetsNoncurrent_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635829278460066260" xlink:to="us-gaap_Assets_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_LiabilitiesCurrentAbstract_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635829278460066260" xlink:to="us-gaap_AccountsPayableCurrent_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635829278460066260" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635829278460066260" xlink:to="us-gaap_NotesPayableCurrent_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635829278460066260" xlink:to="us-gaap_LiabilitiesCurrent_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_DeferredRentCreditNoncurrent_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_LongTermNotesPayable_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_Liabilities_635829278460066260" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_CommitmentsAndContingencies_635829278460066260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635829278460066260" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_StockholdersEquityAbstract_635829278460066260" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_PreferredStockValue_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_CommonStockValue_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_AdditionalPaidInCapital_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_StockholdersEquity_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635829278460066260" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_635829278460066260" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/StatementCondensedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_635829278460066260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460066260" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460066260" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460066260" xlink:to="us-gaap_ClassOfStockDomain_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesAconvertiblePreferredStockMember" xlink:label="catb_SeriesAconvertiblePreferredStockMember_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460066260" xlink:to="catb_SeriesAconvertiblePreferredStockMember_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesBConvertiblePreferredStockMember" xlink:label="catb_SeriesBConvertiblePreferredStockMember_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460066260" xlink:to="catb_SeriesBConvertiblePreferredStockMember_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460066260" xlink:to="us-gaap_StatementLineItems_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_TemporaryEquitySharesIssued_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_PreferredStockSharesAuthorized_635829278460066260" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_PreferredStockSharesIssued_635829278460066260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_PreferredStockSharesOutstanding_635829278460066260" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635829278460066260" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_CommonStockSharesAuthorized_635829278460066260" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_CommonStockSharesIssued_635829278460066260" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460066260" xlink:to="us-gaap_CommonStockSharesOutstanding_635829278460066260" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635829278460066260" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635829278460066260" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635829278460066260" xlink:to="us-gaap_OperatingExpenses_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_635829278460066260" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_635829278460066260" xlink:to="us-gaap_InterestExpense_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_635829278460066260" xlink:to="us-gaap_NonoperatingIncomeExpense_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635829278460066260" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635829278460066260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Condensed Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_NetIncomeLoss_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635829278460066260" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635829278460066260" xlink:to="us-gaap_ShareBasedCompensation_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635829278460066260" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635829278460066260" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_IncreaseDecreaseInDeferredRent" xlink:label="catb_IncreaseDecreaseInDeferredRent_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635829278460066260" xlink:to="catb_IncreaseDecreaseInDeferredRent_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635829278460066260" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635829278460066260" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635829278460066260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6358292784600662601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6358292784600662601" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_635829278460066260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_635829278460066260" xlink:to="us-gaap_InterestPaid_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635829278460066260" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility" xlink:label="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635829278460066260" xlink:to="catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility_635829278460066260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635829278460066260" xlink:to="catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities_635829278460066260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ReclassificationNonCurrentAssetsToEquity" xlink:label="catb_ReclassificationNonCurrentAssetsToEquity_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635829278460066260" xlink:to="catb_ReclassificationNonCurrentAssetsToEquity_635829278460066260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ReclassificationStockWarrantsToEquity" xlink:label="catb_ReclassificationStockWarrantsToEquity_635829278460066260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_635829278460066260" xlink:to="catb_ReclassificationStockWarrantsToEquity_635829278460066260" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureOrganizationAndOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolices" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Polices" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="10301 - Disclosure - Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_635829278460222249" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10401 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayable" xlink:type="extended" xlink:title="10501 - Disclosure - Notes Payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="10601 - Disclosure - Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsTextBlock" xlink:label="catb_WarrantsTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="catb_WarrantsTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureConvertiblePreferredStock" xlink:type="extended" xlink:title="10801 - Disclosure - Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_PreferredStockTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuance" xlink:type="extended" xlink:title="10901 - Disclosure - Common Stock Reserved for Future Issuance" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11001 - Disclosure - Stock-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11101 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Polices (Polices)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockSplitPolicyTextBlock" xlink:label="catb_StockSplitPolicyTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="catb_StockSplitPolicyTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_635728554159523084" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635728554159523084" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableTables" xlink:type="extended" xlink:title="30503 - Disclosure - Notes Payable (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_635728939524647777" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock" xlink:label="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635728939524647777" xlink:to="catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Warrants (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_635728539509935084" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfWarrantsFairValueActivityTableTextBlock" xlink:label="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_635728539509935084" xlink:to="catb_ScheduleOfWarrantsFairValueActivityTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock" xlink:label="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_635728539509935084" xlink:to="catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureCommitmentsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Commitments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceTables" xlink:type="extended" xlink:title="30903 - Disclosure - Common Stock Reserved for Future Issuance (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31103 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635728416870769743" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635728416870769743" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureOrganizationAndOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="dei_LegalEntityAxis_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_635829278460222249" xlink:to="dei_EntityDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_635829278460222249" xlink:to="us-gaap_ParentCompanyMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ParentCompanyMember_635829278460222249" xlink:to="us-gaap_PreferredStockMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635829278460222249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635829278460222249" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635829278460222249" xlink:to="us-gaap_IPOMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IPOMember_635829278460222249" xlink:to="us-gaap_OverAllotmentOptionMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460222249" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460222249" xlink:to="us-gaap_ClassOfStockDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_CommonStockWarrantsMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementLineItems_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" xlink:label="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfMoleculesUsedToCreateProductCandidates" xlink:label="catb_NumberOfMoleculesUsedToCreateProductCandidates_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="catb_NumberOfMoleculesUsedToCreateProductCandidates_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfLinkers" xlink:label="catb_NumberOfLinkers_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="catb_NumberOfLinkers_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:label="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_SharesIssuedPricePerShare_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SaleOfStockProceedsRecognizedNet" xlink:label="catb_SaleOfStockProceedsRecognizedNet_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="catb_SaleOfStockProceedsRecognizedNet_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockOfferingFees" xlink:label="catb_StockOfferingFees_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="catb_StockOfferingFees_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_ConversionOfStockSharesConverted1_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_635829278460222249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Polices (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_635829278460222249" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosureAbstract_635829278460222249" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount" xlink:label="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsFairValueDisclosureAbstract_635829278460222249" xlink:to="catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_635829278460222249" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_635829278460222249" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_635829278460222249" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_635829278460222249" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain_635829278460222249" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_635829278460222249" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_635829278460222249" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" xlink:to="us-gaap_FairValueInputsLevel1Member_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" xlink:to="us-gaap_FairValueInputsLevel3Member_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" xlink:to="us-gaap_DerivativeByNatureAxis_635829278460222249" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis_635829278460222249" xlink:to="us-gaap_DerivativeNameDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain_635829278460222249" xlink:to="us-gaap_WarrantMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635829278460222249" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635829278460222249" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_635829278460222249" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_635829278460222249" xlink:to="us-gaap_AssetsFairValueDisclosure_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635829278460222249" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_635829278460222249" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_635829278460222249" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AccruedContractedResearchCostsCurrent" xlink:label="catb_AccruedContractedResearchCostsCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="catb_AccruedContractedResearchCostsCurrent_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Notes Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_635728945845506602" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635728945845506602" xlink:to="us-gaap_StatementTable_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460222249" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460222249" xlink:to="us-gaap_ClassOfStockDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="us-gaap_WarrantMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2014Member" xlink:label="catb_WarrantsPreferredStock2014Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_635829278460222249" xlink:to="catb_WarrantsPreferredStock2014Member_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2015Member" xlink:label="catb_WarrantsPreferredStock2015Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_635829278460222249" xlink:to="catb_WarrantsPreferredStock2015Member_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_RangeAxis_635829278460222249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635829278460222249" xlink:to="us-gaap_RangeMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635829278460222249" xlink:to="us-gaap_MinimumMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635829278460222249" xlink:to="us-gaap_MaximumMember_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_CreditFacilityAxis_635829278460222249" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_635829278460222249" xlink:to="us-gaap_CreditFacilityDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_635829278460222249" xlink:to="us-gaap_RevolvingCreditFacilityMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_LongtermDebtTypeAxis_635829278460222249" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_635829278460222249" xlink:to="us-gaap_LongtermDebtTypeDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanB2015Member" xlink:label="catb_TermLoanB2015Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_635829278460222249" xlink:to="catb_TermLoanB2015Member_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanA2014Member" xlink:label="catb_TermLoanA2014Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_635829278460222249" xlink:to="catb_TermLoanA2014Member_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanOtherThanAndBMember" xlink:label="catb_TermLoanOtherThanAndBMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_635829278460222249" xlink:to="catb_TermLoanOtherThanAndBMember_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementLineItems_635829278460222249" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_LineOfCredit_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermDebtOutstandingAmountDuePercentage" xlink:label="catb_LongTermDebtOutstandingAmountDuePercentage_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="catb_LongTermDebtOutstandingAmountDuePercentage_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_635829278460222249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract_635829278460222249" xlink:to="us-gaap_DebtInstrumentsAbstract_635829278460222249" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ClassOfWarrantOrRightExercisablePeriod" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="catb_ClassOfWarrantOrRightExercisablePeriod_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_WarrantsAndRightsOutstanding_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_DebtInstrumentRestrictiveCovenants_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="us-gaap_LitigationSettlementAmount_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_LitigationSettlementAmount_635829278460222249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract_635829278460222249" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_635829278460222249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" xlink:type="extended" xlink:title="40502 - Disclosure - Notes Payable (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_635748988062773136" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635748988062773136" xlink:to="us-gaap_StatementTable_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_CreditFacilityAxis_635829278460222249" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_635829278460222249" xlink:to="us-gaap_CreditFacilityDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_635829278460222249" xlink:to="us-gaap_RevolvingCreditFacilityMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementLineItems_635829278460222249" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_LongTermDebt_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DebtCostsDiscounts" xlink:label="catb_DebtCostsDiscounts_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="catb_DebtCostsDiscounts_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_NotesPayableCurrent_635829278460222249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermNotesPayableNet" xlink:label="catb_LongTermNotesPayableNet_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="catb_LongTermNotesPayableNet_635829278460222249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_635829278460222249" xlink:to="us-gaap_InterestExpenseDebt_635829278460222249" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_635728547891536084" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_635728547891536084" xlink:to="us-gaap_StatementTable_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_CreditFacilityAxis_635829278460222249" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_635829278460222249" xlink:to="us-gaap_CreditFacilityDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_635829278460222249" xlink:to="us-gaap_RevolvingCreditFacilityMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460222249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460222249" xlink:to="us-gaap_ClassOfStockDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="us-gaap_WarrantMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2014Member" xlink:label="catb_WarrantsPreferredStock2014Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_635829278460222249" xlink:to="catb_WarrantsPreferredStock2014Member_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2015Member" xlink:label="catb_WarrantsPreferredStock2015Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_635829278460222249" xlink:to="catb_WarrantsPreferredStock2015Member_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_SeriesConvertibleBpreferredStockMember_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_635829278460222249" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_635829278460222249" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278460222249" xlink:to="us-gaap_FairValueInputsLevel3Member_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementLineItems_635829278460222249" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ClassOfWarrantOrRightExercisablePeriod" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="catb_ClassOfWarrantOrRightExercisablePeriod_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsDisclosuresAbstract" xlink:label="catb_WarrantsDisclosuresAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="catb_WarrantsDisclosuresAbstract_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_WarrantsAndRightsOutstanding_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsAndRightsIssued" xlink:label="catb_WarrantsAndRightsIssued_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="catb_WarrantsAndRightsIssued_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_OtherIncomeLossFairValueAdjustmentToWarrants" xlink:label="catb_OtherIncomeLossFairValueAdjustmentToWarrants_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="catb_OtherIncomeLossFairValueAdjustmentToWarrants_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsOrRightsReclassifiedToEquity" xlink:label="catb_WarrantsOrRightsReclassifiedToEquity_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="catb_WarrantsOrRightsReclassifiedToEquity_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_6358292784602222491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_WarrantsAndRightsOutstanding_6358292784602222491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_ConversionOfStockSharesConverted1_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6358292784602222491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_WarrantsDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6358292784602222491" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635829278460222249" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635829278460222249" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635829278460222249" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635829278460222249" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635829278460222249" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635748989977006451" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635748989977006451" xlink:to="us-gaap_LeasesOperatingAbstract_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635829278460222249" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635829278460222249" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635829278460222249" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635748989977006451" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635829278460222249" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635829278460222249" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635829278460222249" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635829278460222249" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_635728521441289084" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_635728521441289084" xlink:to="us-gaap_StatementTable_635829278460222249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460222249" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460222249" xlink:to="us-gaap_ClassOfStockDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_SeriesConvertibleBpreferredStockMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635829278460222249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635829278460222249" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635829278460222249" xlink:to="us-gaap_IPOMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460222249" xlink:to="us-gaap_StatementLineItems_635829278460222249" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460222249" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_PreferredStockSharesAuthorized_635829278460222249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_635829278460222249" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_SharesIssuedPricePerShare_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_PreferredStockSharesIssued_635829278460222249" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="us-gaap_PreferredStockSharesOutstanding_635829278460222249" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfPerferredStockSeries" xlink:label="catb_NumberOfPerferredStockSeries_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_635829278460222249" xlink:to="catb_NumberOfPerferredStockSeries_635829278460222249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock Reserved for Future Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635829278460222249" xlink:to="us-gaap_StatementClassOfStockAxis_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635829278460222249" xlink:to="us-gaap_ClassOfStockDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleApreferredStockMember" xlink:label="catb_SeriesConvertibleApreferredStockMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_SeriesConvertibleApreferredStockMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_SeriesConvertibleBpreferredStockMember_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_PreferredStockWarrantsMember" xlink:label="catb_PreferredStockWarrantsMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_PreferredStockWarrantsMember_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_CommonStockWarrantsMember_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="us-gaap_EmployeeStockOptionMember_635829278460222249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_EmployeeStockPurchasePlan2015Member" xlink:label="catb_EmployeeStockPurchasePlan2015Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635829278460222249" xlink:to="catb_EmployeeStockPurchasePlan2015Member_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635829278460222249" xlink:to="us-gaap_ClassOfStockLineItems_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635829278460222249" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" xlink:to="us-gaap_PlanNameAxis_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635829278460222249" xlink:to="us-gaap_PlanNameDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockIncentivePlan2015Member" xlink:label="catb_StockIncentivePlan2015Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635829278460222249" xlink:to="catb_StockIncentivePlan2015Member_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockIncentivePlan2008Member" xlink:label="catb_StockIncentivePlan2008Member_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635829278460222249" xlink:to="catb_StockIncentivePlan2008Member_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" xlink:to="us-gaap_AwardDateAxis_635829278460222249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_635829278460222249" xlink:to="us-gaap_AwardDateDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AnnualIncreaseMember" xlink:label="catb_AnnualIncreaseMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_635829278460222249" xlink:to="catb_AnnualIncreaseMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails2" xlink:type="extended" xlink:title="41002 - Disclosure - Stock-based compensation (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" xlink:to="us-gaap_AwardTypeAxis_635829278460222249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635829278460222249" xlink:to="us-gaap_EmployeeStockOptionMember_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6358292784602222491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6358292784602222491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_635829278460222249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6358292784602222491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6358292784602222491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635829278460222249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_635829278460222249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_635829278460222249" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6358292784602222491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_635829278460222249" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6358292784602222491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_635829278460222249" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635829278460222249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_635829278460222249" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_635829278460222249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635829278460222249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635829278460222249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_635829278460222249" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635829278460222249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_635829278460222249" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_635829278460378238" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_635829278460222249" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_635829278460378238" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460222249" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635829278460378238" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635829278460378238" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635829278460378238" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635829278460378238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails3" xlink:type="extended" xlink:title="41003 - Disclosure - Stock-based compensation (Details 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635728480376798895" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635728480376798895" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460378238" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460378238" xlink:to="us-gaap_AwardDateAxis_635829278460378238" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_635829278460378238" xlink:to="us-gaap_AwardDateDomain_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AnnualIncreaseMember" xlink:label="catb_AnnualIncreaseMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_635829278460378238" xlink:to="catb_AnnualIncreaseMember_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460378238" xlink:to="us-gaap_PlanNameAxis_635829278460378238" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635829278460378238" xlink:to="us-gaap_PlanNameDomain_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_EmployeeStockPurchasePlan2015Member" xlink:label="catb_EmployeeStockPurchasePlan2015Member_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635829278460378238" xlink:to="catb_EmployeeStockPurchasePlan2015Member_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460378238" xlink:to="us-gaap_IncomeStatementLocationAxis_635829278460378238" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_635829278460378238" xlink:to="us-gaap_IncomeStatementLocationDomain_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635829278460378238" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635829278460378238" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_635829278460378238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635829278460378238" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460378238" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460378238" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460378238" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635829278460378238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460378238" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_635829278460378238" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635829278460378238" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_635829278460378238" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.catabasis.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635728419083015743" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635728419083015743" xlink:to="us-gaap_StatementTable_635829278460378238" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460378238" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635829278460378238" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635829278460378238" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635829278460378238" xlink:to="us-gaap_ConvertiblePreferredStockMember_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635829278460378238" xlink:to="us-gaap_EmployeeStockOptionMember_635829278460378238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635829278460378238" xlink:to="catb_CommonStockWarrantsMember_635829278460378238" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_PreferredStockWarrantsMember" xlink:label="catb_PreferredStockWarrantsMember_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635829278460378238" xlink:to="catb_PreferredStockWarrantsMember_635829278460378238" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635829278460378238" xlink:to="us-gaap_StatementLineItems_635829278460378238" order="2" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" xlink:label="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635829278460378238" xlink:to="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635829278460378238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract_635829278460378238" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635829278460378238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>catb-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.0.103.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2015 12:24:07 PM-->
<!--Modified on: 11/12/2015 12:24:08 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#StatementCondensedBalanceSheetsParenthetical" roleURI="http://www.catabasis.com/role/StatementCondensedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureOrganizationAndOperationsDetails" roleURI="http://www.catabasis.com/role/DisclosureOrganizationAndOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableDetails" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNotesPayableDetails2" roleURI="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureWarrantsDetails" roleURI="http://www.catabasis.com/role/DisclosureWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://www.catabasis.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationDetails2" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureStockBasedCompensationDetails3" roleURI="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails3" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="catb-20150930.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.catabasis.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.catabasis.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635829278459442304" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_635829278459442304" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleApreferredStockMember" xlink:label="catb_SeriesConvertibleApreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesConvertibleApreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesConvertibleBpreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/StatementCondensedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesAconvertiblePreferredStockMember" xlink:label="catb_SeriesAconvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesAconvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesBConvertiblePreferredStockMember" xlink:label="catb_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesBConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureOrganizationAndOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="us-gaap_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ParentCompanyMember" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" xlink:label="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfMoleculesUsedToCreateProductCandidates" xlink:label="catb_NumberOfMoleculesUsedToCreateProductCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="catb_NumberOfMoleculesUsedToCreateProductCandidates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfLinkers" xlink:label="catb_NumberOfLinkers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="catb_NumberOfLinkers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:label="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SaleOfStockProceedsRecognizedNet" xlink:label="catb_SaleOfStockProceedsRecognizedNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="catb_SaleOfStockProceedsRecognizedNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockOfferingFees" xlink:label="catb_StockOfferingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="catb_StockOfferingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StockTransactionsParentheticalDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DerivativeByNatureAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Notes Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2014Member" xlink:label="catb_WarrantsPreferredStock2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="catb_WarrantsPreferredStock2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2015Member" xlink:label="catb_WarrantsPreferredStock2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="catb_WarrantsPreferredStock2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635829278459598293" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_635829278459598293" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanB2015Member" xlink:label="catb_TermLoanB2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="catb_TermLoanB2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanA2014Member" xlink:label="catb_TermLoanA2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="catb_TermLoanA2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_TermLoanOtherThanAndBMember" xlink:label="catb_TermLoanOtherThanAndBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="catb_TermLoanOtherThanAndBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermDebtOutstandingAmountDuePercentage" xlink:label="catb_LongTermDebtOutstandingAmountDuePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="catb_LongTermDebtOutstandingAmountDuePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ClassOfWarrantOrRightExercisablePeriod" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="catb_ClassOfWarrantOrRightExercisablePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentRestrictiveCovenants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="us-gaap_LitigationSettlementAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_LitigationSettlementAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureNotesPayableDetails2" xlink:type="extended" xlink:title="40502 - Disclosure - Notes Payable (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_DebtCostsDiscounts" xlink:label="catb_DebtCostsDiscounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="catb_DebtCostsDiscounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_LongTermNotesPayableNet" xlink:label="catb_LongTermNotesPayableNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="catb_LongTermNotesPayableNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureWarrantsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2014Member" xlink:label="catb_WarrantsPreferredStock2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="catb_WarrantsPreferredStock2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsPreferredStock2015Member" xlink:label="catb_WarrantsPreferredStock2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="catb_WarrantsPreferredStock2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesConvertibleBpreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ClassOfWarrantOrRightExercisablePeriod" xlink:label="catb_ClassOfWarrantOrRightExercisablePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="catb_ClassOfWarrantOrRightExercisablePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsDisclosuresAbstract" xlink:label="catb_WarrantsDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="catb_WarrantsDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="catb_WarrantsDisclosuresAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsAndRightsIssued" xlink:label="catb_WarrantsAndRightsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="catb_WarrantsDisclosuresAbstract" xlink:to="catb_WarrantsAndRightsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_OtherIncomeLossFairValueAdjustmentToWarrants" xlink:label="catb_OtherIncomeLossFairValueAdjustmentToWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="catb_WarrantsDisclosuresAbstract" xlink:to="catb_OtherIncomeLossFairValueAdjustmentToWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_WarrantsOrRightsReclassifiedToEquity" xlink:label="catb_WarrantsOrRightsReclassifiedToEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="catb_WarrantsDisclosuresAbstract" xlink:to="catb_WarrantsOrRightsReclassifiedToEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="catb_WarrantsDisclosuresAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesConvertibleBpreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_NumberOfPerferredStockSeries" xlink:label="catb_NumberOfPerferredStockSeries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="catb_NumberOfPerferredStockSeries" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock Reserved for Future Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleApreferredStockMember" xlink:label="catb_SeriesConvertibleApreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesConvertibleApreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_SeriesConvertibleBpreferredStockMember" xlink:label="catb_SeriesConvertibleBpreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_SeriesConvertibleBpreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_PreferredStockWarrantsMember" xlink:label="catb_PreferredStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_PreferredStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_EmployeeStockPurchasePlan2015Member" xlink:label="catb_EmployeeStockPurchasePlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="catb_EmployeeStockPurchasePlan2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635829278459754282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_635829278459754282" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockIncentivePlan2015Member" xlink:label="catb_StockIncentivePlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="catb_StockIncentivePlan2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_StockIncentivePlan2008Member" xlink:label="catb_StockIncentivePlan2008Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="catb_StockIncentivePlan2008Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_635829278459754282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_635829278459754282" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AnnualIncreaseMember" xlink:label="catb_AnnualIncreaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="catb_AnnualIncreaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails2" xlink:type="extended" xlink:title="41002 - Disclosure - Stock-based compensation (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635829278459754282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635829278459754282" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails3" xlink:type="extended" xlink:title="41003 - Disclosure - Stock-based compensation (Details 3)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635829278459754282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_635829278459754282" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_EmployeeStockPurchasePlan2015Member" xlink:label="catb_EmployeeStockPurchasePlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="catb_EmployeeStockPurchasePlan2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AnnualIncreaseMember" xlink:label="catb_AnnualIncreaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="catb_AnnualIncreaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.catabasis.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635829278459754282" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635829278459754282" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_CommonStockWarrantsMember" xlink:label="catb_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="catb_CommonStockWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_PreferredStockWarrantsMember" xlink:label="catb_PreferredStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="catb_PreferredStockWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="catb-20150930.xsd#catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" xlink:label="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g180931ki07i001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki07i001.gif
M1TE&.#=A'P)/ '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M(8DLL\PRS\E45VW2/*< 4( &&A 26C"3&"0/$PRX(1 YQFVP3L,K5/!/,@L
M($<^ T73" @$#!)RDZIP_Y-.KE8'+OA(\\2"J L&T4/)!HT4%,XK #PPD#X
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MB6=!:Q!U[!  8W#J/U:Q@M8.)1T[+($L!@(/7>1,#?\PARUT.X=SE*(:.X"
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M#Y7XDGIIE !@ 42@ Y. 1?\@#%\0 *P07A+@"!ES"1JP 8=P$/@ !Q/P 7V
M%>>@"2N0!\B@'"Y*#(;P=:HE#$%GB]0P>B,0"T1J@5-9E683#42P 6S0#7<
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M'63;!+':!_%F3D )1X#@&;$*(Y !#[ '"N&M #"" K';O3T0S7 #9!FZ;&
M%?P/UG %,= -Q[ #&, %ZK(0*0, -&#?U%W=!1  29!<2R2*0& *4J,0,O
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MIZX(/Z(E!-+H)BX ,:[]1+@*P YO_U !0%%HUDU]B0" R.8S& @18!&&T_9
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M*!#N$(6(;J0'+\@"*;_0!8W<@ $ \, 2A#"_%%D !1A0HPPX *H2Z$ $-6B
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DQC?&<8YUO&,>]]C'/P9RD(4\9"(7V<A'1@ARDI6\9"4'!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g180931ki07i002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki07i002.gif
M1TE&.#=ASP Y '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MB( .7M$, D3!'$?80^]^UY!C .85RM#!%OSQ#U/,X XO8HC2N$"(+%0(*<7
MPP!2L(9:U(,N +C!$6K@"(/ PQF4$(( SE*%0-3@!+(:B#N2@ !G=(U)BQ+&
M!?_,$+Z&6$("^DL(+*R BH1 8PL6(,(_VB&+%ZS"'G'HP3_D<0?@*20>+O!
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M!XX[R#/<<(-Q#@093 #W/]01BQ(TX90'F0<A%@  &"S[!0<@QC_<#;C+UJ
M,/C<,SJ!! 74! -6: 0HL &U!!DB#BA0+T:J4( U:004 7"#0?+!AAE@;1H[
MB,&ZT%&, > @&HOZA,BO=A#?]L$<W @!%CSZ#"+<X-X'D<4/&%&06G!@"7+Z
MQ0LN@ >$] ,/-=$!-#K\#SM\( ^M<K<V#N*$%$3B&K2P0C)OX DP)( ).93(
M/>)TD4\(!ML8P>QW!U(.,[A]BW6H #,"I;QF(:,!  C$J0O2APQ, <-\V,"*
MZ " _Z:T#U3X&$%J\8$W4^,+%L "_T+.(8+,SWD@GM?$.)9A A\06" G9\(V
MA%$$)Y\@$?C(QQT <(;SYB09,@  O'!^&'$-4, %\280%>=V\  ( 5 &?M4"
MB1(V<: !>-!U ]$)!" #JG J[^ $!I  ,S (C(40NF "=6 0PI %NK!9%M %
M]U(0^C!F-?$+S?(/@P,-]A" 7*!KX9 (*] %TW *W-(%9R40K= "5# Y.6$/
M3T !E[ Q&;$*/\ '!U$/E# #Z: )%P!7Z( ,,N !;4,0<& !8H"!3I4'*A '
MT/8/X9%\"F$/;^ #&S<0Y^ *$0  %-  +G 07S@@ ' Z!1$/@ $-TV %,( %
MR:6! % (K?_0!A+0 KRP#P-A#W)P 6.8$YUP +J -!I!"PG0"%=("1R  @XP
M/0(A#C(06 5Q#?5F703Q*@#@< 41?6N! H,@A0-!#'?@%3K$"5L  !_  S8@
M )]P$.SP #, ! PP V$S$#F(!WG@"RAP"86 <%N #-*V \Q#$'T  &M@9BY!
M#"9  JW$$;10 M5R$-,   %@!R$&#W;  9=@$#JP +<0702Q"DV03&Z0@+F@
M S  "N; "!UP 5.0"-90$-/ !#M "&%P!$\06S4Q Z P"')0$/V #&6P '='
M!Q,P>@<Q.'D  :0@#-93$S7P"_7 ":]0<MO3!1(0.SF!!Q< "\O_EA'^  8O
M-HJ01$WD@ Q]L &J,Q WA05%5&=6-P-@X WG1P^.4 ( 0&(MUSU7EW7=8 XS
MT@!<<"='H&7=D PUD$+;X%>E@ 0%4 690 UIH $+B1!\ P";)A"B  JF,!5G
M$  Q\ T&408!8 3<H!.LA0(8UA&T\ /#5Q#C\ D6@ (%4 3Z$ S&@G@$D0,X
M %'04 @P0 $UL5 %T0TY  !,4 J111#;  A,D(< H!>    3LW9S<#UE,)MX
M@ +"*&GM@ @+T(<)$7(IP'<%H1J#H& #<0H_  !%4)@OX00:T >PN!&XP .B
M2! D P X@ R=8 -   ,XH%4%L0()  0^__   '  77 +,"D0X> ''5 !=G ?
M"S$.W  *T]":KTD0RE 'S70%;*$!03 9YX ("* !JK 0U. /FF00V# "9-"&
M*&0%N903S3  *-"&&U$,+  $ [$/O@4 5O0/]+ '->$ <P &=^*0-1$%'M $
MRV<0KP ()B ">O!P$-&:-3(0VX %HR00^G -I$!@@@( %A &%J$(/J N!.$,
M0@  6'"$.=%LL?!Q'0$.;8" Y] -3   "( Y&'( "@ (M0 $*O #,0 $"_ #
M1Z +Y$!8+3H0EM !*I 'J5":$5$,7_ !)W G$UD">J(0]_ )'EF4$@$&&^"9
M A$*QRD9/$$' ?^@G!TA#I:@ &&@.1M0!9/3>Y$3F NA!!,@"_HH$(!P"]4P
M P 07!;A#&"07PF@!PDH$EH  (BG"JIB!-JW$S$0!_X'$M70!08@ RPU#JX
M.1^P!0XA#,G4!7?2 Q90$Q"0!*&0GA81#K9P"_#)$D:Z I= "$\' $9X% ZD
M?B A#K&@&KI" 2" "Y;5$.Z@"H1U!)M "]BP#5(*(PD1#F- $S41!*E B4=Q
M"Q!P"@2X$=, !!9)KV!A#HE0EF!A!RG@"%NV%',P!%XYL1.["9@P!XR !W4P
M"5O&"6]P!$@0=D< !6=P!$I0!XR0"'70!W[P!H30"(^@";\P"+U@HA3_>[,)
M5 >H< B^\+".( 9>60=OX+"*X >/P F@@ F)\+ /"PAV,K$G6P=EP+14"PJL
MT @W2PF,T :4\ M5R[2+( BPP 9A0 B&D F1\+54"PMJ,+)U\ =HD >44 A4
M.QD/P3=!< 0ED  )0 $J( <2B[.".[%DP =$D !Y2K%=4 -9, (R@ 4NX ,\
MX %J 0 3$ .#>R<@$ 4]\ ,T, &Z$@%6D+E>>4-"H 42X  )T#-<2;H@ZP,Y
M( &WM18+4$@X"P($D #IQF]K 50260(D8 ,OD$R\JRL%8 -W(@54T 7[QF^1
M]!"W, 8AAA'T$ RVT EH8#@&N[TC4;S>^[W@AAN^XCN^Y%N^YGN^Z)N^X)L0
M46 !Q",1R: '*2D"@?!^W'N_,"&5=A"#"W$,=. "%+F$^#O .P%6$, 'R?"I
M!4$-<W $+U 3-A 'B""H!%S!+D$)#=  28 M7DD"&L 67Y +_&O!) P3T= %
='\P6 _ #66"J)?S",!S#,CS#-%S#-GS#&1$0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g180931ki01i001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki01i001.gif
M1TE&.#EA'  " '< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
D! $     + $    ;  ( @         (*A(^I&]#O(IP2%  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g180931ki03i001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki03i001.gif
M1TE&.#=ATP!) '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    TP!) (<    '!P<5%14$! 0.#@X8&!@;&QL3$Q,='1T?'Q\:&AH0$! 4
M%!0<'!P# P,%!042$A(9&1D! 0$7%Q<(" @*"@H+"PL,# P-#0T6%A8)"0D"
M @(1$1$/#P\>'AX&!@8G)R<S,S,X.#@A(2$I*2D[.SLO+R\P,# N+BXM+2TV
M-C8F)B8Q,3$J*BH\/#PD)"0H*"@Y.3DZ.CHW-S<_/S\]/3TT-#0^/CXK*RLU
M-34E)24R,C(B(B(C(R,@(" L+"Q65E9?7U]145%(2$A#0T-'1T=&1D9)24E
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MD# JYH2.#+'@0U6A237BA$#K$""+0ODHL$9!U)C_4,X5,X 4AQP#S7'&3D;
M,0X^I"9E12*H6N"(0HU 4) X2(!R#@#H;40#+ *!8T(U.SE20S/1!(M4";,(
M9(T$W294@X,$I?'<&AYMU X)P_UCC0VCYA3/"<@ ZFU.^EP0+RT2Z).0/1A<
M0Q V2(23#P"/@'3/"N3],T4;2<6PR#[[DIF!OHFT4*]!4MP J4#ES!#*/W2
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M*W(-'1SB$E,XP$ZET()RI*,(+Q1(-R30#69D(%X$68<G>H"&VB;7!Q'ZQQ5
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M80+?.0@XS&&.<-#;WNE(QSJDB@TRW (,3S;('@CQ#T0(^A^7B,4L/&$0;D
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M"%30A8<V !!P E:0"LJP#S='$NBP#@90!P.Q%G\H$$_0"\5(.#8  /2#$.4
M!E#C:?\P#GDP )H073D  O_P!EE0$%<P!9[X#V"@ >%($$L00031 [009#F
M(5^1#L" "1#W#Y# 46@D"=<P#B% !T<R$%:P!;MP"YS  QRP(1B1"CF0 \<R
M$'Y@ RH0 \' "[,T$&_@ @8!#%)0 V)!$(P  "@070D!"\H8!93_( AI, -,
M8"D#T0<4% .?-1!A   /L'0#D4K8@!!C\!L$T06=(1#.  !#V177P ,8$
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MS* (6# -5_ !NI4.)!!"?3(0>R ##  $:"H0L# "?% !$I 7C=,*_5 W%<
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MHN=H!@8P!U"B$,J0 9.@80:!#_KD 9N@/3V0 UVE <5Y3Q,0!"L  (TP#S(
M $2@#(@  !;P"O 0 P!P 12 !5ID 0"07A+1"!ZP 8(#$>[010)A"5C6#YO
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M  .@O2]C,  Q( ,!\ $QP 00X /8,   8$T+A0[O_P"HZ(L3WD!4A540Z6
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M%H$"+SD'B)(0G3 )P D \?]#$,8@ W](! # !]M$ YP0KR(N#9P "082#J9
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DWT""X8#1(YA0(4%PY1(V$R+!SKN$-OPLQ)A1XT:.'1<&!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g180931ki03i002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki03i002.gif
M1TE&.#=A!0%$ '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M"0 &FG8"W1D!D.:=0%( CE1<U4#D&<G5\P-5 ^ 90G@.I'$2*P",X%Y':P"
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M/_\P@@4 4.(@_)##!)" GXB8 0*#>9X$2H$0;0S !F>)A@5$D@4- & 'W"
M9C" "W^4((C_T(<L8@4 $$QA$/7HQQ 'X@P)* AL(CF"&H8QQUM%A!\U\$$$
MQ4  *KA#( BCQ3]$\)9_R$PBJ]"000(! *O1 0 1@ 1!@E$!D0B!54) P#_4
MT)I^2.,0ES!.1!YC#8&4HQDH&A, 8@##A>!@#?_@RPP(=1![9 $ KO@'G0"
M@5R8XP 2 (?+ $  *N(  *OXQS#ZX   /& 3>E*(*@A0 1;P@13:\*-%_%&
M-@S$&E\DH3QH@(1Q+ 8C[H  BPCRC@TH(!]'J0$ K)#_C;FD0"2'$,@\(A "
M%0UK R*9@"4DTK%F[>,$ *B&0!,1",=%1!\2T,5C[* 07?%!(&-J "K^<0\Q
M1.,4(E$!H481@5P$PPTB:<(T'JF0><Q#G!E1QPM 0! H1%0@FP! %9Q TXG(
M@P&:&TA09=!$?>@* "@X(P5P,1 KDD<DE\C&-'XD$0+MX P8\$$JZF41?B0
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MCSL[]!&*!D1#'G&71SF\L3)!K.,<YV#'/)HQ>':XPQWW: 8Y$L\.>#AX)>
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M+YID#B% "O] /;4( 5]@#C? 3$PP!0 @!4S !0?P .-7"!$ "'.  83P#[8
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M I$/JO *KB"6_] -Y%D0LD $.X@0J) $F/F-&2$-/J< 95 +,7L5&IH1:I
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M !; !VJ A/]@"1W@"?G1J[;U#[1@ PF@#VSP(#' 9.W%*O80!#1  R80,/"
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MD-![ O$+!W!8<=@L]' !<U .M=!C%<$/*W  G%@0Z* -XV ,$] !]M ,8I
M&; $9$4)"6 #((,/[<53P1M30E 'CVP0$BH2)3 #4K /BAW/ _'A_V ."0(
M_S@0ZE"2YI &)("FXTL,F"(-"9 #^(T0",-1@?T)\5$.(3$!(? &(PH#R?T$
MZ\$ G3!$X-"KOOH/^P 'U?_4 %F-#P/@!QC=$>J "V<4!AIL#&31!NR /1JP
M!<'PCF; #LZ0 0#  @U !>.0#B*1'10!C)E-$-80"'94#'PA#-<2 9SP+Y<8
M"2*!"N7@#HP(3;DP7U%P "I@ @<P O)K$))" 7[@'/_@"P/@ UQ5O"N@ &R
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$.B  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g180931ki03i003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki03i003.gif
M1TE&.#=A+@*; '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MZ2B)H$=*3)Q8$L@4J$*LEJU2U8J9*5<) @A(,(!  0,'.-*,,P062. Q*"#
M! !-Q!&'''+,,88<#]*AP )" , &'6*( 88:8JBQ(20 I& " Y%TJ**':LCA
M! !/&*#",V" $8<8=#@B!QAB2%)  T  \,HA=*@!QB1R=!C'( &LP (!T%!2
MB2&ED!+)(ZQ$ PL )ZS0@C2*6"+));%@PDHHKFSIP ,NL).*+,O,,LHH\D%"
M"P 0!.!",*344HHLHTPC2RW3S '  @#4@8PMKRR#R"VUH*(**%!$(,$$=E
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M@ ]"7@$&_I(& $1L!D46QPY># X)--D=%Z $LB9PA<JEIQ[_$ 0 V-&*"Y#
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M&,@.0T +8/_P#X,0!&-@#)%P!)L  IJ@"+6@"&5&"T[ 9F# "(BP#P<Q! ,
M'J F7)T  (<!"  @?'#F6+ @  +P#RW  -A0 I*P 'Z5*=GP#W2P )Q1"!4
M!YOR!FAP"7E0 64$ C%P#O6P #C0*E3P N1@#DG@ 2_P#BM  X,@#[E0"5@0
M"%!  A'5  V0 3( #.AP"L[ #CT8CS^Q"@4A$$+X;>%V$*M  4>G$7I@!]K@
M# 1@6.T0 R1095AP HBV POP#_P@3/I #ST@6<I@ 6"@#A_  ) P$#_@!;QC
M!@R 9XS@ %T@ :&P <*G" ,@@)_P /R5" S >Y=P 9SP#[6  3?_4$;_( 8
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M,H (AT!>_S ) $ <=-!\_1>6SQ  TO , # #WO5%K? /GQ  * 8$.M JF3
MZC $&"  /# #&G ' D$&6U =!1"&_P "15!E)Z  D]8" '  JU (=_8/9+
M>K )08 +$, -:; !^_ (0) $); I3V !*O &2' ";0"$K!FF*2$%LR40G2F;
M#$&;U$ # O $T*41C7 %O>!;Z' "*E!:7*  PU .2< %._ $1E!PLU=DW1
M:/ /]@!0B. / O\P@>D@ @0 '@"H;7;0 -!5"@_ >Y@0 'G(;;,5<9*0:!E
M#([09 )A" Q@ T7@>LR7E;8@ N#P"$TP UP #W]77H6U!=.  0&P"57@">40
M S5 !90C$""  BX 7=WD6Q_E"QGZ#X00 *]0@ 'U#ZJP 2>@7!HP#"0Z 9?P
M!UN@C7'  2; .T_09.\P!0A "LX !57P#^4  BOPGE>P ?< :P"0!X20 #D
M@7VP ;P3" $ #&-  1\0">3 !H5P"J"P#)J0!U<P!+:@ 5*  3/P#]M0"+,@
M;F+:L1W1!=XF$)O@>/C(L0*Q#1:T$82P!)? #_K  #KZ!S$ 'E)@ /__T 2)
M\GH"4&3L8 &NUPPS4 8$$ A#X'KX$ 0,$!F@5A:X<"C_H @I"V= >'6SQ7Q_
M\ _-0 %N$059*1!T4 #U$ _P( P#H&QW8 I#< D.@ ^C  #Y$ T6I X* +'8
MX(IW( @^4 W*L ,.8'C_$ (5 (^HL'MBB8?]YUBM8(>-Y@$1> &"  Y;PE^@
ME@]]  4AD _"$ %"0 7_8 1%8!TY\ 52$ ,9, -_8 <D4 7N\ Y:P #>8&4>
M\ GN( H30(IP@ )9YP04L U=V0+4Y0<)  F&T -$< NC( JSH D D'$ D PM
M1ZY4X FM8 O\]0]5YK'8&Q%'D%SP2;*0EX\"_^$-#I )'!$'3B *V:.C-M #
MO',$$U!E/' #R (#7? /RK  AL4."= )W=  %+ ):J@"*@"/GZ  99$&/0 %
M$" (">!7P?</D9 !QM=XB]<,"= (_S ,   %!N%J_B$#%! P<+8&)C *3R8!
M<Y .N1!UU\(',N ;&Q $Z- # *  ," ; C$#C@#! ."L (@;8^98D  !L,4!
MF@ !>L "V" )"C #SO /<7 !HN8$,* &P" #)1 ,5; (%C /Z9 #+6"+:W (
MO# &KZB&-D  WC4$.U 4=, !OPL 698$#( ,$;@!B&8&'A 9A$ !M0 />0
M0/ ( ] ),I 'ZO +>O^P!B,@ 1NP*3!@##>  $2@#?VP#MF;R0JQ#J)370#
M"O]P#%P@G@L!;M>K#6*PD1P1!F$0#1E0</_P@EEF!A00&3R9!.8@ %Y@OP@P
M!/]P#01@!/]0#0"PP_2P HNYDP(0%7)  -[@"@#P [^("Q$ RL V6XU79O>S
MP[=0 5!@!08A#]1K#?- 50*A"]B0=>0 #=Z@#H<%"OH@#K=P#\R09=JP#/]P
M#JT@"\5J$"J "ZI@EO^P=)WP#XWG6$XU6ZL  ,00G1J0 O]0 #: <$?X#]A
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M\- .-^ !81@%0- "0O ""_]@QU$I68L  +I0"AQ0 J7E!!XP.*XVBIHP ^U
MH@!07NCI6ZY67JE@ +ZA"!M07J)@ 86@"YM  #K0"! P#;>P#(=0"550!20@
M P!P!0X   :0".L0&0S.@UH IF(6 &^@!^X\"%:0"*30"X/0"[R "L>0 R:P
M#$? P0) '!SA""M@"_X0!"<0#_S@ S. <".'<!5PL<YI6/80 ^X. AZH  Q
M!5D&!#X0&7Y@ >!Q!RK@!!5PDJ*6"!$P<<IG8U,G?!$W<;HP "WP#J00 C[@
M (7 #1,0 B1@!N^ !)@T 83@!9^'#C5 "Y40!\"0!2I@ \BP!BLP 1/ "=60
M RS_$ ?R(! K8 G "  CR@H/8''3< &@O"7>YC&D$ %LX 6'0 98?%N\< !I
M\ \O<)^00 J?8 J.X 8^$)$3H 6EL !*0 :Z\   < 28; ,[( N.X 1"X 3/
M0 08T*!:T %VK <<4 %T4 $ H .$H <+@&)-RWM +5Q[T '2H'45.J$ \ L9
MEP&P8 D.L *IH INX >A0 JMH F^4 NF] I2< 5P, .-< > 0 BM4//#?E0C
ML!6PN>L&89P @  <@ $) $8 X $<(  6P&X&4#<<P0A#D \EL +Z$ \.D 6M
MP@4&X,5D  #*[0%B,%@2H 7M-@ S\ [\< !P(!!%X .(_Y8IDMH ]["*5T!=
M'^5;'1<(_R ,-'EQPG?$5I $3PL /]D!KU #UM *'W *+P &A[ (<!8  %%/
M% !<0[0$@N!*!*0J5R8=FK9B"K<(;_[]"_$,$8!?_VX!>/3/T@=!_PQE(/6/
M$ !HS"Z4P/:/BHN+N0!D^B?L 1YD.P#LN;9%1+]T#G#\ P( 0*@B -Q<+ &A
M'S<?#Z@$<0#@@[@R)XK]X\*C5)E=.[89,\ R9P]M(B$X^Q=&QK%_@B[T^K<*
MP*!_C #H^M=JP+-_FR[(*F9#09= B59=^*>H1*XK&&(<. '@Q15>X(;!.O;N
MXFC2I4V?1IU:]6K6K5V_AAU;]O]LVK5CGR.]ZT+'B_:0(0O'3QT[8^2^M<.'
M3\Z,?QL.V29-B4JE&NGTN1!R4<@)?.FF;+%A2<F#;.X&:/F7KX(0=_VJ !#U
MS\:)?O_L( #VKQ, %Z;L--#GGU$28.6?6   Y1]B E##0  DR0L 4D+IX9]%
M*&!E% !HL4*563R 900M\KBC&P( H"80 %2AP@A- &BC%G>^"$*1/=JY@@-)
M$LGOGQ0D","4?W8!H)!_IGD@ODDNH$N1O_Y))0$ *M#@ 2-U 8"2?UR)8 ,F
M$!! !0 $D$*==+) 81]^",#!@WGD$."B(C[XYI\1HO"F$@#0>*(%.!1(YY\J
M$-!'%0/_F!CF'S&$X&$)&0@8@ H'NL"&%#@ R$<<51H 3)('"O0KEW]P >"2
M?R(!@)=_?@%@&I$.(*6",PR@PYQ25AGFD#9$P   ,<QX0*DZH".V6&./1399
M99<E+9I/.KDHE .:@8V2.)TSMI$?*/'&G!YNT"X&?=Q)(3LH'L1&%ARB^,<?
M!V2 IY\50@@ %"UFJ.>?)2S(#PP YH 2 0W^\06 5OYYA"./+J!#0  ,&16
M6OY)@H9_3KG A1((:24"&P  X1\9S%C$$&4LV$ ,3TPX!8A,Y$$%"@AT*0.+
M3NK(YQI+A!#@EHM$$ "P4(K\!Y*'_QGZE'\X"=(DI:)8 8\N_PHA)P"(F=G
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M"BH K1@(H \K-" 'J/A'%@(@JH^@0A[O8?_%-$X1 0#$0AM+\0@ ,*&%99#
M%KOXA1H6<00Z;"$##E!%% :H%);T(P*:^,<Q$J"'?]2# F(X10T , ,J9,($
M_YV'!9QX#PQ ;!D))-A>%'2 X,J" GCX@B=6TP88_$,'O*5MI"4]Z6.-(R5R
M!( 48/.-:P[A"\92!@\2@6:_P(4/%& &6 W@#PUE9[IKY $@ 1  ,M=Z<7-.
MP@9@(--M^(" _)" $NI+@L.-0P!+^,<X8H!?8S/A']$ P E*@(40X* $):@!
M#FY0@A2,0 A"$$$.L& #%X @"T7XP0UN((1N@X &-!A!%DH0@A$4@=PXJ$(.
M  "(G!C@M?FP@!G_.'R UY8B (M0T 8>D-,4M"$(L/A"R,CQ P(,:PFO:,8M
MNN!02G#V'QD P!_^$=F0D"HDB," &Z30 1@A 1 ZH,720/*/*4P@"\ 8!A<Z
MX(LY#,&P'+#$"8R0/"O H 1#0$+> ,"&](@)&_YPP22NX8BC04,"3/<'!B+Q
M#VE48.ND"N@T-*"$:#!C *E0AF)7TX((^$$MJ5E#")Q "PI3VNYWMSLV8GX1
M9KBAI:Z!AY, \ H(0T<9,;B$*!S1 VK\ PT44,8__#" 5-,! !>YP@*D80\0
MP* 7P\! %VB!C!LHX1G<( $.VA()!-!R%AVH@R"VX0!G@V,#5S@'.00P_X5_
MN",#GY['[M/C 3%(@Q0 2(,T=MJ)8^PG$,PX!0#D((U!!!+ZTB>&T1@AC44D
M(!;3F 0 &,$,%7DB&OL!G3,.L(?X0B#IPFC :Y],B'\D8@.7P( I_I"#?[SA
M 0TB!P]  E(H@A'PJ4+P 1+X!Q4!#$'  $O( %QP@ :PAU$8 #23!08(+@(0
M B.PAR<  &K9+#3#A@^P *8+ 0#8 6T( AA8@@'H@0E@@U[H DOX!SZ0 !*
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M;* '!&O#I61*VQ@%(U '8ZF^L+$-9U"!4I@!=>H#! "M)EB!<T 5!Z"E+5@
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MI7N*<#" 4:R& 6B8:*@ /_@'>2 !'"J8DE@OG_$' 1@!#G@%(JBI'PT$RHH
M25@#%O!251@%"U! 23 J%\@ T)H& *BI3VB B0D$N%K$%[B! *@$ D@U3<@
M3'"''H "*O &03 *=X@%"D"F/R,%$-"&'9 &6^"!3F"!?W &!8 "RC*L=/@$
M!KB _VDX!P; BUKP #L= 1CH J7(@F6@@!/0DJ'1@VX@AAD(!4:X@%BP)1M
M 7Q@@2--#68(A6F8V((5W]ER!^!0A1H  U? 4-4H!RT @ SHA'3P!$UXBM4
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M"@BN=[!&97@$$ R3 -@!6) $*P" +TA!#3@%3G"! $"!'A" ALD' +"(>I"
ME.0!!@  KSD!(%.&"H"691@ 7D@%)D.!?R@&@OL'9/"!/[ '9L " &@!#SB!
M4; '<GH#?KB&/# !=-"& +B%4N@%&/" $0@& 7"#;LB $Q$"#$B"&A &(E"!
ME&B$ Y"$&C@ _X(!,2@ )[B$.SB C[&  N@!27"&D/B'C4 F=K@!'U@<!>B!
M/JB!(#"58W@J@1J 6> #00  "UB 4_@!8:N& U@#<< !I2"'/C"!#] &>X"1
MP/ !.FB"_W(8@'EPIQGHB(\(*&$@"% P@@^FJEJZAE:0!6:H9M(X!Q@( V(X
M@4!(BQC@A2]0 G?X!]$8C7WXR6L6;V*I@C#XBHN0A!#H R0X@S4HB=,@Z3AR
M-".=@I14#;]0!B.0 4"X@SIP S"H@S/X REP@R7P@7PH !4  13(@AO@ :/
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M&>" &7!H$OB$#A !6&B$(0  ,&B$QOJ!(L#GRZF&&%@!2D "%( $.6@ $6@
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M,5L$7N'P<D>&O'\W!/TSE^/3/WH23*F+0.5)K7\";/TKY@#6OW%4(O]- ""
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M 88^P,$3;8@$'>)PACX P0YW,,(=(J"""=$  09XB@1,H($F^( "/EC $ H
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M<(,C+M$*9<#@$/KXP K*<($ H.$0)-K$+7AAC,;H [76O>YU5Q&$@Y3!$='
M!@4@80\+'.$?:>"#V@BQ2 G=  "D& <V@,$/5^#"%=>X!S6(,8Q0H,(4N/V'
M/^  @#I$ Q:T.,4L4(&*6E1#%,*H!CM8X0M>A&(8V&C&"!(@ CR,XZE1V$<X
MOO_F@G[L( HYW< +SM$,;/X#'2Z(@Q@$8(1%Q,.JF_C'&.#ZCSL 8 [\4-&-
MFP$#J*Q# DGXAS4^0 @1:  +4H@$)P" BYK2=!< X$HXLF!B8,Q@#IX:0!E
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MP A.88D*,+H7)P! >7T0BW_T_T$"KYB7"&P1##!<@ \A(,$)!! 8#T"A>"E
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MAP?H$!'D@C<\ B7D13,&)&H! D(9A!AX@C"83@8:G\/QV3,(@"(P@#'8R"4
M ,5-R"$8@ WX@!\NP0G@0P^4R#KP /S\ PHHP#FDP^24 PF.H R<UC;80 /
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M)5P ",S!)'Q %W0",(9!(TA#"'2"-D@#!*S!/W@# / !2UD1.?Q""HR+)0"
M*?S#(0! +_Q +L1 !#P" #3 'EP!(W2 -4B  F0!)J !&W ! %""*5A 728!
M +B ?VZ T*@" 2R/*23 V>V"FO$@ <!IH^;-/)R ([@"$21 $U!!-'! &NP=
M /S!/Q0 !S  %B1 &P! +(3#E060#F16-<0  MA/@"*$.IC +0P# "R2&'B
M:_7!!Q H%?1 /_R#%RB ]1F! !!H"2P /?!##LQ /?S#)!# /3C_*9S^PR<8
M0#+\@QBH@#[,U1#,02DH0R_T0C#  BJP@#FXP#-XP:'F "=(PS:  SP\2;-&
M[(1,@\@99"QP0CA$P*W^7WO5 0S(@D% P@E$VX.\PPMP@ $ @ :\9(24PR<
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M"F2'+=A =!# "^#E4DS=?)@ +:#&S1 "XAR#)   %9 "'E1+)5P5'CA"L +
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M.Z3 =HU#!1P9,A! )DA#*^  _ P "[P"*+ " !#(-PR &&S#'H !E6#"&JA
M/MB" 0S6'FB '7B"#RB  " !"0" $/P"+IR, ?QO'R != !!+*! &[#!'02
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M/&;,EG&;=>]$$49YK&U4]VYC$C%D %!Q4>(0)%JT!!TZQ>E0;42" +AH3 ,
M58Z(^H1S]R^#C&X+_"US4C)6%'$%$-UY@!59.B7A1CH)\.\:@"K_VO$H\B\+
M@%?_RIW \L\>ABW_W!U8 U\ B%9Y?I@81XV F'_9#EC('R(BL.(< QJA@AH%
M#OFGEP,(^4>;#ABP)Y@#VH F%02ZZ&<0 -8(!QT%#/B'F@/V^ ^ 2O[9Q@0
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M!?P1605,JPP'>* O '")?U""B/] 10"DL6\ W(2J44C%+PY0B6[43A"-J(,
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MBP_08 S&0 NH@ C_@J *^B (I$ <;"!%YB$##N4?=@ "RF$=OD8?4D W[*$
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M%38@%>"N Q:!%5;@ DY !SC@"AB!%]IA6DPB'>1 "!+@(5#B!QA !]X))?8
M "C@!%*-%@"@%*J"W/X! M'A'X" U6@F"#1"#1I@69#@!(PF!F&E'S5'"6:
M8O[@ S3,"1A@'?X!#P9.50"@R!RAWRX!  1KB&XB%"P@ WIB TR@'"P! -"@
MFC: KU ! +;!%RQ@!Z*! ]C !<ZA'.H !;[!'% A")(A'8B 9PYA$A)A%)*!
M&AI!%'3@&<; "43A [@  I#@%ZY!'_!A5A8QN_H!#-" $FCA"  @ ]:  ,SK
M,5I"'M*A"@0 5LH" $SA'Z)3#+QH/DC"'NQE ?_@X _.  W(X T8(0[NX [
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M6N )I@$>\B ""J$-). (UN"XH"$([H 5M( #"J GH* &.L -0.$)R, 7@&U
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M-$A-".N !8X@ 2X!!=Z $F#@"7:!$$BA7=C!$DC@&E: %/\"!3//P!(001M
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M1 ( #,1A !Y@%F"! 1KU'Y3A XH7<+)J#QA@=K2E09AN";AA&2Z "(#!!Q@
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MTPT"9_RSC01X/(9 &+[,<P,D4VVPQ#I'2-##/\P L,<_H@ P!S)3+/'(/]X
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M (CU#0!DXA^LN !J.K(13/#D'Y! @'*Z=2G_C?Q#&PE0WBX H*Q19  UMH#
MN4"A@FDDX@H6>( #2- %.+"B'U0Y80S^H0L0O",5"HA&*LX @ UDH "1,( 9
M6K&'$4 M#SRH&!EDT+8WG, L?$#C/VX  Y M@ 93(>)(0L*-L9GN'YV@@"O&
M1K&W6*!A_#K%/]H @)T= P!(< <G6B")5G " %KKPPY<X0RM\,8(#$"&./3
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M5RC!+S3PBW^<, ?OT 0 -%&."%1A(N20@/S&H0.BB (!M;C""[!@RR&,@1$
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M42@7&X$"QD@-"*"  #E,H!O_N(0%\G&6'NSL$IYTHDH]T0%;2H(+<@"  '[
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MAR*(@ XR?$ "Y^B'"X0P%2Z4#140$(5F"A".<JS"!"ZV P:T\8\IS/(?>P"
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M$$"%4& ! 6 &20  %;8WAU *;Q  LB8'/4 "E- +;T "8U1'VE ,'P &N5
M&O UKE $(F *W> !1  +1U #.3 (F, ##> &8D   \ &7B #". )@0  (H +
MCH !%$ *SZ !E% .2#  ,? +C= #)O 2JN .(2$!;?#_#2/ .UB0  4P! "
M!^*P#L.P 97P#XF08_50#%Q   ( !PO0.9Y% ##0 U]P<6<0 "L0"-O@ +I0
M#MK0 ]OP#\U@ LRF80G "MZ@ 6; "K;P <)0#;!  )-P5#TQ0A?'"1F@$L\
M.WMR 3NC7L2R(:]$"PC@&##6$XXR",)P!DS2"YU0 3L"8^88/!MQ0DHD"+GT
M#ZL 62\!"V4F!#-P!:+0 -R0#GD  W4 !QY@ #[0 TN0 )\ , #P#G>Q"/V
M#5[@!'6@!;7%&$@  9OP!P90!@80#V4@5/V !3U0,;C4$Y\@ &;@!A_@-?\0
M"2Q @T8P  W3>SL3!P] %,F5_P8V 0!OQR^$8P8?  R7T 9O\ X:H )!T&6J
M(7QB( "9$0D48$M'0 !Z@00Q0!T>0(K_@ <<,%8"D6!@( 5+X +]X .8< _.
M  .O] 8:X!@3X -340@#0&:?, "A$093@P7$H0U]T C%( NSH P@T *5@ $
MX%LX, !>L N*@ XG^8&.01_^0 $!AQ7C@ RS"0D-  ZE4$>GD ("L0")XIL-
M" "D9 *-4(,(=069$ DRD (0T"L(X 6:E3HO< $Q  XIT L_4%/G(  _4@5,
MAP)0< 4BX RQ( &(L UDL0S<L Q3D 1L  H7P(;S$ ">\ ]U!@#<  [014,
MH  0 /\$%E 'X> - S87*  ]<I %;,)!VD V ) *,W $#P "L, (#! %A$!;
M1" )@5!'K^!;/  - (,+_\ ."P )090"T9  7[ "1N8# , %S7 T * #E_ #
MI+ "<A # 1": ( PL=  -N!; O$+*;-BP> !'U .O+ !JB /R8 !=< , S %
MI= .S_ !*W8/%H K4   ;S@#2< 0)A!9US"3M9( YS((2;0YY@@.$+ (V' ,
M#?</9Q03H^$MPW0R._%*YP5>2\ #+PD -6 "\L!FWN*0,<$-![ CKP  70(_
MX-41>F M - ,W$  /-!DBV !9,8,(],$+[ '3F!G " +T)/_$Z6 !G6@"<GP
M!ZSP5$7@  (1 LT@ 4T0!,E@#"(0 "$0"9B@ :=3"3*@!XD@!29P!GH ?)O@
M#YT0 F;!+X>B%1<W#0?P2L]%*[3E8G%  +(& !]@"<KP3UPS &CV"3>&'-20
M&AT0?7JP 5)!#0SPG'&P \(P-0(A"'>@ _P  CHP8QG .A/P#](  !2G# >0
M _^ !AD0,7B $V]1 =@@ 0"  3D@ R*P!(# !$1P# _P)OEP#,C06)B "(^@
M E=P G& "*+@#O? 1U0!!B%0'_,P %" %?%@E(F2.!:& .PP!4V@!E1 !D\0
M!&NP!S<0!$8P!B.P HY  #M3G)XC_P2,4@73D YO0 /XD R^  "4F@8L$ -W
M  $"H 9P)0(+L [W  ,7, ET0%4J  0TP )0T 4D,"I0( 1<L )!D <[\ ^R
M<SG9  )-D G"L , 8 8_4 !JH =9  !'X S%( $_\@T+X &DV@&P(0H1H"1E
MD !H< 0!H 4/L 9J\P)]0 8*, 1@8 -5Q0%T,#4S<$8R8 M(H *[Q4(#  +$
M%1K+T $KL $Y@ )HX DP< )7!@ S4 !^L )?P ;(4 @/( K8   K$ 8PX ,A
M  )CY &.H !]8%^S*A!9L **8GDS( (%8 +7< ULD $P4 %$4"76<  _ @P5
M,*+*8 ,C0?\('' RJW !N",./$ *A? !.C $FJ4 Q+*FWK*6G3$:Y[(,#YD+
M.D0+ M$,9[ (&^!Z)6%+R\  X7(32G2/PH(OYHA$Y_(+%G +\* ]KY01DN$%
M/' 5<Q $[M +%R !.\ $B)<H=<D!,:$9&< &01:\;W!?B9 & / "$Q$("8 -
M/@ #-T"#L> #:5 # O$%B" &#9!ABC  AP)R<A ;   ;LI$91Q 7_[ &/$ /
MQ= #+] &=C #0M8+A) !-.@),> ,3M8!>E$'#Y %XT +$0  M? )/< .\0
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M!SAP!,N# U>A"C,0?9&@ <(@#\.0!0&"_PD-X&*X@ )M<PH\H WPX P7@(L
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M4$*PYQ]0(* G'2FT^&<4 +#+)8!*8B, -E(H:"6; R*XP<#/Z)'F,T;_\28
MBOY)9H(D&K7T'Q8 @.322], 0$5.0Q5UU'^XT8"9_T9;,2&<&@$XAB,!,F&F
MCQ[RR*R%)OXY1H$H_BEFAB/Z4B"(?^:AP(5_UA' ,WUX+<BL@@(X8R< ''D6
MB-@ $.,?>@Q ([8.P/C'F@!@$P4 N3H! )=2 5CCGV :$.(?>18@-IMR_XDF
M 3W^F4:Y_:"]QP8 $!#JBB\> 6"4V@Y()+< HOEG$P#8<T, ;OY)! #8'$&
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MQPH JF)$@VY6!* I([[[1P\%]E%G  O>!(/,;Y@  ,!6N+ FP'^8N$"/&98
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MX;'" +5(" )8U@X1,(2D6Q#'-S00"V]DXPF1#$8&_-"/=?C@"_^HQP-RA8P
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MT5BD(ST!C#B##6[ !PY4X -#F ,-E, &%0 @T7OF^F?8P8I8D&(4_H! !%P
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M!W$8@1U(!Y+:KW)( 0_X##NP &"8G@(0D2A,M#< @#E8@U-@@"T  !4H G
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MZ#I];)1W8($!> $P8!$>X(56L $$ )!@Z( 7B!T3Z)-B0 $DV(6K$ ,WH!X
MV ,_F(/D*0.;^@0TH)(["(,*0)DR0  .V(5;0 "(X 89D()"( ,=_P  10"$
M$D 71H@!!D $3U" #^"$3S@-2R $"AB 1: #!9#)."@01M"#$[B 3)@#! B
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M %D$!< ./-" *30!$G"#-2"@$ @%3Z$.;[@![/\H!!DP!P-8 D60 #L$ "]
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MR(%Q)8"@U #>Z(4!6)3S.X#S$XIEB)EF8 6;^H4=6QA^2((G$ =,00-9: ,
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M:X@'\#4$4&@!+/@'9=B!(1"'-0  EDD' 8"!\UR =PD&!,"%-UB #1 _9[
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M-SB!+SD_8+M[P^F#!XJ!8LJ#8;""#OB,+ "@?T""ACX'$__P G^PL()!@ P
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MQW3V#S$(M&</ ,]L<0H:+_SRSP@+  C #S70TH,VJD)@2C;,H-!I-0((40
M*-@QQR@7"(&+'@3](TK4DP @RC^)2/ '*BV$ ,T_@@# B7H/[/&/*AT8 L<9
M,(3QSQ$#E'Z)C]4!D,<_T0"PAP#5. ")$7]X,<<%M2GRSR@ 8/&/"3NH!6B1
M<0<]5!$<R,0#!2H0P :ZA  LF((4M5G_P(@ X*$Y-  9_P! U6HBIG_ ( G+
M^(4*<,$$+P0A#<R:0VU:\ 4 4.,H  C"5&+@CG]< 0J=<!D^ME K #R@$#^P
M!0B*4)LC6.$([N! $DZ@NMI(SP2A8484:A,%4\! $^D !  >(0LWS$0;7@
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MHY  80:45X\($&(S#(@%/VX''6&$#1\6B$%]9# #4&0C2HH@!@9V\?\,4E#
M"=A<[%OH\8 G>.$&7"I& D8@EM!<PQ( <,4_:'$#=@P% (OXAQ=8 (Y_E$"R
MZM!"#]@! @!< AW_X((0A#&-&(" "^,HPAHPL 1*J* >XO##!\K!!.+]XP4
MB($?F#"!>>CC \EP(AC\D81L!. '6Y"&##SPA'5\8@%H,$,<0H") QC ">2(
MAB4TT(4$   /-<"%$XK  74  03GX(<)8' .00+ "'JX@ <JL ,"4$(J0,%
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MQ@/2<XL(K,)1,N\"$/21@6>\!1W2PP=+_L&,>[0 K6L)AP( L $+1( !'%A
M ":0I$$08@Z$L 4'0,&&$;!A#')8! 08,(Z,+[8="9C#/?Y![E&4Y #MD44
M*O$/ B# _L:@ !_*08\37(%47 $ ^,$JZ=,J6(!O= ,'M($^], /O,(\!(DJ
M]0$ 5(0\# !:E0$%P!\XB("'R$("E,Y\C!8U))LY3,(,7($F&(,'*,$D^(.M
MF$?['$XGQ,,C" !CI$ 6^  ^Z(, - PQ , M! /UY%X=A,D_Q((*< (4"(,(
MG(,1X$(*@-8JO$ KV, SO  ;K$$R-,"]O ( J(+_6.1 %AA""5A? 3S# QQ"
M\?A $S3 _1B)-11)1Q' ,82 #,  _(U J]" A_3#0-A#&4! !%C#$E#!BXR
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ME$ ;JH$05( !"( 3[(,4Y$ %C,"')0\;G( 0W (I'$#_!\R0%2C?)(R!5-
M$;A#".Q!#6"#Y<% #Y@! $@!()0##NC&/UA*,OR#$>3 #>2 )'A!&E1  W
M!2A7#9#='=0&!4B % &>#\20&YQ T^V!#Y@>$<0 L]# !YA>$F  2@  &8#"
M*70!$PB? _"".WA"%)A>'_S ,:S!&\#86K""^LB""L!8':3"!#C-6LB# :S
M8X1#!]@ )% ")2 "!%@#& R!(E!")=2"&03 #"Q!HS3&+6" #Z  ":! #>S!
M&9Q!'I!K'@S!$QB!%D3!"J2 &01!'\Q!O,Y!&=  "" !$PS /2"" CR(&FS
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M,$-M+ ,K((!00(,&@$(X= (!2 5F(, )3, !L$..Y  \L$.MM$(X\8%4O $
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M+D  K/5"!C@-YM0'+W0 "&3#>D)"")#"%#!(O* 4-63 F7+&CYR!#" #.Z
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M/V!" M" +CA""QA >H3TA+Y#"#  ,PR"!'B()/  -XQ#-$# D)#&#L!!$Y"
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M029D@ VHQA,T@.$ 0P.0Q'K0P0ZDP@]\0@DD@@8033?DTS](PPR4021D  1
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M  "H\ 00!TSQH E ].^-A&[_M #0\:_,"SJG]K 8:03 *5:* "CY<\$"@ (
M!HRT P&N(P80ULWIL>29H0?L:/0%$"'2 GJF(C  0B(*%1][E"@(8-N%(0V/
M&BD Q&#8/SL AO&+XN;?.25XRBSJ:ZM$E'/_NI#Q\TR=R51)_I6Z,?(*@$G4
M2HHK56H4(0!/ MD2QW(D2 K0HQ9WTF%)$0[^*0$ <M1IXX,XM@'A!%W^P<&7
M?UJXY1\] $@D&@^DP&:<(6A@XA\Q M#F'SD ^.4?4@!PY!]@*@!@EGY\$.(?
M>2#HXA]Z?*CB'S4"<,./?R3HY)]D$+#C'U X_\#A'Q- F.$?(JKPX!YO&N#C
M'U8JZ&"7>FZX(XU5/ B##60 $,0K!2S!!1<-2"DE%0 4D6<7 $+YAY<9_S$%
M@#/^:06 2&K\ 0!DEF@A'#\DD2%);0!0XY]C!EC'%1*46.6,5DKH108?$"#G
M'T@B$.4?3500!8=("NA!@S9BJ"95 %[1)QD"\OBG@P8> 12 3F9AH )<4)&@
M!W[^X:*!5/ZIA@%%;P'@DNQPX*3&!]CX1X$-\LCA$P(<J<46 /@P1A( 1J$&
M %P!G)?>>O^Q!H$ 5JCE'T  8-$2 %CYYY KJ/DB#$KR@884)\:Y9002F #"
M!@LX.2&66:*! H >?O\(8XT?VODGCPS\&8>!/(J9HXH*I/FGDG\ALP 8DB-
ME0^T_LG"AWV*(8.,D<IH(90_ &C@@0P:.-J:701P5KANDBFC G/^ 0"#?OXQ
MPH(R^BK"B#=.&4&<8&98H(A_^K!@GG^@2,&*'0Z1H)]-CC#YGQAL R" %WC:
MP0Q2;@"  CAT&,,>:S[X) X6^FK$0R'&^2<,$#A(((,(;K BAQNT8< $2#XY
M00AG#;E-E3_$*BF6-?X1Q8:1@@ @F95N"><3 !:9MX03ZE7$@W]D ("=D;[I
M*XR1]"F@E']ZT&,D9_I2]!]BA+ !DDL>8-$. J;!2=!>"$CC UJ*(&(D%W#_
M$(>?&*R*)PL#OAD"CP]F\:>!)'.)P DG_O'!$' P1Q:$X8A&<(!)M0" *MS0
M!B0D(A9/"((MR*&""HBA22@8 F0.,*PO2" 1E,B KO[A"D$% P!C*.$%E*".
M8 B #Q80A YB\8\U , 3)8Q #D]Q 3S\PPT:H$8V-C "(* ""LQ0P3KZM(Q_
MW&$#L<N %D8ACASPX!JYTH8RLC!"9HPB 3L)U.ZJL0!N_",;&.C%/V+1 46@
MPQ'&"84P  "(?VRC E;XQSTBH$)V & 5[E!&# !!C59X0!+HR 0 PF ./%@
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M ,#+"B&$XEV"!P^(0REZ\ QE;#8:_YA##.#Q2KYL(@II,,T'\H'"#C!  QT
M !':L0-"H*$O$M#!#B(  #?TXQ"R-LGQ5M"#+R1UJ2LA_T<!,E$O>T2!!Y:(
M!X*"1X(+[.,."T#"2$H! 1STPPHUY $W4N&M_^@" TCP!AV"8(21_&$!S?A'
MP [Q#U\ X(?PVAT_0L"#?^@#!3SJ1P0@88L#% %7(_@ IJ+! /9TXP%U^$$7
M+% )&\CA ;@RH2(&%8$H-*(O2&C$,3/LCQ3>40-IXP4'!N /&6&A%;DX(0#*
M<"@ ?*L2%_C6+)0:!4S8@ *\: 8&P/ /:D2@Z8F@@!;^4 P#I( 4$%A!)]Z1
M@1*8XA]@4  WU)&!'12@'%^PP0^^H0D :.(?OP! JG51 P-$@QEZ]04"^CV*
M_QX" ,R(2U\&D00&M.(?G_MA+/\"H$)1$* +*< '%@"@@%0T0!JV. ($=J$"
M#RQ!"D 0\>CI100 0"(7'5A%=0$@"X(%8/6/,$$_^ &#3!@C&!LX 3@0804(
M4" 4>3@!.1"E('7P !+_: 8 9&" /G@! -2- @WVL8TRA& 5=H!%$>1A0PQT
M?PD+@$N7Z_$.*(1@<IP95AP(D(U_<(9??^C!-1'!@G+$H\[\"$=?(M $. !@
M"JS!#:1@)/#@V>"%"1XA"]I "/[#!F!@9/(  ! A'=;  BS$!0)@$;*A"7Q*
M&_#  W2! 3R@"KHO#P0 RZI  =K!%+;  :SA B(!2M3& K#A'YJ@!)"!&'C
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MYB!)+ D%1*((3J >_L$,^H(</$$"T/_1#A2@9N+  %RA%D8(#,8! -:@,<V
M @K*!D* 'J[& V;A$!)  _S'F6RP"&+ '$:A!;BE&#R@%>Z!% X 5PI! ]JF
M%.K!#(B@>"JIK4HB"MA")0+FV?[!'7C!%G@!55@B!0"  $A+)29A +0A!HA@
M!'@@!&!  DZ@!5X@!$! "T:B$&H !7! !60  SA !8H@!2[!"2H!%"K@&O A
M#@" %^(!Y1(!'HQAEN +"J@ &>3!!T3 'YJ! \B@'9C!!1I@%:K "O[%Y=KJ
M&@; #X9@'$X@%,B@&2Y@&I* "DX %=X!%!( &XY@$'  $!;!!T+@$8R! %"
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MQB$<V*$QQ0$&4D (Z  1@, /VN 4^L (RO] $:X "PAA 6+  &KA'2KA$)R
M%>[@#XY $P+A3RG@ L;@%3B!$P3A#(#!#)Z@"-3A"3Z  5A &DC!#%2!#8X(
M%TI@#@S!:Z:@#=B!%/2 #C"!%8Y #%"A"9I@  C !"* $SZ!"IP #!XA$SIG
M$S8!  [@ \  &LQ@%X" ">3@$8" "NK@'*+@!)Z@$\Q #&)!$[;@#)[ $/"
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M@1.^U"E'8 1P@ 9&X-5-X !0P11ZP1!:8!ZR00M00 Z"H 2$P M:( 5<@ N
M( <HP L4P 5P8;LL@1+@P!(XH1(L80\28 I,8!->8!E/  (\X !\P*?4P 7P
M_^ */&$%2" #/J #-& B%* #@Z /!L :@. )GH (I*#>E0 )\L )I"(&.  *
MZMW>B4#@GT  :F .<,0-/$ $:$ %KF *A$ 'K" #BL @#*$*6L &:H #7& $
M9$ #ZN #@* .LBH%)*#434 $%, '"L#<B> 3JH 94J "/B +7" &-F  !$ /
M%" );B #G( (U&X!6J &OG,$;J$%H \0<F!O]L8$&&4%%H!!;$,"2. $;&,
M<@ "=N#I]R8,;, $/&$!O$'7CB8,,$"=* $'3* +BF KOKXO-.$+J( (L& :
MY+XOYH "FL +/"$4Y$P$UL ,/H$6IF$>*" &8 "I!O_<53'! L@ #E3 ]5Q!
M G;@:@  %*ZA!XX!!P  #G;8,06@;; @:_:!!#9<''8@PZK!!)Z@1[;E'(K-
MN<1!!BZ  /J" DK#"1R '-8!#_3@#?H"#?XA'JZ@#>@@/BQ@'T" "I*69#:
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MH/ "./^@T,0_[4!@QC_)1#!E.P  D=,4+K0BS1=2@ +-'3#8\T\= /P #PX
MA/)/$R,LU@ ,)#  Q37_@*$ ,__8$4%%>@"PQP]KL+"/1SXTU <#L>4!@ I]
MNN!.(0 @D $ %VP##SLL^/#&(7-T.(@#2Q31"0!2-)2'"LC\ TT=_ZQSQQV-
M$*!C BG\ ( B_AA10DZ/&  -) ;P8,,_3OA0SS\W:%!".5=<48XS&ZQ$010
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M0 3Q$ ,/M/&/2F1@ SEX  !"D(44**,"3FA$#S#SAPJ 0Q.TR $ZQC$"$P
M&FKX0CO"A05]P ,!7?@'/A8 *RX 8 1<R"$@_L$) #S#&[H0 3?#T@]T&/.S
MH VM:$=+6O4%PBJU*%$E , !%,AK?6)80#I2H8$[Y.(,61B#,W Q!TR0H 0.
M",8_]$" ?J"" #C0@3G.< /%\L /I[)5*HSQUW^D @!^^,<</N #2/RC"%?[
M+@](P8B5)*!' .@$,;3!#%^$@Q$_8,7_-P#@A'MPX1$;B$:?%A";(22 &_\X
M@@S(00\8V& )#EC) 4P@@@*$8@  X$).NK#,.P" $J[@A  (D9,>Y$"Q7X !
M_3*!@&C$ A(  (,\_J  6]S 'A, @"Z&T5P#/$ +]+,"+LW1H6S\0Q,UN(8%
MK'#&?Z!A"CGY P#RH8\)9.$?T?A (_[1CQ/\XA^( , 5;V %+Y0B83K)Q!I*
M2^8RF_G,:%[?.W9AAT@<2C%DL$(I , .]EEA!7-  0AL!8!5^(,)/JA%+  P
M@8I8^ 5LP!D 2H&-!(CA'R*8I#76Z@IWR& &]%C&(/_A#@'X 1\5N(%@_A&%
M)$@F#W$@1B<E_X<!!DC #V*0@@,Z8H8O_ ,3 \""-/[1AP94) @^J+,=+! ;
M,+S@-%W@ BYVP8$7. "]'L!%)(20DQI0(B<W" (^@%&&,-PK!3& 6AL(P(-)
M!( &Q_@%#Q30J@.H%0!8Z($?).A=FR+ ;VG@@#7^A@!L0(-P4=B%Q6B!"R[<
MP [S6($EHP& ,?P#&!*(Q#]V$2*C@H )<.AE6&9QOC1[_.,@#[G(=5* 'S1B
M 0U1S"(  8V0E*@?/0! $<SDAQ:<@@T=R &1%B& D+0!!%S@ARL (($ V*#!
M!E*"/O!AA$7P Q0RX($ZA"&"&L1*  ! Q#]6\ %XF*& IXA:''S1!O\,>,"J
M. C#*QQI 0D X!4V+<+8>- J) # &T:>@-^^@(+!\H$ ARH#M<5AA2;$89,
M$((48LP)88A!!1/@02>)X)$3X.,?6W@!+,P@"1R\XQQM@(#?PK #7.BB!%'
M!3Q6VXE_ #&>GD  @-$ @(K\P0)> $ !KK"2%13@&_&80';3,0 T_.,>&#B?
M+"HNA@>,PA%NN'98WCGRZEO_^MA_'Q J@! 4P0  '3 !U!2#C97<XQ^*" !F
M,%&!5LF! ;TTA ;X@8.C&4(==J_4&,[HCA0  !.H, -R4 [6@ $$D G,L )+
M4 'NL 93< 6H\#\MX =_T D^H 5#@ +_\ 7_#O</%A !A? ';I #!( ")0
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MNA !UN0& '  W1 +%L XS#WF9([)Y/ ,BY )J!  %N  L[ *%E8&E  #)L
MA# )' ( .H  Z:L,%%"7]" #?3 "FX!B&I#26< +9!  '! "?*!DN8 .7^"O
M_P %#I /M@  <<!,:\  XU 'A+ 2.[ 2H> ,-F  G] *8L "U D"[N .)H #
MR[("2A )&J ':C -CP &'/X/$Z #_XJ@WA: ![S& L4P!#$00&80 <-C"1U
M#/^@!@V 0,#I683P8>D@!#B0!Q\  "3 -24P24ZP$FO@ !!6 BP  UD #-:P
M S5U!R @" :P,4E;YO9^[_0+#XE0!YC@"G2P @ P!:(@!)(P""5P WS@!7Z0
M!K!0&RX03<FP D@VMW(P!%< "A<0DXU@!J6@0 L (@]P =;$!"] /T#$3'.
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ME3<DF""0&=(A(X1S3&,AOBUHT.<?+YA01P&@B*0D 6/6> 0!%_XQ@0][E('
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M?UPB,)X!P#^D8(%,9",'?:B".(#QN\SUH0N-^(,AG+ H *PE0A"R  L*,@<
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M Z#'XTKQ#Z2: 0 /P(,,P/$, -3!I!A( !*B,612E]K4^,Q',)A!ABDPH@L
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C %70!$70A<@@T O%4*Y[AWI(!21H B6@ E?HAW3(B(   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g180931ki03i004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki03i004.gif
M1TE&.#=A#0(1 7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M  9T\*T'4(  +[! !%X0@01D0 8OZ   4@"$*PQA!P#P0 MXH ,-+. %$R@
M!$0P 0TD  4T$"\!%' !"GQ  0-(0 5<8($'(. #!@@ #R*   !0H Q5>((4
M6.  #(S@ !MX0 HHH($+'$ '#4C  V@@@0% 8 80Z$$,1""! !1  ZRZ  98
M-8   . "WZ5 '8!@"$4 @ $L:, "!E ! &#  B5&0 T:P  )<, $K*(!#0S0
M@0/TP/\ #0C !Q#  1^<0 ()D, ,'-""(70K"<RE 04LX. $." !'LCS!@QP
M:$,;0 ,!&$ ')MV!#6R@ QD>@*4+H&0(," "6,#!"US@ @'XX @\P  &E'P
M F   B?(P )T@(,6C$ !-%#!#V(0!!9TH0LIL $,DG %*F3A"4_( 0,FT ,9
MT" $,9#  :B@XB?@S%P7F'2C+X" !EP@ #580 *VF^@-C'L %QB I@,P,!%$
M00;?4D$')""$+W^Y /8N@ 7NK6H+2  !%@BXP/>M[X"K>@(P&((#%# YQ*5@
M P3( A58$ (;H* (,8A!$EP@ AC0@ F_9@$3KG"%+CCA"TW_J$(7MM#?*SC!
M"5R @A(VP#@8N$ &*<B "LH A/Y9 0HQKT+0^\>%*E3A;$;GPA:VX 6ALX$+
M7- "&\#@A3)P8=E.,$$*6J # "B@"RL0P0Y$,&03,.$%2T"!#7#  BH,X!HF
M<8<C0A"&!93A('R( $'& ( AS$,?T " )NKQC0&@@1WZ@ (&@M$/.S @%9)(
M! #.H8\UX  =^K!"!+RACA\H@1;HB(, -' /6)!!( A  %:'@ -DH,,&0WC&
M.&+P@UJ$HPLZ. 4L %"$8$@# 5VX!35@<(-A5(/UQV '"LR0!0P0HAP",04
MA%"/'JR@&%K]P2V:T8(8;'\*$MC%_S'ZIPQ\N,$"K'"%$JYPCG:D( [C: <)
M7B .)0!@$P+AQ!D2\().]"$?]= $0H!Y1V "W30$%: -YJ &&$ ']? ( P *
MX_ ( 4 -R< )&T ,Z& )#; +R"!]7D 0+0  C[ -JT *N[ +A+ +>V )K] +
MHN )*>@'M] "A  *@8 )EG (EE **X@(:; +B' (<@ *C   (, /[9 .Y; )
M - $@@ *B= (7* )7H )AE &;> %@T &*^ '4L !BW );9 '4> &)I ';] $
MCD %"C '3; &:4 %V3(/]/ ,]U $ , 'F! $/; $R/8$59 +B2 (BL +ID4*
M#0 "'M +R/^P"[A0"'3@";C "9M@";L "9RP!ZV0!P!  O_P#O(4"0!0!].0
M"($ "+O "*J82:B0";O0!I7P":D0 D2 "2F8BY5(!JB0@HEP"9N0"KXP  ;0
M#9DR#TZH!()@";J !&20"UF0!\?#!7=0"7Q@!GE0!!E@!W8@!W?P!%;  D-P
M!3)@!GV ;%H@!#_0"!]V#OX #?3 !0"  YTP!T^  CN !R2@!$\P D* ;"AP
M \@&  * ;#FP C@0 OVX #<P?T\P 0K9=2ZP#_91#C?%!JU ")R0"WA "9CP
M!G3S!VF0"XK@!W   -  $O(P"4MP!M%1 P<P#P8!!@$@#@-1!??_]P_*0 -H
M\ _KP -'(!!CD #?\ ^ID #(4"@6< O_8 L0X W_\ DT< __4 8?(!!&( =0
M  "1PPK_P D>P '_@ L00)6;H #O\ ]]0 'I\ ]J( )74@8J(!"+$ )>$@8*
M8 __H L#D S_4 <AD ])  !JX __$ 8/0!./D 0"P0<L0"B,4 &&N0<]L">!
MT &K0%$N8 W_< I+\ _@H 4[(!!70 #U\ ]G  !_\ ]3$ #%\  %( 7N\ ^.
M, %M.084$ [_D D$, [_0 8#$ S_H%4D80P=8 S_, T5P)36X &T\ _$X ,
ML 4B" "?$!&.\A"-T%P$P0D X @1X9L+_T$I Q$( ' #!"&/,^00YJ !U: $
MS? 0P* !!X . S$) % ))S$/ K  IRD0YBD)$:&7$+$-#+ #I$*: & 9$.$-
MVX 0V4D0I] J!)$* ) '#V$JW- 1_* )6V $>W ,C_ # + " " &!M$& , ,
M R$&?D$/!: %_U ./G #I&($%N *_W ' , )_[ ,&] &30D N7"8&_ ,_P '
M'P"50T  ZZ %G\@.J)D! Q $H*  &SH&!N"5:R"9_] $%2 /_\ %$?"@6R
M?DD'#A -_^ ) X"D=Z  +!H! $ H==  R]!C5G /_< %"T"5?Y !R-D'#+!#
MI)@!V* #.H"DC_\  ,&P#S 0 XLB!0>@FY7 7*S "0:0D@/0 .KP#WIP /3P
M#W3P %!I!A\P0U8  )SY# . !__ "@"0"/]@"0R "LD) (KP#Z3@ 7P  %Q
M$"(  *=P$IT  "Q $)D  *=G$K0  !^0**!I! # E YQ#PP@"TA0# _A#0[
M .<P$,?:"2<Q#AX  ?8I$(   &=P$M/P9&TI$(/9K"6A#10Z$+BPAP^!%;:P
M$<_P!B"@!R-B""<  '2P#$D: /\Y$&-0 /TP$)<  '.  V[P#\$0 $'Y#T$
M <?P#W'  +[P#[#@ (OP#^;)"_\P"1+@#/_P!@\@#/^ ! 0@DTT  -G_@)HT
MH P44*5L>@D&L$-HX '=\ ].0 $WVYK:\ ]&P $L6P8>P*;KVAEW< !I&5T7
MH ]X< '&"  N(!!,P ,/FP4%H QJR0!)R0<B, D%H HIT K_@ G5^@\R$ )X
MM 0+  ^@V@-9H)I6T):OP  T\ ][0 #8\ ]\D %L&@<!,*J$RIFE4 %/\:Z,
M4*NG$JL 4+*_4 "AL S321 %&Y\F<:PY0!"21Z\@$0H 0 /D^0\Q9*T-,0X"
M  M+P*T.X0X<T $R*1#X2:XF<0\7P  W*Q"D:+H?40P 8 'I^@\#\Q<F00X,
M4)\#H0OZZA#=8+,8@0Z4D 1%0 >QL M5@P8O_P  LSD,,@  .DH0=) !MN *
ML2 *=)@"W/H./G )/@D#)1"N?7 "\=D*(O +T.D#L_ /@* #?GD'(_"I5P $
M5X('K!(+M> !Y* .FB809( "?FD'*S"J0# "Z_ /8  # M$&'/P/8T #18D(
M*+ G;0 !;<D%0H %#  +AS"TLHH#_X '*" 0;. #HRH&%G"S?) "\/ - #"L
MVC ,"#!#3F $ H$%/]#!=] "_<"C3? ,SF +[98)/6"??\ "T*<&-= .@CL!
M0XM.G?$,$O 8MC  JO /E# !J#(+-> )_R!]3; IUQ .!,  K@L2A@  /S!(
M^K /@P  0FH2I   1/] $&@  *7P$/8@ ,A0!)SI$.>P/.Y 1_C@A/AG$O/
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MH@*A]/5S@].]#GT\_/_ Z0-G'W[N*::F(]@HHXPW-A!C']L>A#!""2>4YQH
MHC.AAPPA8,.^W$C8XXEGG - % _3DZ8,&J"(Q9A//DB CVNX6>">?U3Q((Q_
MA%F@DW]XV8 0/9I#9HL" !BB& 3XX("5<G[XXY]D#'A"'7MX, &C70 HI2,
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M%2Y*D , :%I!9VK#[5,'EWD43K@<>T[4(9 N'ODG&$AI1H<>,')(A!I;ON@
M "<$Y<4!6?XY!0!-_G&G 2MJ8<,!^E+GX;H+[%QG@%F\8"$)RI,IH(EX\('A
MA7?^R82!4/ZQ98-"_N$$@%_^J:."-ZG@0% Z&&#E'R<F_:<%'&9V(X1&JL@#
MA..?4&">?Z(@H%DM./CF'R\\&-$/H]CTX24X!CB*'5H@C']@@0#N^$<<,""/
M?W3!5/_H P2X\0\MI.H?8T! L@I1@?\(_$,2 $C6)A30K#YD %9ID("?Q "
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M41T P)%;7.!,@"B -BPQ@"2,J@D06%,1+A",?S3A 0Q<5*.BIRHP,&!-5H!
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MX$U-2(%# ="]. #@*'C 0 ;H(0@+P.(??N@@J2# 0"_XH%E9@ !%6CJB1P
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MP&D0 !V!.SISF5?@"L!#G@WC"0:H'V_QD;]["EX0@.K",_Z"JJZ3%2/X!G\
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M9-@ .Y0% ]BEL+B*3_" 3/B'0A 3OP, 7 R&!+!#>/R'NML*.3L/.UN>5+B
M7;*S+9H& $ X.1N$?UA*7!0% -@B0A@ 6)@&03@  \,&'_ #=0, 7P!+1OB'
M40  4/B'70B U?&L:5FW>4R& _# 9KPT>@  ^X*&"P #J)  (!"X4/L'<E@
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M%7C73]@ >)J%#N 66"@ QOH[HK$&  "/; 3$OYM'>NB >20& ("%5'@/M 0
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M^ =_(%9.B!9W5(,',+%'F5NHVL#_5D" U6$F,?B';.P0OK-#:KC04:O;8=B
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M@MR8 _=-L@P@4D#K$KA#N/5 40MAK!0&Q&#XPUOK !&T!48VA/J3!2<X@Q%
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M@$'_?@%P]$]6Q7^Y !SZ1PR'!UG](F#Y)\Q#IG^X .CZEVD K7^Z .3Z!\F
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MK*GD,  L,J0#2I<"@%1FVF6,VO]THD&<Z[1PPS]>QY@( D9:<D&,M>P8G@5
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M)@PM7DL^%H ;P=" D1LFZ8<COA8P#"$.9BLQ6^BPH)F&8@B,)$$+WO"/=F1
M/N1P <VP\8+F_6/34Q'!"/Y!C@ H(8L-:)X]C*"%)-PA$QI(RQ!T(&4@2( <
M_V"# 6[QCU0P #'90  52BA4DTA@0ZP  )GKRK(:I* 3336&%^1 @Q0%PP,/
M0@B9*:*T:1#W'[3XYC\NN40S[08B5&-2+$P$@$ ,B0%\7\D2"6,1+.$YSEN@
MTSDTJO>80F(#0L+$!KZ-#0D,_T75_[B& Q#=BQ)Y;2DDXJO7-(./(( @'O!
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MY0$ >/\#(MR5D:Q  HQ"%@& ]/@5)\B103S)TFW)2CBAF? =1*R-F3R(+UP
M&Q'&$_'"!2B)+@A NF )&?P#,VA 'OS#._Q ',A) Y ')V2 D"#" 3 >  0,
M,"B XJ@"G<P"!CC%-'!67WW-TB# $OG5@PP*#-32 PR;.4P >J@#!4B8,J1
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M],"PC0G?K?]! K2"3<B6I*GE/SP# *0$+WA P"1%3(@-W\U" AA))9RA'+I
M2=R# @#1-PR ]"A7"98#COS#/;0 #'@""]3##)2"*?Z#%@@ )H##NQ B#M@#
MK3C$7-2!O:3%/AS>;LR*-YR #,""6OR"!.@#$L2F.<V*"M !'NC!NR7C]\6+
MS]C;6JC""\A%)B  *70C_NP@<AC" D0 .EK&";!16F#" PC@=)Y4%"2!%"S%
M/_C 6K&%'^2==Q;!=*6! :@D0)*'/[@ $)U#!0H*"CP!CQT >P!# ;! /L2#
M#?R /LA2&CP!(/@!,5*%"01&$KP ,/Q#(V0$VTU(.S2 2BK#=S3_TK<1A$$
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M#L4M7(#9#$,'L)&M\1V*(IK8K-(V( #-E ,/F(8R0  CP<,#"*8[M !BA$,
M0($^V,"FZ<," /^"#<3#,T  !4B#2>T#&QQ."-BF6I1!3T'P"LB@ G74)V&)
MJ_Q#,EP "SC/'8!!G.AMIL*+8(V!,XB"+W@"(B2",4 ""9P"(+!Q)@R#&OC
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M0 '_0#YC6ONG%0 >^>>0"Q89$8! _H$$ %C^^_&?9!Y XQ]1(HA"-P7H\"T
M*?Y!1H HY8&@B7_\Z2$$ZQ (P;11=&'D$4D^R82,1PHQQ8(]IIGFF&F*D466
M.&4I!L]<.G#!D3\UD410@QRYQ)&""#5$T445;8 +1/I81)(^**W44C   &&0
M2S1IQ"""($%$'J12*.$PJ.QPI(Q3D<)*JUY8=8H> $Q[*I <GLHD@F<2N LI
M2+;LRKQ5GE(% %N\2L$OI$*)0##"8HW6,$HJ( "0>I#2!H!>Q " F']P6+8I
M+V39K+,J'J@$#7H4P.-#";A0$ !"_J%G@2;<^>>*!LCY_^<()N(Q9X(??&L
MBW^L0:*!143!(,=P<(#@FW^ @.P?63K@3AH,G'PQ"^G.^P0 8\H#P)1_& %
MDR-UR,-%! !XAI8+P,,$ $ D3.6?3Q*@I$@^!BSP'UL T,5$ 'CY)Y4,41Y@
MER(A<7&#2/X)Y0+Y6!.Q%P $1$2#4/"X@X8&FP' 9U\ B#"0!*CF90,@#P%
M9Q)5^<<1I/])(P @N1E@CG]6V< _9 ( ^AP.G+02C'_"T?(??@R0P9Y\B/
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M&P$XV#9@8(-]K$<!\,C'YQGG 18*&DZ@"_XA&VC&"P!A#9C@'\8!FT:%##"
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M!$3D&0(@7NR!![8 '-)!""A@'.)A"F# Y1Y > A)1$1A 2!(&5J@$+  $8)
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M"9Z@ SY@"LQ@ 09@"NS@.?QC&5Z 8.[A!JS2'$+ !()V!DJ '\BA EQ&%"Q
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M'.KA!,IMV&/-&38 V*@R"/9!!9C !Q(!''"@"7Y)"$1@VJI  @BC#8P\%RX
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M?]8:$):E030O ([^-1/^#Q6#WIT,3/HW_=$_4@!<_:O$X!9X!F)C 1#K+ *
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M'(%("';\<XT'O_S3!P+:_!,' -/\<T8!VR!HP2?_A#* ;%QB\L\M'?#R3R<
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ML[ +MZ *JN +IW *W+ -Z[ !QQ%T%<$"SA $)X @#- _3H  5+(-$E!0\"
M'/0,#! D]W  N28/'& #^7!&LJ(/)B #_^ ."@ &)? (6= )#,$!,Y$//? "
MZ\<%"W R]N(@Y+  5'(=I#8=IX ,#\ !:2$*$O ,4N#_ V10 )9P#  P#"N0
M!SE :I''+M#'9[F@ :!05^HB"@) (;<  ++Q9ACR"1W BY20 %U$" L@5;3Q
M"G67 >1G#1(@"7XE&U5P <H":O'"!Q*0%6S  =\0') P'AOR#X'@ - ':A?$
M5W0G" Z0%JJ@/,S  6(!#"FP&/Z0=)-F 522*@M!#1Y $ND0 ;#6"AY +.W'
MD.V7#^1 $1! :N%F!!0@!D\ =Q>Q"38 ! ^%$:Y@"L@ #=YP"L% #-H #,O0
M#, 0#"($  *@&>SG#0(@"W'P 0J0 1"  3)   <@ A%  Q$  Q/P 1^  A4@
M S-0(BQP "T0 CDP Q.0!"6P_P(X< 0DH 1'< 0K< 1"  (0\ LB #-G2!%)
M8 T_$ ;;,#4,40!%TP\!,!#0T #.@PP (&GP\ "+<0\I  )ME !.<A<PX!8R
M,!-($ (U, KH &/_L XI$ 1: @420(ZX  "B!V5.(@T 0&JJH#';T $R< W_
MD&?0=P,BH \40 0^H"XNL &$9B_XT@L60#.;5V@ T$7"2!B%X  J\XO70@H:
ML!P2(AJ2P #FD3S64)NFN #7& T P$%2)![-T &NX6FR$3(IP088D!(])&FL
M01B&8()^11B:8)L=! "U\ ^VX  7@PP-\#WC$ $L,!H2,!S0( !I@!\?H"++
MX $+8?^0L 8.(^  X="0!=J0$# <%V$%#& /;%  S& 1E[4-@#  41)N#U
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M \+P*AM !R<$ 9[ '^69/&0V"06P9(;  (21+7 D#05P+M!0 /@9"Q5 9]>
M '0E#Q8 :^)'$M3P ;W6#2I  Q80C0:JKWUD#H#0!SFE4Y(6@#G  .28G1#Z
M#_F@!?.Q/ " L).B";G5$KL%#KN560Q9#"U* MC7?N-@ 9H  V.)I>M$$2%P
M##'  &F1#02 !GP@#A^P$/Y@ 22!#!<@5L>  ?T##3 0 F)W 8LQ#B!P'^U
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M#!)[W9(M7=0%#$ A#'(M6%  $^&K="9%A'%\=!?&U=I%U0(3"2-I8D9JT.
M 30.#^ JV1"\]G0![0.\) $/ . \\6 "DJ$*#F 9XDO(.-(&#0!>P?  5[ !
M<681^1 !#L!V#V$%(, )%H"<#R$#W8L1EX "D%+(%<&BKT "I=+_?N9P )5
M!83AOO\ OS5P!>.P $[B#!9 !LX@!Q:P <8 #SQ 9R5$&.(P 3C #^EP /+I
M*T60#]8W$]>P &+E BI  )-P#BXP!."@#SYP Q")!QZ@'J6P ><R9</A# :
M?3V@ *&9+:)1"0$ "__P 3"0#2E0!R#010:@'RLC +7H /BR"QT@&L+XOSTD
M%D\%/A)P JIP#2+013@0 /.P58!6+7$&:K)Q"@D@5J/[#[.PC4P6  4#*Y+V
M!A>0$J>  '16"]W:Q&MV'NA8NDN&" \ ,]D2)-"   7C"@F 6#3@,\M0Q\AP
M .TC#RY04.,P ;F+ O'S#U @ ,<6RD_=_Q'Y8  )2C(X< +?\<@?(,D5H0
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M7WM0D20:YB"0B#P:0 !$ VV@VT>*$II0P!WJM-@@X7TKA@X6!E[QSV+G8@&
M#'R?&V2!=28XQ(6KTDHBNB86\.>Y"Z%CXQDO0/OGE0L<24,>'#9@"H!,'O(
MBG]X 4 &YFQX83D=EEW& XF2"6!(9#X 8)@P?!@L'B.B8 X2)-#Y)Q0;D,$*
M@E[^>0>%5/X!HX%9<RKE'_]? !"$M04&(.,? (:<!C1R,*@A%*@ 8 4ENS\C
MC2M&_F%GA0G&)NL?2ARPY)]&0E!@D%3.PJR!3620I0=".E#L=-133_V&?U[@
MAG(/4EV5$0AX<3N RYH<YI]/ +"]E0HD^><7 X+[RI-_8+%@#98 &!0: !I/
M)X(@_AE'!P @(*"&&BK(0(030,AA !9V6"$'\UDP084??K!AA_9S,*$'$W#8
M ?[[\]_!!/UWP & MG%,@ .,S@$V 9UX#$$ %,!&,J21C'>(8QOI",<ZR$ 7
MMDQ''W#H ,4(J"]@>, 5&Q/@*0 @O.A<8@'V: $I%N"E?_P :=$)0@Q@AB'G
M5,'_&#M0@5@&H*LN^  (!W"%!N:6#0#<87@<V,,-KO$$%-1#'#IXT6TD\@T+
MG"%YEM'"&((0@#1PP0  *,(:K@" )-0A"@ ( 1_,D( +I"$*'TB 'J*  UK\
MXQ #0$O=O 0) 4SC"SU@PM5@@8&;T*( USB4X?Y!" "L!Q._^M,L9J 3CUV%
M$Q+P$B$N$ XE9. %86F-(/IQ 2NXH!9 D,0T8*&+.0#C&)& @C!R809);(,8
M+C $,/X @44HP!Y^2  Q&GF93,"ID=+XAQHP8 W,):XU'T(B*"3GB^'1"1D%
M(,TQ$B &W2S #H0Q0!TLT(AWV(,?Z?"'/F"4# 1 0Q_K_Z#@-^1A#G>@@QGS
M<$<YTH&.?<P#'^)@AS[&H0^$)G0?"F7. 73Q08@.\ "#>DX"%5.!TW7 = S(
M7@$ (($"40<<0-A 6"*JGV-DC(06JP<$T#"=2R"( HTX0B*80P0$1><=DVM.
MS)X3@FJXP!+. ,!*N&&!6,#" R@8Q4,&X!'17.%0"3A#/?[Q@2( 9@ 2:08!
M4(,,!^3A'S<H "=\80<"9.(6A?A 'G8A"!W(@1>H*,$<)%$)(%1!$&"@PA8D
M((QG,  \7:*,S6ZPN0_\(04GJ48 'N 5!Z#%#W3B!@!T%0H =&)X$/@$$(2Q
M@5F5Y$F'Z  V04"!<?S#$A@(&O\P+ "+(+!B!AJP04(28 (:?. !+N ! 21P
M Q@ 0 ,\G$ O4N"-'6#C'ZR@P.MH\0)A\$0!E\'# %X6"LMY!0#(LP4"QOF+
M#=CT$0((FB@PT 7;&&"<T8" &?ZQ#0L4IP%2C8XP.D  %+2@!A$X0 1<,(,:
M/& " $[!#% P 1[0P <HH  *'/Q@".L@ L*8  Q/:C%QH$/#&^9PASWLX0=H
MECPI<$$A*L$)1"#"$YY(!" R48E,9&(0^+!./-@ @#DPX\+9(88 6+'2BH5!
M!C263DS_D8)$$,&FK=O!=&J5P7_XU#D_*(8,%@""9M1) !SXF=F0 0"IKJ(#
MLK''#0#_$(Q_2,$$_SA'![3PCV4  #7/T( ?XI(!30C##EVH 2]VD0H6M $3
M@%# &$I!AD"70A1HB(0L5(&)6\B #B!H:F2>4HQ6Y<D"-?@% 9#P#+HY(!$F
MF,4%PM*32X^&53?!K"!B48$8',42GDL$ *HQD0W4IBHV=<8"!,",'^2 #:@(
M@Q9P00HK3,$7OA #)3RABR3L(1:/ ,430B / Z0@ &9H@E+FT 0&H, -3Q
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M?$+HB !3X(8L>((GH (C^,@G& (0\($78,,6H 'N\0$7^  =X( %_YB "#"
M"O !!2"  [  #;  !< ! 2@+\@C""ZN'96"%6@$ !P@I#80&#V"%') #CL&
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M>B"'( " =;"]QED&&:BZ92" (_B',*B!2/@'90"!W""&$T">9:" 6? & /
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M3K@#&5@-=9" JHN&!YB#CS S,]"!,;@'=O &+, &=FB%%J '=@"&) C3<CB
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M\2T( 5;CM1D X"6TYV&..XV$G"09,B 2PQ_')N3Y!^M!*L4G.OW+MF'-/V,
MQOR#UJ'*OWLN"'5F$>@?-1JE_NW_*W'GWS< %BQUH@+ 1CD15!#FT-'OWQ ,
MP?Y)2K#J7S$ 5_Y%\]#G7RT A?Y5TH#I7R@ A_[M C"B%"\,4;C$HN&/.0!$
M_Q !L/6O%X!=DRJ\F/4OB@=Y_R8!,/5O%H!,_S !@,H_(A@!0A_=)""(-0C
M0,U]"13S#QD;]/"/-3+@\H\L TSWB@*6_!-,")S\H\@""7QCQP#>0 > ,9@L
M4,(.J(A%3!%*'''+/YX (!\>!<2R8X___ + )?]D<8%_U"3@R#_;;' 1,E@
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MEN<PN9CN7'ZY%)J+24#G$6$PP ,>1"2  QU@@ $'&US.  ,>,.   +8#(
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M 0/)^(<=-'",BRT0.0+@0\T&@4, $#$[T^F$#<_3@8_2 @42\,4,#* !,,3
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MD8$B')$]@\ !"FXPD3H,(,1ANQ\ 2/&/1 A 0,MH00)F 8P&6*P8"< ,,TP
M  ^@8AF9*@8L8#&-8(ACN^#=-*<[[>E_K ,".<U()V8PC0680[O1^P<X[/%I
MZ+K / NQP3%2T 97 ("%Z1A NY8Q ,PLPP&8P9]^LI$ 2(1K  8L$GN940$#
M:F,RD0& \JAQ@9.BXP-*(%@):+ ]-2$;&0Z(&#<<X-=4,."X[+%8)S1PD%*T
MYQ^% ,!P#(" "E3A_P<\>  20#"!"1S!!A^8 !%^H ,&A( " _##>@9 (OPE
M4H$V)00 9K" $8C@(Y/P@ AP<( !+& %%/@  _I0#0" J!0%\+,M$F!3;F"
M1'& 03.( ( 'J$ V$/A"$ #0 KS<X0%"H,( =K"-?_#! Q^!I'PH%B0 U>(?
MR   )[CQ@!G()Q8-8&\W%C"' @   1/ '0 Z,  . &,#JWXUV]ON]I*XPP#*
MP\@Z$' '>Q3 JA@9Z-N=RP\?@&8A1I %#'J0@NM PP<(D/H'<IH-!\14@6I
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M+ 01;,,+P,#K"4,%6((RP(,'0(8S:  +X0\#&0/_ L34/&@ $0 0!AQ'.40
M$)!& IP+'OD5-6C 1:3#!PC!/\3##<P .Y21 #@2[2U'<61+*'B 'U7'==10
MD+#'<5T"!GQ4<UQ')B! AJC"!UP'(&2 ,?P#*F1 AHP"!4P'_OC')UP )? 9
M WT" !S$(DS 4HP!*R(= ;S#/X@" 1S)-5@ 9%!<)&Z _32%@)R" _#8%=";
M" 4 B%3"!F2@)B3 PO"1-?P#'72 -/9!;&&,CHP0:!!?8ES# Q1"(T@ #;!0
M-PQ X*04B'S#!YR4,,# "A" -B3 1S%A/=HC=)V#!CB)0WS# -@-J"W N3C$
MEPS'/6H.#> !0_R"$0" _PRHP1 8  #\@2[4 &>( @+T4QC^@R29AR@\ !P\
M20(< <!(4'L- &6H @" )"MX0+L\@P^,9#R4@ BHPS^@0=/\PS,HA^U170%V
M (A$D2(JS'D P'&EG\5$$0O]'A']GBQT(LVLHE,2H2,ID'_,6P8JT&GX0L7\
M0QHDP%)P 0<42QP, #3PV6C@CU6-'UC<P@4$"2 ,@'PTAQ]=X[-@P@ 0D1_D
M&7 D@%DJ0@(040U-A"(, %@(@@!$W9[]WI%P@P&(@2=E0 %$ C.  $BB0PG$
M#3PH&\-<0C \0#<$P+,8Y&B29IY@PP7X54,D0P&,@$)<"^\UQ)<X4FFZR0PD
MI/]"L,,,G$ B5 (3( L?Y$ "9$ HI!09N L#I218#!COZ<,%; $^E,,$3) V
M, ";'(,#W)\W ,!C%I<7T,L.Y,!NP$&?_0,E8$!BD$E" H.1U P+X4)77:.?
MG9=Z9 <+\8?%[-4_I((''$0=,,!$K"(159A_@((&9 A_V%21R,=-\E@?)("#
MO,&*=*('1-THF- _4!Q87& %WA8JPIL@="4 ?!1_G$8T?ID F"4?Q K1S):0
M<*(C($ %H@>(JH( '(G5/*8H)  H[ ,)A!T\W,,3?$(#T,(+D!XYX)2&), T
MT( 1TN:30BE#A ,&[.-"S(/0+:!"R&%L,H".1&E)V.;_0IQ#!VC"/ZB"!(38
M.MA ,V1!')@ N2@0 ^%:U,V"!_13.>0 #X"#.!# <FC# !@G'MF--W3 26&#
MJ F. C@!%\U!!CC()#C =82"!"@/,@1 Q!0)"S6"<OW#>3V'+F  6/2" OC1
M+V1 !A:)?VSJ<!""!CQ8;-'" ( &+P" )+B+3>%" H"('3@ )V)! >#%'"R
M@[3" &0DU"A2*DP2AN(D*?X#'H58+6@ :$!2!H+! 4Q$&T# 1-!!3]X66+2!
M!Y 1>H08_E1#>Q7 2HD" $#&-,P (D3"#B" !N"![A@G,B" &?Q#/B"!Y:B
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M7  GKN)I%(E-4>)T9.\J@@4O=(!95L$"\)@:7,!NH$?4Z4( V-1:$HD '$2
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M:$"9KJMY0$Z9,D,!W$8Q8 !524,&< $XT(,.C  _:,2Z"HAM<WG_ES,A.RS
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M=/]2,$*(9TT'\+@=9,"ST($#-*[:EQ!D9(>/D^>U.$E3E"GQ&9 R $2 &_^
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M<FJHH9]^LJ"!F7_4 *"5?VIQ"ZX.(/FGHK^*_RFLK[^"^PR3PCS)X)%_#L%
ME,8 V' 0 +0#1#BJ8IMMS'_H,/.?,2Z0!34'O/DG%P0\[ N7?Q !X!?0/&@)
MS6K^N<.#Z6I*!:L)WOA'F 0Z.50 :/Z1HX!S_K&#@0LG : ;2J?CI#93 "CD
M'U)<^^<1 (C9#@!,_EDF368 D..?*<&@SP(S_F&G 2;HBR *D6[Q@!X%E5V6
MV6:=?1:D5TI00!%T,,IBFA3R8 4 9ZC*P)5_* & 45($<%$8#O(@"@,@S$&'
M R3^:0: +E<!8%)M+'"1%0'P( Z+(%,X 9Q_WOA@E7\"\6"JUNZ0D0$'LP&
MO:#^^L0S)3'PQ3 /0O\YU(&U,-[PC@O$HXT2GM9TAH%:_DFC@UUL4PLU#RSU
MQ.1_-+F@O-T"S4,"9/Z1A+=_Z@#@M#^[G'%=9@I #PPXR7C 6SH$T,Z.! *E
M@X'I/GV+D 18@?7C7?!EE4E8'OL0 S?^4?MA:3*PXC@7E/A';B_2>Z*=C]0!
M !1H!1^<\,(-W^@:$0  ((Q7$C%%%CHA<D*6&":@ ;K.8E!X@ZF& : ,HFK
MXI]N+GA4'!U$I.8"5"T! )7C-M@#+@"V.#$#7/M)@82'EI@AG9==Q=,"VEDI
MX*Y8#' Q*$]FMB75H@G).)(!=LIB@(_U()?#0'N23567E[.T$@L^*\,!2X'_
M /0?1F@F1 #H2#7TC@R&B4R A/< P&51+I@T& 5PVRH\(#0[(& ;;LK./Z"
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M@HL P)VT\)M_3($"=^I#HOZQ"?:U8@!A!,0!GO$/7IQ 5ISPP&MN(8!6QJ(
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M5HD'BEQOE<S6   ],-P 0W&%!O],<8<1\&]6#TA#*T10!(\JPP0 . ((0
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M#U8 "EB "$K_P OPH _*@ J<P S4H _JP O6  NL0 OH( _LX [ P [ @ _
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M<W<O<W, ";0@!R27!+J@!)" 'Y*@!-B "XA@L"  "'[E!,/A@H@B1T#! X@
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M9($%6F) I.$U,N(&KC<3#* CIF$ 'J@C%@ (/<( 3$$3ON(C_J (UB$!R@
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M!0ID%A[  @ @ %  "7A@ )0@ I: !%)@!TQ@ 64U)>F!!SMB%QI@ EY@!9(
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MR/;/) !P=!<EW@'02**(Z8+ HY<P0)@CF/US" "%_$.+<G8!L,L_J5@PVA\
M,/,/'1M$8RIG %BU"P*OCO4,:1U80]MBE "0RC]Z.$#//XT 8,P_FG30VB
M&*O* /[\TTT*WOP#S0X2G',72J$H^@\Q%@Q2!B1%A/$/-_\:8 D,!V4@AX&M
MZMCPP3+BY0C L^TX8(DB0 JI,$+M'% ,?1I0@1 _O0"*D#D()++PQ@7]T08X
M60A0 0VV,N@@A.]]$(6%.[WWS0:HI-*!.7Q,L] ^,"2C1!3P=###%07MT,(_
MC$!P$S@JE)"/C3B:DX,-T+A@# X<*ZR"$$8&F0\-CB $SA&[=&#$-;UZFT!7
MJ@"0VJIB_.,EE<)H(,<_ZC1  DX%['1,! 8"(\%.P@Q0!TX&['0."0W<@YRD
MF@#@24<)*-)1!F"Z8H#&=B@ RS^?O'8K *9$J:Q6FOX3R@6<_)-L6I]$8',=
MN3+*VC^KL-IH*+0QD!<9%K16AP?_E9V*NY=@8H+7/X!8T(Q8P('BP=H H**6
M!&EU,@!'>0# S3_&XTZ*   440,& #R10P(ON  * ]+# D#7EC" :1?O_V-,
M &IT! !+X^30P1ERJ $ %J"AS$A!" ;10P@05;6%20(#[:F/Q!)"#(L=Y @J
MB$<#A32&1M0F%NZ( @CZ$0\)S.1!$7)/8X;%D 7,QV4;2$4C&A"/%FQA(;I(
MP#I&P(5Z" !'\1 :/NHA!0"88QTP<((^QO&!F<C#!P10 CE , RJ;5! )!!"
M*R(B)!U  B'Q:,,W3K"$%5BE&PV80)0*L*EG   7;@. ))B3MW^P@P9W^P8&
MS/"/SRP"_R8:Z HP ) O8%B #?_@QP%"X(Y_9($&LCC6<I8!@*RDPP)N*@8
M;L&];,5F-G8  .X2@8&V4$IZQ@L+)30024, P"EW$$!:5I,ZXNUJ>*(TBP?(
M$1@!C*<0FXQCUWXC/5X8IY.O"H,#>F.\4OR#%Q#HQC_X ("VC $ RQN+,[$%
M 4Z8@0V)$ 03>@ (+P  !1P!!  V\8]3 ( _W?! JKYQ :L< P!^^,<8HV"
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M8"/M$N +WVR@N,;C9!@$4!;C(2(Q:/D'%@!0C7^,00"+XH0 G)D' CAB MK
M C&P08P=[,(>D7" ,CBWF G591@=F(__'KU@/P#\D1X%. 0Y$C &(,TC&<HX
MWA:48! ^'"$7ZK J?+8R'HA-4"%>&H9!W/& ?"G8/6,0! UF\X]^T*"Z$H"1
M2=]C#P7D;R$$&--[G+&7.M" 'W=T"L,D,"T.',$<LI0"#<SQC@H$05  6,$_
M[-&#(M0H!4_X!RD 8 (9/(.J%V8("V)0B@%P-4#KJ("\$'*$:5!@.5MI&PLZ
ML"DIP1$5#:C$/S2I)F14@ GQ@(<)(OJ9+PJC 'P,</ZD@8'"\D 'Z_A'$A8
M($5<(!>J X":T<$!H,G" I+;2G7]@(!9_",TJ?H-8@2Q 90HAI-X<,"P/&&!
M1?'! 6D!IN2D_P2F0R0 =[IX@)HS<8%6W$H MC(,)U_!*F ZDQ<=6%9R_P&)
M"[2FF5.1XS_28(!IX4$ PRJ$ FQ&" 90PU!X<$$ )+"!"]"@  Z $B084-Q0
M) ".QQ# '?2) ,L.P[[_2$8&7J).#\@  @"@P388,)IH?6@&=LB$!J.\$'D8
MP*4.GH@:#!#H@OQI&01?B"1 P8&\))('$@[Q8U &'V<,@ K]4 @'\OD>8"3
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M%#=8$&4  +IB$!,U$5L0 P>1#R/P %5U@VS@"*O!"M_0!3< #B544AP7(/C
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M [3P NWK=%S  9A0 *R\$/6;$"" #$9 0+21 ()@!^\6.J P '_T&?GT#0@
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M)>@/4_'N12-W[*.C?RS!-$$ 0/$0 "<O 6"8*-$D:$E* $#3$094N9)(B0%
MXQ]D$OCX#RC' , C3SH &Q4 <-D&@!)LT$$"ND+X ( *3, ! @]V,('_+AMP
M. " '4"@RX05*@#@!!5T$""%%0@ ( 864@"@A1 "N("#'VB8H08=:#_A!RW
M408 B_ B!H!9\$K'A0S\:6L,"3ZS]ZPY%,9KG@0N^:<')L#!RT4 -J"EL"<8
M,!L;;Y;QIOSREUE&FVH!4:GY>C4[!8T&JC6K%@1<+@N<'8@P!P$7,(['#F[P
M#WY0  0@JX$*5*:"WNSC #%81@]"@0)ZN8\Y!*##*_:U+'^=!0?'2$$8CF$
M4OQ#%!A DXW6\"6(_6,9 /"#>#(@!'#X8P;\488"RF,-"9#@']^P06_:L0#\
MD(, !_S'%"; %CY8P"&6\$ E)C2 2/PC%@!H_\,_K & .>@, (;X!RF(-@D
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M!B)FC0OH*JD16\<!4C:>/DR$;H9"0'S000..A:P)Z#"'&A) C7^XP0+5R04
M2@@D3BQL#(X$ !R !B-]"D23!DG:/^RP 5G\8Q-Y_,<NOO@/I['I.S];FY,B
MZI'$_L,/ -"%D11&-H6LS10+H>3+  "-?XS)&''+E(T:^0P)X <6 /@L&"[
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M,V  #8B"-#@!_,. 25"!^("%"J@B9A@ +R&'&<"8]U I;"@ PD@&">@->7@
ME5(& RB\>F@!_ON'(9B!] *"#HB&?V $HMD0CI*&"R@/&X&10&@ *<*% )"C
M3S&;/'  %7$:.6*%#?B95Q@ &*$%"Q@>DD"32-LU5[NHL.@080  @_F$"UB2
MH;DL3_#_@%80&N=;" $P"2QQ$$/ @ 7!DB)YQWB,!@T0$S+Y!T+(1X@S1E[
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M/5SP$GCXH JTJ<%+Y.$#V/PC" ! QH\*D D*94!3Z,! I[*! "/AH@!IBP0
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M#QZ8@!_G,"^E=6"$RA8- /LY1P VQ$( 7..5=(-%!O8C#0O@U;][L%;@#L$
MN4U22\0Q4C4XT"+BZ I':;.=EX#DZPD,$ALG^ B(.,=*5X8"NEVADQ\T,!+,
M^0A^?&(EG[*KKJ6X<A@ ^$.T F!'+*5.%QY(G'X/TI%K=J0<7 #!"Q[Q#T0
M@*=<4I(S3F"L91#@)=%HP!:B50 T@/$!=/CF 6YR#0)0]A] ./] /7N@ [;,
M@&/]P($"QC69P^DC!U DL0<Z88D,N(.A^B:!NIS"#PSX*,9,$$X]$N"'=13
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M%WB# *";,F1 '?P#,/! #@C%%]2 !<4 !T!B[_R#.23 3(!##1S1%!D)/]#
M@9G##WC -]0- 'B#B[#-K'E(.S@ 8$V#!+C24DRALE7%]2U) &B3-&@ H0R.
MD !"+ %)VO 6 %  =P@  G ';;5)XI3-0D!" GS7'@C Z93" !0._JG+,@57
M-6B ^F#.0K#/(:Q2 VQ(-\D?CT@)OVU$1TC)++  ',"&/AD.CRU*H_\D@P"<
M4V5$AC(0 %Z<0P+LA#,(P$XDPP$,T3P(0-KM !64@^N$P'&T0'#,$".X0@(
MQF3H @/@0P%%0TP%P)0@ #LPU'[<5XX)1204@%)B1A4*!S]8 'D-P@;0AU!0
M <<(QF4L@*8P!@!T [FL(5B PPD<V@3X@#"T@BJP@BQ0 RVDPBNH BV(@C%X
M@A(^&3H,0"O80@]<0ZM)QCHPP!28P](=P0X<!P^P0,OA  VH0S3>ACUP ,=
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M8$,M'0 _P$(H. ,Y_W #?8R!!F2EC'U#.:3"!1P$%5IA6YS#.)3#.[C#/%2
M'>+ $HB#.%A#!ER&MA#&*X2(+WC"!G@"5S2&7(+%!&R!*B@!!2S$DV6&,LQ"
M WS"(6R ,F3&$!1!$9E %HR+";2 4""!#:@#/-C ;-P#!)S'/YQ! ^Q""Z3"
M!R3#^<A%.Z2!%V2!M6:!%KC"%HSFG1F #)@5.D@ )X@"!]P#JPC'"-0"#JP'
M5$R!+*2 '9R" RA),F3 3F!#!C3--S" '?F##N1 /IA#"*A 51[!#* #/,
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M [2:)S@ W#  MC!#"]@1-A3 ><#"!>@;;S%<,2A <@G *K0!#  !,(!#+WC
M=S&+LH#0=W$"^I:0D9C;>@3  7P7<W&AB>[! !##/XA !60#/QS# C@ /D")
ME"S%K3%)IPA:??(" S!<G76*Z#0*+#5*1YS$-;3 ;;R"#NB#JP1!]&"-L3R#
M ^QB,33 33R# &"+/T0 M+AS7$P#I/U#.:1 "(S+$F0 !ZC#%_P!/W@! ##<
M/N# JMQ##F#  8RN7&!" D##!HB".KA#.9R#,M1 ' 0"#>"A,Y3#/*##'U2
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MU&I!R%\K7("Q%(,!7 @]6$ .@<@4<BWG=$/7&@,"U,40+(#\\ (/%( W'$,
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M8/& #HC#/WA!#;2<!2A!E4$2";""7W)"*;C"(P3")*B V#B%%6Q ]DP&/]B
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M\8.%.OJK1P!?=./MGV, \.,?:2S@\!X WOC'F SP/4"&9O[1A8$ $0% LEP
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MF$<"VH"*!: ,?3^"T ZBD% ">.! !6V>+@" A(1&@00 4)%#=T(/^?7!$5(
M@!HTH08 T*$!1<"! H8@!!&80Q_XP(<]7(H/EKH4IBU=ASY:B@^<RC2F.HWI
M3L&A#P*$P M>*,,,(A Q*3!@&..(! !$\8\V9$ R(QA!!XE @P .4%81$(<]
MCO"#?.QC!3/PT0  < 4XP"$% , &INKA@19,- H&( +ZTH$2O0(@ #S_)-X,
M\-"5.\C"!?I)A@?8\ \G3& '_^C'#*3P#W[(0 C@@$<#1O"/?.1@!OCXQP^F
M9P\0Y(@<#:A0.S @A$!H @!0H$8]JI""9_RC"@SP1M@&L!Y86.!G[!! 6;JQ
MQG^@(P!JF%H!0I-(W6C@"6_8@ &.4 JH]28\99'& $;6GE_<P I$*,(Q?B$#
M )#B,\EYA0>2LS=//&T FZC"  2@!"IXP0-V% 4 $F<+NOVC28;@%@#6>PX$
M9$T;-# "*[7U" &\ I7X_0<5") (C[HA"'Q@QP/> XL$&-<9" BL*#:@DV=X
MP)SGJ$!JDE$ *I0$"V;]+ SXP8\*[( 293#9_ROT$0(*_.,>,JC0'0J#49Z4
M P@YL,&1F> I(1,O'$%XP9%M, ).0&3)/$8 %/YACACT\Q]/$.1]U9"(070
M "J8@046\@$,W&98&4C!!!!@@11$0 )K)@ ", "!"&0  P90\YHK8 $,$( P
M+ !#V88 "70$ 0 D^$<:/F"'<3@A#9$@1!H&D QHE$ 'X# '"U;P#WPP@0+L
M^ <2"G"/E!'@JUI80 ' 0 ,"G($.RV.3/>!  BC;  G^I=X^D/$H; Q;'M0#
M;%>P0 P;9 $>$#!G/21P!G",XP:$6\<+8O6. ^C''D$@ +".$(-TH(,'-\"B
M!?1S#AD4H21G0$%)<O]P !/ZP0"]^(<GS/,/_?YL&A,P+C80H)]^'  ._] &
M DJCW.DDAQ@Z&$\H/-";5>3Q&1O@P]"DE@,$!*$* G  $>80"@LDSA0*&,0_
MJA',8FB 0]A8 (.I\0&2^,(#B;M% 1SAF@WP6P#O.8<$) B/#V3-EX)H&2__
ML;=C D($W_"/ /XAA2 $07-X%'$Y50. P#[# >8D1@6,>XT"7(0?4C  .\#Q
M@Q?P8QX3Z(PYE)"U?M2@".8(1PQP -,@;,!'5?;[WP%?$GNDH 3OD,!=V\&"
MBZ##!-R,AQ/4<(M9-$ 2MU#% 13ABT1D8!"[<)\60#$W( A"$!FX BI4L8'_
M1: B$QCP RIPX8$RH (3""C+/_SPET(4X B'D $;9& *'SR@!?+P@P.4,(<\
M   + ?2!H^W1 Q9\%0HZ8,<^B@# ?VBD&0<(%A<"'_X?'9LG7Y@&"EHP@T.X
M" 4#X(<Y#) #S9S T? 0P0\&%@(;O.,?60C .]I! ^0@'X*AN/[!'T0 !_;!
M.%Z @9@ !X#E"A @&Y!) %:),I)C.#A$&2R@"<#A'EI @N8F#/JH-::C-RAC
M%II&,F(! ,;@'Y*A U(#:LHB&1C@.Y)A J!AG @ $_[!%0! G'I! W*.&#1
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M! + '-B!"@9 '_X!#(+R'QP!"YG@:VPE!PZF!"B _U9 !K0!'Y @ LJABF3
MU/[  X!A!':F- $O'FLB"(HA!?JF&0J % $A!.Y*'GI@!\"A'0Y @M9A 6R
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M'69E',PA"?JS'QB@!B A%RX@!Z9!&V9 "+AA'"( !3B!@H"Z'I# !!@H#3J
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MT4(%[%('/_\#&PM@03[* ?BL=6;A"$!=3!V*NTO+1QX0V!DT O @:'C /:L
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M6_90 6A1#TSP 3P1 SC :R2@#_I0 0YY#BA +>HPD6;T TG $@3@D.^P TH
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M, CU*66W,0)-H V+P #I> 42\)I_P #9: <<< W7" #^A L 4 IA(P#7% @
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M--:K#C,0 >ZP#U^P N\P-2]P5E.@ P64!"B )5=  +:A!@2 $%B STWY N@
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M80!!>3B <XC2"4EYP W_\,<-=% 0+L1@=UC(@-WZ(((F,<$''/N!!GP"A0#
M@Q]92,$[\/]!A1JT@U\Q.-H-1/ /?83@,/^X05_^888#R&,D@_E'"#YF#A94
M0![\.$(/S-&/%23A'^LPP0N6!P5]_<,$*-"'.(90 7+\PS/^6 <+:F!''+B
M-6P  "O^D8,3X&,=4Z# OD# -';8  ;_  <(OJ"/="!'."V  3[$T8-X[:<
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M0(=;XH$.VP(Q H'><HAO* $3H($P& 8"@($4  %TP((6X($0&(=,X  0J !
M( <?^)$*\ 45B %! Y2+9(A)2 #I()^WZ<(QH04!F)$=&1-,D "/,!1G(0,/
M^!&AHI/Q  (.\(DX&(#NL*DWB0((D+;.DP(+V)3N61!(V "=B*Y_* .&I(K_
M![BY$_$/\I&)R[(/\E$)4'  FX 4E2@$!_ (/W  NSF=07@4 !@@.*P46HB4
M7#" MU$?,Q( 8KL4_6B%+ED!*V"& / &<?BL5)$%'B 'SNQ,S_Q,T(R\5.
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M1 @ @V"%!%B*TN"$$*  3M@"1<@ ">$% /")NS6(-%@$60" 1[ 4#W $_,F
MOT0$#5B0&@&1,+" %+F# )BJ9A"30J&?UB  *C'0\8"7,ZDV,,E!67R3"E0)
M11B .8D#!$ ?,'" S;&""GB31MR?#<&<0-  1S'5]'$ 6:,/QOHN0*&/GMP
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MKR3@@>/Q @186@N]@I[XAQ#%'$%9DQ4(XW]@ M;[AQ4X@7PH!QJ(,G 8@1F
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M5"("'; @),#->-B!P/X'(#" 7 ED"Q(""8 N )#'%V&!PUX"'_ -PWZO$Z
M8LH!&C '!L. :TJ#%,"<]I(.*&@!@F #!#@7+'@!8N@!Q/AE(+ 12H" 1ZB
M5C@&8C@%#8 $N3($C2R%+JB!GL('+6B)#&"$4)" +XB'7R:/!/@1.%R440
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M3X1CSZ)-^T_/AU$/W*F-^R\*#+1X4L3+Q^\?%@/*_LE9@.T?+@"H6'HX# K
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M;9[<E@IE (SSSQL-8(>##.O$4T4+Y,1C PS-56% G6(\H$UW!@1WQ OMO(E
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M9$A/I@+ ,$7A;Q<=L E.D(** 1 E%QLX"242X"9,   I>!# 2ECQ*,7!BA8
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M2SA@%?_8 !C"HH(.N #_!LB8P88.L LV(( '/,C#(!+PIQ-L(11-@ 4'>(
M0?A! BX0P2<H08 9B$ 883&"$OX!"P!4XA^OJ,T_2*&T?W " *IH2JK^X0P
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M":[%!K"-$51 P1R!""15&-A/'T8:3C $IV#$&V1 (D*")R9$8T)9".+/)QR
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M2!-C'.@ R(C[G\#!"8S(RKB)(R?(3B4WGA2&J_!" NCU#OQ YGS!B_V##IQ
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M=_AX*#@7#TD AG@>-%-9(&:6 ^K^L4F1DT0*=O_> &#U+PJ 6/]J 4CTSQ
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MX.(?4AK[)QH/LK,& $_@ZZ"3$#LX$1D -IG, L&&26"-?X818+5?-@CDGU\
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M;!5P$?\&N)82:-"/>(   ^82P5WF$,-V16 ;*L$ .MI5@YJD 0": </U0@$
MM[D,:GW!SR14TS( '")?@'.89[+A@<P=S#&BD-$_:)$ PQ2-9:/(#7,2X#LQ
MQD%Y#KC#8! VF Z\!A$(N%%_0 0P.9D&C0'*SBT:8!A/=& NGE#.@S[6C0W
MX1^L&$!VJ $ 1_SC>(+*Q'G^48<'D*<*0:37R^BSGU8 (&/]D0T=''"V/I#-
M.*N9A@:0(ZG_].<NA4@ RQ[Q- $B8$6! , ?/"086Z4I0X()1@?(0"-*!H(!
MR'F$!Z#EC-,H#P#94<4!-!$X#QC&5C 3PP5D4S13+&$2SNS_U.S(B24Q+&$5
M#JA).:-5 BX=(A$"P 0$UI(CZP#" RM*D;_FMI9A *"8]VC %3ST%L8(YI."
M^M*  %&]953 !-YKP+#:(#\>,2X]%L4#!NAADP#(#E<=;(,$$#+$LXU4)'V
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M.2)A X+U .8"5VP*#"3@6AZH@-P  SHE7@J(# 8 9D;%,2 !Z]YS\?[A#P3
MA)1 !&+"#"R@4\H5M]#C@=9B$B2@@R"! 3K(# K A)CH.1 $5.H@ \C##33
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M FC! .:C%C# .CH! R+O>&8$34T4 IK@'\+A!;I >0* EPCK1GJ! 03%%@3
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M!T:GVUG'"G+@=OQT6*@G%\Y!#@B@KMJ"89!! PP3WNO=!I( (/31XQ#G7RX
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M*WD@TR[?_4,) RJ% @!PJ@! R#^L4#5@2?]PDH N_U@"@'_:  #'; KL: T
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M ([6Y0@>-!I A^!\T.C((@!--)>"??[X,)US8OS#7L<.W/(/F24'4\!T\DA
MGG+^P1*BDKC\XPH AOSSHQG_O",!"6<!0*H8#(A;B -X@>866KR,!D![U0!@
MRE@!7B?X/[ X %P@AP-8RHLV&1DD-P#\D1P'Q'T#@1;_&+G(/ZAT$%7@=?RC
MS 5W).<"%O\@4P >Q0D0-2L,?*XE(F:7J;8 :=+#@!Y/,D#(#GT( \ S@R:O
MO)[%=/ *#^DLCZ<9-N3)BB;1.%!)"PF!&"1IP%WCJ>D05!0,#^3- T'+ '#B
MMTE-HI<.1:8CL",[,O3VSP@O9/./%AC@#/^H^G8F\/PH*:9@@+;($*A_S*$
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M47C-R(K<'F@#"II&B X2%0'CS'C$(0<#^B4-#+AF& $P8R\$H!<M.>$?Y,@
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M2RH\X*A/9P@"^C3$ +R5B 1PR(MJT=@ODYLZ6J!M8320AV$TL&LF?&#71QB
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M [4++! *&W";TE,'-) GL- '9Z)7B <*MH *((!*\\ !&I@-'M OEM)W]S
M*]8,&V :J_9)]T  %3$/)U,>!8#_*=[P 4. #^+P!3%0#Q($ #X!(JYA#@0
M/&=2%4^Q(D^Q+HZ@ =ZR!QHP0I<P(_"!$'9A$U.A$IV@ 0IB(DDA+V*A08/S
M(QSC"0YP*T^A%KC@ 0TQ(96Q" J0$/KX#\O",;.@  H2.+@C"@& >UQP 1&T
M!"F@5VI0 #N419Q1"Q< ,I,P $(Q%1C3!PX@%&B0 *]&"%SU$$"U+P61<^WA
M;*AT-KTT - 1#)2G#04 '>Z@@. V ?Y!,]#&# NP(T73'L)P ?8A#BD0!/^
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MRM  7\,!Y $,!: 29P(=Y]  Y-0/#2#_N/6\8<V0 .1T)NW1)%SR#)09' !
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M C C#D24#!!0)=>0&_HP#A=0$>)0 QYE'BH5 ZHR#@B VM"0 *A4#@D ,^K
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M%D!OE@,PR=R ,M>LY9\V?"#G'R!08.>?,1[H6X4*-NAB"0P@R&*'&*CY!Q
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M(!;;6 #,1(DR3@0!%J$<I6?8\+/0A&$#MJA&*"@ABT?40@H.*(,,4J W IB
M10?003=$00 '"$,8. ! -KRA @"((QL'D, \J+$" +0@%!6H RAP 8(IQ,,:
MR*0&.TPG"'D$ @ W$(<S). $=U C $UXQR\N(HQ1 * ,[%B3)];ADEUP  ='
M.,0A%A&'$ARB%0#  C,FA!%K("X>]?P)*0 PAG7$ @%2D04 2-"/8P  #?W(
M!0", 0P \& /BCA!!1B1 1)XH(N@F(]?[NF*9_7CH!@QAJST(0H X($<7F"
M*%[!I4L@Y5FC>((&<E$*)<  _QO80%8EWB$?+<@#66,0QRZ,M0Y2+. +['A&
M LQ CK\EP1_94$ !RN&,%73 #B[!A#5 @8$OV*4( (!&-7I@@'5X@P()4$8W
M3*  9:R" S5 QSEF$ !]:(,%:C6&#1) #VZD  YGL$ *ZL -6J! "R,@AP5V
M]0H*%$ ;P4C# \BQC E@H!RD:%5#%I""<^Q" $'@QRH\, 1W&,,"'_B'$0!
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M P38H1I2 , 4,-$) !AA#T)(01%B_S$&!C"!%$,8P ^6X00*(.%F%?@!$B8
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M@@P(@6#!A@7H"S42"VY  '-A!@ZX+F<X  1ZA@Y@CW-H@ 4*!QG8@7P ASP
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M!E;H@R7(AF'PA! (AUU3%Z# A$@# 5E@!WJP@0CPAV]X 7:"AR8( 7<@ARW
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M^   0(*TKSU^'H95Z(6G+]WN9 (32'LEP('N+ $=N/D2_W"!F_D""KCY'OB
M N ^"K  !GB!$_@ !?@  >B 3="$,P #9GJ %X" #V" D;\  2B["\!YG:[Y
MD&_SFQ$ G-^ D!> #-!I+5B$16"$,+B9'G !\+N9D > D(< C\?YFRD JP>
M#?" FS$ "\!Y!B WA/*#/W"$*/  !M@!$[B9#*CY#,B X[^9X;^9!]CY!=#^
M"KAH ,@ !.A]-OB#1F"$\1!_LW> S@2 "D@!"9B &I  "?@ %$B! TB!&.
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M'UC 4$\TT7BS33?++-.--]]EPTTSS42###7+0//,<MMDPYR;V4"VC3?)@/
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G'T2[VM:^-K95_00*9+O;WOXVN!>=AQ6$N]SF/C>ZWUP.=OPE(  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g180931ki03i005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki03i005.gif
M1TE&.#=AQ0 / '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M\%T ,"T</8*'<%D"?U_A0!IX1HF_1&;4G8(3IU$\.8+F%$)S9LX89LQ8N/]
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$*R  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g180931ki05i001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180931ki05i001.gif
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M#B:YE)! %^8 3!9M,"Y<)D4$*JCJ?#([C;&/.G[5DF-ZE 0:?:9&@[("#%0
M=1*5W >:B9LJ>4  '?R !BJ T!6&0Z--_8H'.) !H/W4FL/(0 4D.+G/>6"D
M1?0( R20011*@'LDZ$ %2G<6DPXCDN[C *6:Z@':Z8YVZ'R(6JOZ5)P"*JHF
M8*=1U1$TI]Q4!&K=@$860!"0:&NJ$#D?!R[PSF#4\R%Y95"LB@H1*?GUD[^:
M;!$5.P+=$5%"%A@H3K?Z.5FPLT0*>$ #!' C\    6_!0$/@Y1]:"N,#$IA
M!_9X$X@&@Y;!J$!L%S  P;RKJA 8P(S^,H  LQ0' @28E#\A@(  #&!*(56'
M8Q! @&=**#RNJQ$!.O" [XZ& 01HR@%&2 ] )8  %1"?&YLY@ 105 !>@<IE
M%K !LA[P Q-(@ ,$,"/E0N  M>D& QK07J]P8 '>54"+2L" 6Y(@FF(]  2B
M^:L&I.J!K)*- Q9% /=.8!\.L)1L*M"<!A3@4D])0 +:NP!G6$";7[( >1N$
M#0<D# 4*Z  !N FZ!:2IL0AN2([4,@&^*,>Y#U"7,Y3;&?%10 (M9F%82JJ
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M$E!$Q\-80?L4%, ^$= !:>=\\Q 8&7!$_#$J&!!NK;<]!$ !&,!8B[NC?>$
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MA,O#  0NB0#GDP% )E1"=KI,>%X&B^LA:$6CY8^GS.-X!X"(%W#!!+@NS=(
MQH"""\,: H  AE: (T"&&8/+Q,!;'%QF&:87AT%?PH;=Y &  AM%'T21!!&
MA )505FB"$0F1(#+AM]FIJ:O0= P\; %1X# JT:!0,5'0T #YH;" ,.$P@:<
M @3' 8)#64/!PH'#"X="I-3#B^\O)D-A@8&"A$6?^-%DG$*?!04"LFQQL"6
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M0H<.7"()0(=Z=2$)$@8\<'" PH(),NVZRD !0P$_CAU@6. A]P?^KE4V+&"
M 1F""1\*9&=4HTPLK@DX(($HL& 2@@DJ>%*!!5IB" $?+)#,!0=LP($>'R!
MT0<'$*! 3P9X(\ $!]SB G<?6&"'4 8@ !4"6P#PH QE: ")"PT \($#CF2
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M!VU*.2\0X40D3[H?%$YL(Z$"O]5&1C)Q:J'3-[QJF(%R$$3<ZXDT).6" P)
MT\ %"QS&FSL'-,G;!D50H.\6 M#8[ZM@6.*  V0Q8, !P]:P,\]]^UV"R,T*
M/CB#?V_T8"S^'NA6(@$%;)C5HGN9&  &7ES@700$>!   G*R=X>)!QRPP)T(
M0  D!$?/@%4D" QQXVP""&#.@P;<+"8 GE0[ , ;W)U)3EC.-G !$<18P%I;
M"28#8=)1.H #&@A 0 )8H>$%4[;5!HEW!TR 59$10/+   W4O!=<!'BU+L4U
M%&MX,<'![D%6$)3C:P#Z\68?!*I."X%H"B *-*CH)@LH &X\@  ++& B-+-
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M2R2P #0H[A;^IPS*"S3 G@^X)(@1W*([/YN!21)7 ENR0 -DM0E29<$#]>J
M%V%PH4"IKF)1N$MW8Q"!H71& S;:(@? ^XZ[P"$+=-B2!-B0KT!ES;LNB$ #
M=KLWRO8A9X5)XS:6F 'S?C>\*CT I>R9@;II)8W,Q:QD93M6E-9VM?&DK-=^
MQ0"[N&@ X2$=CFR2DPTD0"XZTH\TW#D'6-;E4@880 7(!P!S'4=A&EJ'(CJ
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M 1$I:48M^[O^#K'2@0BXS1).^>46]+. I0C@^YWPC GI=PM>("D!%1A ,W#
M[$B  #   V1!3N3$),S RSW*+ZF![7R  #116-2?S1T *RE#JY'.R&0*<1S!
M4"3"(/37!]R('>B-##0=9052P:V0EGD3UT" CCB \*E4=0B'Y&V ;MS"HS#<
M.9!&8V 65#V?25'8]%W6OFV6'$!0?!Q#'#"7!>A'!BA1AW3.!&#&!O"9#F&=
M5LQ&%FQ ;317"T" !2B.05R003Q !$B 31#0!$3"$RE.$WS &DZ% W!?"7J0
M]+W 6BQ* YC&HCQ )$S -CQ  ;31'5Y?9V2 2W 9E&R##'% @W7^0+M0S0/X
MQ]K(2@VHX&113 =X0P-(1C;QEI@@V!E=ED:] %0\0#0-Q7G0(1MBA@,LW8$1
MH5BMW1&J5/6)U:29%@Q<$4%EAHK1BU7!0+@8H[PHB" 10;=XU@$0E 08V. ,
MH5KQ5B[&@")=W37" $G9XD+AVS8BU"Y&%4P!EGWM$-;-55WU%&*)UDV]8TW5
MP,L=5E"5G4CA%#QHC6P9UE\]%F1EU3G&(V8IA#>VE!&&XSNY'6[9XVI]EDE@
M%$,6H\MTU#U18[<A)/#<'$*^14&:%#ABY Z-8TMQ%D+F$T@N"B[FHD6*U52%
MHP%H)$(Z7T?:D".DY$D.3A(NY$DZ9#C^%M5)<B)A$1!&MA9(7LI,KE,??.1-
M-HM",EI$7E8Z8J1/+L@RPB." *5:X=XV:MI37E9L'64/*>52-HM(FA1)AB-/
MXM4Z'M5-L24=1DA70M9*1A5/691'6013!91=QB->:J-%V=Q$Q:4YWF-%S"58
M^DTYCB4\%1!J'>0V-IY@JE090$ O(HA+9, &W(5+"-A=:$!FFM=1N 0'Q(%[
MA90V_J(=\%=V(22RG>1['*8Z49MBAJ0B_%@SV$%J/D)2<D0 %(!O-HYO_F9P
M"N=P.D5Z-$YO5)ER+F>5\0IS/J=S/J=T3J=R1N=RVD%U,J=U:F=U)N>&($"O
MU!\9#4 "\%G^B>'- =E#N6P(QU#/&443GRV '2  G]WF +A-^_7&?>IG?@K
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MGE3 R*):+<U*=PP%[RQ$(ESB$/S?"BF0 U"=RA%@F" !O'3 R[B.=RW'*AP
M R2 9#"0PAC J,&,*"A).61%B<3' $!3A\@V45B 30Q%:?#% E#9+<S407C
MCH%@HR  S82) 'HO+VR, S1.$H^/;S*"0A.*;^9&3A1"'TP!>)]N<?O%C6B
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MI^3Q\0"0L/DQ4;40!?%CP?#@%I$VP2#Q4;&!L0#6@^>PD?%@4'&EEYQ,Z@!
M\ $AT5$@P%7!X="P2U&@\)'P\&'@\!: 4.%!T(4P8,#!T $QP)#^09%@44"P
ML$&]H(PT 4" -/\*&CR(,*'"A4A(*7C&,*)$@QX"A",E$>/$B1@ 6"*52I>
M(\HT;HS800  ,"8SK#P)LV"#/@V55!#@IJ#)*SMW(HM(ZD*3'S$3FO1Y4.@
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M'"44G Q@ @.@!@<F(!@'4N!JV7K _S+^<@F:C.\?$?"4 P(PAX2EHX42.$!
MWI62#(BP!;L"50<H\)5T0<-BM'IA 'SEJ<?]HQD1J$!44I*+!4 L%@8XP %
MAH )Q,<2!8C#0-;HDALJ(2 )V*&D%/ U.=IG !# &Z:B42NI>< "U>!? R)
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M3%];>]36MB85D*C)1PTB6M54)2\Y$@L?_D99O3D4(F;U@  &1Y5(T:BT.^2
M8#A:3?6DE9C,_9Z^(*O9J]6Q2ZGARD0"!5&RQC.XIWFH8=5B@ AD]GL=6:D=
M7V37C#HFHZ?-3$:O2UF&S6-V%A @R!20@ )P )@><,!J_P#@#6".0Q98@ ?8
M]:YLM L1">CE&A:26X@^B+R5Q>[X^DE9[J05OFF=KUG-55W1=<3#HF/8DE!U
M :O)+" 0Z$#%+ !!LATL J98@+=FP@$"/(!2,'P  2I@QH>(\5+-(&YTCR,5
M#HLE?.O]W@HI"]>1/K?*09.N6>-CN_#^J@&U#"4%PX T$*A< @$DX,#+%& F
MB,0/#(I#$,$NEA\(U#$ 3G+ Y-(%7)*1F:$!Z9R4I^Q0D9JU 'DTJXC-ZMS!
M9#3##(T/ER"*W[3VV"4CJ%4_X_.C?95*  Z@0A\DT,/A!7@"0#Y <J(RK@(L
M8'@YLT"*D4'I'9)5T8?6BF73>J/B_N%W:=55?)_<9/HRT;Z8'C1#9U+'!J3!
M @AH%@?8W( [@&P!1U9%"SVP- -TX &=(( 'KN0!3CH  AT!)U0"H%Z$)-NL
M 9ELKZT"X. :8%5B%HJS=%TQZ#[;V7;D@]/$7&AAJ]9";!5-=^_*EUS;,2"!
MOK=B%5"=XB[^CLM%RS)$(WUL.X(WHQW)FEDU2%E3K!8D1X#,;2%>&(9(W+3'
MN;3%B_)KL[(EQ([CT;\10F*S-J/B(K<GLQFJ,,I">RS>4>S,QT?QFS?%(<_@
MJT]"\[CSA&3KMNTZ7?-XJ-K,MC;UP4W97RLBF))]V/6)>7EZXW+<=!WMG0%Y
M:^8^G+><%S7-V"ZB.9.7Q)R]=J5IN^%M&W;9ZEWM95]\V FK=K@7S^&]B>OB
M[Y[+.B)UD#_8 $ ?010,Y$#L=W\-YD^/^J[/F^MN%PU2KF[Y^1S'[U*/B0*(
M#E$#")RA%W!R>"OV\^\&_[LY'-F35YS6CN"^FCWL@@#\ $,!B#+^ '5,@ ".
M4P#D3L@4R]]AO6LO4_\,X *=4('YSX_^]*M__1=H0 .R\?[X9V/^\W>_ ^"_
M2W#$7_[X?W_]^T]__P> ]D=*]R=_]L=_"%@!4%$Y!>" !6  !7  !G9&#M!/
M$-@-[0(!!Z  [L<N$&"!J>)^$$""(+AN#*!/#H!'> 0WZY:"756"*L$ $5""
M)>B!_N=^^L0&)!@!:I,/%.,K/PB$%".$1#B$1MB 1-A/%6,.^?" 3T@ "- M
M$AB!!U!&R)1(3N(V[<*!#<  &[( "@ !784 "=!5#&"&#_ N*.A^&'=_FX,<
M-0@!^J1/(,@\-%B#="B'>\B'?>B')$C^;CT$3F!%@A0 B!*(3!O2-@6 3!AH
M ,N"<6A8;<%DA@M087 33 X ,FQ3@QVX+ 5H.BH2%<;$3 >  "BC#J P,X%C
M /OSAZ^XAQ3P !00 64B 4'E)FZ2 1=P9@.F"$%E:Q>@ 1A@?B,P B)@C,FH
MC)6@C,C(C,O8C!RP+A% .@<&?B=Q-2KR, / C;[2C=P(CN#HC1T4CN08CKZB
M#U>BCNO(CNUX)8IS1AB'<6'HCNTXCU=28=YR  M@BEW5CK-3C^O(+%W%+"K8
M!(*!-0FID O)D WID \)D1'YD ^C,SH#,16)D1FY,QJ)D>U4D>TD&!\)DNUT
MD (A$"0)DB?^*1@(*9$MZ9(O"9,Q*9,S29,U:9,WB9,Y&9/=QW'@YQ"TTQ.!
MIQB]E756H7N4!2L70 @=0 @J, P7\%4J$%3$N(M3"95?9953&517"957N958
M"99>V94=LB+$. P8H $I< %>&996>6O@@5)I0 ,>A1,-P92,T@%&@)<:D 9
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M, U3I#1"MQP:MAW  QC1M\5I9 %6 _B#IUVGT&4)ZZQ&#/C' X#&;+0'NUP
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M]( Z+<GW-$#^B4H AQ2 GGR#^&[8D:8.GC@ DUY&(_B-I12P/073>T01M!U
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M:P#!.Q\X.;"J:+Z$G%.(WP8<$*6<&6H!)6./V!C43,&=8&_&" ![+G" M%7
M /K)1 26 P$*>$!'+M/8OAQP@0;LR![HO-7"S@8G24D1H'=)0%DZ 1ET7,,6
M=_!H2.9R4XE0X 'O>D#O/! !B4! +2Y APQT, #:;. $3RT!%" ($S](Q3L/
M?<E'892;LXA@$&G2Q @&<HL,/.LN$A"5!2@ #:1PAP,3\ H3/1>=9+B%)T*Y
MQJ:P.#RMNL#^K"+Q  5XE$A_2>4S?)P$CQ[  )_,]7@=:$#(LBD\XCR# AYM
M2YJ<N)<'!%9X0L(4[9Y(N]7<8X98Z=\&%'"8@UEV*GMLZT_L -?#/-4"&JA
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M*!9PHGPU9(&H%H/3EUX"F%YBMG0XB&J^1W7P=H(<]X,J&(0OAC/^1N9_-L8
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MN(9KM8Z@+'D[#.IR SX+!DLP"R(@"'NVLA>P X'@!W[PM(" N(6@ ?)"LX-
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M!Y+B1^*C,NQ+ !( 13A-LA0(EY2P"?!60*7R1.148[ZC$"J3 0ZC95VDOP,
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MF;-14$(>?+(K*1ER$2 J%ST73KSF=T [%) (#>  /\&[N,4 P.X!5I$)'.
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M6"" @D$2\ 0D!XFB$+A]!@P1TU(!$#:#5@+@X(R,F]?,X.*Q>1> IBVGP28
MV#R_Z@2$^C]*Q $:8*$(0H.AX@O VB(@ 0;A8][!PB1E9AN,SX;^ $S A(&%
MA@'$X%,# X.'DXA XLL !\0 00>"2T0!F0@%0D=.@0N>)@\,!IQQGEWPLMR
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MRP)SFD5&/"  .@X  #&1$0 J8 < -, #M@  (HNIB -H0P%SXN ["    W!
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M@ E7A ^2D(T+-%?31"+8 5<P!3>P,S9_6 $-.*9PCJ0##@%H8[Y!L*AS#_$
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MGEI$W/>4' U0P.-DH#' D#)0A_HMPD;^V(L_24(1+H,E? ^3S5J-6=82&L,
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M/>*'Z0DB.I!B^3 C?HPC@)0#1>AD&W2%!O#2C!F !F"  D3 &MD3X7S *;#
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MW3!^8F92Q!0V(@X0B$R:DDK@6TADDDA@J!X-!VY8AG1.YRE5DEN.)AMXA7I
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MW_+MWO8MX :NX XNX?:MQM83 0"K #5 XD+0KCHNY,Z@"3W7!LS^408H:0;
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M(V@=/I!T B 8<0* @H !*7@"EL.",$'^ ?#PL7 PIV%V1<2DX0&040&Y !#
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M  14H )O.$*68& ! %)@ A"(R ^L]$&+;( #*>C (1Y B.090 P*8,  +-"
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MH" V$('-=6X.W8B"/S-@S0\<C@CH&MT''L T!#B@6HJ4P@O/8+2YG3,Q4G@
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MV=#)L0T]?  355D)"] /'@X8!?T6X($D^)=LVK)C !SW$D#TG-Y(ZS3WXM
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M.;<6R"]=+JGG+Q^*S*X@0F\0N[Y4).D"-3>D!$!R0<*#B57#5:3P%UV5FQ[
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MYU3G<00/ *1+?W";H/ 7$& ?H-('R$?^+V1<+=VS$*7C"<94!$A*) J0#QQ
M.\+#"Z3'"#O8!@' *J#"0"6U31@0249@@NQ" "&V8<Z'/7&PY#E5 $1""C:@
M9Z2)\M3LVMG)D&XL)D2 E!J2"5(A=1PU;@O5))K<PT71 \E8:>I!-4(PBL]>
M(!O= QA6# V=(KD?4.U%61,^#^M)_&6P%229)\RP#]M3(_SP$TPQ#YGP#-X_
M$4P19E]#&@.@#&9LAVV1'(XB!KCT-190%3:X9KO/#).2"J_2$*-7$G<Q%!<
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M5H?Y(3CW>@97N.1^6(@25L&'&!8 #,!@0"R'M6 \[,3P84$!9S^"S:9A=P(
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M  8L4($,7& #)SB!!?R:@0E4H +,2A8&%)NCOC(+)X6=T@8DT#FB/D "%)B
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M=0 $/ +:'0#^)'@ 48F )%A/=8F?$M0<!! 0?9A"@I!>"3;+K(R!!CS $EC
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M;QA?2*#P#1#;<BA(3LN(]<A(()0)62."3'"4BX#R44?+"M2)DXU##@*<6KK
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MP8476H#!!1C^:(C!AAE<L$$&&FR  0>P>="!!RAVL"**D'! P0452( !!19
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M  J9X )S.< 4&@"2Q43@ 2IZ /T\8($&&, X$^@ !/R'"8<$!@,/D "+)-"
M!G1  [M0AP'^%O"!' 5! Q"  (LB( &,K !:UO',#F0 0 PLK@$?@  !L% !
M@8#/$^CY0AT?@,0,-""-V(- '*OA 4M4  +4X(@,1@*;H,3  @]8A0,4L")#
M(!(:XV'B],!0OPY(@"D?H <6-@ !(&+B!Q7H0 -FN)H>#L$E2%E !A*  !F-
M3UDJ>I^+$!@_87U$!@0XWS05 P"Y,. #%VC 6@!0APX "@"I3 <@1!2U#D0@
M  X(! %\@0106*  ]AAE!,A(B*=\P"\!2, %W/( #BP,".7[@ $4H($ '
M&DC '#DP.G>$XP('><  ++"!";A% !B%@.C0]\M P.&A2*C  ?3^L( ("& !
M _D@ 8L@ PX$8$0#H%IP&-(5-@#M WH0@P,$$+F&*F" S "%!CSPN :,) $.
MV$  "B#)7 )  0]X*@+>5Q\>[G0[D=10 (YDHP]0( (R-28* M ."FS 4$R
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M-' @!0(-.!\"PD311A&$*355B$>0L $!?!,#N- F/. A >EQRQ,-QDXPQX:
M]Z8W,&DEA'\2F8,P%;:Q@-! .([T@0Q0@ $*H(EJ\YM>=^0X$9L-!DSO(X2U
MY;(!4WWR%JY)-0)HN8S8T4$#<O.-&$CO P]@7A"^3--QD"2>#]7 0P9P >&Y
MA00'2%@L]')33"0D1 ;(P/D6( $$X)*_-A@ !8;A%))98(@+F -)"&"692X
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M)_GRIO>R"2(2+^6B 1SE:;9"(ASR*:[2)"82*A5P 9D"*IAR2Y^"(Y:2(Q(
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M^Z!QRJ<5'%M8YK8\ 8!1GC8P^?(@11%H"+  L. 75$*_@@ (/>(*WX03 ]8
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M:Q\4], "=H6##1Q 4PE8F!-\&8@)T((ALT1:+>]QRY?P#X]-&  ;(88X8.J
MD+XR  *MI$EN/:-:U+I6$JQU#63L1B![\R81?(;/(2"@B/^8T+J*>0]I[A,;
M RRD/WGIO+QA(Y8,B1+?D%#0(&Q3:,3^RU]B)HH#@M60G.7<HO**]4>[K),A
M*R%,'9&V+(0T:X^Q^,L^V#4N_WDT!P>-";X<Y[2!P8%3"+DF+Z7)$#WZI0?"
M&^E .UK3&9BS6N1P*K?FN81N?<&I[V"$.TH6" -DU*K38L2TOAI5K8;5G3\
M*UG="83'7;6L:$6K6..J5:RR<ZI1+<>_YCK6L]8UGHN0&52CI56(IM6L974K
M.^!JUK3R]:V!T*=8'7M8O<J5KY.EJV,1]M6V^G4=4OWL.]&A+1'D(UA656QD
M$\N.RZK6L5J5J5X9*]O4LM:RE+5K8\OQ+I<N51$*4.H^6N2XO>Q# ONZQ\[&
M!0N-YL LO&7^!2>@HTUE#C2;O8W! CST  :XZ&03B, %+"#*\%Z@ HUI# ;0
M>]X,I+>][&T,%1O0  ;(E[[UM2\#Z(O?^39 -EO)[WSURU_\[E>^_#4P@NM[
MX/T"6,$&MB]_'Y  L"283G2ZCP,R?&$,TPD"$J"  R@P@0PWD@(2D(!34"R!
M"$@  A.@0 4L)X$)6, !$Z"QH4KS  E4LB(0J,"))R !#/^XQ1K6< 0>\( !
M&@M/O>C% 0)   (40 &S24#X"D" B(T)RPKX\@)^FP PJXUN21ESEQN0  +S
M=\U)6;"""]Q@ <-9S@%V@'_C/& '/SC!%?;SAN]CX$ +>M"#/MW^B(Z<80\7
MY0#7<\^4>S&  FSA,5M   '&-)L%&.O+J.GR>U##@+2$>;[A^^V8ZA0 .:]Y
MP0S><YT=/&<XPYK!;'E*ANW\:C_?N@$00/"OY^L "5@./1!P$00>4(&F1( "
MR8[ =V'<@(@Y $W7S8$4Q8$ L71H  (8 +C##6X"B'O<YA8WN0= ;D/FM]T,
MH)M^W2WO_-HF*02>-[[S.Z;\CGD+_!YSN]6LHGDOH)_\5D"[4RV9! 1@OGUZ
M> $&L 6QD5O*"9!,  20\6\+@.-AXSC(P=WQCHM\Y-XFN;@[?H"OE7SD8LOX
MR34N\XT'  %;03"='QQOG <\W_0U(\_^X^USG\-[Z$8?>G]]N8"BOQL!='-Z
M G+2[JAS^<OA<S0"OGR ,6]9 <;:PI@I??&T4!H!"7 -V0UI<0#(_.,#@'"#
M^1SWG0>X[@$?\+T!+&_;]!/>G:/3T0D>^,'CNP$ ,$" Z6UP>C= ?&,R0)BQ
MS( U9[KQXD SPK'\'G$4(-15?O1[L%SP3%N@ 12HRK5E4+%#=C8A,3" 1,DZ
M1PN$%"$1^$B&Q#5#_)6B%</B34F2('M=:.:YQG\##3] -=DS5T%;O **#)D@
M%-5%! ^PC)1&D8_!]"VWQ/0.VV\P@2X.X!S:\FIA<1M;NW+6JXHDF0.:^0$)
M]*GZK4?7_#?^B,D>\UX%E/W_:8V59(D,&X0"UR#3&+7-7*4?9K'?9DU56T6@
M69%+2+@*A% :XFW&$T5@737@70T?59F _CP  <!)/ 6@![8?"CY@;O&5#F'
M #0 27P-<EQ5"JZ@#4)@;BU@5!F-H_"$),'/8-1( 52 !X!([$E5MXP6"C"?
M.KS+@3Q*ZJF Q0B  EA LWC !&2 !GQ8>%E'&9S0C, )H2 (3S0  VG ,4S
M 6P BSS !K )RN#'HH#%![#2' C J@0 !F@5E9S'&6A UMF?(9"-\[#!&CB
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MJ@KHS\5,"+BFP$GZ#8>ZZKSL5+62P7FTJR!DZZ:4:PH4@W;^PFXQQ&/2ZPG
ME#9QQ#!EE+JB@,5TS#!E)C-HCFZPZR_8*]^D*S.(J[(*3V/.T>X,[#IXG9$L
M*T]I%D.8![^B0!P01VEZJ[%BP[Y:%+SV 8 BS<EB[/-Y(U)-0TYI3$D]R L]
M%.[04DRDK(3<Z308#D-$S,HF#B$1@$3^W0/D%:T;+,A>,L-PV%/)6NP=(83$
M_JSP'$U0_1+,ED 5;N+3P.<<38UN;!!"8,C0<BPV7"UR\<^ZS"PV-"73RDO%
M=%'6S&T3W@(.'M8B<B"NAF#>SE-@ 6ZTN.6M\E34UJIMT=7BJA_CBL ]H1]M
M+9;D[NI3.>L(% #0XJHIOFQ5K5;[-:[H#BOI7J9,VA9BW6H*0H3J!JX)#&K(
M*D*^=NV\,%!]'@S"#D,BZ4;M\5*W/HW:3@/;&LA!"D_2_I4M7"SM+F,@>0!4
M\B#T2J *DM;)B)+UBI)X86_V5N_)>"*TRBKW6J(%Q.6L?HP7:< &7( &C"\'
MA$P'C,S[KJ_^)6( !IB0_9H0%YH0!^SO";V7)%GB(R715;PO62B?\Y8, IO?
M^JE58TE@ S]P#D8  SEP].86!L#8]6:P!F\P!V>P!81$!F-P!XLP!XLP!GCP
M!>#B_%J !C3%8GK1!H!,>5U #!?K!Z!O!TR2\M5,#!^PR" P:U6P$'.@7HG(
M6=F@R8@2"7<P$S>Q$V,O-0F)$C?Q$C?Q]I[P^-9O'([OG_P)R6C _FI S63
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M =V>$CC[;:AHHF+-#1\P9'#)L,>%6A8Y;*!IU 4%2$E#22CP@0($"!H^6)A
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M<B:)C0N-Z@'I/D2@91T(1P2*-P.XP!:.P=UV'& !O3-!+[9WAV,,MRJI^D0
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M#J!!E<1V[H  6> ,&C  &H0H? $#'E!U&D0-'5@()P@A#S$%?><!#A!+:P"
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M3X$'RP,Y(QIXGS!7"PV(K"\,!#>@8N'6%5"F#X-(K3'(&^!90VURD,R7.P1
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M-3(TL4%S +2:DX$0T#S>9QA[P(7$IDFG5P#H95@2  :&P)\3LBOKXR8\%P/
MA'F&10$*V,O* 9YRI) %X@W>,$J,9P@G#&SUP97;! NTT-+T2@'^$7"5LK$N
MJ8)V'."N+P.G!GTVO! -U*!BWM"-ETH>:T6!EZ0!F6 ""0 - "#7PL!P=)5M
M4,8+6/$ DUG,AF4:];T -3 !T=!Q=(45"O!0"F@NB] HTL;,'P ]&[  G6MI
M)L#5$V!QN\,2-:"I!W!)'Q !5UJ-%Y(A#>#8$W*@RV,, O@"C-<-8<U9Q<!H
M=P@AAZ!VU_69(Z"?TV$LU>82J>)*X78,RWT>_XP!IT?BU@#=<,HL]R>"7*
M"Y0[-, \8287^95O1L'.1M%>>AT,AQEI<\3,A=72 9@[U0P<2V'B-+@'-=0
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M4F),^AQ:'\OB@O(FHJ51(G>Q 2<UB9:;8C%Z@L&D:3O6B,-K>NH'R9IIGP)
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MNZQ:/^CT6\!25WBP]B7]X'%GC18O"L<[D'?G@$V0K^*U"D\FXP]8_3Z:Y]?
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MUA-; S8Q 3>H2001:!<X9Y@OX^WDDBSRSIG,F<-VZB"6.!E,'?_2''Z<<@=
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M^0 '(,  #%"  T## +]8&)^UY(L!Y,)BB/:REK;LY3 [VM&/!K.8PUSI+P\
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M!-S! 3 2/AB M(P!V1P!C=33^JU SV" 1$DB/A0#!^B//.X&/N)#)4"!!&Q
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M&-LO6(_%^%J<(=H-\*[M3LO=VB[@3@L#=$K++%$"W&T"/$!Z.H!(JC#;:@P
M/$ $V&[*@(J$MK #I L(PZ)\TB<LGB@&)D "Q._]AB\2TZ_[*D MH.M\'C$4
MRV\24W']1G'\7K'[(C&,0G'[=N(P24 $@+$8@_$8F_$PD7$9A_$9JW$:I_$P
MX1*BH+$:.P#^&:^M'(/QV98PV)HP!!@J7HH@I[19IRC [N[21_8'^AZ3?)8!
M#>\N!@XF".N9 SBB5.J2T16Q+DJQ%D^Q%<_O^\[G'T# !;P/\Z8 "086[A18
M5SE?*[LRE)W7\S7D*C G7(G!*,Z-()[8B#GDT@2?\_&R57U8A;1R@6%8'Y$.
MU*R)53&SZY1",:0@3K 19?2H.=GK'.*#KU#&)J"C*<M#*G21 EA'#6P  VR'
M!TR  Y3K:BB2LGH6& ;KIPHHTUJ" _!9A93I=AC$CP37%L+.L_JSGZI.H&!
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MT.*C1$<':&BX$)$ ##<5#.= K,O9E(I[,V^Z(!&:/,L#Z)X+2';* $8F9<D
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M,('=2>X %S!7-J82$ZFPCTMI^T#9'A R#C@@%9H0FP,XH+_@.:#^ KHK0-0
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M=%9<4S#=YSE(16XJ ;   B3P 5P\*7/^:@,<L7J7OPT410-"!%X#>O2!"!2
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MN*5<]0$,!"##!=_WI@H.,%SY+=.]:E2WM;*F9E/7PQRX][T#Q (6<*("*^2
M(3;P@@'%0$&Z'D$*5A@ W *(0"\(>CP;(;@-_$P%&1#TNY=^@7&O?.E+IS>\
MH:[R=VN@EQ"PE, [\'!W SSA\*[ZU.<]]:B'/>IH3[M++6"K2M%[2<F)>W+4
MH)RYTUT-0:N[W)6#=[S;7>]Y[WO0P*><-@P^#D&[1.+C$ <"_2P-#))#'_@@
M.T^8H+,P2,&T:9YTK"*] C,0F$L-J6L5C&!))+B !BXP=$%S_=5,8A+5Y6UU
M=[\@WDU7^\K^3::< 62IW+"CRIIPXY:*V,3WI$E^*@RP?.8W/Q705P7SZ?$:
MU_@C'_D0  ).%V!\A._["/E^^![2"GY$!"(&.=W6QG\ZN<EM:_!W?T3FO_ZS
M;+]Y[(\_3AHB#Q+B)'RDX0S2MPK2]Q(#.( C<8 *R'RJ<!.J0!H/"(&I,!(3
MV'RF4'VMT0_]%WX!41#SP!K>IX$W\8$"P0_V(! $H8'4EX$8V((NV((1 1
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MP ,Q(4>.ZKB.UO8IM10\<18K[KAA(:=A)Y05LY-/]A4Q)Z8OVYB-X:B-6$$
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M0MLG,E3I8QGFC4FS7[D2E=NE1EM#/UMS8-W"-&WI->YF$8P6 ';3DXY$%0<
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MDU05$W";LKE=&+ 819%<Z$.0&!$ &L 0U#0Z.?-IRA1 !."C4A)!KK0 H*8
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M%95^(-.A$K6H1CVJ43] %FPAM:E.?6I,T\94J%X! Q.@ %:SJM6M<K6K7J7
MF1A@U:^2E:L5T&J%H$$!#?0/JV<%*P58 U>P8L "9^V?!3+@(@[^9,"M=J7
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M><INQ:(5$RP0@ TTX%)YM8 $\$,7A5BKKG^P!Q"PD04X 'N=!_@$E5*EV$P
M12-A ,LXP+1,W\G<71/ DA5=F<G53@DH0 <4 #IL@/X4  /HEOZ@P +P3UU0
MRY-L2"A4QT X2/X0A ;P'0&<!XA$3B!]0 20@27MUFY8P 6@1%I40-\AQ0X
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M>0!O@N8*5*?^3DP *SB&)^V )R@&B>R2&ARR6+KOV!P 5KD-$)R'&VV  "P
M.0: 'MQ"&^OC<BW! OA0_2TP$'V 0:O.FXIR]FIO*7L- :(-&JLRO02,VK6.
M;]7&0^!?H;+(_50$7CK(B8'" %"=ESI F;W1."HC[Z7!,7N- 1Q3V%# 4-B$
M@SY" (S.%QAH?YQC [A0N%H2K>6"=HXS"J M5^<@_'K-N(HS.M-+.1.N]JDT
M(+B<*71"#2#6]GE I4R<8M$*#^259^%U!C""7?6J_1*TSASU5YM(W"9&&=B
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M*G5RO(A\TE3V<\/[ :;TRC?!,PB-RJ !S$E :?,VVJRMM7OWW65 W Q<<32
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MJ0RP<$$I5,"!0P9G,,$$"JA:>.&P+JX!M8AS, ]N(Z-*^12?BG#  QM8A9[
MS)+@XP< 2)# ,GW7X;(!(08@@D46!,"! 0_0+BP)#@1]@05/*U^N7Q]$\,X'
MFRH@_?0B.!#^QP7,I<L VJ)W(( %)%B?K&]]H #V\(T$, " ;,D/4_V;@-D*
M,( &;&  ,QO MY"S 0,\9V'2,9OF % H -RE'\PQ!F\^, $ ?" >^R!> ]!6
M@ -L@&002!8)<J6=!6R  <S9P,T84  )I$,# SB/93;PH0\T #K.D0!B- "
M"@B@ $?:G-"@,SCV#6 #!<#  PY@ >9<X ,'<, &"("! I1N@2<(E@&^0[C*
MA0^%I!A Z[!W M9XX#<*$)T<CP&!H&7@9E9C(P_.]P&K?" !S%ECN:Y5"3)T
MP((> "'8F%, #3P +A2X%0DDL(<#1.!-%5B 8/YH2%4(8"/2T2'^ 1*@IF5
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MISD!E'4\MO+L+YXGR>S53!E7_$VZR"-$ W0 A =XC@6$.< .0<=AH/CD8AW
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M1B2%=]QC>LO524G02Z6)*5: >&6)9)ZIEAA8CC*92D&&F2FVC6$&12;C;HB
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M%GJ-V&(Q'UD-W/X1W'51U5\MU=+A(/DAU8T]%BN-U%%1(HOB*-,M(4%1# 5
M)U&1(]7](\S,S%+QU$D-(]%=#HQT#TT!)]"-$X_BW4K-U# M%-B")#FQ)#%A
MWS&QSP =T/ #$_AM$1W!8,\+$0'A#V?G3!@3 =NE)MMU$'KG)O  *';R !3P
M4A.1>Q=S$(#B)O@ ,!6@#P"1X&IR =?\)_LP$13PX?[@7O_R)Q1.$14@ ?>
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MYR%BOM567F%%GG4\'G O(B0"-[,4]R0 "E"MR;*"M!8 LEI3V7DYWYM1D:&
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MP#8.!1@4L"#  @('&:Q\&+ @0@8!#Q85P;  P 0( !1\V##!S(,4'0!4*"7
M@)4#"C+\#$!!PH N$&'4^U,@ ;4!#80D.!!AP2H"(S&I&5  6J;^!0Q&CHP
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MV<<%$&J  GAO<!PP0',6D0&YK 4-[<#$ #JZP0.,1P#[H$!OS >; . C(2E
M (B*."\D>G*0FG0>N>RIR7\"]!<X:N1 >^08 M2@)N6!0 ) ,0!*-<("#3C#
M!_R"#I<QAVW^ ,! !ZJ0 #\LI@$/T-'I%E>!5X!F5\-\GL8ZV:Y@1H^FFH1
M/X6FS)QB@XZF<R2V!I4!=FQC%TR@0! 6U $#=,(KC[% O=0D #(H0R4-< 97
M*O.%!^3K GWU7E/I6H)01B^/TNJ 6<LF4VG]#UL/:*ND< I7K.#"&.U:);90
M\@&?E,,W<WD"5&SFA(9. &MS48  FB  8U!E?$=Y@'  $ &Y:.%#"I/?1T!C
M)S[JDS%OU%\+^7>Q!<BK6C2$(SU/RX>"17<R!<79H-(3HM,Q! /3D"Q#-A"<
M061  UKTVP9$&##BHF*J&EC 8CK@$@]0  (>N !#^"H!_9R,0JS^G-?E:@G,
MSW)*&23KJ>K<14KO N. JD0*A8M7FIMU0 +A99$#ZOBU%#ZSDR-V"//FI=;H
M6>?"&/8%*COLH/%62[.4_%2L*.EC?WU,!05+&VD=E4;/>FM=-I8.6Z'8W1F_
M8 L\U=X6E]R8%-C/RL61I[2,!*^')7EF,ANMDW\)91;D<,40@:::>_5A58%Q
M5U:*,ZYLQ:L@TCF,5:[&_7#&RTP%4HT0#A5F@=5D;YGVS"NH\<^LB,<_8 (#
ML(%H!PH O@E$9@"ST03A+B$)]DEOTU+>Z0MR8(6W+,!5>M%R,=^<L,[6LWG9
ME=9VG5AD19= RFUV2/86O  " !@3%&#^@%L* )RE)A8 $I!*0#Z T X<A1[[
MT E7((  "V2@ .:SP!)*H*(+-%4"[/B6"<GJR2?_41N#3F9H-3F2>4V@2KBV
MY0>DC$!'+W@KI0& 0 J  2\3H!=6R@>P3\*BCRA!FFJIP";*Q=MX*\ 9L%D,
M5 2 C@J NAHHW*4*#8EN3J&U6;..\&MO':A$S_L$NM[PGPP*"*X,(@H*Q02
M$6X# U1PHGFX ,*Y,(4!(*@-$%!# 38 @0S<X-=D4)$$(A'+=+V8Y'^VE)?5
M:-.9EJQ:4U<4VRR3<A8H8W8\W;40WUS"TDB@  Y0P'RX =)+B-O? 8@  BC0
M@9U8P@&2H,C^!,H% 1I$8S<+4!P'VA04#AL  C$>(JM1LW5'H=Q2GV1B/E$,
M1WE_G04KQQDTM:> M32@@1N8Z$I*8X5?$Z$ "]#.ZO4Q@ L40 J(R,,!1#R
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M22T*X^@QHYV^A(MJ@-&LZ+_%:"5.ZC4"QP;(USH-PC;!XBMV4C$J8SP@8P<
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M&%##5M6&^X;(+RG)(&RO<=A/"4X!4FRL ' %%8] B,3'!3>V''*?P2B#'Y2
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M [R%*/% :@#5KJ%3$. !BQU)""=91K4L4!=Q8\@I@/A( \01  9(X-O/ML;
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MD#.9A",Y?( )]7, D+!1GQ$IU+ 0A/ X_5@3X@.-U.,!$@ !T5 !TL@T'1
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M#6Y@A&QK1D^QG>9A$A%0']E2A450M=I )VD(4+'@EQ&9 )E,Q U636Y1"#N
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M\0'Z4$-$;1,P#=5+6X#@-AZHHG,+*#%STHA7$"\LI=3T0P^+,@C^ Z $%:
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M! X(.+"@@0,5//! !.S$$^ %\5@03P7U6 !!/1!(0$$#$D( P8+^$G C03P
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M VT/<P$ $ 3 KJEWP-%V\1DLU;PW \S^P00 /!# !@:P8VLORFL  $7-?_
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MW !P85$73"!;+A .^S@ @%MB( &\J%51WUDI%KH $S"<U !R5\Q.X# +3P/
M!U["M&@2E%?6;$ !$#BXT75  J1K%105@(%8,JX( AAG"LS6JB5X( T>1-X:
M 2F(LG2K<IO,0-5NI30Q".=I:'C  ?30  /(03<;.  I/4 PO"Y">4JCFC8^
M$3W*7I0-8-@ &#C(&P]$P)B>$P %>JH!S=[L Z7]  8/  $\L&1+TD- !1@@
M@/!M )H6 8 #IJ5! G@ ' (XT75$^ %LTC$!M0(=$_II"*W]C'4,N-("*!##
MH:ZQ5EG-'>+^&#" "@1@ 3KB[.:6J8L!X'&E>.N*\&C7 %J)Y9+!8!\"WW*
MG9J&A>M#2SKA2:H;FC20V_  '1' QU0I4Q@!,  :=&G!!+@. Q%(@(']Y\("
MH ^BN\":!LA(D.M(M[.7@@,">7&C#V" )(Y#HBS%8@$'T,(".9@ !C; FP<$
M4FL34, %/,  ?,@! X& 2KI2T-,-C&12'&C  F@!@6*$Z!8MZ7!_;\8DG2D
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M=BB%0AV%)VJB)UZB)BJ%*(XB !C')8JB*HXB*X8B4X#B*#;%)\[^(BF.! .
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M7, \+(@%" E"A (^B((]A"&/A,(:'L[4R.<\D (&!(,N- @<+DAXXH)R)B>
M,F<#;H'[?9_^%2J+RW3@L/':%JS*'P0;"ZJ!-*#@O/7218W@O<T>:;K!M[V;
M[87:9 VH)2C3JY7FTUS-T*0H]6'?XKR3Q+PHW5BAEVS@BK*HC3(<"62 #Q3#
M!JB"'O3:T;A@C5[?]6G?_^B+_"4I#*;?^C7I"OR*[CR LID E[!8$1&A Y1H
M$/R+]+&HTE#"C]Z+^,%-TC0 O81+!.1-R"0HFQ+!K=W.!&1,G#'HAEH!IDQ
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M ,R!>2V=!K 0>&0'C$1C)%2O!9"&;+DJY"*H(DD \5A  FPEX4BO&R$.8%B
M K06T9)/X7RK"[7$PU'F<I5/!6Q ^"AM$<'NTM[B)AV>XZQ*Z$U/)YUP&E'$
M!LREW6X!%XU7,UI%L4V6L1  8I8K'@V ]E0M&RA/!N"65Y3/TCW" >2 V6!8
M CP !10(D2@.O!(,K6R  A1 4>G9!F?5.+7J 7H  FB ABS0&OL3O%W2_9Y
MX=B*TB2QJ&@?%.D=&"G3D\T7-4(-B\62,O'" D.-9'G  @B"]HS^9F4-0) -
MP \!P 48P&HJ%Y0EC3QU0 -4  9<Q2CI<>*NS^%UP $,0ZRML"<,%1@P8/%T
MP.J5SZ!F@""P[ !0E=U4P"RH Q2]W%SZH08D " /E0ME:>X\[A$$G!B#P8D@
M0.D>CU I+.,80("$4TCU#6/%0GR5<_\\D@? ZE6)@0<E%F!5D-9J0 &4:"N0
M3>7<0!,)P)LU41J%E60MT _=<3;LLM^!+"^'#C0QE +P1PHTP"285>7HV'G*
M4&*)#QJK 0[<SNMI2$#4;6Y%K/A6"I:DT=1.'3QAP0]QT"!U  1-3[NXCGG)
M5A.% 284@ .X4$U3[Q>Q3R/-T"/"\E;^_3%+#:H=4V-@WJHB5"\& (9LB8;"
M(3,4& N%X>H&O\%8]/,N>(<KZQ%/8=4$K9>$B$4"> !Y3-D\%3-@D7($I1OL
M#DX=RY+MY,4!Q%54\4P%I/(%/.\!1/ &V,TX:4(^\X(!^$U4474>!0!+-D U
M#U9.V8]HV%HE^$J";#!O09.<N, @$4\^6= N#\B$M&KPCB^>&D"/&M+O2I(+
M6,!*NL0%T&P.WQ,&2.D!>&T6OU+%G&><RA8'S!8"89*&?DH!D,8,1<!*BTH.
M@<+3V*S[N(!)X0C<Q&FM@FV.:0"/:<+MB$$#@8\=7,@>9(!7DK<',$1]!\3B
MC75E_8K BHG^$8DI64?!&_C!C)*I$66 P.IH76D!M1H1"8C):C'XCXZ)%=QF
M%715[YW+D>[+LF1W&6C?O0#!C[K __@WN&C!#(X)W?C3K] +):?J:M&,!Y9&
M6]'IL.!H_RI"=2<WL5A5IIT!0F^RQ06X%V144RM=D4=>SN$S$WA=CD^7[NU:
MH/I"M$'?OYE* C[;)G^1E?^>M%UY93GTQ "?D!*INK(RD5/!"KX?[0%/YPG.
MDRO"/-'H_$Q:GPZ+"E=:NX6:!L9Y&D?*=%^H.2.2G:=Y%R2OOX7JI[P=GVOR
MPN%?9ZF<Q.&=Q#4 0CFYQ'4=U$6YH4^!4*5!=3# !#CZODQ DUO^&J.+(*D+
MF/& **?#$Z57(*["G*H%@"5C6T8_.E=WNM (%<( %QWY$!BF06K:X#RDP(99
M2E=]&C#1.JS=>J2W7<55C)^W 0-<NM;IMX#96[6O0:'S>A4,GFRY0 2$E0(\
M6-RP#GE,<)NYF]LQ8*AIG^B!J+Y67*QW5I>%6LV>6P $.:$?,[BKX 8;0&M9
MR9.=.]\J3I=!RN]:2JIC'8^+&Z1?E*2;&#@S>W)$_.9\4;D-^B9/?,#SP!O\
M4 -$;0'4C@$8M!'USW<=VLBEJ](U4ZBEVJ9K?"_4^,H]7Z:=D\U[&.*J6D[-
M>\@7S8!O7$@ZP/KDQ31)8E2560>Q!;+^E@;B? R8_YN?QUW-IW',O&C\E9_(
M7)/N'0V"8I0+^AZU']^5WUK1).G$+!^+D@27<KV;MJF2DLN2RKT,Q-J2O@#O
M\7W7(]_(^%[[.5O@EY_A SZ;3A_BP\#MO/K0&XN?M0 &'-J?Q3BWX,*XC/F#
M=M$@<Y^45RJ74LJX8/(+A'[AQSV1OI^5=V"K=[F6BTJ>=[4E!-.[9?RY.4*H
M8>B/R\W02X&8E4:^@$D=!'_P>XGQ"W^^"'+Q@XL=U($<-+_P1[_S@XL<<& 4
M4L'TJ4#*SEH^X8J"9H@$,"PO8V4\?.8$D'\\G#]6UL/Z3T $P&9X%K$>&5'/
M@<GRUX$>#/_^_]P_\MN_]!,_"'19UVE;5F%6=4Y65BA7)$U21543=EE1ALF8
M.)D-B4-*EH@UB=/FC-*B4JHS0CD<*-,H1 L^&,3:,;E\)IO5Z+1A;6@D&FK
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M-".@L040;,# ![9]T  &-5\@(=,-+N!!#K#<5]@'<H]->>66DYO^MP(=8)!
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M "!@4(%/"B!W[3MFR< H -<@TP*C9$ &!" !C*;R5G[S  8$L,L,,. !?[#
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7+X[QC&M\XQSON,<_#O*0BWSDO X! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207999305600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,771,416<span></span>
</td>
<td class="nump">9,274,809<span></span>
</td>
<td class="nump">1,771,416<span></span>
</td>
<td class="nump">9,274,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,012,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,012,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,712,011<span></span>
</td>
<td class="nump">1,214,700<span></span>
</td>
<td class="nump">1,712,011<span></span>
</td>
<td class="nump">1,214,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=catb_CommonStockWarrantsMember', window );">Warrants for the purchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">59,405<span></span>
</td>
<td class="nump">34,839<span></span>
</td>
<td class="nump">59,405<span></span>
</td>
<td class="nump">34,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=catb_PreferredStockWarrantsMember', window );">Warrants for the purchase of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_AntidilutiveCommonStockEquivalentsExcludedFromComputationOfDilutedNetLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=catb_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=catb_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=catb_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=catb_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>22
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`+R+;$?#F.=LP@$``#@9```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ!
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M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY"
M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%"
M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_
M83)Y!5!+`P04````"`"\BVQ'2'4%[L4````K`@``"P```%]R96QS+RYR96QS
MK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][
MCZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&10IXV+!XUE])"1#M@
M2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE89.D\^(GT%V-NFM[2
MENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`
MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`O(ML1Q8J%YF?`0``8A@``!H`
M``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\79RVZ"0!3&\5<Q/$"'<X[W
MJ*MNW+9]`:*C&.429IK6MR]UT=#+?.G"Y-M`8)(S_]4/`JLZY,LG?RGBJ:E#
M>6K#Z+VZU&'9WU]G98SMTKFP*WU5A(>F]76_>FBZJHC]97=T;;$[%T?O-,^G
MKAO.R3:KG[-'V_TZZ[9[R48O17?T<9V]-=TYE-['X&XG>>@WZ)>OK?_/]LWA
M<-KYQV;W6ODZ_E'AOC;(7#I(TT%*";)TD%&"QNF@,25HD@Z:4(*FZ:`I)6B6
M#II1@N;IH#DE:)$.6E"")`<RYIPDA#5':P%<"\=K`6`+1VP!9`O';`%H"T=M
M`6P+QVT!<`M';@%T"\=N`7@+1V\%>BM';P5Z*^E=&[UL<_16H+=R]%:@MW+T
M5J"W<O16H+=R]%:@MW+T5J"W<O16H+=R]#:@MW'T-J"W<?0VH+>1OI6@CR4<
MO0WH;1R]#>AM'+T-Z&T<O0WH;1R]#>AM'+T-Z&T<O<<#O4-9='[_'+M3?0SW
MKODV'!8-\`[Q>O'W3[E-A0T#K6._DW>WX]T?';>IGR'NU^^$S0=02P,$%```
M``@`O(ML1UA%'$2H`@``=PH``!````!D;V-0<F]P<R]A<'`N>&ULO5;;;N(P
M$/T5*T_=AS84]E9$(W6AU:[4;='"ML]39P)6$SNR'03]^DX<8).2A,O#\F2/
MS]S.&3L,I.GTQUJEJ*U`PY9)+$V?C-?>W-JT[_N&SS$!<T$02:>1T@E8VNJ9
MKZ)(<!PIGB4HK=_M=+[ZN+0H0PS/TVU0+QCD66[2-!8<K%`R^"VX5D9%EMTN
M.<8#_R/`>5#D"?),"[L*.@6F;'*8"8<8AY0KB"`V6*#^&1UFJ)(4Y,HO=O="
MOIJ_Z52-P&+9JWI01)^#QI"25J)OC0[S<T5]QKGO<`YRAF$9NWNXX>()M<D[
MO>Q>=.BWI6!C+V(CA$+.QB"T"08+VU\@MTJO95K84U4*%<]%-T]3JL]X[`4,
MYLMK;P%:@+0>,^*-MEVO2%M8W3I.C=7!L]*O9HYHS<#?&MVRC"VOQ>>@=^40
MM*HB_6UGP9JV2M^Y92ILC.8Q&H.V_XD*U].&B-Z55^I^$X*!#-FMM#2.[)<L
M4I%X94JVJZ&B>R$-ANP'Q"`YLLD.?WO![(P(P'T))I8F.*_/,!6Q1QI!*NLH
MGR&8.;N+:WT>]0RD>'.=.@+6"92L[V62)0GH51YV(F92D`:D.KOA7&6RH:X[
M(:EK`3'12GM'=GUT"J,SJO]VF>:-U(,>E*7';0PK>(FQ%O$,6D-3#GI`$F&;
M:R`6%_E;1\'96&.$6CM&%7]MC$?<.0#[@P;U@O`T/NPNLYFN9S$'G^?3&3).
M#QHUVSQK#VC9O3+4,FKFWJOCE;G\=K@R[&R:,VL^'211.[JB53MT(UH[JJ3>
M?F"C+-W>4;*L,QVH3GM=+1>.G8U.D+9[E+0CM"#B@[5MA7\0]P0LZ^Z;A=:@
ME6'8@VR\U(VLMTY0[\N1$^3*.]ZG5Z]NN\_W@R>UCK2=#_B'S[5?_9L9O`-0
M2P,$%`````@`O(ML1VEQ_'T^`0``:0,``!$```!D;V-0<F]P<R]C;W)E+GAM
M;,V334_#,`R&_PKJO<O2:2"BK@=`G)B$Q!"(6Y9X6UCSH<13UW]/EG4M`RZ[
M<:MKOX]?QTDI'!/6P[.W#CPJ"%=[79O`A)ME&T3'"`EB`YJ'4:PP,;FR7G.,
MH5\3Q\66KX$4X_$UT8!<<N3D`,Q=3\RJ4@HF/'"TOL-+T>/=SM<))@6!&C08
M#(2.*,FJ5[,UMC$E&?15&1W7/.#<2K52(._:H>QW*G9&\#H<Y2#[]NGOGQY2
MAF1=Y3ZHOJIIFE$S275Q8$K>YT\OZ6QR90)R(R"J@F+8.IAEI\YOD_N'Q6-6
M%6,ZS2G-:;&@-ZRX9=/BXS#9F;_!L.Z&^+>.3P;3=E%A#1?N-FED6F[Z3"`)
M07CE4%ES$2YAOHD3+.R6GR#P<E`G3)=M"VUCO0Q5NE]#='@Y<65KZ]MCZD=T
M]JJJ+U!+`P04````"`"\BVQ'F5R<(Q`&``"<)P``$P```'AL+W1H96UE+W1H
M96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL
M>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[
MMR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)$Q+#W(*+"$MX%,O67.!;&B\C
MUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$35T$FN8BT
M\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:B.%4PL3`:F<_5FO'T=)(@(+)
M?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+<!P$X%&[
MGL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMWW=..B<:M
MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3(`!8<';6S-(#
MEEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X`-\313%!\KT&V
MBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_::L!I^V[
MF\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E)3+/[_D*
MZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@MNN01.+5)
M#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X
M$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V</!T3$LV4
M"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S&L%&KQMU
MAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U%H&V
M<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>ACA*
MFNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$
M5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7O
MN?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@YG\#L_6@^
MGO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2GD(;;NE3
M]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*]+',<$X>
MRPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/Y
MZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAG
ME<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>AP
MYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.
MS_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./FQW%.4[@2
M=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)
M1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83`<V4
MR43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK`,!2$7<N/O[Y-J
M=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@2\-Z;ITM
M)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!
M?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9C
MC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-
M:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`+R+;$>A
M39_(@0(``%(-```-````>&PO<W1Y;&5S+GAM;,U776O;,!3]*T(9(X41.^F:
MM*MM&(7`8"MES</>BFS+CD`?GBQG27_]].'8B5F:)DM+_**KHWO//9*N+3DH
MU8KBQSG&"BP9Y64(YTH57SRO3.:8H7(@"LSU2"8D0TIW9>Z5A<0H+4T0H][(
M]\<>0X3#*.`5FS)5@D147(5PW$#`Q=^)%(?PJ?_Q=R74[0?@VMZG7L]_NKCM
MXGT[<`&!X_B6AG`XOH+>ZTD'OK^;V`QVR,<'DK_$W:&>[*!NI#BI_<U^A^+Z
MT*F_//<N_<T>^I_8['**Y8YMZX[_:_LFODGBU742!9G@;;F,H`.BH'P&"T2U
M_]"X)X(*"92N1ZW&(APQ[#SN$"6Q)`;,$"-TY>"1`6P)UWZ,<"%M;I>AFV?@
MMYED'H?0KY_7IXM;=MN8Z1%*MZ>G@2@HD%)8\JGN@-J>K0H].2XX=B*MWQ[O
M7*+5<'2U$6`;G3<64N]#DWD(UU`44)PI'2!)/C>M$H61+I023!LI0;G@B!K*
M=41M:-H$4_IH/AB_LBWN90:<C]EC'P*C8FWJA:C-M@Q<$6RR.>Y-VL]'\8)E
MUB30T:@HZ.HK)3EGV(EUT%34O7WTPQWT48#6K&`N)'G6_J80$@U@"<$"2T62
M3>2/1,4,+U5=P=XRVZ7PV"F_I:;3KUJK1I?@>R_/T<DM=%^Q&,NI_40>+NER
MLG_+[-L).S+?MVJ.D'""Q3'G^]E*&Y^OM+>IJ9-(NSY?:3=G*VURMF_HY?\N
MFE>?]!O7B:W+1(."N")4$;Z6@,SU[][(IEOG?'N1T)SILKU#V%&%8OV#LY5%
MDZ4X0Q55#V0AE!T,86M_-_*'X\9KUE"$L+5_X)14S%Z:O?8O*OH+4$L#!!0`
M```(`+R+;$=;?6R7DP,````-```/````>&PO=V]R:V)O;VLN>&ULE9;;;MLX
M$$!_A=!3]J&U1=I.8M0%MKGL!N@F01VTS[0TCHE0I$!2N7W]#FFG&<6,ZSQ9
MDC5',^09:;[XZ8-U=PMK[]ACHXV?NEFQ"J&=#@:^6D$C_6?;@L'_EM8U,N"I
MNQW8Y5)5<&JKK@$3!GPXG`P<:!F4-7ZE6E]L:'X?FF\=R-JO`$*CU[!&*E-\
M_>*G2Z7A)SB/8";;]E(V,"L>=<&T].&L5@'J63'"4_L`O0NN:[]U2L>3\7!<
M#"+LI=1KQRI;PQIVLU+^U^:/@M6PE)T.-YCLRW-G1<E'G$_6C'C;3P4/G@+C
M!2:KH.[A1BYFQ;!@L@OV7.D`[E0&^,?9KE7F%ED%6RKGPSR6F^YLE%&->HYY
MXYE?V8=_K5//U@2IYY6S6J>H^$<*PB?XWU<PQZ"JWHU!+G[$G9@5DR$"[Y57
M"Z55>)H5Z5A#K&3PII2T_*]'S*3%>=EB)DW-SDQ`"KLPZ\W#I8DYX,T7=7JP
MFRH\<!=UN5XJ"CJQI@;CH6;?I):F`I9J\83`"8'O3V`'U](!3440D-@%F@?<
MFEB>9W;)KEIP6!4!C0AHM#_H1/H5.]<$-":@\3;HRMU*HY[3DJ:5WJ2"S40@
M$P*9;$/F7=-(]Q03F*M;H[!#)6[<WU5E.],KZY"`#K=!Y\K@\BJI<:=]<&G_
M:1Y')/QH.QP?Z#I<D[/'-BX.C3PFD<?;D9<V@&?7\DE&1XE:0^K6<#OPEW1.
M]I,L>SYFA6P:%=[65E()R[R%]['E,$-V[6`)SJ7]M]4=Q5`%RZR#38-[G>+8
M#_#@[A&#?<7.N]`YBJ(2EAD+$^/30D8/*]O$1=_J3>I?F1'P$H^^6X^+#P[;
M"ON)1E/QRH^:5QY2%%6OW-<]=G`3C?!_41*UL-Q#PRR$"EG^R<@<@5,U^0XU
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M#:EK\LO<_O5_4$L#!!0````(`+R+;$?6K_1A40(``/0'```8````>&PO=V]R
M:W-H965T<R]S:&5E=#$N>&ULC95=CZ,@%(;_BO$'C()?;6--VFXFLQ>;3.9B
M]YJVM)I1<8'6V7^_?*A%0J;>J.#[GN<`!\A[0C]9B3'WOIJZ95N_Y+S;!`$[
ME;A![(5TN!5_+H0VB(LFO0:LHQB=E:FI`QB&:="@JO6+7/6]TR(G-UY7+7ZG
M'KLU#:+_]K@F_=8'_MCQ45U++CN"(@\FW[EJ<,LJTGH47[;^#FP.()82I?A=
MX9X9WYY,_DC(IVS\/&_]4.:`:WSB,@02KSL^X+J6D03Y[Q#TP91&\WN,_JJ&
M*](_(H8/I/Y3G7DIL@U][XPOZ%;S#]*_X6$,B0QX(C533^]T8YPTH\7W&O2E
MWU6KWKW^$X/!YC;`P0`G0Q1^:X@&0S09]-0%.C,UKA^(HR*GI/=8A^1J@XV0
M4QE$1/:8BD;U=(F1,=%[+\(\N,LP@P(JQ=Y4@$D1B-A.`/3G=FC8H0MP,!71
M<T`T`G1S%QGV^+D]'NVQML>&/9GGIQ5[4Y$^!R06(#'LV1R0:(!6M'J&XR3.
M5NOGF-3"I`9FY1R'J5@`R"Q`9M9!Z"3,)`MJ964A5J8?.A$SR8)J65N(M>F/
MG8B9)'F.`*'%D*?'(T+JA,PUV0(*L"FSC>E>\KEFP:(#:%-F^S=TU>]AT`P%
MG,!UEJT7[$00V2QS*T/@W"N#IAWR6;0^]I8'YHZ&5IVE`V>FL0LM,`[9!M.K
MNGR8=R*WENLS=NJ=+K@=5(?T0U[D';KB7XA>JY9Y1\+%4:_.Y0LA'(LDPA<Q
MZ%)<P5.CQA<N/S,Y&_I2T@U.NO&.G2[ZXC]02P,$%`````@`O(ML1ZG87/;2
M`P``]A$``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R5F$V3FS@0AO\*
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M>7`;[8*C/A6O5?_%7/_62PUR3/ALJF[Z#9Y?N][4:\@NJ(OO\[%LIN-U_B>)
MEC`Z`)8`N`4P\<<`O@1P)R"<G4UU?2CZXK!OS37H+L4XVNQAD+=CDB%ST$W9
MVKF[ALJZX>[;`<0^?!OS+!*8))DEH12YI9`W23BT3YJ`U<1\^1YP?'P_GJ_Q
M8H[G.%[9%M5<Q"QI)HD"%:64*L<J)N(XN>]%.%X$]I+8K<C9BT"MR)11FAQK
MN!3W?4C'A\0^4M*'Q'W">1213K"*R0C@OI?8\1(C+YQL)8M1*\!BTHFE23S&
M1CD^%/9!]GNF<+6,DSZV-)L^$L='@GT`Z2.Q:B5M8(D4[+Z-U+&18AMDJ5EJ
M39%8*M)):DV1-/:8KBQR&#`B]Y<;GPS,*8=A#'%)UK-H%JLJH0?85C'N,>49
MN&XPU#@YH;-%LXRRX'3OVBJ5>DPXYA*28432[60,TX^S#3#9*L31;3,N(AEF
M)*<9R3``E6`;9K!*@->T<4'),"DY34J&(4AK<DL3*P\G+B89YJ2@.<DP!&,I
M-KQ@E1#<9Y1<6#),2T'3DMDH%+09+`*?V>ORDF%@"A*8.<,X9)''VX&Y/&08
MB,)!P[*.8!;KQ&^OB&4A8<F21'G0&2+'#F`B"J=O9TUF:R2ER;<TVTYN9%W7
M9YBLPF.!!BX-`=-0*+H6\*AE0[/MQ"4A8!**A!QDL-:!DAQA6^-AQ*4@8`K2
MSW$&PC(RL)]^85DZX#YK:'`Y")B#DJ8/8,;]E28BHA]Y6Z<D3R(/1RX/`?-0
MT@0"3#J92O<Y60W%EB$>20\.@8M$P$B40,\=3+OM)9,E\UPS@<M%P%STJBAU
MGVQK#>CA@;N4XI@NDN[]1;.\CE22>M"9N\L[CB$D/1Y][FXS.?S?8G_;:/(_
M%+ON(:T%$H!PBPW1#OU2O.A/1?M2-EWP9/IALS_MS$_&]'I(%KT;>O"LB^/M
MHM*G?CQ58]?.GR7FB]Y<UJ\LMT\]AY]02P,$%`````@`O(ML1U'K6TN^`@``
M&@P``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R=E]^2FC`4QE^%X0$D
M?R`!1YVI=CKM16=V]J*]CAJ562"61-V^?1-`-V2"L/5""'SGG%_"X3,N;J)^
MDR?.5?!>%I5<AB>ESO,HDKL3+YF<B3.O])V#J$NF]+`^1O)<<[9O@LHB0@"0
MJ&1Y%:X6S;67>K40%U7D%7^I`WDI2U;_7?-"W)8A#.\77O/C29D+T6H1/>+V
M><DKF8LJJ/EA&7Z!\PW,C*11_,KY35KG@8'?"O%F!C_VRQ`8!E[PG3(IF#Y<
M^887A<FD*__IDG[4-('V^3W[MV:Z&G_+)-^(XG>^5R=-"\)@SP_L4JA7<?O.
MNSDD)N%.%++Y#G87J41Y#PF#DKVWQ[QJCK?V#D%=F#\`=0'H$0#CIP&X"\!.
M0-22-?/ZRA1;+6IQ"^29F:<-YUI>FR0Z<R";;'6[7'IF4E^]KA*RB*XF3R=!
MC61M2Y!/L>DIDH<DTO6]$.@.$;<0R(:@_1)I"]%*JD8"9@!`GVHSK!IDP0X+
MMEG2?I6D9<%6E00T'Y]N8^O`.$GLD,0V2>8EB;T5;`:_8I`A<1@2BX%X*ZR3
M40:_8I"!.`S$9O`^]S69U!W#JD$6ZK!0FP5YUX-:56#7'OYUZ2DQ<I2#3*G#
ME-I,V,N4]IA01FD6>Y&>"@>),H<HLXG\A3*K4)R9R8^7@<"I8VSZXQ7!$S)`
M-X-M723Q-E>G&>NN)[)A'M<)H6V%A'@?)D2C;UQ/0M(44PJF+(]KAM!V0T+]
M.'Z;Z^'@_\-Q'1':EDC\Y@S'/;$G^02.:X[0=L=DPN\>=*T-D@GM-\W<GLB&
M>5Q[@W1"^]'Q!;8EF*88Q'3*`KO.!M,)[9>.X]@2'$.4)73*ZKBV!K,)[9>-
MXV3C.)&UBSNS(__)ZF->R6`KE-X0-KNW@Q"*ZWQ@IO.>]$;],2CX09E3:@JV
M6]=VH,3YOA-__!U8_0-02P,$%`````@`O(ML1\FH<4]-`P``4@T``!@```!X
M;"]W;W)K<VAE971S+W-H965T-"YX;6R-ETV/FS`0AO\*XMZ`/_B*DD@;H&H/
ME58]M&<V<1*T@%-P-MM_7QL(L:VAR64!YWEGYC7VCEE=>?O>G1@3SF==-=W:
M/0EQ7GI>MSNQNN@6_,P:^<N!MW4AY&-[]+ISRXI]+ZHK#_M^Z-5%V;B;53_V
MVFY6_"*JLF&OK=-=ZKIH_VY9Q:]K%[FW@9_E\234@+=9>9-N7]:LZ4K>."T[
MK-T7M,P154A/_"K9M=/N'57\&^?OZN'[?NWZJ@96L9U0(0IY^6`IJRH526;^
M,P:]YU1"_?X6_6MO5Y;_5G0LY=7O<B].LEK?=?;L4%PJ\9-?O['10Z`"[GC5
M]7^=W:43O+Y)7*<N/H=KV?37Z_!+[(\R6(!'`9X$4QY80$8!N0OH?P5T%-!G
M,P2C(+`R>(/W?N:R0A2;5<NO3G<NU'I"2XFW*HB,['1]M'9X(7+N.CGZL0F3
ME?>AXHP([I&MCD0^A&0Z@B;"D_G!(K!K9L":'$,)4IV($%C#PR#Y3)#9,LFM
M3#+,%='U^+&>WO1TT%-=3\P2HV$F!J3ID2!&()3J$`TH"&4ZA$(2^A"5&Q0B
MX1.S$EBN`MT5-;,,BFV@9<$DCB$HU2%$<01!F0X%21A"4*Y#E&KS,^LIM#R%
MNJ<`]!1J26+L(]!3:)1K;Y[1DPYA3#!L2J=0$/OTL:O(<A7IKL`LVTC+\F76
MED'-^C*H>6,&]J2SV-J9L>XL>JQ/K)E)=#VX/+>)X0:<%AT!B2PQMALX'3KR
MQ,I%OF5%-<>[EP3T,C(W,S%LQZ0">$.:4.2#"?/94/.^D.U+[S$QN.*V(S/Y
M`O\;I285@-L[,Z$P`1=%;H5Z8N4B;/O2NU)LK8FQ*XS,;5O2.("PU,1"'X-8
M9F*8^)A"7&YR<F<&\1/^B.U/[YKV2DM&?T3/Y"_L=Y*,_@P,D1DN,SFZL'=:
M,OHS,!(OR#/OSV[J2._J,8'7I=%F`YQ$43*S-HW>3FD4SVP[XZ`@.R%%X";.
MS8"RPV/[X.)I!\::M<?^J-XY.WYIQ'`&FD:GSX$7K`Z<UO@6+5,$C&?J\Z$_
MH-[#;U;GXLA^%.VQ;#KGC0MYS.W/I`?.!9.%RT7@.B?Y@3,]5.P@U&VDG`U'
M_N%!\//M"V;ZC-K\`U!+`P04````"`"\BVQ'Q]X=JPT$```C$P``&````'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;)68RX[;.!!%?T7P/A%9%$6IX3;0UF`P
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MYB[_V&L->FQPXZIN^HPVYZYW]2UD$=7EK_G[V$S?E_F?3%S#^`"X!L`]X)Z'
M#U#7`/4>D$R5SLZFNOXJ^W*U;-TEZD[E.-KR:9"W8R-#RU$WM=;.W354U@UW
MWU99LHS?QG:N$I@D:RR1=T4\-,YF@`4-!Q0.7(("*TQ`!G7+,%^^*%R#_C@^
MN<4G<WR"XU-JT<Q%S))FDGP")2#A9`6129WI[&,WVJM&8S?FX_C4JR;%\1FU
MJ>=J4F13*L%I"J+)Q<<^C.?#8!\YZ\/@'#)1K!$L2D7`\&:>D0P9R=EBUQG*
M`8(U6Q!-P"S-O7'-L8V`>"F\.D8HO:\D?F2OFOM$-6PI5"4A#7`C?3<8"SGP
M;B3NLX`DX"?!:%":3P)X@DA^\(A()TF`%^5[P9A1*>]%D1G-]DI!13ID*OC$
MDAA9.;MNUI+`*.&M4&#E`5:T;P7S*F?3K*^:VZR40O/,H3J9)'G(I$F]A28Q
M`?,`8$@?71*S*V>'NI"&=&]N0A:1CR9)V,0NUK7$X/F4/N@Y(I(Z9"1SWPPA
MU`.^Y"%FB$A+%3`&(+Q1!$R[/*`>\`D%9.,B>/*#)/0P(<,(/J8`2";)9\((
MDJ!4R%[*AQ`HDHG'+F#`:-9-`914`<]W\"$$"?'"4P@P8;3@1Z%XK'ILQP<1
M:&*')Q$0PO!/1ZJ!+(!!X&_"("5F^"<7X#V6R>6CH<*R)(.`/27X1`-#_/!/
M+\!(TYE('O@QE-(F:'7ZZ(.,..+9!QAK,DE3EDH%D2F1F(#G._CX@YP8XOD'
M&&T&S(.](I%)G9H``BJ?@$H00P&=K'P$*H)`R2-02;KXV(J(*.0=#?QJ""-E
M2!,^_!2!'[^[6BL"-G]>7=_3U!_33_GT4X1^DJ>?PEQ3`2!1/M44H9KDJ:8P
ML:0)>6M4/K$4(9;47+^M%481"/]9&:.SA]JV^^E,IHLV[MST\\'`_>[]W.<%
MQK,+[_Y:/A7SZ<U[,ZOEJ=S;+V6[/S9=].KZWM73,<;.N=X.[L3GH1L.MMS>
M+RJ[Z\>?9NRG^0QGONC=Z78D=3\76_T&4$L#!!0````(`+R+;$=ZO`[TH@$`
M`+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULA5/;;IPP$/T5RQ\0
M`[NY:,4B91-5[4.E*`_MLQ<&L&)[B&V6]._K"Y#=*&E?\,QPSIDSOI03FA?;
M`SCRIJ2V>]H[-^P8LW4/BMLK'$#[/RT:Q9U/3<?L8(`WD:0D*[+LABDN-*W*
M6'LR58FCDT+#DR%V5(J;/P>0..UI3I?"L^AZ%PJL*MG*:X0";05J8J#=T_M\
M=]@&1`3\$C#9LY@$[T?$EY#\:/8T"Q9`0NV"`O?+"1Y`RB#D&[_.FN\M`_$\
M7M2_Q6F]^R.W\(#RMVA<[\UFE#30\E&Z9YR^PSS"=1"L4=KX)?5H':J%0HGB
M;VD5.JY3^E/<S;3/"<5,*%;"71:-IT;1YB-WO"H-3L0./)Q=OO-P$T2\,K%1
MS:3IO5'KJZ<JSV]*=@I",R91#A>8%<&\^J<M"GI)+\[HQ?_IFX6^20XW7SC\
M4F"["&R3P/9?(R;,X1)S^Z$).]M3!::+5\>2&D?MTI:NU?5VWA?Q3-[A53GP
M#GYRTPEMR1&=/]EX#"VB`V\BN[JFI/?O9TTDM"Z$MSXVZ4JEQ.&P/)#UE59_
M`5!+`P04````"`"\BVQ'D>`9&J$!``"Q`P``&````'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;(53VVZ<,!#]%<L?$`-+VG3%(F535>U#I2@/[;,7!K!B>ZAM
MEO3OZPN0W2II7_#,<,Z9,[Y4,YIG.P`X\J*DM@<Z.#?N&;/-`(K;&QQ!^S\=
M&L6=3TW/[&B`MY&D)"NR[`-37&A:5['V:.H*)R>%AD=#[*04-[^/('$^T)RN
MA2?1#RX46%VQC=<*!=H*U,1`=Z#W^?Y8!D0$_!`PVXN8!.\GQ.>0?&L/-`L6
M0$+C@@+WRQD>0,H@Y!O_6C1?6P;B9;RJ?XG3>O<G;N$!Y4_1NL&;S2AIH>.3
M=$\X?X5EA-L@V*"T\4N:R3I4*X42Q5_2*G1<Y_2G+!;:VX1B(10;X2Z+QE.C
M:/,S=[RN#,[$CCR<7;[W<!-$O#*Q4<VDZ;U1ZZOG.L_O*G8.0@LF48Y7F`W!
MO/J;+0IZ32\NZ,7_Z;N5ODL.=^\X?%>@7`7*)%#^:\2$.5YC/OW5A%WLJ0+3
MQZMC28.3=FE+M^IV.^_C(;)7>%V-O(?OW/1"6W)"YT\V'D.'Z,";R&YN*1G\
M^]D2"9T+X4<?FW2E4N)P7!_(]DKK/U!+`P04````"`"\BVQ'(DJV#Z$!``"Q
M`P``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(U3RV[;,!#\%8(?$,JT
MTQ:&+"!.$;2'`D$.[9F65A(1DJN0E)7^??F0%#L(VE[$W=7,["P?Y83VV?4`
MGKQJ9=R!]MX/>\9<W8,6[@8',.%/BU8+'U+;,3=8$$TB:<5X47QB6DA#JS+5
M'FU5XNB5-/!HB1NU%O;W$11.![JA2^%)=KV/!5:5;.4U4H-Q$@VQT![HW69_
MW$5$`OR4,+F+F$3O)\3GF'QO#K2(%D!![:."",L9[D&I*!0:O\R:;RTC\3)>
MU!_2M,']23BX1_5+-KX/9@M*&FC%J/P33M]@'N$V"M:H7/J2>G0>]4*A1(O7
MO$J3UBG_X=N9]C&!SP2^$KX4R7ANE&Q^%5Y4I<6)N$'$L]OL`]Q&D:!,7%*S
M>?I@U(7JN=KPHF3G*#1C,N5XA5D1+*A_V(+3:SJ_H/-_T[<+?9L=;J\<_D?_
MW2*PRP*[OXV8,<=KS'N7[&)/-=@N71U':AR-SUNZ5M?;><?3F;S!JW(0'?P0
MMI/&D1/Z<++I&%I$#\%$<7-+21_>SYHH:'T,/X?8YBN5$X_#\D#65UK]`5!+
M`P04````"`"\BVQ'=9BH.*$!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;(53VVZ<,!#]%<L?$+,L2:H5BY1-%24/E:(\M,]>&,"*[:&V6=*_
MKR]`=J.D?<$SPSEGSOA23FA>;0_@R)N2VNYI[]RP8\S6/2ANKW``[?^T:!1W
M/C4=LX,!WD22DBS/LANFN-"T*F/MV50ECDX*#<^&V%$I;OX<0.*TIQNZ%%Y$
MU[M08%7)5EXC%&@K4!,#[9[>;7:'(B`BX*>`R9[%)'@_(KZ&Y*G9TRQ8``FU
M"PK<+R>X!RF#D&_\>]9\;QF(Y_&B_A"G]>Z/W,(]RE^B<;TWFU'20,M'Z5YP
M>H1YA.L@6*.T\4OJT3I4"X42Q=_2*G1<I_G/[4S[G)#/A'PE?,NB\=0HVOS.
M':]*@Q.Q`P]GM]EYN`DB7IG8J&;2]-ZH]=53M<FW)3L%H1F3*(<+S(I@7OW3
M%CF]I.=G]/S_].U"WR:'VR\<?BE0+`)%$BC^-6+"'"XQQ8<F[&Q/%9@N7AU+
M:ARU2UNZ5M?;>9?',WF'5^7`._C!32>T)4=T_F3C,;2(#KR)[.J:DMZ_GS61
MT+H0WOK8I"N5$H?#\D#65UK]!5!+`P04````"`"\BVQ'3S6T1:$!``"Q`P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6R%4]MNHS`0_17+'U`3<FD5
M$:2FU6KW8:6J#[O/#@Q@U?:PM@G=OZ\O0).J:E_PS'#.F3.^%".:%]L!./*J
MI+8'VCG7[QFS50>*VQOL0?L_#1K%G4]-RVQO@->1I"3+LVS'%!>:ED6L/9FR
MP,%)H>')$#LHQ<W_(T@<#W1%Y\*S:#L7"JPLV,*KA0)M!6IBH#G0^]7^N`F(
M"/@C8+07,0G>3X@O(?E5'V@6+("$R@4%[I<S/("40<@W_C=IOK<,Q,MX5O\1
MI_7N3]S"`\J_HG:=-YM14D/#!^F><?P)TPC;(%BAM/%+JL$Z5#.%$L5?TRIT
M7,?ISVZB?4[()T*^$.ZR:#PUBC8?N>-E87`DMN?A[%9[#S=!Q"L3&]5,FMX;
MM;YZ+E?YMF#G(#1A$N5XA5D0S*M_VB*GU_3\@IY_3U_/]'5RN+YRN/M>8#,+
M;)+`YJL1$^9XC;G]T(1=[*D"T\:K8TF%@W9I2Y?J<COO\W@F[_"RZ'D+O[EI
MA;;DA,Z?;#R&!M&!-Y'=;"GI_/M9$@F-"^&MCTVZ4BEQV,\/9'FEY1M02P,$
M%`````@`O(ML1XNF(7R?`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3$N>&ULA5/;3N,P$/T5RQ^`T[1<MDHC41""AY40#^RSFTP2"]L3;*=A_QY?
MFM`B5%[BF<DY9\[X4HQHWFP'X,B'DMIN:.=<OV;,5ATH;B^P!^W_-&@4=SXU
M+;.]`5Y'DI(LS[(KIKC0M"QB[=F4!0Y."@W/AMA!*6[^;T'BN*$+.A5>1-NY
M4&!EP69>+11H*U`3`\V&WB[6VU5`1,"K@-$>Q21XWR&^A>2IWM`L6``)E0L*
MW"][N`,I@Y!O_'[0_&H9B,?QI/X0I_7N=]S"'<I_HG:=-YM14D/#!^E><'R$
MPPB70;!":>.75(-UJ"8*)8I_I%7HN(ZS&#M#R`^$?";<1`)+C:+->^YX61@<
MB>UY.+O%VL--$/'*Q$8UDZ;W1JVO[LM%?E.P?1`Z8!)E>X*9$<RK_]@BIZ?T
M_(B>_TY?3O1E<K@\<?CG=X'5)+!*`JMS(R;,]@2SS+XU84=[JL"T\>I84N&@
M7=K2N3K?SML\GLD7O"QZWL)?;EJA+=FA\R<;CZ%!=.!-9!>7E'3^_<R)A,:%
M\-K')EVIE#CLIP<RO]+R$U!+`P04````"`"\BVQ''5XGV*`!``"Q`P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R%4]MNG#`0_17+'Q`#NVFC%8N4
M314U#Y&B/+3/7AC`BNTAMEG2OX\O0':KI'W!,\,Y9\[X4DYH7FP/X,B;DMKN
M:>_<L&/,UCTH;J]P`.W_M&@4=SXU';.#`=Y$DI*LR+)O3'&A:57&VI.I2AR=
M%!J>#+&C4MS\.8#$:4]SNA2>1=>[4&!5R59>(Q1H*U`3`^V>WN:[PS8@(N"7
M@,F>Q21X/R*^A.2AV=,L6``)M0L*W"\GN`,I@Y!O_#IK?K0,Q/-X4;^/TWKW
M1V[A#N5OT;C>F\TH::#EHW3/./V$>83K(%BCM/%+ZM$Z5`N%$L7?TBIT7*?Y
M3S'3/B<4,Z%8"3=9-)X:19L_N.-5:7`B=N#A[/*=AYL@XI6)C6HF3>^-6E\]
M5?DF+]DI",V81#E<8%8$\^J?MBCH);TXHQ?_IV\6^B8YW'SA\$N![2*P30+;
M?XV8,(=+S-\NV=F>*C!=O#J6U#AJE[9TK:ZW\S8>(ON`5^7`.WCDIA/:DB,Z
M?[+Q&%I$!]Y$=G5-2>_?SYI(:%T(O_O8I"N5$H?#\D#65UJ]`U!+`P04````
M"`"\BVQ'^J!$WJ(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6R%4]MNG#`0_17+'Q"SP/:R8I&RJ:KVH5*4A_;9"P-8L3W4-DOZ]_4%R&X5
M-2]X9CCGS!E?JAG-LQT`''E14MLC'9P;#XS99@#%[1V.H/V?#HWBSJ>F9W8T
MP-M(4I+E6?:!*2XTK:M8>S1UA9.30L.C(792BIL_)Y`X'^F.KH4GT0\N%%A=
ML8W7"@7:"M3$0'>D][O#J0R("/@I8+97,0G>SXC/(?G>'FD6+("$Q@4%[I<+
M/("40<@W_KUHOK8,Q.MX5?\:I_7NS]S"`\I?HG6#-YM1TD+')^F></X&RPC[
M(-B@M/%+FLDZ5"N%$L5?TBIT7.?T)_^\T-XFY`LAWPB?LF@\-8HVOW#'Z\K@
M3.S(P]GM#AYN@HA7)C:JF32]-VI]]5+OBJ)BER"T8!+E=(/9$,RKO]DBI[?T
M_(J>OT\O5GJ1'!8W#LOW!<I5H$P"Y?]&3)C3+6;_3Q-VM:<*3!^OCB4-3MJE
M+=VJV^V\S^.9O,+K:N0]_."F%]J2,SI_LO$8.D0'WD1VMZ=D\.]G2R1T+H0?
M?6S2E4J)PW%](-LKK?\"4$L#!!0````(`+R+;$<BZIN8H0$``+$#```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;(53VVZ<,!#]%<L?$+,LN6C%(F53
M5<E#I2@/[;,7!K!B>ZAMEO3OXPN0W2II7_#,<,Z9,[Z4$YI7VP,X\J:DMGO:
M.S?L&+-U#XK;*QQ`^S\M&L6=3TW'[&"`-Y&D),NS[(8I+C2MREA[-E6)HY-"
MP[,A=E2*FS\'D#CMZ88NA1?1]2X46%6RE=<(!=H*U,1`NZ?WF]VA"(@(^"E@
MLF<Q"=Z/B*\A>6KV-`L60$+M@@+WRPD>0,H@Y!O_GC4_6@;B>;RH?X_3>O='
M;N$!Y2_1N-Z;S2AIH.6C="\X/<(\PG40K%':^"7U:!VJA4*)XF]I%3JN4_I3
MY#/M<T(^$_*5<)=%XZE1M/F-.UZ5!B=B!Q[.;K/S<!-$O#*Q4<VDZ;U1ZZNG
M:K.]*=DI",V81#E<8%8$\^J?MLCI)3T_H^?_IV\7^C8YW'[A\$N!8A$HDD#Q
MKQ$3YG")N?VK"3O;4P6FBU?'DAI'[=*6KM7U=M['0V0?\*H<>`<_N.F$MN2(
MSI]L/(86T8$WD5U=4]+[][,F$EH7PEL?FW2E4N)P6![(^DJK=U!+`P04````
M"`"\BVQ'1&\U(J`!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6R%4]M.XS`0_17+'X#3M%RV2B-1$(*'E1`/[+.;3!(+VQ-LIV'_'E^:T"(N
M+_',Y)PS9WPI1C0OM@-PY$U);3>T<ZY?,V:K#A2W9]B#]G\:-(H[GYJ6V=X`
MKR-)299GV0537&A:%K'V:,H"!R>%AD=#[*`4-_^W(''<T`6="D^B[5PHL+)@
M,Z\6"K05J(F!9D.O%^OM*B`BX%G`:(]B$KSO$%]"\E!O:!8L@(3*!07NESW<
M@)1!R#=^/6A^M`S$XWA2OXO3>O<[;N$&Y3]1N\Z;S2BIH>&#=$\XWL-AA/,@
M6*&T\4NJP3I4$X42Q=_2*G1<Q_0GGVA?$_(#(9\)5UDTGAI%F[?<\;(P.!+;
M\W!VB[6'FR#BE8F-:B9-[XU:7]V7B^55P?9!Z(!)E.T)9D8PK_YEBYR>TO,C
M>OX[?3G1E\GA\AN'WPJL)H%5$EC]-&+";$\Q?SXU84=[JL"T\>I84N&@7=K2
MN3K?SNL\GLD'O"QZWL)?;EJA+=FA\R<;CZ%!=.!-9&?GE'3^_<R)A,:%\-+'
M)EVIE#CLIP<RO]+R'5!+`P04````"`"\BVQ')2&,KJ`!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6R-4]MNG#`0_17+'Q"S+&FK%8N4314U
M#Y&B/+3/7AC`BNTAMEG2OZ\O0':C*.D+GAG..7/&EW)"\VQ[`$=>E=1V3WOG
MAAUCMNY!<7N%`VC_IT6CN/.IZ9@=#/`FDI1D>99]8XH+3:LRUAY-5>+HI-#P
M:(@=E>+F[P$D3GNZH4OA272]"P56E6SE-4*!M@(U,=#NZ<UF=R@"(@)^"YCL
M64R"]R/B<TCNFSW-@@604+N@P/UR@EN0,@CYQB^SYEO+0#R/%_6[.*UW?^06
M;E'^$8WKO=F,D@9:/DKWA-,OF$>X#H(U2AN_I!ZM0[50*%'\-:U"QW5*?_)L
MIGU,R&="OA)^1`)+C:+-G]SQJC0X$3OP<':;G8>;(.*5B8UJ)DWOC5I?/56;
M(BO9*0C-F$0Y7&!6!//J'[;(Z24]/Z/G7].W"WV;'&XO'/Y'_V(1*))`\=F(
M"7.XQ+QWR<[V5('IXM6QI,91N[2E:W6]G3=Y/),W>%4.O(,';CJA+3FB\R<;
MCZ%%=.!-9%?7E/3^_:R)A-:%\+N/3;I2*7$X+`]D?:75/U!+`P04````"`"\
MBVQ'3<0K]]P!``!%!0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R-
M5-N.FS`0_16+#UAS"0F-"-)FJZI]J+3:A_;9@>&BM3&UG;#]^_H26(R0TA=L
M#^<R(WLF'[EXERV`0A^,]O(4M$H-1XQEV0(C\HD/T.L_-1>,*'T4#9:#`%)9
M$J,X#L,]9J3K@R*WL5=1Y/RJ:-?#JT#RRA@1?\]`^7@*HF`*O'5-JTP`%SF>
M>57'H)<=[Y&`^A0\1\=S9A`6\*N#42[VR.1^X?S=''Y4IR`T*0"%4AD%HI<;
MO`"E1D@;_[EK?EH:XG(_J7^SU>KL+T3""Z>_NTJU.MDP0!74Y$K5&Q^_P[V$
MU`B6G$K[1>55*LXF2H`8^7!KU]MU='_2^$[;)L1W0CP3LM`F[HQLFE^)(D4N
M^(CD0,S=14<-%T9$*R-IU82K7B<J=?161+LDQS<C=,<XRMG#S`BLU3<MXL"G
MQPMZ_)B>3/3$99@LW:/LL<!N$M@Y@9U7XLXOT6'./B9];)*N3%)/8+]IXF,.
MCTWV*Y.])Y!MFOB8+X]-#BN3PU(@#3=-?,Q_O(EL99)Y`O&FB8])5B9X\<X9
MB,:VLT0EO_;*/?,Y.D^,9]M8^!->Y`-IX"<13==+=.%*=YMMC9IS!3J)\$E?
M6JMGVGR@4"NS/>B]<&WN#HH/T]":)V?Q#U!+`P04````"`"\BVQ'IK?*%Z4!
M``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-4]MNG#`0_17+
M'Q"S+)M$*Q8IFZAJ'RI%>6B?O3"`%9LAMEG2OZ\O0""*U+[@F>&<,V=\R4?4
MKZ8%L.1=R<Z<:&MM?V3,E"TH;FZPA\[]J5$K;EVJ&V9Z#;P*)"59FB2W3''1
MT2(/M6==Y#A8*3IXUL0,2G']YPP2QQ/=T;GP(IK6^@(K<K;P*J&@,P([HJ$^
MT8?=\9QY1`#\$C":54R\]POBJT]^5">:>`L@H;1>@;OE"H\@I1=RC=\FS8^6
MGKB.9_5O85KG_L(-/*+\+2K;.K,))174?)#V!<?O,(UP\((E2A.^I!R,1353
M*%'\/:ZB"^L8_]S=3[2O">E$2!?"?1*,QT;!YA.WO,@UCL3TW)_=[NC@VHLX
M96*"FH[3.Z/&5:_%[I#E[.J%)DRDG#>8!<&<^I<M4KJEIRMZ^F_Z?J;OH\/]
MNGOZ'_VS62"+`MEFQ,-VQ(@Y;S&WGYJPU9XJT$VX.H:4.'0V;NE276[G0QK.
MY`->Y#UOX"?7C>@,N:!U)QN.H4:TX$PD-P=*6O=^ED1";7UXYV(=KU1,+/;S
M`UE>:?$74$L#!!0````(`+R+;$?E/">QI0$``+$#```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;(53VVZ<,!#]%<L?$+,LFZ0K%BF;*FH?*D5Y:)^]
M,(`5FR&V6=*_KR]`H(J4%SPSG'/FC"_YB/K5M`"6O"O9F1-MK>V/C)FR!<7-
M#?;0N3\U:L6M2W7#3*^!5X&D)$N3Y)8I+CI:Y*'VK(L<!RM%!\^:F$$IKO^>
M0>)XHCLZ%UY$TUI?8$7.%EXE%'1&8$<TU"?ZL#N>,X\(@-\"1K.*B?=^07SU
MR<_J1!-O`224UBMPMUSA$:3T0J[QVZ3YT=(3U_&L_A2F=>XOW,`CRC^BLJTS
MFU!20<T':5]P_`'3"`<O6*(TX4O*P5A4,X42Q=_C*KJPCO%/=CO1/B>D$R%=
M"/=),!X;!9O?N>5%KG$DIN?^['9'!]=>Q"D3$]1TG-X9-:YZ+7:'NYQ=O="$
MB93S!K,@F%/_M$5*M_1T14^_IN]G^CXZW*^[I_NO!;)9((L"V6;$^^V($7/>
M8K[]UX2M]E2!;L+5,:3$H;-Q2Y?J<CL?TG`F'_`B[WD#O[AN1&?(!:T[V7`,
M-:(%9R*Y.5#2NO>S)!)JZ\,[%^MXI6)BL9\?R/)*BW]02P,$%`````@`O(ML
M1Z5.+1BD`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULA5/;
M;IPP$/T5RQ\0`TNVT8I%RJ:JVH=*41[:9R\,8,5FJ&V6]._K"Q"H(N4%SPSG
MG#GC2S&A?C4=@"5O2O;F3#MKAQ-CINI`<7.'`_3N3X-:<>M2W3(S:.!U("G)
MLB0Y,L5%3\LBU)YU6>!HI>CA61,S*L7UWPM(G,XTI4OA1;2=]056%FSEU4)!
M;P3V1$-SIH_IZ9)[1`#\$C"934R\]ROBJT]^U&>:>`L@H;)>@;OE!D\@I1=R
MC?_,FN\M/7$;+^K?PK3._94;>$+Y6]2V<V832FIH^"CM"T[?81[AW@M6*$WX
MDFHT%M5"H43QM[B*/JQ3_),_S+2/"=E,R%;"0Q*,QT;!YE=N>5EHG(@9N#^[
M].3@VHLX96*"FH[3.Z/&56]E>DP*=O-",R92+CO,BF!._<,6&=W3LPT]^YQ^
M6.B'Z/"P[9X=/Q?(%X$\"N2[$=/]B!%SV6/^=\DV>ZI`M^'J&%+AV-NXI6MU
MO9V/63B3=WA9#+R%GURWHC?DBM:=;#B&!M&",Y'<W5/2N?>S)A(:Z\,O+M;Q
M2L7$XK`\D/65EO\`4$L#!!0````(`+R+;$<_;-SYL`$``!8$```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;(54V6ZC,!3]%<L?4!.R32."U'14=1Y&
MJOHP?7;@`E:],+8)[=_7"U"H(N4%V]=GN[)-UBO];AH`BSX$E^:(&VO;`R&F
M:$!0<Z=:D&ZG4EI0ZY:Z)J;50,M`$IRD2;(C@C*)\RS47G2>J<YR)N%%(],)
M0?7G";CJCWB%Q\(KJQOK"R3/R,0KF0!IF))(0W7$#ZO#:>L1`?"/06]F<^2S
MGY5Z]XL_Y1$G/@)P**Q7H&ZXP"-P[H6<\?]!\]O2$^?S4?TI=.O2GZF!1\7?
M6&D;%S;!J(2*=MR^JOX9AA9"PD)Q$[ZHZ(Q58J1@).A'')D,8Q]W]NE`NTY(
M!T(Z$7XE(7@T"C%_4TOS3*L>F9;ZLUL='%Q[$:>,3%#3L7L7U+CJ)5_MUAFY
M>*$!$RFG!69"$*=^U2+%2WHZHZ>WZ>N1OHX)UW/W]/ZVP&84V$2!S:+%S;+%
MB#DM,=O;)ML?)MN%P.ZJR1*S_V%"9@<G0-?A?AI4J$[:>&Y3=7H"#^&FD&]X
MGK6TAK]4UTP:=%;679]PUI52%ER(Y,ZE:-PCG18<*NNG>S?7\=[&A57M^`JG
M7T'^!5!+`P04````"`"\BVQ'WK!M8J0!``"Q`P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6R-4\E.Y#`0_17+'X#3Z6:95CH2#4)P&`EQF#F[D\HB
M;%>PG0[S]^,E"0E"@DM<57GOU2LOV8#ZU30`EKQ+H<R!-M9V>\9,T8#DY@([
M4.Y/A5IRZU)=,]-IX&4@2<'2)+EBDK>*YEFH/>L\P]Z*5L&S)J:7DNM_1Q`X
M'.B&3H67MFZL+[`\8S.O;"4HTZ(B&JH#O=WLCSN/"(`_+0QF$1/O_83XZI.G
M\D`3;P$$%-8K<+><X0Z$\$*N\=NH^='2$Y?QI/X0IG7N3]S`'8J_;6D;9S:A
MI(2*]\*^X/`(XPB77K!`8<*7%+VQ*"<*)9*_Q[5581WBGYMDI'U-2$="^HG`
M8J-@\YY;GF<:!V(Z[L]NLW=P[46<,C%!3<?IG5'CJN=\<W63L;,7&C&1<EQA
M9@1SZE^V2.F:GB[HZ??T[43?1H?;9??M#_KO)H%=%-BM1ORU'C%BCBO,=?*I
M"5OLJ01=AZMC2(&]LG%+Y^I\.V_3<"8?\#SK>`V_N:Y;9<@)K3O9<`P5H@5G
M(KFXI*1Q[V=.!%36A]<NUO%*Q<1B-SV0^97F_P%02P,$%`````@`O(ML1WG&
M5A:D`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULA5/);J0P
M$/T5RQ\0LW42M6BD=$:CF<-(40[)V0T%6/'"V*;)_'V\`(%1I%QP5?'>JU=>
MRDGI-],#6/0NN#0GW%L['`DQ=0^"FALU@'1_6J4%M2[5'3&#!MH$DN`D2Y);
M(BB3N"I#[4E7I1HM9Q*>-#*C$%3_.P-7TPFG>"D\LZZWOD"JDJR\A@F0ABF)
M-+0G_)`>SX5'!,`+@\EL8N2]7Y1Z\\GOYH03;P$XU-8K4+=<X1$X]T*N\=]9
M\[.E)V[C1?UGF-:YOU`#CXJ_LL;VSFR"40,M';E]5M,OF$<X>,%:<1.^J!Z-
M56*A8"3H>UR9#.L4_QR*F?8U(9L)V4JX3X+QV"C8_$$MK4JM)F0&ZL\N/3JX
M]B).&9F@IN/TSJAQU6N5WJ4EN7JA&1,IYQUF11"G_F6+#._IV8:>?4_/%WH>
M'>;;[OGM]P+%(E!$@6(W8K8?,6+.>TS^7Q.RV5,!N@M7QZ!:C=+&+5VKZ^U\
MR,*9?,*K<J`=_*&Z8]*@B[+N9,,QM$I9<":2FP-&O7L_:\*AM3Z\<[&.5RHF
M5@W+`UE?:?4!4$L#!!0````(`+R+;$?M5+WXL0$``!8$```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;(54VVZC,!#]%<L?4!-"FBHB2$U7J]V'E:H^
MM,\.#&#5%]8VH?W[^@(4JDAYP9[Q.6?.:&SR0>EWTP)8]"&X-$?<6ML="#%E
M"X*:.]6!=">UTH):%^J&F$X#K0))<)(FR3T1E$E<Y"'WK(M<]98S"<\:F5X(
MJC]/P-5PQ!L\)5Y8TUJ?($5.9E[%!$C#E$0:ZB-^W!Q..X\(@%<&@UGLD?=^
M5NK=!W^K(TZ\!>!06J]`W7*!)^#<"[G"_T?-[Y*>N-Q/ZK]#M\[]F1IX4OR-
M5;9U9A.,*JAIS^V+&O[`V$)P6"INPA>5O;%*3!2,!/V(*Y-A'>))MA]IUPGI
M2$AGPD,2C,="P>8O:FF1:S4@TU$_N\W!P;47<<K(!#4=NW=&C<M>BLT^R\G%
M"XV82#FM,#."./6K)5*\IJ<+>GJ;OIWHV^APNZR^?;@MD$T"613(5BWNUBU&
MS&F-N;]=9/>CR&XEL+]:9(WYV0E9#$Z`;L+]-*A4O;1Q;G-V?@*/:1C\-[S(
M.]K`/ZH;)@TZ*^NN3YAUK90%9R*Y<RY:]TCG@$-M_7;O]CK>VQA8U4VO</X5
M%%]02P,$%`````@`O(ML1^IWT<&C`0``L0,``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C4N>&ULC5/;;IPP$/T5RQ\0LRQITA6+E$U5M0^5HCRTSUX8P(KM
MH;99TK^O+T#8*%+[@F>&<\Z<\:6<T+S8'L"15R6U/=+>N>'`F*U[4-S>X`#:
M_VG1*.Y\:CIF!P.\B20E69YEGYCB0M.JC+4G4Y4X.BDT/!EB1Z6X^7,"B=.1
M[NA2>!9=[T*!525;>8U0H*U`30RT1_JP.YR*@(B`GP(FNXE)\'Y&?`G)]^9(
MLV`!)-0N*'"_7.`1I`Q"OO'O6?.M92!NXT7]:YS6NS]S"X\H?XG&]=YL1DD#
M+1^E>\;I&\PCW`;!&J6-7U*/UJ%:*)0H_II6H>,ZI3_WV4S[F)#/A/P=@:5&
MT>87[GA5&IR('7@XN]W!PTT0\<K$1C63IO=&K:]>JMW=YY)=@M",2933%69%
M,*_^88N<7M/S#3W_-WV_T/?)X7[;O?B/_L4B4"2!8BMPGUV/F#"G:\S[)FRS
MIPI,%Z^.)36.VJ4M7:OK[7S(XYF\P:MRX!W\X*83VI(S.G^R\1A:1`?>1'9S
M2TGOW\^:2&A=".]\;-*52HG#87D@ZRNM_@)02P,$%`````@`O(ML1P&%7;?1
M`@``#PP``!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULE5?!<ML@%/P5
MC>Z-!`(A96S/U$XZ[:$SF1S:,[&QK8DD7('C].\+0G:`XECRP1)H]^U[3RS&
MLQ/O7L6>,1F]-W4KYO%>RL-]DHCUGC54W/$#:]63+>\:*M6PVR7BT#&ZZ4E-
MG<`TS9.&5FV\F/5S3]UBQH^RKEKVU$7BV#2T^[MD-3_-8Q"?)YZKW5[JB60Q
M2RZ\3=6P5E2\C3JVG<=?P?TC1!K2(WY5["2L^T@G_\+YJQ[\V,SC5.?`:K:6
M.@15ES>V8G6M(RGE/T/0#TU-M._/T;_UY:KT7ZA@*U[_KC9RK[)-XVC#MO18
MRV=^^LZ&&K`.N.:UZ+^C]5%(WIPI<=30=W.MVOYZ,D^*=*"%"7`@P`LA^YR0
M#83L@T`^):"!@"X$^#D!#P3\03"]-+7WG7N@DBYF'3]%XD#U>@+W"M[I("IR
M)/IHG7DAJG="S;XM0`%GR9L.-&!@CUFZF"R$6;D8%,(\N!@<PCRZF/R"250M
MP8+@N2!D"H).`.**&,J#P;0&<ULB\R0R1Z((2F26!+PM@3P)Y$B400DTK0I\
MELB,!+8ERO1V@-S+,7<"@%".R]S*L4QAB5%Y6XAX0L01@L%F$+O?".<C5D[A
MR12.C+?,B9$I+)DO98%2%((].C""LV)$>TLOG7+J^P&I]X;U/CDQ!/"2`(X?
M2Q3J_6H`F7(QP:GZC-#RG0L<ZY8XU-DE<+P+0YC5-<SU5'R'`\?B91Z6L3V>
M`S*J:-_HP'%Z2<)*MM5)-DH(^T+XMEU7`VBB7X&_,P!W:RA&A"#^VB63UZ[O
M9U#<WC>6H+BZ<3B-N0Z[GI#O:.!:>D1GH6]I.-G2T+<T'&-I:%MZK*/A?[_%
MMJ/AJ!"97W`VN6#?8A`Y6817/K0ME@&<%_ZJ3:R#U8'NV$_:[:I61"]<JC-:
M?Z#:<BZ9BI;>J:A[=3J_#&JVE?J6:#ES7C4#R0_GX_?E/\#B'U!+`P04````
M"`"\BVQ'T9R\=\H!``"O!```&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6R%5-MNHS`0_16+#XC!0*@B@M0F6K4/*U5]V'UVPA!0;<S:3NC^_?H"+$2H
M><&>\3EGSEB#\U[(3U4#:/3%6:OV0:UUM\-8G6O@5&U$!ZTYJ83D5)M07K#J
M)-#2D3C#)`RWF-.F#8K<Y=YED8NK9DT+[Q*I*^=4_GT!)OI]$`5CXJ.YU-HF
M<)'CB5<V'%K5B!9)J/;!<[0[IA;A`+\:Z-5LCZSWDQ"?-G@K]T%H+0"#L[8*
MU"PW.`!C5L@4_C-H_B]IB?/]J/[#=6O<GZB"@V"_FU+7QFP8H!(J>F7Z0_2O
M,+3@')X%4^Z+SE>E!1\I`>+TRZ]-Z];>GVRS@;9.(`.!3(0H^980#X1X(I#H
M6T(R$)([`O:MN(LX4DV+7(H>J8[:Z8AV!BZMB%%&RJE)?[_F*I3)W@H2DAS?
MK-"`(0[SLL3$:YC#$I.L88YS3/2TG3#8^%PU2T:SL3=+%D72QP+Q*.##YW@A
ML%VZM%-BV_6@UH'"39AE3R1Z7"JY\YK,FTW#QP+IG==TX35;>LW\K:=SJVN(
MXSK"F\"S4>GH!7Y2>6E:A4Y"FZES(U()H<'HA!LC5)O78PH85-IN,[.7_H?R
M@1;=^#Q,;U3Q#U!+`P04````"`"\BVQ''28<#5<"``!0"0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6R=5MN.FS`4_!7$!RP<KB$B2+M45?M0:;4/
M[;.3.`$M8&H[8?OWM3&DV&)#Z`M@,V?.C&$P:4?H.RLPYM9'735L9Q><MUO'
M88<"UX@]D18WXLZ)T!IQ,:1GA[44HV-?5%>.Y[J14Z.RL;.TGWNE64HNO"H;
M_$HM=JEK1/^\X(IT.QOL<>*M/!=<3CA9ZMSJCF6-&U:2QJ+XM+.?89M#(B$]
MXF>).S:YMJ3X/2'O<O#]N+-=J0%7^,`E!1*G*\YQ54DFT?GW0/JOIRR<7H_L
M7WN[0OX>,9R3ZE=YY(50Z]K6$9_0I>)OI/N&!P^A)#R0BO5'ZW!AG-1CB6W5
MZ$.=RZ8_=^I.-);-%WA#@7<K@.!N@3\4^$:!HY3UOKX@CK*4DLYB+9)/&[8"
M3B6)8+98ST;5<@EG3,Q>,\_=I,Y5$@T8K\>\:)@Y1*XAPAO$$0)F57BC"C5\
M]C05R3*!/Q($BL"?$H"KBXR5#85I>HR[W"(P6@1:"U@F"`V3H4;@+1-$AH)(
M(_!UDZ$R&4U,QB*RX=Q2Y%,4^*$;+8N)#3&Q)B:8%1/?%Z-0>;Q>S,98VLW:
M]R<QW"2:FWF=R53G)"J?-@'7Z"(_*Y,V#Q@%,)P"K+4*GJG"NQ>6P>P`6N/6
MS"3HH8P?H`A,M\':S$!HJ@@?2,T`6GI3-=B#KRJ8*8;H7G*&;Q4LY'@4]!]!
M!C/)H$?YD4=MY@]6!Q#,!$*R_`G/X7X&G<G>UZ(S_H'HN6R8M2=<;*/]GG<B
MA&-!Y3Z))2S$[\UM4.$3EY>Q7%NUX:L!)^WX_W+[B<K^`E!+`P04````"`"\
MBVQ'`N:F:_8!``#6!0``&0```'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R%
ME-^.G"`8Q5_%^`"+XK\Z<4QV;9KVHLEF+]IK9L31+(@%9MR^?4'4@K'U9A`\
MYWR_CQ&*D?%WT6(LO0]*>G'V6RF'$P#BVF**Q!,;<*_>-(Q3)-64WX`8.$;U
M9*($P"!(`45=[Y?%M/;*RX+=)>EZ_,H]<:<4\=\OF+#Q[(?^LO#6W5JI%T!9
M@-57=Q3WHF.]QW%S]I_#4Y5IQ23XT>%16,^>9K\P]JXGW^JS'V@$3/!5Z@2D
MA@>N,"$Z2!7^-6?^+:F-]O.2_F7J5M%?D,`5(S^[6K8*-O"]&C?H3N0;&[_B
MN85$!UX9$=.O=[T+R>AB\3V*/LS8]=,XFC<)G&W[!C@;X&H(X_\:HMD0;0S`
MD$U]?482E05GHR<&I/_L\*3D7(>H9$],:=QLE^I,J-5'"<.\``\=-&O@I'EQ
M-'N*RE$DJP0H@%T*N%"8Z3.T_"&,C@.B)2`V`9$-``,7,C-M&$V_%,GV1)4M
MRO+TF"3>D,0.2>@620Q);!7Y%`1[FLK6A&&0'Y,D&Y+$(8&[)(E=)<EW21)G
M2\)CD'0#DCH@T2Y(:A6!\>ZV5;8FSXXYL@U'YG#$NQ])YG#\XR-Q1%F^_5Z!
M=00'=,/?$;]UO?`N3*K3/!V]AC&)553PI'IKU26[3@ANI'[,=-/FWC$3R8;E
M%EVO\O(/4$L#!!0````(`+R+;$<5C>*ZU@,``$`5```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;)V8VVZ;0!"&7P7Y`0*[.\LA<BPUAZJ]J%3UHKTF
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M?+)E.WX&3R]M9ZN3R2JH\M_3=U&/W\?IGR1R9LL&TAG(LX&`=PV4,U!<`W`&
MP#70SD`3@W"J?>S<?=[EFW5CCT%[R(=Y$M>]O!F<])Z#=O363!>D[UW;GWW=
M2*G7X>O@R&GDJ+G%FGA)<X<UR9+F'FF6%`]S12+.DK`O9+$:>:I&3=5(E$5Z
MV8$Z.8#)@4(.,IQD,I4Q:>I1HZ,H6A(]O"EZ,Q4@M<`\%<5PH$DM>N9`9*3A
MD\F]GJ4I0<?QY3`Q"1.C/`4.DTUAXED8(:\$7`Z3D#`)"B,O.TA)/U/?V<A(
M!MGEV;C-O"^[B$B8876;5:H8+@0I50C?6H6D62"4%"Q-SZT3>95+B1,,Y.Z$
M/TX":"`,E&:XT+2OVKNOE!81<_HZYZ7?V5GU4F`$)H9!MJ#("&]F!(5&(&I4
MLKBBBCDV@E>OI-S(Z+W..CZ=R'66-TE2T$@(+Y4NKJQ.-$7B=%]2!"5&D)`!
M+@P2`:<<2J!$!()8CH-%C/574@`E`A#4<APL8FP4DE(J$:6<G5-22B6B%/3R
M%9Y3RHE""96(4(@7V7"BV<1R0J4T%"(9DN7>8Q$#=TEQEPAWR"Z[4!&Y?"KR
M7704!50)QD1CD69T55%"%8)/,VY8E:+5*N]J*5<*.-4BD6;PJ^C]I$)<:<:-
MB8IIM;$OFHI"HQ`T&I:KQ2+&7J\H,0K!H!D+N,IHM9EOM4`W-4`PZ.7M$^:;
MFF`]:U!B`,.0+L<1WG$H,8")8:P/0(D!Y=U52@S,87CKT<B)7+4Z23F;$5!H
M`&]&!$XA7*SY<UATE>F(01?070L073&G,PEM;N+=7`H.I)R13;U'B6XUD'%&
M-O.-HRF"&B$8,Q9Y39_'M/#MJJ;@:,D862W_8V0UO1_4BC.R6ET:V7#V)NJ0
M/YLO>?-<U&WP:+O.5N,;J)VUG>F]15=]+GN3;\\'I=EUP\]D2')ZP3<==/9P
M>E]Y?FFZ^0M02P,$%`````@`O(ML1X2.!EZS`@``N0H``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULE99=;YLP%$#_"N)]!8.!)")(2="T/4RJ^K`]
M.XF3H`+.;*?I_OW\`<1F[J!]*-@Y]]YC)^";WPE]91>,N??>U"U;^Q?.KZL@
M8(<+;A![(E?<BD].A#:(BR$]!^Q*,3JJH*8.HC!,@P95K5_D:NZ9%CFY\;IJ
M\3/UV*UI$/VSQ36YKWW@]Q,OU?G"Y410Y,$0=ZP:W+**M![%I[6_`:L20(DH
MXF>%[\RX]Z3\GI!7.?A^7/NA=,`U/G"9`HG+&][ANI:91.7?7=)'31EHWO?9
MOZKE"OT]8GA'ZE_5D5^$;>A[1WQ"MYJ_D/LWW*TAD0D/I&;JOW>X,4Z:/L3W
M&O2NKU6KKG?]21)W8>Z`J`N(AH"ACCL@[@+BN0&P"X"/`+77@5Z*VH@2<53D
ME-P]=D7RYP%6`J<RB<CL,96-ZOT56\'$[%L1I5$>O,E$'1,I9FLR6>A"=B8"
M!B(0`DZ+R+<K1*:%L\`D45I$,NT0]PZQWHG8VHEX.@$<ME(;;*#*T.H,(4AL
MS4POU806,70QNQE,:3(0I-.Z2:^;:-O$MDWM*AK:FE`L_ES0;@Y4FA!(TVQ:
M.!T)I[9PYA1.YPC/@<KTT\+92#BSA1=.80M*PM`I/`<J30@(:EIXT0OKX69A
M/@(1=/HNS"IA^('P+*HTJ<2$/C1>CHR7UD/K-EX:5;Y$J5MX#E3:4!)-^X)P
M)"R/(L,X<1IW4%<H!DO@=)Z'E2,L7,[0!F-M^YQPORPZ2!=*$[AT6_^?ZEYO
M%@5A/$<Z&DM;1T(\XQT)QH<"^/2I`.#8`IK'IW.U6V"^S>/QT]*="A:4_?.T
M!,;!WV!Z5AT4\P[DUG)][@^S0Y>VB53C\,"+_(K.^`>BYZIEWIYPT7ZH7N%$
M",?"(GP27^-%])'#H,8G+F\S^?WJSDH/.+GVC>+0K19_`5!+`P04````"`"\
MBVQ'JVS7[>\#``!"$P``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R5
M6-MRXC@0_167WR?6Q5>*4#60A-V'J9J:AYEG!P2XQK986X39OU_?<-2]LA$O
M`2NGNT]+.@=9RZNL?M<G(93SI\C+^MD]*75>>%Z].XDBK9_D693-?PZR*E+5
M/%9'KSY7(MUW047N,4)"KTBSTETMN['OU6HI+RK/2O&]<NI+4:35OVN1R^NS
M2]W;P(_L>%+M@+=:>F/</BM$66>R="IQ>':_TL661RVD0_S,Q+76OCLM^7<I
M?[</?^^?7=)R$+G8J39%VGQ\B(W(\S934_F?(>EGS390_W[+_M:UV]!_3VNQ
MD?FO;*].#5OB.GMQ2"^Y^B&O?XFAAZ!-N)-YW?UU=I=:R>(6XCI%^J?_S,KN
M\]K_)XR&,',`&P+8&!"3V0`^!/`QP)_%^P/>'_%C(^:`8`@(Q@`V'Q`.`>%G
MA7E*T1`0H0"OG]QN:5Y2E:Z6E;PZ]3EM-RQ=-/"J3=)D=NHN6]6O>+,X=3/Z
ML6)AM/0^VD0#AG68-<3$)LR+CJ$FQ"O,DHP8KV%II,I<2(/I"2)BI`$P1AH`
M$9@@;P#"0A-F"S'1_6[XK1N_GWBN3UB"N`9]-SVF[(OX01C>+^.C,K[.DZ.5
M2?HROE:&LB?JWR\3H#*!5L9'S?01+X%6A=RO$-XJ\+Y""%:?WD\0(8H12&">
M\.CQ"8]1F1CL+WX_08(2)""!#WGVF!>(">X7H01-9VO2VG18\*04$:5`T9&1
MZ1J!`A-H@T"A"?2*0!:2HPPSAA82FQE#4&)FS&P83V6:9HQ=@NHVP6)B9@Q!
MU,R8VS"&F9@%8VPX%#A.S,V,(<BX=380-,489K*1`O8N&H`4%IJGV)SHP^Y$
ML3U1X$]Q9/+0-=4-BI+8:+23H&DRV,0H<+$X-IKE`+K5L1$D]CH*C"Q.S'42
MK<X7FX,#0648,+N$&,L,H*$,(Q;[@&%+9,"C$FHN1(V_A-H2O@*(U1(R['4,
M'G1LNN%H5S/^Z*YFV`V8;S,AX`!"+`X'#&N8`0V'-BFPAMG#&F98PRR:ZW:0
M)XL>[A;+D^GRM/GY9PEN-GFT68Y%Q8&HB'EIN2XJ3H,PMMC+',N*0UE9_"QQ
M+`>NRV'BO/TV@(QL-=QV#C=-Z7]O`$!>^&Q.Z<!)?PD@3TE`N!&XG0-.D_+1
MQN#^PQL#:Y$#+9I/VF\\L)SJ&=PTI5[;'9EPC)\/P5KF\'W!>/I80U"")]S3
MWL4+41V[:Y;:V<E+J?IWJ'%TO,KYRMIW>32^IHL--8VSQ<:$;]I>;)O6#1$\
MNMT6>9^45LMS>A3?TNJ8E;7S+I6217=%<)!2B:93\M2LPTFD^_$A%P?5?HW:
MA>JO>/H')<^W&ZOQVFSU'U!+`P04````"`"\BVQ''_(*<Y$"``"/"0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R55LF.FS`8?A7$`PR8-40$*7M[
MJ#2:0WMV$B>@`4QM)TS?OEX(P<@TZ27`GV_[;8.=MIA\TAPA9GU594T7=LY8
M,W<<>LQ1!>D;;E#-_SEC4D'&'\G%H0U!\"1)5>EXKALY%2QJ.TME[9UD*;ZR
MLJC1.['HM:H@^;-")6X7-K#OA8_BDC-1<++4Z7FGHD(U+7!M$71>V$LPWP,)
MD8B?!6KIX-X2X0\8?XJ'[Z>%[8H,J$1')B0@O]S0&I6E4.+.OSO1AZ<@#N_O
MZCO9+H]_@!2M<?FK.+&<IW5MZX3.\%JR#]Q^0UT/H1`\XI+*7^MXI0Q7=XIM
M5?!+78M:7EOUS\SM:&:"UQ&\GM#[F`E^1_`?A."?A*`C!*\ZA!TA?-4AZ@C1
MJPYQ1XA'#HX:73DW&\A@EA+<6K2!8L6".8<3(<*5+2K5B)IR/CN45V^9EP2I
M<Q-"'<:3F)6."4V8S1`3NR;(;@@!/<+A(8U)/5M/X6DI(I/%6L?$QJ0:QH38
M#A$Q,/;R5&0_(3+9KG]OUU<3XVNMS)X+!'>!0`D$FD"BAU28]1#CN^YSDW!D
M$FH"P&2R"O_7)!J91)K`:+@59:,PM>K6=4V8[0N8W1`3F3'[(29\I:%X-+>Q
MUI#_7&#6O[5J=2UG6BM@]$Z&:DPTD&_$[*8PDU$26Q-8)GJ2R)AD"$K\V)AD
M"C.9!+BC*&+G&68Q^FPT5!"9PTR"IM.`T:H%VF?3"XS+M@,I'Q#YB7%13J-4
M'&?PS:\0N<C]G%I'?*V9^C#TU?[,L/3$GC&JK\!\#0SU#9AO3?6=.'O(O>=A
MFZ4-O*`?D%R*FEH'S/@.)K>;,\8,\7;<-S[(.3\=]0\E.C-Q&XO15^<%]<!P
M<S_^]&>P["]02P,$%`````@`O(ML1R8*+O2]`@``,`L``!D```!X;"]W;W)K
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MOH:$04W?^VO9=-=+_R1+AC!_0#P$Q+<`C#X-P$,`_@C(/@U(AH!DJ@(9`LA4
MA70(2!V%J$]6E^HUE70Y;_DE$">J-R`\*'BK211S(#JVMG^#*ME"S;XM,4KF
MT9LF&C!QAWDT,9!C'V9E\Q`?9CV!Y\GF27V8C8W);IA(K=>[Z/BZ:-PO.K8(
M\G$"?"5(>@)LKJ0`VR7IL]9CF@Y3H+@@23$NE#A"B>6T\`D])8800=W/A]N8
M.#1NA3A6B&D%'(F\MT),B1E"X$-M[J/NFDD=,ZEEQI')>C.I(0,QQA-D,D<F
MLV1B;_HS;UK-Q/L1=TWDCHG<,H&])O)1$W[$71.%8Z*P3"1>$X69\'$)0(Z&
M_A`8937!)8!3V0!?+6V(71?Q>'&O!]`7JQO</@)V(R&^??P(V-K(/LSZ'N:^
M%;?3@-EJ")G`0-S<DR_GWBUK2,?[W0K,PB8IBE,R::^XQ0W99\D'&-2LZIT5
M!.$)6FX-0S[>L%:0VQT+35F56ZA0C/>L%5BEJKZS<9&ZKSPR#A(G>F`_:7LH
M&Q&\<*G.)-T!8L^Y9(H/S13O41U?;X.*[:6^S;1@?Z#K!Y*?KN?3VR%Y^1]0
M2P,$%`````@`O(ML1\\-WQ1T`@``GPD``!D```!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&ULE5;+CILP%/T5Q`<,^,4C(D@S5%6[J#2:1;MV$B>@`4RQ$Z9_
M7QM(QEC1Q&SP@W///>?"!6<#[]]%R9CT/IJZ%5N_E++;!('8EZRAXHEWK%5W
MCKQOJ%3+_A2(KF?T,`8U=0##,`H:6K5^GHU[KWV>\;.LJY:]]IXX-PWM_[VP
MF@];'_C7C;?J5$J]$>19<(L[5`UK1<5;KV?'K?\,-@4<(2/B=\4&8<P]+7['
M^;M>_#QL_5!K8#7;2TU!U7!A!:MKS:0R_YU)/W/J0'-^9?\^VE7R=U2P@M=_
MJH,LE=K0]P[L2,^U?./##S9[()IPSVLQ7KW]64C>7$-\KZ$?TUBUXSA,=R(P
MA]T/@',`O`4`_&4`F@.0%1!,RD9?WZBD>=;SP1,=U4\;;!2\UR2*V1,C6S^5
M2SD3:O>2(T"RX**)9@P<,2\F!MY#%`O$)TF@!-Q5`:\JIN4S7*B('A.@*P&>
M"-""(%Z*)).-"=-.(A.`8R.1@2M,7(HQP00\%H0M0=@01-#C>&)5A*RM2&0)
MB!Y7I(@,IP21*$T=$L56HMATZO#L$\MILM9I:@E('9RFYK./"$E3^#@1"*U,
M^K-@I$H<*(#E%H"U=@&T54`'PS-H<@P@3!S>06!W%5BV5>I`@6V_>+5?8JL@
M#LT]@^9W.<4AN5\6$X9P@EP\V:T%%KT%0P>*V"Y+O+HLB:TB<2E+8K[X)(8I
M2>\7Q@0"E!"$';YZP.Y%L&A&Z$`!0ZLT,%Q;&@@L%1`XE&8&S8X3B(C]20B,
M7VE'3^P7[4]5*[P=E^JO//Y"CYQ+IMC")\5:JM/2;5&SH]336*>;S@_30O+N
M>ARZG<GR_U!+`P04````"`"\BVQ':3#&$'P"```*"0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6R55MN.FS`0_17$!RS8F%M$D))45?M0:;4/[;.3
M.`E:P*GMA.W?US:7&`LISDO`YLPY9\89AJ*C[)-?"!'>5U.W?.U?A+BN@H`?
M+J3!_(U>22N?G"AKL)!+=@[XE1%\U$%-'<`P3((&5ZU?%GKOG94%O8FZ:LD[
M\_BM:3#[MR4U[=8^\,>-C^I\$6HC*(M@BCM6#6EY15N/D=/:WX#5#F0*HA&_
M*])QX]Y3YO>4?JK%S^/:#Y4'4I.#4!187NYD1^I:,4GEOP/I0U,%FO<C^W>=
MKK2_QYSL:/VG.HJ+=!OZWI&<\*T6'[3[088<8D5XH#77O][AQ@5MQA#?:_!7
M?ZU:?>WZ)VDZA"T'P"$`3@&3SG)`-`1$CP"D,^V=Z;R^88'+@M'.XU>L3ANL
M))PI$LGL<<W&^G+)S+C<O9<1A$5P5T0#!FK,UL2`"1%(]D4)Z,_#H1&^*+";
M(>+G"M&HT"\WT2R)Z#D!&@E03X!,`I#.3<9]&CVF[4UF`*4@6<+M3%R.4(QB
MAYK%EJ%XEA%Z3I!8)4E>+4EJ.4AG!/%B25(C51`F&<S2YT*9)90YU#XSA:12
MDCG\2W)+*)]EM'AXV]P0RI(P1]ES'1!:0NKM82@YU`0`Z_@`>/7\`+1=0(<3
M'$!#96&>1I'#GPU$MM:\`[.Y%AJTYJ#<0<?N4S!KU"ATH(CMRL8O5S:Q720N
ME4W,]T6<(^B@9#<A2!V:`\S:$"4)3%W.T.Y#D#GT!S`[T2Y_8(R>AK"S'LG<
M.]!;*_K),^U.8W\#]>AZP,OBBL_D%V;GJN7>G@HY`/6T.E$JB/00ODDO%_EA
M,BUJ<A+J-E4F^U'=+P2]CE\>T^=/^1]02P,$%`````@`O(ML1QD_,1(,!```
M(Q,``!D```!X;"]W;W)K<VAE971S+W-H965T,S<N>&ULG5C+DJ)(%/T5POT(
M>?,!&)81K9;1LYB(CE[,K"E-']%`VH!ES]\/+ZV\MQ.EIA8EI.>><_+!(<WY
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M`/H"N!?<==P%O"_@'P7B88'H"\2]`-3#`MD7R+$*JB]0'PIM@=\-5CO4ZZ1*
M%O/"7+WRG#0+D,UJ>-&0U,Q>V;(5W0S6@UW6K>\+SMG<?V^(>@RTF*6-"0,7
M9&U#G"0;&P$JOF/\VJ33*4RP"[`)7!(K&Q$Z7:R?DKP^)]D@$OF\)_S6$]Z-
M.4=C#L\)Q(U`=`0"$7!L4G8][3!Y-R,`BHG@N9`D0A()":>0M(2D#,(X?*ZC
MB(Y".M*IHRR=/T`&8L3(AT0G1#K*J1/:.CR.(O9<)R(Z$=()73K+R)Z@D$'`
MF-//2-PF^C\3'A/C,3(>.8W'EE`H9:0"I^\'L$$[+"!^FG>#92AV&NI!?==K
M)1AX)AX"ATTQ\OPR%)ICAID![1<@"C*C<6\7++MBRL0((4Z%4-@(DGF,]TK<
M'A@V'9//C*820[$D^("4'4PP#48\Q8S&$D.Y),2`$DJFJ5`CE&@P,91,0KKF
M:<GL:%)3&0[X>0R+^_>D^ORDTYAC*.>$<OI9,COI^!2&;`_"A@W1/&0H$(6S
MYTL6H?'A[F=B"#1L)J:/+PHY$3VG`!I+@&))D%@2_5X#@63@`FT(:,2[!A@U
M@^)(@ML,&V.&?=H,#39`P2:YVPP&C5CB0',-4*Y)Z=;!H!$!`((L%D"A)D<L
M?J!I!2BM)'FIAOWNU@XK(550_[F`Z['`#0(J&<8V<-@]34!`"2C=;V"P0XLK
M&?]FJG\#/P0.FZ(!!RC@!C8@8`>7$-%(+9I=@+(+QE#0Q('XLXN(T\3A*">4
M<PNXY/;^QKDJ5@@"P>^KIQ^\I[B.[Q7A.,8-]X[NJ#@*'C7B)Q&GP<-1IBCN
M?,JXO:.2P]U:/P0.FZ(IQ5$`*>%,*0*B&R+?^D&?Z>+0GKV4WM9<\JK[;7EO
MO9_O?('F0("T+]ELQ1SM:S9[[4YO/N@7\W-RT'\EQ>&4E]Z;J2J3M6<&>V,J
M7;L.IO5".>ID=[])];YJ+L-F!75G.-U-9<ZW(ZG[N=CB/U!+`P04````"`"\
MBVQ'`0,@T\D"``#7"@``&0```'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R5
M5MURHR`8?17'!Z@"HB9CG&G^9O=B9SJ]V+VF"4F<JF2%)-VW7Q!CD9+&W$3%
M<\[WG1,$L@MKWOF!4N%]5&7-9_Y!B.,T"/CF0"O"G]B1UO+-CC45$?*QV0?\
MV%"R;4E5&<`PC(.*%+6?9^W82Y-G["3*HJ8OC<=/546:?W-:LLO,!_YUX+78
M'X0:"/(LZ'G;HJ(U+UCM-70W\Y_!=`T2!6D1OPMZX<:]IYI_8^Q=/?S<SOQ0
M]4!+NA%*@LC+F2YH62HE6?EO)_I94Q'-^ZOZNK4KVW\CG"Y8^:?8BH/L-O2]
M+=V14RE>V>4'[3Q@);AA)6]_O<V)"U9=*;Y7D0]]+>KV>M%OTK"CN0FP(\">
MT-=Q$U!'0&,)44>(/@G1MP3<$?#8"G%'B*T*@0ZKC7I)!,FSAET\?B1J`H*I
MA#=*1"I[O%5K]#\HP^9R])RC.,Z"LQ+J,+#%S$T,G&`79F%BDM`%69D0T","
MV:2S4^@/NX!F%^X2BP'&A5B:B`0X^[PKLKXA<M,*NEI!.G1DA@[1?8'H*A!I
M@<@02"?#'A,=A8;4+21*4Q=F:6(@@B[,RL0`$"$7:&V"XA#?-X0M0]A,=$0@
ML95H_&BBB=5`\DVB6">:F$DDR(59#C!AZ,*L3`P.L0NS-C'0Z.>FG]3RDYJ!
M1O?Y$RO0R:.!@M#J0"WK]R9IA]$^$<#.63H`@1O3=`"*D7.^KZUR\0A7P'8U
M6##AB(\?0"M:`!_.%ME=#%<0YQR:=Z`NMQ0B#$>4LI<:8*XU*$Y&2&#;,'[8
M<&QW,?S`K;\WZ@R;((C#$77L90`D`[>I.UCSZT1QE'Q9\0)C$ZYHLV_/2]S;
ML%,M]';0C_9GLF>H-G%K?`&F2^`87ZDS7+OI?\KGV9'LZ2_2[(N:>V],R*-#
MN\_O&!-4-AX^20,'><KL'TJZ$^HV4<[TN4L_"':\'B/[LVS^'U!+`P04````
M"`"\BVQ']$).0Z4"``!T"@``&0```'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6R55MV.HR`8?17C`XR`_XTUF?YL=B\VF<S%[C5M:6M&I2-T.OOV"Z*6$FSM
M354\YW"^4X0ON]#F@QT)X<YW5=9L[AXY/\T\CVV/I,+LA9Y(+=[L:5-A+AZ;
M@\=.#<&[EE25'@(@\BI<U&Z>M6-O39[1,R^+FKPU#CM7%6[^+4A)+W,7NOW`
M>W$X<CG@Y9DW\'9%16I6T-IIR'[NOL+9&D82TB+^%.3"M'M'FM]0^B$??NWF
M+I`>2$FV7$I@<?DB2U*64DG,_-F)7N>41/V^5__1EBOL;S`C2UK^+7;\*-P"
MU]F1/3Z7_)U>?I*NAE`*;FG)VE]G>V:<5CW%=2K\K:Y%W5XOZDT".IJ=@#H"
M&@C#/':"WQ'\*R&X2P@Z0C!UAK`CA,8,GJJ]36Z%.<ZSAEX<=L)R/<&9@#=2
M1"@[K%5KU!\BLF-B]"OWHS3SOJ10AT$M9J%C8F"#K'0('!">,&!U@=S;&9!&
M1[8)ECHBAE8/#T76(R*C-OW>IJ_"\O6PM"1&!8)>(%`"P8V`48:B+!2F5E'&
M,0Q@9,,M=5R*XB`!J0VWFJBWOJ<W6F!H%!C>%(@>"T1&Q-&S$<>&@_AQQ,M8
M*S4!$*5);(WD'F[44&(82G1#:$)%J1%)^FPD$!@6Y(;Y<-UUH'ZA0`2@/;U;
M(()!#(!UY4U57-]5'"\3FF7>;&9PPO*%R,@:HJ?#]DT7_I2P?:WB,`U`:(]:
MA_E!XML_\6EJZSMJX^696QB\V<-@,D$B-$,.GPXY,EU$$S[S#M0O*Y3X]EC&
M8<J0IQVI%6D.;3/#G"T]UUP=$L/HT#"](GDD&^,+.%M"R_A*-ECM$7Z5S[,3
M/I#?N#D4-7,VE(M&H#VU]Y1R(GR#%^'_*%K`X:$D>RYO8UF8:HK4`Z>GOL<;
M&LW\/U!+`P04````"`"\BVQ'%JEH*/HO```5Z@``%````'AL+W-H87)E9%-T
M<FEN9W,N>&UL[7W9;AS)E>CSU%<D&FJ8!(JE*JY2M]T`14FV/%IHD>K!8'`?
MDI51K&QE999S(46C'_P1]^4"]_Z<OV3.%DMF1&95J=N&KX<P6I8J8SUQ]G/B
MQ&^KJHZ://USHRZ*)J]_]\W1V=$WT9=5EE>_^V99U^OOGCZMYDNUBJM)L58Y
M?%D4Y2JNX9_E[=-J7:HXJ99*U:OLZ>%T>OIT%:?Y-S_\MDI_^&W]P\MBWJQ4
M7D=QGD2O\CJM'Z(W.8^0%GET$%7+N%35;Y_6/_SV*?;A?L^C=T5>+ROHDZBD
M^_5*K2?1T70<'4YG)]V/[XN[232=A3]N6$^WN;3XJ&[3JBYCZ/<^7JENJXOS
MZ_,7YU=OKJ++/YQ_?'=^\>K3]9N+\[=7T9OW%SU#7L`BRCB#R1/U)?IW]="[
MTNN'M3?C;'KPI]X.EZI,"]Q=$KV,:Z^O!M[HW_XM!*%S&".A<5YG\6WWZR+.
M*G__35E2A[2:PY;^4\5E[^P'![/#@Z-9'U1DI(]J791UFM]&5W5<-QYZ_*>/
M,3+"ZS13970!,]\6I0?4]T5^$,_G"MI`BX1;]ZVE6*T`0Z_J8OYY'%T1FD8?
MFKJJ`7=@:;WP=\'P&G[TEMIM*0<6;/NG(P_:!:!,7L'J7\19G,\5K`W(KP):
M^G3U,MI[LA\]B=(\NEX6305+]:=7<T``)I#COK.,JPK&_,[['%=+HITY_D7]
MN4GOX@S:>Y-<EFH=ITFDOJQQL15U*NHE',Z\-46WXW51`TB&VUR6P(I*.",<
M%!>Q1G".HUS5W:8?%1!N.L?#QB5W/W^@%>6`%MNL*OQ-@RQ+XYLT2^M4^7`[
MG\^1O5;1.GZ(;S*/+.![V2@+KKXYB"P`*XL%++I69CS:._Z:`$KA3,-@=9;J
M8\="0:,D*C5(<=AY>WZ?KD)KZ72BT^I;'Q^$7I='N/\1E\1^>QOP_@;VA>2<
MUH@G5;2'ZXW.]CMM4.Q]5ZWCN?K=-R#7*E7>J6]^B#P&BAQA662)*JO?$/H!
M)NXE:I'.TWK?.WJ@!(%HQ:SDR70RG<X`6F4$Q-.H"'"9Q>`X.AE/IU/\CX`U
M%>D8Q4V]+,KT+S!(7$?`P6NUNH%>6@92:Z!K^55H>PQG6*W5O$[O5/8PML.E
M587(1B39S]"$`?:L>AS-3J9FM;NL<W9T.-S/V\CW,-?X\/G9^.SY,0UQ_/QH
M?#C=L)^O!Y5'G4F2(@8#AB%3.P#N.H_7*6!<@(Z;59.1<!&,"&-J-8A$&[%[
M',V+_`YX8`H$%ZW;*$9;W&V"*Q!!`,ASD'IV6(NYA/(!0=2W`D`7P!8777HF
M?+'CA&')MW<9(Z-9JCH%>;H/DO!)]+1'L_3(T=+A'IQK4F197%:6)CU0>0-8
MY-W8E!%U8[.MB7+7M;=[]R^\W2Z\ZG:;P24/X,GN.Q@8;&A#`]WZ]C?097B[
M@J6HNRJ6."`-/ZQ1Z00NPKH0@`]&74)+8#G1VZ+:7H$[VMHX\M0[600P1ZUI
M>/(*-";07.>LYB4*^&%!ZE6WW>]5KM""P69QLDIS,I&0@8:Y5^%-W6U'0%B4
MQ4JW!5B%]80]&6(?X#0O5LK;1+A94$-\D]<*^$2ME]6S>AJPI\E[T'<R7#QI
MQJV#Q9][FQLTAZ._B:MT+BI2UJ#\V(X@_D.EMTMH?A`#ML:W"N<GNF31Z,K#
M!I$2!LVWGY]'"5%A$,?)/'B=%??;([/%R!BE;U!WTP#S416DX!Q$8FR48KVU
MNJ"_DYFB]UT$IO(PYZ6"TYO+B(3;*U1?_Q+T#Y"8.@#0*3YW@`EW[$,46"ZN
M*-V`<Q?+.+]%Q287FX-6,F1@,,*'#9262A^"[48H^31S!ZL?;G/9`!.)T?2#
M<XGOXC1#X^!@490'%=B,4:7`/MC<<QVT]3;N(MUBA:_3'+2(#;LHB[E2B?`E
M8')UBEI@<Y,!M10+`"ST-Q8/2A)23.9%%31;W;%T6]ID1[Y\Q7CJBRKG:47C
MS1W9#`<:Y*3MWC=%61;WL)<`]MS4&Q9BH`^'=9>"3(IN'J+%%M#%CL":2P6G
MC<HI_PW9-8^WC:>AUR4QCF[4;9KGN`2$,7E9=NBMT)SHZW?5K-<9,3Y`!S1J
M@>LT)0,?1UH`$X1M]'H6:5[RD$`3PP]"_BH>;@M@BHU<T8C`#@!+F8YP4976
MM[NV@MA."/$B_ZG)Y\2_[M-Z&<%I@-T3+>)YT.1^$R8&1A%B71VG![-3\70,
MF.K`UC/@9"F8*H:Q)WK5;RX_R`R$M[[K!EE_O+7!%IKKONMLV&W(#^5MG(O`
MH"U_Z-5F9I-HH/7H&@X1]<0X?QA=Q'6,,KJ*+D$FK^*Y:LC:`41]D\\GT1Z>
M^-_^^G^E_=_^^O^`C$!N1/,,N!8T/``]`-2#F[18MP8@P04]`&WFQ#UA'3@6
M>6I`IW@8NUJ@5G%6R&SB3"^<_%'0"'N6\9J&KB(6C#*>6=C_J8BI`S[6<?D0
M7<4+,+FC=_"OFR(C'\`YS/$Q9FC#I^NXO%6@D8#:7497[\X_7H_A;/+/(/!J
M-5_F15;</D1KL+J1W";1=6<VZC+0`^'46BIJ%6I-'+@&CD1B!,"A2"8!:ZM2
ML/%!JU*@T\#Z5D6")C^VPM]38`P(9IB#X%O3\HDBBESA'D"C4"",Q4W``P-6
MU<O[^*%JK1^8$+`P!38\C'BP$/)$'"QATCFR7=#MDAC=;_4RAN,I%1/R+?V&
M.[@O8,(,I&V&?@.8'M9&7`3_J6+0](G:/^?%?1X);IC%"[L!)/BI@(409Z==
M+(8/U0&Y[*AU"LX2<<6)JM);'!U9E\J7*&I`VB^0*N<L^M,5"A=D6X`OH@[4
M!3KRF4;;8*N4^DR<0%!7\#+58)(C4_;`G%,2['=/I3VZ;NL@.VXC9C4-_4C(
M3RS*$'QQA\1F<HRXK4#RK8"](HQS$L/W,)B*@-_>J"R%55?X]_LTRZ(EJ/9(
MR*A@UBD>''"C.Q@'Z-G'=B)C1&E$9L1>ULX1LB7!6E8UCJH&K;PJ>@G_KW(X
MU'=-!5@"%OG+![#E@$\\1'O`4EZ^>XGLI`T#Y"U990!,0I9TT`!F:H%DEJ,E
M$M`/8,0Z)2HHRL0@BY[E/J[(=BO7!4=LY'C([,!17@(5W>.V8+=_;&`/AZ=H
M^4Z?349:/EVR?/H@\@E^EY;3V<G8Q6*"<*9H&H!83W_#:4$2,5C.X8R$'GR'
M9%5D9M4HN^X5T3X&%!7*,Q#2J%K5)&/D`_-_$-!B6^'F7B.CNCJ8C?'$8@S2
MJ02F!IEQ>PN]!!PGX[.3EF<5C3(GD-4W,ZZN9VY:,.T"V0L<;PIJH'0QHC]Z
M,CN<P*S6H@3K<9XU9'=N6!*-W5V,J\W&P#C1N,VR0K"'--KH%J6T2G07EP@:
M`$]Y#^8%<D[6;7+EJ#9R&G!XJ(*NM2HLIVC.Z<GI;'(6K8`(H2=`?@'C`<8C
M?I-!K6<1`<'JSICD(Z"`\?5HU>A`\WP3%=.:$7!5%Q%QTVM8U9<4M$>4CD_.
M)D=Z'1/`S+X-P1H!&2V@NW`9\AIKO.YX84F3(&C$35V@-CLGJ2Q#$4TB[G8P
M\?EX>OA\?'+\W%D-4E7KZ(FQUVTOQ;U68V%0H\$>`:F>/GOFC-59Y18K#`Y\
M>#P^.3WM0<W)Z)Q^\Z,(;;ZQC!/:O^_\)])X_FQR;`_ONM41Y+I2.5+5*BY3
M6#08KD6&<HZ.M>QQQCEF`'U:,I]L""#6@D=7B+3(\610=!CSQ/.U@8A"$R\E
MY<=;*S#\JKGY"9".657>$$1@@V5:?<;.L$60'?"QD&#>`AC'/%5L-^(H%+DP
MC`$,M*;&."8T7:5,R225YJJJ%DUF55!O^X),2=G<.H)F#!(NK<A*LMJZ:.EM
M+1;H#?MKD5J4%7N/[JU^2*(9S,?BCJ$S1C91"\V)8T*K.XY2B2N%H_RL\(P0
MD-K&#ZA+R$<Z`@\0%/!F;14ZK00`,L.1-L1ZZ:1;"H5WY%KDYNI+#:*6V&?T
MH-"7&)-FH<=K:4D($U]^3WSC=[7";2-I.(N0(#>NXA(T^;EOV1U.HBW[`J:,
M/N*R@4:9/55K4/-&0ZRO"^&;(BX3#HJ7T`$/N1L98S:+Y!9',_)-@1Q[=@)T
MYTT=.L,6,[M?IJA+`WA!<564<J"5DIFD(TTB-W@,FB[@7L82;%'&6K?70=&*
M%((*-%0]=VA9L#65\@[8!Q,_$(J#U`,]LB$"I28(6V\6UEXD^LR2VSI!"%Q6
MI,<K,>>1*Y'D1945YB$%E?A8G/S45"*3@4%GQ"W""V>\)]9#1A6#;P.#=^47
M,?4>G6+SBOB,J@'(3G32CZ]#46H`6RN+ID:_CW&0V9DMF,BRQ_.T$HE->3)B
M8'9Q[U!<V/C3Q:NDJ(79!@^!NH7`;C)Z06,QR'!&XE?D/$`/#&$KG7UH$KT"
MQQH55Q9;9DT>`Z^N19EM;6X=EZR0XRQE0KLG@OR44P?2T:OHEN-$(-J8'ZI$
M.X9P4<!"84V@=5=D:GR:7$VBWY^?7Y+60>H!20M%>@T#@1<.+`"D!'(2S>H6
M<5IJH!NO1)=B+1#6144BPKK+R-'GH/>$8&@A0%ZZ=(5'(-&/($C;L^H-!(A%
MPW#LJ^)HJ]/V0:$BWP**9QGXRCC..8OQRYRB!82CK'4:5>[JU06;*!>`=3&Y
MQ6WN)79>%$6-B42M<\^Q298Y2X>>P:T.8H$^2F?'%G(`\P)D/H*5M)!Z"2A<
M4MH?63@I1:>D!;I<T%8-@F5"LJ-$A0*37&#GE=IT1-6R:,#HN$&\C\/.SUZR
MC#F@D2<&<5"L1F20^8DEK'L5+,X!`5##<<$:T`HH#P4,XX0(DDW58ZUV+M),
MZX:$"Z\N6LCS$2`4'1\>[]WL[QWO6Z/X1))?K(ZOIR'\^#I$#W`#<:!58*!J
M%E<Q_Y*A0P.108.-T(W00[>K.(]O%:?YU5W.MO/*4?E!<N@R%99!R/<L>T'9
M#)P%R$$8PS8\)1ZT&UBH&Y/(T<"-IV19*O:7YRF<WXKC_8QC/3E-!MM(L764
M?*T)[C(0ZFD("0<V,4<W8F$/0H9H<N`1Y#&*09'ILKW=9D:@@RF@`<^V4$)N
M^3MEQ71[:$UZN(0N[9V0LQ-;DG>;Y30S^<GH$[L67E4UF=CL:V<TWD)V.*C$
MO`.Y*@8*.IRO1%T*6:I%7\2G5?P9%!`]-8=%0']8<:!.'+FDGS"NB][%[-'R
MC5Z!WB(.8C[().L&6FH`SHD!)BEZ)I@#$X<UBYJXP8>HJ5/VS+LV1_\&,'%!
MU<B^*?AFA#,G^H0<`:`&%&0ZB@O..0%0[1FM`NJ\GD6Q$J-7E'2FDX.TTQEO
MOVO&%F3<DG<5K83&_',1TVR.Y1J!5:5*U*+%U$-^DTIR#QV<WO=-6CC&(2`T
MT%.)_FD<TFA?Y%2KT,'&',C5'\@]9M7<`0^.YHQ+=!]K,[G7@P#6.L"KR-%L
M)I[=$&V48,[?+@61>`(TX"MVV1K-`QBAG)@'W)BQ%HY"F0UFZ6>5I<NBH`/D
M)9*=#E^`1!*D'5@;<G?ME8[SOG`[DC6E$+1IM`=E[V+V,R,V,&FO5+TL$K+Q
M515270AA2Y!A]T7Y6<]ROH+)`?%!6`&:U0V[N5"Q`H*`><1-+(8L.9I0HSU_
M<W%YCD)V')VCD"*0N-8N660P\WF*?!&CM-]%/YJUDE8/YAAY`?^@LL1L\!6G
M=#K:X!OQ.A-MV5P4LXK67+PD.#]--%N0*=-A%WRBS&#W#^R8A153K/H=M92C
MT!3Q(IY_KM#%I3_OQ1%%X03.VGF"ACD&I]"3EENFY^]DWV`9:#4W$@XZT'E1
MH!^OV1C_J$`"Y'I69@'-6C26M>U*O&#.065VW<Q%>Q89TD'9ZA>@;/0*MQA"
M3:-]5YLDA0B9Q)-7/S7)+9+ZI.5IF4MND9#N9_70&E(GT.`WLRXM+\0;@?R=
M)`?R$8LROJ4,JU/M#:)2&R34RD#9;I=,=B1-ZS`G.Y50J>AG;:C>(8*P;XW-
M`?K!CCUV=#WK?-56L,`F4_DML`,.5MVEC`RT(3W@6,*71@QU'/E&T*3YNJEU
M$I'(#L`Y<J>ZNBU@T;U"K;0R=E&9'(!64C^814B630E"^C4"_T=-KZ^-0H`\
MJJ1+1JS9.'0-K+=$J#VPT`5T_0L;)[Q&@KH]+Q)>>#U0,`.U%Q53JHLS)KEB
M6&>]`:I-`')P&J3\+XH,U=#OHK?X4S33LR#<_MP4"&V1?GN@QHN78Y^Y,DE?
MY@>L\L&N<TY:D%R/HG032;Z720[=2>2O[),&@LD[TQH&AJP?IM7K-.'TX@8!
M3V$:K7;2[.[D8'BJE&9@Y01PB=)Z]+^^)QSEH8_<U36Y,[P^`*9JZZMRB1J#
M]"Z]QC=%4^M%F5^%B2+>D#N9C!LB83A%!.Y:6'1X-Q,'E<()B)QH(*DSAF.D
M)?DT2PS0MS(J``4PW9'0@B0+D0,[N*N65BFDYR"7X!MQ,D+F>5R6I-I:Q9A@
M91G7C=P/J/A^`!Z;G]]5MJ^&C5G]W^;.VEA^U?\:3'2RH]F(GL#*99T[759)
M&AV"3=$Y"U;!`7(@UPHK75=D7G39?E?D@"[=E!HA!AT:.QAUG506GA/74,9Y
MM:"D%E7?XP(UOQ#?+&?>$:<MS550,=UD<^0.AGW9L5"Q#'&%[B3AC>Z^M_/0
MB;$N;3"T:X(8,DXPJ]+!"-=D&3NA!$>T-!39:O,0UR:)-6,SV<4E"=N/<(2=
M"$M9Y/#W.9N,H]<D:%!=1^1(.4_^ONVE=3LP6V5E4^2=91?.-%<8T@6;K8I>
MD.F&BNCK\ZL7Y-M%!R`1426M0+S5U.VF2+1O,TZ*=>U+U=CX0B77AI.%Q%PC
M%2/ZE(-Y(VS_'A,)T,/9`'XD[=BMR;8A9D1B$#[,:QTWR9&7RV8KLR$C'-!E
M\0#<TTY/T3K\6=)V\'1+A(P>-R>].N`T0MO+>H8<KQ!IJ00+C,IB#.P<^'?F
M(!R"5:_R_.I3]+Z8T->#Z=$8M#^PJ=/%@\;ZRXZ/G#)\W^@`Q@4E5R*9(6?6
MAT,9)T`-7U+.JKX%#9B:DQY&"JCHT>VQ$S][.,BD.=HEJ17HE&?EQV/VUA&D
MX^PW;J(F0,R(>1E1+&3@?R6F2[TAB6./B_U#.?M&VJRF<A*(.?7#<,/9B29W
M#&$#%\'PAAQ0RW?MQ=!%DF2&'^I3$?00-'1A;Y/`/-QQG*B(%BP=0@B!7PYP
MO=W#MY3K7.7XVU__=_3[`E=V@:F0I1B1=ARV'IE-]8%3`U'<<V$(GJ()-``]
M9TZM]U;$G0P"HH4[VW>4:.*O>)T32"<5O$"SPH+[?JD(38J2"+7FS#O*;T"@
MDP&7%`UR:-*N8ITC2T,[2<$F*$^X=EMP^C-#3-1)3)8D,6,P.C'&=M!_9WEK
M4/X17]P[W#<4$!C%C>;X"2>X9<U8<1D&DDB[\S*]88;K0IX,K$)Q7T4&M607
MW+<X@;"\EI>0_9A#F-MS+Z-MQFS5R!OJ:#)D%)%I0O2'6IN)_+6C9$:_#KN"
M>]1C(F.K@(D.2SETKJ#G""=YN<4("UIJPO2LTB:6@G%R40Z':`KLCK#CM#'`
M-/.FDTFZ:6$F;8IOS9_N!Q612?1"T94')(3*YGCT@"<,#_;(VJ`"1Y#V2%[(
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ML**BRXT"?,@G8SV!>T>4",9^8'^B2JQ7DY1ETP+P<*$HNP,`NU#.JLG$L408
MKLUR&:X[0ZK_2Z,M=#^#E=OJ/OH`'*BY;<"V/#P+T!UZ?U1I4H*[-\B8!MZE
MR46\=N3R=0D#CJ/7&<`?5*@Z>G?Q]BKZ0Y&AW@BD^/;M!='\U9\;1(]9]"+.
M/[M&,NIM@".L5DMN/,J2=P1''0Z.]FSF/*\:KTOQ"E_+"IU[#NT/5OGD^WKL
MY;>W)BG1]V0RU7F^G!L.("".D!4QJ]#7^*^W^*]SD^'D$%![O&:-%//D<.H-
M*\Y,/33`B"@%6!CPJH9"*4\.G=5,HDT'9[((W5SXUH:,_MJ^N%I@SE$!PIZ3
M7'A]SC9IZO9!_#UGCO,.;#I@?V%/N%18JL[U(YI;R@1.<Q@R-!EEQ,HDD@_H
M2G&7)B?7.'LE_M@`#MJ=9BJ^XW!%W3Y?/::/::`2/9E-W</#%$V]QM:%_OXQ
M2A9/`+T/\[H@@XN6](Q1CE(I,^3J9<P:).58&?,'Z<C>:FDE**FRTC?0Z&+V
MV'6MIV3>URI#?VSCM$+SE+U2!T6.N32<I5JQ-,.EDK\-Y7&^XU[1VY0Y>L+,
MJ@ECMNW(]!Q;OQB'MD4%L$O10`,.?W2*0@?C^[(JE#T`$;E+A0C9ANL)AC^*
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MW.')T`ZCO4JI2&O.A`(MH.CT/SL(LV?7C$A7>&V5\U%,2CA>,,D/R,V5X;WB
M'<8650I&(Z.*/`*PPYF1_MC/_:%;U<Z2_(LLGG\^N)HO"W3FL#OQ0`<Z5T6B
MLK8KQ!`S.9'-_3V!<?\*F+Q<9:3>O-ONLFWZ@65P=/4TKKZ.K>%%*;'6M%Y#
M+$F6ARR6PJ=H8''HS#JQ\)95SNL&E0JKW[A)QAT9\7VT+.[QNH1(5\F7U=?+
MS%`ZOJJ7[FH1]OJ:&\&B:V`ZV5U*W^"YZ`@)-%ZI\I:"?:#JS<$LE`_?@^4Q
MITP^2;:ANZ$<%9.LM0<+UG1`4?E>[M&Q68R8H9*<(DF(VPJG`A[*%S[1(``K
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M]D^.8`8^`[&-DRW$)X-!]#*=4A;$E)2O.;&F<HMW_;59`,8H70%G_KOQ+`3$
MW9RSD+;I@(%4.EAV3V1^"[<AQ6YT-J-$@]N9JZ2*!99!$@2U(R"E@O3%(=S!
M^\(821%`<$P'>S<Y34=^-?JHJ0]4@T(BK&:J=O:-R5!!3WM('[4).5C//6DR
M%3*")M%K&Q7QN8^3.Z$9D4&I`!_:RMX%'0;,`M_Z85UTK3B@N'+"C0L4-$L8
ML30WZ<AQQ.5-3B;3;\<8M]%\CYVWG&ID\P'B]3I+YZC3M/,14>I49,_#JA"(
M3`$+15Y=>[VK:SAA_)ZV6$B:VN)!*+-6'%)$S$L0N<Q8M*I[07,.HM^D"]`B
M8YT0P"D*.=TF)T%M;O_I00#=*\>BHEN%<?8`0&GCMMD7J1$P4+%*YQ061[]C
MB7']N5RNHOO<X7VZ[!Q3N+AT5I8YRPE&FX2BW)9]D.2+GID$U7%\O`69/7BZ
M2<RTL"S$I$]2)JL0*"49@%*IJ2ZC3=QSKP^V(F&R4"Y"LC+$'"@W$;[5Y`+"
MN\.-Y6(J$OMV)M9Z(G1SPES9@^!V*[B7TMH>S"8KOK*BG'2=#CZWO.EL2^H2
M_WHKW3.VAF'7<R=PO*$2.C90X-Y!.[^ZB*Z+-2#7\=GTX&0:O7-:ZCN+N$[0
MWI:2N_#*WMR0>SH!]TR8JY?*23/UW//V,83N%:$1>V5&'TE=1LHEY_V3$68E
MX!]G^,<SXUA_"X?UG;$2")CWKK;/N2V40`A`8.UKM"_=.J70X7>RPG:IF`Y+
MV!)*@4N(PT#2+S;T@>B?'C`OK5C:[>:<YXHN;G-RAX*]=]0U`,_Z3%!*:.V8
M;)U4\@Z)>6$K;2;V_>YU.)T8TS(0E:$E#WG=Q7NQA>'J.39,E1>_*,NO[-?H
M>"]ZZOATY0>'!D]^#0>':^8;9T?<=G<LU`X3&9<#\5$;1^7+E`=N6D0G^X><
ME=8/`/^U"A_JS.]=H\YA!)!?NZO_5PTZ8S$V@A$5C$IC['.S51R:C]Y?(IL"
M]CSE$K%^\$'?=O3V/K@UTO0&KA6[Y8CR(E14R<GP#V5`V2`G*-_P"0NBW,NE
MR["*M`GIVS=C.O<?NF+(7F89Z0+_(6D&_/Z-XWNSLL9-)1I=&#/=S;=JTQ_2
M1)$[YB-;O\&RX2"9O%JA@Z<%'9Q=!-($.,_EVH-K+R%]';_5=I.)"9CJ9E]'
MSH,5LT0Q#[+WV>$$[6TJD&,4F6'O;=3RWCJ7,PW>WG?+GSN\\+L1%3\PJN+>
M;#^0F_$1K)V#!2H-K2#(Z%OXG[D[J'U]T4.JLJ3]C0QMQ&4JK[1O/]P5>%>-
MLIVP`V:I?E228UC9"%2+6R&$MY*B]KC<PZ*;+D[QYX%7<+J?SB:1\Q7C.^_!
M@B98`9RF@WD>:)"3/!QS05[$>@ZD.X6IJ)XF+K#`NIXL4*$1%G;$*#X]O$/B
MRYP1S#MKSRME0F,9S5HR3@AD!GP&/YJ7S#@2@N8G$':<Z\NJ-`3=<5ZE5-C5
M)'N+9*K02DZT.88X#*,?&FGOS<,%,?%JN)G#]<";W'E>NPXVNCAZ-C"XXY,D
M;&5]F,T;;=G1_BHF'-D5N9_QF3$^!>YEG#U4"Q-56%^*:%!+0L4`P$]^+8#3
M9<<.O$\,2+QIW!NRX0WJL*VU9P>@[H1CM2%@!M1:/=GG6"03N<Y!AA8&V^@F
M^B*'JW0A8H$;Z,R<--+*(W(HA_&F,N&EL,[FC#YZS38@%EG`G!^S9W,?V+K<
M-A!E;[P7E7!.YN6WF?Y.=C8_L:$WDDGA7=X.-/SHGD"[0LK6A5%0ZH"!<=BU
MZ0[#-MTD"DZZ6S$6F?.T.^=)SYQ#+]#L\!93IZDW[+/)T*-+(Y.N-3L*L(7>
MPGKV!2^7B7"QPE(8GG*;V<(;5I4PKT)U<UYAG)/3\?3P='SR?!HR!"E71I=.
M3/H',H7T._6BW0Q"L8UA_]/3P_'STY-M5LAAZ[8!.]9%<CC!+>^4FD6-R%9U
MY8@?^CI#`5-4VG0U)ZOU4SZ-H^;W%W[ULOHW*H"A`J[M8A#;6B.5\ZR='<MS
M"UC4H!1+4?&'W\NCL\_QCHT<&JH7%B"34>=MK6@5HS]=MUYT;SYVB[2S*B9E
MTA%5\6J%Z&?ZO@O])H&"BAW`M`Y@'B5[W(VE6Q59PUY0%@-4ED]X"RVI.T?G
M`F2`\+H%);QL<5+^9=OP,XHAKCA')G%B(NFE>\^2ZVW3]6#=4U]*^D*E\6,W
ME.(^^Y'%]P%&YE@(']WJB2+#M#W7[?A\$FW=M^7T7I+]/5"FL6U%A'B1._&6
M:=X7-CIC6<6YQV'1[`LV];@*-1U\UV/G#NZV1A]T'1''1])J\`H4D.)!*8&_
M?IDGN@3#UE[?V/99)._YBZD41`VT!<IM%QAR66&;P^@ZX%@(/J'-J"R]9:O)
M+8!@]2$L$&^].7C)%W7#=2;IPO09M\C)PKT%XWN%H5"M=J6YS</59XW#C>'\
MQJSITJX)ONHU:9O^1LVQTIZ3Q^<X+]<N`$T3SF7Q!025V;HR8K`7\&[M=4Z9
M);"S'1J&.R7\NL"7G;`/RORSK1IC2YJ$O>L:'JTGC=C:1([;L`G9_N@4>!`1
M0P@2^-#D*0:/I=7:>0',*8:EKZM;?.7Q_"<8E%`-QJ/)UL7B8>TBQ'C#A-X0
MT27;DCM\`8$A:L#(+D)%-<D8N4-@Y*I,DOJ_B96Q729</5&8KB<%/)'NJD5L
M"ESWSX@FT@R4HV?CPV=G,@^(E*RIZ"KNX<GX^?&AGI]CW*1NM-+K^7`[-,FC
M]R&Q5HY<!S9>A275?-.^G>+EK4=B_5WJ=32N0F;G-)9MBAH(^S<ID[CD<C%&
M+%;DGD\4E7AE\RO#O\+N%RH5+:%45A1WRQR05SK%>\J`#Y3OK,47>]7:;T?H
M.T1RE5VS:D[[HEO#1_M.3KG6R\?:VYUH.WV1EE4=)?&#*<*QX(?*V<-CS7:G
M4*KYWE>-\=3-7N.$_CK-]`U84Q%^N]&PGJG)<R>[F.O+P'IG]%#PT=%Q#QZ,
MHV.35+T19UQ$*7(?.-W5$B6;%*C>LE`]<F.7YP:,<C,;'Y^>C@_/^O8;PFR*
M6+($(=V9,T:1H;4HM*,S[1)^<)8WFYZ.3Y^=;+,\82_.\IZ=3H&7&)?WE@L=
M\="BW8S.W0O)07FLI9I^[4CLMDR>G+&WP74UJQ&7!A^9US>C<_$_O]*.;[JS
M&VCPT:3G7C@$2VGF>^)!/M<1UC?0(,WQ8<X?S1NYUNLR^M!^[#H4*7DR^CUK
M1R.]L&2T/[K0S$@JI#([&GDC!J,63_107.JHM]6/JK*6D+C*B^A.TKMZ.J$H
MX[M2J=F[B8R(9#?!A>27>8/&&YU`7[F:KW(3>:ZIHYY5C08*#_%BF]S)9'"5
MZE!V0D/)RD85TI0@JI)3\M0FGS#"-"3U:?4G=O6=FD]T\J:2'RV)Y2=FA;#7
M-/:#..+6+KK/X!Q-9AQE$1(?>'IUY+RS/M#,]?;*";:T2/>1(:/625'O_*#]
MBWG-I5NHM\UOW$+Q3M+P@'/UFK#;??2YC0"C]XAP`]^)O(@CV+_UO?-,9$B,
MH_>!9^?&/[&#(2/Q'VD\#2VD';!X=77)3PSTV%$AU<^SEHSU@J-9_Y4NILA7
MA-UK(GRA-Q8J167EV>'XZ.2P5U4OK"'%+V=KP\`@'J_"4V2T<E>Q_O;'&%0^
MD'\S?IM*\5.BZ$^T'XR.IHR^T]6Z3L>HR%@%IZV"H:^+"RGG1,%S)[#>JF#H
M.RQM02\I_480;)D!L!1VE[FJZ-'I\?AL:G0+5K\>2!LLOUH+ZU5SL#.5U:M,
M53VC,'34&,0(SPV&3XW1&^>7T)04B,TMO$%F,WZSK-V,W@"9AU[VQI)3<3:7
M9ZD``A3*)J>7;BQ@T5PXTEPX\(2XD__-/)I=L%@BAVHF)#HOOAN(=@MQ3**7
M\L3X-NOEFJ!NK']H@5H$TR/F2,FZ_M"B=SG!_GIW7OT]DK(EY?4\'%0Z?6B)
MA0E?X]76IEP7E?7!)_T[U=LD">\E;71\&<%TIG;EC+SG,J+G:.=W=.BP6+#=
MJ'[@8'TS\DE\D9L13F4VLWXFH+Z=CB4G"ZN#\FG<Z^<W,&9SH,_J>R8PO.DP
M#KQ''P`AN14H5(_LFR*J6=;WD(MU]_9N5I(!OWJGWELRNK930B*&:Z]JA0K:
MK002%$?0K\BY(!&`_9U4@(O^_!)3G^?*Q</1A0LYC6U>D,5\D$&^^OVP:$_^
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M4WOYE/+QJS'\"'^_UK@6T,XFAD!M?_YSL/&GJY?1WI/]37T`IEZ?<$O@;A/#
MV:1EM\T[$?`V'P_,%Q'V]?(^?JBT0U-JKF&=\W5&&7:8BH0A_1H][.+"7!6)
MW'+4T3I\,@F)Q,-Y,R,,Q2D#-E5!Y;>`3/#Y)CU82#XYIVY@H`#KSB1I$DHP
MM:->O3O_>!UE:?X9)'BWV9MPOM"@6B/>6;Y%W5(,-M2Q?-^]R,PN\?88&F$#
M/IQFI4%*+^;4T<^1QT%<,XDI`#DBS^?SD*7DW\Q90";X"EKID/X^3F'PL-O]
M4I=[E+R:("B-B=P)`@76_@DUT'M,:,'+N/K%0K[5S1<Q)*(O0Q]H%[CQ:^GP
M?0@P/9EA/T=;*V`>[X!C.S@'N5-SMN?:7']I]$X"*->]N_5SM"42>I>^]+JM
MM31TUMM?2W38WD8.IV_O;<.=AJAJB_N-?*>+'SK75_"],:]WS2;8,OA@8'(0
MR6XV0,?U%/=]\W3CCR9*\'/T+AA-\-@">[(]=NXYML,ZGHYD#$W!+5NI0T/-
M-^_!TEST"R`!'R1.\`OZ'FVS%M])OS,VA!SD_6UZ?.5]'3S7>5]#\G4%CW>#
M4SVXWYU5HG=Q:?00CV&<-[<3\\*/3S`Y<^/V:SC#`LD5A?`%10C64:0+&;Z*
MA"D0_6F:K[P7'PSW#0M.#\KVI>7^3^<^Q+CNH7EJ$#V-L'E_ZQ_(C6F&\ECM
M,."8Q.V#AOV:BWXRWGBT</M6:=0_>_M_TWJ#>YB'TT/PWMER8_0#(&>79)!6
M]0X)P^M+WL.3T`/RWC'WO!D^/!0^&C[UQGKM/T`<:N(^.\J;<MY-K,OT]I;>
M)R#GG%P-65"BT$HEWCFVH6R*DZ>=M]IC\S[J\,9.)E-_7]I2^'D3-<Z"O06C
M-_8^"O7>R*HMG9+/T\,L=F-W?VZ%-+H??^R&7(*\0ZNK@T/#K@>(O15&&?S8
M&L?C)V'>'1UN+ZW>818JBWK8]UOSX"KNU&/-7Q%="X_1B:&%MK53W*T_ZO;K
MB+/3EH_#P_[#P<\MBW]3^"\<^NMGTBW9U&,/.!</SOMC3#WQHTT,<?+\S*/=
M_YK]KT"[$Y\'A\-2&Z:<AMA%*XKE'Q_Q@NA4$H7[OC_3B<1PHDG\$%`-O(C8
M)OEV,CGS!=S9L\GL=#/'LZIKMZD3>K1YBRB3@ZQP<SS5TR%V#:_JY[9-0#6@
MJ.\071W8K^2;AW?:?4+Q9QO`V>$1$@QP1O]<(<Z=K9#9($MRW82>3?6^N#/\
M:NHIGR9F28\8]7K9W`>C-@103\*2^I5Y1XC&&GA,2+NC[*-"/O;91W`\[KA3
M:%C"N-N'AP?P[I=YG<G$TF_;_`)'\J8^+9?RIL:='8XCQSDKY=4O8RV,R`=/
MC..E36+=.*)4(SHWSZQL[($S`K%=\8LF/+>-NNS@]G3XJ'<A?&O79]^&^$[Q
MMJV=&.1F_[YP*>UIYQ=:.CL8](,/A_<=YM2#=DZUK]_(>Q5!!_6&QTX&=)Q=
M8O$[]1WT"F^(TGLL;2!H'X19,%2_';BCS<^6F$+E/6<1>N=@4XBAVVN'([3/
M,OP<G3,7UDQ9F[?#G@+71="^'-U:DEW+H.IV'%(S3>GYG8^K992%3ZP(*^:=
M=(.`PC<$5<EL&&IBDAZ&&H6S(89Z=-;=4MRV6(Y.G-BZWW`JQ=;#F&24<++*
M5Y[.9K>A>U";6[?/;'/[@>/;W'GC26Z]WOY#W3S$KN>[>43OJ/O3CG8_]FZ/
M9V)DSMC(C&;3H(W9;79X'&PV="2[P+[/%(;5B2U\.`LN8(?3Z-OB67#@3CK7
MAHT[5Y#K99\OL`.`K?J\;CEB=)X3/S'0O^3^1Q6Z?3ZY;QOLFK7UZ==Z&*&7
M(DQ2\@K=;9(THY\SP-<..#>$7C_`6X$.#E!I0+TZS]?;0>_3(`YLEJ9'.P3D
MPKH$:!F[Z&.71:WXNJ#K:Z]".H]1,.)NBCQ5Y='%M5Z:XEH#TBB4)K91`3R'
MA9H<L98F],K)$7O5RA'#[+O&N2@L.6*;:[V?MS+2G,)5OZ3^])`BTN]IL4V?
M5E7]PW\#4$L!`A0#%`````@`O(ML1\.8YVS"`0``.!D``!,`````````````
M`(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"`"\BVQ'2'4%
M[L4````K`@``"P``````````````@`'S`0``7W)E;',O+G)E;'-02P$"%`,4
M````"`"\BVQ'%BH7F9\!``!B&```&@``````````````@`'A`@``>&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`"\BVQ'6$4<1*@"``!W
M"@``$```````````````@`&X!```9&]C4')O<',O87!P+GAM;%!+`0(4`Q0`
M```(`+R+;$=I<?Q]/@$``&D#```1``````````````"``8X'``!D;V-0<F]P
M<R]C;W)E+GAM;%!+`0(4`Q0````(`+R+;$>97)PC$`8``)PG```3````````
M``````"``?L(``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`O(ML
M1Z%-G\B!`@``4@T```T``````````````(`!/`\``'AL+W-T>6QE<RYX;6Q0
M2P$"%`,4````"`"\BVQ'6WULEY,#````#0``#P``````````````@`'H$0``
M>&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`O(ML1]:O]&%1`@``]`<``!@`
M`````````````(`!J!4``'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(4
M`Q0````(`+R+;$>IV%SVT@,``/81```8``````````````"``2\8``!X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"%`,4````"`"\BVQ'4>M;2[X"```:
M#```&```````````````@`$W'```>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L!`A0#%`````@`O(ML1\FH<4]-`P``4@T``!@``````````````(`!*Q\`
M`'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(4`Q0````(`+R+;$?'WAVK
M#00``",3```8``````````````"``:XB``!X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"%`,4````"`"\BVQ'>KP.]*(!``"Q`P``&```````````````
M@`'Q)@``>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`A0#%`````@`O(ML
M1Y'@&1JA`0``L0,``!@``````````````(`!R2@``'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+`0(4`Q0````(`+R+;$<B2K8/H0$``+$#```8````````
M``````"``:`J``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"%`,4````
M"`"\BVQ'=9BH.*$!``"Q`P``&```````````````@`%W+```>&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L!`A0#%`````@`O(ML1T\UM$6A`0``L0,``!D`
M`````````````(`!3BX``'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M%`,4````"`"\BVQ'BZ8A?)\!``"Q`P``&0``````````````@`$F,```>&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(4`Q0````(`+R+;$<=7B?8H`$`
M`+$#```9``````````````"``?PQ``!X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L!`A0#%`````@`O(ML1_J@1-ZB`0``L0,``!D``````````````(`!
MTS,``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"%`,4````"`"\BVQ'
M(NJ;F*$!``"Q`P``&0``````````````@`&L-0``>&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+`0(4`Q0````(`+R+;$=$;S4BH`$``+$#```9````````
M``````"``80W``!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!`A0#%```
M``@`O(ML1R4AC*Z@`0``L0,``!D``````````````(`!6SD``'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"%`,4````"`"\BVQ'3<0K]]P!``!%!0``
M&0``````````````@`$R.P``>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M`0(4`Q0````(`+R+;$>FM\H7I0$``+$#```9``````````````"``44]``!X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!`A0#%`````@`O(ML1^4\)[&E
M`0``L0,``!D``````````````(`!(3\``'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"%`,4````"`"\BVQ'I4XM&*0!``"Q`P``&0``````````````
M@`']0```>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(4`Q0````(`+R+
M;$<_;-SYL`$``!8$```9``````````````"``=A"``!X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L!`A0#%`````@`O(ML1]ZP;6*D`0``L0,``!D`````
M`````````(`!OT0``'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"%`,4
M````"`"\BVQ'><96%J0!``"Q`P``&0``````````````@`&:1@``>&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+`0(4`Q0````(`+R+;$?M5+WXL0$``!8$
M```9``````````````"``75(``!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L!`A0#%`````@`O(ML1^IWT<&C`0``L0,``!D``````````````(`!74H`
M`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"%`,4````"`"\BVQ'`85=
MM]$"```/#```&0``````````````@`$W3```>&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+`0(4`Q0````(`+R+;$?1G+QWR@$``*\$```9````````````
M``"``3]/``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`A0#%`````@`
MO(ML1QTF'`U7`@``4`D``!D``````````````(`!0%$``'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"%`,4````"`"\BVQ'`N:F:_8!``#6!0``&0``
M````````````@`'.4P``>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(4
M`Q0````(`+R+;$<5C>*ZU@,``$`5```9``````````````"``?M5``!X;"]W
M;W)K<VAE971S+W-H965T,S`N>&UL4$L!`A0#%`````@`O(ML1X2.!EZS`@``
MN0H``!D``````````````(`!"%H``'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"%`,4````"`"\BVQ'JVS7[>\#``!"$P``&0``````````````@`'R
M7```>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(4`Q0````(`+R+;$<?
M\@ISD0(``(\)```9``````````````"``1AA``!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L!`A0#%`````@`O(ML1R8*+O2]`@``,`L``!D`````````
M`````(`!X&,``'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"%`,4````
M"`"\BVQ'SPW?%'0"``"?"0``&0``````````````@`'49@``>&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+`0(4`Q0````(`+R+;$=I,,80?`(```H)```9
M``````````````"``7]I``!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M`A0#%`````@`O(ML1QD_,1(,!```(Q,``!D``````````````(`!,FP``'AL
M+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"%`,4````"`"\BVQ'`0,@T\D"
M``#7"@``&0``````````````@`%U<```>&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;%!+`0(4`Q0````(`+R+;$?T0DY#I0(``'0*```9``````````````"`
M`75S``!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L!`A0#%`````@`O(ML
M1Q:I:"CZ+P``%>H``!0``````````````(`!478``'AL+W-H87)E9%-T<FEN
<9W,N>&UL4$L%!@`````P`#```@T``'VF````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207999354112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Nov. 30, 2010</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Initial term of the operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Extension term upon the completion of the initial lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum annual lease commitments under the noncancelable operating lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">Remainder 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994612752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,012,987&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,012,987&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,011&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,214,700&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,011&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,214,700&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Common stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,405&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,839&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,405&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,839&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,283&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,283&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,771,416&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,274,809&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,771,416&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,274,809&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986943424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">1,712,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,712,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">755,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at end of period (in shares)</a></td>
<td class="nump">1,586,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 6.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 4,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,579,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period</a></td>
<td class="nump">3,659,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,659,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period over which cost is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207987125568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Accrued Expenses</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Accrued expenses consisted of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;">
			<tr>
				<td valign="bottom" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,237&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>796&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued contracted research costs</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>800&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,109&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued professional fees</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>791&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued other</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,437&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,793&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001104659-15-078291-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-15-078291-xbrl.zip
M4$L#!!0````(`'.`;$>:%V4DAIP``%"$"P`1`!P`8V%T8BTR,#$U,#DS,"YX
M;6Q55`D``ZG^1%:I_D16=7@+``$$)0X```0Y`0``[#UK<]LXDI]WJN8_8#4W
M6TF5)).B7E;L;/F5.]\YL<OV[.Q^<L$D9.%"D5R"LJW[]0?P(5$/2Y1$BB#5
ME4HBDGCU`XWN!KIQ\O?WH8E>B<NH;9U6U+I20<32;8-:+Z>5$:MAIE-:^?O7
M7W\Y^6NMABY<@CUBH.<Q^DY<EYHFNK!=QW:QQQM`M5I8\)_G]S?(L/71D%@>
MTL-:;]0;3.J=N]1X(0BUZTI=5;2Z,JU]CADOS=OSFVG4U<F7J'_;ZB%5/5(;
M1PU%;2&UT6MH/:6)[KX'1=^?71-QT"QV6AEXGM,[.GI[>ZN+UW7;?>&U%.V(
M6LS#EDXJ0<F>2:V?*XJ+S\]\9%'Q]X7R;YI?6CT^/C[ROTZ*\H8,.BD;;[=]
M%'R,BNK8>YYIE+_`O%O*ZKH]],%5CC4E*DZ9W6RHG550!B6B"IRF+Q@[DPI]
MS)[]PN$'OX>:HM8T-3YZN@$>#3('*B-Z_<5^/>(?1//-N>89789%WK1Z],_O
M-P_Z@`QQ;=())R]")P*[/>9_NB=]Y&.[YXT=<EIA=.B88C#^NX%+^J<5@=5:
MA+OZ.S,JZ"AH2#"5;7GDW4,/1!=<[',0_Z*'KZEQ6CEC3[?]I^,G37D2K3R%
MR'KZAJG[#VR.R/EX\O._*'&QJP_&-^25F&?OE"T6O[:<D<?\`MIW,GPF[J3,
M@\<Y7$R;"Q,S=MM_\&S]YTPK?V+7Q987U`OPP8?+:U!O'#[Q9VJ(-WT^&.3C
MB<P@.2+)Q?7_5+XJ'-7-5K/3/3XYFE:;-L7(BQC0Y`5_%3!MC[P[)M5I.!9D
M4%XN$"7A8'O),%3YNE!^$44G1TM[W6I8'V)Y.I(9-*_K^^1H%DDG1S/T.'&(
M2VTC1AV?G;VOP6P[KFG*R5'T+FHA5N?D*.3&CUA3;3QIJN#-)O`F\&9JO-FL
MJ0TNJG?CS46Q^3$?"4']],`;)^R<RV6NF7CTV21W7(ISO8$8?LEB<-<*,@HH
M>\F@E%WP;$G<,_T0B+L.2MF)NV15@:DKP]1-12YO2UV8NW)3]W(4F.-/[2<U
M$,V/-O^](*='SXP:%+OC!VR29<K<+8?_S#1M3X!QZX@V"T+ACT";:E`?PI8V
M73D%7>^2<UPHE=O<^N5M3-Y."A++F"DFA'?T;FL&B(@>YX#,J;<Y2@2L^T*)
M&I\4X8.$*%&3<8DHMAU*@D5@&[EP?7=;&CDP@25;7:R]@RXVX5TU)L\7]>ZS
M-^SZ?#!=K\\L:X3-:TLX8!F9,^;O3&S]P,-8<1\]O+0`[)6([Z*#8I!Z!OIP
M(5\&?IJ&>AR#D>ZP`H59KRQJLI7E.`TQ&K)B4[#B5(^42XPVDZ%DHFWMB)+.
M^MGY.';(C"2]&CJF/2;$9YLB:5@SX$REZ8?P9,W[G3WR?B?&^Q&AFT#H/1"Z
MF8S0S0R$'!!ZSX1.)KIW(O1''DS0I`Y,DTK;;[IH5"VRR,S$NANY^H!CMEB<
MLH1J":`J@*&UVG&VNW@H`>TED1(Y\%N>#CWM2=4FG#E]V,A]']NU.'=*Z[Y?
M!V767*'55"T!5P3%=N8*38UQ1?00<<6-;;UXQ!U>DF=OHJ_Z#/'(W][8V#HO
MCMQ9!DQ(^"709$]E+<G<U]+P+W2?&IV).3)]2$[E,U&^-%2.09.U*=*M-3H)
M3)&@V"ZF"$ATB23ZK%X9".I=C()%P7S!`:#>-ZQ3DX]CQHUP3UYM\Y5:+[-E
MBD'/1;BF_H25@&5-PEU/3&RSMMYZ`^(^#KC`LHSS8M`O@?1=`E49B0=+YMZ)
M-?6^ANY7Q=]C4D,S7)%KCTFIJ4D<E7ZQ-#S2C0`GZLR^FRH73E2QH;8>)^I>
M]MU@C<UXC<US)TY=?<"M7-$*>8<%;'G<(!6_U_+C!D!IF;;B=I+F*[?B8)-5
MOHVN30ZE`?T*?.3KPUB!2U[]%8O-V?/Q#^R-7/*QQ,TR*#'6Y'>"&1^'0.BY
M")F>93KFT2&'_[8_J3'Y<4F9;MJB;J+&O[GDWR-BZ>/E@XV59/=$'[DNU\6*
MP>#+B;KENK-)QY+&8JYAKI@(V("[LA_@#(,N0=H*#I4WKB4S201BHPQB`^:G
M%/-SXX#@D#?8;)!=<7:DU^U>K8-/7AT_;8(6Q).^-4'WXEO?@]$&/M,]^TSW
M&;FS_&RC0>C3#7G!YI4_\!F:+XM^+E.T((>]-P?[E"^V"?W>2-CD&**8YTG&
MU1((CKU(<Y!Q;RZF3;B@\([$!"[^`CJ%/R)DN0)D2A:LLBVYE&ZIR!6!4SQR
MK5DL2Q!LLFZES#WJ*`>R7MC#H6WY+R.#M!S$_!`PV4FXU<$$T&`D]&%NFQD-
M+)(#H>[905!W*93EH^ZLBZ=<B^DJV,I'2=")9*/A)J=R5Y.P3![GS,F^T2!*
MD23O(RMJH^#G0]FR3C>(.DV.+]]F^49!9H>RQ9YNL-I>&%#ZS?VTHXP/R_3-
M[&Q`J>SO5`)Q%W-7`(L"BZ9GMH2).-)8QO//:#L+68I.:DTFT+1L3IZF$&VB
MPK%QN2_@4N%0N=2'RC,RJV`>9C,/@>&E8/AL[G.$Q0P6,YC;>>^)K)[;,!%A
M-2L/QR>]'84/QZ#F2!S'?!"P48\2=O6NFR.#&-]<>WAA#[F4]-NZ[5]AU^+`
MLSOB/@RPR_&XO(%RG+3*$#D2I+#(X>:6')BPV,<3,N7`_1YPD"5=&<A`>3@P
M=QF8P\UM(`-EXL!\9>`^V6_-Y6D@`P]2!N[Y8K?\F?"BV%>H[X45U^`(&#*U
M1;G()^"S7Y?W>8;^@)D0-$/)-$.Y;EL%S?!0-<,]W`0K$1."9BB]9G@8#`F:
MH=2:X0$Q(6B&\FF&^V2_U=MVUY9N#\GD7/J-K?NUYJ((&!'G<,[X0,0Y&]L1
M1:_>'4XQ4@Q>6@%F/`Q@+9QEVE#;G3'^DUC$Q2;'UYDQI!9EGNNGL2X?:R2"
MM/3,D7O0@[S[SR!'I9*C\NP)@QR53H[*LV,+4D,>J2'5?@%(#;FDA@S,(9?V
M)=7^!LA1J>2H/-XUD*/2R=$],$<8*10IYKD+SIGXQO#*\QTC0I9?1#+)Z%&B
M+&]PQ4<VN1GF;P)=GVVY4-=`2WHE9H+$SS+>0Y[%!24[YRVZQ];+[&65W_FB
M-AP-B\&A4F0DFN!PVO<,$F4/]=\/6^%W8*N=V2J.Q,-AJX-E%WDN:I3<C9*#
MM2SYMIX\NS<E4XI!^\R=U[/+=203:%LDOOAKK?:'13WT0'0Q,6NUX/5(O!/@
MBH\Q(`WZR@<X[5R4^S$:<@//LV=TEF&0^>,K97:SH79Z?SQ<GAQ%+Z>,O+R^
MW^PEL>PAM3YJ6$P1VF/BS!G[J.7%)DZ.8A`$A98!/$TTN;Z[CUMI?-"*PW\F
M;6.AB0\1&F^#4_5QY)ADGJS\_97IBZ+Y+_[)O#-==T?$N.`,XF+=(T;DU;ZP
MF<<N1JXK:H;\<T_Z2V8#$H/P/P7#1P;1Z1";[+12XUA55>68<SMGPL3]I3"^
MJ1Q:,[RNHFP_NE"ZAZ+\UKVG+P/OZIVX.F58'/OV)^',\+):#^\Z_PJ!2#:H
M&!0BO;D/H,@F9(\LC^U$\%JCU9BB=+'Q37M.3,I:HZTD[C@X$7W-VZ'8O!L]
M\U7WML]?"B6<U[JV@M.OUQ;G";_V'1X+[`F??L`E-Q0_"S6=$K8!A=<!H<W@
M+M51QN"?..'.&",>X\5CY1XYWS#>"3LGWALAEN^B8V=#T<%.G!'!M77O&4&0
MF#AI`L!IYW)93BY)\/^U%9'[?EZDK;&SUDT+-29_5_>:SO`V8_A:<XO1B9L9
M'L.;&6Y'GE!]##XG`B1?CH2,$]>FXA>RBMR[^QSF8&O$@>,JE%)7M&8W!"[Y
MF.4#-+'/+@%")M0N*T)F?./K$:*F@Y`?MD<B\?^#[":HFTTM)C,^Z&&K,206
M"^U6<Z,AA%CGE@7'^FV?+_I"@-QA;_"&Q^R[;8Q,KE$9#[R0R?%*[!$SQYL,
M<(9RUS^^<<TV'-Q67<>&'E6\H=9/OFRD,ZBY1I=T]]TVB3XR"?N#$>/1YES.
M1WGG\N'JWH7@/(,_[Z+:+`ZN,3>X9$-8,G8^$V(A;<%M#JF.=!Z-RSJ,C>O6
M&Q`W.!IR8S,VU0^,_QTQ3^CQCW84^;2-.2#!-O2Z93PV6S?!1@R)]T070Z%]
M&IRI^6%;H<D5J%F/]M6_1UP"IZA\J)UN9SKNI`-8,>:9&+<,!MQ0VA^/=VGG
ML<'&#G;P2:838H@4K?:+1?^/&//R.H,3,*M@:W&1KW;BQOBZT<8!TP>$2UF1
M(G?DC5PN0JBE4X>;3'CL9Z+UUXU'L6H\<OC.3=[F)D3Y^C?3^V+0U[^]>%]0
M^!LQ;VR2T\H0NR_4JIFD[_64W[^$CZXPNL5S1=0158["^EM4__67O_Q%5'-F
M*_44Q_MB4HO4!L0OSS6)W[_T.5BU/AY2<]Q[I$,N%W^0-W1O#[$5?&,<?SVD
MBLJ3UOWFQ=>H!X,RQ\3C'K5$!R$4>.A\L9Z9$\`CBL='=^2L&ZM`=XU:PMW9
M4[O['7R41=E`?9]%D!/Q"')")D%8^,@<SV?6*;":4D6""Q#FM3!#?=LT[3>&
M/E$+>0.^F/.%BGWN;8F3_:!@H>:J7N)D$F5G6)0_.]@0:JGXC;0V_T<)_L9X
M/<)#(K;:H`+``7``'``'P`%P`!P`!\`!<``<\L.Q6$$V"VES"S=FQ+]1PQL$
M@YM`Z@EO`]*):89X/ZTH%?^9.5B/GL,&GFW7(&Y-YZ8E=ACI13^^!"VCKE)7
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MZNK;MTU1$ZW:'*JZN@I3H2:`:F'![9&58.6\)T,L.G1]5VEF(BXU+.ZRDJ0A
MZM;-F:8B+[`)V.$_TN<`5:NW5R(E(43J9"<B$"6^A/]2X?+]S<7.:27X?Z+&
MQ;2\OFECKR<6E(5-G:[6W%U&RDKOO<O*4DA$+@?;4JMZ$BMV>4YEK:IIFAP*
M3X&F;,G5&SZ9.Z#4I&Z_2;F6IR0`"D]56,UG!4`75O/BK>:-:DM18#7/=LKN
M!.XVOJR`7R8[%\N]]D6=H;DCY,#<L(6ABVR"*C>$@-&22&=YM#UL@M4"KMB#
M<L6J2E5)0^63E>2R*X-RRL(;PE@/&6$J`-2W7?06Q6-A2^@\C/]R,-<]/!N9
M1&QEE4*;/#![[U.CG<+<EU*0?P8=*2NYH(=Y9!S;%5%@H#,=AJ?WDU95C]4L
M5040).D+DF+:K,43$[FCJD!^**!8P>RJPONN2J%]B;!\$7XMCLI7D44\9/?G
ME3'?/(L,-S#)DONL#M0SU>KF:X&VJZWF<;$<^<5S,A53]LLJD"1'2.B"3TN[
M:_#OACT2T5FPS;BE@`5BR$",`][S#1Z%WCB__D9?BQ1*6M!D24O#&T4`4!-R
M)>4?<PUP`!P`!\`!<``<``?``7``'`"'_'`L5I#-0MK<P-UGKJ2.MI`KJ=-8
M`&_37$F=;KV;IN-+ZEB'+!+,_(O@F*,@OTQ):6V-%2134KNN-0O/MH>2*4GK
M%I@WYSRTFV\%1B*VW"=.,\N/)'.<2NH''%K2')/;B@FR./K0K'>;LIZT;:KM
MW26CK/3>NX0LBQS,)C]2_F>?,E?G\IS*:K7=[LBAYA1HRI9?J<DF/U*IE)J-
MK38IU_*4!$#AJ0JK^3[R(\%JGO%D;K1V#)@]P-7\($[<R3I#<T?(@3E?"T,7
MV015;@@!HR61SI)=?J1262W@BBV5*[:U>WHD,-_*9KY)DQX)S+U,)_^G1JNQ
M^]R74HY_!A6IR.F12J4RE</1^TE3=@QD7ZTH@!A)7XP4TV`MGI#('54%<D(!
MQ0IF517><54*W4N.Y$@%-,B2.*P.V"V5ZSG`:E-+0:<L"$/F),Z**?ME%4B2
M(R3TOT,^'@F($?G]@1@2$..`-WR#QZ(G1XJ/>T[#F(G6G81Z!G-"B?FG?5"C
M^L&@^)!/*ZI?`GV`XQT[CE='\8>3(QU[S[T'?4",D4EN^]_\Y$IW46ZENS"U
MDE#\V:,@WR-7O\Y-6__Y]==?$#J9J_XPP"YA]X01]Y48WVPW:.^:L1&V=#+;
M`M(YG/SAGO1/*Y<C%POSX4GE?T1`TM.C_73\I"G^0^5K"/4$@ATPL`OE]L>D
M\R57M2IQZ/@"Q``'P`%P`!P`!\`!<``<``?``7!(!\=BA5E3.'K:9QJEKK*0
M1JG57#"B-DVCU&[46_MUX&Z5`F8VXTO&'NVTTOWGFI%(\@N:2I>%Z($XWGS&
M+&4Q8]:SBXX2"*`D/6:6N`;X'_A_8VY,EC`N7?9O9L#^Z5WA4,RD7Z%"4/)S
MU!>V]4I<)D[LV'WT0%Q*V!3)9^C.)7WBNL1`#YZM_\Q,S,IQOFQ?XC938!>.
MQF3*0#Z&?GL70B@[)12X(_<S]ZVJUFI7CX_;4Z!W7UT*3]>T5ID#6$O.][:6
M%(1W-I$)L"X<"J7SE/&-:KO5XC*^D::,+PB-P%Y(-*W_C(*O122V-R#(&;GZ
M`#,B1#X8"V`LY+\H`'?D;BRHC6JCJX&E`);"%JO(A3T<<A,";(0":8ZMXVI3
M::4SX8%`&1!(:U:[VC'H]:#7+Y?(MXXX=L]$$J6)+-Z+("[\PEY\;:U1;74:
MU>-62N(!Z"H)7=6JUFU5M:8*BC@HXLO%_M70,>TQ(8&01W>1Z+\S<3;9M$"U
M2W^:=QM5K962S[:T%`)G&6CQ!Q)T+>M,EQLAY3@*60Y:`',"<TI+BQQ6SMP0
M`MZS1*I:=A<V@"M%"E=*H]I5F]6.FM+I1Z"K)'0]KC:;K6JS!2XRJ:5^,1?/
MXLD"N5&5MA*\118[(!-P-'#TH9%)JG5=%ELP>(1<C@&H4?U@4#+E<MPH&>/2
M=([1:;UOF+K_P.:(G.D>?:7>&!(Y[H%#5XTU[NE0N_L=_..`H+YMFO8;EWPH
MR/#BN/8K-7@G&+G\4ZUONV_8-<2I3G'*L\\92$C:$8G>B,TM]&?\0C?!'M,W
M!O&(.^1]&NAYC&[(*S&1AJCEC/C'3]3BC=@CQNNQS[TM<;@?E"W47-6+Q`F!
M``Z``^``.``.@`/@`#@`#H`#X)`?CL4*RRVDO2;R;"\D\A18F3.J-DWDV6WL
M^^R0[(D\&ZG=U95K(L/D%XMJZ=YV!$D-OPC7WY1BOA,P$S>[VBPPH\XYR#??
M-@]%5\D/2YUC4SB>$?;0TER9**.$E@V)+K1.01RNO6-,F@,86W%)%M>,-NHM
M:>^T5Y7N[J)35GKO78260E!&6W1BL^1MLD?BQ;91I%86)58-\YWH'3ETI`)-
MYY)K1!<#;+T01*W8U*XBE^C"RC`0%ONINCUTN(UA>='6J<W_<=$G\NX0BY'/
MO#8O$MS'#LI3ZK:DE#K#IQUO+%^M,DBI%G[>B+=!G8BA[I[H)F:,]JGN'\T1
MN5X$7.(W-I&#J<$'A'3LT&RB64"UR%H>-)3V[A(!YGT>3F39C\#N?_+FCI`#
M<S@7ABZR&4BY(03,JTT=SLLO)T,9W2!6,J,)/,ZI>YPA*Q'XL?<BF8NYP!5/
MS$J.JE!(0[RAU&2*E@T@D]1DDFJQDL4("1XA+#0`-:H?#$JFL-"$09W+`T(Y
MH3S^</9*7/Q"SA@;.4,_?_BD-0@-3<ZE\R57M2KQ$>.R')4&.``.@`/@`#@`
M#H`#X``X`(XRP[%88=86CI[V&1K(FUZ(#5PTHC8-#6PW4[L*(J'E)W]H8%JW
M(N0:&G@`N=.E"@?\[Y%%9G;0IP_^5OKDZ9.ZV<$MX%K@VLRX=FFTX0SG9A%V
MJ&9Q_5"!@EK#1;?D9XSN*?M9Z[M$1'%PRA#F(1=[V01HR9-:>U]"4,KH"[5^
MW)G"6UZ2)N#^W]/G<]E)G])EUVJZPE%VTJ>UFI1BS;AZ=XCN$0-QKJ*\7P.-
M*3$-J15FR5:&/(6`\%"D*?]+-M4/CXSI:?H2D1'T_\UDN<A7[6>F'A/LLNR\
M'[*J#`=D`+3K*2F!0%%I*)J212>W6K]WYT^Y1/RK;6*/FM0;@ZI>#!VOTZIW
MCD%7+SX=N_6TKN`\!&4]>"SZ67P8Z\9C%=NNT^$N^75/')<P(A+*B5Q2!O:(
M_V.29JYONX@1E_)!G8O3^Z_$]6APQ0_I$]?ERR#SPI/]XINP?.S9ZKH]'-I6
M4$Q^E$%8R':A'?$`$4'IVSYG#RY2OQ%.G*5A'^U8V$<["OMX&K':"\;.T\/H
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M&C;F7]<8Y'SD/T;F9#3+!LJ!)32`2<=L@!P\'HH<D=1")B4C434H(N[H6^BE
MCL[,\'<U^.__V;OVYK9Q)/]54+F9JJ1*TH@2J4=R.U6RQ][Q7A)[X\Q=[5\I
MF(0LSE*DA@\GVD]_W0#XDJ@'9<HB951-92R)!!K=C48WT.@?87]%-CC.V`8R
M<,%\^0.=>Q&N[-)O@"YGS&?0SXP^,?+`F$NH]6<42$\`O`0'^+&)\`Y!^$!N
M3@-$]A-\E&,'HN\2+T/R&?K*N2&V"YVDS^>$LILB(:Q@"V<[15[3?7%_OL36
MY%[/E*-K$CNNW9L2DW(.WJ0NBCAUGAYH8`N=Y4")M@LOVRBH$%RS.7?48+*8
MCA<(1RT9F6@BP+DBV-EYC?[+IO4[L\;'%UXGKO4%&P^PO+)@X)XK?.*!)*[0
MQ3+Y\W<;'";?G"TY2&7.84F>N>&XE?R!OG!A4K<GEO,EUF@L<GLD_7NX/OTW
MOVK=8>KY;!AY`6_$#]>>?Q?!4&@`_E<R$SE%-^ZEY_X9N=R._!_8YDOXQ0ZO
MJ<GWP[8R4\\R4]\Y`JV[/H+GTO?20U[Q$`\1VA&&?.L+-4@+@C+KJW<%EK_4
M<!HT'7K=P3IGM[&A@&LJ)CB9/YJ>!XQ6G%/2?D'W="UF>"/.C-;6O#)M'.T6
MD=9[SBVBE*K^P:^OL2J>2BJ".BKQMRZ91(_@'F9RVX<"5H=[F)_0,.>2X'E\
MD@NON`/+K+U`NL&Y7LC%B?NUCX\^>\0=Q3XT.AB-,G[Z7EN*%&,/PGXPW[0#
M_-D6&!@_=3MCH]O/!"70,Q((X0H/J>SBT%$LB"19L=]^]H`XXYT(0G:-CH<>
MDAA^Q<V>SZ$]&)^S1$\^\?3Q5>[M4QCF$W/;F`$"8=B4E>@H7_3?L>F#H!D?
M]UE[SF@0(:>`1XQ"R.2SA0=LA.B.[^%&`0=CG_$@P6V;$;`50SF@<;[@VW@=
MLB'`1H`!A_'O9%B4A-SKE,MO5ZFG40CZ&]HF=9QE)KKAT5JR.9QE)H9,V6"J
M)8->'`:'=^<LR=<M3Z(VAV+CLMT,L[86-D?.YK:ZL^J[(:*<,Q$WFKX=@@93
M?.<!AFN:&!3+R`\W`80/9;M!Z$<\:A.B7R<1MPRR\L1-@`3[`54>&N1!:YF:
M[1#/<]JW5#G-3_(9M8CK$0_<L!#$BDQ?(W5;/*FL]?.)1_V8>H[C?>=3EPJ+
MZ&%&,-\#@I]PM^J[W.#BVP.IILAO=MD6BV%>&O1IX6X+=[E)'_04'7">K1;.
MO"B`]X)W[\],W@K1]!RO+2M$4W495"&:UC[_[]45F%>(ID?*(E3UY16B:8WD
MK1!-#YD""M'T6*[A:2>Z0C15'I%"-&V4P:BGSZ`0394[L3_K%*+IN;L6"M'T
MM/.^F9`D=9V\)V?(*]MP;HQ<ZA8@G8PA*KPJN^&L$$W5CG.==IP5HJG:QU:(
MIF=D9FO.*H5HV@0Q*4331HBI5HM578(0\?&<JZB<//TUE\^Z,4_\L.L$+7FY
M.%IX;IS6_IQL]9[>,@:#39GB/)V^^/8"V$!-;XG+XD%HSWGR>IJP?^'`K&O?
MFS//P79YMCY_&Q^8>Q9STES]-%]89+DQJTU%P8YLJK_*Y%4`1/7/Y%50+LW8
M3*U5]JX"(%):VSRM50!$I]AX>AT%R!4`T3&-8"V3I10`D0(@.O-*Y96+OJK5
MY"S6#`5`]&SS<$HCH`"(E!B/Y.G72(S*_R]GRQ4`T:L)`!0`T?E)5`$0*7=]
MEXE7`$1-\_$4`-&9R%$!$*G4&47K3EJ;!$"45<L52]#HHOAKA:M%46N+V>\G
M<^9:6)_RVJ&/I>I93ZD3L/_^9:V1M.U+47/TV@Y,ZOP+8M`KU_H-Q5NFFW9;
MZ[7[FNAH4XMIG[]Y)B^W*1ZY`[7QK&OX;@,"T89._]D7_6UL;5.'2%/Y[O#?
MH@Z3UM:[$[0<PE#\M]T=M_O=?)>Y%M<[_+I<E.M'Z[;_F>\!FT@;OD+4D^4E
M?.]3YP:\YQ__PTK5T/^UV^UJNJ$/1V/13V&+:QUR4R!@(GCBWFVFY&FV]TGP
M[7;Z38O[7BTLW\]6EK_Y?`T#-GKCX7"LYXC9TML:94*YO\1U?+'R?4E%^A<+
M<KT7MKC:[[7M,/\2A/[H^>4$\-ESV]0T&;S/4QAY2UD"<DVO]ON%/=I!B(;I
M,YV7TZW+R=?)Q>3^YI[<_3[Y\FER>?7'UYO+R<=[<O/Y,DM`O@]!@<0->#\1
M-7N#.[I$OV3B6O"-'S'KHRQX"RO.;P)I)?)3F#-5]/^EW95:%_W75='_?5DE
MIQ>Y$F5]5/'_XQ(?LUM64>(K26!SJ*BX>G22/-ZDPL]'FS)8H/GP*5/Z!34.
M-0XU#C4.-0XU#C4.-0XU#C4.-8[ZCV/]A>((Z24OJ8[[:W=4M?R])=YEV4NJ
MP\ZX`9=4=]RU.O*MU<'KPI_I=48#=1>P2OTLKMNVIJL//OGED*VW@AZ/5A).
MS04U%XYP+_:X4^%(-VTK*K';T)NVPG,X\TS[>(<=\0N8&_"3P*/9U<9G\.X[
M<WHU3E?>0RF.46I3ZPP&=4U4UUJ]?F67CY6BUV2P2M'7,W['U>7[UJ;\:0V<
MA#-S!3#[C-_-P*Q6ZILS^"X(@^HG2X7Q5HVCJU/.^%%UMZJ5I([LA&C=BF[5
M5!>Z-<@&OY)`;>%[4Q8$`A1JRMCQK'+C5_>#=\-JZ;MI1F5W[I1T:R?=X5A3
MGKGRS+?;?HXIJKSPYOEV/;VBV:TD=61)556$\%6ZX*\"4*&N$_7D#'EEA\Z-
MD8M25*6HC9!+W5;4DS%$;8GM%19]]8X%A'Y6&R3J#/>LSG![+5TE*RA%?PV*
M/ASWU:9HG?V"9KI7S3..-6>5-*T*#[768HJ-O1)3K<6D#(\R/.<E)F5X&B&F
M6GG)==E[$Q^;7O0W2_=*`-;4JK#/+(&XM8ZB+#I95$NS]ZW/JR3JJ\4TL[4T
MV_TWOVI:OP>6:2.ALH\#Z4CK,^XB8SCJ'T+&"@>KX$@/POE54HJ[.9R:O?G2
MT_O#9Q!SE\G"O&;5\&<XUHHHVM#5,\G:7X&,\>%4P7H1\D?NJ&W=N)=T88?4
M>9X6]7N#/$'%G1Q*20G&@#[W#R#%`?N#M69Y-=T+&C#K,G/Y4E:6W%JB5<^6
M:-W)L4'7R%.Y%P%')OJ;;/G;C6MZ<X9E?1D66/Z(W<!;DQ]VD#SS=^8RGSIH
MVZVY[?)RN*']Q&2WG_A]ZUULZ&N#AK/AB[R-`WSXC3TQQUO@HZ68T!N-3\J$
MX2$*W%M=2>M`],LK\)I#T3@V5*#`&H_W3CZ+5XID[_0%]7[]J'YY#1[T1PUG
M0P4:;)QX.1X>HL'ZZ+22*R3Z%#Y$#67WXB9X6($QFR.<PW_X`[?3:]NE+M:+
MN\1KQD@:!.P\2JW0#>ZM1%=[4G`$NLM-O5YW7`7A;FA;MA.ARM\S,_)YB'OU
MPW0BBUG7OC='F46A;/:*^BXT&MPQGTL5.HU6XLARTEC'&AGWAOJH.\X,K`H2
M3SOJ9)H]L^.+97$#?"HC'M*W#"I+#(U4/'O7&=_71WW%]L/8?A?C=1W$>:W7
M&_45Y\MR/N[C,@5.R\MA7_Z/NEIO/!HJ"1PJ@:OYPO&6C'&NWRZPI?UU7].'
MN76L4;S?:^/B[!:Y[2&_6N3.D^VO>)$['>?5(E<7";S>16ZO^+1@U,.AIFN#
MLQIU(Q8Y8ZQW#<7V4TSTH0;D:DWE_5Y[P&<WT;?OGJJ)?G9L;\I$#P*VLF5<
M.MO,&`_T_#8Q;W3/CO;>C![V!\9PSWXJR:(SNKU>07_%Z48[NBTQRO[J,?.N
M7J^I[?\O=2*6YAIN'7BBF\F+%\M/C.)[>"!S00-[18>#$"@,V>TT>:.@3Z'6
M.QJ_]ME?$7/-9:Z#Y-G,D\$7U'`?%'C?%`6C.RA@7`&EQV)B\N?O-O/QI&OY
M$<^YBH=ZX\),#?@#VEZL4W+9+)=UVWY6/!R"'3).RD.EVE6*A8_W=BKSH:&_
M.\^QS:7X-\D3+Q,H_RHSW)-L]6=DNS\G2[\!%Q).3RM_<1U9!Y]]CTF[MBG:
MXFJ":.-W6`S=#=<14NHVLFJD<$K8]Z\S1JB)D#3472*V^U1D.5`'WI+9+0&A
MKL4AX'WF8/8)L9*)#K^!=8U<&EDV_H)/SN@3(P^,N63ALP7\;A';Y;WX%K3-
MR'<[G!$T,?`+SZ$)R*/(&7*6^!Q"G%G\!6$NH!T;:%HX\.!;SN[_^@%FX/+#
M'YW[3LK^OT\F=^FOOWUXQZF!-S%>(-`XH=:?41"*,;G,9$%`_269>KX`N`<[
MAB0GNH>ZB#]<"O:D;8\_!!E&+;R`YZ(G#2V8;WM6$+?%K([2XJ-K<:J#-@)?
MV7-<3RS,A[**E3HOW%A/0'V9ST!?U[6X11:1'T04:`D],1\B4,F4<ZAN/GN,
M'*X]20]I[,H5$@+8&74?><]SFU_L(&_QN:QFWU]=YE2Y0RZ9'U*@RW9!S>9"
M/[&YJ>>%KA>RW*1T\1&<3<FHX,U"+FR=HC"]",ZJ##-2IH*R>W,[1(Y/(1:'
MH8+UAM8\/VP1&A#X!!-!/O&P)$%DSG9PK$,FG`28\\ZRA<P3Z7G;Q!C,O,B!
M#M`Z43X,>.'/R#4YA_@X^.0NM&M<1H*+8NHN&?4)<Y%CA>AR!(,A_@;R/,!W
M?!9ZK1RC-]J,A>\%"V:&44`L;DC_$;DL;;^G\_:-%E#KP*\)\:`-.=W[`EQ,
M7]-[^MN'=V_U=^E7,/*5I@W1]+JFW24TY15.F:SZF:R"E=43ZA;0.?S"'2C*
MM9+$31<UU"$WXC5O8;N[%CH8*WWD[[5$PUEWH?00T,E',[:Z''^?V6`>T)E(
M%V;0=%R3P8S)E;34:BPF=S%>JIQFPJ<)(D<L!S;^#VR6--^Q30AG/F-BSH/X
MR!Q&,`NDD=C2/'\C,1?8MDF#&9DZWO>T[<-:[)![-*99_B'GT)9)TT^$997Q
M'7%I".M"AWS-#/A`$E!"7IA(R>:+C&6;/,4[5J35/F*SBK1LM*L@$'@<7\'U
M>!HAR=*7VF:-SOC&]7Z!<S[8O@0EF[@6_N_JK\A^H@[JQR2\I+Z/4Y9'ZMOV
M^OH[4_.[^C"_`[Y7G]60N7<2NF8,AL:IJ"RQ[:X/!J-3,W/W-GUON)(;7QF5
M=WR"W[@FN&\!`^/`_U_A;82VI@_'^Q!?3,F1QE#N9H(QZNI:54-P:`!&11Z,
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MIJ!$H$K]>.FSCQ1F9K1R$$+:+W@4LI8:PM\<=M9V7,NTL4;.-M*S0\=G<SH`
MGS.56(G62QF74:8R='*J^@>_OL:JS#Q3!W9')?[&)9^]IY63"[!(W58NC0#S
M/<1Q>N@12J;V$VOCZ4<+RR2W33Q<=[`::'S0Y#X2AV\6XKF'-YU"4,?/;N`A
M#W[W_"4)%M1D_,AN_>@$,^;S!`3VHXO9,[)9"KIAH7ZLG_SBN^0C?VH2/Y7/
MGPEG-"3L![2+QT+X/F\4H='9'&+0@#PPD`VFW<?GW@'#`T#R5T1]8`2>!T%;
M/7'R5-0A@?75@SY"EO2!2W]\D,1@_<XP*9SY7O0X6SG<EH=3PRV]R./Y`$6"
MIWD\;UV<+26'5'R@/!TC&1Y*@@4F=82DQ%MTF1ZB_B/"1(7T-'%5"BX'$MY+
M%D;EL@AGMK\J"B.3,)7^)?FV1D+*MTU<$(>;\/MTRDQ^!+B/C)*D&\P8,;U'
MU_Y/TC*399GP")=@[2B<W6V<B/*`&V:AGS*`JXMH57+Y$03,B5_XWI.-Q/,S
MQ70N"G7CDHX6\@`=S[0=ELWZRK2N3.M1B;\61[U8*VP>S5/5PDQF&XUI!'3)
MP^KM1G3GF3\_OPZB.8P<J+7PA:GG\"/YMWS6>%$`&AV\>W]F,L^XN1(JH)OU
MB'G==0)L=:3#\[<WW3?\,ZX^\6?9@$0`,(%Q=!&P]_$?'T3+9-CO=%/_F;M2
MP][:\+;`*146S1^..J/1:X$('1U2E7\]QQK;2IH2AX.IUESQ?(ST<V%BQA'`
M#_H=O2($ZPP.FLD=KY?$P-L?VW;0Z3<?V_9@7A]#E<7=SJ,`<Z"H&JN;*Y`:
MY6'K8B-[WG"V7]B<VMRG0)_@:":N'O@N+P#W:>CU'>P>ZG`,N$^],]J*\'-2
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MK?``P3K])V9=>[[(1KP)L-J66:ZX1P$JE:X;NJ'EB2]%P#'I?_:%Q]+H4(T<
M?J4H38WDP-K-X,EA-X.-OC$8CP?GQHT#[TGW!H8Q'O>:RXTJ4!_Z(Z.OU\M`
MEKG"/-+TH58OA5Z_4'L\\[X"E]+$T>>4]R[RS1D-V)U#W5)W@T>]OE&OF;S.
M"!S49SK/W*?F/=RXF*`*'J48='>T]Z#UP:`WU,]BU"5$#5'H8-1<I:_`:/>,
M86]L',6MNZ/^K<^)MW@)N1C-IY0?GBNLT\?".MUN\1*SJ;LJZ-NO]%2UY`FV
M3Z)PYHD+3L\+7[1^K[N"S[.EL^=0508;S>A61Q0JY//99/3&P^&XV!)F^SF4
MF%+<J8:6VR@,0BI*MCZ/._H8M6@+/9FN-A)50:7-31I35*IR=\=[UV[4C%(=
M8U`1<$"S#(=DK,$LK42IC).7?=HUEDJ&/L@,/:WD9#'[VT?V2)TK6.-7:F45
M@?T>IW+3,SF"]6]4M90:;&_7NEJ*H:JE[,NJSQRSX8XN^5',82<=#5+;DY[*
MW+ID$CU&09@I5C(4^!E;*Z:8O(`AF<H*A@($XY-M05Q!KI,J_U]]:+E%KAWV
M8^'!F^33Y<=[\CM(&B%`6^3CQTM^>'*/U2\8T<@%=?_=DB@#>,P2@)WG0&DA
M8@[-Q2&-YY)/B/:V7IJ>O(5WY&."_&SU#E%TD<15%U>06WC!B_P3^=(4-JP>
M.*@'S_>][S@`K&+PD]'I)@=!H@("%;51'(^Z>2`DK(M&L#`:F:PC(.&<Q"5B
MK8=H@1`+/_6Z:QV)JB5)9\!044)C3G_PC#<DKY>AKT/V%K?/3`91-]8M\4S&
MK/6Q2C091NPXX(4GX&D$R\%Z.`)Y11":&3BG88/XCDE"7.-EIV@N5@!6-M1A
M\?GE5'2[*;_E#'KW1&U1[P*ED,@P*8N!H!^X;2=0.O`P4E;-B`)1X@*(QT(U
M17QQ&,6RH:`(85X_TIH;J[I+0_*3EM&9PI%,$-]#TN]E0HDMS<(\M2)>]^76
M#+W<4:D@=R34F0?;#B*1^=3AX21'%WK`/G`>X82&WK=AFBS`"^,3`F0*?X?+
M5JSR,Q`48G4@G(GC("Y.YBE5".;8-;9P*0C"MN<BZ$M<!^8[DZK!3]3A%SP9
M+Z5;B)[A%)W!:^D1?$N`.=$IT-`2<#9`"E<YB3^'FI"4/9(DV2[I#PBL))@/
M+,FS72#)<<2#W)1L4&@C*9:TD;11\>R2HT<*-H_Z`6L=I0/!L<!_+I(*00.W
M:<../OZ95[**5XD6KY3DIF.5@X.5HM_11S\+Q*QE(@#+I]_=+438DLJXT!+0
MY-BB'!5^G",R#3Z'@%@MCO[G2`2>^)%T&4)\&(Y\)`A#2G"BPY?4#]<?%TMO
M?C`VULGBQM4T_4B8Q\P"F7`KSNB(`FX=D?"XPE4[>6C.PIEGI:N%);F:K!JQ
M>(M&*NIF8?DKWY)@7Z!,LEZ8YSZVQ4!L^H",A`B]4!/2OR2D$WN2K$D9E5_]
ML(+6@V,_<@`RD"H\1+2?N7Q_CGDHA!M_RLZQ="I8;"$1?1+9AO8</\O74@*$
M(-(280D#N1KN+MJ$#INF=7H_*P-\]"*':^AY&1=K59'X;N5W>63(=4D>GQ'-
M&+9&NDX"OL&!\@WX+A.YP`[BC2:2;#0!4;BS(6P4DR7N4=F$Z_63*(V/Z[9H
MLK""GD[BX\N5TGF>+.B&1DK4[=LRRHO]1TG=K.TXR9B-O<9,W@:,$0Q_R>!=
M4B8QY5><@I:V)A9=217W/>WY'"P[3%CTKV*8UP#-C2BJY\#,#DJT+:,>:.T)
M]T$M[E=V.]IJ\IM6G/S6RICF"X>:_V[?FS,/(6(]?I;51D;B`W//8DZ^[&!B
M="WV$'+@3.E,3+=3("Q=-B8(=X]VE>P4Z2Y=B%@H5J*#EI^D'F(:.61+:.)2
MJ.SFT=$<09X"&R^#16B":%RA%1`WFC9?<A-4SQ5/Z0.9>=]A.OG2$95@B(\"
M6"]M"D4/JAW&BE$8X%!4%>XUQ-"DO$@BK,]A#$Z+"(D!X^H?8R;"PW/F/Z+!
MP'#?_"NRY0\?"'--7MJ<+_`^>43=YNJ+)5^%8Y,HIKTEAOJ`]$A80I36`_#$
M90'O$1Q#[`J\!OS5LG&+Q+7@FSG]-S^'2C!PP=2(#-`/HD8K!Y_D+8+ABQ\3
MOM0#SB'L(`22`VH*I-D&*EFC9\@?L8_HF2A]YLHZQR9/WXT2AQ^7PMB#M=B4
M1HYT7^.5C"\[W-HAV;C.)4MG+/?_9^]J?]LVDO[W`^Y_6/AZ@`/0JBCJS4D;
MP'72>U*TC9&X=[A/!DVNK&TI4L<E[>B_?V9V28EZM6Q1TI(:%$@MB<N=G;>=
MF7WY@1\$R\+K>Q]<S,7FYO,<RWQ60L@4.#,GG6BLS6>*YH1XGBN#\H^/.<)T
M-H3\'ET+(VLTH*S8H(N5`U<$>`%J%HR[VR1W2(>,`NC(TTC)1<8J(-`1C@Z]
MD.OCHE.6&>3S3^%"Y*4',WSJ[!;AW'ZL(C8J&"O>\ZR=`SN?N;PH*QX^@4#>
M+&)L9S7$K#L!7XHXS^1TQJ"QB/'S?)H'C1%8NI`59CF,]EHKQ@\M<N9K)LY[
MA3G7H\I*6:+X9^H_Z(NI5R@/`M?FM0=P@1R'HFM&W[4Z3:O9;.I`XUE99"SV
M%':U1DO-$+B7TM\"&U2."60WV%7R[(F"]?C5\P$NR#&#KE973"L;$'_Q0`PC
M#"X&.>CO$F$J>,+4#.PM4BGM)FT:N@HS.V>-KVC$UFFHNE-PO^K'W$0A3HYB
M/M^5ARO88B`TT+9FLJ[1K$R9\<9H7=>7WI#[:<!7%7,:[&=U!W#N`A9<E#]S
M#KFWFBK9"F>U50T5`OH@6%&@T1GQ6)65PW0TM5:I;J]F0W@C\DY?A*U6/J1"
MS>TTFO\$`=Q'N7/$URAY8KJ?&R1SQ^-`>!C.4T2X?WSOZ90#<994I7B0.:JH
M]C@#KE"9Y=1++E;.P-)BI4`1PT`H$8-)Y@D3KBK=#`W<1].=ODO)_"ES*^KZ
M;'8O!I"P9J:KP97O><@'(HM1\ST)TY>`>Y&%DAHN+X!GG(#*S7N.Z;A4?@(O
MBD;"0WN/(<H")R`3X>FAPM]_K1MG<48=I]J8/>34C)PB,WV.'!1A[J^*3Z[C
MI,HWO0!+CSH`P"T5*H]=",M=[6F&45;X]85V6JM8J;P=B$<\Z@@]=SL399!(
M!H*7Z^0V)RPC5+DRR*=S5YDEZ\\@FQ?QVXL<>8+D-/=,*HA`T%>I(MY9ESK@
MS\$`8.C:A<#34X8RH8B<3$<K$6->5>BF`-3D-@[H-C37^0RA8@8@D6O,HBG-
M:JQK5T(SO04U'T4^3*69.H_3&,L:ZM577Z_9;30&8V[WFA>=YO)9OV=W;N!/
M;W$CL/#TR'XK=*:=PL=OJ%&08@ZU4I-J[97XC^".1\K5#33>PJI5K6?"RI@3
M8L+#'A`3^LTEQ(1.>VEX+T5,@+=V6Y6_>'Y+=:@W8H+=JO"M]"^_%Z^CS*'B
MBGLJB`FMDT9,R)TL(2:4X.+,N&/Q`)??F7-;JC'7XCF-[D:F'//"O+[3WMU'
MFBKO@_O*6GC$O6$EE!7J&1S8'=.4'<MQ'#,"G@J9;,W#F[WA)-0JJ'EQ_F;D
M7%Z2`ZB\5&DVGW<`?9K-JS>;MZQ.LTFS^7Y-MIIWL)IJH4=GR(F582LC%],<
MU=$80DG+=GL%\,@N92U4BCVI4JRMMME2_D;Y6]$*?N52OIV>Y%(;IIZ*)[*\
M2":XIU&H(Z_Z+$$MHLD3R_?.6]T2;-](1_Z&8J1]^87\G$!VA(1BIM.H])X[
MEGUI[S-4($=2OB.I9LY:/3=Q=%95J`Y%$JM87E7YVE4MHB]UX<A87[=IL9"K
M`V4+P5AVSDHG;I22;5^S.M'*5*=_W`RT:W7:E]4JY%>OR%1-WV^J0S*<(5D)
MGD!:#1!&YF!)&"8(XX37?/5'0LP]ZE'@]3?(T$G@?9T$[CE+)X%[K:7AO?0D
M<*_?Z)?IUHW>R;./XY/_Y6[!#(YW#KBLQ*\BYX"[#:==>;4]E7/`3K_"NKES
MHIN[V'JOI^[M]*_)N[!*+]]UC%D$,J:PUV[TVZ:N([?M[NZ>T51Y']Q#UL4/
M[N?T[_$K^WL/YXZZ>]3J=GMFA#D5,MGZ!S7[.?U;JZ#FQ5F;D7-Y20Z@\E*E
MV?P0IW]I-M^S,;<Z.VX'/\'9_"36DTRUT*,SY,2*KY61BVF.RI258$I:#GWZ
MMU99"Y5B:U6*[>Q^^)?2M[JE;\8<_J5T;\^'?SNMW6W?2#_^AD*D*A_^K57(
M5(]"[[G3W/&8QN9`@=Q(^6ZDF@EK]9S$T5E5H2(42:QB657E"U>UB+W,./I;
MP81LFX+5"9>ECKH/T&H[)<24%5'(([FS:OI^4QV2X0S)ZN]TVM0`8>1U?Q*&
M`<(XX05?_9&._NZ'^`]IC$#K"!Z=#&/.50P>PL]L!"V'DN'JB+\)!7@>`S[F
M7O00`C4^^Z[9<!B0'.2A/7S1R[^PX$DYUMC4`4*D#YC`LUU<)HQ_&_-0<G@B
M4(>25X-;;\*'+FK)0CQ7/$D[.UBK/5"SL!J@A)6WUUR$4?UX9JLGEA&P2^FX
MV)P5/_SP?2HO'EQW_/8#OT\^0(X41#*-^2VHSD]!Y/WU_N]_8^R'XD.?0IG$
M*1[>_I0Q]@MP\V,."'[#8SQ-YSYPA14/[_G"!S^>7<F[SX.[RSNG>8?"O<O>
M>*>9G_/^ZIN0TY^^\,<H>`0MFG_F-Z4O9RP-A7[U'_"'W3IC/O?$R`WDCV?.
MV7M(/>W6_.BV)GS;,7\*O9B[DG_@^O]S`P8#4!CD=S;\IX9\&QUT_,U.<YOQ
M+PYBV\%_3="&3)!V6XVVU[[<9KB+9&\:[A=H$PNE'-?1(P_50N\A9?Q^K017
MD;9I*'^$[@B+(>`_/^3KU]L(3+$+7W`=N%)^'GQ-P">H$7AN<G_WGVSY^R;F
M`Q[#$-3O>'/#:KD5Q7;1.7MOJWAMW2!7$&W2&#L'&J/N]0L2J)3D]RC,"US+
MP[-;=X[2Q?9&NL!#='L+9*WO9R>*I@Q_CB#G\M4$C2$\$,H4X>^`XQ]7H7^E
M.:N^WVBW[:+=/LLX^W)1H,]W7S+!\X[F68*=W0F.Q:.+WN97X=ZCBQ)<7F^A
MA%,CF[WAI\GO+EX&,^<',R/3%C7]]F=7Q/]V@Q3:_`9S$S1"D_G)E4+.M<[O
MF?D\F+:8_C&+:;9Z^<\Q_U_*0V_>34^?+3PIOW#41O#=6_@!E$*SOR"%]3PU
MC?O3/_]/\-B-O>'D5P[Q]6H>?0K':2+5`PX)M`2!;FWHY1%3TARS%8O6NO6I
MH#\/,`V$W$VYIB\Z?;O&W79?AV[,07\@I,LNE)IF+B]QH.^SG&J:'^V07^V2
M%U:[X#!;(>PO5!_8Q0'K#ZIA\7H:U=)N-I9RZY>\9(F>3;07QX[/SBD!?"[4
MV]CEC'$%97H)F8HHY]7-EUBE`MR+>[0J,**9X;VR#%4A#3YJR>PF%E$\+4KI
MNI<:T#^^@9.Z?"?9IYO/\U6Q!YRV04KNDQO[$MOR0#P(K(6/78CE\*X]3%I3
MW(JL6K::S3Z#&1&23"9"3(+!&3.@)63GL\ZNWZGG;N#KV9<?WKUIL$\A^R4-
M^8S12Z6Z>9+O(Z`,JW"^@)@SB6+)7#\:*Z)#?WT[B3HX!)7DV&(\CB'+];,1
MV!VF5!2(R0=PLV(`\-C2`"SV-!3>D-USSQUQQO/B#Q.C$:08,*\$$[RE<":(
MZ2,AEQ('LDDZ#?8UO9<JX$B>ER2P`0/]AVP'.5YUB'+4E<G5@HQ"H*\HS6R0
MFXJ69)N[$W];9#9#;10^E^H(`,I!B5#7FG.-5`J<B5A:N`!U(1,(O<$$)HL_
MQEDU!R2O?]'VO.('#+?@^^RI\2R/8RJBT.<0(B`IUL]D7ER_K\%NU^DC'XV#
M:,*YQ(KY0'A@=5;19-7IAE"F03(][>#ZCT*J'T%QI]H*F@N-.'(@<TJKM%41
M,G*_B5$Z8F&*T39R3V(TIXP,B!S!H+29)T,W@:<G8+407P;P[AC&)$*&TY(<
MN)YB`+1:WR,3DME6L]NW6OU>UH\%;B^5[-Q^4_!F'>NRW<H)41T_<33,1U<$
MZOY-%+D6]X)3U=VL<R,8R>*"2.9`E/V?MPH]X[?/<D*F]W^"2/"E$>18(`P,
M(U:-.R<H'6,I8:ES/33^;0PB!N_-XY$(@6H&!*,XE08]"0EJK")S'SEN,<\-
M\;I1_!/8,.`"%1.:Q'R<0E*H5.U^,C=#02_P4<"@0$&ACP`D(5-\#_('_TUC
M_*S&Y*J8/0:!IO#@[*U:N976G3L%GKFX_A/BLR*K8EOX&E`3B*^RZ6(@8IDP
M'[0'1L]=\/T#R"N@R82[L07/`E4A,N=)),.LQ?1W7*7"W];>4-O-32,188I/
MIO!78*EO@:8@Q>;62U\+6HAS-#R=:4\0/>$"%HS`MEJ7/<MQVFM4Q&+M?^9R
M?E:=BCH4A<OL6B1;F3WP7-WM"*:H]69)Z,]%`#19[9?X*R7IK9=6AZZ/$PV/
M,<*RK7:W:[5ZZ_1KE9-1JZPZKE+[+&(^<I5:S'O-[`[HW/X;!1Y/_]J-=+O9
MM;K]SC:D9_-"@?1^MPF^OY\WWG80]5?E`V;MZJ>W(G$#X15R4?991TI&#Z`&
M?@-F^Q'0,MF8YA1C5X:QUR/FDC@UY/LJ1`B6,M)A:79S.UW5_OJKVN'52W>U
M+P_OI5>UMVWUTHK?E[[7O7&M1J<.UZ!OWHW9.C;F8>VN/E=K$I+T<=T@MS^4
M1[I9MF[^1_W,_8LE];R/V?>O63%8T<G5(X_=![[!-Y?8V<=O//:$+/1V@W4%
M,C^:#LCD]M/9%Y4:SR'3[+.[ZUE-\#`=WO)X-.OI'$M?\@TY%)K/S7,N5P\Q
M?X"D^S"&\0D,4812>+/NU":JP_1^+L+B<DF.`K<'PRPO-:XFQE!6&ZCYM4V?
MBRMHFU`(]^;ZS;C(XE`QI9'7-]E6J]6U[/9.ESV>DC3!.=ITE^FBBC>?N:#J
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MK0F9$R*8S:IG`P=B%1F@F9N5Z\$JTBIRZ^36C[^`=.*L*BLWK<4"4G;@4-U,
M?Z0%I(J4-%X2#1RS!-7K=*S^;D6H^LDEFT]/N%YZ3)5T&JW3NP'$=#_1;?3I
MT@]R$N8X":O;*>&FKXHHY)&"T&I&[*8Z)+,98L!B!PF#M-.<R=9LAF13,#&$
M3(8VQ).&D%,EITIG2(PH]-?\#,F_N4ST+37\VYA[^'<2L4>$EJ<C)?NO`9JY
MD=6V.OVNU7(<DF8%5^P-*RN:J>+=AD/X/G7P5?U&LT6")#>UDYOJFJK=;:N]
MVT*=29M^#%@Q,8,1AF>))KE$LUEEP"H+B8DTFO8>T]YCHUE%!EA>LD6L(JTB
MM[Y?M[XQ'R16&9E=FK+2I#_BF8K%9#[_]?F1-U^;5&]30UDSS"GMX^=H+:Y2
MV?W#$G\[Y"R)$C=@(DQB$4KAH8ZFG$4#%HT3$862\1Q("Z$76()-AC'G;`0O
M'\+/0+J_:6V+N:&/?[39DRO9=_`M?O%=L]%B,*0`^K!8S"6NEXE''DP:[)5D
MA3"N5U,UHR8GSUE#WBOE3#JY'?%7&Q=*+:V`2CG2,.9>]!!"3W@7YFC,0^FB
M<JC5UU!RD%O@9HNP:?BH%V=E$GE_95K$W"<W]J4%>N8%J;KZ#QX2(]4H`QI)
M0?B65I+.3$FTDEY#IVXXR59[)?8S)0D(=1,@2R8L>N0Q<]F3XA_W+USX[#YP
M-N:QB'Q4:G<\CJ-OJN-@PIR&S2;<C>4IZ-IA:-4-\:>W`G1'>+KI5U2&BWM7
MKM$@H\=4?5N_578LGQ$"$Y(5+!W=?=&()7O00-9H?GPT#J()!QK1BX=1>#'_
MS1#L^)[S$%XXCF)L)$+E4C)35NS\QS=P-9?O)'0#!CD"SD@]\X#9ZA[A+8,H
M"*(GR<[5"Z)4PNOEF[<UTYC"PDH>T.=(/"JF5:==$9PI"TY_/&N>J<]R['KY
MY^P%6>T5HMK`'4O^-O_CG7XSC*6I(F#-%EWC71[>AH6*E6'UX4]W]%\3/.O)
MX>U]%/B%=_4/DGB4M_>SL&+G@=GP^)"KM=/KL#O/7(?=ZNI21[5Q(%[-ZWWH
MYRVF!#.1_::B\-GGCQB.SSZN#O!(LTFSS=/LW^%!\Q2[O$GM*(J]4.6AB9TF
M]FW<W[:XM^3^2M-/X^^K(<T\7<ULDV:29AJIF>0S23/-U,Q]^,S3RD;J?8UA
M11(2@QU6O4&E280D0A(AB9!$:$S05*$0J>870'SADKNQ-U1[#7S^R(-HC/L'
M]A9*F;%;]`"V8LZ&ZU<IQJG="&#WG)D.D)J3FM=4S9M-4G-2\[JK>:?9(34G
M-:^[FK?ZE^6HN4DGN0Q(^FJ1VOV+ASQV`Y79N?Y(A$(FN!W\D9=O):=1WCFF
MJ3MVJ3,:26I_(;;3(DE50E)=IT^2JH2D'+M;9J!3$4D=*9RIYCE\4RWUZ`PY
ML>U+E9$+*2HI:B7D0HI*BEH)N9"BDJ)60BZFY2A'8TA9&4[-=^FH:T?VYA(K
M7_:GU:W7,L7HU:UVO]3RG*F2)S4_;35OE;M>8*KD2<U/6\UMRV[3%DM2]+(4
MW5C0GFY9>\]H4PZ!]U39-1K.JLRQ$GB/T6+*8QH2D]%B(L=#CJ=>8B+'4PDQ
MD>,AQU,O,9'CJ828R/&0XZF7F/*J&HG):#$951<T9>>(_EAGV+7#T*H;XD]S
ML$,?,TP:IO"'V$T:>T-7<G83N*'1XRF']\>$'/H4LE_2XHW^,U2QE1!`]Y$;
M*X@N7\3<2Z)8,M>/QH@<A"=!-T`'@62'40#N66IXKT>N'U?H<YLT@)WC8[/7
M7;_33;[>W,R^_/#N#7L:"F_([KGGCCCC@X&&J&/I.`J9%T02\<R`\K4T?KKY
MK'',IN]G;IH,HQB8*U4S$8I$(`Z?E*D;>@J`+QTCT)*;@;#!%W:_93F=%I-#
M-^8**0EZ&P$->FSP\-B-$^&)L9LHB#7PQ@*GL2DTDZ8B3!$Y`=MG;Q*A%W/@
MBF3<A8'^XH:I&T]FHK,MQ(L:\=!3(PU7/@%CZRI1\=#/'OO`O460!O5@JVNQ
M^PD\S-P1S`0)X_]+88@P`.1%P*74Y.$<.^8Q7E"ZD;]1FLC$U=UF0W)EW@+(
MR?\4,`9?:.RW,6@95RT&0GK0.P+!6<SIMJU>LS-]#1Y"#B<LB)X06DY3Z_.$
MQR/0=!]'\0*-;K`K1=8FN$1X7<QG\%DA:`!JFT@F#.9,'A=4&_1H$W!=<399
M6`:<0WZ:`D'IZ":'G9HZEKR]MGA0V1_/;/4$6S/S[=AQL3DK?OCA^U1>/+CN
M^.T'$!G871KSSX/K`I+9%XU#>!W)1'Y%"?Z$8&<W[D1AB]V"._PI`%-Y__>_
M,?9#_K*/;AR"'L@;'N=MA'<5^A]$D"8**BU$1_J%#WX\^Y!J9+([&_[#2W[O
M;J.[RSNGJ3Z<@8B$?O`/^`._\+DG1FX@<2_S^PNGWW#:LV$\TW,)9/9>1:;M
M-#J=0Y*9<;-3)+/S+)GMAFT?@9DOI+)9'B^G"OP2+K[/3'!J3CN8XRYNQ+#X
M9-?@:K;CNK\P$G9QP+&HAL7+R%5+VVXL^>:7O&2)GDVT%\>.SR[""A;R.G8Y
M8UQ!NUY"IB+*>77S)5;]SA/V:R0E`R-CRLHH,=@K\<KCL1#8'B#;(;[3P1:B
MCT(<YJ4:2A@B*_`T0D5HTX>S<"L'^&4YP&\>$1?B0#^-\7_XN(;_M=B30/Q0
MQ`H.I?`SC%$%<^KI.%JCG4(P*A[=`".&!LLGA&WH=?T_4ZDB[VT(S-&T?>P!
MTPF=6&!\N(Z<E>WST16BTE3F0T\PKD_CR85^UX@#!_P&^QG:CM-X'$D^C9/]
M]2/-AZDPNB%P'O`XSA&>+3:'$8L(SC'"Q"J0YG&>;LTE*AA4KWQJX=5,]9T)
M2\/.WO/US+D'T6(+_@TQIA'`-HY&:F@%^G4\OFZD%N8-T$+$N32>HC3PL5L@
M5ESDLGJGPW00`32Y5PJM+J)=S\(GC.J1%HDY),K.#8),=A('+A&%P3\%(.JC
M`B$/>08HC!:R5I64M';0HP7CQ`S;%Y[V$]QS4\1:GB*APW.C3,^&X"_@'U^E
MQD6%R]214(\)]9C`$8\,I^00-BRA'I-FDV:7H=F$>GS\HQLTL9^T^SN!&T:,
M<GF$VDG::)0V$KHQ::,YVDB^D;31'&TD%.-=LXM3O?SK.@H?>9RH#6@+"SM[
M\W!F;"X^E*?;ZV!+Q//<=M5`[9QKU_W,R]&U8TM*]W+)2-]JVBWKLM^C&W7(
MZLGJR>JK?I#(@#BR%M'BU^(F(J,S8,,L_IAV;5L]L.NF;9<YFY.,2I91R\8C
M+:7BYY*,R(Y.3D:EVM%)`GK5ON)5V$Z:;W"FO*:^>4WGTFH38G?-A.JTK;Y3
M$CXU"=40H9*EUE"H95HJU93J5U.Z63A.MO>0K")*\A++IT6%4Y'T49/KEM7J
MEXJR44,!D2F>BJ3K8HHG6>0ZB6L,3350LQE2CRVJ]9`%*2<II[&R(.4DY316
M%J2<I)S&RH)0Z%^>L=1\6?X`OK#RZP;57PRRK5[/MMIVEQ;Y:B772ZO5:UO]
M)JW(UTNN9*_UE&O)]DKK\@0F765?8#:KRLY<"3J+-)HTFL1$&DT:?6)B(HTF
MC:Z7F(S*O4PILNN/50?L+-*]D-I7'1IN+6;6`K16!HF8(<;]*MQ[$8A$<'F=
MQC$"#A8AMJ[DW>?!G=VZ<^R5"&I%S*\+Y^Q][[(+7JA`U'.][4[<6D"R1=KL
MEM,K@[BO/'X4'I_![!6!^'['R[\DO.WJR8U]>8L0EL7?$:'O]RCY+P="O>@A
M!-7Q;Q16QL]1G'V%S]DO0#J[RRB\4WW>3L;\ZIN0TV^G=.-9@,_JHHG?U&7:
M9^__G[UK:VX;1];O6[7_`>7*0U*E>$3=+">35"GQY!R?BF-O[)FM>7)!%&1Q
M0I$:@K2C^?6G&R1%ZGZC))#LG=H9DR*![OZZ&PT0W;BK_VG<M*[F17(<'H\D
MWQ3C<I4"[2S'58K7//O8K*FQ^0A23G,Z+=POW/+^X'8@.E(*7W:<M+K?J+.2
M1._6@:9`]<&-P`-`@!=?XME5\@&]/QW%E^&)8,)V7_`X+<YD,`2BQGBZ#E<(
MJ7.5[`0C-HQ`8MQG?4`38YA`X&FSG$UP4F<R2?;:<A@>^26A$?E&[\-SYMY<
MU<LV1^[56_N<N;?U"\0'\4%\$!_$!_%!?!`?Q`?Q07SHS\?\"XMG2,<\LK/=
MFCNQ$Z4R,ZG:]F2ONG%^22=[K?F6U6[G^(2&F,G)P8:&L>9DPU;CO-K*?0J'
M5H>'=%+G&+K]Y.\EAQA.+@YT!(YQ;K1RK-(SGZ'(\9'CV\3QU=;X/:-^WJZ1
MW\M2/_\3N'[ZT-8[SS+%?,VIKL=^V2`LVZ1'RTEZZYAX7/PA>[OAW@^QH(A6
MAEV\_BJ>A9TP9;PA4\_$U!MDZEF:^CV08?4MDX->+A^5,C2,VZX4WK/:?7*4
M_JZ=47!<4Z^1J9.IDZG[[W]WW,(;>YV,/1MC;Y.Q9VGL:I,1K4'LN08QG\2X
MVP)$*:M*9.7#=/58->WJF6:;HUT""!L$(4%($)X^]"LVA-D%33D*D0I>DBO<
M?3^](3M+@]<C9^T4'W+R<CKT0?Q\.6%O$.P$.\%>$M@/SKB^L(>18.YAIV6T
M5"1XXSIBS(9J3P'K`ZB'.9VKZ+/`VFD/C;FH5:K9':]8=+#T6W79=+W[D&<Y
M$>J$>O%0;Q?',9=R(:X4-8YT-=:3"Z1D^ZAS@PLIZKXK1Z2HI*BDJ*2HI*A9
M+<J2HFJ@J,>?HYQ,(%G-<++?:E!;N7:16EX^].+RH?;Q%NS[TSJ3JFM3!7@G
M+7B5O088M?/FRN^O15GS(4W7AEE--9W6M,ED=&663(9,ADPF)R:S<FM/4>(I
MVL)TF+EG/J?P^?..FHLJ\JUTL)#6,,4!$L&D-4SD>,CQ%`LF<CRY@(D<#SF>
M8L%$CB<7,)'C(<=3+)CBA36"26N8M%H7U&5'2WB9]Z-VXRLZ-X/*Q^_V?8_.
MS2A5\<EEYV9<"7/VV`QC^MB,QL$&IMQJ])8?JLCOD=\K3[J75FZ/CLV@8S-T
M-?7\YR%I9>IT;`8=FT&F3J9.QV;0L1FG-/;++#]@D+'3L1F'W2Q;B'I_.5F&
MT-1CT;$9^8=0OSIP!"%!6#((LUK0UQ?"4E;KHV,S"K#Q[10?<O*2JTN%]+,<
MQ`EV@IU@+P/LAT\VUA=VG?:6:A`C%B(2I&,SL@K]-J3M()4EC'JE66UE6:FK
MR&#IM^JRZ7HW':!`J!/J6X9K17',I5R(*T6^DJ[&>G*!E&P?=6YP(47==^6(
M%)44E125%)44-:M%65)4#125CLW8>H9#QV:4_?L3E7DNU+$9V2_&ZPH^:?KI
M-9W6M,ED=&663(9,ADPF'R;36BF4HL13M(6)CLW(LW?47%14RS4/,%$1Z5S`
M1(Z''$^Q8"+'DPN8R/&0XRD63.1X<@$3.1YR/,6"*5Y8(YBTADFK=<'<[V@I
M1&+D5XMW+=OR+7'`.ADY66[>94\>51C+/X3ZI<P1A`1AR2"D"F-:09A5D%3P
M"F/_Y9['X9$XC!H7?+7@!-$5;7`B32E8G2K2%&TUY:0[P*IMVDY_T,)EA4!7
MIT6\(D68^5S-S)]'.+FH<E1N@Q`CY2YLY0-"C)2;E+O8B)%R%[$4""&6LWE:
M:3=;E*1(2$[F_)L:3OW()3$U2E!MZO<I6Y?E:E)R4G)2<E)R4G)2<E)R/92\
M=>K*\]E^5<N)8IYH5I7/*:BNCDES@9P^\XK`T"BQD\`@5T&N0G\PR%5H!`:Y
M"G(5^H)!KD(C,,A5D*O0%PP-"CP0&'3\2'3)06]F%P+C7]=S7MUUB6[CY?-Y
M-B>TCV;IGEGJ#*D.C0@(C2Y#FX#KLRE6X_=#HH#D#V>&>H(MD?&>':=?9^F+
M7W\)Y-LGSD?OOG#+^X/;@>A(*7S9<7JI"A,W@LO`$[U;Y[LP`\\#[84'OKF.
M%U]^XM*2#XCO@_CI?[)=\\?'?_^+L5\7M1\,1[[E.O*WGR-A^J)W93U;/>'T
MOG-?,!.8AR:^B_Z'LZO`X_CDHP'_X)>-QP?WT:@]UJ.KJ/''>Q_>'`K'_VQS
M*6_[]S[TW_EIR<D34;[GC1AVA7?&`L<*>_@=_C!J9ZPG3&O(;?GAK''VL7J.
MCFVQ;%;1OB/'5N_#V370_Q8Z!5)6":")`F@]UJOA16[Y?Q#>\"A(?[QK_=F^
M,6I7FW&#=&W)11J]^E'00YY:-X=@Z`_7!H(Q'5H?4[QH&ZW->)VF?F>NTX`V
M]##'B^;%Y6%D\-V2/[YX0EP#DYZ0OCZX5XW+YFJ>%]&^(\=IS`T],`?^+S+C
M_\J2INWB&"XGX_-Z+B]C+L\^1D'')(#8(P#9)W#*08RX@M:D%$8[_J*>;&1M
M'XT7]>)+V$O7M7OAF_7SN=ASFS;FR%E%>IIU?'9*!^`Z-4-B1BT17$J9MJ%3
M457?^?4Y47VQ'.Z8%K?9M2-]+T"SEWNJ1+UU2I7(1+VGR#\V\0\#P?JN;;LO
MH#A,S30E&X&_`V*8Y?1=;Z@<'.-=-_"9#X]_=H<C[HR3C5.7[R7K3[#E:B+$
MN--C=C(5@C>YSP;\6;"N$`X;1E,C!G?[X&YQ!2`0%?4:B,(RP2E+U5WR*QM8
MPN.>.1@SMZ]^P]LA>98S"J#7``?Q?Z!9WX6!`?S[$#AE,C`'J7;.V4/"1O+8
M7'=1)R"-OO"05HF#$WL)!R3)7G]S80QLO6&!1.%]%<_"9O6(E'/V28!4F06B
M``*&@+<B>XEX%LN#H>#99+;(NCA=9*\M!PAS`PF-R#?O=M0Z72TD-<9%:W'5
M]'"H5)29PK8C;_?AK'JFKN6(F_%UU$"TQ&:"@O.1%._B/]Z'+;-VZ[R:#)[*
MCRJ',LW>BIU&"]>KCK_9J+W+>E7:/R=MM8^RHI?=XG]J@YTI,*([YD;)20J;
M8:S)86LUSJNMW!]GO;.P#Z&@'9D`YO:3O^_%R%>3A>16O5I)+C`RUWJ1^B0J
M/;/P3(Z/'-\FCD__DB*%\WO_"2#L["68W7F6*>2<KG8]]LLN4[4%/5I.TEO'
M]*UG<<C>;KCW0_@'9>BUBM43IHPW9.J9F/II:U`4SM3O@0RK#Y-AT,OEHU*&
MAG';E<)[5M^;C]+?M9HK']/4:V3J9.IDZO[[WQVW\,9>)V//QMC;9.Q9&ONA
MBJ.4:PVBV"<5Y6090E>/1><4Y1Y"_>I)$(0$8=D@S#[6U0S"4E;"*/@Y1>%N
M_,.=\*A'E<M3?,C)RYDS!_'SY80]3T<-$>P$.\&^[U)?26'7J8*U!C%B(2+!
M&]<18S94>PI8'T"=_P!!L\"-0K\-:3M(V<.+6J5:;693^;#X8.FWZK+I>C<5
M8B74"?4MP[6B..92+L25HJJ)KL9Z<H&4;!]U;G`A1=UWY8@4E125%)44E10U
MJT594E0-%+6\I0@UVFI0DD,.<_\A8E.3JF>I)44Y::BY\OMK4=9\2-.U8593
M3:<U;3(979DEDR&3(9/)B<FLW-I3E'B*MC`=9NZ9SRE\_KRCYJ(Z_1DM!%,N
M#GHBF,CQD.,I&TSD>'(!$SD><CS%@HD<3RY@(L=#CJ=8,,4+:P23UC!IM2ZH
MRXZ6\#+OAVO&5W1N!I6/W^W['IV;4:KBD\O.S;@2YNRQ&<;TL1F-@PU,N=7H
M+3]4D=\COU>>="^MW!X=FT''9NAJZOG/0]+*U.G8##HV@TR=3)V.S:!C,TYI
M[)=9?L`@8Z=C,PZ[6;80]?YRL@RAJ<>B8S/R#Z%^=>`(0H*P9!!FM:"O+X2E
MK-9'QV848./;*3[DY"57EPKI9SF($^P$.\%>!M@/GVRL+^PZ[2W5($8L1"1(
MQV9D%?IM2-M!*DL8]4JSVLJR4E>1P=)OU673]6XZ0(%0)]2W#->*XIA+N1!7
MBGPE78WUY`(IV3[JW.!"BKKORA$I*BDJ*2HI*BEJ5HNRI*@:*"H=F['U#(>.
MS2C[]R<J\URH8S.R7XS7%7S2]--K.JUID\GHRBR9#)D,F4P^3*:U4BA%B:=H
M"Q,=FY%G[ZBYJ*B6:QY@HB+2N8")'`\YGF+!1(XG%S"1XR''4RR8R/'D`B9R
M/.1XB@53O+!&,&D-DU;K@KG?T5*(Q,BO%N]:MN5;XH!U,G*RW+S+GCRJ,)9_
M"/5+F2,("<*204@5QK2",*L@J>`5QO[+/8_#(W$8-2[X:L$)HBO:X$2:4K`Z
M5:0IVFK*27>`5=NTG?Z@A<L*@:Y.BWA%BC#SN9J9/X]P<E'EJ-P&(4;*7=C*
M!X08*3<I=[$1(^4N8BD00BQG\[32;K8H29&0G,SY-S6<^I%+8FJ4H-K4[U.V
M+LO5I.2DY*3DI.2DY*3DI.1Z*'GKU)7GL_VJEA/%/-&L*I]34%T=D^8".7WF
M%8&A46(G@4&N@ER%_F"0J]`(#'(5Y"KT!8-<A49@D*L@5Z$O&!H4>"`PZ/B1
MZ)*#WLPN!,:_KN>\NNL2W<;+Y_-L3F@?K:,UO2_!:!^7^(YD;I_=BY$OAEWA
M);S4JQ56JQI-QIT>NQ+F[,^&^KE18?Y`L,_N<,2=<?(AX?*]9":7`R;^#BS0
M;&`-;KB.M*0O>FSD68YIC;AMC['[X=Q1W17V,K#,`>.CD>?^M(;<%]B1Y;$^
MAW]!BX%@/?B_[T;WY<#U_+>^\(;,X7[@B7-V[6"7CC!]RW78B^4/%+$F$&L+
M=0_ZQCO7=[?089C7*9GX*3S3DJAQK.]Z[,X3?>%Y0/:][YH_V(OP!.,!&"GW
M+5/Q`-T\"P\YLQR@:&E3("?@-6RGPCPA`]L'>X:W%!V>,&TNI=6'9M/T><+F
MV'C4+K/CU%-D'UT"/LQM-N)6#Q0))#^R?+CF4KT^(0>>'@6>.>!2@+PX](\]
MI(EB''DS33=PL$.D&1I!$*$SRY&^%PP5EJ^_N0!)Z\WY"IU/V^K,\GZH_>'`
M`?H=78;C`%R?39E,_'ZHRZ#I'\X,]01;XE?V[#C].DM?_/I+(-\^<3YZ]P6T
M\`]4PBM+FK8K0=_D`YCQ)QN$^/'?_V+LU[E';_M?+(>#WG/[.I'DG6M;IM(@
M=`/?1?_#V57@*?@?#?@';?#QP7V\?*Q7U<79QXBE"7E[L+</+#GWNL>A5;WX
M$O;2=>U>U!(^^PYMU#+#ME!+F%(3-,F)HK"4IFC-9_Y'P@?PE*G!96`)CX.O
M'.-@Y7K@8O\1H3NUG%$0.E-\,G34OC`'CO5W`(\$$APG_#@4'-U"NDTU./@#
M3PC6]5S>8[9X%K9$%]MW;=M]D>_85[S%C+@7],=_!VXT:)K0_NO`X;V_`AQ'
MW^#`P6%X>Q;1Z"F5R[90@#@T0<L2;\(].ZGZ]#[JI);N)/K3!0X]H)$[,]W"
M@&T'/1R$8!R%;F,ZX5%?->!VI?">)T,=2DKUGNY\7&'"4CWT+!CL?!S^@5PG
MOGJOHHVPZ7J:NL!)-1\#@#W#V&S#J\NC$/?%03J"X0B!@M:Z;N#'U$WN1K''
MB'L@-PA,<(A[<0.[AW"BE%$*.%(O9NL\9;&1R)&1E,P5%_'HKN*$*&Y!I#P!
MHVN7H^*X820`NB"D'^H'.@3%<LBQ)6$,?')4D``:'09`:2V+%`]]QJK1F7Q&
M-C[#A.AJC*K!AQ@UR5@E)R`#LC;H!H9<(K;0V=A8!8,^Z!B^AC]60.,$QG,0
M0XZ$(T6H4:%YF@&$HT!9J&J5Z&Y\%85O$K1YK.P%7X2;7B#2K:V(K.%7?Z\Y
MP;K('.0&YC#@X+>Z0C@P[6<0E3I/0L;ZG+C6H?`';D]"FUYL@&/!T7#0&RVG
M@D5.R`&T<(;A#V3TS@K.%&FQ(V$BI`*I@@!:PBQ``KW^"Y(<N^[0EPC$IL\$
MASD+X`8,(ZTC`4-'+V97S1N`TZ0M>&.A@Y[M9#'K>S#960EO.*>;Z/5S')4L
M];$]T?73"M5+Z5(\DWOA^!QJ`9"*;A6;GO;TE6B04<84#S\P9@JT#08QL2C[
M;&/5%&)ZUO$_PH'XQ>XXO4X/)`[3;IQ3/(O?0OM?.=]HI.<;C3,8?*WPP=_A
M#^,,8#0!9EM^.'M;/_O8:#3JU6HUH79-UQG0>;$+G4:C=G%D.A?/W];0V;QL
MM4XCS^WHK-7;[=WIO'9,#^(4`?Y;_??:Z43#UETT:F6GH<U&8XK0M7UG2>IV
M0FT9EYF3BN-^JN9KAH(UFL9Z:F>ZSYC@[<1K&+7,";[%X.N;ZT1!62<<T+.C
M>1W%"_M?1_1=&%Q>12N;D8F"Z:K6-N!A2T6IM=9PL0E!!V=J6P=X<0"FPF@G
M^V&Z.4OL5$<[4+'3()PY%3LA=U&=];(9"6-+!6K/VO;F9%QAR+VY1!ZC9AX_
M@QY:_A=NJG6+SD]+3G[Z+IY=^QF"[^EG;M0L824O311I=14O2.Z._"P4[<'Y
MJ>_*SQW.V3/TG`NIP$YV['[+8'2)&.8)^"K`G8FOX/A`XAW\X/2DEJ#D+<R"
M.4Z'\3<AOT.4^,+M!UP.6$QG+2340$+AHAY>G7V\:_Z9$+)#=[O1BV_>]C\#
MI1XWEYE<)-NJ(MF(A%O=D>3I'F>H7A(6=>3C;3^1UEJU:K<OIC5K:<"SNL?-
M(Z^&8=2W[A&&2O59<N#:/>')W\+OD/LP;L#TJK&,CH7=[4W<YL-2O34S/NY,
MV^=HA7`?435J]:62BMK?H?_-I0$:LVOW"S[/KA3%9,R8O/@)QHG),OHG,%DY
M-;;\)GVUTG7;G[RQH,]PJ%G3^!=/_!T(QYP>O";/IIX$9X9!/CB*#<8P-7:T
MEPEP`;&SPG2`N7#D7(7BP0=B(]PK-L5&0MIRHN->)N*][<.4>1AO1#E:W/2Q
MWEI,^@H"UW-UPW]:PV#XR?4\]P6[YB/X9:'[J4=*GO#RU76><"$6@YB'\4@H
M;DSN=Q]QZ/GJ<J>#1K$9/LU5\*PC]^2,JHG8PP`X=GJ?-F.XME(A3\SQH:RP
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M<E:1GF8=GYW2`;A.Y9\RHY8(+J5,V]"IJ*KO_/J<J&Z])^Y8_X3[AG&/<F)4
M)=@(KU="4VH?M=;\Y#\)X3/W>1?'3G8WX-Z0FR)0R3^RDK!U[9CG[#5NX$YV
M;G]^/[>9^^K]&\POX<R$YK$-`)8_"=:UW-%4VRJ)%K?(]UTS2.6M`'VF^RR\
M<05&21CYW=%0)2HXN"EA.,1L6%"1?R;9K8Z+&\!Q$9Z/5--R.@]FX7;SD>>.
M/$OXW!NS>]X7]IC=P!5H(XBPQSK0V7<>IL3"3P^`DO!%KX)[Y>]O.M\?*@RX
M^X%I3IBUY=KNTYB!5/V^ZPVG$@"FNU7OKG@5)3=%/(SCI@`'B5OG/:&^\*.`
MU$=^UATS:0T#V^>.<`,)A`[=7F"'3^%]:V0KP4,?2N*^X@,3L1@620!FAJZ7
MY`9'#;,1]P<O?"QG,AD<T%2A\A>LM_W`,>.,80\ZQ6T-@)#5"U,=XH0N(/^O
MX$G=0PY>7.C0AMC(%E+)$F@+<\_@4B4^J`SK'PYF7$7:,B%>/:CRO_YRU?Y_
M8%]QL2*K8`KFE.PCUJ;@2-&*I/<$IDA%"<S"&6#Z38^)/N9,F6.ECM80VG^&
MNQ(TR`_O^<"?-TGI2LM/"O%#Y:9$6AVIK!7+*\).),BEX(H,(PW/=.OQLRD[
M0#9XF/,C1Q!O`N6)[BA!IY/``F<H@`C14\(&H'OPD$HZL7S6%;8%5$O\^\6R
M[3#OABL3%KZEL@=Y[QG:`5-?H?_*U%')4;U1G\./J2AB3PD](J_"9("I^Y)=
MP7^%`S#?!!+TAGOL:BQ]@'4P9J_3CNCJYFK*"9VG'/+DK[3$T$G9<@('VDR8
M!+5`H>-LQ`G-J'424W.`'=L:6<IX5"62&:O!G!7+,5UOY'H\E=!U[R/4T,H5
M&-^+2GYTV/\%CDB(K;4PEZ;:+D,&GEZ!QS5,TC`/\R[HPCUVV^\+G,QIS5O^
M@Y#K.0.8))+%UA35W4`S`K>Q!*;Y(.7Z[G:];^C8=CR61(4M+"DQWU$Y4-"6
MV'2AM3`1SQ-/6(L$RWJ,`D\&42XMCWX(IPW`,5AZZ#,<]@4&^:3+^[=&!9T<
M'ZJ$N\5DP33DZ0E:C/Q%LW+1K%:P]-&2\AM+J`J+@"RD2S&C.,1A.\S6CE\9
MA;*%3EX9M7/H%:9#8<_L=9)JMX8DU?8L,5%A$\44AX#D&3-_;#=RKRJIFCUA
MT9$P%W[I&!_@MX`7S_(Q-+$6UVL!R!:#_@TSMCW75,-=4LHE%,FKEG%^P4#3
M;6@,@.K[F'4N<'!`IB<=1T%9F%1345$JJ$Z8*JZ2.D.]?!O'69,$VCB[%B*9
MM):C0)),2`CK7EV<UV,ZEM:D415H0((I$);7U0F+S5C8^6A2FT8JL.:L9Z9X
MS72HO[Z2#9]1X,M*M799:38N4X2B-4_7D'%"$W<#'_3444JVL`9-'5Q$J]U.
MM;5'K9UTP[5&I=EJ+='H,@S)6I>4FAX6!KRGU,PT@V$0S64$Q+66BM->7;;/
M&XGY/$R]*,/L<?!YP/K_M_>MOVTCR8/?#[C_@>?9'Y``LB)2[V1G`,6Q9WV8
MC(TXF<5^"BBR97%"D5H^[/C^^JNJYEN43$FD1$J-P6XLB>RN5U=755=7`2(@
M$9CQ$Q2IP"OU#*/4))`I=Y1[(T9PJ7[.S3R?Y,X.D[$ETW;#:_<6+@"TD^G>
M_@PK=4@SQUZ$3Z.V<`V\XV^0R[<"*Q9M\*=_4Z4*W&0L'TF#"#J&^P-?!A3!
M/H8?N1UK&C-0ZYK!<%#N;!LL>4.Z)4U]K)>'U:`6!M>S9'EKS'5GOAF[XBOH
M!VM6=_S'A)W<`BO>H%O9B8I2026IM#</&L^@+$KN/]C\)KL%XA-YQ>2'&!:X
M]YPZ6,[`]@*M!P\G?;N$*XV0!J4X0!Z`D%0WX14G$55ZQG!7+5[&(_)G0]<'
M0^N&Q:L3$,M3;M0*[T/7P8+E!"X#[7)T!9]JM@29L3A>RC=$XJSZ(6=Z=WWU
M?"-S_L&\*UA4]^",&[`]?WSYYC+]U@KNN5N/DVBM7G%:PW<%STJVO,<^4M+I
MTOM!=C`LM[SZ-LY>VCT`FK>P8[O>(9EYV<>3Z`)H%@3M8&ANQ\W+0>?02$:7
ME0['2[G7&RM%\"P(V\'PW)*9BMSI%^+GKGC>6K!GLS]@;RN5/?U1?T5SQE-M
M#<5.%XMA)2@K"WX/(';D8+>C],HGQ990C'JC+4CQ'%24`-$!.;/@3XTERLKP
M_X]J6XKDA#,/KWYA&OH`L=!(::FI-9+-=ZYOT.OT8$@*J\&_+7*\U)@=RQ0[
M>&U''@L-(E5QJ<($$Q\P4*,ZNBM]M.&?]/',S>3A8SIR!'X1]U/=X#WPCCP:
M:&KKH5^MZO;2B^>-G+,HO!6<;/&C.<;K6**OU):^62:XL7R.9XPSHC?K@T^F
MIX,'T=D6>7E4G1-^T,C'=4A2,2K`T7<C%*,C3G2?7\#9C*<G+Q&_#@[),(CG
M(*W"<2UR[V81#9>V:W"OU@D*.A-ZB<"`O\1L%)U'147PJ?)SB,G2,<R\@P@4
MXU`8)@_?I#_M=OJQRTZWM>HIOYK%M*(C'T!83&/V$A;MN\=(E.5%60]T2>O6
MQ8BZAK+L9M1F$40QX(%1I7#]T3$$5APWR-*7'GU#I^%!3V#NH^$P?B:0@85J
M]QDA+!K"DENWDHXZP@`ZO$KAKU2=0%[_,ENSG,:/"Y;#HH@*S`8C!@%?;8ZG
MX&WIEDJ<QBN2:I!;E@]K+5M9$>-_('06S4X!_M5RD,A\+@(8+V.J`PHA7(PX
MT1(K$GH`Z4K`+BBH9$9U($-V!JH@4#E))L3'ZRMZ(CJQV1@($BJ@%!6@1)T)
MLFL>?[E$:<BNR7A7?(@XE3A)Z7V0?K=1`*XPJ<>QTAMD8N34/AD6OUPGT*$8
M,WY(\HH,#W)/P:XWB'3NF60,*]H*Z%BZ9$-$&@-&>2._C=\`EJB\5$DZ]@H4
M7&)+AV!I@]9(+)3G.:.5#LCB=NKQ;!0*@^-RH;-?;`?C!169U3"E+#U'HM%!
M%+LEO?%(W-`";@1%J3&EB"JD1MI)#^K;YJ[$I'&46[J5S)@W2H(6H5K+&8YL
ME*`7P*L)+'CF@'0);20$,6(`ZFC-,:;<=DHRC$+Y-N/OXE%D4/HZQ3^@56"]
M)(/;7`!W54RG'*'>T@7..-#P?!B.X4YV^;7;+ON9H,*Z.?<";;>X2[]_`-!V
M#(Z.1X<CV[:1HM&.+(WO"Y91XZ>;J827,_XN`!2_]"N/Y>T`B&*?UV$B1IGU
M3$>=-%M69ML)F-U*)8Z'G0I@V:W4I=+-5/`LE3#;`3/"VFJ[P%)9^'N=T*P+
MNA:&:$>5O%9R]@9HQ[#X>O$IBT3;ALC7RM"K`/$B?3<^'FM_-BPL>!/6;?JT
M^4KEZT4<,A?5"\ZY$Z"W%M6M^`\E,^P!="]3>&*'Z7>%_]G>&_IQ=U?H@\FW
MA[WT<@Q*YJ1[9R`VXO(%7@OT*^9=EJ1`^ZLE1C?.NS>(VVO4J.37H4#<7L<"
MB(-C4'$[$/>A(M7+7BG-7H8%/,XH@(TS[0E5\27=D_>$BFJ+QU7A]RM#E@M-
M9H;=@-BB5O9.("2(51(QE.XJ(+FS[`'-%OT,>KM#<XC(10ZQ"GJZNX"XD[FL
M'!3$'=M6'(.,VQKY.\-X']6)PH.Q\%R,CL5*%,5LM?T-LY8#WK8]"?8"[JL]
MT>B0;_*D&B9&3VYLYT$UV0-6,RF[\4MO/!SDPEL`C%?@OW=09+R7>U.UO(FE
M8Z%KGG9>9IQGO!GZM4!4`OR6+8(ZY<`>WK2A.S'WJG/GT,&73C5J[IGS,%=?
MJ9J=A;27!!4@[;0['3D!::$92X)R+3DK!Y(><">^-[<=JD>P#0F[2>AN_[P!
M^-;!EIUG3YBZW^5NNO!3=`YZA6U+[V8T4EQ"^8$Y/.\TO(SV<9F:,[]ZTBJ"
M_4%'&<""/!">:P4C![)L*=Q]`;OE1XV5"@2?8P]8CB8(<K<S4,:#?L7X;2$`
M)9'Z+G$/LE+>)R;:%ZKRJ%00*)%A+,J?Y=7T&HGR9T5)E5#!V8O4(N6L4N#O
M+.DSWC1.I&QU<^XZIU.;II1HC2F88+5K=(U6C2V79)8SOZQ*305Y`_KXL?@B
M<7S9G6_(,2P?5Z[5PX#]00OLKA887GEU%S`[,[I#JQ<8<19>%\S43?*G+A7>
M3.1A`VE@HV_!3K\5S*HG_:/3'O<[W;B,18L2HC#1V\!;WU:F(`16O8AK+X@U
M4"GPWS#-'?/?PC397*''^APKQ9+BP@!8`B-9-J)`.8QL"8S72T;D%;%(%XC(
M2YO<MJJ!*_6QK$JFM$H6VL12QKS0,!&[A;(.CJFT5(,^ZDFAIR5J8;)CL*3P
M.D9,-2'IU0)_G^'A0L6+*"$O9MD;.MF*?2ZINJ!F'BINK);&OXQ2-^D[;%U$
MA08H19.XS'YB;J@;ER*#3[;I\XLF/)L7ETU8MX!`RLZ1N9:3LPVEEUM[M2H+
M)34':,/7#+Q#O1657R%(51Z-2MS^X574<(N)W@QS;W]2G40U>>$G2$VF]TWU
M^4QS4]?X2)L<*5[9^Z=KO+<,\]<+S_'9Q98G7N]*&']#/'-U>.R2G-L=N90<
MQTSV;('YR@"P>(_53`KD#O!QDP?O!H9'!4%Y-5Y=+2JN5F(46AYFCP"*0O$Z
M\/S4H\SFUZN1O'6S[@?=Z+LRC,"+/X21M&H[[U6%U!Z=@P\`7=P$#\#;I0?@
M1WS^*"1/*U98Z?P+K/G$-]H2CY"5;C>K9G8!J3JTXK@S\?$@0>B59J-*MN]W
MV52BG^_HJI9['111++5?N+P>_MRYRP1U2PVQ7AZ+09I_S)E-6MLZP6<TRL*U
M=J*]0"J>^R2O[+0%(?H25,"#AS[%!=S*3_.1Y>X@S<V-,^\-Y$Z)/KU^KWM`
M&'=3TX-NYGS_((3<<N&.Y'T(Z3F&!OXG%C:"%_`?%.`GU639WLQ;=T%<A6OC
M9'N#MD4&UWZ0>2I6S;]6';SK[D[B6IF?@E*9^Y#M<MCOCK)2]]J,)4!8/+=L
M/.IE[MAL"^"#-F>Z;\+>O9I&^Q7SE,3YXWD&\P)QB.LZ:WBEW:5X&P^#S6S3
MI';66#0;OK%]5[5T]^W[6H=9*SOX[`[V.?C<^@6!A\!#X"'P$'@(/`0>`@^!
MA\!#X%%_/%9?R/>0$B[OLZ%[<^X216][U&-'8Z89X/+K1>>"/KM+50L_!P-,
MJ8G;I08.F[ITV?OPCP]\9&G<;7=B7YJH1.YFVJGRG.@C_ZQC!H[Q:.$$GF<O
M+M(`#X;M,8R:H'5BP*)NX*`]&!;V!$>9*7:L[8MC14.M<>+3#`L8Z.G;4:BC
MM`>C<BA$$D]SO<?JKLS9T7O&:=,8%T`2Y`FD#K!4+C8C+"OMT>!_/@3RZ-G+
M]_+2XQE;OWP:XW]2^".7PG6_\M'I=]<V#5WZA9]`1@_P@-#J^T>E=17RF9]Y
MMR*K4T=Z5T`[%9D1(WQB+8BU4+^UL%HAM"M7O11Z%2P%N=U1&KP4^&<G]7F#
M\0"BGV\Y3%7MQZ-C^Y:.IHOMO)=^N;JZOKZYV98T\46>3EO>1*GX>@]_<'=B
M;1%AIWYAEDOG*97IU=)HN8]]5H9^?6WE*&4*3LG(%A"*?Y0O`;+<'@PV$:4@
M1G)T),45"FTK'RY@4WEVU.6O%_S?R$-).#`STU:]][B+K9SNR2VE.XRE0`BZ
M$/33%/3A>%".F'/CH*Z</[B1<&*F@.4Y*J:_Q$U:M=PV&'7RMVKL71USQ8\Z
MG3(W-L&I"HT0N3,N4SLWA%?"4=M*.R\=>\9<EW>`GC%6G59N_.Z^<S2LEK:;
MW"]).PCNUI"[P[$L+'-AF6_6_70!6UCAS;/ME%Y)JUMPJF).C4N*`YZE"7Y(
M='<YN>-BT["DBL80Y,P.G1O#%R&H0E`;P9>Z[:A'(X@(B15RB[[:GFJ*\)<X
MPSVK,UREU1/)"D+0ST'0A^.N"(K6V2YHIGG5/.58<U(%JK4L-PF+M^NVCW>+
MBOI)@DW%E;U@4ZW9)!2/4#RGQ2:A>!K!IEI9R76)O?&/>,\YZYZ$OS:AOE<2
M[HP#UO0B[,5KQZVM.6=YAFY@G?ZG1"?,ZY^:Z>M,QXJG6&O?]^ANU-TL+&H7
MMAL4M>D*R6[VR4VCUKARP@K&`@^!A\!#X"'P$'@(/`0>`@^!A\!#X%$1'JLO
MI#W]\-,A*[?!T"NEVU:=P6TKM_5D&E14;MMT4M`OB4+UJ%;5?24?4QD0P@W/
MQZQ5M:JO<X<EFKU^AB?FB4Z_UZ`$]?ACP3IO0K*%9!]=LO\TK!H*=GF;6A.J
MJHF-_:S5WVN7*SI"Y94JDY451172**2Q+G5)A30*:12Z44ACTZ6QHIK-39;&
M+;V+U?L-@6MQXO<>$XVTI:B1-KQ@:S\JTW#UR`H\E*:K%-F5>U*5"@M1Z)>?
MJ'"J\U2%=!S]MMRHU9&5UGA4VM50P5>QZH5TG->J+]E\:NP]V=U"U/6T%A_0
M+I3L)6:C5U,LMBP/N&8K_ICK6FX-85UWY-+*!@H>5=$U1.ZUAN456!<\$NOH
M+'E4ZCHZ^.ER'2R5DX]X+1:VQ4-<TK/J.*I543L2X=?4PJ_ICUN]3E^$,DZ*
MJ=U>:]0MK8F!8&HMF"I6Z@DRM<R5*F)*IQ=3ND^?.E9ODC5$2+99^>)0X5PX
M?53G6FDIHY*J:)XL@\12/!=.G\I2/,L@UUG4'ZOK`JTW04XC1?4T>"&$4PAG
M;7DAA%,(9VUY(813"&=M>7$$G^-H!"G+8SGQ8_D#Z,+&GQLT_S!(;@V'<JLG
M#\0AWTGQ==Q2AKW6J"-.Y$^+KV*]GB9?2UZOXER^&E.MF19O\W1!O4E5MN<J
M>MX(B182+=@D)%I(])FQ24BTD.C38E.M?*^Z!-GY1]%ICZ,:OL^!,FK6::^D
MCGGK.O)=+Y:F_<)@;.?)T!B]]%%UF8[#,LNE<2<F#!',\(5I]J,%5-)A#L.&
MYUS/%8WYJA7U3;`FSZ+DT6&!_VI[JLDO)EQ.46J`_['82.PG_LTDPY6<2&RD
MF>T$=QF"2AG2(]YH@%\\6V*!/+J2:NFXWUVFOYFKKC1ES((!E[:#+QF6Y,V9
MA/*J6B]QMN[X@PO3J!Y;`&5<R9[!=(P+)`SE`A@@U<^N](8&L'T7AG??OM^1
M"X<A^LJ;FV:I<6L5@8?`0^`A\!!X"#P$'@(/@8?`0^!1?SQ67\CWD$1+1-$Y
M:0L*U:-Q7%\TCA,M$85D"\DN0[)%2\3C)R"*C5VH/U1_RBOJ[S2NOM5*_8D6
M8$(R:RN9HE6BD,QZ2J;0F4(RZRF9HH5B9=>AQ/WT^M7J.(+"JEEEQ')O>PH6
M"A8*%@H6"A;6QVAJD(ETXL5]OC"7J8XVIPQGG3TQTUYBUG)EIE0]KL,<8*W(
M2GV1+2`8_RA?`D">1Z.ZUMV0AZ763Z\KYX68G[F8E]O(LJZ<%V)^WF+>%\VJ
MA)B?OI@K(U$F3,3%URR&WYG%'-4DST[5%X9EN!Y>0GUB(DZ^6WCGF$N]*Y>Z
MHPE.56=B=Q7!J49P:M`="4XU@E/=LNK<GF4,^RP*#=5UI1Z=(&>6OM08O@A!
M%8+:"+X(016"V@B^"$$5@MH(OM3-1SD:0<KR<$X\2X>*'5:F$AL?]A>G6[L2
MI=:G6[U1J>&YNG)>B/EYB[E2[GE!73DOQ/R\Q5QNR3V18BD$O2Q!']15T`=E
MY9Z)I!S1NZ_)JK'FI`H4J^BB4VLVA3:-8%.MV204CU`\I\4FH7@:P2:A>(3B
M.2TV"<73"#8)Q2,4SVFQ*8RJ"3;5FDVUB@O6)7.$?Q1]93FJX?L<**->?65+
M[ONZKKWLC>_Y#OML6,;"7_S!8()[]84:<M[8SI6Z-#S5I*_=KR@VHH]LM:*]
M"=9C]I'E8B(MN)Q(RT!&)(?]US<<IDN@8)E#?5ZQ):RF6AHSJ8E0T-/5>I1,
M%"-L[&K/I/R&"A**BP2"+KG^`C!'81:=8)>B,Y;`0^`A\!!X"#P$'@(/@8?`
M0^`A\&A<)]AA=Z41[%!9<:JV;1@W')5[$E3K6WE5=`_A\:+8$[^V$)OX\R>F
M97UUN8KFA]UVK\GM1D(DBU\G';2[99XDB$8X'R8+VZ^D++=,K&JL;&;.`;;/
M+@Z5[&G?(/W"%JI!D<R*>GUQ%5>/0ZD25-UK:Z;?JR^R!<2ABCL9O?9HXT65
M@AA5=,>NM#L9W8T73QHBYF5IS5UUH[)Q#TEHQJKU(FC#0:T-OAJ;=\=<T./N
ML,P%W1!.U=?8J=."'@KSIG1/KI:[>F]0JA)H/'=KIQZ:F5K6/(UP=%(U*#(D
M.-8PA7@T4AW;2:I5`(E*D$5I<CSC+4R6$PY4\:#1N8:&CMV4H37HEM8KYPP]
MQK-0^'55334G2!`-/^*U(<&,C*H5S*@#,XZP5=3%6.8?Q7TLCFKX/@>J9O>Q
M=KTHM>[B5?Z%K@</7KE;XI_N1/.,)\-[$1>OBLOPB23OG4H2HL!#X"'P$'@(
M/`0>`@^!A\!#X''*>-3QT@T,O7+K9M6)VO;2S>%[IE9Q7>``E<\:>V6@6"#U
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M<GNPEXYM)(>*<*7D8`_G5EUP;";;MEU8I\W"@Z?KU,&&.>$"3N&Y=77V3>,M
MX>9[[&^4?JO3J]1IKZ7ONMNAS-8'B;7D.<`FHC1E+=[3WM-/C-7EK=_39KL(
M5)U6H.J*FB6:3)=L1YK9SHP9(F[5F+C5F^ZX-1K)^_/EC"VQH\8=V[V!6%1G
M%P]I)-M$2.OL0UIG426IKDNXW@0YC?SHT^#%.0KG,7:GQA!'2,N13-#3(,@Y
M2HC0)PTRC8]&D+(,Z_.ZK?+`EE[VNDJG5577PQ,[J&CNX:+<&LI*JR.7$*X\
M#VZ*//#&Y8&W^R4DD=:5X6>DJT9MH::$FCI5-=5K]0=[71H560#5F._-](*:
MIQ+K3:JR8^D[-`@1;!(276Y,J#XF0KU)]:KA($@E%F`]DY5/@U1"JH1:%VK]
M^`=(9TZJLGS3DSA`"BX<4F7Z(QT@-22DL8TU<,P0U+#?;XWV"T*='E^"_?2,
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MQ[RSJU-=)(:R!LT(]F46[DRX@D/-'1H`-/C(_9-DS7M"-7R?`P4@_WHATQ/2
M&AKO.7'R=2GYX9_O?/?R4567[Q^T.=-]D]W-'N:JPSZJ+M.O[,626:[J&;;U
MX-G:C[LE_NE.-,]X,KR7K\C/K^RG]]&$'W_[W_]+DOX9C9<[BJ0!:O#"%S;[
M]>*3[]"7WV7X3^G(O>]?[>_C[]T.?;B0?,O@#WZ#/^0+26>:L5!-]]>+R^[%
M;X-.'SS!!`*Y$^X-5#\)5/\UH&2YURT)JHGCJ-8C6S#+^_@2/W*OON!7DV?5
MT?_T\13R;C8!?8*OJ"8]YTY\;VX[(%9Z/FJ#!&J#$+7O`3C?:>A/JL<F/PWW
MNZ9ZT^\3R_)5\];2'`8P?*;#S^CY>U.U_E07B<>O%TO3?F&,9.;>=[0YO(6/
MX3S\[2PANTE*WOYY<_%;=]`;=OJO4;(4*I7,CHU,F+C?[V8Y5*^(BO)(Z?:5
M$JEX?-J-"]".:`;R"L,;3P'1.J.B1%/ZXYZ@V9:"UAF,E-'PQ*FVOV[<D\K*
M>-CM]AI'Y2?5,-%8N+$=ZE9^E&7]ZK:\/UZ-HUYQT1L-.N/>Z"@DG+X^RS0[
M2V"J)BYSWUJ>8UBNH?VEFCZ3-Q'Q-3.O.^B/5\V\2L`L2:)6Y^%LV(8*JS(Q
M[/=!+$J0B77@58;]O\FI9/KDB3GJ(PN;#-\[AL:VH4DO21,%)*.ME+$';@=P
M94LF,^D7ME`-R[`>KX!`CJIYL/%]9<Y"WL:#^NU^\!^Y\UF1/U6R?(J"7(ED
M,??6NF>.8>M?;0^-@N12WL+W3=L;7U^67(N'WZ8\`PY!OA9/Z2T@?9=.3TN7
MSXUHUX70PT,26CEC0N<N>T'HRB2Z>D)WRK&=CT;B&]YJUD=ST]*O?RX-3L$(
M@CTB@#F!J_%H))='KE>!/S"M"EM.V]$Q:TAAM](#$G%+\VH/4,C)B>;]W;%=
MMU3QZ_<[PW&)-F@.O.42)-&P98/6XW:XK'SORL6.!_K#'!>M"C"/1XW"_FJO
M/RAWFSP\,=:ZJ^M%(B]\I@SD7C5TJ,)A+8+_%JI!'LKP8(E[T^'0W])?7R\4
MV7VFUY;+"*=N!W%=R%1X-\9>,W6@TAXQ@O63KHL1**][[`DY^^U^]!_YL](K
M,:RQ`\CUIME**`A))G=J1[(]9)M?'>9&)MT<_FKC5V5K\OYHH'2[Y2W)HF`?
MFEC5*;1NB6;`?GB4NV:WAJ6DJ.[H/\,2UW%Y6%1!W=`;NE$-)^<T:;\<HEYO
M5.[ATCJ82UK+,"P>*0(/[F8)_E"$Z;/ZTUCXBYT#A0<[:E<R^J'3[I1A%A:@
MS;&Y4,-DL!0S>L0,N13OM7QVN-L&.P\4/E/:6^7.E8I&R21,!Z`.1#]9;@_&
M)1*P.!(YU'-O7=>'8?%G&("^RS%^NM_E;GKU/GBP<A&4*U-UW;L9"7I"00(P
MS(4-$\#PC*G)/BX=-F..PW2^)')79V]E=8[[G:PIF@?R[IBMZJ4'?^H:NJ$Z
M+P\J)2U'F(5/W-[?%8`?68UWB[8'WWBTC)FA`5LGFF;[L,=8C_>V:6A`TB@G
M>BL3*DCLCI*T]TCRWB<YO0%Y^!M@C0M*C<+*`W'IJ-'!<*$7G_DL4]O4^9M*
M>R6_?YLQ5L#9!'H2=7PV)0/P.7$+19*5F'`)8=H&3H*JN_/K*Z1Z\!<`\8MD
MSZ3$4I/BM2:%BVTW.6F23!]+9OE(^.Q[PU.!VGRL+PSV"Y?!**CA8`C#JS5>
MY?`@N9X.J$CHP5NZHV*!(PS;A_1L>'/)FS,)MK@6_8%&B6J]$(Z__(3=9/S!
ME:8VF!^X?G3#@3=MQY7`W.5<FP-[&7ZQ7#KV$],E59(O9[9S"9OAJ"\YJQS&
M@=9.!5\N`##:A*7GN:'-I6?5E=ALQHOGP6__U[=8S`-9YO7RVOR=$!STU#R3
M5]N;H1-OX'4-R:4M68(150#-]<T(FCQ``5EF<)PTU9U+2VZ-288EF0;S\57^
M""J1E5G:TL0,_F[Q?R3V7]]X`BL#QD`"+ID3_*`N4!>Y$EA-+OP*4\Z9PV">
MN?K$I"ECEJ3J?_MN4#\0;"L3Z+$.\+;T%7]`$P&8]Q+0,<`=@+X/;;.0SHS;
M2J'Q!@C")/'S*::\#A%GEKN!LNW$&HK^>LB?#RGB(!-`J*29CR?OD@$VE0KN
M>`*8F'+PIFHABP.,X*NIZAI<9A&@F6'!RP8R*K1J71!M5S-M`!.?B##C0[BX
M5C@YVV>@G^JU1WPDWG&I10Z3X5MKS)J_2Z#Z4,$^(@5-RBUOR83KR6&FBHLE
M6$(^:5A8I;ZE^KJ!O^"3J:6Z5%'[@'[#61R=UC)M1NA7D5Z"$5WID5G@UIKF
M"SZ'M5)U>B$PVY:.`3`M37CP3;R+7'WXUGY(*)C?)Y/[^-=/']X2-/"FZ>N`
M):AHOMHY3K`S,M=%<Q'5#6D+U7!"[<(O>6[:OV)"+6V7+@E&`RW)84_H^'/0
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M>U^`BO%K/:7W9OKV3>]M_-6*\:ST^="KDG8?P906.*&RZJ>R<G96FXN;JRY8
M:/RZW+(-ALX;J"W=\M?LI6&]MM$!KBH/6'/',64N;(T"!C=1C66W8^ZYH#$1
M;\SHT<&>#&HLV$FWVHWYXMY0>+T5V#3H'-*S!OX#.BM0WZ%.\.8.8WS-`_LD
M<%B\N1LHB0W#TQN1NL"QR;6<F?9S//9N(X(+C,HT23^D'.JR0/5+7+/"QN,@
MFRP5O:G`6PP0WA$$Y)#M15PR:)/1#4W%`]/8$TS/$:I5A&6M7@6&H.,'_\/]
M.'``N2UU#MJH7L[8-Y>8>>UZQ@(M]%HC=1K;`=?IVW@>";W*[1XT#0WO)6N^
M.1B.0KLPUN6H7!?J#R:QD,.D,E37]1?\^!$`4#U)I1`/5_Q!Z(K;>+&IL]9E
M3.T49"^A@8=9-I&"T,AXTPV8Q>%F))F)$5#GL/"/+7>A!^1[ADE5+=S$X<EZ
M\0#NZ\Q#"Q]3J&(/^HEN'@3;:2K`!VX\[@>VA&)ALJ2@W][?\=TI)P(=SL)X
M$"*$2,],%ZR7>#K*;:(@H63Q_$EXRI[^C2'Q)[ZANW[T<:;2;*$ECR@!7YB#
M85Y@U@]&)11X.2`W6!8AWE,#A%N;6[9I/])V"-LRV"\N(1!%3Y9X,NQB-QAN
M["2]3Q=4<2(.FPS11N?K/*X:&F%S@SWQE4S!:1=V6#0)8"X=?C#M)?T&(@/T
MLBWF\O=<GS941Z*#7,Y4/@&S-#ZW&[NK8',%'%LAKLIU`K""10B:Q@]F&G/;
M)@9R$)%$*OP""DA'S02PH2%)JQR#\^C0PF1HN/E3V'W@30`&WX*)7=5D&54H
M%,(1%,(3V'DV.*VXUOC^M&#>W-91WE%.<F('I`X<\$J>;>='R,/)`E@+:@7<
M#UC$GN\1=S&R`>H&YKGG(A`<V&+V2SK>-[F]NI^DW-26-$'_@T0P><Y+1S0`
MR\1`<Q935MY+?T704XS9>`(E`M;KOQ@LO1#E:Y!3D-)$R(9G=:"LINJ_K<*5
MFC0#)*R@4&T54)1<$V9)',07\'6>((0X:(CM9WHR8%>HDSZJV@_0*J#9@I_?
MJ&A;+T)>!#J-3O-@J8+6F)&*#3;U593>1NO\WK&GZA0F\UXNP[0D*4RZE;XP
M,-RM<%:NA/UEX*<NXU=)&VOHH:#J(:T7A+@"TS^C--P]E(9TC2CFB6\4(G-?
MLX0"(TI?;YC][>N/J'7;J?0#'NUS0RWZ@[VDQO;=F.@1@*%A%)Q<XE9+)A*J
M]%AV5H_0`$R6QA3C3$)G'EQGNI$PQU)%AZ>H):E#G.4REQ^HT(JUU^_A6I"=
M[I)>X!%1^B(>NY6(GX"9L>!^>7A<$TB>R:Q'T,RTQ3M/!E]S)"[A@"T:(&%O
M35]25DID41G6TO>XO4YQ'S228&FC+96*%\%B?688Z7&C&+&C7X*7X[U$0&`V
M@8%'^><@IO5R\C&O7_HKW(9N(C\.MV?')T>NUGB>ANI(&`-@,3NH`UZXKP1[
MW/_CAPQ\Q9$.B74[^1RP2;)@%T&7GJEX`I0<DU(\>`QS"EN]#GH`=`O%B6>V
MB='(]](?^)4DA[.@%OBO;Z/N")R6-[X5IDJ\Y>8>.4W<B.!Q/@,)"%L>KG87
MOX3O3(-O]F#!?`@F49*3!'_:>(R"NZR5F3:R>M"FA&E#.'EH`D.>4U0C6,0I
MBC72[,G)7UH2,V@&[E."9D1PK?#3!]*X?.AN$CK?2@P?,H";`G$.3*XE8#];
MJ4U>G=J^%T(7?1N88*@.P9!;DKW[3/L^L!.IO`P,O'RTVHD5&Y`<$4G0G+#0
M,(^;V]?<S#`<2IIRF)?0Z+1!V,_8KI3D@^Q2TO*$L>&FH@+!CI*0LD#PR/P1
M.J-RG:&ICD-AM3@H1R(9VY)3U21OS)VS<(72^4.<F096`]@<'L@8)4#!CRT>
M@S02%@I*%%^>W%+W`E%K!=^&GX)L#1=3YVB]!`%`!YVG>#3T-GY&?A!(3]*:
MW=PGET9<?RC;DG000RZ8!F;;V8YWB89,\O##22:267;6-L\Z""Z,Z80+L-C1
M\"Z'*MS?"XTLQJ%`J!S5<F>8Y#AEWC."'*KN(/W.TB,3C@=E*5F&GY@$Z%+&
M'V`:CX6AF3P%G9TD'_4]D)QL9"^/3T5RG0WKK>I8G4V]I$`EXX&M1$9IPISU
M71PZK>F3`3\UW'[(J$5=Z)R)^U0ON_0+PRMWZ8".;<'?&A-&:?7`WY"KAI%=
MU(OP;TNR8.A40EZ2'=R4XW&RP&.,+9,$$Q_P[J3J@%K]2%'^5`SM9O+P,9V]
MAPE&M,>XP7O@,GHTT-36PVPJ5;>7WJJGJD;95YC<PJT?GJV,9BL%1:1OELG<
MP/A\-ER>0>6#:M1;::^7F1AK#VP_,L;A!\T+L\(MM"@#]-T(Q<A$Q=/R%S#=
MXNF?#7")\6O:BU0)M9>#M`K'M2@DF)/3@('[.%\AD:M``3:B!7P\!X5UY*L5
M$S#-S41Z5;2!H1B'PC!Y^";]:;?3CUUVNJW5EBVO*<U5'?D`PF(:LY=PC[[/
M)*Y^PNWQ-DR?O[+=C-HL@B@:$6CYA^M/A>4.HLU^&BZMPT??X"%_"E]1>#2(
M\J9AH:TZ2N77$)9<,Y5?UP!#PN?9>T',:,7<C=-,@GQD'#_RBW#3COS)8,3@
M!`WL/><1EOXM>33QBN1))Q8_F4X;4F@7@=#1&:<Z@X6:8_W)_="&F?H8@<64
MI7`QIO(@TY8>_!(8U69D]H7L#%1!H'*23"#M09IC14\D,KR$"JA:!7"G(V_-
MXR^7*`W9-1GOB@]QID2\Z?4^2+_;*`!7-BP))WO(%(^<.5WBMNXZ@0[%.$B_
M>D6&![DW=JXWB'3>\PE8P_BN2S9$I#'P"$U.9*S&4>.TE0\4A*W--8*EC0'U
M>*$\SQFM=$`6MU-*QJ50A3_%Y4(G1-@%V`L",*JDY7D2H=Z@S`0T57S&]<8C
M<4,+N!'$H+!I,#E$D7;2HV.]W$R8V#C*]=3(C'FC)&@1JK6<X9)9WKF43^J7
MN>H274(;"4&,&(`Z6G.,*;>=D@RC\P>;\7<9'>MQ=R_)/Z!58+VDLD5XMM".
MBHG^.M%6:86N_F?*!22N.0;GTOM4-[T<=CO]3*>QE1EV@*!PD:+^N-_K[3G_
MG^">?XJ6@*B9(&HFY!4"&(N:"45)E4H?^)*\@7O#LS!"%T(8E`?+(<!]>^-E
M:+(UZ.R.,FNCY,;\B]SO:\VZRA9;=[#/8MOZ!8&'P$/@(?`0>`@\!!X"#X&'
MP$/@47\\5E_(]Y`289YG0_?FW"6*WO8HZ4ECIAG@@BW0Z+.[5+7P<S#`U'9T
MYEQJX,*I2Y>]#__XP$>61IUV)XX?$97ZO16GRG.BC_PS7M0QC4<+)_`\>W&1
M!GB@M/LP:H+6B0&+NH&#]F!8V!,<9:8H%,VA5Z,WUSCU:?X$_/+T[0C2Z;9E
MI1R"D(#37.\Q(8`Y.SK+.&T:XWV1E/LD2X'(>?;RO0QKR\)3C%\^C?$_*?R1
M!&WMKWQT^MVU34.7?J$^BIWH`1[G7'W_J/3=20174Y12,IF?Q;8BGU-'>K=+
M7"YG1@Q<"_D7\E\/^<]-?ZU8_'L5B+_<5@8-%G_^V4E]WF`3@.CG&P135?OQ
MZ-B^I:-%8COOI5^NKJZO;VZV)4U\)M1IRYLH%9\4\0=W)U8!V^XJKNQ)]8#P
M,G`B4R%;([4R-5L:F?>QR`ZF;BM%-K'<2.E6*T#)!!TA'=5*1T%("=`5*;B`
MC??949>_7O!_(^<LX;O-3%OUWN-.OW*8WV]U^X/6>#R(D=Y_=VD\7\O:9<Y@
M+_EXL+VD(;*SC4X0^\*Y</J8.EYI#?I]T/%*F3J^(3P2_D*A9?UOU:'&6W$Y
M[Z`!74Y#!6$."F=!.`OGZ"S(2DL9=86G(#R%'7:19':FL!R;83GVQZU>IU_.
M@A<,JH!!W5YKU!T+NU[8]?D:^2XLYFC'NO@@BKCQ&WOSK36EU1\JK7&_)/4@
M^%H3OLJM[JC?ZO9D88@+0SQ?[5\OEJ;]PEAPQ>T^5/WWIFI5IO(;(BA-,>WD
MD=+J]DN*V9XLAT2P3%CQAT5WY_3>Z,V&I/>>!D%.(Q7R-'@AA%,(9VUY<82=
M\V@$$=&S0J;:5]M331$B.]U0BM(:R;W64"XI^U'PM29\';=ZO7ZKUQ<ALEIK
M_69NGLW3!?4F5=E&,-8;PP*8)BML!0LV"8D6$GUN;*K5OEX77Y!_Q,(.6:,J
M_+4)%0^3<&?,QL97U2U:'[9(65GZ]F%I&EY\R^<+%I*5\ZO+#K[+<7G9Z$.V
M"*Z2K(([N/BMT^X,AR-%?@V)]=#DX,)[U'ZBACWW5%3Z@2I!QJ_>S:[BEM*)
M[K;K,$L@%M3-_1[,^/W!G[J&;JC.RX-JLKL903#Y:;C1$[?W=Y_I@GB6&-TD
M,6[_O+GX;=Q1QOW>.$.-G?$Y!&U">B2)4V=$0=G03\=G=G_8[ZS6?WX5[OK@
M>@>,F)BF[6$I<YY/5A3WRE&G'X,<M^N?S-$,[.RW15WL5U%0^IU>OR`&N="D
ML?G*%DO;`6ISI7<5M/B84(>/B><YQM2GS?>K?:\Z82/<==7/8RZ&I>:OL.]A
MDHN:ZDV_\SN;B34U6897>NC)?'YF2YGWAJ/Q*,7/K;&I)3$^[D*,KJ+TJB0&
M/'+G$"8Z]:H%.2,A*Y$$$RVFP7T!$O22-.C2KMZ1U^*_#H%C8_WQJLE8CU<5
M^.FS>D>D:\AIOD],?&]N.^!,Z$=<S:M;W6`TZ@Z'G>Y:E+/0'PO5;1F[BFIW
M..IV>L/#H7J@=;N*Z?H-JB8H[L_,4E'DMET3UR6'_!@HEK`>>S)XBL/UVK8L
M%&N[#H^&6O7KKS!J=[Y'#?^"_F--6X`)\(^&[,&68IG(UG91U@#)ZI?G6B2_
MN>QN=NUZU&A\37!)=!O;\Z#B^+#2BP7ZDW_CU_@C@:@U4N4PX-B]L98.6ZI.
MU$DUT9\[OD2"O3QS6W`:%B[9F8TM2U^HCZ?TK?W0EGZ?3.[#QL6N%+<@Q3O"
M"_4'DUBTY*G7..S>B_`6,;7WYNTN$1C>F-@-NGN"51+T-\YO"8J#:4$O4FKA
M9<,<;6FB>;P%,6_QK=F^J4NZ`;,$W49=7YO'0(DFOX?KR>9[ADG>7JK=Z5KQ
M`.[KS,,>N5;8T7FF&@X>POND.[`_:JKWWM(QL%*(32UJ3984]-O[.]XX>FIC
M`VALJ`T"JWFVXT:S!.U=0XCTS'3!>HFGFZIX/(!-XQ/]X^SIWT'_8,3']:./
M,Y5F:P%>FNG3M@Y\88X%T@K,^L$H'JT;''F^+$*\IP8(MS:W;--^Q`:^NN]Z
MSHOD$@(T$6\9;FA(1R_H9IQ8X)C&KR=ZVR5L'2F*5P,?`2W>CUG5Y@9[XBL9
MGL=6>JH#8U)C6_C!M)?T&X@,T,NVF,O?<WWJR.M(M(=RIO()F*7QN=WX>-!E
M5L"Q%>*J7"<`*UB$H&G\8*8QMVUB(`>1^C'#+Z"`=-1,`)OEM?@JQP;$%I#+
MH"[&2W\*NP^\"<#@6S"QJYHLHPJ%0CB"0GA2069\5PK:4H,0+)@WMW64=Y03
M4`6HZQW>-YDV'U('CKI@S[;S(^3A9`&L!;4BW5JPB#W?XZ6"4-)G!LQSST4@
M:!],M872_<%OK^XG\1?4&7P":]4C$8R[#DOW#JQF6&W2Q-"#&J;OI;\BZ*G*
MG?$$2L1\D?[%8.F%*`<M@!-'Y($'KI(N6S++Y4.LPI6:-`,DK*!0;150E%P3
M9DF,6BE0@?S4$7'`MBO29WHR8%>HDSZJV@_0*J#9@I_?J%BH:1'R(M!IZG+I
MV-BS6V<S4K'!IKZ*TMMHG=\[]C1H*'[Y;Y)*>.^:NFC#'U^8YSM6."M7PO[2
MM@(=&+U*VE@#.I/J(:T'@J#"_$$OT(S2</=0&M(UHI@GOB\A9=W7+*'`B-+7
M&V9_^_HC:MVVE.B%+6ESU7ID;JA%?["7U-B^&Q,]`C`TC+B91%LMF4BHTF/9
M66F#BEJ9I3'%QNU"9QY<9[J1,,=2!0(`)@UH2>HX;[D,36E3Y5:$O7X/1U<<
MUZ%+>L%ET1?QV*W`I,`3-3`S@"Z`)1\=!99+GLFL1]#,M,4[3P9?<R0NX8`M
M&B!A;TU?4E9*9%$9UM+WN+UN6(&1!$L;;:F$C]'"Q?K,3!/_I8>]N>'HE^#E
M>"\1$/#>DX&989O$](0S_-*!EW10)BRQ-['T+V2P;1U'O`%M02>6'U^B/_]E
M,`<E[>4/E+)4^D_TS"URV*4'NCSV5""2%3X1@%TLMT+NI#,K-N&\%W6VCLF%
MXZ<C<4C>`ICU$;-.TS#KUQZS^@OT;G0)[*@)^'V@/O\DAQ5`09<P\=)'U34T
M&.V38?K>*\EOO628MK<Q=-RY^*TG=P>*D@!])X"J0VJX$U*]WG`TK"]2VZ<I
M`E+]_GC0D^O/JNVPDOO*>#@<]\I!Z_]<7M[8MH=!1W3F$*S+2_X3V&T_WL^"
M'_^`#])/^LI[6<*FCC$?L"+UB^!;Q\:M?NYYR_?OWCT_/[=_3AVS;3N/[Y1.
MI_L.?WZ'#U[0X.'PIJVE1H7/JF<[X:!S!\GPRRUHG4O0HTKXO:E.F?GK1?3]
M=W-J7DCO4D.'D$^<]!2@_\)AX,]7P`Z>>(=!K\MPQ/!UM-16@`BFLG^]".EZ
MV0'-1]>2T(;*0+D=`;IK"-"M`P&Z!R!`;PT!>G4@0.\`!)#7$$"N`P'DG0@0
MCID"$9P\VW<TMHUZR0(7D"@%Q,^%"=]C"UYF77Y[N/CMC?P6(/G"ENA68O`$
M_3@]C#\])TMWNQ0?DSYNBCJ'OW%O,O6ZQ@,0]-@_WZ50YPHW_1UJ7/C^G^\0
M4_CC_P-02P,$%`````@`<X!L1^`_]$WL"@``RI@``!4`'`!C871B+3(P,34P
M.3,P7V-A;"YX;6Q55`D``ZG^1%:I_D16=7@+``$$)0X```0Y`0``[5U;<^(Z
M$G[?JOT/7L[+[@/AFDE()7N*P&2+JF1")3E;9Y].&2."ZM@6*YDD[*_?EK#!
M@&5+!L8RR<LDX[3:^OIK2:W6Q=>_?GBN]88HP\2_J33.ZA4+^0X98__UIC)G
M59LY&%=^_>=?_W+]MVK5ZE%D!VALC1;6`Z(4NZ[5(W1&J!V``JM:#05_OWVZ
MM\;$F7O(#RPG+/6.@^FJW"W%XU=D6=_.ZF>->NNLOBY]:S.0!GU"3?.LL?I+
M]'[B7UF-1JW1K#7KC7.KT;QJMJ_J%];P827Z`"`F6$'6Q?Z?5_R?$;S6^F#X
MBCE3Y-GWQ!&H;BK3()A=U6KO[^]G'R/JGA'Z"KKJK=JJE%2"_Z\:B57YHVJC
M66TUSC[8N&*!\7TFWJWPDD@<:K@A_=Z*9!NUWQ_NGT7EJ]AG@>T[ZU*@$Z>\
M94=^IU;A>QJ=3J<F_EH!ZUG6-24N>D(32SR["A8S=%-AV)NY7)=X-J5H<E,!
M:XZJG()ZIU7G^']Y#H!,[B$]XH^1#Z3?VBZOQ/,4H8!5+*[ZMZ?!1C5`C0WF
MP.S,(5Z-2]0R]0A(2B:N'1[3Z@E[G#S.T+*IL*X_[A%O1M$4A/`;NB=L'\`Z
M+S'&&CV;3>]<\GXHX#%]/Q%C'S/')6Q.T1WVP>NP[0Z@,5'1][$^"FSLJB-4
MU%8(OJ[CT#D:?_^8<=/O`4VFJ!!4/TB`V-!>V",7A35IYL"4K*9P1#W;=9H'
M@K6EJQ!LT)]Y.-BS:24IT4;C@#7FKNAH[^%O(0+^IOW'JYB!T$>`0&J\>HH#
M_@88[>L0,EDK7?#[2IT5ZK.T!T`!#<"YQ-FHA<N#(4(W>0K5"543FXV$/@@:
M7VU[)H*M&G(#%CT1C%;KC3#Z^25\_$>7L1AHUQXA]Z82/:P55J'>G%(PZU:]
M$F7^^-8ZOVQVFA>7[?-.\_);JW$>JWG,3[IT$X1-G4@__+KC.IL<A1(U-O<\
MH:V*@?FH_(02;VVV\"5$I\*$CA&%.4#%FC.H!YGQ=]ANQ7I'^'4:B+\400<?
MU7D@`S^^_W>.WVR7M]MNT+,I7<`\Y=^V.T<2FI3*FD.?.EF[!.>':BKQ0XIF
M-HZB!,#V&$P156F="B5/@_2\0$/*FVF4SR@F%`<+(58,_P1F,L%B"&-9`-BX
M6\_X4/<#R8F7%S&'<7DOK5U_%2*+X.X)P9P%.P$:)_=+$OZRBI6!PUP80AY;
M1C?(6.?R@_A.:A><*%L&^M0K'G+6-JWMW6-[A%T<8,030,\!<?Z<$A?JRK@7
M!HLMQK+%"P8A\;"8A#E^I6K[N,=E`5&)SPKO&V(@TF.S74%SV%-E))7#?>=8
M:RH+ZC^ZCD/F,%!%69_TB7"BL-&4ZH78&@!-G4B%Z5;E)BJ5/RU:-3":&F9O
M9&=3.4V0/"$V5=&5(LSNHPD"".,GGB&&GSC(C+;3BAA-LR*_VOCT$ARM@F(F
MXK^^(.K%O5<6-26(G@*QRKCT6FY!A(JY8\P(:K/DQ`(;1FBWFZUZNW3D:J)3
MF4\73G$?4?P&IGI#.CQGE#H%LO-`#!D_-YKQV&*QV$_C!]A_1;XCSTRDE#@%
MIG7AA2Q_,WK2FYDFDPN:PVF>[),B'E-G0"_(X]M/Z6)9]VBUL^OQ27LW""@>
MS0,>5;R0H9W20VOK,8=U329W7>`PV$N1IAS2<"8AC)6V=2!!\H0H5T5G:K/G
M8Q#Q,TG<%CLA!I6@J<R:"LE(CF$*+ZHRM/%XX/?L&0YXO9+SD<G2)T2F#D)3
MEQV?^$Y*'XV_V]2'T8-U'6?N<0;0N(\FV,&RH3>[X`DQG1.LWDQI-;A>U[9V
MJ1Y^ZZK6R8,8-=)]K<V4?:WKEUED8JU?9]G^V-IXH:5YUJ&(Y#T*!CY8=L,X
M8=O8^EL1[7G]_CMP_>4T;PXNN[;Z+9H0BI9R+_8'8@_8%QXX\`-$$>,[F#:U
M+)O*`PJF!/[R!B)>RFZ@GU@#<WJ81*^(]R!%6Z44:]BA,?Q7:0M+D33'&4SA
M/"&WJV@V4]?$5_6/#B%EN4<D9YYSJ%*10F(JN$P*J\5M,D5@*+['LH_>D$O$
M5MD0BWR'J;R,P=RF,I049NK"-+6A_@OY8`(7@'3''O8Q"ZA894BG.:/4Z1"=
M!ZBI29T?Q">;?5DZR5)Y\^@U;P#7,UXI#HR(]69=)THO9)XGZ555LBB?BWS%
MB+^@9=JHF:2SO25U>O2J`,QLS%4CLDGQZQQ4$D<MY<01UVSIWA1AS-'7(0)J
M^%A`$=2KCY8_92L@6BH*&?51P&LWI.0-`ZVWB]^`L(&_"HBZ#L0SRSVA"<.F
M+#382ZEYW4(>3]@8[0]OCU+D@=)RK(DRYE%_!.H2_>,`B9S"(\`^FE'D8`$=
M?G>18`KF1AZA`?Z?>"[=HI==]),Z1V[3E&+6\#RU*1)7SO$%)`@7TKPD6?B3
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ML8=>^KFP^XZ)@]!8[.T:,#;G-[@/?`!JN\/YR,7.XP0B1@`KZZ)4RYOG,D>@
M/*&'VLL^I5C_3(+X.-D\[`M-<_D`\2\.\"<:_I2M[,NY]C56*59-XW@%E$=1
M3?;]`U$'L_7VK!2G2BSWY3\:=BG%LFIRT^BC4<HM[I("7\ZA8I!2+)9&\X4E
MC@B56`W.F((EE/BL?J%ID;QKFP??^*OZE;,84Y)MO^UZJ]ZPJM9:(_QGI=2*
M:;7^'NK]A]F;?F-K`'<VIN)RCS6ZK;:1)6S,%7GIM].F%3&G;:LQDWDI7AHN
M]5-X1VR3TL_SJ33']FYS#/59D<*RM$35>[-3Y(IH?]^]F4L6"#TA<:V(<B/,
M+&=.2\QD)MX(\^$Z\GQ?LM0:`N,Q`;7Y-V2B@[QB4$_F3[U@R0C<$U@IYM$A
M/(@3)X@Q4<$[I'A!OZ10R5C>`U0IIK_+#8>:GV!(+U12AG.`4K_L[(CQD.33
MOBK1T'F]N1T-"6U6J&X5"EE-PX.AZ*;VE+Q-7(2S>=&^[%Q>7C0N.JW+\V91
M'R:*5>K!#L*E["<T6\V=AQ3#9''&IZ#_@9'ECLRI`D!E7>8T5F6>=IONX9"7
M8AU%&^X+O#WKVPUZRCZGV\BAER*:T\?[3@[F->_DD_J,!'@IHD,-M$_(LS%$
M&92?GF+`)@>_O_<DJOULGJ1NA)R+*S\I/.V!ON:A8U2A]&0CU0-E;K@JD9*0
M'1.52)G=TG;2,8H`-'>%%G1GT.$^GV<T<;H@]$*M]H$:4-*GP':_])XF6AY&
MM%'DC&6...K$O@*DMT!TL;M`%--5EK6AU=&@>[Z-E=W-(;Q`#]C'WMR+EN7[
MTN]2*):.XIQ.O779KM?!(XK*82K45R<\S:W/O":^#Y4)*=*#&J84N19%`PY\
MF.=QI)DW-:OJ^?(E%8.4(N^B#I7GEP[C12M-7WZD9I(#QC#7M25W80``3_X/
M4$L#!!0````(`'.`;$=!^+I,`1T``'(D`@`5`!P`8V%T8BTR,#$U,#DS,%]D
M968N>&UL550)``.I_D16J?Y$5G5X"P`!!"4.```$.0$``.U=67/C.))^WXCY
M#UK/R^R#RU>YNUS1-1/RU>L(VU+8[NZ9IPZ8A"1N4Z0:)%U6__H%2%$B)9P\
MDS)?JF0)1V9^"60BD0!^^M?[W!V\81(XOO?MX.33\<$`>Y9O.][TVT$4'*+`
M<IR#?_WS;__UTW\?'@ZN"$8AM@>OR\$#)L1QW<&53Q8^02%M8'!XN"KX[\NG
M^X'M6]$<>^'`6M7Z[H2S=;U+XMA3/!C\\.GXT\GQV:?C3>U+%-#2M+VXF=-/
M)^M?TOY][^O@Y.3HY/3H]/CD?'!R^O7T\]?C'P?CAW71!\K$Q!&6_;(NZSK>
M'U_9/Z^TV\%[X'P-K!F>HWO?BKGZ=C`+P\77HZ/OW[]_>G\E[B>?3&E;QV='
MZUK"$NROP[38(?OJ\.3T\.SDTWM@'PRH\+T@[ENCD[0XI3!7^OM96O;DZ-\/
M]\\Q\8>.%X3(LS:U:)MVN*Z8[>+\*/DQ6]21$+33]`X#*Y).+BXNCN)?#ZB@
M!X.?B._B)SP9Q-]]#9<+_.T@<.8+E[45?S<C>/+M@`K^]9"A=7QQ=LQ$]??G
MD.+.E.G*]VSL4?VX1"XCXGF&<1@<#%C3OSS=Y<B@S2`J.2?X9/GS(U;B2-E.
MS)(6&D<U\S1&A/XVPZ%C(;<J!K<:;9#;:R>P7#^("!Z1*?*<O^+!-?3LT0(G
MTT=PC4/DN/I@FC39"J>WCD=%[R#WC@X9$D^&)9B4MM8*?X]^B*E*+=&KBXOS
MQ6T%"C^GU3!TVA)'OR%"4"FMVVFA%3[H;$:]E-"A$AW3PM2'P/9SZ%M_%&=,
MW61+G,[GOA<3\H0#3-ZP?>N3VRBDO]T%0<3F\C),&[3>"O\Q;;$'2&E=4`L6
M3^3%.5:T!X_'(C..JD%X7)Y5S>596S8#A_=^$(PQ>9Y1YZJ$&10T9,Q53#@B
M5LK=ZF.6F'4+CA<>V<[\:%7F"+GN@5(<`E+2=01;YIS'4HI;JX`J^IFB3;$^
MM/TY<KP*2=QMN@IZXZ8.YWC^BDF5Q.;;K8#2&26*6-$K/EP+HD)ZN:U7JP]X
M@B(WK$<ATK97%-._'<]A4\X];7?5.J.G_*(S0SQ^#S$M9:^_=4+6`UW='Q\/
M#@?KMNCG=7.#57L#XU5LS!E#P[=R5+@L^.$3K@SCIB8H>(W;BX+#*4*+.+AR
MA-TP2+^))\S#XY-5M./OJZ]_7W/PPOSCM`<7O6(W#CEQ"QVU2>B5BX)@-(G-
MS_#="50T[Y9?D[_1H2'),T)U.VUWI>8%1Z]/;$R^'9RDK4V(/Q<+=D6"K\5&
M%%"B_`4C'[GM@)(EZCIG#+;0X!6L"89=&Z*)@4BQLG#P^.@V#K__<';^Y?3B
M],<OG\\O/G\^/3O^W`0TZ6Q>*S9<WDK!M>M[LF]^?\;$P4%F#3M<Y!:Q#SG?
M8X6)4<VZ$,G[,'(TQ%K&8#!BIQ$0+@N#(*C9*`BGU8$@8`?`Q+4>X-2)PW?T
MH]*<9PK6!$>\3M*<EW;(YMKNE77?DG?BZWZU?"^D;N:-&Q>E_C*>L@^;W^F"
M%-O?#D(2M>1Z#8.`^K'#UR`DR`H%`&T7@C!6]&#:IGQ!')\XX3)&'\`82>B[
MB@C;+-)"8:<L!.O!UZ)=(':(AX;'%0IF0\]F_]W\&3EOR&5[/\/P"A&R=+SI
MK\B-1"LIS;IP\!*H7<[OTN,)&HQC@A?(L6_>6>P2LWW*<(9)CFL!B%HU(<Q_
MVA!J<00-0!VHV@3EK"0HP,4_)OZ"^I?+L8LH'Y[-QOZ"&=M'+!XXLBIP1HQ\
MJ,AX@`;2$Z:<.%:(;?XL+0!*70W.2)*!I>8#&F"9B??1]RSIY"8HVR@TGXM"
M(R`>&AX)A5+KTK#$S\NYU_!$?.^@5\>E4L,!':%QA&+FNY37@(W4<*E8\NA7
MAS!GZ2U)]7D"#*;>BE56`<(RR%0[!3""7]4.+<N/O##-E%.XU8+"P`#3<;(%
MG`"$AT38WF5.C)"H/`0_VQ@D$3/0<,IFF\H1XI:$8*+,L.&R`0T5[6'3^G@1
M^--FF'1AH%RO=J2>V.XN_=\)E>L=>15@TYJQLR#G#AI\][XW?<%DGAW^HC'%
M+0ILIC/W[;A<08,I7F5GV-2+*0@J`)L(C2&3\08-N&M,G#<4.F_8!#UE+0B1
MBG*3I()!:#AFR%2['`WC\T.M*UYX6+#C-DX8G]1CH6#?"QUOBCU+C(VT1J-8
M_5@]5E+FH&'W@N?L8#M9)GRE>\O#.5N]#\.0.*]1R&SPBY^<JA4@6J"=1G'^
M4CW.!5B&AKYQ4!A,&/BB>CR[%`[.G^649<9P2T*()YJ!PV4#&BJ9<Z?29*6=
M8A#6V.9&+L\#-#"&MNTD_8^18]]Y5VCAA,@58"(L#6$];0:-D!5H"#VQPY\>
MMF\0\:CA#(:6%<TCE]U]<TV%;3DB*Z13$<*BV@PW':Z@0;C+H;;C`&/17-9%
M@`>)R@4JN-W?M--P7.LB6L"B&LN?CO('9.L]-+M]D5%&U)(3M.>:)V@'_\BU
M_S\'_8G:_D1M?Z*V/U%K?CIP:(GN&5*=#E37A+!8U3X=J&:G.G]!BLBE\.8G
M%2+JFA"6J]J(J-F!YL'UAS<[<'AS*_I+/:D1B7FSXWA(>L&17KA<7!O"4-,#
M5ILE:,-MB_"8RF`8A3-*Y5\;!UN.X&XM&(&C`LCMLM()Q-C%?F9HI35@A(H*
M(Y6RT0F41E'([E5F5V^;0)6K!B-N5!BO'"_00,M[2(963;<RA&P,/0!U.8(-
MHZ9)4U6"D)A1!#;X!HU'K]2>R2I`R*LH#A-4:\:C56W,E+4@)$T4!PNT*<ML
M41O:,:V:(+9#]*#3X@<P?)KV2UJC6;A*A4BD?("'26JWA*6;A:=4H$/(`WAH
MU/9*7J59D$K%-.2,-+[/:_2(2T:<@EW>S\<GQR>#P\&F6?I'MN4!Y72P:7OP
MCU7K_1YOEM``6Y^F_AN%VF$T?F8?&&F?,Z31KWZ_QU/DWG@ARR_8W<?EENC"
MSBV7\,KF+5WA)IUS]V1W?VYY)U:B#*E`\_1"EF;N%M_S"_KQK/T;B@TES.4!
M@.E-$FO8`Q[(6W(W7*4EV]SR%FE1;BW((QJ"V-4;W?*B$'(-)+HC7H\#`N$Y
M>@T<VT%D^8Q<K)'_)"[?@A55+0W$^4]B-B"`LJ'I$<WIQQ>"O`!9C"9I/I1.
M12CY42K%R\&EP==^XP;2_M>$)50_X6X\DEJIS.\03).^-F;AR3`!0.2C-TR&
MKNO')W1',2E2""3E(4"RHT&YFQG$M`-`HMN)TJKP5)\HW2=*9]-R,Q')]+59
M<2:NI#"$24<C^5;"`0`M[U-L:TVQ%0R!!RJM>31_C)@>C";73H!1@,<HG'U'
MR^#!MY/3CL^TD!LB#_M1X&Z?5RO3$/QDVC+<U7ZP("7H@3)M12X.?J$*\N)?
M$4S)&1-*EQ5>L2T6F_Z]/:`*M0`_A[806XTAQ7:I,)%"L2X"/PN63S>T7=?8
MY&761?E#G)L=.]7#3P7:Z4YB;`'F0.*<;/U?1\3QIF-,*;23W>9'_#W^2>Q6
MZ%6&X.P55N@=P#48!H=R)L-C3!Q+E3HF*0_#^Z@"2S&/]1]NW$2@J&&U,+:#
M)VSY4X]E1^V^D*-9!X:?40(:33[KAX=U/II,,!OBMYCO!7(*P7`^2@.PRQBX
M^4PV#R<G95F@933)G)I]IDXMD5VU6;91&'Y+W59.0Q#0M"5+<B:7;D4]MD\$
M"J%1#\89H`HPU^`5'*Q)^&X5EQN1)V<Z"].%U48?KY#K8OMRF<;O5@6%E[J6
M;17&^:(J5**L)*`IS/[<U%;J-&`U-[35EEI\ZWC(LQSDWGE4-Z/X!F*SK.*S
MW:SB=:.#3*M=R2>^10Z)C[FL7G'SLF_=/&#$>+1'WA,;DLQ<TP*/OD?2/R^9
MI&6IR!6VW\:P7I-_N5P1R]"])?C/"'L6+]?9J":<'.C*]2`[*VC)`L`DOJ:3
M1Z5TJU>K)I"]7P.=YH(H8W'?002=$58?L%"3PWBD!^LY2IJTI%<50G390*%5
ML.XR"`G$G-K&%L78OF9JP<F,;L&V9N0`">&-W\Q6$,D[$('>G"RM"MJR[F@R
M%SXI?_N/80<-:VE<H5K5FR!TYG3)/IJLN>"P([6N9DV`LK(:^IT%VHQ3`.AF
ME'G]\7\=3*C49LM[_(9=/:LKK0PGV[@IXRL5!R38L^[@+M'&"R1)&_"LLH;"
M*UUH,;\?$>6NV.TZD8=JQ]?TWGF+*`QBAD_T%L6\&J"LM(E^<X'E<0@4LS-C
MS,Y:P4RU_*T2LS-`F&V>AKU</J*0LBCQH$2%6_"8!%D^M7I,(O9!P<A.;DI-
M)+\H$']'KHY\,+)L=!\*T$Y).7B@^AJK#`VII=HJ`\&?D"E:%HHMT@$(O(I9
M^EYQM*_B/MH[%5B+L+@N2GF;V=7G/A+..;$OQ2D>C7J@O-BZ5$A##M"2WAY\
M#R\?$/D#A[>19P?#,'WB6_:XK[(6!,.@K<U9")6<00-0R*7I6(4Q1@N!)N$)
M&ER9&<=\GM6M#.&D3^V3K:XPH&G`QE_-<'!%N4Y\`?D"B5<%PEQKIM;\%1*/
M-VC@R?DL-&QAS+O%`51QUV*N^*,?XF",ELPK-\L1/]_-$8\;&ZQ:ZTIN>/^>
M,,Q;J378`##;]==DP8BE=C0R)[]`JXZXG.#`=GKV+'^;,+M87'PYF;H.!!%S
M-6-]5%O-0^UGY84DG!<0_3FD/=&"HC^O7O05'7]$WE2VZYGY'4Y>MMK"9LB&
M(F3I/)XK`<2&[JC&CH`![:H8B1CT-J.NV*%N**ZN^)-BL54&@DWE*%`N0IRG
M&(*<T;M:SODR$`RH2LYYB@'(^8J:<2>\118+=\@.#O,*PDFG5MM,'OW@Y"]?
MD'*+`C&G8CT2@P!H-5H2!M`FMS@T4(WP$W[SW3?'F^:)ECM(\CH0C+1,"?.W
MF4A9`0#0O>]-0TSFU_@U?*&=2>P*ORB<M%.U9>%S`!`%Z;0F*@S$OL@T2@8&
M(!M3`1R@[4PYB*JW-8+HW0OM^MY'WJ4\8,<M!L%*R-5H':SCTE][:#3M=2@/
M1'.+05B_&0HW1W]CPAV%,TQ>9H@]0WRI%C*W.(1T&D-A<_F`%G'NWR?I0$XP
M8W(TV5H7J=+49%4@3%UZ$,KY@#::LM1J``/$0&MHEP@2V!"L5YI)&//2)\3_
MSM:A:$%_";=?_"G6!(2Q5`9"-8?0($[OG+^E,F!W8"//HMPPJRP`5%8!A&-A
M")^,'VA@\7A;7[LVFHS1,C[(;#`4N;4AW.M?Q2CD,@<-4Z9IFTMZ[ZC[1'`0
M/E%['AMU>XR)17]`4U&VHTD#$.[L-T76A+_:EV%LV?*R6K:,HC`(V0-AWC2Y
MDNDZPD*TC&M#N&!;%RICYKHS"&\F$VRQ;/X2XY#;!H1[\ZL;BEP68:.L>LI-
M6+I1Y+[4@1S@!]KZ5RXD%P-(U7>OW[+@,G3S3B<;)\#Q<V;K']=<"-^Y*=86
MA+5I6150<UF[!R6CBT46D\>7>-Z3;DT(JU`-H(QX@C8>4\T9>G:B.AF/3S#L
MY%4@K#D-1I><&6AHY1G[Q4-SGX3L?4%V()"YYUHN$+<>A!6E`6X:',$&[XDZ
MW'3R9J[VE?^&/22.]^A4A+#*+`P?GR5H^-U3J4X1H^`9AV&R,98LBH5Q.G$%
M"*M&`[QDK$##2;RXO?,L@E&`KW'ROW$`8+<!"&O(PN-.SAJL\_%K1UIY0/Y4
M[X#\X+0_(O\QCQ\4/A3?'S\PF\0^UO&#/J$=>$)[G];5@;2N!W9M;1S4'$VR
M.U&*(+^Z&H2PGQZ4:EZ@N=Q9*C?4/^'%:K=^-!D3Q[.<!7*?,).7S>+7M]1)
M0^Y_,!+-CN6;A3"!ZFKT=GI].<X[K")W'F/AY;M?7BTR34$8_S6K0H;;[L-/
M>Q?>6U>P,0@;"LVH0,)OYY7@UH\JL`W9MB!L3S2B`@F[D#5``U@8VQ)E\6I@
M,Y9U<^4'89!N?VPO;82E(&P<F`A8R`@T5<_&,.6WZ')+0M@@**+X7&8:2^?,
M]OZ(MP4N+PHAE&\\$H3<0!L.Z5[#S?L">VR;06@`N"4;!>>BNN'`9:;%G94T
MW\'LUN$?=F\=3AOJ+QSN=U/ZW91^-Z7?3?FHNRF=O!A=%:#O+T;O+T;O+T;O
M+T;O+T;O+T9O3/3/F+##/+[WADGH4`-TN<@1(P9`MR8$&.23C!$[`&;Z]=-"
ME\O==\?CY\0E/I%NY2[=T:O+$R3L3%Z/%T&HUP80'\M,:[GPZO$+">4[;Q&%
M0<S=F=0SD]:`X$044EPNBCP.`6#6I^IU(%6O/^)=,M&O/]W=\=/=*B?)'/W^
M8'=#23ARC#I]IKO;#_D*DG#TQE13C_8J8B>;G5+1Y33JXA`2<S0&B90':".C
MV[<=;#F=NAK7QG4'BO&Q[IY=U(BYMD18M$WWSD3D<BYJ%W5\T?:=9_ES?.\'
MF\7AT/Z_*`CCU8>?4L>3OUG]-KTN8U#,6&ML4*0^WA.VF./A3!QLO_@W?T:[
ME_(:U&O3URH\7.0L0;,J29R:1=]64>WG&2+K\#6VA2L<=;TV/:\B]D6#)6CH
M;88_G9KG,2ELNG[`X<RW?=>?+F]]0G_#\2R><2L5)Q(K:!="#K">WUT!LUW0
MBR<G^..68)R].,,`?GYU4`'ELH-`I11\$70!>Y;!:X7L@JDWQ\;4GS/#GE\=
M0JRR,>SY(N@2]BSCNP#F234(D<G&L4Y8[Q+&O_HN"N-DRX(C?+L!"-'.QG'?
M%D*+1QXR:23YW!ZS,Q!?=L]`9%H>K)L>Q&WWQR+J(K23Z<:%#TGTZ<;&\V*G
MTHT_1B9@H73CKF4"/D>O@6,[B"R?D8LU9BAQ^4X=B!"S`0&4#4V/:$X_OA#D
M!=2AH31)9RR=BE!F,)7BY>#2X`L`;G?CD31%+_,[A)E,7\URAX,W3``0>9]S
MUX&<N_P*9ITK%D?9QVBU'//L>(M+G8506:L0XEAZBE":56BQC)B/9%OY.B*.
M-TW2DK(;+\E^3,:)VN06"H=XN48AS,D5#97\+%).+-!T)R^BA(UA%,XHD7_M
MI&7H5H(P%]2`O8IMV-A2ID<D>6<Q9IXJ;LR"%L;BRA!BVK5C+68?&N8)T\D$
M%6<0*V"6E(<0M:YC!A=S#`U,_H/&>9E0[I,O,/TQ_D8XH(LU!B'UMY8!7DP<
M\'1DURAQ<RIU*D#(.&[(<%>?AED?GNH<964M"(E$#2';;$)SR@:U(EE*XJ`U
M+SHO+P_A!L(*8=+@N-5MX?G<]V)JGG"`R1NV;WUR&X7TM]0DF.T07_!VB%DG
MJRWAM)O!Q">#I*-!VE-G]HNM&;:C=;#S<AGOX4@WCV4U^IWDJG:2U;CTV\K]
MMO+V;NJP\+:RH":$P%^1;64!._V5/]"N_*D=D;P#E)Y_$.,@+P\A0*8A?3D3
MM9PRW[A?:AE+"D.(4VD(6,(!`(-[,U^X_A(G48Y13(IT]UU2'D+`2.\:0PD3
M=2A\KKMQ1*P9=>''+O+D5^MI58,0N=$8!%J\`!@.659V-I,E+N@]A'P(*?&Y
M-8!LR=#5_(C,/'N%%DZ(W"1T(5SBBV`U;P>:HR4%OP!_+<9J$@6EDX5-Z68/
M*<1/D1M%9TZ.=Z,S<;.'+)1B#ZQ,PQT,QC#P=@0T9([&-+D=[G*Y*3-.'HT:
M?D?$U@S=E&V_E6`ZM2PL&T\2V\D7`1G.J0;97-@\QS0`>YL2)(WU;!<"$N?A
M*1E/V(!R:PN(^_<?SLZ_G%Z<_OCE\_G%C^>?3[^<-H$`GJ#(#:N%@,M*+:&=
M.%F,FDZ/W4>E]O3EY2$$UOB*LPGA2!FH/Y3&Z?[XBYF\-^4A>',%Y+UA`-K6
M=FR3KE$H,\=;90`=@ZG3'F]Q#0DKJ8G8*07$)',UC2MP0$:YD,A!FV53&!HS
MS$//B]@SN1;!=(R*#02_'`1#+%"6M67@4P[-(BBG4M%,JHK)5=%PBP>:*A.+
M(-I7UH)U-3986+#Y+"CE`8D:^H'@C=:DE]4+:V_FN3%U4^EG-*6C-I/7F.R'
MHW=G'HEN(ZJW2PB;VL"T44MNT!3SHVR6B*Z`KT6%:ME9Z<B$M34GOR''92X#
M9?EGEO)0L[W<[0Y",@*PB4HI,ZC;?&NO1+G/=VJ\SS<X[7?ZNKS3E_1/>U'%
M%C=E/LA>WQ;773`N0B8WO'BVUAY6/5U!BG)NZ[R1B2C$?:]!9;N"'[1M6JNJ
MC_Q^[+38HH'%$N.FB<3:/NK<1YT_4-0Y&3G9`\U/ONO2A1K[L6H=5'36QY]-
M);8W,9U=/I,00OT:F/;3"=M9:A37I)"I`/=-%^-(57#G);>O_4S\H'*;+.NI
MTY-AX_K(%2$XC91=[)?Q8X/T?5ZA`2[04*>WT\SUJ8"$P*E+26E1\4RP$\87
MIWCVS?O"(7$+ZV%2TW2FT6^G-^8:G]PT!+IONIMY`+M61Y#33Z>W\QK738X`
M]TT7?\5!B.UDY"7/3?GLJZ;6*OK=0SB@W1W-U9?KOBETAL7?,'L"EXKA#1,T
MQ:DW%%]:RN0_:2H0I$U(I_W8IH)$VM+\H*K=KC[O7;#)<!9I0>D[J.G"K0IN
MR*,.;:^2@CT+9]6I\56*?>^T/N6O5<4W)*+3+@LLW3>4?.?4OVPDJ`6GIR1-
M>Q8*;-$5*@G$OHV53&2JA5&AW?N>A1M;U']MD>^;IJLC62T,@+)$[5DPL\5Q
M41:)^N_4J4W,3YBA3;^_\KWXY8@(N2^8S`4O5;9.3:>=(6YPLW61@ISL7]6R
M>*U,%J>R&;YI2MJ,?+:NBX*YO6D,]FU(B!T_D1!.:AH2A2AI,S2ZAT.B$`;[
M-B2,?;ZF1TJ5!+897]W#`50E-%U:.PRG4X*G*,1WE`O'"QPK>8>NF;6"LO=.
M!XH:61LH10AREJ^&]SS+]><W;/>W3WZ]YD104QK#MF1!*FTU_EF>U0:<\IT.
M]\GW+JJV-8D6I-Z6WU[8;#V_^"&[_K2!>5>OZWUR@UN8@O6$#%*K2SO[*<NW
MR"&USL7B[MH,?4/1WEH$"TUCUQ=W8/+F6)@O]D?V1&>\#&4\!O%0S/Y^Y0?A
MHQ_^!X=/V/*G'KN35;!0:[#?3N]92G/3&Q#>A]'3[/'3IG4UWS>$-/3&IH-&
MU#DOWP^CTBNKXY/55ZR<R(5HF@@(F>?[I>0"04.]TW6]5%'>Z7IF?J?K67^G
M:Y?O=+WS**Q4?:BOSLBY9STQJL4WO$IK?)#[7J4R`&#G!/1)+^%4U`%R'ZN&
MOFH`!>B:U<JA`GWQ:97P0;W/E#U!0`4T&WKV-7[#KK]@M+.]9$_P#I9130AK
M%BVES0*IQ1D`['[&'B;(I60.[3F5+G,NV;./.NAIUH7@CAOCI\D;``2[\!QU
M&\]?]L]1=_4Y:D'B3^[^YW%$)U>J"^KWC[6J0;`QBF=YM?B`%G^*ARCXUWE%
M)ZC[UWDE:`&;H;B:5M_KO/T;L/T;L/UM_)7/DUV]C7_HQHUCFR^!U:I!-*5J
M5H:PD*I'@W0EL#?3S`=[^K<;M^KU3_]^C*=_&WVWM5ZY[8UBIF-O:-M.PD!3
M4Z.LQ_T[@=.(V%K,"WC$X;T?!'3PQ&2M-NTU\P%.CD^V\P%H>P/6X("V.(B;
M7&<"0,\#2(/=TLW\K4*M^,Y>Z-B.&['P^C.V(JHY#@YNWBTWHB#=TL'`5#0*
M8PT=36X082</UQ!?+OD-R").=?8(*".`JP$YO[M.00`P1WSRE$%X=34H0:_Z
MAXY:78`]XUH3YJ"S#(#I`=1$A2N6^DA"A\Z&8]HL)F25ORO=YE;6`A&VU=3Z
M+(Q*Q@!`UM6W<@7ALR(PU?7NK6`+@\X4<]^+._L-D?CF:?$^AJ0PA`"3B;A5
M_-1^L45^#*IE+R\/(:)B+'XY2^""'>MT(M6F$:=@BYM`0K+S[^GE%P_-[\P(
MMU@W2I49KC=_1LX;<MD>D]#ON6;5L+T5(Y!=]U)C9Q#,D5P5ZI8`M/%<THL>
MSOW($YU%K:CMUB]=J7WT51B>2(56*!SYTU$"XRJ"1[_Y?U!+`P04````"`!S
M@&Q',KHI\6Q.``#?#04`%0`<`&-A=&(M,C`Q-3`Y,S!?;&%B+GAM;%54"0`#
MJ?Y$5JG^1%9U>`L``00E#@``!#D!``#M?>MSY+B1Y_>+N/\!-WL1[HDH]6-Z
MO-Z9LW=#3Y_BNEL*26.O8V+#09$HB1X664.RI"[_]8?$@P2K^`!9()&LV0]V
M:ZJ`?!7RAP202/SQ/[ZN(O)"TRQ,XC]]\^'M^V\(C?TD"..G/WVSR4Z\S`_#
M;_[CW__G__CC_SHY(><I]7(:D,<M^4S3-(PB<IZDZR3U<D:`G)S(AO]Y=O>)
M!(F_6=$X)[[L]1KFST6_LS0,GB@A__KV_=L/[S^^?5_V/O,RUIK1XV2^>_NA
M^$;Q3^(?R8</[SY\]^Z[]Q]^3SY\]^-WW__X_@_D]G/1]#-38AD:M(W"^)<?
MX?\>&5OR-0M_S/QGNO(^)3[7ZD_?/.?Y^L=W[UY?7]]^?4RCMTGZQ&B]__BN
MZ-78`O[K1#4[@8]./GQW\O'#VZ]9\`UAQH\SSMN`B6K.)*RT?OVHVGYX]Y^?
M/]USX4_".,N]V"][,9IA"Y>]]GM223X??OCAAW?\VV^8]0CY8YI$](XN"?_L
MQWR[IG_Z)@M7ZPAH\<^>4[JL9QVEZ3OH_RZF3_##@H5^``M]^%>PT+_(CS]Y
MCS3ZAD#+G^ZN&[7XH4)+=N+J&)GWG=!'C`?H_(G]55&+?LUI'-!`*0;L6DAS
M:4I+`>W$KQ",8(PE:=50[*/'$QBK[W_X^)Z;`3[Y^X5TI],XN(SS,-]>Q\LD
M7?$Q>OJ8Y:GGYXH0%U]0,NW7TTR@##`Y3:L:>:FOA&!_=AA(MGCG)VSDK?.3
M2/YDO/LR35;]5!!B)#TZ_3UZ'#!$E.X5Q5.:)9O4I[W&AJYOW]^LD)WU!+2F
M\<E/]SV4^7?%A'AQ0`0;HO'YHQ"OU]"57#G'I9<]<K9L&GGRO#6'WW<TRC/U
M"1_D)^\_2#S\%_GQW^]SYK\@V8/W6**(M$]C(Z0#N%TI&*WU+1`.S0Y!AX[#
M@ASYF1/\+P0CCT$_O69_9ETFT!O.903N*5<["HM6<QB)^\):&(U`E'"J>T/2
MBF8YB[OI)T?J'>ID&?7?/B4O[P(:@G]]#W^`6WVON17[Z.]B8KFC3R%,6W'^
MQ5OM0GI+,Z0NU:48.%13&X3NU"GJT-$FHXJ2*@&RTPZ]<S;84R^Z9H'[U_]'
MMXVJ[[=#/_@:5*N.OIU&J(=?DZP'CC])EG"ZA!&>:@2J$/N!D:U1>N=KQ..M
M3A$US/3OD(ZN6A$/7C<!M:E'TBU-PX0M"H,+-H^W:+K;;@9CJU:UW4%6:81\
MM-7+>O"P$V39BCT@0'BJ$7C*F`<@P%7D/=5HO?L]XA%7JXH::94OD8ZP>AF'
MCJR"&@%R4XVG\TV:@@9AYGO1WZB7-H-:2U/$HZQ+037@FMHA'7N=X@X=AI(P
M$90)D)X<Y&08*B2YH^LDS</X"1;-F]VM((/FB`>GB:([ZXC:MD@'J9'(AZXJ
MY'@MR!-!?]JQ>A5&-#UG+O*4I,V+V]U6Z$=FK5K5`5EI@GH<UDMZX/#C1(FB
M.C%`)JM5$M_GB?_+_;/'#':SR>'\&/(&FKVQO1/Z(6FB]`YDMO1`/6"-!#\4
M/CD/PIDLB&!#-#Y3KZS+@.:*?5(WVS>W1#QV.]3;75_O-$,Z2KND/7B-K<>@
MG+2;T2B6^F;CL=IV-B.R1L7Z,:DUG,6HK)/7UKB46T!61J:%T_*;Y548>[$?
M,JV3+&S)2.K9%>DH'F*`VC/VEGX(Q_@@\0?O!B1Q0&-(!#WS(LA,9"$"I;G#
MX7Z:98Q_Q\#>:X1\"-<KI0_6:@O$P[)!T,&[HIP<^5D1=)0#,HI6KIU(;IT8
M^=)^VUFX5(.*^YZUTQ"]@S7)>]B(7!3;:3@<SK:62CN/4__1G0.>>]GS:1S`
M/Y>_;L(7+V)B9:?YN9>F6[;L_HL7;9IR;DW[(G?07B;0'=:H(V('[B?_X*'.
MR/.<<OZ'QFA!O)PH7H0S&\7%U^K<O<W-)[:%#W]0W1:4?9HLB1!V1#NP:#W-
M45OBD3Z%<0QC8EQ[=$*_8TNXFQ1N4[KVPN#RZQJ67,P$-_DS32LS88/)S'HB
MGQ!ZJ*]/!P;=$$\&?:0?.M0E#R*9\%'/V9"=J,^-OT]I`BJ89-P&";>!7XD)
MD:S)3*)B_![=Z;MS\5*[@W$2KTMR+S)>8!VLT@.P0^-*MVG"`IA\>\NTX;<W
MV>R^AJW2+[1Y!FWM@MS13!2NSIG-[1&[H9'8PZ<(07Q!.'EQ'U<Q6!#&PM7T
M.('27%M::AOO:SN=^][1+$]#/Z=!_5*@P5`&W9"[L:GBNBMW]4'LSL:B#QW=
M)0.Q"W):LQWBQJFG5!T6N.Z<60OFOS`/:`UOF]HB=]M6%75?K6V(V$';Y1TZ
M-*M+SY*P&T\<4\<XB4^PQ,1"Q=;%`'Y/JRJQOY)$[$L[`MH].9YRR6AIK>C:
M'SZ%WF,8A7E(,S;]\OS7YR0*&%S`-)QO.T[%>W1'[E-]#:%[G6E?Q'[96X6A
MPUYC5*PMV<++]4&[,_TSC=7O^-J36>--0)>A'^;?H@`&LP29U@[S<7Z#5)GF
MUO-P<-OI)!II/)DS(^JK5(Q*%@YS:$Y]/]FPM?*MMX6"91TG)TV-D3MHNY*5
M"+BV)6+'[!!X<(0LR1))U_'IYMA:K@5=IVZ8;FBP#SO-!FELC]\9VU7=\<?Z
MQKA=LD/F`\8K4"9U4Z8SQQQ95Y5LX&BU/II^?`'O#G"^)#DUF_3K6R('F1;U
M='BI:8886-JD'3H,.4TURX^#)?6US*=2\!/-LA^+I`I>WF*_(/0T8#F&>N=5
MQ2#M-.8_Z5H%;C'-X=,@S'BP@VE/P'CQA1]PS,*96<4Q(TQZTP4N71/[6#-Z
M@33:\MZ=RUW0)67B!'=,HG/V;YAW'A]W=$'NAB8*ZP[9UAZQ:QJ)/?B&OB1.
M@#H1Y)V?,$^C<:KRMF#&[(@9)IPXD_CI@:8K/7YH@K7ZILB]MDW!RO19TPZQ
ME[:*.W@*940)4"65T-W1-OD8&GZIC5]WO)&??KF/:7F*BA9+F&5G-75`[J;=
MRN[E:=6V1NRR!D(?ELVD'^"ZGE-'5U;%P`>7]#LD`D[#%R\/7V@?+^WNA=Q5
M#=6NAL*M71`[K:GDP\-#11^5^XZM]E^]E+]S@L"+-06[U_/XO;-&G89=(L1>
M5R>EA7TAY]M!EO:!4.S_0&'2,%_QJ_]Q<)[$4-N9QGZS'[7W0.Y7!NI6:J`T
M-T?L=R92#Z]45]`694]TZHX*64RD[AM8=I(_.,R9?*`K>'XZW8J<456IXW0%
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MG-RS04A7CZS7Q_<+`H[&6U]07W[Z@7_Z_8*POFOJPW9;Q(*?@ES(C2Q*8=E[
M\>.P);]\[Z2U_NE^,^1PT*38[HI>;X,8"!I%/60Q6SY"@P("QM*QP?D7Y,/O
MWQ=.W\?=/WS\KKW?'A[\'\9K\=T/?UC\X8?O.8GO?_BX^.Y]!RP,1QR'5U."
M@#^'X$6W7AA<Q^?>.LR]QH3YQM;(X:5#S<JEE/JFB,&F2^+!ES0*N@0(DS`F
MDK2CZRCCZPD5,$^8GGZ]GE,6^,J],*;!I9="P>'LU/<WJTT$.?878FW28"2C
MCLB]U5SY:IFOKEZ(?;B'\,/K70D61/$@;S0NY**AK,`TOCV!_KJR<GV/::/.
M>.L#O_\V*]>^(8?8/UN$G6`#SLVQ^0@ZB]/S&=0UJ2WTTIU>T-0-N<.:*MZG
ML!%B9S86W6XA(^?)+^,HNY<1LR!^\VD9ZL)&.^>*#'QO4OZ(8,!W.&YIRI__
M-3N5;.F-'`YZFJ'E&+ZI*V)PZ*N!O2-WQHHD*1',Q!X?/*`JGIQ&<=`^FC%:
MC]?+_?\W;&D>)%'DI5EY%H`'+\3;X*?%WJ*946MZS0L?FM1NP87=+O/!@T;)
M[>&`?&*^Y('"]ZTKWNKS7J/RCKU;G+GT,5G18XY>756WTZ-%\[EY\X[4UCUY
MQ'.Z85YL2>%6#PYKE7;LO3?E:5T?>U6[S=&/:Q3O=&:MS]P\NDYTZVY]TYP1
MXM"W;:K>ZN`H$F*J>4@]%^S&G9%[?#\C-*?7S7"UWE,!:TEX"-?JDYL"_?*\
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MPU/HC&DE?!W[R8KR1<"J^]W;YM;(/;9#3=U9&YHB]M,NB0_(E@C@-;N`%+0S
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MN\'[K9![:X-:U;/%2A/$_M@DZ="!J.B-L_/S@U`HID^0S-KF;Z/I1>OU0A``
M]PTB\'M:KREQCK/A>!-"W10XZF9LU\IT/%7EUA"?`9U[9[GNOF)#63P,N6$J
ME[D49W29I%2T>_"^TNQS&"=IF&\5Q)S&096*J)+QF>;/"?OFA37A*1J-R#>E
M!,@1Q,'/L9]C-`E[Q"CGP@K#YWEM#T_L>I4":QE1Y)&+K,I?"T&()LE"H2[7
M9\'`EZW8DS0(8ZC(<YW3%?L0WD5GU)D%(X'30ELW"#VGGXGO2<J?X)'&=!GF
MXL<2"Q^2@W0.8S2:=YX*[+9!CJ2U*E7B+[T!8C2JEW-PG$7SZKX_JDKX]G6-
MP/'@P)M17:?TF45;<,X/'[NZZ3B.DN[`0STEHJYIGGE9Z$,^4AAM\L8K4-V]
MD`.,H=HZY'1T00Q"II(/'<7%4SG%/>0%X3Q$MIW@XF8G=&S5"Y0J;AZ3$_)8
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M[/X68I']G6+V=4]8=8Z?*$VNY`@Y2D/P6*R:F(GA;Q_,K)9420WX.LQXO:#K
ME/I"=O9W1.$/N+.V2M(\_"?_O.'7,.R*'!W[&$!'.Y-^B-&KE_A#74-GLB`%
M&W%54V/D!DTF-X&XJMFB]X2;)7+OFP;GR0J2EMH<O;$Q<M=N5[*R-5+;$K'[
M=@@\=+1RLB?P=T!TPFX<="PEH3"65-+7"+M/W].1YV9Y%<8>"RSBI_,DRS.^
M$9SYR:8Y]ZY'=^2>V]<0E66(85_$WMU;A<'+!8T11*X%*\)YR:,2R<U5AL5D
MUH!\.`C50S39]FQ=DU(FVP45_VHKF7-O'>9>U%U*SYP`<E#H;XR=9%C#WHB!
M88`2!Z2B<A;DC6(&][JT?0')T/FFP(0V.7]F_6@&=O"RC$J`9"O_1[;\=[R0
MWS?#;4K77AA<R*<QU.7=..#7]4ZY`L8V-20V.PCI8Z1V.#&A-"MHZ:6099B1
MO-6E(>YGXI:IX.ON8I\3*RESJ+HSW![BSI&_22'#5P(2)OQ1EXZEA#T!IZGW
M[!"FU0P=$4I=UUEA2+L&MF,3=?U>^<086'%`6#**+832^+S_U!>KLEMO"W<1
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M#%^@HJ(/9E4<R-U8EWE;T'`*K0L%ZVXKSR7EOF$6.9@H4LRU:S1[J?6(XRI+
MBKE/I7=64,"U^3IS.=&!ERA\,M)]H?[$YPEF`XUH`&H]*<\/W(8J.!+(%>+,
M][[0U!8M388!YFZ]K;P!<.K_N@E3>OKBA1'LDUTEZ;T7T7O*UAAM6U/]*"`'
MK`'FT%&I1W?$T#-$B\%GL9(7W.Z0W$C![H2M8D\RQI"4'%V=54]J%";_LP<G
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M`/+N'7DR==DW*S9E)^F6Q$GN[I[(9,H_)FF:O,+[)>Z/T86"2EU>C:?C3+&^
M!W:HZE:W[F2\ICEFL#*0^N"S;XE/I0>?UP794Q]TCZ$R5Q/+6N*PK>-1]J/Q
M>[T=H]D[]$&,'984<W_(@^HD>TKS\9/LM6:^):IC'C#/:1S`/Y!\].)%@-NW
M_!+@[K6T!B/W)($<G(881(>B/OT1`\\@-0:7?@,?@3U5_H?&;T$$1U)SG=T-
MHDQJ%\"/NGO"82Q@A3_6"G_04A2'9:\WZW7$7WGR(O68U'6\3-(5A].NY\*,
M>R,'D)YFJ%3*-NN*&#;Z:C"XS+3&IWQ/C&BLG&>5.#%%$&9^E&2;5&S"@F&6
M8)BP9.RRX(TH_7OKA4UG+#M-D+MZG4+50C7E]XB=ME;,X??99'UGH.:JB)1%
M?3BX\/J04$-#5:]V&[`#E,AZVF52;AS4+&LN"CSHF'XMD$7NK+8,MQOL'T(3
M,2A84^T@QP,)%D35CM?NRK+(MV[W@92".`\`G%N0,3X1(8"E+8>&2EA_]=+4
M8TL/V.>EP562JLM'NVDHU_%Y$O]C$_L0A_PUS)_/V3=A?N7!"U_Y=L>.MFDC
MQ:=13%C4X;)%&'O%+NMZ#G6Z.WB3*A/W$9\IO$BUB7GZTZN4D)]=4!%.K*60
M-6E3HDI76#2'-7\I.'EEDA.?BTZ64O:):W6A,;D2A%R7EKW5++N;O<=,>;YK
M2B$243(Y*0.&SZ!@21C%^CC-:`H3[=G>@#4?J!;G'E7;K#;]&@X<KV,_V@30
M8*>2+#Q&UU5O=206F&>BD0Q:3$B6Z6.?E\92U_KT%"AG;KADP$_:^7PD!>8/
MM>P44Q:/,,J:J]K3+1//3-B,7A1@;+C'PI,UR+5FV-UJW.)53_?%>U&:][IE
MQ&9]AJG%>>F.^I&79>$R]#DVL+78N?XTP4,"QT?U:YX>?3'/)'U-4$P1IAVQ
M8W]O/2R!>BRW2](=_OSY[/(!#_G*5IX0+V#1&6L`/N2%P0D_7^2O>TT,W!-:
M;,<TC!,YK[QL0AX2(KA-NWWDV!!Z*'!]>R-!E"?(QK"?U&/PC`BG?!FDEBE]
ML+2IXYR`M%7Y1A2M[34W"&U78@+\%$O=8B\',WB.9:L=HX@]E6++`!-J3F2!
M<G.O"":W]I'1SO'A3?KDQ?*]W_,DSI(H#$0^`K\BFBEG+-X"]J)[]@G/+^@J
M7F.+-E(L'L6$^FFB%<*(CQ3MZC?4?74IQ-.7C4G*$]XC\/)-2F^6W7<#ZAHB
M=YAFY2HY_'NM$`_E%F$'G]9RDC"9Z*61'NC7G)RQD?>+J^)(]C5%Z8%RIRJ,
MGVX9+ODA[9KM6CL@]\AN977/;&Z-V$,-A!Z><;E:>>D67/4^?(IY(`C;!@5'
MPEFZO-:AR;5O",`4#BD-IC/NC'R4]S-")1';J"?BT=]3@<&>T#+\X9#8_?0U
ME2'P0\*5%Z9_@=?CRDRSKBFNHPMR]S=16'?ZMO:(7=U([`-K4GH1N8X92;Y9
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MVS21-#9".B#;E=J[!8MEMC"^SFIQLM`JP\1%`J.C*Z/VU"KR#MTMID;6S&&I
MD62U"G.1?14'HD+B$XW]7G5%>M)`BC,'F:12,:0/`<23X#`]!M<"*;DA=X>N
M%5IO(L?@$*WKN7X4YNX2]N8'C9VHG:DSQ+7-Z,XR#D^J*4^<S&Z63%^V<,Y#
MMG#=>96I(_NB%P7D.#'`')4S;?/NB!%BB!;#G:#@L%L`Q6'^1E79KLFRN37R
MT=ZA9O7]G=JFB$=QE\3#7V.IENEQ/V^-I6F+;SI,&0;VSTD4,*N(FW*PK]55
MM;FK$W)'-5.ZDAK<V@.QVQH*?DC05=P&O:,935]D*:ZK#;_8HEZ!<90'/)WV
MV%S8?'':I_\L'=MP26K<>7;N/L9R2^?T.WGYFP`S7(O0Z0PR&`HG3"LHU(:U
MR`JR</A9Q!V-X&TO_E+7_;.74M`H4,]Y=:7''$H4.:;8,5HEE^$@BHC1QY)B
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M3VF>)OPQ&$KH<DG]G#RQOV-XH+;"<>($P?',+G9C.&E1BV'K.F5PS"'V`ISU
MW]'=I,QBY3"[6>Y4W]BVPV/OSDCA<I@1]+G;K"?BB;RG`D/'/&<#\%<R6A2.
M+O]UOL"<VA9Z545W"/`3O&!SF>7ABJVBFPH;[C5"[M'U2NF>6VV!V$,;!!TZ
M^GX2[P05!/&YX<@*(RB/HY50U<J="/LW&,6T+W*_[&6"VK(Y;1T1>W$_^0>7
MT6%<"&<#0[ZVJ`X^?T=C&H<%ANFK%G6D2<S^]*FFOED\/H`,<KP8:IA*Z>*>
M-!"CR&!5AN_&O5;*)%98XH.2R>US1WVZ4TFRPA5!L"&>I#F-]:HQGZD'^UK!
M3<P4V*2I>/?X2Q*GZC_Y(N4!KO,;%_"SR0@Y+(UGW-J8QQH7Q-`VHK(60@8I
M@(2]0@B^8ZN+07[F,KA'0H3FU*KPRO>IP'K:`W]D)>4B'KQ&RXS_(N*UF'BD
M-/$CR.8PC==_IL$FHGRC:*<:EQ%@]B*`'`C[&Z.2R6O<&S%P#5!BL`=)5G(C
M=:]Z'1;P<6022,I)8GYV)P[L1GQ!M%119`W?,FCRP[47J;PC7A*I%0\.H8,4
M%@XV37DT/8`(^E/K0W0:ZB",W";RTIW3;#AEIG)'-"!+D?B^5O+`2[PKY4<Q
MK^TEW^:=^L#9A<4*2+E9JBL!!=\R'U*4/-L%7!<'U4YMQ`:(P3@:!7A5"9XR
MU(6,B3#?]D%=<R+S@-R>1JG!6T,*\P';O@K91UI/,F2+&)%HG2?E(Z7!AJ]J
MH-V:IF$2O)5OS?.USB8'`&9!S"J4'1_I4QC':O%)8]'.B^#*T@+RCE*VBF(&
MHN(/>&$=:.OKJ:6K"F/3_R@ZF!?5R+2%O6+K/'9V9)^[)(I.EDG*!D2@AFO]
M4"$!9<*OPI@-P\<M^41?F#D^LN&UWHP%\#1\8O($IR\T]9Y@)V.S7O&'Z`JK
M](+Z`>1F`OI##54'_WUIS6@B&*R:_2GAE4)Q4MCJ$L+`EMAFM1;O2FXR`?6%
MQ[4AN,ILX#U?*6,AKJ@D`O?/(L__Y809@1F+Q?,B#Y5%:#Y,&ZLDH%,_A.WR
M]ZC,!I([D>S)J?8+:#,$JA#?H<E@S,E!>U(S:#%LR(H%T.<P#E>;U2>(?M0:
MZ"I)S\7CWOSCOANU!Q!&.H/8-U[]QNY0JK/8\#U8.1M.*;<HI!2$\RNW*>"2
M@I1$?(5QEQB%'>7FQ4K:T8OC#;-9Q,WI:]4<-W%`4[8HBWU8<47<EHEX(IG-
MJ+S]*-$POPN5J8(5S##":JI:19](N"\II!AFPT`U$7`O.O.)?H>I93?RS;@,
M)-6KKDB_"Z4<SJ+1:>VC1Z*"<UF+YFJ_%@VN*-21J439@K)X3]LPPA".EL4(
M]'(%7/8;$30;[5A;)8P4RNT;KSX<'4IU%N'HP<K9\%"]>(@NQD(ZK91D@6?G
M%9,ARQ0IV+L![EZ\_5TF[XK*W1MUG(`!XRY7ZRC94GK/D#CT:;WE3B,N"_OK
M9GE'_>0I#O])@UM^VL'+MIA#GWU^LT'$D4Q=#Y26F<T"/\?2V0:L*MF(%*X%
M9TL)H6,I(Q%"BBI/4Z&NP:-T\_@!LH;J3X2*5U(Q@/%IG(=!&&V@<,0]Y,OR
MK+?+K[P417#%<`4,N<FE]?H6Y!F%T6S@U[9Q&Q)A+7&9!>!:5]9*8JTF%"FE
M(DHL`@.$:()Q>):BE56+$(:U*,WM,:%."GO[8GTOPEWZZR9\\2*^ZTHKUO>]
MR-]$A?5Y=_9=3',20>VH-?L5,LNUH^3V])?-ZI&F-\N+,!,;U?GSJ[?-/B?!
MAN?VW+-&4>[%--EDT>YM[H,((47*PXU3[,$.HH)]!_8PI2S4L8*5I#K5B+D4
MPF>X'&0M!2&YESY1\")(&$NIQX\[(--G)43D^0),Q'#-'/<Q3*+D*61^*/ME
MY#7,GT6NF49UXMU<-[961V^"+>SH2L9$<28%:U+E[6`;UZV-6@:@'$"RAEK+
M2(/9=5485.5/JB%K$?*5C3XSJ[+YAF8_L>C_(3D'5O0V92+X^;D7!V%04SIG
M&`7,(#_,'`6Z]^N.'=8':F,)STLW6BG^"^+]XH&[B,*![+]YJ"3<"?KX8C>1
MT/@IC"G#"-;X9+F)?5`1DO6%T"RX4E)/C-X3F[2$ZX(A`8[D(2&")Y%,2<G5
M`6"[,0L;6N58*C(2U=CI'#HCH/`GUI(9JLU$99,YX.B.0GM`*;^?"Q+NBFL=
MZM@H6Z<AS>&$Y/[SZ=T#>7/O+6FT)9_9AX])Q'<Y3^.`W'EB8+*O'F18^RV)
MA'QB+.M!KB.8LV6O$L<D18<895DG.$_D/W14K]G$CW<]I%Z<>1STLEL6A<9L
M?.80FI9/$W2]PC.$#E(L.]@T>X]Z]2&">8-SL"Y#W>4Z#G,H9K;>/$:AS]QF
M26%1-`ZPF;WEA4%_QW`!^5`TN.#K4W$^)1*GOM!7_E53L57CSG,`!F,C[*%!
M9T_L$&"NP&%ETP4?(AC)4U[YB@];!4()-\'.(1J,;XHB4U*=U9(W+,83":??
M.@0"+H!0_S8-?:I.4YJLU=(>N[MWJ5KQ\*;&F)VZ4^;!?BPR@`7I!>'$FQ]`
MF<AOQ]66WT&DW$F#)(J\5#NU&^2O31<H/)[1!XAPFR8^I4%69HU\H;MQNFD?
MI+[82^7R[D-'!^P[$,;R6]J26$LF4)1.)5<];BN;K%[&_HRS,.`7@Y*8YZCS
MMU\\+9]('5YX>Y$[>8"Z$2NH*JISD<_*!$6>.^,"V5QK+PQX/0A5]0K^#C-^
M(LZ8*;(GJ@"%3%K*),&&4A/\JM,KI`FP[^$F!X@CRO;Q&U%9!M']U#<VQOZQ
M@0&_EL%_(<5#3Z1C7%S<OQA;\4)5?G`0UJ^I%FI,54>@[4>Z;B2[*UI_L%;7
M"#4F-RE5?8Q+;X$>=1L%M@2S2T9SKT8H`ZQ-FI;GOAPZM?$I"P$6642`I`P(
M"R@--CX5Y.5'8F.YP',:OJ@L(P[UN[@L:O,P$H"7@+`FD+G0\7)1REK`L*/R
M:M9_07G'0^D'-%V]W655KY^Z?U8^4ILG6OD+(]V2.D]B>)2,Y_V)O_.025MF
M"0Y9W)L018K9=HUFO+7521'SZMB.8F-NA952B+NDA1Q:GB_"3;+QC5>Y5AL*
M&V[6[!._8K%;!D>43[Z\I3LLTRTB'FK4#,5@]T.#F4WZ(4<D8]5UT.GLA!A7
MS&4?/OKU0<YY*,P@!1LWN#"^\CL^79;[\Q4/'!OIYY&7945=Q)OT#DI1J;2#
M$@K/O2BBP=E6U4^4#9OBE\.I8H<+.V:K@,EA)#%#C27-!@,1\`<,DI1)DA).
M>D&TA)CR2I(0!+8>B]*FJH>C.,:U!4LS%3C6@EY6;&)PPQ6/560!'F_)?LF=
MX$X9S/$*]3F)V%([N_QU$^9;*%U>/L1=3H8\OZ\IR!M`!CF(#S7,WKJS!PW$
M,#U8E8/6EI+A[XA@R1\`4$5-.-O*^I)S=G:C?FH#U3QI3_BY%WGC9;!%2U-X
M)\]A^'C--,Y$!;^B4FJ9B=:1M&G<&3F.]#."CAYF/1%C1D\%ACK"2*_,-IR4
MM3[RQA,PV=(N.Z/Y*Z4Q+]B>G?)#C[I-\T.((1WW=HQ4G-`-IH3]).]PQ8;Z
MRVEQ!I<K-M7W`=^Q!4WM$X%UCP*29,-IB;<)/M2\9_`<TI0-G.<M">,\D0V_
M@U53I>MWIET_3'QBY^Z7TM_,$+\.7+317Y\KV!/)7]B(->02.#@'=&>MAYK1
MO#.2'Z61(L[W"!X*;IAY;=)'.L^,9LI17@-&'*79U]$"W/5\^W>OS(\#5S[;
M:D)?I?37#8W][>G7L&D?W*SG7-RO6_U:QVKN-@>7,9!^</&.DC`I*).?@3:&
MT5ZG]T6R\L+=8+=?S[F,]F[U:T=[<[<YC'8#Z>U"OS[P!2/7+[M/8H)%3QNX
M=?^LF)T_4SCRZ&'"FJXS!(`F`W0AP&Z_F4%`H_B6PS\M^OM9<$($`M:-4-!#
MX.25Z(;'^;VC6;W77%R[7>WN*+;H,@>'[I#<1O3*J>*)7,L3B.N<KL3>4V86
MNK9WG<OX-C!`[2!OZ3>'D6XBOH6IJV1#@(_<B,VP!+`364'W?_=AJWRM%5Z]
M4W:H,4AK^-J3!'(L&&(0'1/Z]$>,#8/4&.H=BAE<<]4\I1XZW$:ZD]I%;3$3
M+]>._A`$"F?;XL__J\XA^8&5613<WADY0/0S0D-,W-(3,2CT5,#&=D]!'D^4
MK*]Q]\W0>Z>WC<9<7*&/23KW?IH(S,$Q>NEA>S=(^UQS&QS!]=2&Z3:``^2X
MCM>;/.-`^<%L1[BVQUQ0H5G=6@S8;SX'CV^1VL(P%M1%YM('+)N\(Z@LT]=P
M^>C'WC[Z<<X^^K&?CWZ<I8_N2FW91S\B]%%;*@L?_>C.1R]H&KYX\`+`V?:+
M!^]KMRPW&QLC]\QV)76GK&^)V!\[!!XZ+DNR"[A[*B@[7RZ64GWQ5K1U5=C0
M=#8#=5_!^F%:MIO%(*T1]_`A2H"JXT79R"HNVG6<S@7EQ>76*&ZW#7*GJU5)
M][9*`\1N5B_GT,&G"A2X#;[&T4FEG.\]SC>O.QF?PIB?JW8>#UCB@=R11S&I
M[?L9!0/$0#*.GC:.+DZ+6X.5>VG%H1Y<RV^^O2%3@T`TGBVQ'\M.O*+$8U]Q
M`7*E[2B[@T9AE?YW^$WZ(8<P8]5U6.KLA!AJS&4??/^8<U@T93XH/HZ@8"K]
M?W3GSI^3F&X_>^DO-+_:Q$%VFI^S,&S+@(RKW&"8[E[(7=E0;=V1.[H@=F-3
MR0=G[0!](A@0SF$!"3R*B?!K-QX\C>HKH?H2.""<F?NB&W[W[535:`9&[++=
M,H\RXX[CI$GN18.FV</+0`#KHIH)CIQ";371/XHV[HS<@?L90?=FLYZ(7;NG
M`H,/+TLV6,/KZ2WA,-`NCPLT><[A*96]<F"&79"[N(G"]<=F^^T1N[.1V!:.
MT8I=\061U%V?I8V@KSH"B)J.`*SH:%#!<U0M$1QPM$/O(+S&CTAF2IL'&XA1
MR5#PP;O216%-N8V_+#[HCCO<+#)&MHA8:>CUY9`L-RY7ZRC94GHG'L0R#CY,
M^B'W=V/5*]<9NSHA]GISV0=?7)0<B&11.>AS&I>,K_NI?-H5GIBE<<:KN5HL
M)BS)GR<Q7_;0X(YF%&YTG,/[GO7.VJLC4F_MKWQ1$-BH%_;BO_V4&/RTB=J,
M%V?)7J8J[#YZ$7]%-GNF-"<!7$J&!XL?H_")BZR]^)D_I\GFZ9G]Z\F6\*BR
M7PA.4BFY>)+V+?DI$X]RLF$?43\7#S0+A<@Z27/Y\@5\K,^<;P(FX6N8/X?L
MZYB2+2,*U5OE1]`\3M(5FV^3-7_>F:GE;_V(DG!)HB1^HNFW$]<%GN9'+!&H
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M:_YHZC\33S96P_+\LB"2(RE8$L73/0B,;A6E?`$3Q&]0WBU<%!7G;Y:WWI;?
M/>EAOOK>,P2)%C-TX4--UYE!0YL&UE&A?.*`?:O8X0&$,6Q1/@^]2N+\.=J2
MM23-'\^.BZ_5QP[?<;V@CWGYF.9US(Q(L_S.@^=MX=SM5KPTZSTU)9'T(H`<
M*?H;HYKP9MH;,5X,4&)X,MQCKCWDNB"*&SSVS)^"YB?2)4=7"7*36:0P0`J'
M<8<_]=QP,@UKM0>V5`/-;C9YEGMQ`!=?><'PBPUM]/G^O9$Z_$`S%`?5YEVQ
MGU8/T&3X\R=K.-V$:1".?#WQ5&T@3J_E5,A/H*-B+R$`B*!?H1\</4.[0AZ8
M0'=:)J4"$Y\73VA&8$6`%^$`JG&3[Q$0QL\9:DYMC=O*>)!C2AL':GQYQ0@[
M'%;'CKPNETOJ0Z[R`<%7/0VD<'R02<Q"L!H"LXS"VO08*Q`K>"*.Q<:P2ZEW
M:#DP&P-!LHZ3P>;6LT*%/36;_3^;P5%@E\26?-KAH<5YY&79S5)>!;I)[\*G
MY_SR*_.>,*.W:>C3XLM,?IM]:+#64%K(1_A!)M+'_R!"B+WC,'T&Y]8"5P@G
MU?4UMB;AM-E4*'D3SEQKDQ6-'&UNNC%588^ULL>KL@=L=09)%'DI7[61[-E+
MJ<UMC#:-X>%X%@F$25"W/C'NB10W!JA?;%V8=<.^;=%3B\%'_^&*PN!EM/B>
MQ:OF["EW(<(&-:$EXP6+%<GM^F_;SZN+`'8S5EX^\5[$1+81*'E3HN2-!$"B
M\2*"F8,]B(FL4`)@K:*3UPJ&^H8"W+6-EX8IHZ,+4O#KHW!-8>':]HA#(".Q
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M1N0?F^")YU'(7`M>/.(UV40!8<#P]$13$K%5%2TVR""C!UXY"!QFPC>?&U_'
M?DJ9>A=4_-O[X+F&`'*?[V\,LQ2+W=Z(,6&`$F,E5RB&Y(UBN7=&8L4<1D42
M)[-*-=,U5#:0U6#H"P`,Y'.1@"Z]380G:^LS/,[([YK?+/4TMX[D"X-NR%'#
M5/'*$PL=?1`CA+'HPR^,*08PT,OKL\#$8?"KJ5I*>$?5396;Y6W*O#5<>]$=
MA=<1V41_L[QB:W(O^AOUFAXIM$`6N7O8,EPEW#Z0)F+WLJ;:X??5002XO*J$
M@,5W<5\+[JPI0>`+*0I\+H0A((VC4-^U#4MS`)K,`K2N8]#\X34YW*8ZJ>,!
MIST##02D@LYQ@-"^.A,"#X3%P)XP_NBAQIZEF+?_ZYQ`A7%OK+0^E-C1`8MN
MI,.@!2@=%;A4%'("+R#!7`#&BK68[_]A1A!SQ0QORX"2UK$!C&ZB@_`%"!T3
MO%3T<8$N(,!,P,6*K9C3_QL.;#$PR[R0H,O!9^*WEMW1T3LL-A7BI?8L7A$!
MH7C%=I6#M)N:T]P*J3MTJ%5<\]AO@OU*1XO$EBI.J-0Q-D'%Y56.,,N@U"]D
M0/,B$O#?/%N65^`G:R_D;QZ(0^ULXKL<(QB%'TARFD7"X,2916-I]HEFV8_%
MK\P3#U[U!/>Z'W2$LCI?DIQFM]X6;IE\H;5/O#0WQ0P['0KN5<?9:8<=@+K$
M'GQ1JM]3+3&PAVHE_/[4&W@DA:S*P\(P9O]Z4;05E4V6.9Q&:(^J/-)M$HO;
M:LVOJ2P(_>I'&UX@9><!EX4&D^`T53AT5%;']D]2UM#AE(DD31AMA^5R;&L)
M]-1`6I"8\I2*W?=Z^+SG/*=:Y8-<?H6GN&C+JJ6^)5+8-%!/7\/4-$.\E&F3
M]N"\($ET,>+*IFO;8%3]J"!J,?Q0%ZK*1S";*L(8-$?J3Z:*%J%(2UOLX8B)
MZ,-G!DBLXZ$$3`$O7AC!)#'Q[#ZFAG=)%)VP%0!;`/`;GN73K8=>"^QPO^(^
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M><.BD6SJ)V<G-:5XUT]P(\".`#\B)JN2(WE(B@)G#F!S4I.</[-^_`I*.7H6
MID.&;Z^,$$VJ2FUWU(=Z1GR:?D@N^73>-M%T],.,K7U4WPLZVSIAQ])>.AP<
MCM:'H*G&$Z)*$3C^)@+04<U>1*.J2%I&=#Z`LX*37=U_$+K']`E>JN@,3T<U
M04G4%U>FV9CQ@H!O07@1/Y8[8>#K>^MP8!*`G:WH<I9A0W2U!O$@;O],\^<D
M2*+D:7N5I.P[RL-Y[?'9CBN`-N@BQ6WKIM,WQ0\FBG@+W9YN@R_U:V%?*0,N
M[[L+LU^N4DKU&\D]#-K0?8:^U&:(+I>IZSLSSVA5P:X#+`@P@\?K:/7"OINC
MJ,FL`41/EJ`USB</Z@P!YW-^#G7&7L*`QD%/>&CH/D-X:#-$%SS4]9T9/+2J
M8!L>%#.BN"%#AU&,42@=**6W(8V"6:`#)-@,L)_L-F,TT!4W10'H,U/OKX@^
MFM<#%WS.;D7W0L>\1D<<OOR7)/)R_GSOP+E^C\",_;O>&*:>7NT]4Y]O4&(T
M[R_YC3?K&]3KFM`DA>HOI>I89OU[_YD&FXC>+&]4PO,G.`T,Q,;)`V0V-5C0
ML"MR=.AC`!T73/HA1H1>X@\=^(H)')D4;(C@0P0C\C-G]5_N/*!6_T]A3*]S
MNFJJ1MW9"?FH-U-:'^_M/1"/=$/!!R<#-(UK8$$XC[W!/4VP.YGB$=!W672:
M\R_DZ3A*:FZ-W&<[U*S<YZYOBMA+NR0>?JT1Z"ZTZ>=G1=N16XZEZ0X0.?5'
M!C44I`#]X'3\B8I:$15$RF#%?;,\3^)V=QU(#+TW'V*DJK,/H80:"PY2Z)`;
MT)02R9?HC!>[X2O[A-^`9(&MXN\*39S8ZEI<I.7;7.I&;E(-"/#CSQV-Z:L7
MM6QN#Z-T),A38YXAL*.1.0+,J=-F(L"1K!UNG[LPTN77G,893WD#K-FL$Y&E
M#MG$$>6Y<!)_Y.5^@3Z.-^#W#:)NPNX7M3#M@QQ6C%1NWE'8Z8`8*LSDMA7&
M<[_7KG1/7F5A&K6YD@?<ZQ[%;:\V^2:EGQFPK#:K6UGP[F)#.W88^E.9EVN;
MFJ7%V;M(S,?]C36Q!PB")9$\B6)*+N#.C5997U68W#K?\YC:9M)"*VDA+XXW
M16#``H=5F`N+;6)U$R-F7@"702->R@;-4L;$<'W>$CF$WA&`E/'K(8.)S1RX
MQGGK8A?"&A$,UQLA[@R&Y7$00]R^CA]>$U#<[+C4C,X1P$VM:09$1261F<-+
MO2X'PTI'8+2`R(A<Q_`$"(<31X\!3V\AMZ^`F.L+[Q'8P0^=TM$@R)YYAF%(
M0>8H4&1?FTE66!Q'@/<\D,2>E=P^]V&H\6'V.AK,.``GYH\-TRU7+O9+1-GQ
M_ZYW`Z:RQ.`G!>PX_2VC1=.4!O=YXO_R9;-ZA'76_;.70JE?F;X=![S237?E
M3GM4D8.$);/IX'$@2<2@8DNSH2Y6\"=<@`41(L`&B!!BP?!&W:B`>M.B^I0F
MBL7*24K]6YIJ1KFG:4AKJ])UM$?J)\:J%A62VAICKXQD)+NEJG)Q,78S3E_4
M/EIY6_)(R28399%X]2*R+L9]!O),7+=H5*-(#[Y9DH*\<&XB&#@H!C>JOBHN
MVOOU6W]Q#'>>N!7.MN=06\GLJE-=#Z0PUT/=^HM->\T13^,F4MNXQB3\^'%+
M.'WWMY?N&?#S'"PNC]3^]&O8M)/6UA[[..Y2M3**FQIC'L.=,@\NS\D':S%\
M?P:B#@>MKM]%`D==#1:I;8A\F#8KIX_/_5:(!V:+L(>-R)MB1`JRCM)31M,O
MZ=+O@+6:"-[.D_B%IGG(9J'3=64I^YE"-%87#!KW1.II`]0O5G)FW;"OZ7IJ
M86%U%\;+)%V)VJ-KQI0-9O[.0L+7?4(><DK\4J3=>']!7I]#_YFLDRRCS#=$
MTTP]H\7:45&&@2PIY*W1J=]+F\BHTE8:'U(R4G`A>$T,APZL<%JQP\Y>V)A@
M>388+)MZS@HL6]5O!LO:;K,#RW8MI@++L^,"RW&,6@.69YC!<E0KG-D&2_NK
MN4\==5.:VB(%3R,5FY9UGV90'*5=7EN+GT^N2Z&,HR8G)UYSR'XG7VEPZ(;)
M:I7$7*9S\0R`.#^\8Y-2^D*#JR05>0+JW:LF6PV@@]U]AYJFXMI]B6!V^\&Z
M#(8$SE&=<4NF\H2;*+;\U7F9;*,X.P*,R0TD39'JIE@*4Q2OB+\)8Y+Q=B@J
M!G*1SYCT`3,7W-SD$:]^+_QL6[:1>4FG\*BHX5G;P?21XY)U4S:<XQU&'#&.
MV=?1RADA\#F!SP.B2U.I\`!GB'I#*1+A,KD_5[QE=OCBK6C+4>).$^2^5J=0
M)<--^Q[QB*\5<W#N&>M'@)KS$T&E5NMIX%ZCF0RYYE/`:HL9##M+IV/:P'-Z
M\#>Y6H=L84,P>AU#O>CPA0(K:-.R<=W>'JGO&*M:;E*W-$:_-6TB^^@;TL!3
M;M44LA`^EM]\P[^#O[^9^DG?46U3IRU7U>5F\I@*%[_CR(CT_M_Z(9+6?FZ(
MM*MJ*R*IQG-$I#W9)T"D]__6C$CL.S2(9,TV]8C$5$6&2-84+GY'AUM979L&
M37L&7<=<5@@CQ4/[QJOL6AU,%?$JRJ)R!VTS=^Q-=6Q-.3_-PV!&<0V`F\?7
MA)@AEE6O/)YN\N<D#?])`]O&;^%SK$C795HKP-?$Y!AQL%-79["X?V^7E.+-
M#";'M7)&O!<OC'B=13CD?&+RY$B.-H=:[%:\X^8]P7M:FSS+O3A@RQF1`^9]
MA=N1MG\D,Y;'BJP]#&X%9`WX'2/>]E';(?268O*7YDI!Y1Z"%'5F,#R%\:N6
M2S3+Z0D[.XA=YJ-@><32TDRGM+Q*TC_#K#3RQ%K#[ECQVM#08P3$N[R.$:=-
M5485'E<PA<LY,X">Q.J[X3+.G,"A)KP1#R]KT]M=$D7,@O"E[=^KB]FQ@J^1
MD:U`;RNG8P1>,X4/VV5,Q$4OS\_#EYH;!LA!<CH+.7SQTJ)UQ*0R_J]0\/GM
MH%[5M",!GF#RV\"Z'5T=1I=2MH6^^%<QYRB`R1:]81)<QL%$H&G)U/K>B)<3
M&@<0D0MEVD))BS:[S[TTG[75'NE3&/-T%2/;S6<:XLN6[#J^Y3K].4TRZPD.
MK9R.?"IJ,:_-R:B&S1%/1VW:8IB0A'R$P8.0$#YA,LXSBA_#V)PFQ8*@/.,-
MRI4&%YN40;S05.S$\"^E)2Z_TM0/L^8TB2&$L./?8.-4*S/VI8(9O88K@P&<
ME%0:/MD%IA^$"6/ZY#$?;X6FZ2U94$*"/0>"\U62+FG(BP&=QL'EUW68<@H%
M7H\T*9CPQ8YL4YG>9IS7R10S;DZF.P:8U:3EY;LT>1$`+_J?XIP_S!LQ`\/Y
MEV!W+*`MYR`XWAMUY[>.SY&#<J-I;8+P'I,C!MUF73&`K";=J#N_HR^R[9M9
MH]AKUW<^,/H7FK$I0<P_U&=_/B3PT53G:CW8'SGH]OTA;&*Q*>\CANC>)L"`
MW$)H%1ESL>$B,'P\W8'>Z+`^V4\CS<EB9:I9\X5]>J3@KYGPKS1\>@8SO]#4
M>Z)JA^<V#7T*>2?+J3++S`4Y\@EA^(\S4H*&H11'/$D<8`P,TT5E1E`*$*E!
ML:5-N`[D9_50Y]SN*KO[K12?DWJ3'OT\X?:7_.\98>=G<#`-_#?VSQ;PCR+9
M;]1?IC,%,&!SB9=F\)%8&QQ+-N"49FW*$>PV+J+YM+%F<FTZT!ASJE4)YCZO
MVO\Y>LVM]MC/>7X=P0ICSK'M=<9;\Q1=S+2,TV-RX(H*T2^DYS8>%?(7B6,N
MP;^O$,>._X-^%*M30"\)CGD6&&8(%!-!34ZHF[G@\+TU7+]2-=UT5M/!H2E@
M#K;;#I5I[I/%%#_9I-FLQSJ53&(7#-MX1EFP<YUJ4/^*+0FTQS0-:6EN#B8<
M<^Y'/K7T_!E&RL;]C4X7?2V`86*H9.X>)?Q/]:MT)OH>$]QW)]0YF`4.%NK(
M)P<[/]JT6<._T:G$DF$PS##F&<9'.?TX_B7[)B3;F:2:'BT;+9_@CJ[$*U;G
M2<Q3#C=>]$#3E<I`W/EQW4N#=*IQ;YABCG$L"OK'XMQ;9B@FQ>^\B1^/FZ^M
MN%SDS&PFENVJ;T9)'2JE^?=FVD(/HBE"0!-G6=QS_^7V4KF;;>QX'?C8;=]'
M:_;]KBW.FEP2I-,P@I]G;YDWK1C8UW:.K(%A0=>^9C-'N0G7;S/[M;KSF9TF
M`,[;FI4U[WQGWN9M[29+?ACI-QTFR9'/O`?\/#9GW@%B'/',>X@U,,R\[8=U
MQS;SNOBUV@[QYCM7]-Z#GGH*L2K@D<\L]G],FQ../>F.>!X:P4@8IJ<#3OJ.
M;>Y"]`OW.`'$>=1W^O24\E*JU\PR89R%_E^\:$,G.MKKYHYTOG'T,XQQ=-?!
M&N%,X<H"N(Z9"JE)(3;A<A_-H=+8O\N.W>:;,*C9K&JJD=)NVO@A!>S)3#U2
M59\J,X2@/)W.&*+Q2L#=@2/S2*4;S^X[1P3Y,U6!,?PY]^T?;5.K:K<)3@3V
M&<X!?4<U]DC[^SO<L./ON$IC`.#*;CT>`,9I^)V-=XP(?,#,M5?LX"')O6B2
M0-B0]1Q0>:(?8(1+D:U\L2/U5.HCPNQJ`18\V(W]IR@M]<*W>1A\)W)?B*H*
M+/.-H\5.NK+?E1>FHT;1+>SF@-8C&MK^@>4^+^RH/*;*&)!8'EMI,`R".D=@
MC&;GAMD#W!?.SAW:7J[64;*E])ZF+Z%/Z^>O+TDLY.2&ROB<I']_GF3YER3_
M&\WOJ)\\Q>$_6=/Z@[\I^2+'W\E,KP/QZ$P1(_)TN@]>7TL)B121-&'U@A1R
M"DQF6%S!<A"3M<G)EN:DE-3Y:Q_X?X.?XK0T5P;/:DO[^[I](4LCSAP>]8UF
M2/TE\:E_Q!W>OU4`K_L))@%QG?%O$<AK]7</YOLXOB!<5!6('QF66_T9*GA>
MA^$DI9$G$^XVZG?@P"^C=.)QT8\0Z^4B)TGE1]"N::-D<B%^J^C?^J-,,@W4
M2O!;G`_:#>%^8FB(\A=R-P8JF1)-]".;)L;Y=8J*$)[,>O=629J'_Q06ET68
M$O8=>7T._6<VI;#?(,PJ>=N/,*DH,2WF:Q>FA-GIEOU2STSD6Z8H-/U,:][O
M[M$-*=[V5;Q(;3;H@[U\4!\5AH[W.[IFLE/QM`T#C%4QT'-YV8,-:#C>!YZD
MQ"X>("F9"`A%WGPCVMS?WG[S[=MIJP=-8:HVY;GF/PM&+M*E7>OO+CJ^CEE4
MS_1F,3PXTR?@!%O^7\.F_8OV'DAQL(>Z>I#8TAQQ1&<B]?#C;Z!-"N)$42<_
M`_T]YW4^DB\2N'76SU)%GWF.YJK*!N-9=)C?B-Z1>X0Q+3@XVN['IO5TOGS'
M8BKF!\^G<7!!7VB4K$'"2['E5!NJ]^N)W*][J*][MT$WQ#[>1_KAX;K@01@3
MHG$ADHVC&-2)">`.>U!R<>?L?Z8Q3;V(*7T:K-BB"8XB\_"%FKB[:5_D#M_+
M!+K+&W5$[/3]Y!_\3JK@PKV^R@>)XT]K!O!\K\+'G?.?1IPX#>IW-J4!&LQF
MW!FY^_<S@N[_9CT1`T!/!88._8)-XW&!0@)792<G,L0]VIR<P=G_7S:`CC?+
MTR#@IQA>Q-MEIYO\.4GA$*'!Y.-R1(XY$YC;RBVC;G:(T6T*K1UFL@LI(2.[
ME%.TST@IZ<PN$TU@^MLD9]Q"9JPP]E,*IP!A+-ZBR8CWXH41OR0*!]!AEFW@
M>4WB96RUQK1F81O[(=CO`J=*9PG4I6'VOPA3ZC-@SO@+-X*2S6=M3IFX01AM
M(%AD]EPE,9](+G_=A"]>!.=?EU_]:!/0X(JA#%A\(P[F;I87T(T&7VC^*<FR
M6YIR<[:5MAJ3&5)4GL;(Q>GN:)RPGPF/K_AL7HS!:PI=,B)$DX>FFG!$24?`
M@X@FG\!#+B%A(A*0$7)Z9&4OIW6Y?J-&=[B_H*EU3_U-RN9TVFSD2R^%K(W2
MO*MD$S==P[)%&^F<-(H)*YL7-@@CCO[MZF?%L4LQVEU9R5*Z\(((>=Q$\WA,
M>5+8,BMM22NVA,C<]R)_$Q7V#"0TQ@P:(X#&XO')D0+V>YHRP4Y]R`Q-\Y`M
M)VY9<YJF\H)`<[ZC<4^DL#5`_;*@JU$W[$%N3RV&)Q`T)3P*`<@IT40@:R6#
MN!XR<8;C1#91FNN*%XQD/.4PSW%B*T"E\R8S6,>ZL_.A6&?0$S_6F:J_@W5=
MW>:!=<9:C(9U9VUCW0G6C6X3$\W=@QT*,QRZ_F6AYMNGY.5=0$-8^GX/?P`0
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M7QG.G;TPCVMSX0\:X#=J@`,7^"^-C^-KI5.9H/1QYXNQZ]N;UCA0_QZYS^ZI
M4KG?K;Y$[('[,@[>E">WY,9Q1&=1&ZC!Y$5DO7F,0I]Y#POJPOC)G=/<O-`4
M;J7D<``C"@JV.E%;>^1.U:FJ[F2-C1$[7;?,@]^5@V)>!6E94].Q4XZK[4FI
MK2QQ"8GZFSB@Z6L:@G`6S[:U)-&_>G!Y(<^:C[/;&B/U0#,EBT/KQI;8SZF[
M!1]^_LC3T.!"B)>3I_"%9CP#[3F)V(CD?Z90E`\.J]>JZ)2\:\)"-%^D^HJ2
MK6%,/-]/TH!?.7D-\V?>'ZZ=9.JALC#.\I0KNR";;.-%T99LUG`N+B\'L78>
MR=;4#Y<A#:`"X";.)SX"'\_<E=1H1=OE,?=XJA;:`;[Q-^K4\&$_L6X'BWBG
M>%9WRN`LLAGV#/I@1C]3E0L0[.J`'0N-Y1^Q*B.@&OO?JQKB<,].E!\M!KE1
M?@NOVOA]`0235VX<W98%".QHSM5V"'NC*U[Y7:=`N)8:M`9]9HEP3=5GNSK,
M%N$FKSMK!^!^CQ#@;)FR!>"<UJ0=7?'*[^JPUA]<R&\Y)=2_1PIRC:I4JO.I
M+Q%O$^W+.!B@@)+STSTN17N]R$J+.8ROEOJ/Y=?8QYBM:5",,K=%&^WKX_R\
M[#.+(5:;5:OG[+9![CNU*NG>4VF`V'_JY1PZXB0UQSXTBDX.W<?[VNT^.VVP
MNT^=2A7WT1M@=I]:.0</-4'-M?N,H9,[]SEGBYTPO_+\,*J_R-3:$+DC-2NG
M>]-^*\0NU2+LX%,63I(HFLX7$E456Q,#&YK.:E@V)__5M9O-T+24W;8W.)VF
M\SE5<<HG(5Z2Z"6,GZKZ=CP&T=X'N4\:J5Q]`**E`V(O-9-[^%ZYI$[V1K7C
MUQ[&U'I'5W>.^RF)GR"!Y((^Y@^,64L\U]`4N9NV*:A[9UT[Q$[9*N[@R^N,
MZ`E0)4!V08"P\^!N5]/6\*ZQ\<Q&:7.(5]]R1B/54@RDR/*A*D>JTTAO1#WW
M??*`@*\A\>&!L?B4>/%9>ZY#?3.DWM6E6)'14-,&>Q)#F\CVZR@!-P+LR-G$
M&09CZ*EIXSJ/8&3U1@"(T_9TS_IF<P"(&L7V`$)K,Q>`J!-Y3(`X=000-O74
MM'&=23FR>B,`Q$W^3-.'9R9R')QU`T5]\SD`1HNB>\!1TW8N`-(FNH4,21[;
M1C`8$V`$%V78N.3/X+F*-<;0N/0Y3IT\<#5!20SH,H;&4D^EMT6DJ29==M^\
MZVB/&6M,5"W`IJTQ=K0QDMW1+;R=XMC'<Q%O5*/OYJICN(XWJL*M-_+0U(&Z
M7*VC9$LI%\.@<$!;>Z3(::RJOK':V!CQWFJWS(,K=4K*TG=1%`X83UM!+*O`
M_Z%7:.UX*W_T\,++VP[F=ML@]\I:E2HO#^D-$'M?O9Q#QR"G1H"<\R.W0K'6
ML[;]5G,9>,VG:SM-YC#X+)TSZ<//Z3F:`\4.>GHU9K']M7PHMGD)VM`.J<=T
MJJ:]5;K?"/M2LU7FT>_\>IQ[^;8P6QNTORW,:Q?QKK**\^\RL0ZM>RA^S<3/
M)EY%CF)/090HJBX7C6/JMY(W?-1P<#SI=Z2`[;9!"E^M*NU-]S/(]JJ7\[`9
M$45R5^<[\%G30_"E2>+@EAD"BJ6VEP0>AQ5R%QC3P)6RPR/P0>R0HZH[>)>;
MOUC*.1)=+*++1<ZV1&\H92,"%#1H@+,I$%#42'9<%!FCN>'E[7PK3>;^"L:!
MC_">;>L)M$4#HW)$#JP3F-OB:]QM[!##[!1:#P_@ZU_N=AU2U:O<&1X9=)NE
M1[:'+5U]9N<;%N>WI@&.(!YPI?NB7?D);SSW>DW9O!=R%^_QBK)A%\0./O;3
MN/@>!G:A^4YNCZ[P']^5PGUB?[$/U4>2%/OD_P-02P,$%`````@`<X!L1]L`
M0[.^,```H\`#`!4`'`!C871B+3(P,34P.3,P7W!R92YX;6Q55`D``ZG^1%:I
M_D16=7@+``$$)0X```0Y`0``[7U;<^,XLN;[1NQ_T-9YF?-059;O[NC>$_)M
MCF-=ML/V=)]YFJ!)2.8,16IX<5G]ZQ<`28D2B1L)""#$Z8AIMPTDD9D?$HE$
M(O'K?WW.@]$'B!,_"G_[,OYV\&4$0C?R_'#VVY<L^>HDKN]_^:__^[__UZ__
MY^O7T54,G!1XH[?EZ`>(8S\(1E=1O(AB)X4$1E^_%@W_Y_+Y?N1%;C8'83IR
MBUX__?1]U>\R]KT9&(U.OQU\&Q\<?3M8][YT$M@:TL-D#K^-5W\IOQ^%OXS&
MX^_CP^^'!^.3T?CPE\/C7P[.1D\_5DU_0":F/D?;P`__]0OZOS?XV=%GXO^2
MN.]@[MQ'+N;JMR_O:;KXY?OWGS]_?OM\BX-O43R#M`Z.OJ]Z$5N@__I:-ON*
M?O5U?/CU:/SM,_&^C*#PPP1_F^,C97,XPHW6/X_*MN/O__/C_@4/_JL?)JD3
MNNM>D*9/^4JM?6U4Q7?&%Q<7W_%?OT#IC4:_QE$`GL%TA'_W2[I<@-^^)/Y\
M$2!:^'?O,9C^]@5*\^TK4L'!Q=$!XO\_K@N`E/^>A-Y-F/KI\BZ<1O$<2__+
M"-'_V_/=QE@@+0?*Q$^^N='\.VKQG8\89HY+V-^[<O>20JBBD5Q%H0="".E+
M)T`B?GD'($VX&6/2,8>G)R>&?WL'J>\Z@2P&MXAJY7;UF^1Q^K@`N=E+(-2N
MHODB!N^PD?\![J.DBWI%/F*,-*Z<Y/TVB'[*8KQ";X<\7ON)&T1)%H/'>.:$
M_I]8]E#T:SWP&R0>6EIX>\GF<R=>/DY?_%D(%TG7@>;2=:,,VLMP]A0%O@O:
M\,E)5PO/MWX(38KO!'=PH8OQ"M&&Q68R6CB"DHTSX-U\+M#D:<-,C8(6/AZB
M%$`COW3>4"]A)C:[:^'@#R>.G79X6G?5,G*XHLS]M.UDV.BM:?PAW+RD/M3]
M$VP,MQ9H%8G<?[7BADA+FVZB$(_@&20@_@#>;13?9BG\VUV29+FWWDII;+)Z
MUB4T*+SY0YX.M$F".P`F(3WV#:3(5WL"\<L[=&7;F+AM"N9Z#8J=!_-\B%>T
M[LCR)$IB)O@3K1DCT-'N6[1FJ(F(5C^C-2?;!'3['*T9::!A[!K=B4E>X@:M
MUZWYI9,S8>UN;T*:Z9@5V;@&J>,'4@,<*Y+F>BSMN18C;XS'TIYA*C43?);V
MK)$(:?=:VK/42,44?@[E,'2HV1-KKYT:!=V^6'M6FHB8%0WJPAN+I+%^9S>%
M<E,WR//LL)33Z9G'8QO[R2)H'I='LKD\,F,?T6%1)Q`2Y@H/O&2M:1C5_A?Y
M,$(P0]DW]\X;"+XPY=%$*XCC#5(H(^8"9<2,3['$-K_0?:BO($Z`^O%6/U,,
M>A%#RQFF&'SW\"/%IQ`Q29DL%7;`9PI"#WBKW_HI^LP!'.S!Z.NH)%3]T0F]
M44YUU"Y!!K.)M!.Y&V,)4-I4%+/F!OK-/V@<3M[@'L-QTY)0@,3[VQ>^+M^%
M1E<PBQE-@/MM%GU\]X"/\L6.T0]HY,=?#\9%WM9_P%_](__X,YCYZ)MA^N#,
MP=902<W^<7IT<GYX<7AV?GQZ<'!Z>GAZ4!EQ%3B3>'/T3NR6WX`_UK"TJ:FB
MQ?<%SI_YZK[[P0H@TSB:\\JR&$`DR%`4>R#^[<OXRRA+X#"C!:+J!+O3S17D
M+$9[50]\_C^P)"IGJYT%VN'AJ%#/H0;UE(R]0K(-6JG^N=?*8#)2Z.!(HPZ@
M(^%'D"7O&JYC%&5LM+-"*VR."O4<:U#/!([00Z.\#9Q9@UHV_MYK=;`Y*=1P
MHD$-5UF,>+V%[K<3_!TX,7FBD)KV6CE"3!5Z.M6WX.>C?0:+*$81>)1.FB7D
M=;^Q>:_U)<Q8H;,S;3J[]0,07T%(S:*8[*)MM+)`0VQ^"L6<ZYM,ZQ@@CC0D
MCUF*;HB@FT'D*47I9(':A-DKM'BAT<%;V^Y;^)LF:TAHV6M]B?!4;E0/M&LI
M=TGY]%1I:Y&F6%R5NB)%%7[]OAUWZQR-8U^_X@G$C0]0(&Y%"_Z\(C<JZ(V$
M[W.UAN?42=XPO2SY.G.<!;X9^1T$:5+^!@?K*F`M?OV/%0>/TU4VP%.4^)2(
M'5^7]G--`C.OQ>6!ZK";&QDSUT04@>::`#L*(G<2='05.$GR.,6K[^33W[:0
MS/;&:$Y`$Q3U<;%'U.0"FMD8&F@<`-2AUNKPKZ.YXX<$?=8;FJM(+IW4=<K)
M(D6916+"?2XZ(DN8G[1V5M7Q$.<%KMD@J21*3%8#PBS]`/,W$&^I5Z"G<?KF
MU-=:T5V9[8WF+UMKOK&GK9KG9Y9X2K,KS4M>Q*'O#>[@C\S5>]70.`QT6[;I
M?%FB[DF2P(T,83O0W,A<-=,U5E<U!U_:[;E,-1?19BYM;[4U3ND<NB,IG(<U
M2_2.2G.@:B3P7S?_SOP/)X",)Y/TRHGCI1_.?G>"C+2;YNIK*"YX5-S@W;?F
MV!*X/,5@X?CEU0IT/2A]!_&&2`E@X>AI%53:\JO`;5@'",8&+"X\BXI52.#6
M>3UW2%#G4>H$6HU#M("[HN53X.3G!M!$+I#;]0#(5H'<Q5`0"-L!00XMV3<\
M`R@FWTV!U[QH$@#!ZF8'*%IQ*<M*-*X,QWI04ED4'Z+0I:X0C6WMP`,_:\0\
MQGY9AYQ7JBM@AV8IO!!S(?NUZM_[SIL?^*D/4%E+'`1]CP+(6H(,6KID!!-X
MNQL'A]9!I4X<6^(=5&3`%W,B=S`.&)WT2X7+'L6EBMH;98D`QMZQL;')P&BY
MD^3GTQX8H%(>=<F1D=#<WDHP"+!JR;I1+1M"1T)#2_LPP,NDC5M';INP#\9`
MS`ITWCUJWG)<%X-]1GE:\-]^R@P>T+J8#`<9'J0P[TK/($XTF8LHG+V">+Y5
M8KS18#0TM1TCW#PK74HT80.'WRH"Y0M%-G:P'2>"G"L(5VI'RS6(_0^HP@\@
M`AE&+]MQTX9]60'21O`<:?=:V>ZJ[:!@L4J\A=[>7=6^;:D46,2O0.'ZLB!T
MR8"@]+`=(**L$Z_`]RO*\0KFZ!G&>)D+K<PNF\Q1]&^2IK'_EJ6X@GV4/ZA&
M0(XP'=OQ)$<@Q/O\_4*9\%%=CP[G)..FW2%=O51`OP"R6227E@G<T-(X2'0&
M`2^3DHY>/D#\%ID3;JW4RZ#FA&\ULP\&7!Q*BJ!M8D#+`9SG^?G8GQS?NPNO
MG(6?.@%!^X36]H%`A%$%$3,]"9VIXX?`NW'B$/I,R<1ULWD6H)*YUV#JNS[)
M;6!WM`\?+7E6&B[3M'#49<GM7MJ'"TX>]R0UL&5*H'&P4!<6X^>?7/FJ*V9V
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M>^.-Z6U0>EB)"Q$_HWMJB3EF@\.Q(+2V&`9LEZ+AK;:>0X#M4/3B'4SY8.!T
M)<;RPYT[R3=;_29YG#XN0(RIYI<,Y_!#[[`1NJL<);R/`AY2'@5<?VP434?K
MSXV@?$<;'QP57S0X(>TNA&(%*Y8(.6C$5EKJ.^02#V=%-7;6<R;$]L;,=X82
M-BHV"#%CR?'6,]0$E"(JK7P-/D`0X9+;A02(]Q0H?8S1?#NUUF$ASJTET/@K
M"*'D`LCWQ)O[H8^DANI2T,'!Z&4=/-KP:\D!:$UTO*N$=2#@X]"2URM6S.9K
M:]7U(RE^W=(8U;=Q#!ALR)K6FO7[$(71)L?EVSQT9Y#9KX^Z;\>4)3D-N(89
M40*D24_M9`P&NBFXP4B(LZW`3]3^@M5="(<#$L8.8JN5M:#@X;/KJG&1HR`$
M,W1H8>*Z(;I>6`N'5N9!IKNH/6MA[4'=0@GG=<HR*(UUJ.\23*,8Y.U>G4^0
M_/!#/.9R+L&=UB:5/)_L!TC?(_B7#]@$1Q")IF=G(S`&QP+^CF[Q6%)X^P&D
MS-W11IL^8H7-@"7E&<KB)&4RP*63^"Z*!_I!EA+/11F]^JCQ-BPI2+[3@8$_
M@#][ASQ./J`AG(&'#-V,>YQB,52.`/F@T8Y8'Q$CD5-EV7H[/T=%CUC>!M%/
MWB/3(^XC4T1Y5)(V^&RT4B-B)0QVD8Z&IIH6=S22ISCZ\*&Z+I=_@XJX"U=A
MPHF;^A_Y$R,-_A,KBB:%N#&F@D?16SZ%*O8M.9;KKVNY`QUW<%)5E2$]U56/
M\I]9L=%ZC9Z!&X6N'X`-:;Q&G&I@F"P5G]IOT.Y,HI:<1%\#.%[7Q[*&/P<`
M`R/T)O,H3OT_\>\)X.7I:AP8=X:/.C1;RTOI:8>NDIW%)AC@;$CHD-.0UMQX
MP%8K"5EBN*JS9E4N+YQ=10E^R./:3_*';$DK+V?W`6229";I3,:PDO50Z#&`
MT^X:Y/^NB+FHU\WP`/D)#$B4)C5+:B/4I?`4@X7C>^5KG.59:^CA'(M)D@#:
MZ5X+8L:!LB,R>*#66BY=_;C&?`4#\E9J$B\2>HJ']P1AU]A['W'&+PBEC^EJ
MBL+4Y3%Q<_>"_K(NL]\^0HE'!$I?W34)1'$&66&^D<G3=4^AQ",%22X6R=T_
MEU3MMLY?]27S+6AP]+`7$6V9EY3(0@*")J>G6TQ;R0&F<=#;]6&5;-E9<NF(
M()D\G5#1F;L@<6.@*^G,70;[EH1IH<=91(@F[K\S/P:3#\</D!-Z&\4O3@!>
M`-S?T!PQ`0K&X&@'^*B#L:N@%(<G3@P!(%0&E'"Z?`J<$&5<HQQK?#&=%W]$
M`@/\.LC)GLL\G82N9)W=;V`JD)W=KN'J9$^%:RA(W!CH2G(-9;!OR1UI*!H7
M``]?=$)UX=#[B7<A%(D3/&5O@>\^3B$WM#*LG/V-P=`.L-&P+G<2DYTOS3?)
MY'&Z6>X6>BSY+P!Z-!3]1@"';&(#*"7)3-)&V6"$8MX?,5_)S2>(73^AU"IG
M]!MP)RX>I4=C!@!L/0.OP1MQ'TSL,$!*0"Z*#\9TH:G8_.>,EV+`F8&,L$I#
MCSW'DZ!@NAZP,<)VF@#53>1*MJ3[#4L%LI-UOUUS%`6)!55UAO]"(<X/)T#3
M]PGNJ5#1CLT#<P(P14@8`T/1B$AG)BVI<-(LAPF<7G&\A+,&OYXA!)2MOI8A
MA(<[25DF"PQ&..PXW3.`C.U&R%C::I-#Y";4><3TDBT6`1:;$Y1BNPNG43S/
M=48/S'/V[JT5Z<*?)>^:E07%GAR?%"BJ-C%&U3)4V)3$RF#5DOH6I:30G0'X
MX_J`,_0:W'1T72^(DBQF52?N2M88=+59;*0SKOU]/$(F]!]P!77@6IJ_T'0;
MQ4]9[+Y#5WP[+'\7P@W>/[/010/_PT_?K^!?_/36<5$^^+(I9UH6;6.0I!0A
M:R"J%Y[BXSWA[&P".,LL\\9S2Q0:@_O'(/-0@ZVK+JB^`NO*AXI/["54=R%#
MQ<=]LA#[#-S`21)_ZKM8RU#L5]5[?*]17MNU"8J\??<28YV$H_0@3Q5TL'$O
M5P$1W#1V'$`C)!D%I0(:$*.@CN9:4(_QS`F+LAWHEGKME(1:0W-\`/\9?1VM
MZ<'_J)+$+PQN$#6X>F9UX-!;2J+`]TK!/%6$O2IOX@3K,J&$?9(DFEI.V9P4
M`63*/CFK-=R8+8?P?\<7>NR(5)5NG'CQ\:PL>*#4*+QD\[D3+Q^G+_XLQ'81
M+J"Y3P;M[1,4H@MX#<1AW4`4Y%%AW<H'1NLOC-:?,-A<;$F$7-"1UE!+A)BH
M53BT5ZC)RX"<T,C7V1@#P%;21G2X/7/]G.DKJW<70JED&R]\,";V47UBKZB-
M-LD9/(EO'3_&YT)K1EAW%^A==$SHIA&QYC&UCS'35T1-U8DLSAUQ_NY@%A;1
MC>WW/AD3\+@^`0M"HPHE@^=>/:A3ULFJ_HJXIHKTU5*$DB.*M=8>:[ZVI&;,
M3&ZE[(T"DQ(%T,_%^B%*P7:!*X:-.*G;"$QEM"9CL(%`.:[<)Y&DQGH*9U?'
MPIK:A-;&3%T^=6Q6L^;G2,DITPYF8QDAY)R)I_696*%@\"0L1PD-[C-Z="A!
M!H1[5G+WEGI.39IQS8V,FVB"(J^=!MNX^%U%\[F?BFQ0S^HS;I.(P9.N,E"4
MT8B3YF<@='E2<P3[:DE&XADB:]D4(V+,)&^EVHW,H^Y\]]4$A'"53WWHMVXF
MMW`:A/,F@[`B.5K1')5$#380MP`?0*!7[TA2886Q1"CHN81:'0O+&A!:&S/M
M.RAN\T(I/YM]G>7S>7$(_PS)Q1\XK^TV0U(K+SQR3OB+9@\@"O,9/BKICZ91
M/,J_,*I\PN#IC\?_'@50P4F>H(!<1.)3C_3&6LZ@&L?$O_AS]S?&`/"I;.,T
MJA./_9S]F&?BTT_T^3X^:#AK1O2^HFGJC=Q-B@9/[TI^SK0JAV<0H'O8^+XW
M?M4),U9>"B=,_Z[$M`30>,=\61TS,]#6C:HQID0./#8"=@HDTT\#]`!2]#A1
M^10[I^5I2(.#A$:(T@B2&I6T#+8YVX_0,[8/Y.8Z[,7V:%B6@-C>F#G.JY;J
M+!;C2M+\#,Q*2Q/)3CL\@/^TSDX;_:7XX3_-GM@:\M0(X7GLC+TL`C_%'UA2
MP_3$QL9,4;[<LA;,6'+E]!)-Y,?IEIB6=-V+=>X9%B0P9TGI_[^A*XHW2>K/
MH7])2BS?;-1377,P84G-WE72726;OI((FJ.;E8Y(Z]M3!+3GS9*W2!_`SXK$
MXBB$/[J@PCS?DB!*IJ=PD<*FI)I'!J2COZ(\-3Y__N@`_L.5E#[Z2T[6<-==
M<G8Z0LK9X?G)R?'XY.+D\.C@7%,!Q]4@\VNYD[":Q/D#.&C4WF/XC-ZDB?/K
MG@]1&)?_B=TGK$#N+'=I'S+&J+16.&6!4BNE?@8$MY+SA<S1<=T<;:?H]\02
M69ZK_^*^`R\+`-Z3;0V6R]#P$S#&@'3.R._(<S_-034)7\@6G-1MP48J?D\,
M@82<_&)5NCB"2]+QZ?$9_)^L`.,*D7DVQQ-<GEQ_X03EB166.'5"MZ9CS+QN
M(?SM:*4L]OLYQ5=IU"+3^[0^O4LZ/9G9.TGT+SU2"+^#BXNCDQ9;$.;<+X>R
M=FOS"C%+D8G/2<2X6=]%#T0ST$48V@\SV'@!_@RZ/=[D`\3.#&V"LL4<U_18
M\2N$'%%R>X(A*6)1=ORQJ\LK0HO*67U1J9#JR;IB^5V6;6?IAQ_Z\VQ^CUXJ
M*/VEVRB^<A8^>EH`_5IT2]F6L#&&I?.=%T6RZ*=_RI,A+V1F+IK-#%>>?$^,
MD,:$>:;_@7.U$KHJ.7T/(5+&F`?^U'CI[/;3`C1GR8O,^?%!?<Z3<N5[,L7W
M/FE^:U[4\%%]TY)K2RR/L#&F1G[JO"+A:-\VR\;DS7P11$L`7J"M]EW0+*Q)
M@,>"*W(^`S>:A?Z?4`WX61VL&WZH2O[>7B!X%S)34J-]]Q=#A!;;<</93^UZ
M2$^664GW1(K@T?'X]/SLX.STXNSX2+>%FL!MJ><'&;31<`:X68Q/,F\^\V<)
MT!.^:!ID9<5@T3LG\C]DC$UJI6SJ@;)*"?73YR=6:K\&J>,'?*;H6+!@^^@O
M!77#C=)0NGTKVE&,X[5:*[!VA;[:R!A;HJQD.P>_%,M0/LMPV$6C"7"_S:*/
M[Q[PD3*/T0](A\<5'<)?_>,>S)S@!MK`=#GY]+>O1S2T,$9[`L)>:XB7(5/4
MDP_S.IH[?MB@F^J?C5$,KXPWM<)DQ9)MZA.6&_(IG'#Y`\S?0$RPF@TMC=(Q
M4V-UP\C+DBVZWBBA1%=V0U-CM"VJO@;%\[)GB>9?LK<$;BN<>/GBX(`=KK95
M7V"9[8W#@-!RVXX]2MQ&RN+;0:WKT3\X<_CC:^R$B8.?NFQ<I/D[FJ=H(9TU
MZ+P=RY88@+NG1ZJ]7_W=/+VWTUL=`'06+='SXP>(49@:IYSD9R]4O1/;&X<#
MNOKJZA;CS!+UKU;#*_2P(\<Z3VIOG/K;K?-"[%&*$6A>YZO#IZ[K]8;F*I)+
M)W6=<K*H?4(3DI\J*6QELG&C@:8W-DZKG%K9RF<2XT^[2B7;Z'L_!'?P1Z9Q
M7C4T3NW=K#*=+Z5O#,NZ>U.DXSYD"+6/TVL_R1-ST_>?SC+Y$7D9SDUX@8V"
MU`E!E"5!XRO5K0B9BP>Z:K?,@#S>%9@(^2^9EWS^@)]RLP`D?TN`]QI=Q0!R
M^11#=MWTR@D]=/I3JQ#5@H(E*)'`M(([-.K@@<[+X8=H^B^:6*9@&E<*"H9U
MT*#$#/U*5"/)X]KO(/5=)^`O@"-,I_^XD<NZ61Z'1'"A:P'`N\Y0S9H\73&_
M/_``?N(_D3U0GLX&PD@&&@@H:R<.I8[)B29H8;YS>3S%O@NV2X=OHXG4?G\`
M)"0!I=Z*,&9(E[G6X7GH@[D`>,DZ-?H!;*]57'VLQT-[*9CE_]"J73].X7B@
MC;P%S7N86J,]T3H7VTH]$5V'U;35,W\2+,'9C97GP=89T&T\%"91ZR&G4$P*
MZJRN(2I<%DM6P8:U)/+"]14!I<`;DXY=6/WV!FCM)%%@Z=0,3T?JF5UQKO$8
MXWHR98AC/;>NG"``WN6R//\H&I+L74>J^X-#!7(J4'HF]?Z>=IP^HVLN(?#*
MFT03U\WF><#]&DQ]UR>%F]@=#41;R_A22UZ5KI$K6>I_>DCL(M9APV.%_$\/
M]>-:EH:GAS24B^'K9(P9$'N-H`53UF0H-'&^?LEI[>0]([61O&)1,L;@I`,"
M>&$D*`5)P"*Y'IK.)NX@YTE>'*VAEC_#YO!U-@938K:G`W/$J+&4T![UP03L
MQT,X)I<@_0E`>`\^0)!,YHCQIA!@:V+&:%6"OK;B@W)EHO38Z7`G#FC3RSAB
M_N91W=\D/(W3#]]2X&T<>M->/X!#6!:DT3?&QO"H6\F;-F(612N8+I<%8V@B
MW\;@WQD(W:8*`@(]C0'`;A1+`9*@C,R$2!,+U+L4'#W-A8B@RBC*%^3>DBUP
M$_O):F91K]3Q=#47.(+JY@,.%_NV(6=C"F+C*[P>K7J9BQ>M:Q%=/I)VPLJ<
M=G0`D>_=$KZ%B-+57(`(*(RB=E'6+3$FY>O9C].5)!I$0EV.1$B8BR)1_=>A
MU%D.ED"J,C%7/_ZW#V*HE/<E#BCQ+5.4SN;":/>KE:B8B`F>QGC!=8Z$MU%$
M&N8B1UR3G*ZQD"ALLT%WX2)+$RS',=^FJM[#7,RT5C,%.IS\6PR4(V&@'.TY
M4&C\*WM6;M>/\\;^AX.*9E\N'QST%`[%BVEN;"X\=N2U"(B%>#]!K^Y1@3"J
M,]+4U#B]"^B!ID0&AY:L$$7F+G5-V&ACL+H9&JLKF\V8)5J680KO&>5VI'[#
M.)1IVP(KDZ:"Y&H=T,[E(Y[_QNQG)03ID*C#L)V4++&:/Z(0+'\X\;]`>IN%
M7C))K^""L82RQ,(@`(O1RSA8M5-Q'2IM^%::7Z<I*Y<H3U%#9"U2Q#B6M<..
MT/O.^HQ)Q5:++U9\G8T#C(X5JX.HK(OE5&1Q!44*:FGD/%V,0U4'#=/V^YR<
M*[E*8IY!:F6([(9*"]Z5K5U*KPQ,7#?.@'?SB5YN%;V=>ER_+5#0&Y4$^W)1
MH!AW1>_H^<3T'<357Q'OI8KTU9(<4[S96[S_R[U8,/L98P9:*7`CZ:45J]JW
MOX3+9X4XKJ(0,PR\9Z@)=$2&'U]N5CI_Q_YKO2.ODHQ]H#&6EO/^%$=3D"1X
M]*C$%MT<T#OU'Q4=^%10;4[+HSA(2G7YT6%![V0/+%KPJ:`ZG49KP8V(/0!#
M*QQT/H'9[>X`E5](GIPE.LP2VQJ<U+<&F-BHH-:7?<$U>$NY0W?-C1$>S@[/
M+XY/SH]/3@Y.(2B&![_;9P!PB[@^90UXW'MXKZRNT]V]5T93JZ87#8;WROKW
M7MF0CB6DKUXF8Q'B*F7UR\U7L6&[8_+3=*P^QNF5K9ZM0$HK#GNGXI,6*CZQ
M7L4T#BTY97UVPADM27[U=^/4W,JUHK-C[A/O>-S4Y;32PCA5T:5.T)+)YE52
M8E[^X"%5K1MMS%2LT'O<;'YL4:[SR59NM8T-RF7R8\FJ>04'ZJ>WCHO"H[0"
M8_6&QJFYU3K*R9?!;ZEO,$"/3C0T-4Z+G`IA:=+^T,0S^(B"#S^<;3).]ZUH
M?0R'@E#P0IQ12U!Q'X4S.(8YBL&_PH]13'I34^,PT,JH<W-&.?G5;-:W6:`:
M]N;&QNF26RULC9ILW@DAJU<X_/O("2_I4:J&9L8KDLLT"W%GNA(G]&AR0S,+
ME<CB3OL>B:%$G$GR^@X9";U+MC(;FENH5%XN+<FEJS^AQ3JJOS?V3GRW,WHZ
M7\3<*#U794+P.-W:*;)N[)&[F*M(NDX:W"11+LU-I:FRPJ%3XW0HK`JZ-O?F
MNG:3W(IP[&44Q]%/M*EW%O`OZ5)@KI-(V(Z;5OPK<-RTXZI\D_X62AN]'.V$
M+A02\I,(*")WL!$S@MPJ\/ZT(Z1)BJLW`QZG3\X2%S04,#H-O6W$3A?6%=R]
MT`XD-&O6[W#=A7!P($F?'?1,(KJV^`1B%VEY1LKOYB=@(YPZ<J_TD6)A1!%"
M$&B?_EKLTQ^S-$F=T$,%-W`A^.L,$"$BV-LF?,A@O0#'J1)P:,I.)\^7F^D4
MN*B61@>+TT##)E#)$T`!K3,S[(X*:)%J*S!:VP\7.JL%,,[-B[$4=P.*M.''
M^-F?O:</&8KY/DY?4-FG_,ZD$P3`NUR6Z<5%0V*J4#>JQL%%1-<-:2D*I*'X
M^>P3@]!X\PFMKI^`I]A'&])M\9#>:F]%:Q^0UTH&2N-!PF@CN-0T=M%Y"%R^
M_<AK<J?Y>EJ"CJX<*XW\:/*@RUDP";U\&E1V%@0#0^MB"5):LZHTIG-D@B?\
MM]"91W'J_PD\=-$=[3VY?.*&?I:!I1V_9L5L5"#F&>XFX9*+]I%7T0<('7(D
MF=W1:LQP,ZPTEJ/M#"+U9UAS+R!-`YP$D,>VB,<.I`Z6@4204?NC,=48U5WH
MQL!)P#7(_RT<Y=LF8!EX.C).B>#(V&^OX+3K.E'K`CRL0E&'?(6B1H=[4BKJ
M^/SB_/S@]/#L[&A\=#J4BE)0*FI;Q/59W>M24</-2Z&;ES0-:MH2#C<O1;G3
M?JMCN'DYW+P<;A(8<9.@?IB@I[A%6AS`/4ZKJ24,SY#5S5R%TG535VHK3LWU
MNJHLK%E[!HLB1_%Q^A3[H>LOG.`9(*OGH6/:6^BA.L'?@4.R[EW)&H>75FIO
M"-JHD(N5MQ[X!747(LF\_HRZ8W%%:L`?0Q8VWH@0%P[\.O$AJE;$!MPQI6'C
M>;NP>&ZC3,+2NZ8UX(XE#!OO952EPX&F?0")TM/XRCL8:]T+!\L)Z5YH]/@)
MJ#*Q8'N[36AEFU9%V%1Z8JXI:[1ZK$5_[Z:AI6U@$&6UZRGY10Z($,SP<WS;
MD+B0--=+2539>@"-3^,1FMJF:&%>)1UA&^5&EN?XQ3NFE&6]H:5MB!!EM0#$
MA5H'3VE&0YF8*O;JU6G]U:N24%\>O*IEY"(+P)W6P-D;'\(?GI\<GYU?C$^.
M3@_.-;GM-N0Y=)'YD/@P)#XT:U#3A!P2'X;$AR'Q84A\V#:"PZ.'XNR9^U+/
M\.BA,(N63.CAT4.3C?;PZ.'PZ.'PZ&'?'STDJ/@%Q*@82!1^@#CUH=-QN=A@
MBZQHOI[&J5O84G=E5KOFY:S1MXX?_^X$&;A<KG[\;Q_$4/+ORWOP`0**!\[7
MV3BLM'+'._!J[J-?*TY^``?%#W%R1YT]JMLN1,,X+'10*P4CK46AW660C*N[
M<)&E"9;C$74?0.EA+F9:JYD"'4[^+0'*<-E%Z+)+/8W.F`)K0[D_65=E>ECI
M3]/-]:'2GUK0F5?D3U;6Y]X5^1,&AM'U_31MEZXANQ\.JBAU[SMOZ%@.V6%J
MLBBM2_]!TII+LZX%,.*DZ_P:4N5J5O/^:[H5AY(N``2&Y(G:6MZSE6Z)9U["
M]3V[.J4+O`A!1,>ILJ+`-=[0VT:@T4$@-+5%V\(\*O4'A2T!0;_XM=*[T(WF
MX#Y*UL&<B??/+$GQICXJF6Y2NDA_JY#0F7&S[J4RIG^Y\WD&+O*,_:D/O-?H
MYM]9_1%![GY6P:$UPUT=0L8-(FL]AG$OL=*>64DN9>XSW(1UI.AZM`*?02>0
MF>(0^^4="K\\F@8>,6S%ZF>+>>G&L-(;JR9%/PT,P_?;1"F1A]*JTN>:SWPG
M<"\PQQPAN_X#I.^1%P71;'D;Q?!O`)O[2IR(<<VL,UUC+&#G,)L:45!LHRGI
M*15^G_WD7[<Q`-7BVP+(:>IN'$#4Z)D/3]P"LK%\6I-`T`5H-T4/CWSX'H".
MJAC@FKH/@&LC(!MKI]$$@B[NMP`:ZC8`3$0P-CY"3Q/$[U$`=8\N%;:T99L$
M!K"U$Y&D,U"]KX%<1?.YC^.\@N4SSNKE,RJT^E)!HS)D"*6K*$S]<`9"%X*)
MNXZ&$`U<V0$]:7%Q<79V<'!Z?**K]B)ZY29Y7(#80>-E\$AH;9SIZ*Z+NID0
MX=V2M-Y[`*TK0(PCAE%$9)9G2:^DD`L%+<F/4R1F*G;:$#,.6B(P:`*1-"'8
MN''C%<\S",%/)Z"XUBTH[2G46!*P<;]6%T%9(*U>1Y"KCV78$>?5QLW7EA1N
MLQ1Z#3_\T)]G\Z>BA/)UQO(+!:D8AR05OI0,F5AR<Y='%")OC[2F9QSP9("D
M'?3V^_$13KG?A:\_(R08TA&T,)T!@0)RV0.WC"(9]#Z&'.RM*`WH$Y+,'CM\
MW3`WX(PI#5G7BN@O3B@.J*^*T6Q6(A(+KY\WA==7E$<KTB-,NR_A]EN`BINC
MRN9$,;&RB?@IE$64#\?'Q^/#\XNA<'67,[F.<J_;B5X7KQYJG7:O=6KB4]Y#
MK=/>U3H=*N@)Z6NM:$D5]/I^UOF2O26^YSOQ\L4)`(<I)[4W#A'M3+D0>^:6
MK:Z,_L&9PQ]?8R=,H'L"!T@U[>R.YBE:2&<-.F_'LB4&X.[ID5K:;O5W\_3>
M3F]U`-!9M$3/0ZTZH5IUM'*GFG+6-O>;JTM<^`+ADU/D<H8>OM/.+OHBB:JY
MV*"KN8X/%8(P=Z^'F<SK7EQGL1_.\F)8U>NH^2W5BG.\OB](-!U=B!H')16(
M:+)+TH6F]'A6TQ7S367DTIEDZ3L<U9^U4C9\G?84<"V$8NY&9Y,9**3'&*\`
M'A86G$J8/RYXD#H/,!$5CKDEXW,AY=86UP5E((38?D]!(28/L^HDRC(XD0N`
ME]Q"Z2,Y."$J+KMU%A1Z^2\`_"/^#=$`M2&VI]B3*"Q)=7A(E]<,<I$:*_VQ
M.^PMQ(0$8F[MB29&V-6[&+T&4'!+A5(BIS4R"$=])=MP):X.$Y]L-1WPT=KO
MF8;;R:/0[;G:FH_*[SU'(6;T&9*+/X!W&\5YLEJYM(IE;%TT7XB.PB)%J_S,
M:!K%H_Q#H_)+?<G?PIR\1P%4?Y(7@T3OUQ/BJZS&6G8_[COPLM6IR>42GYI3
M\[+(/8RQ%7QJV=C%"')%C*<-R5=20_>":E&6B34D7PW)5S*3KR:MDZ\:>QJG
M;TG)5_S,*CW@D%5V>\C!Z^$KMO)AL+F%*2NLDI5/:V^)RH595'#K2LY#7.M]
M%%NQQ,:6:%6,/P5G`SK<MIOY(HB6((\U/V(FJ.ETQ/;]!T$[%B6%XJ5/[0TN
MGK+8?7<2\!0X(6I*GN0<W?JOZ4Z<*BAFKWN_=L](J6QL:QP,NF^_^?FTI(I)
M9<F[<A9^Z@1Y:)H85"4!1)2.<>#A5WT#;*1POYND-Z5A^7S>03/J09&@NE.8
MG%`@?GQ0#\1CLE]1U-P;N17"?8F[KYE!29#K\3^#`.4C745)FF#$8!;+6_:$
MN'Q78IKC]FAD-814R]Q=+M=MBM%/?CJQQQGE[T;?&+,D!S*$,P,%,C(J%(V<
M.'2CAG*H4&UBC-)WHZJ&!`&6,(S4+O608;.1<1IF2IRLI#Z>)^`;`M#O"=$;
MU>P]**V]L:H4"!B+LM>/TX(&K@[.Q91<MK=4R53VS#H+D&.J\4IT#1T6RDJ\
MT<8XQ>]Z*69+P]RK+*NQ4U?FK5;&:9RM`8K6>K@X3\(P<P)HJ6)4\(ULKYO:
MF:L\?D/-S9=V!4J\042S8R0SQ@H2=R=L')QV;?T5B5#[Z;-FY&ZF73,OW4K_
MCGFX5H,SB8`6$J6-U;Q;2^X)Q&C3X<R@U:K<\LA3D9Q/5,=5-NXY/CE,@9U)
M5>E&4M/-P.&<<N>XE7JH:56Y<5F+VH?C!\@YA)+\*\HV4^R.;']N?Z&]4XDJ
MK2&PF]MVU&/]0^YS_4/A<_W1X7"R/YSL#R?[P\E^-;[W"K_".E`HVQBC=JT'
M"E1I&*7@]D)9,QIZ7"D"*CYE'-S8ZF_A'LD2C"41=7NO4.P,"740MKJ$T7<D
M#6<SYBZD:L]F^GZ1H+5T\JE=K4?T'`4!W%&C/\I&,_5CYB'<^'B(N#SWW5#7
M)9;'E-0C/?^./2`7QYY2X%/$*PGSB[RL=NK$:8^1CP.ER5V8%PG_:QPETGT6
M\I<&],M$/Z^`;7%Q:'7N*]N4Y.83Q*Z?D/-+A`D-N.5^<(!??EV/)B]R6(9@
MAN*V/3;)4/I3X./W0>%N_>9SX<>8PFIJ*S+0S.\.L)=IKMN)N^OQI36SQ"27
M?3Q,`]7RE536)7?:;\(^([]81E&L3"GR:]\9[+],X/.)UY+J-EV%]3M(X'*5
MKY/`A3^^1NA7NUH$>#\_S!"9,Z23U"D5\_=IXE2$]0?P9^](H!\@=F:@W(WA
M9W>0<J>["O)S#L2>R:3Q`*"+K&T)%.U&FGKGC3V312Z&M4VNX>B!?,[?&+!6
M,;?DC6"87]+FEV*E2%JU-M]BZ^7\*F6E=8H)#6*893N;9=WULN_7V'GC^!J<
MQDYC&B:A,4=`;>=DWZO@[^N6S9Z#)+,F6B>-#$=/36<6&N85Y]>']4O#$5;;
ME6HXV&*=<6B8:-T&-<P_<P[(VDY+?<=FI'*VRG3X#-`U./C[JRC$=[HS)W@%
M\9Q0%4#S:.R97+R'8B8*W*;0QQM;JF_2I'I(6[%V.Q)C9I*)`">L509H2&EQ
M04V5FH=Y:$089)B(0BI2<M!F1C6Y#N(E[XE)XATKFHLM1C*LB3N=BK(T-+BC
M[;;#NYZ1\@8X3-2=3E3%BM-^:J<^Z#*9S6)\Y^P.RL,/$]_]W0DRL*,@"^/K
MQLRFW@95V@A8.^K-.`&H2'%3>.I/IS>_9\PL,`&<2L^@.>1N4V$>.1[RIM!V
ML&G:^N`P/7:U%^(1_'`WI3F+\S5*T>M9.UA'>#Z]H;JCL_/#H_-ASAB@`FN?
M@>B\QRLE>>OXL=*%AO2Y8<KL8"?/*7:E;T5HFB:K0KX@_O!=T*S@ARC\R$,>
M2'0)-BO5OZ.J^`]1^G>0/@,WFH7H*3#"5GYGWS5FXNS\NK`>T4I*BS7J72ME
MDJR60=OU!*E^V[A)H@>[.YQ#3.G;F-"@3)K%LAW%Q:]0.Y*'MMM!##-KUS.+
M7PU*GV`TX,VOHR\;@**\^74D_N;7T3Z]^26'*`+AV>'Y\3E$X.G9Q?GYA29_
MII_/@9E@/14`H&$SJU1\1CTDA<=Z#47'>BFL;&,<(M0JJPX.MC0HGF.Y.!UI
MUC;UQ:^M5L9IG*T!BM8H/&D_VR.D>TS",$/A8S<&$+B-;V81VYFK/(HBMO(A
MN/G2KD`YL[1\"(QBDJM-C%/QKBTR4QC$?89.[5)-,.4M.!,TS)0X64D]M+\;
M;^P]9;'[#M&*^$%-R>:8HYNQBN4WSFVY5!I>&^N9VG")BN90$G!U0X;L'GT)
MZ8YLQRD]C,/&KLVZJ&PHA^>:PZX$3J@K`+6/<=@0U16WMDU>+N2`XQDJ"PKZ
M?1)ZU^`#!-$"\8\2VD."LR_0LR]`X5IONO)M"6#^"D(0.P'D?N+-_=!'H:W4
M_P`\D.'J:R5HVG.^[RF-][M]--D$P.W:U5$D0DMN<DP"3!QXS6(J9C`IF,G5
MV3P$JD%$0V"TO7PDK:>DB^::8N2M)9\_>E*8C&22I>^0D3_)SUO*_L[^8G@W
MHE2:K:`S.;N-Y)Y`["(XS>`:64DFQE&@'\ZG/\_FLG'/\<EA"NQ,JDJO*NA*
MR^AJ1R:>Y^=RV-4B0/[B,!=V)=3=7$=0FL;V`."N.DF@,<`<%SEFG.EKXX/Q
M=OH:I#="!$>0X@B37"6N&9ZV=N/$J#[$2A2LZQ.$YF6FT?CBX/P(?NGL6)<[
M6T9-J/EB&XV,LQQ"0FZP!VSN.%)V-)T=3,+4]_P@0[&J%^!F<#`^2&X^W2"#
M<_$6R@D9N2S7Q^-T6U27RV8"M'0O=5\T#ED<T&C8,N]80'T#)S.[@=7-.)CL
M6N.\F#,]H4(.RJ[0)80X]>$,?2H'GN]/:$<=C%X]P1AW,D87MBW!R48J2GZU
MBXH08GM;L2'&L/9S+T(Z%C2U\RC$//SAQ/A10G(2%K&Q;3INP:WV\I0$!6_:
M+;:.:>VM5+,PPY8<!*XS`%A'TK6&QN&@U<Z#DR^*Y6X=827>35C#N6)];OZ=
M^1].@,['B5[R->H&O*W0$ZWRI+*/F8L.WMBG!ODHS>#5=4&JVT9O,H^RD!0J
ME$+;&*1J`)ST2`Q%I+NI_M`8T__U>XZ>(@@.?_/_`5!+`P04````"`!S@&Q'
M;FM7T!L,``"V?P``$0`<`&-A=&(M,C`Q-3`Y,S`N>'-D550)``.I_D16J?Y$
M5G5X"P`!!"4.```$.0$``.U=W6_C-A)_/^#^!UZ>>@^./[+9;8+=%DZR.01(
M-D:27OM6T!)MLY5(EZ22N'_]#2E1EO5!2;&W7>&$`MU$G!ERYD=2\T$Q'W]\
M#0/T3(2DG'TZ&A^/CA!A'O<I6WXZBN0`2X_2HQ]_^.<_/OYK,$"7@F!%?#3?
MH#LB!`T"=,G%F@NL0``:#!+"7RX>;I'/O2@D3"$OX7JA:I7R70CJ+PE"[X]'
MQ^/1R?%HRWV!)5"#/"-F<CQ.6VS_G)VC\7@XG@PGH_$I&D_.)^_.1Q_0["XE
MO0,E%K0![:OTSZ6W(B%&"HLE45]P2.0:>^33T4JI]?EP^/+R<NQAA>=84GGL
M\="(&IV=@+FP4H+.(T6NN0BOR`)'@0+3L3\B')@!@$4#HNVP0Y!I!@B8/(=A
M[/3W<G+,Q1(Z&HV'O]S=/IH16F)!%CO$KW,16/+W0VA-I4*#KU+:+-WI,&ZT
MI(PS%H7E8GTEAFJS)D,@&@`5$=1+NP@JAW(R_.66LM\M)<RG)<;KE'R!Y=R0
M)@W&JH/1>'`RSK`('A!9RF-:2I@"Z-,Q)MT,2)),'UJW\CY,2TD?#4R5-U-^
M5`G"X[.SLZ%IM:0>CY@2FUW4)/&.E_QYF#3J(9WDAD26>G%4:GXVU`8;)F26
MRR>TO"-HT)V\V^U$JK4HI]<MFF&\RZ!IJ`,-RJ3"S"/;=4#KU\$@SP6K<]YD
MN<*"1\@L><P85V;;,L_LT_6:L@5/'L%#C<NYMML38(KT#S\]W#AZ,B9^!,%F
MR5]RYA,&N]D%#O1P'U>$*'F$**!41Y2.P8[")PO*J!DQ&&,$&R9*9<#/J1B4
MR$&QH(_#/'=><`1,]^P'\_-:$`GRC&'TVDVX$Q(7IX<#+PK>P+@=635?\M0"
M<7!\TB?R?G&_)O'[3$Z9?\E#,,D*B.@SN>6R$KP6$MS(3AS(;CM!?(&VW2#,
M?+33$=(]]="WA/X2R]5UP%\:H;PE=@-ZTAA0+1$9D3UR!>2NJ/0"+B-!KBF#
M_8WBX`;>`L+XF/***$R#!+=FI"[4W@%J8T!J*PE^286AC#3T72+OWSUF#LRF
MGB<BXG]^7>N)7P57!94;J7=%I!(YR`KJ06H$TA>NB)SA#9X')#'8)`]1*8T;
MH-/1)`^0D8(2,2DZ:-+CTQ2?2U!@T@2D7<(]D3+">KP:X@4>64B5Z_U40N%&
MZ$-QL\O(Z/<Y%RY)/LK^"[[Y9Z:HVMQ`Q"="HT."3Q-*M],W.M-.GQ60_5&[
MZK$TE!'7X]4VBIYA`6TKHBCHU"BDWN6HBZ]/&\;7Z+L=N?W*<^V(]V*)&?W3
MC!I6U3:"S6^,U80NW,:`6V%_S(HRJV\KK,?*@=5C%(98;.X7CW3)Z`(F-^R$
MGLD_4K:<\8!ZI(!;,R8WAI,BAHE8'21G!*.M9)2([A%M&3@WB9AK\&H:*O?8
M-`^0:R+C&D0:A,0]&`T#+5=L50/#:1&&G7"JQ\"!P<]8"%RR0:7/W;9_7[2]
MY>S-WBQF=02K-<9W1ZF]_9WV9\]$*`K;PTR0!1%"5QVX]WL1C2I"-S;?EV&3
MBD*I+&2$]5C5K!7.C)T>0''Q3/QK+JXC!6TW4D9QA;JXB&IYW`B>E:\NB&Z,
M6&3EH@47*):,K.@>3U?$H\UG3A_I6BJX2=F<4!V5$[/QJ"2FT7(&<W/8R<M(
MZB%R>69$Z<KVC(C'%19%YRS7[`:E)%D``DSI'($(9&3T<.R;(]@G5=`D8S`9
M38IUB\89`_1=\D.?N6N;.WC204RC#$)"Z4+Q9`3_-2RYQ^)ZP%HD%,JQ*B=R
MP_2N"%.QWMXCU"[+4`Y/"84;F],B-KE2>P],\]1#.2BY5C<@[XN`6/X>BY;Y
MB'(XB@1N1#X4$=FIH/>@'";PK4:K(:<;QK-R&!L%P3W(;X^&RV%UTCJ!A,BX
M`&159-SC]H80N<*S*"5R(S4N<2X*X7*/T5[G("K.B=72NY![U_)41'^*['"Y
MCPH\6_&ZL=WGM$2/]%O/13<X%EU[UM9='.ZQ:16K5>"2;W9CXB@:]W#L5[ZL
M/`!=0^\&K%TQL\?P8-&=XSQ[4U8WLOL4.7N<]PCPJCP6)[$3RS;%SQZZ_:$K
M?`Y40UT'7K&V5@=>_V'0'O"=M(+OI!:^%ND5"]])#U^+#$M52%!.Y8:KT9&$
M_ZM-4O]/S]4'LD#FFI1S?;W*IR-)P[4^G1L_6YDK<?0U(`-[V<>OH.[Q:QA8
M$BW?<1&)P3AOH:1C*P(+KR"E<(T+".%K[8$2.;2#/T+#@ZD%6+15*P??MZ@5
M3)2V6NW.K6]1J0#/VRH%+"3X.OI\'.:ON$F>[%Z%8R["`=6X4(B5WH7EN.PH
MODGKEGM&7C.N@;Z<:#">#,;OCZ%O.^`WC2-[/U6[L7#V98_A.*].JAA(*8_^
M8;!E?J-!2JY[:F*-0(@=KOV1R=WQU&00AD7_EM[RI(=QHH?1QA[E=YTU'(!E
MT#V?[O19V9_S-C/7#"AE'))`2?MDL!45C\5<>M7DNKB,H9);Z,S(]:>RX`,^
MK@.J3"IX\T1>U460'C/7V]BO#IIX`XROC#M7]OF-(J%^@X.^T5PJJB*M[7\$
MC]:?CLQ%8.<42(X0HT&@<YR?CI2(]`YJVF#GHMQ_,J+]2"2';RM5<'V=/87N
M!?941IMFY+%B\7C@&67+QDKA1(A5Z@U*6@6W$&AWK^#Z3W5*<FE(+S9;DAG>
M&`5?L/#OUZ:4<Q\IO83T?8X_$[I<P9J>/A.!E_!J"3&\/=GRDC,S[`@'3T2$
M6U,D$^7O'$'.@@<$QP7&`5;7X8PV72Z%V8QOF-984N^_.(A(R03_*SO]QI9)
M<O[03B3BZ^P@>$RK2RZ5O(R$_D#?SNBFQ([)%W(&`9C8-%:ZJ%3\;E.V:1[?
M*0#Z".)3U7X2%K<.Z(S(J5>58+\CX9R(=)DWI2ZU2O(B\+E>T7L8Y>UKL$+]
MB\KZ0IGZ#:B[HOX-T[?N2G)%XG]OV%6BST-F*=12?=TUD-%W=Q'X9'Z0-6"+
M=[HP8"H1LPC6.2AZO]C%]X8!]+]%S-/#^9FJU:59AM?8H^#^;*R]#BCO;[+L
MP;87.U%N=`2.@UDT!Q?Q?@$/S1M=*IA;0>1K@N3<@2V/@P.6;,&W%,^U/:@^
MGY0X=0<7VW5#F_ED+7!-MJ8J:^BZLIGZH5UKNQNUBZ`K>_/N5E&N9PU-5U1-
M-D,/'M)G,H/IHD/9W+O73=-E54??UZN:H>F*JI_#=<`W)"Y,V5=@.;C-2+NB
M^!1&I+]KB[VE74TKVKJBFF[WHP`\&1,D2O?I_$PJ*)G9;V9W&:A]9NDOB"DR
M0<)T71M3-*#NS!3)*W312OTJZJZH_R72`P9/GXB,&K&:5ND:&H=[MM9KY)O0
M,_V^+;_&RQJZM'K3+<HJ<HVIB!-;$*<]0UQ6M[<U9^RF70A=JE6:H)W"EKT.
M36XP5;C60F\0T2%;;8&7DBC]YQTRP>83S`T)RUY>$/5""+LESR20TU!'J=92
M^PCH>D(RG22Q1S"#N-6C:PCRXURT-,??ZR98*]X.S:Q;SI:Z^G%%YBJ;B3?@
M7T4$WB@Z;(`U96W2BJ/<$F"&=4QUD(ESJ#?/;O"KB^&[KD4#NJXX%96JG#94
MN7M!E)ZSMQRSBZ*6Y4U=4VQ:G+'E35U1[#+`4J;>S[UXT'7<SZ^P<U"I%9B9
M;M,475-JQ_O,#O[;T%_OL*8XJ,]EFISS-EU=TO+WO*</53.QKY7L%VU?B,J_
M=8K-'7=/TB_%TK.W,G\6PDW2C<,*E7J#*VI6:E+<RNM<;.YZK<%JENQ0\H%X
M>N<R?Y7SB7_^(RHI_-70=KQ<>D<9#:/0)C%@FNM4Y@RKU0O>R#ONZS/$X'H`
M40"+D?!(!JF)WLK\]7(BAW-,K5)W/"`>A"'R)ZEQC_\<[4R`;IZZU.ZW#[\7
MDD&-N3J1'K):Z3/*$*KFE=T^[@*PVW4<G\S\PEER`"B.S_/[0`OZKF^/>55W
M"I%U=JDB[KI1[M6*B!OF\=#\*<]M-L?_+9+F!JDGOKVX/+9-2YZNF\B&.D;M
MIQ76]Y5<E$=#Y21=B8JF3%&?!I$NY6:.)>BY_HP#G93Z_!J?5;D6/-1G,J/X
M*PO]<@0VXN>^$,N[FU^S@XXZJX_8E!A-,5EPCQ!?NV)\R>B?1MLT7UA/UR%?
M+?Y,)_Z&`'[]'U!+`0(>`Q0````(`'.`;$>:%V4DAIP``%"$"P`1`!@`````
M``$```"D@0````!C871B+3(P,34P.3,P+GAM;%54!0`#J?Y$5G5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`'.`;$?@/_1-[`H``,J8```5`!@```````$`
M``"D@=&<``!C871B+3(P,34P.3,P7V-A;"YX;6Q55`4``ZG^1%9U>`L``00E
M#@``!#D!``!02P$"'@,4````"`!S@&Q'0?BZ3`$=``!R)`(`%0`8```````!
M````I($,J```8V%T8BTR,#$U,#DS,%]D968N>&UL550%``.I_D16=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`<X!L1S*Z*?%L3@``WPT%`!4`&```````
M`0```*2!7,4``&-A=&(M,C`Q-3`Y,S!?;&%B+GAM;%54!0`#J?Y$5G5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`'.`;$?;`$.SOC```*/``P`5`!@`````
M``$```"D@1<4`0!C871B+3(P,34P.3,P7W!R92YX;6Q55`4``ZG^1%9U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!S@&Q';FM7T!L,``"V?P``$0`8````
M```!````I($D10$`8V%T8BTR,#$U,#DS,"YX<V155`4``ZG^1%9U>`L``00E
>#@``!#D!``!02P4&``````8`!@`:`@``BE$!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994207760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_AccruedContractedResearchCostsCurrent', window );">Accrued contracted research costs</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,437<span></span>
</td>
<td class="nump">$ 2,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_AccruedContractedResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date for contracted research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_AccruedContractedResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207999553504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">72,005<span></span>
</td>
<td class="nump">$ 13,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">72,005<span></span>
</td>
<td class="nump">13,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Measured at fair value | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Measured at fair value | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">72,005<span></span>
</td>
<td class="nump">13,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 72,005<span></span>
</td>
<td class="nump">13,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Measured at fair value | Level 3 | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207985674528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Aug. 27, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=catb_TermLoanB2015Member', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Promissory notes</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=catb_TermLoanA2014Member', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=catb_TermLoanOtherThanAndBMember', window );">Other Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPayments', window );">Number of monthly payments (in number of payments)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_LongTermDebtOutstandingAmountDuePercentage', window );">Percentage of amount outstanding due as a payment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRestrictiveCovenants', window );">Financial covenants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Final judgment amount that would trigger lender rights for remedy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate increase in the event of a default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_LongTermDebtOutstandingAmountDuePercentage', window );">Percentage of amount outstanding due as a payment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_LongTermDebtOutstandingAmountDuePercentage', window );">Percentage of amount outstanding due as a payment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ClassOfWarrantOrRightExercisablePeriod', window );">Exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member', window );">2014 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member', window );">2014 Warrants | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member', window );">2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member', window );">2015 Warrants | Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ClassOfWarrantOrRightExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time period the warrants or rights are exercisable, in PpYyMmDd format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ClassOfWarrantOrRightExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_LongTermDebtOutstandingAmountDuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount due as payment for long-term debt expressed as percentage of long-term debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_LongTermDebtOutstandingAmountDuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRestrictiveCovenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of covenants that limit or prohibit certain actions or activities without the lender's prior consent within a specified period of time or until certain specified targets are achieved for example, reduction of the debt or an increase in net worth to a specified amount).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 470<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRestrictiveCovenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=catb_TermLoanB2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=catb_TermLoanB2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=catb_TermLoanA2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=catb_TermLoanA2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=catb_TermLoanOtherThanAndBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=catb_TermLoanOtherThanAndBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986856448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder 2015</a></td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2016</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2017</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2018</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_DebtCostsDiscounts', window );">Less: discount for warrants and costs paid to lender</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Less: current portion</a></td>
<td class="num">(3,191)<span></span>
</td>
<td class="num">(3,191)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_LongTermNotesPayableNet', window );">Note payable, net of current portion and discount</a></td>
<td class="nump">6,549<span></span>
</td>
<td class="nump">6,549<span></span>
</td>
<td class="nump">$ 4,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_DebtCostsDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the discounts on warrants issued and debt issuance costs paid to lenders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_DebtCostsDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_LongTermNotesPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion, discounts and issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_LongTermNotesPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208249498016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">3.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The following tables present information about the Company&#x2019;s financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. The Company determines the fair value of the preferred stock warrants (Note 6) using Level 3 inputs. Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;September&nbsp;30,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Markets</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Observable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Assets:</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Money market funds</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Markets</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Observable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Assets:</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Money market funds</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Warrant Liability</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of September&nbsp;30, 2015 and December&nbsp;31, 2014, the Company&#x2019;s cash equivalents consisted principally of money market funds, which approximate their fair value due to their short-term nature. In connection with the completion of the IPO, warrants exercisable for Preferred Stock were automatically converted into warrants exercisable for Common Stock, resulting in the reclassification of the related warrant liability to additional paid-in capital as the warrants to purchase shares of Common Stock are accounted for as equity instruments (Note 6).</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207999397552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Aug. 27, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsDisclosuresAbstract', window );"><strong>Roll-forward of fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ClassOfWarrantOrRightExercisablePeriod', window );">Exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.97%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">75.79%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant Liability | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsDisclosuresAbstract', window );"><strong>Roll-forward of fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at beginning of period</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsAndRightsIssued', window );">Issuance of warrants at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_OtherIncomeLossFairValueAdjustmentToWarrants', window );">Change in fair value, recorded as a component of other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsOrRightsReclassifiedToEquity', window );">Reclassification to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member', window );">2014 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsDisclosuresAbstract', window );"><strong>Roll-forward of fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member', window );">2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsDisclosuresAbstract', window );"><strong>Roll-forward of fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsDisclosuresAbstract', window );"><strong>Roll-forward of fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred Stock warrants converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">315,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Credit Facility | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,688<span></span>
</td>
<td class="nump">315,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9503<span></span>
</td>
<td class="nump">$ 0.9503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsDisclosuresAbstract', window );"><strong>Roll-forward of fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,688<span></span>
</td>
<td class="nump">315,688<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)   Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ClassOfWarrantOrRightExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time period the warrants or rights are exercisable, in PpYyMmDd format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ClassOfWarrantOrRightExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_OtherIncomeLossFairValueAdjustmentToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in the fair value of warrants recorded as a component of other income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_OtherIncomeLossFairValueAdjustmentToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_WarrantsAndRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities issued during the period that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_WarrantsAndRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_WarrantsDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_WarrantsDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_WarrantsOrRightsReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of derivative securities reclassified to equity that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_WarrantsOrRightsReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_WarrantsPreferredStock2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986615952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,709<span></span>
</td>
<td class="nump">$ 14,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">73,300<span></span>
</td>
<td class="nump">15,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,657<span></span>
</td>
<td class="nump">15,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable, net of discount</a></td>
<td class="nump">3,191<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,411<span></span>
</td>
<td class="nump">4,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of current portion and discount</a></td>
<td class="nump">6,549<span></span>
</td>
<td class="nump">4,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liability</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 14,113<span></span>
</td>
<td class="nump">$ 8,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share, 5,000,000 and 0 shares authorized at September 30, 2015 and December 31, 2014, respectively, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 150,000,000 shares authorized at September 30, 2015 and 132,000,000 shares authorized at December 31, 2014; 15,297,794 and 493,200 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">157,933<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(98,404)<span></span>
</td>
<td class="num">(75,380)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">59,544<span></span>
</td>
<td class="num">(73,053)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 73,657<span></span>
</td>
<td class="nump">15,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleApreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $.0001 par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $.0001 par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleApreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleApreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208003312432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">1.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Organization and Operations</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The Company</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Catabasis Pharmaceuticals,&nbsp;Inc. (the &#x201C;Company&#x201D;) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on the Company&#x2019;s proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company&#x2019;s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of the Company&#x2019;s proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company seeks to develop therapies that modulate multiple targets in the disease pathway. The Company targets therapeutic areas and specific diseases with significant unmet medical needs where it believes it will have a competitive advantage. The Company&#x2019;s focus is on treatments for rare diseases, such as Duchenne Muscular Dystrophy (&#x201C;DMD&#x201D;).&nbsp;&nbsp;The Company is also developing other product candidates for the treatment of serious lipid disorders. The Company was incorporated in the State of Delaware on June&nbsp;26, 2008.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Initial Public Offering</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In June&nbsp;2015, the Company completed its Initial Public Offering (the &#x201C;IPO&#x201D;).&nbsp;&nbsp;All of the shares issued and sold in the IPO were registered pursuant to a registration statement on Form&nbsp;S-1, as amended.&nbsp;&nbsp;An aggregate of 5,750,000 shares of Common Stock registered pursuant to the registration statement were sold at a price to the public of $12.00 per share (including 750,000 shares of Common Stock sold pursuant to the exercise of an overallotment option granted to the Company&#x2019;s underwriters in connection with the IPO).&nbsp;&nbsp;Net proceeds of the IPO were $61.7 million, after deducting underwriting discounts, commissions and offering-related expenses payable by the Company of approximately $7.3 million. In connection with the IPO, all shares of the Company&#x2019;s convertible preferred stock (the &#x201C;Preferred Stock&#x201D;) were automatically converted into an aggregate of 9,029,549 shares of its Common Stock and its outstanding warrants to purchase 315,688 shares of Preferred Stock were automatically converted into warrants to purchase 24,566 shares of Common Stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of September&nbsp;30, 2015, the Company had an accumulated deficit of $98.4 million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since inception. The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company&#x2019;s products. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=SL51803626-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994540880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,814,716<span></span>
</td>
<td class="nump">9,445,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleApreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,356,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,655,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_PreferredStockWarrantsMember', window );">Warrants for the purchase of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_CommonStockWarrantsMember', window );">Warrants for the purchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">59,405<span></span>
</td>
<td class="nump">34,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,572,959<span></span>
</td>
<td class="nump">1,385,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_EmployeeStockPurchasePlan2015Member', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">182,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleApreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleApreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_EmployeeStockPurchasePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_EmployeeStockPurchasePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207989017776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of future minimum annual lease commitments under noncancelable operating lease</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Future minimum payments required under the non-cancelable operating lease as of September&nbsp;30, 2015 are summarized as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;">
			<tr>
				<td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Period&nbsp;Ending&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Remainder 2015</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2016</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>937&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>467&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,639&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208003654048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,814,716<span></span>
</td>
<td class="nump">9,445,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=catb_StockIncentivePlan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for grant (in shares)</a></td>
<td class="nump">1,068,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,106,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">860,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=catb_StockIncentivePlan2015Member', window );">2015 Plan | Annual minimum increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for grant (in shares)</a></td>
<td class="nump">1,297,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding Common Stock available for issuance (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=catb_StockIncentivePlan2008Member', window );">2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for grant (in shares)</a></td>
<td class="nump">25,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,466,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=catb_StockIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=catb_StockIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=catb_AnnualIncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=catb_AnnualIncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=catb_StockIncentivePlan2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=catb_StockIncentivePlan2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986540800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the Company's stock option activity</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Average&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Average&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Remaining&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Contractual&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Term&nbsp;(years)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Agregate&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic&nbsp;Value&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,226,140
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.14
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.15
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,579
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>550,797
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.69
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25,045
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.05
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Cancelled or forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,881
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.46
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Outstanding at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,011
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.57
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.11
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,560
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Exercisable at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>755,860
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.27
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.89
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,659
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,586,233
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.30
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,489
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#x2019;s statements of operations as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>289&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>638&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>316&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>488&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>232&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,143&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>605&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208003331392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Polices<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Polices</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Polices</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Reverse stock split</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In connection with the IPO, the Company&#x2019;s board of directors and stockholders approved a 1-for-12.85 reverse stock split of the Company&#x2019;s Common Stock which was effected on June&nbsp;11, 2015. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of Preferred Stock were convertible into shares of Common Stock have been adjusted to reflect the effects of the reverse stock split.&nbsp;&nbsp;Shares of Common Stock reserved for future issuance have been presented on an as converted basis and the financial statements disclose the adjusted conversion ratios.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (&#x201C;U.S.&nbsp;GAAP&#x201D;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The unaudited interim condensed financial statements of the Company included herein have been prepared, pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#x201C;SEC&#x201D;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules&nbsp;and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements as of and for the year ended December&nbsp;31, 2014 and notes thereto, included in the Company&#x2019;s prospectus dated June&nbsp;24, 2015, filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;on June&nbsp;25, 2015 (the &#x201C;Prospectus&#x201D;).</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited interim condensed financial statements contain all adjustments which are necessary to fairly present the Company&#x2019;s financial position as of September&nbsp;30, 2015, the results of its operations for the three and nine months ended September&nbsp;30, 2015 and 2014 and its cash flows for the nine months ended September&nbsp;30, 2015 and 2014. Such adjustments are of a normal and recurring nature. The results for the nine months ended September&nbsp;30, 2015 are not necessarily indicative of the results for the year ending December&nbsp;31, 2015, or for any future period.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The preparation of the Company&#x2019;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company utilized significant estimates and assumptions in determining the fair value of its Common Stock prior to completion of the IPO. The board of directors determined the estimated fair value of the Common Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of convertible preferred stock, the achievement of research and development milestones, the superior rights and preferences of securities senior to the Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants (&#x201C;AICPA&#x201D;), Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation (&#x201C;AICPA Practice Aid&#x201D;), to estimate the fair value of its Common Stock. The methodologies included the Option Pricing Method utilizing the Backsolve Method (a form of the market approach defined in the AICPA Practice Aid) and the Probability-Weighted Expected Return Method based upon the probability of occurrence of certain future liquidity events such as an initial public offering or sale of the Company. Each valuation methodology includes estimates and assumptions that required the Company&#x2019;s judgment. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract, are determined by the Company based on input from internal project management, as well as from third-party service providers.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate their fair values at September&nbsp;30, 2015 and December&nbsp;31, 2014, due to their short-term nature. There have been no changes to the valuation methods during the year ended December&nbsp;31, 2014 or the nine months ended September&nbsp;30, 2015. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between levels during the year ended 2014 or the nine months ended September&nbsp;30, 2015. At September&nbsp;30, 2015, the carrying value of the Company&#x2019;s debt approximated fair value, which was determined using Level 3 inputs, including a quoted interest rate.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In April&nbsp;2015, the FASB issued ASU No.&nbsp;2015-03, </font><font style="display:inline;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs</font><font style="display:inline;">. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability rather than as a deferred charge. It is effective for annual reporting periods beginning after December&nbsp;15, 2015, but early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &#x2014; Going Concern (&#x201C;ASU 2014-15&#x201D;), which is effective for annual periods ending after December&nbsp;15, 2016.&nbsp;&nbsp;Early adoption is permitted.&nbsp;&nbsp;ASU 2014-15 provides new guidance on (1)&nbsp;management&#x2019;s responsibility in evaluating whether or not there is substantial doubt about a company&#x2019;s ability to continue as a going concern within one year from the date the financial statements are issued each reporting period and (2)&nbsp;related financial statement disclosures.&nbsp;&nbsp;The Company has not adopted the guidance prescribed by ASU 2014-15 and does not expect the new guidance to have a significant effect on its financial statements.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986772096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">132,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">15,297,794<span></span>
</td>
<td class="nump">15,297,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesAconvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">68,837,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">68,837,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">68,837,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,830,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,129,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,129,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (27)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.27(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesAconvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesAconvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994564512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Polices)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Polices</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_StockSplitPolicyTextBlock', window );">Reverse stock split</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Reverse stock split</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In connection with the IPO, the Company&#x2019;s board of directors and stockholders approved a 1-for-12.85 reverse stock split of the Company&#x2019;s Common Stock which was effected on June&nbsp;11, 2015. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share, share equivalent and per share amounts presented herein have been adjusted to reflect the reverse stock split. The ratios by which shares of Preferred Stock were convertible into shares of Common Stock have been adjusted to reflect the effects of the reverse stock split.&nbsp;&nbsp;Shares of Common Stock reserved for future issuance have been presented on an as converted basis and the financial statements disclose the adjusted conversion ratios.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (&#x201C;U.S.&nbsp;GAAP&#x201D;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The unaudited interim condensed financial statements of the Company included herein have been prepared, pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#x201C;SEC&#x201D;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules&nbsp;and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements as of and for the year ended December&nbsp;31, 2014 and notes thereto, included in the Company&#x2019;s prospectus dated June&nbsp;24, 2015, filed with the SEC pursuant to Rule&nbsp;424(b)(4)&nbsp;on June&nbsp;25, 2015 (the &#x201C;Prospectus&#x201D;).</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited interim condensed financial statements contain all adjustments which are necessary to fairly present the Company&#x2019;s financial position as of September&nbsp;30, 2015, the results of its operations for the three and nine months ended September&nbsp;30, 2015 and 2014 and its cash flows for the nine months ended September&nbsp;30, 2015 and 2014. Such adjustments are of a normal and recurring nature. The results for the nine months ended September&nbsp;30, 2015 are not necessarily indicative of the results for the year ending December&nbsp;31, 2015, or for any future period.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The preparation of the Company&#x2019;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company utilized significant estimates and assumptions in determining the fair value of its Common Stock prior to completion of the IPO. The board of directors determined the estimated fair value of the Common Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of convertible preferred stock, the achievement of research and development milestones, the superior rights and preferences of securities senior to the Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants (&#x201C;AICPA&#x201D;), Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation (&#x201C;AICPA Practice Aid&#x201D;), to estimate the fair value of its Common Stock. The methodologies included the Option Pricing Method utilizing the Backsolve Method (a form of the market approach defined in the AICPA Practice Aid) and the Probability-Weighted Expected Return Method based upon the probability of occurrence of certain future liquidity events such as an initial public offering or sale of the Company. Each valuation methodology includes estimates and assumptions that required the Company&#x2019;s judgment. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract, are determined by the Company based on input from internal project management, as well as from third-party service providers.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate their fair values at September&nbsp;30, 2015 and December&nbsp;31, 2014, due to their short-term nature. There have been no changes to the valuation methods during the year ended December&nbsp;31, 2014 or the nine months ended September&nbsp;30, 2015. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between levels during the year ended 2014 or the nine months ended September&nbsp;30, 2015. At September&nbsp;30, 2015, the carrying value of the Company&#x2019;s debt approximated fair value, which was determined using Level 3 inputs, including a quoted interest rate.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In April&nbsp;2015, the FASB issued ASU No.&nbsp;2015-03, </font><font style="display:inline;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs</font><font style="display:inline;">. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability rather than as a deferred charge. It is effective for annual reporting periods beginning after December&nbsp;15, 2015, but early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements &#x2014; Going Concern (&#x201C;ASU 2014-15&#x201D;), which is effective for annual periods ending after December&nbsp;15, 2016.&nbsp;&nbsp;Early adoption is permitted.&nbsp;&nbsp;ASU 2014-15 provides new guidance on (1)&nbsp;management&#x2019;s responsibility in evaluating whether or not there is substantial doubt about a company&#x2019;s ability to continue as a going concern within one year from the date the financial statements are issued each reporting period and (2)&nbsp;related financial statement disclosures.&nbsp;&nbsp;The Company has not adopted the guidance prescribed by ASU 2014-15 and does not expect the new guidance to have a significant effect on its financial statements.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_StockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents disclosure of accounting policy for a stock split, which may include a description of the stock split arrangement and the retroactive effect given by a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_StockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207987340512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Nov. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CATABASIS PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001454789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,297,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207988402944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;September&nbsp;30,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Markets</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Observable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Assets:</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Money market funds</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,005&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:64.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Markets</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Observable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Significant&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Unobservable&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Assets:</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Money market funds</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,506&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Warrant Liability</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:31.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a,b,bb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2C<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986514112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,813<span></span>
</td>
<td class="nump">$ 4,543<span></span>
</td>
<td class="nump">$ 16,360<span></span>
</td>
<td class="nump">$ 11,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">5,966<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,201<span></span>
</td>
<td class="nump">5,970<span></span>
</td>
<td class="nump">22,326<span></span>
</td>
<td class="nump">15,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,201)<span></span>
</td>
<td class="num">(5,970)<span></span>
</td>
<td class="num">(22,326)<span></span>
</td>
<td class="num">(15,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(698)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (8,485)<span></span>
</td>
<td class="num">$ (6,025)<span></span>
</td>
<td class="num">$ (23,024)<span></span>
</td>
<td class="num">$ (15,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (13.55)<span></span>
</td>
<td class="num">$ (4.11)<span></span>
</td>
<td class="num">$ (38.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding used in net loss per share - basic and diluted (in shares)</a></td>
<td class="nump">15,297,794<span></span>
</td>
<td class="nump">444,787<span></span>
</td>
<td class="nump">5,596,412<span></span>
</td>
<td class="nump">413,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208242757744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">7.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Commitments</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In November&nbsp;2010, the Company entered into a five-year, non-cancelable operating lease for office and laboratory space. In December&nbsp;2011, the Company signed a lease amendment (the &#x201C;2011 Lease Amendment&#x201D;) that expanded the leased premises beginning in the second quarter of 2012. The 2011 Lease Amendment also extended the term of the existing lease through June&nbsp;30, 2017. The 2011 Lease Amendment includes a free rent period for the expansion premises and escalating rent payments. In July, 2015, the Company signed another lease amendment (the &#x201C;2015 Lease Amendment&#x201D;) that expanded the leased premises beginning in the third quarter of 2015.&nbsp;&nbsp;The 2015 Lease Amendment includes escalating rent payments and is effective through June&nbsp;30, 2017. The Company is recognizing rent expense on a straight-line basis over the lease term. The lease agreement provides for a five-year extension upon the completion of the lease term.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Future minimum payments required under the non-cancelable operating lease as of September&nbsp;30, 2015 are summarized as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;">
			<tr>
				<td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Period&nbsp;Ending&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Remainder 2015</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2016</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>937&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>467&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,639&nbsp;
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Rent expense for the three months ended September&nbsp;30, 2015 and 2014 was $0.2 million and $0.2 million, respectively. Rent expense for the nine months ended September&nbsp;30, 2015 and 2014 was $0.6 million and $0.5 million, respectively.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207987265296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">6.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Warrants</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">On August&nbsp;27, 2014 and March&nbsp;31, 2015, the Company issued the 2014 Warrants and 2015 Warrants to purchase an aggregate 315,688 shares of series B convertible preferred stock at an exercise price of $0.9503 per share to the lenders in connection with the Credit Facility (Note 5). The 2014 Warrants and 2015 Warrants were exercisable immediately on issuance and have a seven-year life. The 2014 Warrants and 2015 Warrants were recorded as a liability and re-measured at each reporting date using the then-current assumptions. In connection with the completion of the IPO, the 2014 Warrants and the 2015 Warrants were automatically converted into warrants exercisable for Common Stock, resulting in the reclassification of the related warrant liability to additional paid-in capital as the warrants to purchase shares of Common Stock met the criteria to be accounted for as equity instruments. The warrant liability was re-measured to fair value prior to reclassification to additional paid-in capital. As of September&nbsp;30, 2015, the Company had no outstanding warrant liability.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The following table provides a roll-forward of the fair value of the 2014 Warrants and 2015 Warrants determined by Level 3 inputs (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Balance at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Issuance of warrants at fair value</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107
				</td>
				<td valign="bottom" style="width:01.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Change in fair value, recorded as a component of the other (expense) income, net</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Reclassification to additional paid-in capital</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(206
				</td>
				<td valign="bottom" style="width:01.14%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Balance at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The fair value of warrants exercisable for 315,688 shares of series B convertible preferred stock, which upon the IPO were automatically converted into warrants exercisable for 24,566 shares of Common Stock with an exercise price of $12.14, was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;2015&nbsp;(1)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.97&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.95&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.5&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75.79&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78.16&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(1)&nbsp;&nbsp;&nbsp;Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure on warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208243102544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Reserved for Future Issuance (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock Reserved for Future Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock reserved for future issuance</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;">
			<tr>
				<td valign="bottom" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Conversion of Series&nbsp;A Preferred Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,356,996&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Conversion of Series&nbsp;B Preferred Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,655,992&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Warrants for the purchase of Preferred Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,283&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Warrants for the purchase of Common Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,405&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,839&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Options to purchase Common Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,572,959&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,385,341&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Employee Stock Purchase Plan</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>182,352&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,814,716&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,445,451&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994364096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accrued liabilities</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Accrued expenses consisted of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;">
			<tr>
				<td valign="bottom" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,237&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>796&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued contracted research costs</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>800&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,109&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued professional fees</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>791&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Accrued other</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,437&nbsp;
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,793&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994424496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">10.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Stock-based compensation</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Prior to the Company&#x2019;s IPO, the Company granted awards to eligible participants under the 2008 equity incentive plan (&#x201C;2008 Plan&#x201D;). In June&nbsp;2015, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the 2015 Stock Incentive Plan (&#x201C;2015 Plan&#x201D;), which became effective immediately prior to the effectiveness of the Company&#x2019;s IPO. Subsequent to the Company&#x2019;s IPO, option grants are awarded to eligible participants only under the 2015 Plan.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The 2015 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The Company&#x2019;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2015 Plan. The maximum number of shares of Common Stock that may be delivered in satisfaction of awards under the 2015 Plan is 1,068,287 shares, plus (1)&nbsp;25,942 shares that were available for grant under the 2008 Plan immediately prior to the closing of the IPO, (2)&nbsp;the number of shares of Common Stock subject to outstanding awards under the 2008 Plan upon closing of the IPO that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right and (3)&nbsp;an annual increase, to be added the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2016 and continuing until, and including, the fiscal year ending December&nbsp;31, 2025, equal to the lowest of 1,297,334 shares of Common Stock, 4% of the number of shares of Common Stock outstanding on the first day of the fiscal year and an amount determined by the Company&#x2019;s board of directors.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">As of September&nbsp;30, 2015, the Company had reserved 1,466,274 shares of Common Stock under the 2008 Plan, of which none remained available for future issuance.&nbsp;&nbsp;As of September&nbsp;30, 2015, the Company had reserved 1,106,685 shares of Common Stock under the 2015 Plan, of which 860,948 shares remained available for future issuance.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Stock Options</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">A summary of the Company&#x2019;s stock option activity and related information follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Average&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Average&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Remaining&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Contractual&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Term&nbsp;(years)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Agregate&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic&nbsp;Value&nbsp;</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,226,140
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.14
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.15
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,579
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>550,797
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.69
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25,045
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.05
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Cancelled or forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,881
				</td>
				<td valign="bottom" style="width:02.50%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.46
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Outstanding at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,011
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.57
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.11
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,560
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Exercisable at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>755,860
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.27
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.89
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,659
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,586,233
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.30
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,489
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The total intrinsic value of options exercised for the three months ended September&nbsp;30, 2015 and 2014 was $0, and $0.2 million, respectively. The total intrinsic value of options exercised for the nine months ended September&nbsp;30, 2015 and 2014 was $0.2 million and $0.3 million, respectively.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">At September&nbsp;30, 2015, the total unrecognized compensation expense related to unvested stock option awards, including estimated forfeitures, was $5.2 million. The Company expects to recognize that cost over a weighted-average period of approximately 3.1 years.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Stock-based compensation expense</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Total stock-based compensation expense is recognized for stock options granted to employees and non-employees and has been reported in the Company&#x2019;s statements of operations as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>289&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>638&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>316&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>488&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>232&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,143&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>605&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Employee Stock Purchase Plan</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In June&nbsp;2015, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#x201C;2015 ESPP&#x201D;) which became effective upon closing of the Company&#x2019;s IPO. The 2015 ESPP authorizes the initial issuance of up to a total of 182,352 shares of Common Stock to participating eligible employees. The number of shares increases each January&nbsp;1, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2026, by an amount equal to the lesser of one percent of the Company&#x2019;s outstanding shares as of the end of the immediately preceding fiscal year, 364,705 shares and any lower amount determined by the Company&#x2019;s board of directors. As of September&nbsp;30, 2015 there has been no activity under the 2015 ESPP.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208187844576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">8.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">On March&nbsp;13, 2015, the Company&#x2019;s board of directors authorized the Company to increase the authorized number of shares of Series&nbsp;B Preferred Stock to 56,026,590 in connection with an anticipated Series&nbsp;B Preferred Stock financing. The Company subsequently issued 13,062,965 shares of Series&nbsp;B Preferred Stock at $0.9503 per share, and received net proceeds of $12.3 million.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Upon closing the Company&#x2019;s IPO on June&nbsp;30, 2015, all outstanding shares of the Company&#x2019;s preferred stock were automatically converted into 9,029,549 shares of Common Stock.&nbsp;&nbsp;As of September&nbsp;30, 2015, the Company has 5,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share, with none issued or outstanding.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Preferred stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the board of directors of the Company. Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208003301008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Reserved for Future Issuance<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock Reserved for Future Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Common Stock Reserved for Future Issuance</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company has reserved for future issuance the following number of shares of Common Stock:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;">
			<tr>
				<td valign="bottom" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Conversion of Series&nbsp;A Preferred Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,356,996&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Conversion of Series&nbsp;B Preferred Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,655,992&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Warrants for the purchase of Preferred Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,283&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Warrants for the purchase of Common Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,405&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,839&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Options to purchase Common Stock</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,572,959&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,385,341&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Employee Stock Purchase Plan</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>182,352&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,814,716&nbsp;
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,445,451&nbsp;
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:62.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986900704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">11.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Net Loss Per Share</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options, warrants to purchase Common Stock and warrants to purchase preferred stock are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,012,987&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,012,987&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,011&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,214,700&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,011&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,214,700&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Common stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,405&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,839&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59,405&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,839&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Preferred stock warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,283&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,283&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,771,416&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,274,809&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,771,416&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,274,809&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207999441584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 13, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock, Number of Shares, Par Value and Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common Stock issued upon conversion of Preferred Stock</a></td>
<td class="nump">9,029,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_NumberOfPerferredStockSeries', window );">Minimum number of series used to issue preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock, Number of Shares, Par Value and Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common Stock issued upon conversion of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,029,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock, Number of Shares, Par Value and Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,026,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,062,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_NumberOfPerferredStockSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of series that may be used to issue preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_NumberOfPerferredStockSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_SeriesConvertibleBpreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986540800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ScheduleOfWarrantsFairValueActivityTableTextBlock', window );">Roll-forward of the fair value of warrants determined by Level 3 inputs</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The following table provides a roll-forward of the fair value of the 2014 Warrants and 2015 Warrants determined by Level 3 inputs (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Balance at December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Issuance of warrants at fair value</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107
				</td>
				<td valign="bottom" style="width:01.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Change in fair value, recorded as a component of the other (expense) income, net</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Reclassification to additional paid-in capital</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(206
				</td>
				<td valign="bottom" style="width:01.14%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Balance at September&nbsp;30, 2015</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock', window );">Schedule of weighted-average assumptions</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;2015&nbsp;(1)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.97&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.95&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.5&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:64.00%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75.79&nbsp;
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78.16&nbsp;
				</td>
				<td valign="bottom" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">(1)&nbsp;&nbsp;&nbsp;Represents the date the warrants for series B convertible preferred stock converted to warrants for common stock</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ScheduleOfWarrantsFairValueActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity related to warrants during the period. Including but not limited to beginning and ending balance, increase/decrease in the fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ScheduleOfWarrantsFairValueActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average assumptions used to determine the fair value of warrants. Estimations were based on the Black-Scholes option pricing model.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ScheduleOfWeigthedAverageAssupmtionsFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986644304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously', window );">Minimum number of disease pathways within which multiple biological targets are modulated during treatment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_NumberOfMoleculesUsedToCreateProductCandidates', window );">Number of bioactives used to engineer bi-functional product candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_NumberOfLinkers', window );">Number of SMART linkers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Initial public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common Stock issued upon conversion of Preferred Stock</a></td>
<td class="nump">9,029,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (98,404)<span></span>
</td>
<td class="num">$ (75,380)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Initial public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_SaleOfStockProceedsRecognizedNet', window );">Proceeds from initial public offering, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_StockOfferingFees', window );">Underwriting discounts, commissions and offering-related expenses payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common Stock issued upon conversion of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,029,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial public offering | Warrants for the purchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Initial public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares after conversion of warrants</a></td>
<td class="nump">24,566<span></span>
</td>
<td class="nump">24,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment option for underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Initial public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Initial public offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred Stock warrants converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum number of disease pathways targeted in treatment by modulating multiple biological targets within these pathways.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_MinimumNumberOfDiseasePathwaysModulatedSimultaneously</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_NumberOfLinkers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of proprietary SMART (Safely Metabolized And Rationally Targeted) linkers used in treatment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_NumberOfLinkers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_NumberOfMoleculesUsedToCreateProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of molecules, aka bioactives, from which the company engineers bi-functional product candidates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_NumberOfMoleculesUsedToCreateProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_SaleOfStockProceedsRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the proceeds recognized by the company as consideration for the sale of stock during a public offering. The amount recognized included issuance costs paid and accrued and is net of offering-related expenses including but not limited to underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_SaleOfStockProceedsRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_StockOfferingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fees and liabilities incurred during a pubic offering of common stock. This amount reduces the amount of proceeds received from the public offering. Includes but is not limited to underwriting discounts, commissions, offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_StockOfferingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockTransactionsParentheticalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=catb_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=catb_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207986985648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,024)<span></span>
</td>
<td class="num">$ (15,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Noncash interest expense</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(237)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(21,050)<span></span>
</td>
<td class="num">(14,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(5,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">61,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs</a></td>
<td class="nump">12,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(282)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">79,151<span></span>
</td>
<td class="nump">4,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">58,041<span></span>
</td>
<td class="num">(14,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">14,668<span></span>
</td>
<td class="nump">30,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">72,709<span></span>
</td>
<td class="nump">15,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility', window );">Warrants for the purchase of series B preferred stock issued in conjunction with credit facility</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities', window );">Initial public offering costs in accounts payable and accrued liabilities</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ReclassificationNonCurrentAssetsToEquity', window );">Reclassification of deferred IPO costs from non-current assets to additional paid-in capital</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ReclassificationStockWarrantsToEquity', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of deferred initial public offering cost is included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_DeferredInitialPublicOfferingCostIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of rent made during the current reporting period for benefits that will be received over a period of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ReclassificationNonCurrentAssetsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the noncash reclassification of noncurrent assets to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ReclassificationNonCurrentAssetsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ReclassificationStockWarrantsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the noncash reclassification of stock warrants to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ReclassificationStockWarrantsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of warrants issued for purchase of preferred stock that is issued in conjunction with credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_WarrantsIssuedForPurchaseOfPreferredStockInConjunctionWithCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208003287520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5.</font><font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display:inline;font-size:3pt;"></font><font style="display:inline;font-weight:bold;">Notes Payable</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">On August&nbsp;27, 2014, the Company entered into a credit facility with MidCap Financial Trust, Flexpoint MCLS Holdings, LLC and Square 1 Bank, which was subsequently amended on March&nbsp;31, 2015 (as amended, the &#x201C;Credit Facility&#x201D;). The Credit Facility provides for initial borrowings of $5.0 million under a term loan (&#x201C;Term Loan A&#x201D;) and additional borrowings of up to $20.0 million under other term loans, for a maximum of $25.0 million. On August&nbsp;27, 2014, the Company received proceeds of $5.0 million from the issuance of promissory notes under Term Loan A. On March&nbsp;31, 2015, the Company received proceeds of $5.0 million from the issuance of promissory notes under another term loan (&#x201C;Term Loan B&#x201D;).&nbsp;&nbsp;The remaining amounts available for borrowing under this arrangement expired unused as of July&nbsp;31, 2015, leaving total borrowings under the Credit Facility at $10.0 million.&nbsp;&nbsp;All amounts outstanding under the Credit Facility are due on October&nbsp;1, 2018 and are collateralized by substantially all of the Company&#x2019;s personal property, other than its intellectual property.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Interest-only payments were due monthly on amounts outstanding under the Credit Facility until September&nbsp;1, 2015 and, thereafter, interest and principal payments are due in 36 equal monthly installments from October&nbsp;1, 2015 through September&nbsp;1, 2018.&nbsp;&nbsp;Amounts due under the Credit Facility bear interest at an annual rate of 7.49%. In addition, a final payment equal to 3.48% of any amounts drawn under the Credit Facility is due upon the earlier of the maturity date, acceleration of the term loans or prepayment of all or part of the term loans. The final payment is being accrued as additional interest expense using the effective-interest method from the date of issuance through the maturity date, and is recorded within other long-term liabilities.&nbsp;&nbsp;&nbsp;In the event of prepayment, the Company is obligated to pay 1% to 3% of the amount of the outstanding principal depending upon the timing of the prepayment. The effective interest rate as of September&nbsp;30, 2015 was 11.2%.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">In conjunction with Term Loan A, the Company issued warrants to purchase 157,844 shares of series B convertible preferred stock at an exercise price of $0.9503 per share (the &#x201C;2014 Warrants&#x201D;) to the lenders. In conjunction with Term Loan B, the Company issued warrants to purchase an additional 157,844 shares of series B convertible preferred stock at an exercise price of $0.9503 per share (the &#x201C;2015 Warrants&#x201D;) to the lenders (see Note 6). The 2014 Warrants and 2015 Warrants were exercisable immediately and have seven-year lives. The 2014 Warrants and 2015 Warrants were initially valued at $0.1 million and $0.1 million, respectively, using the Black-Scholes option-pricing model. The Company recorded debt discounts of $0.1 million and $0.1 million upon issuance of the 2014 Warrants and 2015 Warrants, respectively, which are being accreted as interest expense using the effective-interest method over the remaining term of the loan.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">There are no financial covenants associated with the Credit Facility; however, there are negative covenants restricting the Company&#x2019;s activities, including limitations on asset dispositions, mergers or acquisitions; encumbering or granting a security interest in its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and entering into certain other business transactions.</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Upon the occurrence and continuation of an event of default, the lenders have the right to exercise certain remedies against the Company and the collateral securing the loans under the Credit Facility, including cash.&nbsp;&nbsp;Events of default include, among other things, failure to pay amounts due under the Credit Facility, insolvency, the occurrence of a material adverse event, which includes a material adverse change in the business, operations or conditions (financial or otherwise) of the Company or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against the Company in an amount greater than $250,000. The occurrence of a material adverse change could result in acceleration of the payment of the debt. At September&nbsp;30, 2015 and December&nbsp;31, 2014, the Company concluded that the likelihood of the acceleration of the debt was remote, as a material adverse change had not occurred and was unlikely to occur and therefore the debt was classified in current and long-term liabilities based on scheduled principal payments. Following the occurrence and during the continuance of an event of default, borrowings under the Credit Facility shall bear interest at a rate per annum, which is five hundred basis points, or 5.0%, above the rate that is otherwise applicable.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company assessed all terms and features of the Credit Facility in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. As part of this analysis, the Company assessed the economic characteristics and risks of the Credit Facility, including put and call features. The Company determined that all features of the Credit Facility were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company&#x2019;s financial statements. The Company will continue to reassess the features on a quarterly basis to determine if they require separate accounting.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">The Company accounted for the amendment to the Credit Facility, effective March&nbsp;31, 2015, as a debt modification pursuant to ASC Topic 470-50 </font><font style="display:inline;font-style:italic;">Modifications and Extinguishments.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Estimated future principal payments at September&nbsp;30, 2015 are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;">
			<tr>
				<td valign="bottom" style="width:80.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Period&nbsp;Ending&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Remainder 2015</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>834
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2016</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,333
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,333
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,000
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: discount for warrants and costs paid to lender</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(260
				</td>
				<td valign="bottom" style="width:01.26%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,191
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Note payable, net of current portion and discount</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.58%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,549
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Estimated future principal payments at December&nbsp;31, 2014 are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;">
			<tr>
				<td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ending&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>416
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2016</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,667
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,667
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,250
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: discount for warrants and costs paid to lender</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(252
				</td>
				<td valign="bottom" style="width:01.38%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(309
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Note payable, net of current portion and discount</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,439
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">During the three and nine months ended September&nbsp;30, 2015, the Company recognized $0.3 million and $0.7 million, respectively, of interest expense related to the Credit Facility.</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207994562544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Details)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 11, 2015</div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio (as a percent)</a></td>
<td class="nump">0.077821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount', window );">Transfers of assets or liabilities between levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets and/or liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2 or out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Stock Split<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>93</ContextCount>
  <ElementCount>191</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/StatementCondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureOrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Polices</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolices</Role>
      <ShortName>Summary of Significant Accounting Polices</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Common Stock Reserved for Future Issuance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuance</Role>
      <ShortName>Common Stock Reserved for Future Issuance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Polices (Polices)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices</Role>
      <ShortName>Summary of Significant Accounting Polices (Polices)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolices</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureNotesPayable</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureWarrants</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureCommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureCommitments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Common Stock Reserved for Future Issuance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceTables</Role>
      <ShortName>Common Stock Reserved for Future Issuance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuance</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureOrganizationAndOperationsDetails</Role>
      <ShortName>Organization and Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureOrganizationAndOperations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Polices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesDetails</Role>
      <ShortName>Summary of Significant Accounting Polices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureNotesPayableTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Notes Payable (Details 2)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNotesPayableDetails2</Role>
      <ShortName>Notes Payable (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureNotesPayableTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureWarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureWarrantsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureCommitmentsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureCommonStockReservedForFutureIssuanceTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stock-based compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails2</Role>
      <ShortName>Stock-based compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stock-based compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureStockBasedCompensationDetails3</Role>
      <ShortName>Stock-based compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="catb-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catabasis.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.catabasis.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Condensed Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Condensed Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>catb-20150930.xml</File>
    <File>catb-20150930_cal.xml</File>
    <File>catb-20150930_def.xml</File>
    <File>catb-20150930_lab.xml</File>
    <File>catb-20150930_pre.xml</File>
    <File>catb-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140207997676864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=catb_EmployeeStockPurchasePlan2015Member', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for grant (in shares)</a></td>
<td class="nump">182,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=catb_AnnualIncreaseMember', window );">Annual minimum increase | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding Common Stock available for issuance (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Potential increase in shares available for issuance as determined by the Board of Directors (in shares)</a></td>
<td class="nump">364,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=catb_EmployeeStockPurchasePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=catb_EmployeeStockPurchasePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=catb_AnnualIncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=catb_AnnualIncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140208189193136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock', window );">Schedule of estimated future principal payments</a></td>
<td class="text"><div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Estimated future principal payments at September&nbsp;30, 2015 are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;">
			<tr>
				<td valign="bottom" style="width:80.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Period&nbsp;Ending&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Remainder 2015</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>834
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2016</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,333
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,333
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,000
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: discount for warrants and costs paid to lender</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(260
				</td>
				<td valign="bottom" style="width:01.26%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,191
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Note payable, net of current portion and discount</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.58%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,549
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:80.62%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.12%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">Estimated future principal payments at December&nbsp;31, 2014 are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;">
			<tr>
				<td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ending&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>416
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2016</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,667
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,667
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,250
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: discount for warrants and costs paid to lender</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(252
				</td>
				<td valign="bottom" style="width:01.38%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Less: current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(309
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">Note payable, net of current portion and discount</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.52%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,439
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:78.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:0%;margin-right:0%;">
		<p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated future principal payments of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">catb_ScheduleOfFuturePrincipalPaymentsNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>catb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
